<SEC-DOCUMENT>0001193125-21-272111.txt : 20210914
<SEC-HEADER>0001193125-21-272111.hdr.sgml : 20210914
<ACCEPTANCE-DATETIME>20210914060936
ACCESSION NUMBER:		0001193125-21-272111
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		29
FILED AS OF DATE:		20210914
DATE AS OF CHANGE:		20210914

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tyra Biosciences, Inc.
		CENTRAL INDEX KEY:			0001863127
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831476348
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258970
		FILM NUMBER:		211251160

	BUSINESS ADDRESS:	
		STREET 1:		2656 STATE STREET
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
		BUSINESS PHONE:		(619) 728-4760

	MAIL ADDRESS:	
		STREET 1:		2656 STATE STREET
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d189651ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on September&nbsp;14, 2021
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-258970 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO.
2 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Under </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>TYRA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-1476348</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2656 State Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Carlsbad, CA&nbsp;92008 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(619) <FONT STYLE="white-space:nowrap">728-4760</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Todd Harris, Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2656 State Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Carlsbad, California&nbsp;92008 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(619) <FONT STYLE="white-space:nowrap">728-4760</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Matthew T. Bush</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cheston J. Larson</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jeffrey
T. Woodley</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP<BR>12670 High Bluff Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92130</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">523-5400</FONT> </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>John S. Healy</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>General Counsel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tyra
Biosciences, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2656 State Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Carlsbad, California 92008</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(619) 728-4760</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Frank F. Rahmani</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Samir A. Gandhi</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alexander
E. Csordas</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sidley Austin LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>555 California Street, Suite 2000</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, CA 94104</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">565-7000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after the effective date of this registration
statement. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to
Rule&nbsp;415 under the Securities Act of&nbsp;1933, as amended, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this Form is filed to
register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Accelerated</FONT> Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;Reporting&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Title of each Class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>to be<BR>Registered(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Offering Price<BR>Per Share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed<BR>Maximum<BR>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registration&nbsp;Fee(3)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">10,350,000 shares</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$16.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$165,600,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$18,067</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes 1,350,000 shares of common stock that the underwriters may purchase pursuant to an option to purchase
additional shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(a) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">$13,450 of this registration fee was previously paid by the Registrant in connection with the previous filing of
its Registration Statement on Form&nbsp;S-1. </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman"><B>The registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act of&nbsp;1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#c21128">The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any state or other jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Subject to Completion, </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Preliminary Prospectus dated September 14, 2021 </FONT></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROSPECTUS </U></B></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>9,000,000
Shares </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g56o91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This is Tyra
Biosciences, Inc.&#146;s initial public offering. We are selling 9,000,000 shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has
been no public market for our common stock. It is currently estimated that the initial public offering price per share will be between $14.00 and $16.00. Our common stock has been approved for listing on the Nasdaq Global Select Market under the
symbol &#147;TYRA.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company under the federal securities laws and are subject to reduced public
company disclosure standards. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman"><B>Investing in the common stock involves risks that are described in the &#147;<A HREF="#toc189651_4">Risk Factors</A>&#148; section
beginning on page 11 of this prospectus. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">We refer you to the &#147;Underwriting&#148; section of this prospectus for additional information regarding
underwriting compensation. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also exercise their option to purchase up to an additional
1,350,000 shares from us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares will be ready
for delivery on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="middle"><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><B>Cowen</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_3">SUMMARY FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_6">INDUSTRY AND OTHER DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_10">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_10a">SELECTED FINANCIAL DATA </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_11">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_12">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_13">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_14">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_15">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_16">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_17">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_18">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_19">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_20">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_21">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_22">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_23">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc189651_24">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide any information or to make any
representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of,
any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this
prospectus or in any applicable free writing prospectus related thereto is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and
prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: Neither we nor the underwriters have done anything
that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this
prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have proprietary rights to trademarks, trade names and service marks appearing in this prospectus that are important to our business.
Solely for convenience, the trademarks, trade names and service marks may appear in this prospectus without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but
any such references are not intended to indicate, in any way, that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All
trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. We do not intend our use or display of other parties&#146; trademarks, trade names or service marks to imply, and such use or display
should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should
consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes included elsewhere in this prospectus. You should also
consider, among other things, the matters described under &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case appearing elsewhere in this prospectus.
Unless the context otherwise requires, the terms &#147;Tyra,&#148; &#147;Tyra Biosciences,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; in this prospectus refer to Tyra Biosciences, Inc. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a precision oncology
company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The widespread availability of approved targeted oncology treatments, such as kinase inhibitors, has transformed the
cancer treatment landscape. Despite the therapeutic benefit that targeted oncology treatments have created for some patients, the response rate and duration of efficacy is often limited by acquired drug resistance and other shortcomings of existing
therapies. We are using our proprietary SN&Aring;P platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SN&Aring;Pshots, in order to generate next-generation product candidates that are
specifically designed to address acquired drug resistance and provide alternative treatment options. We are initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are
altered in approximately 7% of all cancers. Our lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. We anticipate filing an Investigational New Drug application, or IND,
with the U.S. Food and Drug Administration, or the FDA, for TYRA-300 in mid-2022. In addition, we have pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, or RET, and
FGFR4-related cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our SN&Aring;P platform </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We developed our proprietary SN&Aring;P platform to efficiently identify and selectively target vulnerabilities in the mutant proteins where
genetic alterations have eliminated or reduced the effectiveness of targeted therapies. Through the rapid generation of precise molecular SN&Aring;Pshots, we continually gain deeper insights into the structure of inhibitor binding sites and how
commonly occurring genetic alterations lead to acquired drug resistance to existing therapies. Leveraging these insights, we aim to predict the genetic alterations most likely to cause resistance to specific existing therapies and develop compound
candidates with innovative structures that are designed to inhibit the target while avoiding those mutations. Through this process, we identify product candidates that may have the potency and selectivity to, if approved, be used as important
treatment options to address critical unmet needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our SN&Aring;P platform is driven by our ability to rapidly and concurrently generate
iterative data from the following three key pillars. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Protein crystallography.</B> We have developed proprietary protein crystallography techniques that enable us
to determine the <FONT STYLE="white-space:nowrap">co-crystal</FONT> structures of newly synthesized compounds in target proteins in as little as three days. This enables weekly generation of detailed structural insights on the precise interactions
and conformational changes that occur when our potential product candidates bind to a particular target, creating opportunities to further refine the structural design. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cell-based assays.</B> We assess inhibitor potency directly in <I>in vitro</I> target-specific
anti-proliferation assays, in addition to enzymatic assays, to enable us to simultaneously understand target potency </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and cell penetration as well as target-specific cell killing.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>Our process allows us to generate data on newly synthesized compounds in as
little as two days. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B><I>In vivo</I></B><B> models.</B> Our direct structural insights and <I>in vitro</I> datasets are
complemented by <I>in vivo</I> pharmacologic data generated through <FONT STYLE="white-space:nowrap">in-house</FONT> animal models that provide us with bioavailability, pharmacokinetic data and anti-tumor activity in as little as five days.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Programs </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is an
overview of our programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g34h50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our FGFR3 <FONT STYLE="white-space:nowrap">Program&#151;TYRA-300</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing our lead product candidate, <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> a selective inhibitor of FGFR3, initially for
the treatment of muscle invasive bladder cancer, or MIBC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">One common mechanism of acquired drug resistance in kinases such as FGFR3 is
the emergence of gatekeeper mutations. For example, the V555M and V555L gatekeeper mutations have been shown to block access to a portion of the binding pocket accessed by first generation FGFR compounds, such as Balversa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (erdafitinib), the only currently FDA approved FGFR3 inhibitor for MIBC, as well as Truseltiq<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (infigratinib), an&nbsp;FGFR inhibitor
recently approved for cholangiocarcinoma. Because we believe the gatekeeper mutation represents a key limitation to efficacy and durability of the therapeutic effect of first generation FGFR compounds, we have designed
<FONT STYLE="white-space:nowrap">TYRA-300</FONT> to avoid interactions with the gatekeeper region of the inhibitor binding site. In cell-based assays and preclinical xenograft models, we observed that <FONT STYLE="white-space:nowrap">TYRA-300</FONT>
had similar inhibition against both the wild-type and the gatekeeper mutations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to addressing the gatekeeper resistance
mutations, we have designed <FONT STYLE="white-space:nowrap">TYRA-300</FONT> to be more selective for FGFR3 over FGFR1 to minimize <FONT STYLE="white-space:nowrap">off-target</FONT> side effects, providing potential clinical advantages over less
selective first generation compounds. For example, inhibition of FGFR1 is associated with a well-characterized adverse event, hyperphosphatemia, an electrolyte disorder characterized by an elevated level of phosphate in the blood, which is commonly
observed in patients treated with these inhibitors, limiting their dosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have designed
<FONT STYLE="white-space:nowrap">TYRA-300</FONT> to be more selective for FGFR3 over FGFR1 in order to potentially reduce&nbsp;the need for dose modifications or interruptions due to hyperphosphatemia, which we believe will result in
</P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased efficacy and improved clinical outcomes for patients with MIBC. We believe TYRA-300 has the potential to address additional indications such as non-muscle invasive bladder cancer, or
NMIBC, as well as other FGFR3-driven indications demonstrating resistance to existing therapies or for which such therapies result in dose-limiting adverse events, such as hyperphosphatemia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our FGFR2 Program </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our second
program is focused on the inhibition of FGFR2, initially for the treatment of intrahepatic cholangiocarcinoma, or ICC, a cancer of the biliary ducts. Acquired resistance mutations, such as gatekeeper and molecular brake mutations, have been observed
in patients treated with Pemazyre<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pemigatinib) and Truseltiq<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (infigratinib), the two FDA approved FGFR inhibitors for ICC, and in
other late clinical stage inhibitors, such as futibatinib.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>We are developing an inhibitor with the potential to address key resistance mutations, which we believe is necessary to address the
problem of polyclonal resistance. We plan to nominate a product candidate by the end of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Achondroplasia, RET and FGFR4 Programs
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our pipeline also includes development programs targeting FGFR3-related achondroplasia as well as RET and FGFR4-related cancers.
These programs are currently in lead optimization stage. Our achondroplasia program is aimed at developing a potential treatment for pediatric patients, benefiting from our structural insights into the FGFR3 selectivity we have observed with <FONT
STYLE="white-space:nowrap">TYRA-300.</FONT> This genetic disorder is caused by a mutation in the FGFR3 gene. Our RET and FGFR4 programs are focused on overcoming acquired drug resistance mutations that are clinically observed to arise in response to
marketed or clinical-stage drugs in <FONT STYLE="white-space:nowrap">RET-</FONT> and FGFR4-related cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At Tyra, we do not accept that cancer patients with acquired drug resistance should be left with the devastating reality of limited or no
treatment options. Our vision is to become a leading precision medicine company utilizing our unique approach to designing and developing purpose-built therapies to overcome acquired drug resistance in tumors and provide treatment options to these
patients who have limited or no options. Key elements of our strategy to achieve our vision are as follows. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance product candidates for acquired drug resistance mutations in FGFR3 and FGFR2 through clinical development
and regulatory approval. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Harness the strength of our SN&Aring;P platform to rapidly develop additional next-generation precision
therapies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage the recent advances in the precision oncology landscape to potentially expedite our product
candidates&#146; development. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our product candidates across multiple therapeutic areas through accelerated development
and potential partnerships. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Leadership Team and Investors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are led by a team with extensive experience in drug discovery and development with a particular focus on small molecule drug development.
Todd Harris, Ph.D., our <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Executive Officer, previously founded and served as Chief Executive Officer of Sienna Labs. Daniel Bensen, our <FONT STYLE="white-space:nowrap">co-founder</FONT>
and Chief Operating Officer, is a structural biologist and protein chemist with over 20 years of experience most recently at Cidara Therapeutics and Trius Therapeutics. Robert Hudkins, Ph.D., our Chief Technical Officer, has over 34 years of
oncology and neuroscience medicinal chemistry experience, including 26 years at Cephalon and </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Teva, where he was an inventor and team leader advancing new chemical entities into clinical development. Ronald Swanson, Ph.D., our Chief Scientific Officer, has over 25 years of biotechnology
and pharmaceutical experience, most recently at Janssen. Hiroomi Tada, M.D., Ph.D., our Chief Medical Officer, was a clinical lead for the development of a portfolio of therapies at Incyte, GlaxoSmithKline and AstraZeneca. Our Chief Development
Officer, Piyush Patel, Ph.D., with nearly three decades of experience, previously served as Chief Scientific Officer at CinRx and led drug formulation, clinical manufacturing and process development at Cephalon and Teva. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, we have raised $157.2&nbsp;million from leading investors in the life sciences industry. Investors with 5% or greater ownership are
Alta Partners, Boxer Capital of Tavistock Group, Canaan, Nextech Invest and RA Capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risks Associated with Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision.
These risks are described more fully in the section entitled &#147;Risk Factors&#148; in this prospectus. These risks include, among others, the following. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are very early in our development efforts, have limited operating history, have not initiated or completed any
clinical trials, have no products approved for commercial sale and have not generated any revenue, which may make it difficult for investors to evaluate our current business and likelihood of success and viability. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant net losses in each period since our inception, and we expect to continue to incur
significant net losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve our
objectives relating to discovery, development and commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require substantial additional financing to achieve our goals, and a
failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are early in our development efforts and all of our development programs are in the preclinical or discovery
stage. If we are unable to successfully develop, obtain marketing approval and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an organization, we have never conducted any clinical trials or submitted an application for marketing
approval, and may be unable to do so for any of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the
results of preclinical studies and early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in clinical trials and our product candidates may not have favorable results in clinical
trials, if any, or receive marketing approval on a timely basis, if at all. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling
patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to rely on third parties for the manufacture of our product candidates for preclinical and clinical
development. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or
commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct some of our preclinical studies and will rely on third parties to conduct our
future clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain marketing
approval for or commercialize our product candidates may be delayed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition, and, if our competitors develop technologies or product candidates more rapidly
than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent protection for our product candidates and other proprietary
technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize
our product candidates and other proprietary technologies we may develop may be adversely affected. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate History </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware on August&nbsp;2, 2018 under the name &#147;Tyra Biosciences, Inc.&#148; Our
principal corporate office is located at 2656 State Street, Carlsbad, CA 92008, and our telephone number is (619) <FONT STYLE="white-space:nowrap">728-4760.</FONT> Our website address is www.tyra.bio. We do not incorporate the information on or
accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act, as amended, or the JOBS Act, enacted in
April 2012. An &#147;emerging growth company&#148; may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements and only two years of related
Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended, or the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden
parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the last day of our fiscal
year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth anniversary will
occur in 2026. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange
Act of 1934, as amended, or the Exchange Act, our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be
an emerging growth company prior to the end of such five-year period. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the
registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might
receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The JOBS Act provides that an emerging growth company
can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected to use the extended transition period to enable us to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date on which we (i)&nbsp;are no longer an emerging growth company and (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS
Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting company even
after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less
than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>9,000,000 shares. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares </P></TD>
<TD>We have granted <FONT STYLE="white-space:nowrap">a&nbsp;30-day</FONT> option to the underwriters to purchase up to an aggregate of 1,350,000 additional shares of common stock from us at the initial public offering price, less underwriting
discounts and commissions, on the same terms as set forth in this prospectus. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding<BR> immediately after this offering </P></TD>
<TD>39,115,139 shares (40,465,139 shares if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $121.9 million, or $140.7 million if the underwriters exercise in full their option to purchase additional shares, assuming an
initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us. We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the development of <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> our FGFR2 program and our FGFR3 achondroplasia
program, as well as to fund the discovery and preclinical development of additional product candidates and for headcount costs, working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for additional information.
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Reserved share program </P></TD>
<TD>At our request, an affiliate of BofA Securities, Inc., a participating Underwriter, has reserved for sale, at the initial public offering price, up to 3% of the shares offered by this prospectus for sale to some of our directors and officers and
certain other parties related to us. Shares purchased through the reserved share program will not be subject to lockup restrictions with the underwriters, except in the case of shares purchased by any of our directors or executive officers. See
&#147;Underwriting&#151;Reserved Shares.&#148; If these persons purchase reserved shares it will reduce the number of shares available for sale to the general public. Any reserved shares that are not so purchased will be offered by the underwriters
to the general public on the same terms as the other shares offered by this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;TYRA&#148; </TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
30,115,139 shares of our common stock outstanding as of June&nbsp;30, 2021, including 1,512,699 shares of unvested restricted common stock, and 26,228,089 shares of our common stock issuable upon the automatic conversion of all outstanding shares of
our convertible preferred stock immediately prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,586,835 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2021
under our 2020 Equity Incentive Plan, or the 2020 Plan, with a weighted-average exercise price of $2.88 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,570,000 shares of common stock reserved for future issuance under our 2021 Incentive Award Plan, or the 2021
Plan (including 1,032,150 shares of common stock reserved for future grant or issuance under our 2020 Plan as of June&nbsp;30, 2021, which shares will be added to the shares reserved under the 2021 Plan upon its effectiveness), as well as any annual
automatic increases in the number of shares of our common stock reserved for future issuance under the 2021 Plan, which will become effective on the day prior to the public trading date of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">380,000 shares of our common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan, or
the ESPP, as well as any annual automatic increases in the number of shares of our common stock reserved for future issuance under the ESPP, which will become effective on the day prior to the public trading date of our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of
26,228,089 shares of our common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock in this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated
bylaws, which will occur immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a 2.5974 &#150; for &#150;1 forward stock split of our common stock, which we effected on September&nbsp;7, 2021.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See Note 7 to our audited and unaudited financial statements included elsewhere in this prospectus for a discussion of
our outstanding restricted common stock. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_3"></A>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following tables summarize our financial data as of, and for the periods ended on, the dates indicated. We have derived the statement of
operations data for the years ended December&nbsp;31, 2019 and&nbsp;2020 from our audited financial statements appearing at the end of this prospectus. The statement of operations data for the six months ended June&nbsp;30, 2020 and&nbsp;2021 and
the balance sheet data as of June&nbsp;30, 2021 have been derived from our unaudited financial statements appearing at the end of this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of our
management, the unaudited data reflects all adjustments, consisting of normal and recurring adjustments, necessary for the fair statement of results as of and for these periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial data
should be read in conjunction with the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our audited and unaudited financial statements and related notes
included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months<BR>Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other (expense) income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of simple agreement for future equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(943</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Weighted average shares used to compute net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,650,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,542,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,414,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,139,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Pro forma weighted average shares of common stock, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,187,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,479,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note&nbsp;2 to our audited financial statements included elsewhere in this prospectus for an explanation of
the method used to calculate the historical net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unaudited pro forma net loss per share, basic and diluted, attributable to common stockholders, is calculated
giving effect to the conversion of the convertible preferred stock into shares of common stock. Unaudited pro forma net loss per share attributable to common stockholders does not include the shares expected to be
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
sold and related proceeds to be received in this offering. Unaudited pro forma net loss per share attributable to common stockholders for the year ended December&nbsp;31, 2020 and the period
ended June&nbsp;30, 2021 was calculated using the weighted-average number of shares of common stock outstanding, including the pro forma effect of the conversion of all outstanding shares of our convertible preferred stock into shares of our common
stock, as if such conversion had occurred at the beginning of the period or their issuance dates, if later. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro<BR>Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma<BR>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited, in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">257,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gives effect to (i)&nbsp;the automatic conversion of all outstanding shares of convertible preferred stock into
an aggregate of 26,228,089&nbsp;shares of our common stock immediately prior to the completion of this offering and the related reclassification of the carrying value of the convertible preferred stock to permanent equity immediately prior to the
completion of this offering and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, which will occur upon the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gives effect to (i)&nbsp;the pro forma adjustments set forth above and (ii)&nbsp;the issuance and sale of
9,000,000&nbsp;shares of common stock in this offering at an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma as adjusted balance sheet data is illustrative only and will change based on the actual initial
public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, would increase (decrease) pro forma as adjusted cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by approximately $8.4&nbsp;million, assuming that the number of shares offered by
us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions. We may also increase or decrease the number of shares we are offering. A 1,000,000 share increase
(decrease) in the number of shares offered by us would increase or decrease pro forma as adjusted cash and cash equivalents, working capital, total assets and total stockholders&#146; deficit by approximately $14.0&nbsp;million, assuming that the
assumed initial offering price to the public remains the same, and after deducting estimated underwriting discounts and commissions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our financial statements and the
related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below,
together with all of the other information in this prospectus, including our financial statements and related notes included elsewhere in this prospectus and in the section titled &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations,&#148; before making an investment decision. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that
event, the market price of our common stock could decline and you could lose part or all of your investment. Additional risk and uncertainties not presently known to us or that we currently deem immaterial also may impair our business and operations
and the market price of our common stock. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Position and Capital Requirements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are very early in our development efforts, have limited operating history, have not initiated or completed any clinical trials, and have no products
approved for commercial sale, which may make it difficult for investors to evaluate our current business and likelihood of success and viability. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Investment in drug development is a highly speculative undertaking and involves a substantial degree of risk. We are a preclinical-stage
biopharmaceutical company formed in 2018 with a limited operating history upon which you can evaluate our business and prospects. Our development programs, including our lead product candidate, <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> are
either in preclinical development or in the drug discovery stage. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, research and development activities including development of our
proprietary SN&Aring;P platform and identifying potential product candidates, establishing our intellectual property portfolio, conducting research and preclinical studies, and providing general and administrative support to these operations. Our
approach to the discovery and development of product candidates based on our proprietary SN&Aring;P platform is unproven, and we do not know whether we will be able to develop any product candidates that are successful in clinical development or
products of commercial value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As an organization, we have not yet initiated or completed any clinical trials, obtained regulatory
approvals, manufactured a commercial-scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our
future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the
foreseeable future. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since our inception. Our net losses were $4.1&nbsp;million and
$9.3&nbsp;million for the years ended December&nbsp;31, 2019 and December&nbsp;31, 2020, respectively, and $9.7&nbsp;million for the six months ended June&nbsp;30, 2021. As of June&nbsp;30, 2021, we had an accumulated deficit of $23.8&nbsp;million.
Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. <FONT STYLE="white-space:nowrap">TYRA-300</FONT>
and any of our other product candidates will require substantial additional development time and resources before we are able to apply for, or receive, marketing approval and begin generating revenue from product sales. We expect to continue to
incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, and seek marketing approval for, and potentially commercialize any of our product candidates and as we seek to
discover, develop and market additional potential product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to generate revenue and achieve profitability depends significantly on our ability to
achieve our objectives relating to discovery, development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To generate revenue
and achieve profitability, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including identifying lead
product candidates, completing preclinical studies and clinical trials of our product candidates, discovering additional product candidates, obtaining marketing approval for these product candidates and manufacturing, marketing and selling any
products for which we may obtain marketing approval. We are only in the preliminary stages of many of these activities. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates do, we
may never generate revenues that are significant or large enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new
and rapidly evolving fields, particularly in the biopharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated
with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we obtain marketing approval for one or more of our product
candidates and achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our
ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your
investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we will require substantial additional capital to achieve our goals, and a failure to obtain this
necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our
ongoing activities, particularly as we conduct our ongoing and planned preclinical studies for our development programs, initiate clinical trials for our product candidates and seek marketing approval for our current product candidates and any
future product candidates we may develop. If we obtain marketing approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because
the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, following
the completion of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to
raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based upon our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash
equivalents, will enable us to fund our operations through at least 2024. In particular, we expect that the net proceeds from this offering and our existing cash and cash equivalents will allow us to complete the Phase 1 portion of our planned Phase
1/2 clinical trial for TYRA-300 and Phase 1 clinical development for our FGRF2 program, and advance our FGFR3 program into the clinic. We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources
sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private
equity or debt financings or other capital sources, including potentially additional collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations
even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including, but not limited to:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the type, number, scope, progress, expansions, results, costs and timing of, discovery, preclinical studies and
clinical trials of our product candidates which we are pursuing or may choose to pursue in the future; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of manufacturing for our product candidates and commercial manufacturing if any product
candidate is approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational, compliance, and quality systems and hire additional personnel to satisfy our
obligations as a public company, including enhanced internal controls over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities
increase; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is
approved for commercial sale; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors
and adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial
requirements for approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT>
or acquire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we do not expect to generate commercial revenues, if any, from sales of products that we do not
expect to be commercially available for many years, if at all, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or
require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate
substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. We do not have any committed external
source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that
adversely affect your rights as a common stockholder. Any future debt financing and preferred equity financing, if available, may involve, agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights
to our future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or
debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product
candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery, Development and Marketing Approval of Our
Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are early in our development efforts and all of our development programs are in the preclinical or discovery stage. If we
are unable to successfully develop, obtain marketing approval and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are in the early stages of our research and development efforts and all of our development programs, including <FONT
STYLE="white-space:nowrap">TYRA-300,</FONT> are either in the preclinical or drug discovery stage. We have invested substantially all of our efforts to date in developing our proprietary SN&Aring;P platform, developing
<FONT STYLE="white-space:nowrap">TYRA-300,</FONT> identifying potential product candidates and conducting preclinical studies. We will need to progress <FONT STYLE="white-space:nowrap">TYRA-300</FONT> and our other product candidates through
additional preclinical studies to enable us to submit INDs with the FDA and receive clearance from the FDA to proceed with initiating their clinical development. Our ability to generate product revenues, which we do not expect will occur for many
years, if ever, will depend on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies with favorable results, including those compliant with Good
Laboratory Practice, or GLP, such as toxicology studies, biodistribution studies and minimum effective dose studies in animals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance by the FDA of INDs or of similar regulatory submissions by comparable foreign regulatory authorities
for the conduct of clinical trials of <FONT STYLE="white-space:nowrap">TYRA-300</FONT> and our other product candidates and our proposed design of future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in clinical trials and completion of clinical trials with favorable results;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful identification of new product candidates utilizing our SN&Aring;P platform; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing
capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities, including new drug applications, or NDAs,
from the FDA and maintaining such approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if
and when approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product
candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining an acceptable safety profile of our products following marketing approval, including acceptable
results from any post-approval studies or clinical trials agreed to by us or required by the FDA; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and growing an organization of people who can develop and commercialize our product candidates.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA or comparable foreign regulatory authorities can refuse to accept INDs or similar regulatory submissions for
many reasons, including negative or ambiguous results from our preclinical studies or disagreement with our interpretation of data from preclinical studies. If we are unable to develop, obtain marketing approval for, or, if approved, successfully
commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As an organization, we have never
conducted any clinical trials or submitted an application for marketing approval, and may be unable to do so for any of our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are early in our development efforts for our product candidates and we will need to successfully complete
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, Phase 1 clinical trials and later-stage and pivotal clinical trials, in order to obtain marketing authorization from the FDA or comparable foreign regulatory authorities to market <FONT
STYLE="white-space:nowrap">TYRA-300</FONT> or any other product candidates. Carrying out clinical trials and the submission of a successful NDA is a complicated process. As an organization, we plan to commence our first Phase 1/2 clinical trial in
the second half of 2022, subject to receiving clearance to proceed under an IND. We have not previously conducted any clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not
previously submitted an IND or an NDA or other comparable foreign regulatory submission for any product candidate. If we decide to develop <FONT STYLE="white-space:nowrap">TYRA-300</FONT> for multiple indications, we may be required to submit
multiple INDs to the FDA for these indications and may not conduct a clinical trial in the United States for that indication until we do so. In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of
<FONT STYLE="white-space:nowrap">TYRA-300</FONT> or any other product candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in
a way that leads to regulatory submission and approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining marketing approvals of product candidates that we
develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from, or delay us in submitting NDAs for, and commercializing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and
early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in clinical trials and our product candidates may not have favorable results in clinical trials, if any, or receive marketing
approval on a timely basis, if at all. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Preclinical and clinical development is expensive and can take many years to complete, and
its outcome is inherently uncertain. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and delay or failure can occur at any time during the preclinical study or
clinical trial process. Despite promising preclinical or clinical results, any biopharmaceutical company&#146;s product candidate can unexpectedly fail at any stage of preclinical or clinical development, and regulators, such as the FDA or
comparable foreign regulatory authorities, may not accept the results as demonstrating the product candidate&#146;s safety and efficacy. The historical failure rate for product candidates in our industry is high. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the
product candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy
characteristics despite having progressed through preclinical studies and initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trials. In particular, while we have conducted certain preclinical studies of <FONT STYLE="white-space:nowrap">TYRA-300</FONT> and other potential product candidates targeting acquired
resistance mutations in FGFR3, FGFR2, RET, and FGFR4, we do not know whether <FONT STYLE="white-space:nowrap">TYRA-300</FONT> or the other potential product candidates will perform in future clinical trials as they have performed in these prior
studies. The positive results we have observed for our product candidates in preclinical animal models may not be predictive of our future clinical trials in humans. It is not uncommon to observe results in clinical trials that are unexpected based
on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. We are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies for <FONT
STYLE="white-space:nowrap">TYRA-300.</FONT> If unexpected observations or toxicities are observed in these studies, or in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for any of our other product candidates, this will delay and
possibly prevent or limit clinical trials for <FONT STYLE="white-space:nowrap">TYRA-300</FONT> or our other product candidates. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies
in the biopharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the foregoing reasons, we cannot be certain that our ongoing and planned preclinical studies and planned clinical trials will be
successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could impair the prospects for marketing approval of our product candidates in those and other indications, which could have a material adverse
effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our discovery and preclinical development activities are focused on the
development of targeted therapeutics for patients with genomically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs based on our SN&Aring;P platform is novel and unproven and
may never lead to approved products of commercial value. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The discovery and development of targeted therapeutics for patients with
genomically defined cancers is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. Although we believe, based on our preclinical work, that the genomic
alterations targeted by our programs are oncogenic drivers, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. In addition, even if our approach is successful in showing clinical
benefit for acquired resistance mutation-driven cancers for our <FONT STYLE="white-space:nowrap">TYRA-300</FONT> inhibitor program, we may never successfully identify additional oncogenic alterations for other receptor tyrosine kinases using our
SN&Aring;P platform, or succeed in identifying additional product candidates to address such alterations. Any product candidates we do discover and advance based on scientific approach may be later shown to have harmful side effects or may have
other characteristics that may necessitate additional clinical testing, or make the product candidates unmarketable or unlikely to receive marketing approval. Therefore, we do not know if our approach of discovering and developing product candidates
to treat patients with genomically defined cancers will be successful, and if our approach is unsuccessful, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and
could potentially cause us to cease operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any difficulties or delays in the commencement or completion, or termination or suspension, of our
planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before we can initiate clinical trials for our product candidates, we must submit the results of preclinical studies to the FDA or comparable
foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND application or similar regulatory filing
required for regulatory acceptance before proceeding with clinical development. We are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> and expect to submit an
IND for <FONT STYLE="white-space:nowrap">TYRA-300</FONT> in mid-2022, followed by initiation of a Phase 1/2 clinical trial. We will also need to complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and submit INDs for our other
development programs prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initiating clinical development. The FDA or comparable foreign regulatory authorities may require us to conduct additional preclinical studies for any product candidate before it allows us to
initiate clinical trials under any IND or similar regulatory filing, which may lead to delays and increase the costs of our preclinical development programs. Moreover, even if these trials begin, issues may arise that could cause regulatory
authorities to suspend or terminate such clinical trials. Any such delays in the commencement or completion of our planned clinical trials for <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> or any other product candidate, could significantly
affect our product development timelines and development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not know whether our planned trials will begin on time or be
completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other <I>in vivo</I> or in vitro data to support the
initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory clearance to commence a trial or reaching a consensus with regulatory authorities on trial
design; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to reach an agreement with diagnostic companies for the use of liquid biopsy companion diagnostic tests
in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining approval from one or more institutional review boards, or IRBs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment
of additional patients, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying sufficient appropriately qualified investigators and other professionals to conduct the clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of product candidate for use in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up,</FONT> including patients failing to remain in our trials due to movement restrictions, health reasons or otherwise resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients choosing an alternative treatment for the indication for which we are developing our product candidates,
or participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in clinical trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components suspending or limiting manufacturing
due to violations of current good manufacturing practice, or cGMP, or other applicable requirements, including infections or cross-contaminations of product candidates in the manufacturing process, or the facility being subject to other enforcement
by the FDA or comparable foreign regulatory authorities that result in temporary or permanent manufacturing shut downs or product supply limitations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials or
being suspended or disqualified by the FDA or comparable foreign regulatory authorities, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other
regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or comparable foreign
regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the
likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of
the institutions in which our trials are being conducted, by a Data Safety Monitoring Board for our trial or by the FDA or comparable foreign regulatory authorities. These authorities may impose such a suspension or termination due to a number of
factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols and to make the appropriate required records, inspection of the clinical trial operations or trial site by the FDA or
comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a clinical trial drug, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may
require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay
completion of our clinical trials. These risks include the failure of investigators or enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional
administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive
compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. These authorities may conclude that a financial
relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data
generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of a marketing application by the FDA or comparable foreign regulatory
authorities and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we experience delays in the completion of, or termination of, any clinical trial of our
product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will
increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our proprietary SN&Aring;P platform is innovative and unproven, and we do not know whether we will be able to develop any product candidates that are
successful in clinical development or products of commercial value. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our
ability to identify, develop and commercialize products based on our proprietary SN&Aring;P platform, which is designed to efficiently identify and selectively target vulnerabilities in the mutant proteins that commonly eliminate or reduce the
effectiveness of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapies. Notwithstanding our preclinical study results for <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> we have not yet
succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter. <FONT STYLE="white-space:nowrap">TYRA-300</FONT> is in late preclinical development and
we have not yet completed any clinical trials for any product candidate. Our SN&Aring;P platform utilizes the rapid generation of precise molecular SN&Aring;Pshots to continually gain deeper insights into the structure of inhibitor binding sites and
how commonly occurring resistance mutations lead to acquired drug resistance to existing therapies, which we believe aids in the prediction of amino acid residues most likely to cause resistance to specific existing therapies. This innovative
process may never be successful in identifying additional product candidates with innovative structures that are able to inhibit the target while avoiding those specific residues. Further, because all of our product candidates and discovery programs
are based on our SN&Aring;P platform, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies. Our future success will
depend in part on our ability to maintain a competitive position with our innovative approach to compound identification. If we fail to stay at the forefront of technological innovation in utilizing our SN&Aring;P platform, we may be unable to
compete effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our
clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to
complete clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. Patient
enrollment for our clinical trials may be affected by many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility and exclusion criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that enrolled patients will not complete a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and
risks of the product candidate being studied in relation to other available therapies, including any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
new products that may be approved for the indications we are investigating as well as any product candidates under development. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. The patient populations for our
product candidates are limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted
alterations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations. Furthermore, even if we
are successful in identifying patients, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type and commercialize our product candidates
and achieve profitability. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory
authorities. In addition, the process of finding and diagnosing patients may prove costly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The timing of our clinical trials depends, in
part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. The eligibility criteria of our clinical trials, once established, will
further limit the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent clinical trials for similar patient populations or the availability of other
therapies, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting clinical trials and obtaining marketing approval of our product candidates may be delayed. Additionally, because
our initial planned clinical trials will be in patients with relapsed/refractory cancer, these patients are typically in the late stages of their disease and may experience disease progression independent from our product candidates, making them
unevaluable for purposes of the clinical trial and requiring additional patient enrollment. Our inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or
more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our clinical trials and, while we intend to enter into agreements governing their services, we will have limited
influence over their actual performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot assure you that our assumptions used in determining expected clinical trial timelines
are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude
approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects,
operating results and financial condition. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not evaluated any of our product candidates in human clinical trials. It is
impossible to predict when or if any product candidates we may develop will prove safe in humans. As is the case with biopharmaceuticals generally, and treatments for cancer and rare diseases in particular, it is likely that there may be side
effects and adverse events associated with the use of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory
authorities. If adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the
trials or our development efforts of one or more product candidates altogether. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, if our product candidates are associated with undesirable side effects in clinical
trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less
severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. We, the FDA or other applicable regulatory authorities, or an IRB, may suspend or terminate future clinical
trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Many compounds that initially showed promise in early-stage
testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, including with different dosing
regimens, or as the use of these product candidates becomes more widespread if they receive marketing approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur
or went undetected in previous trials, may be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients treated with our products, if approved, may experience previously unreported adverse reactions, and it is possible that the FDA or
comparable foreign regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. Even if the side effects do not preclude the product candidate from
obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. If safety problems occur or are identified after our products, if any, are
available for commercial sale and use, we may make the decision, or be required by regulatory authorities, to amend the labeling of our product candidates, recall our product candidates or even withdraw approval for an approved product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects
caused by such product, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against
its manufacture or distribution; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way such product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning or a
contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide
outlining the risks of such side effects for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product is distributed, conduct additional clinical trials or change the
labeling of a product or be required to conduct additional post-marketing studies or surveillance; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly or the product could become less competitive and our reputation
may suffer. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the particular
product candidate, if approved, and could significantly harm our business, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to submit INDs to commence clinical trials on the timelines we expect, and even if
we are able to, the FDA may not permit us to proceed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to submit INDs for our existing and future product
candidates on the timelines we expect. For example, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or
that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that it will not change its
requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our planned
clinical trials may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely basis, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause
unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The clinical
development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our product
candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we receive
marketing approval from the FDA. The process of obtaining marketing approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product
candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval
of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, marketing approval is never guaranteed. Neither we, nor any future collaborator, is permitted to market any of our product
candidates in the United States until we receive marketing approval from the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize a product
candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that
such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are
promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical
studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with the design or implementation of our, or our any of our potential future
collaborators&#146; clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or ambiguous results from our clinical trials or results may not meet the level of statistical
significance required by the FDA or comparable foreign regulatory authorities for marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by
individuals using drugs similar to our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in
countries where the standard of care is potentially different from that of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or any of our potential future collaborators may be unable to demonstrate that a product candidate is safe
and effective, and that product candidate&#146;s clinical and other benefits outweigh its safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not agree that the data collected from clinical trials of our product candidates are
acceptable or sufficient to support the submission of an NDA or other submission or to obtain marketing approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may require additional information, data, qualification, or validation of our manufacturing and
testing processes as part of the chemistry, manufacturing, and controls information we submit as part of our application; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or
with other significant restrictions on distribution and use; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our
third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulations of such authorities may significantly change in a manner rendering our or any of our potential future
collaborators&#146; clinical data insufficient for approval; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not accept a submission due to, among other reasons, the content or formatting of the
submission. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any delays in the marketing approval of our product candidates may negatively impact our ability to
successfully position the product candidate in the market or the product candidate may face additional competition from other products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With respect to foreign markets, marketing approval procedures vary among countries and, in addition to the foregoing risks, may involve
additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA or
comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining marketing approvals. Any delay in obtaining, or inability to obtain,
applicable marketing approvals would prevent us or any of our potential future collaborators from commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are
required by the FDA (or comparable regulatory authority) to obtain approval or clearance of a companion diagnostic test in connection with approval of any of our product candidates. If we do not obtain or we face delays in obtaining approval of a
diagnostic test, we may not be able to commercialize the product candidate and our ability to generate revenue will be materially impaired. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are required by the FDA or comparable foreign regulatory authorities to obtain approval or clearance of a companion diagnostic test in
connection with marketing approval of any of our product candidates, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such companion diagnostic test would be used during our more advanced phase clinical trials as well as in connection with the commercialization of our product candidates. We will rely on third
parties for the design, development and manufacture of companion diagnostic tests for our product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of
our future collaborators in developing and obtaining approval or clearance for these companion diagnostics. To be successful in developing and commercializing product candidates in combination with these companion diagnostics, we and our future
collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel
therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared at the same time the product candidate is approved. To
date, the FDA has required marketing approval of all companion diagnostic tests for cancer therapies. Various foreign regulatory authorities also regulate in vitro companion diagnostics as medical devices and, under those regulatory frameworks, will
likely require the conduct of clinical trials to demonstrate the safety and effectiveness of these companion diagnostics, which we expect will require separate regulatory clearance or approval prior to commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The approval or clearance of a companion diagnostic as part of the therapeutic product&#146;s labeling limits the use of the therapeutic
product to only those patients who express certain biomarkers or the specific genomic alteration that the companion diagnostic was developed to detect. If the FDA or comparable foreign regulatory authorities require approval or clearance of a
companion diagnostic for any of our product candidates, whether before or concurrently with marketing approval of the product candidate, we and/or our collaborators, may encounter difficulties in developing and obtaining approval or clearance for
these companion diagnostics. Any delay or failure by us or potential future collaborators to develop or obtain regulatory approval or clearance of a companion diagnostic could delay or prevent approval or continued marketing of our related product
candidates. Further, in April 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than
individual therapeutic products. We will continue to evaluate the impact of this guidance on any companion diagnostic strategy we undertake. This guidance and future issuances from the FDA or comparable foreign regulatory authorities may impact our
product candidates and result in delays in regulatory approval. We may be required to conduct additional studies to support a broader claim. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include our
approved drug products, we may be forced to abandon any partnered companion diagnostic development plans we undertake or we may not be able to compete effectively upon marketing approval, which could adversely impact our ability to generate revenue
from the sale of our approved products and our business operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, even if data from preclinical studies and early clinical
trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators
may encounter difficulties in developing, obtaining regulatory approval or clearance for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with
achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for our
product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of our
product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or
manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter
into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be
more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial
resources, we focus on specific product candidates, development programs and specific indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates that could have had greater commercial potential. Our
resource allocation decisions may cause us to fail to capitalize on viable potential commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific
indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through
collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain or maintain orphan drug designations for any of our product candidates, and we may be unable to maintain the benefits
associated with orphan drug designation, including the potential for market exclusivity. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some
jurisdictions, including the United States and Europe, may designate drugs or biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan product if it is
intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which
there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the European Medicines Agency&#146;s, or EMA&#146;s, Committee for Orphan Medicinal Products grants
orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European
Union. We have not received orphan drug designation in the United States for any product candidate. We may seek orphan drug designation in the United States and the European Union for TYRA-300 for patients with MIBC and other rare tumors susceptible
to an FGFR3 therapy, and similar designations for our other product candidates in qualified patient populations. There can be no assurance that the FDA or the EMA&#146;s Committee for Orphan Medicinal Products will grant orphan designation for any
indication for which we apply, or that we will be able to maintain such designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, orphan designation entitles a
party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product candidate that has orphan designation
subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same
product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The
applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable that market exclusivity is no
longer justified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from
competition because different drugs can be approved for the same condition. Even after an orphan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drug is approved, the FDA or comparable foreign regulatory authorities can subsequently approve the same drug for the same condition if such regulatory authority concludes that the later drug is
clinically superior because it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially
defective. In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs for the same or similar indication containing a different active ingredient. In addition, if a subsequent drug is approved for marketing for the
same or a similar indication as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity. Orphan drug designation neither shortens the development
time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we successfully develop
our product candidates, we may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our product candidates, but we may not receive such designation, and even if we do, such designation may not lead to a
faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may seek Breakthrough Therapy or Fast Track designation for some of our product candidates. A Breakthrough Therapy is defined as a drug or
biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life- threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biologics that have been designated as Breakthrough Therapies,
interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Drugs or biologics designated as Breakthrough Therapies by the FDA may also be eligible for expedited review and approval. If a product
candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the sponsor may apply for Fast Track Designation. The
FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we obtain Fast Track
Designation for one or more of our product candidates, we may not experience a faster development process, review or approval compared to <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures. In addition, the FDA may withdraw
Fast Track Designation if it believes that the designation is no longer supported. Fast Track Designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Whether to grant Breakthrough Therapy or Fast Track Designation is within the discretion of the FDA. Accordingly, even if we believe one of
our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either of these designations for a product candidate may not result in a faster
development process, review or approval compared to product candidates considered for approval under <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if
one or more of our product candidates qualify for either of these designations, the FDA may later decide that the product candidate no longer meet the conditions for qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future conduct clinical trials for certain of our product candidates outside of the United States. However, the FDA and other foreign
equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may conduct one or more of our clinical trials for our product candidates outside the United States. Although the FDA may accept data from
clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. Where data from foreign clinical trials are intended to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population
and U.S. medical practice; the trials were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA or, if the FDA
considers such an inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. Additionally, the FDA&#146;s clinical trial requirements, including
sufficient size of patient populations and statistical powering, must be met. For trials that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in
accordance with GCP and the FDA must be able to validate the data from the clinical trial through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection if it deems such inspection necessary. For such trials not subject to an IND, the FDA
generally does not provide advance comment on the clinical protocols for the trials, and therefore there is an additional potential risk that the FDA could determine that the trial design or protocol for a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial was inadequate, which could require us to conduct additional clinical trials. In addition, such foreign trials would be subject to the applicable local laws of the foreign regulatory
and legal requirements where the trials are conducted. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept data from our clinical trials of our product
candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, topline and preliminary data from our preclinical studies and clinical trials that we may announce or publish from time to time may change as
more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials. These
interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For
example, we may report responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations. We also make
assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from
future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures
that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses
of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data
become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the
price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the information we choose to publicly disclose regarding a particular study or trial is typically
selected from a more extensive amount of available information. Investors may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may
ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline or preliminary data that we report differ from late,
final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, any of our product candidates may be harmed, which could harm our business,
financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Where appropriate, we plan to secure approval from the FDA or comparable foreign regulatory
authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and
delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek
to withdraw accelerated approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Where appropriate, we plan to seek an accelerated approval for one or more of our product
candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a
determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is
clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or
other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality
that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug or biologic over available therapy may not be
a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to conduct, in a diligent manner,
additional post- approval confirmatory studies to verify and describe the drug&#146;s clinical benefit. If such post-approval studies fail to confirm the drug or biologic&#146;s clinical benefit or are not completed in a timely manner, the FDA may
withdraw its approval of the drug or biologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not yet applied for accelerated approval by the FDA. Prior to seeking accelerated
approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other
factors, we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply
for accelerated approval or any other form of expedited development, review or approval program, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory
designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis,
or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form
of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our
competitive position in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns
could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our
business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government
budget and funding levels, statutory, regulatory and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability to perform routine
functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is
inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days
beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020 the FDA announced its
intention to postpone most inspections of foreign manufacturing facilities and products and subsequently, on March&nbsp;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing
facilities. On July&nbsp;10, 2020, the FDA announced its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. And on
April&nbsp;14, 2021, the FDA announced guidance regarding Remote Interactive Evaluations, and how they will be requested by the FDA and conducted for the duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> public health emergency at any
facility where pharmaceutical products, including biological products, are manufactured, processed, packed or held; facilities covered under the FDA&#146;s bioresearch monitoring program; and outsourcing facilities registered under FDCA section
503B. The FDA intends to use information from remote interactive evaluations to meet <FONT STYLE="white-space:nowrap">user-fee</FONT> commitments and to update facilities information, when deemed appropriate based on risk and history of compliance
with FDA regulations. Facilities can choose to decline the FDA&#146;s request to perform a remote facility evaluation; however, this may delay the agency&#146;s ability to evaluate the facility or product and make a regulatory decision. The FDA will
not accept requests from applicants or facilities to perform a remote interactive evaluation, as decisions to offer a remote interactive evaluation will rest with the FDA, based on risk and compliance history. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory
activities, it could significantly impact the ability of the FDA or comparable foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As product candidates progress through preclinical studies and clinical trials to marketing approval and commercialization, it is common that
various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize safety, efficacy, yield and manufacturing batch size, minimize costs and achieve consistent quality and
results. For example, we have recently changed the delivery vehicle we use in our formulation for TYRA-300 from polyethylene glycol 400 to a cyclodextrin based vehicle. While we have observed positive results in a preclinical model using this new
delivery vehicle, any further changes in formulation may result in effects and results that are different from those observed in our completed preclinical studies to date. Similarly, in the future we may introduce an alternative formulation of one
or more of our product candidates during the course of our planned clinical trials. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and
affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay initiation or completion of clinical trials, require the conduct of bridging studies or clinical trials or the
repetition of one or more studies or clinical trials, increase development costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
intend to rely on third parties for the manufacture of our product candidates for preclinical and clinical development. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or
products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale manufacturing
capabilities. We plan to rely, and expect to continue to rely, on third parties for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the manufacture of our product candidates and related raw materials for preclinical and clinical development, as well as for commercial manufacture if any of our product candidates receive
marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA or comparable foreign regulatory authorities pursuant to inspections that will be conducted after we submit an NDA
to the FDA or any comparable filing to a foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of products. If
these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or
maintain marketing approval for their manufacturing facilities. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance, qualified personnel, and accurate and complete
recordkeeping. If the FDA or comparable foreign regulatory authorities does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations
could result in sanctions being imposed on us or the third-party manufacturers, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products,
operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our or
a third party&#146;s failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with cGMP could adversely affect our business in a number of ways, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate clinical trials of our product candidates under development; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease development or to recall batches of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize our product candidates, an inability to meet commercial
demands for our product candidates or any other future product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we do not have any long-term
commitments or supply agreements with our third party manufacturers. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of timely obtaining sufficient quantities of
our product candidates or such quantifies at an acceptable cost. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our schedule or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">misappropriation of our proprietary information, including our trade secrets and
<FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product candidates and any products that receive marketing approval may compete with the product candidates and
products of other companies for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Public health emergencies, such as that declared
for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> might cause third-party manufacturers with whom we contract to prioritize the production of other products, possibly at the direction of the United States. or other government. This could lead to
a delay in the manufacture of our product candidates or any products that receive marketing approval, and negatively impact the supply of such product candidates or products for clinical trials or commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any
related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our
existing or future third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. In particular, any replacement of our manufacturers could
require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original
manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced
or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our
future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance
on third parties requires us to share our confidential information, which increases the possibility that confidential information will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we currently plan to rely on third parties to manufacture our product candidates and to perform quality testing, we must, at times,
share our proprietary technology and confidential information with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or
disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share confidential information increases the risk that such trade secrets become known by our competitors, are
intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and
confidential information and despite our efforts to protect our confidential information, a competitor&#146;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive
position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to enter into collaborations, licenses and other similar arrangements and may not be
successful in doing so, and even if we are, we may relinquish valuable rights and may not realize the benefits of such relationships. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of
our product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. We may not be successful in our efforts to establish such collaborations for our product candidates because our
research and development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential
to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time-consuming and complex. We may have to
relinquish valuable rights to our future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering into
additional agreements with other potential collaborators. We cannot be certain that, following a collaboration, license or strategic transaction, we will achieve an economic benefit that justifies such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may
not be able to maintain such collaborations if, for example, the development or approval of a product candidate is delayed, the safety of a product candidate is questioned or the sales of an approved product candidate are unsatisfactory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our
rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the
same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the development and commercialization of our product candidates and
reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct some of our preclinical studies and will rely on third parties to conduct our clinical trials. If these third
parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain marketing approval for or commercialize our product
candidates may be delayed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are dependent on third parties to conduct some of our preclinical studies and expect to rely on
such third parties for our clinical trials, including our planned Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">TYRA-300.</FONT> Specifically, we have used and relied on, or intend to use and rely on, medical institutions, clinical
investigators, CROs, contract development and manufacturing organizations, and consultants to conduct some of our preclinical studies and to conduct planned clinical trials in accordance with our clinical protocols and regulatory requirements. These
CROs, investigators and other third parties play a significant role in the conduct and timing of these preclinical studies and clinical trials and subsequent collection and analysis of data. While we have and will have agreements governing the
activities of our CROs, investigators and other third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the
applicable protocol and legal, regulatory and scientific standards, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GLP and GCP requirements,
which are regulations and guidelines enforced by the FDA or comparable foreign regulatory authorities for all of our product candidates in preclinical and clinical development. Regulatory authorities enforce these requirements through periodic
inspections of trial sponsors, principal investigators, trial sites, and other third parties. If we or any of our CROs, trial sites or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third parties fail to comply with applicable GLP or GCP or other requirements, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign
regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our
failure to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time and resources to such trials or
perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended,
delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other development
activities that could harm our competitive position. In addition, principal investigators for our clinical trials may also serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection
with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the
data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could
prevent us from commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our CROs have the right to terminate their agreements with us in the event of an
uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if we make a general assignment for the benefit of our creditors or if we are liquidated. If any of our relationships with these
third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and
requires our management&#146;s time and focus. In addition, there is a natural transition period when a new CRO, investigator or other third party contractor commences work. As a result, delays occur, which can materially impact our ability to meet
our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these
delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of
Our Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive marketing approval for any product candidate, we will be subject to ongoing regulatory obligations
and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be
subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following potential approval of any our product candidates, the FDA may impose significant restrictions on a product&#146;s indicated uses or
marketing or impose ongoing requirements for potentially costly and time consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product, may contain significant limitations related to
use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS, as a condition of approval of our product
candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition,
if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advertising, promotion, import, export recordkeeping, and other activities relating to our products will be subject to extensive and ongoing regulatory requirements. These requirements include
submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post- approval. Manufacturers of approved products and their
facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. Later discovery of previously unknown problems with our products,
including additional adverse events or adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitutions, disgorgement of profits or revenues, civil money penalties, warning letters, untitled
letters or holds on clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
and could require us to expend significant time and resources in response and could generate negative publicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if any of
our product candidates are approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products.
In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless, in their independent
medical judgment, prescribe it to their patients in a manner that is inconsistent with the approved label. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#146;s
communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability.
The FDA, the Department of Justice, and other governmental authorities actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly
promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant sanctions. For example, the federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined
several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into corporate integrity agreements, consent decrees or permanent injunctions under which specified
promotional conduct is changed or curtailed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional
government regulations may be enacted that could prevent, limit or delay marketing approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we
are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation that may
arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, the current U.S.
administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight
activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and
the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our
business may be negatively impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects,
financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The commercial success of our product candidates will depend upon the degree of market acceptance of
such product candidates by physicians, patients, healthcare payors and others in the medical community. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product candidates
may not be commercially successful. Even if any of our product candidates receive marketing approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our
current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of
factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstration of clinical efficacy and safety compared to other more-established products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indications for which our product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limitation of our targeted patient population and other limitations or warnings contained in any <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> labeling; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of a new drug for the relevant indication by healthcare providers and their patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in
relation to alternative treatments and therapies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government
healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of our products as well as competitive drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our or any of our current or potential future collaborators&#146; sales and marketing
strategies; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable publicity relating to the product. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or
patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources
and may never be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products,
and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate
product revenue. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any
of our product candidates ultimately receives marketing approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be
expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution
systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and
incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our
internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales,
marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and
distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not
successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health
insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability
to generate revenue. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as
Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable
levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Moreover, we are initially developing <FONT STYLE="white-space:nowrap">TYRA-300</FONT> for the treatment
of MIBC, an indication with a small patient population. In order for products that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such products must be higher, on a relative basis, to account for
the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate with a smaller patient population that accounts for the smaller potential market size. Even if we obtain coverage for
a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. For products administered under the
supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or
procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or
eliminated in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and
Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among
third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require
us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and
regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may
refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to
reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for
our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product
development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on products that we may
develop, once approved. In addition, in the event that we or third parties develop companion diagnostic tests for use with our products, once approved, such companion diagnostic tests will require coverage and reimbursement separate and apart from
the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement applicable to pharmaceutical or biological products will apply to companion diagnostics tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market
regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products, once approved. In many countries, the prices of medical
products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or
other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products, once approved, may be reduced compared with the United
States and may be insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and
third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide
adequate payment for our products, once approved. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations
and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being
erected to the entry of new products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition, and if our competitors develop technologies or product candidates
more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong
emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products or product candidates competitive with our product candidates. Any product candidates that we successfully
develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the
future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in the precision oncology field. Our competitors include larger and better-funded pharmaceutical,
biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also
compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing
clinical trial sites, enrolling patients for clinical trials and in identifying and <FONT STYLE="white-space:nowrap">in-licensing</FONT> new product candidates. Smaller or early stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to face competition from existing
products and products in development for each of our product candidates. There are three currently approved <FONT STYLE="white-space:nowrap">pan-FGFR</FONT> inhibitors: Incyte Corporation&#146;s
Pemazyre<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pemigatinib) and QED Therapeutics&#146; Truseltiq<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (infigratinib), approved in FGFR2 gene rearrangements in
cholangiocarcinoma, and Janssen Biotech, Inc.&#146;s Balversa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (erdafitinib), approved in specific FGFR3 and FGFR2 gene alterations. There are a number of other pan-FGFR programs in
development for FGFR2 and FGFR3-specific populations, including, among others, Taiho Oncology, Inc.&#146;s TAS-120 (futibatinib), Bayer Pharmaceutical&#146;s BAY 1163877 (Rogaratinib), as well as isoform specific FGFR inhibitors such as Relay
Therapeutics, Inc.&#146;s <FONT STYLE="white-space:nowrap">RLY-4008</FONT> and Kinnate Biopharma Inc.&#146;s KIN-3248. There are two approved RET inhibitors, Lilly&#146;s Loxo Oncology&#146;s
Retevmo<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> (selpercatinib) and Blueprint Medicines&#146; Gavreto<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> (pralsetinib), as well as programs in development such as Turning
Point&#146;s TPX-0046 and Boston Pharmaceuticals&#146; BOS172738. There are currently no approved FGFR4 inhibitors, but there are a number of FGFR4 programs in clinical development, including Blueprint Medicines&#146; BLU-554 (fisogatinib), H3
Biomedicines&#146; H3B-6527 and Novartis&#146; FGF401. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial, technical,
manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain marketing approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness
of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of marketing approvals for these products, the availability and cost of
manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or
marketed and sold more effectively than any products we may develop. Competitive products or technological approaches may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our
product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may
suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown.
Our projections of both the number of people who have these diseases, as well as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a
variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these indications. The total
addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates which receives marketing approval for these indications,
the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The
number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult
to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because some of our potential target populations are very
small, we may never achieve profitability despite obtaining such significant market share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend, in part, on our ability to
operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive marketing approval from applicable
regulatory authorities in foreign markets, and we may never receive such marketing approvals for any of our product candidates. To obtain separate marketing approval in many other countries we must comply with numerous and varying regulatory
requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our product candidates. If we obtain marketing approval of our product candidates and ultimately
commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for approval of drugs in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of additional third-party patent rights of potential relevance to our business;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters
including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business Operations and Industry </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results
to fall below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual operating results may fluctuate
significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development, marketing approval and
commercialization activities relating to our product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the
terms of our agreements with third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for any approved products, which may vary significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies or clinical trials for our product candidates or
competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results.
As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results as an indication of our
future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This variability and unpredictability could also result in our failing to meet the expectations of industry or
financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the
expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or
recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our
continued ability to attract, retain, manage and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, as well as our senior scientists and other members of our management team.
The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our preclinical studies and clinical trials or the commercialization of our product candidates.
Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services as expected. We do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have
adequate compensation for the loss of the services of these individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will need to expand and effectively manage our managerial,
operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified
management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among biopharmaceutical, biotechnology and other businesses, particularly in the San Diego County area. Our industry has
experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will
significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have recently substantially increased, and will need to continue to grow, the size and capabilities of our organization, and we may experience
difficulties in managing this growth. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have substantially increased our organization from four employees as of December 31,
2019 to 18&nbsp;full-time employees as of September 3, 2021, including 16 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, and as we transition into
operating as a public company, we expect to need to continue to add significant additional managerial, operational, sales, marketing, financial and other personnel. Future growth will impose significant added responsibilities on members of
management, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, maintaining, retaining and motivating our current and additional employees;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the preclinical, clinical, the FDA or comparable
foreign regulatory authorities&#146; review process for product candidates, while complying with any contractual obligations to contractors and other third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing increasing operational and managerial complexity; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improving our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to successfully develop and, if approved, commercialize product
candidates developed from our FGFR and RET programs and other product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away
from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time to managing these growth activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we
may not be able to successfully implement the tasks necessary to further develop and commercialize <FONT STYLE="white-space:nowrap">TYRA-300</FONT> and any of our other product candidates and, accordingly, may not achieve our research, development
and commercialization goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to various federal, state and foreign healthcare laws and regulations, which could increase compliance
costs, and our failure to comply with these laws and regulations could harm our results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and
customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval.
Such laws include, without limitation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which is a criminal law that prohibits, among other things, persons or
entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the
referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program
such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which
prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or
used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and
civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics
and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information
related to payments and other &#147;transfers of value&#148; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by such
healthcare professionals and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided, as well as ownership and investment
interests held, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; some state laws require biopharmaceutical and
biotechnology companies to comply with the industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and
other transfers of value to physicians and other healthcare providers or marketing expenditures; some state laws that require biopharmaceutical and biotechnology companies to report information on the pricing of certain drug products; and some state
and local laws require the registration or pharmaceutical sales representatives. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current and future business arrangements with third parties will
comply with applicable healthcare laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain arrangements with physicians who receive stock
or stock options as compensation for services provided to us, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in
violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from
participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring
of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against
us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal,
civil or administrative sanctions, including exclusions from government funded healthcare programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We, our future collaborators and our service
providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and
otherwise harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to laws and regulations governing the privacy and security of sensitive information,
including confidential business and patient health information. The global data protection landscape is rapidly evolving, and we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our
operations continue to expand or if we operate in foreign jurisdictions. These laws and regulations may be subject to differing interpretations, which adds to the complexity of processing personal data. Guidance on implementation and compliance
practices are often updated or otherwise revised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, there are numerous federal and state privacy and data security
laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and state consumer
protection laws. Each of these laws is subject to varying interpretations and constantly evolving. By way of example, HIPAA imposes privacy and security requirements and breach reporting obligations with respect to individually identifiable health
information upon &#147;covered entities&#148; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or transmit protected
health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the U.S. Department of Health and Human Services, or HHS, affected individuals
and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to
significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA <FONT
STYLE="white-space:nowrap">non-compliance.</FONT> Even when HIPAA does not apply, according to the Federal Trade Commission, or FTC, failing to take appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or
practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act, or the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the
sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive
data that merits stronger safeguards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, certain state laws govern the privacy and security of health information in certain
circumstances, some of which are more stringent than HIPAA and many of which differ from each other in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant ways and may not have the same effect, thus complicating compliance efforts. By way of example, the California Consumer Privacy Act, or CCPA, which went into effect on January&nbsp;1,
2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for
civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, in November 2020, California
voters approved the California Privacy Rights Act, or CPRA, through a ballot measure. The CPRA will amend the CCPA, giving California residents additional control over their personal information and imposing further obligations on businesses
processing the personal information of California residents. The CPRA includes the creation of a privacy-specific enforcement agency, the first of its kind in any U.S. state, which will be responsible for enforcing the new law. The CPRA takes effect
on January&nbsp;1, 2023. More recently, Virginia adopted a generally applicable privacy law, and other states are considering similar steps. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These laws subject us to increased regulatory scrutiny, litigation, and overall risk. State laws are changing rapidly and there is discussion
in Congress of a new federal data protection and privacy law to which we would become subject, if it is enacted. Without an overarching federal law driving privacy compliance in the United States, however, the risk is high of a patchwork of privacy
legislation formed by individual state laws, similar to the patchwork created by differing state data breach notification obligations. Requirements to comply with varying state laws not only increase costs for compliance, but also create the
potential for enforcement by individual state attorneys general. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the European Union, in May 2018, a new privacy regime, the General
Data Protection Regulation, or GDPR, took effect in the European Economic Area, the EEA. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European persons. The GDPR introduced new requirements for
the protection of personal data subject to GDPR and provides for substantial fines for <FONT STYLE="white-space:nowrap">non-compliance,</FONT> including fines up to the greater of EUR 20&nbsp;million or 4% of a company&#146;s annual global revenues.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The withdrawal of the UK from the EU further complicated European compliance obligations, as we must also comply with data privacy and
security laws in effect in the UK that are substantially similar to the GDPR. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in
place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us
to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United
States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and
reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state
levels that seek to reduce healthcare costs and improve the quality of healthcare. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For example, in March 2010, the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, was enacted in the United States. Among the provisions of the ACA of importance to our potential product candidates, the ACA: established an
annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in
Medicaid managed care organizations; expanded eligibility criteria for Medicaid programs; expanded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the entities eligible for discounts under the 340B drug pricing program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; created a new
Medicare Part D coverage gap discount program; established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and
established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme
Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#146;s decision, President Biden issued an executive order to
initiate a special enrollment period from February&nbsp;15, 2021 through August&nbsp;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to
review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the healthcare reform measures of the Biden administration and other efforts, if any, to repeal and replace the ACA will impact the ACA or our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. Most recently,
in March 2021, Congress enacted the American Rescue Plan Act of 2021, which, among other things, eliminated the statutory cap on drug manufacturers&#146; Medicaid Drug Rebate Program rebate liability, effective January 1, 2024. Under current law
enacted as part of the ACA, drug manufacturers&#146; Medicaid Drug Rebate Program rebate liability is capped at 100% of the average manufacturer price for a covered outpatient drug. On August&nbsp;2, 2011, the Budget Control Act of 2011 was signed
into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect
into 2031, with the exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2021, unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law,
which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost
of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. Although a number of these and other measures may require additional authorization to become effective, Congress and the
current U.S. administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate
demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that the ACA, these new laws and other healthcare reform measures that may be
adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product.
Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able
to generate revenue, attain profitability or commercialize our product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and any of our third-party manufacturers or
suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We and any of our third-party suppliers and potential future collaborators will use biological materials, potent chemical agents and may use
hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce
hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be
expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific
biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the
event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or marketing approvals could be suspended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance for certain costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in
connection with our storage or disposal of biologic, hazardous or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in
order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production
efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit
commercialization of our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as a result of the clinical trials of our
product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of
warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or
cease the commercialization of our products. Even a successful defense would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of our management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant negative financial impact; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in our stock price. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently do not hold product liability insurance coverage, but will need to obtain this insurance coverage prior to commencing clinical
trials of our product candidates. We may need to increase our insurance coverage as we initiate additional clinical trials or if we commence commercialization of our product candidates, if ever. Insurance coverage is increasingly expensive. Our
inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we expect to obtain
and maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance
coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our
coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter, including product liability insurance. Some
of the policies we currently maintain include property, general liability, employment benefits liability, business automobile workers&#146; compensation, directors&#146; and officers&#146;, employment practices and fiduciary liability insurance. We
do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and any of our potential future collaborators will be required to report to regulatory authorities if any of our product candidates
or approved products in clinical trials cause or contribute to certain adverse medical events, and any failure to do so would result in sanctions that would materially harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA or comparable foreign regulatory authorities would require that we and potential future collaborators report certain information about
adverse medical events relating to any product that is approved or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidate in clinical trials. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of
our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a comparable foreign
regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of any of our CROs, other contractors or consultants or potential future collaborators, may fail or suffer
security breaches, which could result in a material disruption of our product development programs, harm our reputation, significant fines, penalties and liability and loss of customers or sales. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection,
distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the collection, use, and
dissemination of such data. In the ordinary course of business, we collect, store, transmit and otherwise process large amounts of data including, without limitation, proprietary business information and personal information. Despite the
implementation of security measures, our internal technology systems (including infrastructure) and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses,
cybersecurity threats (such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, cyber-attacks or cyber-intrusions over the Internet, hacking, phishing and other social engineering attacks),
unauthorized access or use, natural disasters, terrorism, war and telecommunication and electrical failures. Our systems are also subject to compromise from internal threats, such as theft, misuse, unauthorized access or other improper or accidental
actions by employees, vendors and other third parties with otherwise legitimate access to our systems. Third parties may also attempt to fraudulently induce our employees and contractors into disclosing sensitive information such as usernames,
passwords or other information, or otherwise compromise the security of our electronic systems, networks, and/ or physical facilities in order to gain access to our data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Given the unpredictability of the timing, nature and scope of information technology disruptions, there can be no assurance that any security
procedures and controls that we or our third-party partners and service providers have implemented will be sufficient to prevent cyber-attacks from occurring. The latency of a compromise is often measured in months, but could be years, and we may
not be able to detect a compromise in a timely manner. New techniques may not be identified until they are launched against a target, and we may be unable to anticipate these techniques or detect an incident, assess its severity or impact, react or
appropriately respond in a timely manner or implement adequate preventative measures, resulting in potential data loss or other damage to our information technology systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a security breach were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to
personally identifiable information or individually identifiable health information (violating certain privacy laws such as GDPR), it could result in a material disruption of our development programs and our business operations, whether due to a
loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable
information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Also, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, all of
our employees are working remotely. As a result, we may have increased cyber security and data security risks, due to increased use of home <FONT STYLE="white-space:nowrap">wi-fi</FONT> networks and virtual private networks, as well as increased
disbursement of physical machines. While we implement IT controls to reduce the risk of a cyber security or data security breach, there is no guarantee that these measures will be adequate to safeguard all systems, especially with an increased
number of employees working remotely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any security breach or other incident, whether real or perceived, could impact our reputation,
impact the integrity of our data, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in
delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also
have a material adverse effect on our business. To the extent that any real or perceived disruption or security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result
in a loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and
security laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to risks arising from <FONT STYLE="white-space:nowrap">COVID-19&nbsp;and</FONT> other epidemic diseases.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> worldwide pandemic has presented substantial public health and economic
challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. A pandemic, including
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> or other public health epidemic, poses the risk that we or our employees, contractors, including our CROs, suppliers, collaborators and other partners may be prevented from conducting business
activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. International and U.S. governmental authorities in impacted
regions are taking actions in an effort to slow the spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including issuing varying forms of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;stay-at-home&#148;</FONT></FONT> orders, and restricting business functions outside of one&#146;s home. In response, we have closed our executive offices with our administrative
employees continuing their work remotely and limited the number of staff in our research and development laboratories. To date we have not experienced material disruptions in our business operations. However, while it is not possible at this time to
estimate the impact <FONT STYLE="white-space:nowrap">that&nbsp;COVID-19&nbsp;could</FONT> have on our business in the future, particularly as we advance our product candidates to clinical development, the continued spread <FONT
STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;and</FONT> the measures taken by the governmental authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of drug substances and
finished drug products for our product candidates for use in our research, preclinical studies and clinical trials, delay, limit or prevent our employees and CROs from continuing research and development activities; impede our clinical trial
initiation and recruitment and the ability of patients to continue in clinical trials, including the risk that participants enrolled in our clinical trials will contract <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other epidemic disease
while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and impede testing, monitoring, data collection and analysis and other related activities, any
of which could delay our preclinical studies and clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations.
<FONT STYLE="white-space:nowrap">The&nbsp;COVID-19&nbsp;pandemic</FONT> and any future epidemic disease could also potentially affect the business of the FDA or comparable foreign regulatory authorities, which could result in delays in meetings
related to planned clinical trials. <FONT STYLE="white-space:nowrap">The&nbsp;COVID-19&nbsp;pandemic</FONT> and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global
economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT>
impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business could be affected by litigation, government investigations and enforcement actions. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We operate in a highly regulated industry and we could be subject to litigation, government investigation and enforcement actions on a variety
of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims, privacy, anti-kickback, anti-bribery, securities, commercial,
employment and other claims and legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceedings which may arise from conducting our business. Any determination that our operations or activities are not in compliance with existing laws or regulations could result in the
imposition of fines, civil and criminal penalties, product seizure, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Legal proceedings, government investigations and enforcement actions can be expensive and time consuming. An adverse outcome
resulting from any such proceeding, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare or regulatory debarment, injunctive relief, product
recalls, reputational damage and modifications of our business practices, which could have a material adverse effect on our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees and
independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of
unauthorized activities to us that violate: (i)&nbsp;the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the recording and reporting of true, complete and accurate information to such
authorities, (ii)&nbsp;manufacturing standards, including cGMP requirements, (iii)&nbsp;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (iv)&nbsp;laws that
require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of
fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory consequences or sanctions and cause serious harm to our reputation. It is not always possible to identify and
deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such
actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of
significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, contractual damages, reputational
harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of intellectual property, products or technologies. Additional potential transactions that we may consider in the future include a variety of
business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could increase our near and long-term expenditures, result in
potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development
expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may
never be successful </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and may require significant time and attention of our management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a
complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature
described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity
and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and
confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity
and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse
effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other
partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. tax law may materially adversely affect our financial condition, results of operations and cash flows. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, the CARES Act was signed into law to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> crisis. The CARES
Act is an approximately $2 trillion emergency economic stimulus package that includes numerous U.S. federal income tax provisions, including the modification of: (i)&nbsp;net operating loss, or NOL, rules (as discussed below), (ii) the alternative
minimum tax refund and (iii)&nbsp;business interest deduction limitations under Section&nbsp;163(j) of the Internal Revenue Code of 1986, as amended, or the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and Jobs Act of 2017, or the Tax Act, also significantly changed the U.S. federal income taxation of U.S. corporations. We
continue to work with our tax advisors and auditors to determine the full impact the Tax Act and the CARES Act will have on us. We urge our investors to consult with their legal and tax advisors with respect to both the Tax Act and the CARES Act and
the potential tax consequences of investing in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use net operating loss carryforwards and other tax attributes may
be limited in connection with this offering or other ownership changes. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred substantial losses during our history,
do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses
expire (if at all). At December&nbsp;31, 2020, we had federal and state NOL carryforwards of approximately $11.7&nbsp;million and $3.7&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Tax Act, federal NOL carryforwards generated in periods after December&nbsp;31, 2017, may be carried forward indefinitely. Under the
CARES Act, NOL carryforwards arising in tax years beginning after December&nbsp;31, 2017 and before January&nbsp;1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss. Because we had no taxable income in our
tax year ended December&nbsp;31, 2020, which was our third corporate tax year, we do not anticipate that such provision of the CARES Act will be relevant to us. The ability to use federal NOL carryforwards to offset taxable income, particularly for
tax years beginning after December&nbsp;31, 2020, may be limited. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our NOL carryforwards are subject to review and possible adjustment by the IRS,
and state tax authorities. Under Section&nbsp;382 of the Code, our federal NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership of our company. An &#147;ownership change&#148;
pursuant to Section&nbsp;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#146;s stock increase their ownership by more than 50 percentage points over their lowest ownership
percentage within a rolling three-year period. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in
connection with this offering. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from this offering or other transactions, or any resulting limitations on our
ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future income tax liability to us and our future cash flows could be adversely affected. We have recorded a full
valuation allowance related to our NOL carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to obtain and maintain patent protection for our product candidates and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and
commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and other proprietary technologies we may develop may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our product candidates and other proprietary technologies we may develop as well as our ability to operate without infringing upon the proprietary rights of others. We seek to protect our proprietary position, in part, by filing patent
applications in the United States and abroad relating to our product candidates and other proprietary technologies we may develop. If we are unable to obtain or maintain patent protection with respect to our product candidates and other proprietary
technologies we may develop, our business, financial condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Changes
in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value
of our intellectual property or narrow the scope of our protection. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will
provide sufficient protection against competitors or other third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming,
and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of
our research and development output in time to obtain patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects
of our research and development output, such as our employees, CROs, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing
our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior
art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in
some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our pending patent applications, or that we were the first to file for patent protection of such inventions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The patent position of biopharmaceutical and biotechnology companies generally is highly
uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our
patent applications may not result in patents being issued which protect our product candidates and other proprietary technologies we may develop or which effectively prevent others from commercializing competitive technologies and products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, the claim coverage in a patent application can be significantly reduced before the patent is granted. Even if our patent
applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents
issuing from our patent applications may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether our product candidates and other proprietary technology will be protectable or remain protected by
valid and enforceable patents. Even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition, results of operations and prospects. In addition, given the amount of time required for the development, testing
and regulatory review of our product candidates, patents protecting the product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient
rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its
inventorship, scope, validity, or enforceability and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of
prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, post- grant and inter partes review, or other similar proceedings challenging our patent rights. An
adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and other proprietary
technologies we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Such proceedings also may result in substantial cost
and require significant time from our scientists and management, even if the eventual outcome is favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not own or license any
issued patents and substantive examination has not begun on any of our pending patent applications, which makes it is difficult to forecast the extent of any future patent rights. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot be certain that the claims in our U.S. pending patent applications or corresponding international patent applications, or future
patent applications in certain foreign territories, will be considered patentable by the USPTO. Patent claims are subject to revision during prosecution and pending patent applications cannot be enforced against third parties practicing the
technology claimed in such applications unless, and until, patents issue from such applications, which will likely be several years from now, and then only to the extent the issued claims cover the third party&#146;s technology. There can be no
assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology. At present, we have only filed U.S. provisional patent applications and
international patent applications under the Patent Cooperation Treaty, or the PCT. None of our patent applications have entered substantive examination by a patent office, which makes it impossible at this time to gauge which art will be cited by
examiners or the extent of any rejections we may receive. For example, examiners at a patent office may uncover prior art of which we were not previously aware, and if this cited prior art encompasses our claimed inventions, it may restrict
patentability or prevent allowance of any pending patent claims. Furthermore, the patent prosecution process is expensive, time-consuming, and often a multi-year process. We and any future licensors may not be able to file and prosecute all
necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially advantageous. Therefore, we cannot be certain that we will own any issued patents or develop a patent portfolio, which could have a material adverse effect on our business, financial
condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the
world. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our product candidates and other proprietary technologies we may develop in
all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from
practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where
we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products
may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical
products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In India, unlike the United States, there is no
link between regulatory approval for a drug and its patent status. In addition, some jurisdictions, such as Europe, Japan and China, may have a higher standard for patentability than in the United States, including, for example, the requirement of
claims having literal support in the original patent filing and the limitation on using supporting data that is not in the original patent filing. Under those heightened patentability requirements, we may not be able to obtain sufficient patent
protection in certain jurisdictions even though the same or similar patent protection can be secured in U.S. and other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert
our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims
against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the
world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many countries have
compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the
patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired,
and our business, financial condition, results of operations and prospects may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent
protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity
fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and applications. The USPTO and various <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> government agencies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by
payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application,
resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse
effect on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents
in general, thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the
patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Since March 2013, under the Leahy-Smith America Invents Act, or the
America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled
to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering
an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United
States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&nbsp;file any patent application related to our product candidates and other proprietary
technologies we may develop or (ii)&nbsp;invent any of the inventions claimed in our patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The America Invents Act also
includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and
additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared
to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence
would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged
by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense
of patents issuing from those patent applications, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. For example, the scope of patentable subject matter under
35&nbsp;U.S.C.&nbsp;101 has evolved significantly over the past several years as the Court of Appeals for the Federal Circuit and the Supreme Court issued various opinions, and the USPTO modified its guidance for practitioners on multiple occasions.
This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing
patents could change in unpredictable ways that could have a material adverse effect on our ability to protect and enforce our intellectual property in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents relating to our product candidates and other proprietary technologies we may develop
could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
we initiated legal proceedings against a third party to enforce a patent relating to our product candidates and other proprietary technologies we may develop, the defendant could counterclaim that such patent is invalid or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a
misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of a patent before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms
include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the
revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our product candidates and other proprietary technologies we may develop. The outcome following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to
prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates and other proprietary technologies we may develop. Such a loss of patent protection
would have a material adverse impact on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to
protect our competitive position on our product candidates for an adequate amount of time. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In
the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&nbsp;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the
protection it affords, is limited. Even if patents relating to our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development,
testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to
exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term extension for our product candidates,
our business may be materially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval of any
product candidate we may develop, one or more of patents issuing from our U.S. patent applications may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or the Hatch-Waxman
Amendments. The Hatch-Waxman Amendments permit a patent extension term, or PTE, of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent
beyond a total of 14&nbsp;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar patent term
restoration provisions to compensate for commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate, or SPC. If we encounter delays in our
development efforts, including any clinical trials, the period of time during which we could market any future product candidates under patent protection would be reduced. Additionally, we may not receive an extension if we fail to apply within
applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
less than we request. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to
exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patent rights, trade secrets,
or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our
product candidates and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, trade secrets or other intellectual property. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other
proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our
trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to seeking patent protection for our product
candidates and other proprietary technologies we may develop, we also rely on trade secrets and confidentiality agreements to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, and other proprietary information and
to maintain our competitive position. With respect to our development programs, we consider trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be one of our important sources of intellectual property, including our extensive
knowledge of crystallography structure-based drug design. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. In particular, the trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> in
connection with our development programs and other proprietary technology we may develop may over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the
movement of personnel with scientific positions in academic and industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We seek to protect these trade secrets and other proprietary
technology, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, CROs, consultants, advisors and other third parties. We also
enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or
proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or
unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete
with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that third parties have an ownership interest in our trade secrets. For example, we may have disputes arise from
conflicting obligations of our employees, consultants or others who are involved in developing our product candidate. Litigation may be necessary to defend against these and other claims challenging ownership of our trade secrets. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable trade secret rights, such as exclusive ownership of, or right to use, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trade secrets that are important to our product candidates and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result
in substantial costs and be a distraction to our management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may need to share our proprietary information,
including trade secrets, with our current and future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors,
and those affiliated with or controlled by state actors. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining necessary rights to any product candidate we may develop through acquisitions and
<FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently solely own intellectual property rights covering our product
candidates. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it
necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any
compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our product candidates and other proprietary technologies we may develop. The licensing or acquisition of third-party
intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies
may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license
rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required
third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or advisors have wrongfully
used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of our employees, consultants and advisors are currently or were previously employed at universities or other biopharmaceutical or
biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others
in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer.
Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to our management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, while it is our
policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to
bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition,
results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement, misappropriation or other violations against
us or our collaborators may prevent or delay the development and commercialization of our product candidates and other proprietary technologies we may develop. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability to avoid infringing, misappropriating and otherwise violating the patents and other
intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biopharmaceutical and biotechnology industries, as well as administrative proceedings
for challenging patents, including derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, as a result of the America Invests Act, procedures including
inter partes review and post-grant review have been implemented. The America Invents Act adds uncertainty to the possibility of challenge to our patents in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are
commercializing or plan to commercialize our product candidates and in which we are developing other proprietary technologies. As the biopharmaceutical and biotechnology industries expand and more patents are issued, the risk increases that our
product candidates and commercializing activities may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates and other proprietary technologies we may develop will not infringe existing
or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert as infringed by
us. It is also possible that patents owned by third parties of which we are aware, but which we do not believe we infringe or that we believe we have valid defenses to any claims of patent infringement, could be found to be infringed by us. It is
not unusual that corresponding patents issued in different countries have different scopes of coverage, such that in one country a third-party patent does not pose a material risk, but in another country, the corresponding third-party patent may
pose a material risk to our planned products. As such, we monitor third-party patents in the relevant pharmaceutical markets. In addition, because patent applications can take many years to issue and may be confidential for 18 months or more after
filing, there may be currently pending patent applications that may later result in issued patents that we may infringe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event
that any third party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of
competent jurisdiction could hold that such patents are valid, enforceable and infringed by us. In this case, the holders of such patents may be able to block our ability to commercialize the infringing products or technologies unless we obtain a
license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a
license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to
obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize the infringing products or technologies or such commercialization efforts may be significantly delayed, which could in turn
significantly harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology in the future, our collaborators
may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us
to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial
collaborators against certain intellectual property infringement claims brought by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Defense of infringement claims,
regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products or technologies. In
addition, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products or technologies,
which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidate or technologies, which could harm our business significantly. Further, we
cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop our product candidate and
commercialize our product, if approved, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be
nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of
actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Engaging in litigation
defending against third parties alleging infringement of patent and other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of
litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and
continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of
invalidity is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be
public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our
common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other
resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. If we do not prevail in the patent
proceedings the third parties may assert a claim of patent infringement directed at our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to
protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third parties, such as a competitor, may infringe, misappropriate, or otherwise violate our future issued patents and other intellectual
property rights. In a patent infringement proceeding, a court may decide that a patent owned by us is invalid or unenforceable or may refuse to stop the other party from using the invention at issue on the grounds that the patent does not cover the
technology in question or that the other party&#146;s use of our patented technology falls under the safe harbor to patent infringement under 35&nbsp;U.S.C.&nbsp;&#167;271(e)(1). In addition, our patent rights may become involved in inventorship,
priority or validity disputes. To counter or defend against such claims can be expensive and time consuming. An adverse result in any litigation proceeding could put our patent rights at risk of being invalidated or interpreted narrowly.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct
such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed
intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not
advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#146;s or potential competitor&#146;s product or
service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing any patents that
may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our
stockholders. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue any clinical trials, continue our internal research programs, in-license needed technology or other product
candidates, or enter into development partnerships that would help us bring our product candidates to market. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other
non-litigious action or solution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition
in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks or trade names
may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions.
Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose
pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. Moreover, any name we have proposed to use with our
product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed
product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to
expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many
countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners
or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition,
there could be potential trade name or trademark </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if
we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to
trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to our product candidate or utilize similar technology but
that are not covered by the claims of the patents that we may license or may own; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to make the inventions covered by our current or future patent applications;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to file patent applications covering our inventions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our current or future patent applications will not lead to issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any patent issuing from our current or future patent applications may be held invalid or unenforceable, including
as a result of legal challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we do
not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file for patent protection in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through
acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The growth of our business may depend in part on our
ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use third-party proprietary component and process rights. For example, our product candidates may require specific formulations to work effectively and efficiently, we may
develop product candidates containing our compounds and <FONT STYLE="white-space:nowrap">pre-existing</FONT> pharmaceutical compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic
test or tests with our product candidates, any of which could require us to obtain rights to use intellectual property held by third parties. We plan to work with diagnostic companies to use liquid biopsy companion diagnostic tests to aid in
identifying appropriate patients </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the initial clinical trial. In addition, with respect to any patents we may <FONT STYLE="white-space:nowrap">co-own</FONT> with third parties, we may require licenses to such <FONT
STYLE="white-space:nowrap">co-owners</FONT> interest to such patents. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights
from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use
of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and
development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which means that our competitors may also
receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, we might sometimes collaborate with academic institutions to accelerate our preclinical research or development under written
agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Even if we hold such an option, we may
be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our
ability to pursue our program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party intellectual property rights is a competitive area, and
companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our
product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor
may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product
candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of
certain programs and our business financial condition, results of operations and prospects could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We, our collaborators and our service
providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and
otherwise harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may maintain a large quantity of sensitive information, including confidential business and
patient health information in connection with our preclinical studies, and are subject to laws and regulations governing the privacy and security of such information. The global data protection landscape is rapidly evolving, and we may be affected
by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. These laws and regulations may be subject to differing interpretations, which
adds to the complexity of processing personal data. Guidance on implementation and compliance practices are often updated or otherwise revised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use,
disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and state consumer protection laws. Each of these laws is subject to
varying interpretations and constantly evolving. By way of example, HIPAA imposes privacy and security requirements and breach reporting obligations with respect to individually identifiable health information upon &#147;covered entities&#148;
(health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or transmit protected health information in connection with providing a
service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
HHS, affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a
complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and
corrective action plan with HHS to settle allegations of HIPAA <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Even when HIPAA does not apply, according to the FTC failing to take appropriate steps to keep consumers&#146; personal
information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5(a) of the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#146;s data security measures to be reasonable and appropriate in
light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered
sensitive data that merits stronger safeguards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, certain state laws govern the privacy and security of health information in
certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. By way of example, the CCPA, which went into
effect on January&nbsp;1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is
used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some
observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the European Union, in May 2018, a new privacy regime, the GDPR, took effect in the EEA. The GDPR governs the collection, use, disclosure,
transfer or other processing of personal data of European persons. Among other things, the GDPR imposes new requirements regarding the security of personal data and notification of data processing obligations to the competent national data
processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and
investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having
&#147;adequate&#148; data protection laws, and imposes substantial fines for breaches and violations (up to the greater of &#128;20&nbsp;million or 4% of our consolidated annual worldwide gross revenue). The GDPR also confers a private right of
action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Moreover, the United Kingdom leaving the EU could
also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be
regulated, especially following the United Kingdom&#146;s departure from the EU on January&nbsp;31, 2020. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force following the
United Kingdom&#146;s departure from the EU. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms
ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and This Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no public market for our common stock and an active, liquid and orderly market for our common stock may not develop, and you may not be
able to resell your common stock at or above the public offering price. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market
for our common stock. Although our common stock has been approved for listing on the Nasdaq Global Select Market, or Nasdaq, an active trading market for our common stock may never develop or be sustained following this offering. We and the
representatives of the underwriters will determine the initial public offering price of our common stock through negotiations and the negotiated price may not be indicative of the market price of our common stock after this offering. This price will
not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. In addition, an active trading market may not develop following the consummation of this offering or, if it is
developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital
by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in
particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public
offering price. The market price for our common stock may be influenced by those factors discussed in this &#147;Risk Factors&#148; section and many others, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of our preclinical studies and clinical trials, and the results of trials of our competitors or those of
other companies in our market sector; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll patients in our future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marketing approval of our product candidates, or limitations to specific label indications or patient populations
for its use, or changes or delays in the regulatory review process; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success or failure of our efforts to develop, acquire or license additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">innovations, clinical trial results, product approvals and other developments regarding our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or
capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing, supply or distribution delays or shortages; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achievement of expected product sales and profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the biopharmaceutical sector and issuance of securities analysts&#146; reports or
recommendations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our stock by insiders and stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any natural disasters or public health emergencies, such as the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property, product liability or other litigation against us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of
volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert our management&#146;s attention and resources, which could have a material adverse effect
on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may allocate the net proceeds from this offering in ways that you and other
stockholders may not approve. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this
offering, including for any of the purposes described in the section titled &#147;Use of Proceeds.&#148; Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary
substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our
business. Pending their use, we may invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S.
government. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause
our stock price to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase.
</I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible
book value per share of our outstanding common stock immediately after the completion of this offering. Purchasers of common stock in this offering will experience immediate dilution of approximately $8.44 per share, based upon the initial public
offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. In the past, we issued options to acquire common stock at prices significantly below the initial public offering price. To
the extent these outstanding options are ultimately exercised, investors purchasing common stock in this offering will sustain further dilution. For a further description of the dilution that you will experience immediately after this offering, see
&#147;Dilution.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After this offering, our executive officers, directors and principal stockholders, if they choose to
act together, will continue to have the ability to significantly control or influence all matters submitted to stockholders for approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our executive officers, directors and greater than 5% stockholders, in the aggregate, will own
approximately 60.5% of our outstanding common stock (assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options and no purchases of shares in this offering or the reserved share program
by any of this group). As a result, such persons, acting together, will have the ability to significantly control or influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management,
the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding
a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other
stockholders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your
investment will depend on appreciation, if any, in the price of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash
dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any
return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur
could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on shares of common stock outstanding as of June&nbsp;30, 2021, upon the completion of this offering, we will have outstanding a total
of 39,115,139&nbsp;shares of common stock, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of these shares, only the 9,000,000&nbsp;shares of common stock sold in this
offering by us, plus any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable, without restriction, in the public market immediately following this offering, unless they are purchased by
one of our affiliates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers and holders of substantially all of our outstanding securities have
entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or
dispose of any of our securities, without the prior written consent of BofA Securities, Inc., Jefferies LLC and Cowen and Company, LLC. The underwriters may permit our officers, directors and other securityholders who are subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time in their sole discretion. See &#147;Underwriting.&#148; Sales of these shares,
or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, up to an additional 30,115,139&nbsp;shares of common stock will be
eligible for sale in the public market, of which 25,539,007&nbsp;shares are held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, as of June&nbsp;30, 2021, 2,586,835&nbsp;shares of common stock that are subject to outstanding options under our employee
benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities
Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After this offering, the holders of 26,228,089&nbsp;shares of our outstanding common
stock, or approximately 67.1% of our total outstanding common stock based on shares outstanding as of June&nbsp;30, 2021, will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to vesting and
the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. See &#147;Description of Capital Stock&#151;Registration Rights.&#148; Registration of these shares under the Securities
Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a
material adverse effect on the trading price of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company and a smaller reporting company, and the
reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year
following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed
$1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five- year period. For so
long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited
interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting pursuant to the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules are necessary for protecting the
public; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have taken advantage of reduced reporting burdens
in this prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging
growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our
common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This
allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new
or revised accounting standards as other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also a smaller reporting company
as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less
than $100.0&nbsp;million during the most recently completed fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Participation in this offering by our existing stockholders and/or their
affiliated entities may reduce the public float for our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent certain of our existing stockholders and
their affiliated entities participate in this offering, such purchases would reduce the <FONT STYLE="white-space:nowrap">non-affiliate</FONT> public float of our shares, meaning the number of shares of our common stock that are not held by officers,
directors and controlling stockholders. A reduction in the public float could reduce the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock and depressing the price at
which you may be able to sell shares of common stock purchased in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time
to new compliance initiatives. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that we did
not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial
condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and
maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and
regulations in these areas, such as mandatory &#147;say on pay&#148; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of
government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently
anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial
compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business,
financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For
example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We
cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors, our board committees or as executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to U.S. and certain foreign export and import controls,
sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other
serious consequences for violations, which could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and
regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt
Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we
conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving,
directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a
commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated
hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have
actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments,
breach of contract and fraud litigation, reputational harm and other consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and
financial condition and increase our costs and expenses. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our operations could be subject to earthquakes, power shortages,
telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely
on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a
<FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. In addition, our corporate headquarters is located in Carlsbad, California near major earthquake faults and fire zones, and the ultimate impact on
us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and
increase our costs and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports or publish unfavorable research or reports
about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend in part
on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or
industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our stock, our
stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements
could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, our management will be required to report upon the effectiveness of our internal
control over financial reporting beginning with the annual report for our fiscal year ending December&nbsp;31, 2022. When we lose our status as an &#147;emerging growth company&#148; and reach an accelerated filer threshold, our independent
registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a
reporting company under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we
or, if required, our independent registered public accounting firm are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common
stock may decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control
over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to
conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once
that firm begin its Section&nbsp;404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by
Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict
our future access to the capital markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders
may consider favorable and may lead to entrenchment of management. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and
amended and restated bylaws that will be in effect immediately prior to the consummation of this offering will contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control
or changes in our management without the consent of our board of directors. The provisions in our charter documents will include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to
change the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect
director candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exclusive right of our board of directors, unless the board of directors grants such right to the
stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote
to remove a director for cause, and the prohibition on removal of directors without cause; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the
price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder
approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote
to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual
or special meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive
forum for certain actions and proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may
delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of
directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise
attempting to obtain control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also subject to the anti-takeover provisions contained in Section&nbsp;203
of the Delaware General Corporation Law. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among
other exceptions, the board of directors has approved the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our current amended and restated certificate of incorporation provides, and
our amended and restated certificate of incorporation will provide, that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders and that the federal district courts
shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our
directors, officers or employees or the underwriters or any offering giving rise to such claim. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current amended and restated
certificate of incorporation provides, and our amended and restated certificate of incorporation that will be in effect immediately prior to the consummation of this offering will provide, that the Court of Chancery of the State of Delaware is the
exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and
restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine, our amended and restated certificate of incorporation will also provide that
unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act,
including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving
rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. These choice of forum
provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors,
officers and other employees and result in increased costs for investors to bring a claim. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and
regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of
provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs
associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us, because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a
diversion of our management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent
or detect all errors or acts of fraud</I></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will become subject to the periodic reporting
requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and
recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to
substantial risks and uncertainties and are based on estimates and assumptions. All statements other than statements of historical facts contained in this prospectus, including statements concerning our future results of operations and financial
position, the timing and likelihood of success, plans and objectives of management for future operations, and business trends and other information contained in this prospectus are forward-looking statements, including statements about: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope and likelihood of regulatory filings and approvals, including timing of INDs and final FDA
approval of our current and future product candidates, including <FONT STYLE="white-space:nowrap">TYRA-300;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our preclinical studies and planned clinical trials to demonstrate safety and efficacy of our
product candidates, and other positive results; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of preclinical studies and planned clinical trials for our current product
candidates and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will
become available, and our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates, including <FONT
STYLE="white-space:nowrap">TYRA-300,</FONT> in any of the indications for which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of
any of our current and future product candidates, including <FONT STYLE="white-space:nowrap">TYRA-300;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to research, develop and commercialize our current and future product candidates, including <FONT
STYLE="white-space:nowrap">TYRA-300;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract, and negotiate favorable terms of, any collaboration, licensing or other arrangements that
may be necessary or desirable to develop, manufacture or commercialize our current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our continued reliance on third parties to conduct additional preclinical studies and planned clinical trials of
our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our current and future product candidates, including <FONT
STYLE="white-space:nowrap">TYRA-300;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our current and future product candidates, including <FONT
STYLE="white-space:nowrap">TYRA-300;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future
collaborators; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of the number of patients that we will enroll in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of our third-party suppliers and manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or become available; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our
business; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product
candidates and our ability to operate our business without infringing on the intellectual property rights of others. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
some cases, you can identify forward-looking statements by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target&#148; or &#147;will&#148; or the negative of these terms or other similar expressions intended to identify statements about the
future. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as
predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not
be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which
we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. You should read the
section titled &#147;Risk Factors&#148; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment.
New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this
prospectus will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances
or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the
registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements in this prospectus by
these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_6"></A>INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain market, industry and competitive data included in this prospectus were obtained from our own internal estimates and research, as well
as from publicly available information, reports of governmental agencies and academic and industry research, publications and surveys conducted by third parties. In some cases, we do not expressly refer to the sources from which this data is
derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated
or the context otherwise requires. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and involve a number of assumptions and limitations. While we believe
that the data we use from third parties are reliable, we have not separately verified this data. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our
industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. The industry in which we operate is subject to a high degree of uncertainty and risk due
to a variety of factors, including those described in the section of this prospectus titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent
parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from this offering will be approximately $121.9&nbsp;million, assuming an initial public offering
price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the
underwriters&#146; option to purchase additional shares from us is exercised in full, we estimate that our net proceeds will be approximately $140.7&nbsp;million, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which
is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $8.4&nbsp;million, assuming that the number of shares offered by us, as set forth
on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. A
1,000,000 share increase (decrease) in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering by approximately $14.0&nbsp;million, assuming that the assumed initial offering price of $15.00 per share,
which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a
change in the initial price to the public or the number of shares by these amounts would have a material effect on the uses of the proceeds from this offering, although it may accelerate the time at which we will need to seek additional capital.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for
our common stock and to facilitate our future access to the public equity markets. We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $18.9&nbsp;million to fund the development of <FONT STYLE="white-space:nowrap">TYRA-300,</FONT>
including through the completion of the Phase 1 portion of our planned Phase&nbsp;1/2 clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $19.4&nbsp;million to fund the development of our FGFR2 program, including through Phase&nbsp;1
clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $20.8&nbsp;million to fund the development of our FGFR3 program for achondroplasia, including
through advancement into the clinic; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder to fund the discovery and preclinical development of additional product candidates, as well as for
headcount costs, working capital and other general corporate purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may also use a portion of the net proceeds to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in additional businesses, technologies, products or assets, although currently we have no specific agreements, commitments or understandings in this regard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our planned use of the net proceeds from this offering and our current cash and cash equivalents, we estimate that such funds will
enable us to fund our operating expenses and capital expenditure requirements through at least 2024. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently
expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from this offering represents our current intentions based upon our present plans and
business conditions, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion
of this offering or the amounts that we will actually spend on the uses set forth above. Our existing cash as of the date of this prospectus, together with the estimated net proceeds from this offering, will not be sufficient to fund development of
our product candidates through regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval and commercialization, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. The amounts and timing of our
actual expenditures may vary significantly depending on numerous factors, including the time and cost necessary to conduct our ongoing and planned preclinical studies and planned clinical trials, the results of such studies and trials, as well as
any collaborations that we may enter into with third parties for our product candidates, and the amount of cash used in our operations and any unforeseen cash needs as well as other factors described in the section of this prospectus titled
&#147;Risk Factors&#148;. We may find it necessary or advisable to use the net proceeds for other purposes. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term and intermediate-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock.
We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our
board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our capitalization as of June&nbsp;30, 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the automatic conversion of all outstanding shares of our
convertible preferred stock into an aggregate of 26,228,089 shares of common stock upon the completion of this offering and the related reclassification of the carrying value of the convertible preferred stock to permanent equity immediately prior
to the completion of this offering, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, which will occur upon the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of 9,000,000 shares of our
common stock in this offering at an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information set forth above is
illustrative only and our cash and cash equivalents and capitalization following the completion of this offering will change based on the actual initial public offering price and other terms of this offering determined at pricing. You should read
the information in this table together with our financial statements and related notes included elsewhere in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro<BR>Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma<BR>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">257,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 50,000,000 shares authorized, 3,887,050 shares issued and&nbsp;2,374,351 shares
outstanding, actual; 500,000,000 shares authorized, 30,115,139 shares issued and 28,602,440 outstanding, pro forma; 500,000,000 shares authorized, 39,115,139 shares issued and 37,602,440 outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; no shares authorized, issued and outstanding, actual; 50,000,000
shares authorized and no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.0001 par value; 6,223,046 shares authorized; 6,223,046
shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.0001 par value; 3,874,793 authorized; 3,874,793 shares
issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
forma as adjusted amount of each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by
approximately $8.4&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us. We may also increase or decrease the number of shares we are offering. A 1,000,000 share increase (decrease) in the number of shares offered by us at the assumed initial public offering price per share of $15.00 per share,
which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT>
capital, total stockholders&#146; equity and total capitalization by approximately $14.0&nbsp;million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering pro forma and pro forma as adjusted reflected in the table
above excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,586,835 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2021
under the 2020 Plan, with a weighted-average exercise price of $2.88 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,570,000 shares of common stock reserved for future issuance under the 2021 Plan (including 1,032,150 shares of
common stock reserved for future grant or issuance under our 2020 Plan as of June&nbsp;30, 2021, which shares will be added to the shares reserved under the 2021 Plan upon its effectiveness), as well as any annual automatic increases in the number
of shares of our common stock reserved for future issuance under the 2021 Plan, which will become effective on the day prior to the public trading date of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">380,000 shares of our common stock reserved for future issuance under the ESPP, as well as any annual automatic
increases in the number of shares of our common stock reserved for future issuance under the ESPP, which will become effective on the day prior to the public trading date of our common stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) was $(22.7) million as of June&nbsp;30, 2021, or $(5.83) per share of our common stock, based
on 3,887,050 shares of common stock outstanding as of such date, including 1,512,699 shares of unvested restricted common stock. Our historical net tangible book value (deficit) per share represents the amount of our total tangible assets less total
liabilities and convertible preferred stock, which is not included in our stockholders deficit, divided by the total number of shares of common stock outstanding at June&nbsp;30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On a pro forma basis after giving effect to the automatic conversion of all outstanding shares of convertible preferred stock into an
aggregate of 26,228,089 shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity immediately prior to the completion of this offering, and assuming this conversion had
occurred on June&nbsp;30, 2021, our pro forma net tangible book value as of June&nbsp;30, 2021 would have been approximately $134.6&nbsp;million, or approximately $4.47&nbsp;per share of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After giving further effect to the sale of 9,000,000 shares of our common stock in this offering at the assumed initial public offering price
of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as
adjusted net tangible book value as of June&nbsp;30, 2021 would have been $256.5&nbsp;million, or approximately $6.56 per share. This amount represents an immediate increase in pro forma net tangible book value of $2.09 per share to our existing
stockholders and an immediate dilution in pro forma net tangible book value of approximately $8.44 per share to new investors participating in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering
from the assumed initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to the automatic conversion of preferred stock upon the completion
of this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share,
which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by approximately $0.21, and dilution in pro forma net
tangible book value per share to new investors by approximately $0.79, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estimated underwriting discounts and commissions and the estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase of 1,000,000
shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by approximately $0.18 and decrease the dilution to
investors participating in this offering by approximately $0.18 per share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering
expenses payable by us. Similarly, a decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this
offering by approximately $0.19 and increase the dilution to investors participating in this offering by approximately $0.19 per share, assuming the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range
set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase up to additional shares of our common stock in full in this offering, the pro forma as
adjusted net tangible book value after the offering would be $6.80 per share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be $0.24 per share and the dilution per share to new investors would
be $8.20 per share, in each case assuming an initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes, on a pro forma as adjusted basis as of June&nbsp;30, 2021 the number of shares of common stock purchased or to
be purchased from us, the total consideration paid or to be paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The
calculation below is based on the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. As the table below shows, investors participating in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Average<BR>Price<BR>Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,115,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,166,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,115,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">292,166,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The information presented in the tables and discussions above is based on 30,115,139 shares of our common
stock outstanding as of June&nbsp;30, 2021, including 1,512,699 shares of unvested restricted common stock outstanding as of that date, gives effect to the automatic conversion of all of our outstanding shares of convertible preferred stock into an
aggregate of 26,228,089 shares of our common stock immediately prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,586,835 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2021
under the 2020 Plan, with a weighted-average exercise price of $2.88 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,570,000 shares of common stock reserved for future issuance under the 2021 Plan (including 1,032,150 shares of
common stock reserved for future grant or issuance under our 2020 Plan as of June&nbsp;30, 2021, which shares will be added to the shares reserved under the 2021 Plan upon its effectiveness), as well as any annual automatic increases in the number
of shares of our common stock reserved for future issuance under the 2021 Plan, which will become effective on the day prior to the public trading date of our common stock; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">380,000 shares of our common stock reserved for future issuance under the ESPP, as well as any annual automatic
increases in the number of shares of our common stock reserved for future issuance under the ESPP, which will become effective on the day prior to the public trading date of our common stock in connection with the completion of this offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See Note 7 to our audited and unaudited financial statements included elsewhere in this prospectus for a discussion of
our outstanding restricted common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may choose to raise additional capital through the sale of equity or convertible debt
securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent any options are exercised, or we issue additional shares of common stock or other
equity or convertible debt securities in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_10a"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have elected to comply with Item 301 of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as amended February&nbsp;10, 2021, and are
omitting this disclosure in reliance thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results
of operations together with our financial statements and the related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans
and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives and expectations for our business. Our actual results
and the timing of selected events could differ materially from those described in or implied by these forward-looking statements as a result of several factors, including those set forth in the section titled &#147;Risk Factors.&#148; Please also
see the section titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for
patients with cancer. The widespread availability of approved targeted oncology treatments, such as kinase inhibitors, has transformed the cancer treatment landscape. Despite the therapeutic benefit that targeted oncology treatments have created for
some patients, the response rate and duration of efficacy is often limited by acquired drug resistance and other shortcomings of existing therapies. We are using our proprietary SN&Aring;P platform, which is optimized to enable rapid and precise
refinement of structural design through iterative molecular SN&Aring;Pshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. We are
initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Our lead product candidate, TYRA-300, is designed to selectively
inhibit FGFR3, with an initial focus on patients with bladder cancer. We anticipate filing an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or the FDA, for TYRA-300 in mid-2022. In addition, we have
pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, or RET, and FGFR4-related cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We commenced our operations in 2018 and have devoted substantially all of our resources to organizing and staffing the company, business
planning, raising capital,&nbsp;developing our proprietary SN&Aring;P platform, undertaking research and development activities for our development programs, establishing our intellectual property portfolio, and providing general and administrative
support for our operations. From our inception through June&nbsp;30, 2021, we have raised aggregate gross proceeds of $157.2&nbsp;million to fund our operations, comprised primarily from our private placements of our convertible preferred stock and
issuance of Simple Agreement for Future Equity, or SAFEs. As of June&nbsp;30, 2021, we had cash and cash equivalents of $135.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since inception. Our net losses for the years ended December&nbsp;31, 2019 and 2020 were
$4.1&nbsp;million and $9.3&nbsp;million, respectively. Our net losses for the six months ended June&nbsp;30, 2020 and 2021 were $3.3&nbsp;million and $9.7&nbsp;million, respectively. As of June&nbsp;30, 2021, we had an accumulated deficit of
$23.8&nbsp;million. Our net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our clinical development activities, other research and development activities and capital expenditures. We expect to continue
to incur significant expenses and increasing operating losses for the foreseeable future particularly if and as we conduct preclinical studies and planned clinical trials, continue our research and development activities, utilize third parties to
manufacture our product candidates and related raw materials, hire additional personnel, expand and protect our intellectual property, and incur additional costs associated with being a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our existing cash and cash equivalents, together with the estimated net proceeds from
this offering, will be sufficient to fund our operating expenses and capital expenditures through at least 2024. We have never generated any revenue and do not expect to generate any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenues from product sales unless and until we successfully complete development of and obtain regulatory approval for our product candidates, which will not be for several years, if ever. In
addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can
generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar
arrangements. However, we may not be able to raise additional funds or enter into such other arrangements when needed or on favorable terms, or at all. If we are unable to raise additional capital or enter into such arrangements when needed, we
could be forced to delay, limit, reduce or terminate our research and development programs or future commercialization efforts, or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such
product candidates ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">global&nbsp;COVID-19&nbsp;pandemic</FONT> continues to evolve, and we
will continue to monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation closely. The extent of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, operations and development timelines and
plans remains uncertain, and will depend on certain developments, including the duration and spread of the pandemic and its impact on our development activities, contract research organizations, or CROs, third-party manufacturers and other third
parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of
Results of Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, our research and development expenses consist primarily of external and internal costs related to the development of our SN&Aring;P
platform and our product candidates and development programs. Our research and development expenses primarily include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external costs, including: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred in connection with the discovery and preclinical development of our product candidates,
including under agreements with third parties, such as consultants and CROs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with consultants for chemistry, manufacturing and controls, or CMC development, and other
services; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing compounds for use in our preclinical studies, including under agreements with third
parties, such as consultants and third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">internal costs, including: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, related benefits, travel and share-based compensation expenses for
employees engaged in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study materials; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation and other expenses, which include allocated expenses for rent and maintenance of
facilities, and supplies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expense research and development expenses in the periods in which they are incurred.
External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date.
We track external expenses on a development program and other program specific basis. However, we do not track internal costs on a program specific basis because these costs primarily relate to compensation, early research and consumable costs,
which are deployed across multiple programs under development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model.
There are numerous factors associated with the successful development of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our
stage of development. In addition, future regulatory factors beyond our control may impact our clinical development programs. Product candidates in later stages of development generally have higher development costs than those in earlier stages of
development. As a result, we expect that our research and development expenses will increase substantially over the next several years as we advance our product candidates through preclinical studies into and through clinical trials, continue to
discover and develop additional product candidates and expand our pipeline, maintain, expand, protect and enforce our intellectual property portfolio, and hire additional personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future research and development expenses may vary significantly based on a wide variety of factors such as:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope, rate of progress, expense and results of our discovery and preclinical development
activities and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">the&nbsp;drop-out&nbsp;or</FONT> discontinuation rates of patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient participation in the trials <FONT STYLE="white-space:nowrap">and&nbsp;follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phase of development of the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA <FONT
STYLE="white-space:nowrap">and&nbsp;non-U.S.&nbsp;regulators;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of our product candidates following approval, if any;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work,
particularly in light of the <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic</FONT> environment; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish additional strategic collaborations or other arrangements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of any of our product candidates
could significantly change the costs and timing associated with the development of that product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The process of conducting the
necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates or any future candidates may be affected by a variety of factors. We may never
succeed in achieving regulatory approval for any of our product candidates or any future candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative
Expenses </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses,
benefits, and stock-based compensation charges, for personnel in executive and administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional
fees for accounting, tax and consulting services and insurance costs. We expect our general and administrative expenses will increase for the foreseeable future to support our increased research and development activities, manufacturing activities,
and the increased costs associated with operating as a public company. These increased costs will likely include increased expenses related to hiring of additional personnel, audit, legal, regulatory and
<FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with exchange listing and Securities and Exchange Commission, or the SEC, requirements, director and officer insurance costs, and investor and public
relations costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of SAFEs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We issued SAFEs in 2018 and 2019 for which we have elected to account for using the fair value option. We adjust the carrying value of our
SAFEs to their estimated fair value at each reporting date, with any change in fair value of the SAFE recorded as an increase or decrease to change in fair value of simple agreement for future equity in our statement of operations and comprehensive
loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2020 and 2021 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six Months Ended<BR>June
30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of SAFE commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $2.4&nbsp;million and $7.9&nbsp;million for the six months ended June&nbsp;30, 2020 and 2021,
respectively. The increase of $5.5&nbsp;million was primarily due to additional spend to support the advancement of our <FONT STYLE="white-space:nowrap">TYRA-300</FONT> and other development programs, including preclinical studies and chemistry.
Further, we incurred $1.3 million higher personnel-related costs in the first six months ended June&nbsp;30, 2021 as compared to 2020, as we expanded the number of research and development employees to support our programs, including an additional
$0.2 million of non-cash stock-based compensation costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses by
development program for the six months ended June&nbsp;30, 2020 and 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External research and development expense by program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TYRA-300</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other development programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $0.9&nbsp;million and $1.8&nbsp;million for the six months ended June&nbsp;30, 2020 and 2021,
respectively. The increase of $0.9&nbsp;million was primarily due to an increase of $0.3&nbsp;million in personnel-related expenses including $0.1 million in non-cash stock-based compensation costs, and $0.6 million in professional services related
to accounting and recruiting services, and other consulting fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Simple Agreement for Future Equity </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Change in fair value of SAFE was $15,000 for the six months ended June 30, 2020. The SAFEs were converted to Series A convertible preferred
stock in January 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2019 and 2020 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of SAFE commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(943</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $1.8&nbsp;million and $7.2&nbsp;million for the years ended December&nbsp;31, 2019 and 2020,
respectively. The increase of $5.4&nbsp;million was primarily due to additional spend to support the advancement of our <FONT STYLE="white-space:nowrap">TYRA-300</FONT> and other development programs in 2020, including preclinical studies and
chemistry. Further, we incurred $1.4&nbsp;million higher personnel-related costs in 2020 as compared to 2019, as we expanded the number of research and development employees to support our programs, including an additional $0.1&nbsp;million of <FONT
STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development
expenses by development program for the years ended December&nbsp;31, 2019 and 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External research and development expense by program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TYRA-300</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other development programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $1.3&nbsp;million and $2.1&nbsp;million for the years ended December&nbsp;31, 2019 and 2020,
respectively. The increase of $0.8&nbsp;million was primarily due to increases of $0.4&nbsp;million in personnel-related expenses, including $0.3&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation costs, and
$0.4&nbsp;million in professional services related to accounting and recruiting services, and other consulting fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Simple Agreement for Future Equity</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Change in fair value of SAFE was $0.9&nbsp;million and $15,000 for the years ended December&nbsp;31, 2019 and 2020, respectively. The SAFEs
were converted to Series A convertible preferred stock in January 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since our
inception, we have not generated any revenue and have incurred net losses and negative cash flows from our operations. We anticipate we will continue to incur significant operating losses for the foreseeable future as we continue to develop our
current and future product candidates and may never become profitable. From our inception through June&nbsp;30, 2021, we have raised aggregate gross proceeds of $157.2&nbsp;million to fund our operations, comprised primarily from our private
placements of our convertible preferred stock and issuance of SAFEs. As of June&nbsp;30, 2021, we had cash and cash equivalents of $135.2&nbsp;million and an accumulated deficit of $23.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table
sets forth a summary of our cash flows for the periods indicated (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six Months
Ended<BR>June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash increase (decrease) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since inception. Net cash used in operating activities for the six months ended June 30, 2020
was $3.1&nbsp;million, consisting primarily of our net loss of $&nbsp;3.3 million, offset by $0.2&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges related primarily to stock-based compensation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the six months ended June 30, 2021 was $9.1 million, consisting primarily of our net loss of $9.7
million, adjusted for $0.6 million of non-cash charges. Non-cash charges consisted primarily of $0.5&nbsp;million of stock-based compensation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2019 was $2.6&nbsp;million, consisting primarily of our net loss of
$4.1&nbsp;million, adjusted for $1.0&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges and $0.5&nbsp;million for net changes in operating assets and liabilities. Noncash charges consisted primarily of $0.9&nbsp;million related
to the change in fair value of our SAFEs. The net change in operating assets and liabilities was primarily related to $0.5&nbsp;million increase in accounts payable and accrued liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2020 was $7.8&nbsp;million, consisting primarily of our net loss of
$9.3&nbsp;million, adjusted for $0.5&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges and $1.0&nbsp;million for net changes in operating assets and liabilities. Non-cash charges consisted primarily of $0.4&nbsp;million of
stock-based compensation expense. The net change in operating assets and liabilities was primarily related to $1.0&nbsp;million increase in accounts payable and accrued liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the six months ended June 30, 2020 and 2021 was $0.1&nbsp;million and $0.3 million, respectively,
consisting of purchases of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&nbsp;31, 2019 and
2020 was $20,000 and $0.3&nbsp;million, respectively, consisting of purchases of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $23.4&nbsp;million for the six months ended June 30, 2020 and was primarily related
to net proceeds of $23.3&nbsp;million from the issuance of Series A convertible preferred stock. Net cash provided by financing activities was $129.4&nbsp;million for the six months ended June 30, 2021, due to net proceeds of $23.5&nbsp;million from
the second closing of our Series A convertible preferred stock, $106.1&nbsp;million in net proceeds from the issuance of our Series B convertible preferred stock, and $0.5&nbsp;million from proceeds received from the exercise of stock options,
partially offset by $0.7&nbsp;million payment for deferred offering costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was
$0.2&nbsp;million for the year ended December&nbsp;31, 2019, primarily due to proceeds for the issuance of our SAFEs. Net cash provided by financing activities was $23.4&nbsp;million for the year ended December&nbsp;31, 2020, primarily due to net
proceeds of $23.3&nbsp;million received from the issuance of our Series A convertible preferred stock, and $0.1&nbsp;million from proceeds received from the exercise of stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our existing cash and cash equivalents, together with the estimated net proceeds from
this offering, will be sufficient to meet our anticipated operating expenses and capital expenditures through at least 2024. However, our forecast of the period of time through which our financial resources will be adequate to support our operations
is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.
Additionally, the process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, type, number, scope, results, costs and timing of, our ongoing and planned preclinical studies
and clinical trials of existing product candidates or clinical trials of other potential product candidates we may choose to pursue in the future, including based on feedback received from regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of manufacturing for current or future product candidates, including commercial scale
manufacturing if any product candidate is approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public
company, including enhanced internal controls over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with hiring additional personnel and consultants as our business grows, including additional
executive officers and clinical development personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of the milestone or other payments we must make to any future licensors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of establishing or securing sales and marketing capabilities if any current or future
product candidate is approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors
and adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients&#146; willingness
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">to&nbsp;pay&nbsp;out-of-pocket&nbsp;for&nbsp;any</FONT></FONT> approved products in the absence of coverage and/or adequate reimbursement from third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with any products or technologies that
<FONT STYLE="white-space:nowrap">we&nbsp;may&nbsp;in-license&nbsp;or&nbsp;acquire;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or issues with any of the above, including the risk of each of which may be exacerbated by the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product
revenues to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to
raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our
stockholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that
include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we
are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product
candidates even if we would otherwise prefer to develop and market such product candidates ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, we entered into an operating lease agreement for corporate office space in Carlsbad, California. Remaining lease payments
were approximately $0.1&nbsp;million and $50,000 at December 31, 2020 and June 30, 2021, respectively, with a lease expiration of November 2021. This lease represented our primary outstanding contractual obligation at December 31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2020, we entered into a lease agreement for corporate office and laboratory space in Carlsbad, California or the Carlsbad Lease. As
of June 30, 2021, the underlying asset was made available for use by us and therefore, the Carlsbad Lease is considered to have commenced. As of June 30, 2021, the remaining lease payments are approximately $1.4&nbsp;million. The lease has a lease
term of 60 months from the contractual lease commencement date. We have the option to renew the lease for two additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">thirty-six-month</FONT></FONT> periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations and commitments as of June 30,
2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Remainder&nbsp;of<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">2022-2023</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">2024-2025</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Thereafter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating lease obligations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business for contract research services, professional services
and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not separately presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements, as defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies, Significant Judgments, and Use of Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our financial statements,
which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of
contingent assets and liabilities in our financial statements. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and judgments on an
ongoing basis. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this
prospectus, we believe the following accounting policies and estimates to be most critical to the preparation of our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued
Research and Development Expense </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to estimate our expenses resulting from obligations under contracts with
vendors, and consultants, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match
the periods over which materials or services are provided under such contracts. We reflect research and development expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. We
account for these expenses according to the progress of the preclinical study, as measured by the timing of various aspects of the study or related activities. We determine accrual estimates through review of the underlying contracts along with
preparation of financial models taking into account discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, we adjust our rate of expense recognition if actual
results differ from our estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we do not expect our estimates to be materially different from amounts actually incurred, if
our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no
material differences between our estimates of such expenses and the amounts actually incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of SAFEs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our SAFEs were accounted for at fair value and revalued at each reporting period with changes in the fair value of the liabilities recorded as
a component of other expense in the statements of operations and comprehensive loss. There are significant judgments and estimates inherent in the determination of the fair value of the liability. If we had made different assumptions including,
among others, those related to the timing and probability of various financing scenarios, discount rates, volatilities and exit valuations, the carrying values of our SAFEs, and our net loss and net loss per share of common stock could have been
significantly different. Our SAFEs converted to shares of our Series A convertible preferred stock on January&nbsp;6, 2020 and therefore no longer require fair value accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
recognize stock-based compensation expense for all stock-based awards made to employees and consultants based on estimated grant date fair values. We use the straight-line method to allocate compensation costs over the requisite service period. We
estimate the fair value of stock options at the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of subjective assumptions, including the fair value of common stock, expected term,
expected volatility, risk-free interest rate, and expected dividend yield, which are described in greater detail below. We recognize actual forfeitures by reducing the stock-based compensation expense in the same period as the forfeiture occurs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See Note 7 to our financial statements included elsewhere in this prospectus for information concerning certain of the specific
assumptions we used in applying the Black-Scholes option-pricing model to determine the estimated fair value of stock options granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense was $0 and $0.4&nbsp;million during the years ended December&nbsp;31, 2019 and 2020, respectively, and
$0.2&nbsp;million and $0.5 million for the six months ended June 30, 2020 and 2021, respectively. As of June 30, 2021, there was $4.6&nbsp;million of total unrecognized stock-based compensation expense related to outstanding employee and nonemployee
options which we expect to recognize over a weighted-average period of 3.6 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The intrinsic value of all outstanding options as of
June 30, 2021 was $31.4 million based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover of this prospectus, of which approximately $3.2 million was related to vested
options and approximately $28.1 million was related to unvested options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board
of directors as of the date of each option grant, with input from management, considering contemporaneous independent third-party valuations of common stock, and our board of directors&#146; assessment of additional objective and subjective factors
that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant, including: the prices at which we sold shares of our convertible preferred stock to outside investors in arms-length
transactions, and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the progress of the our company&#146;s research and development programs, including their stages of
development, and the our company&#146;s business strategy; external market and other conditions affecting the biotechnology industry, and trends within the biotechnology industry; the our company&#146;s financial position, including cash on hand,
and our historical and forecasted performance and operating results; the lack of an active public market for the our company&#146;s common stock; the likelihood of achieving a liquidity event for the our company&#146;s securityholders, such as an
initial public offering or a sale of the company, taking into consideration prevailing market conditions; the hiring of key personnel and the experience of management; and the analysis of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initial public offerings and the market performance of peer companies in the biopharmaceutical industry, as well as completed mergers and acquisitions of peer companies. These independent
third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide,<I> Valuation of Privately-Held-Company Equity Securities Issued as</I>
<I>Compensation</I> (Practice Aid). The methodology to determine the fair value of our common stock included estimating the fair value of the enterprise using a market approach, which estimates the fair value of a company by including an estimation
of the value of the business based on guideline public companies under a number of different scenarios. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Practice Aid identifies
various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the following
methods: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Option Pricing Method, or OPM. Under the OPM, shares are valued by creating a series of call options with
exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. This method is appropriate to use when the range of
possible future outcomes is so difficult to predict that estimates would be highly speculative, and dissolution or liquidation is not imminent. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Probability-Weighted Expected Return Method, or PWERM. The PWERM is a scenario-based analysis that estimates
value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hybrid Method. The hybrid method is a PWERM where the equity value in one or more scenarios is calculated using
an OPM. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our early stage of development, the difficulty in predicting the range of specific outcomes (and their
likelihood) and other relevant factors, we determined that an OPM was the most appropriate method for allocating our enterprise value to determine the estimated fair value of our common stock for valuation dates prior to March 2021. For valuations
performed after this date, we used the Hybrid Method which takes into account a PWERM or OPM depending on the scenario. In determining the estimated fair value of our common stock, our board of directors also considered the fact that our
stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the weighted-average expected time to liquidity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and
estimates include assumptions regarding our future operating performance, the time to completing an initial public offering or other liquidity event and the determination of the appropriate valuation methods. If we had made different assumptions,
our stock-based compensation expense, net loss and net loss per share of common stock could have been significantly different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following
the completion of this offering, our board of directors will determine the fair value of our common stock based on its closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note 2 to our financial statements appearing elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our cash and
cash equivalents consist of cash in readily available checking accounts and money market funds. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Exchange Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research
and development services that are denominated in foreign currencies. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not
been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. A hypothetical 10% increase or decrease in exchange rates during any of the periods presented would not have had a material
impact on our financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effects of Inflation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material
effect on our financial results during the periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging
growth company until the earliest to occur of: (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least
$700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities
during the prior three-year period; and (iv)&nbsp;the last day of the fiscal year ending after the fifth&nbsp;anniversary of our initial public offering. As a result of this status, we have taken advantage of reduced reporting requirements in this
prospectus and may elect to take advantage of other reduced reporting requirements in our future filings with the SEC. In particular, in this prospectus, we have provided only two&nbsp;years of audited financial statements and have not included all
of the executive compensation related information that would be required if we were not an emerging growth company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS
Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies.
We have elected to use the extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date on which we (i)&nbsp;are no
longer an emerging growth company and (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or
revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; meaning that
the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than
$100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less
than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth
companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation and other matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a precision oncology
company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The widespread availability of approved targeted oncology treatments, such as kinase inhibitors, has transformed the
cancer treatment landscape. Despite the therapeutic benefit that targeted oncology treatments have created for some patients, the response rate and duration of efficacy is often limited by acquired drug resistance and other shortcomings of existing
therapies. We are using our proprietary SN&Aring;P platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SN&Aring;Pshots, in order to generate next-generation product candidates that are
specifically designed to address acquired drug resistance and provide alternative treatment options. We are initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are
altered in approximately 7% of all cancers. Our lead product candidate, <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. We anticipate filing an
Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or the FDA, for <FONT STYLE="white-space:nowrap">TYRA-300</FONT> in mid-2022. In addition, we have pipeline development programs targeting FGFR2-related
cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, or RET, and FGFR4-related cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our SN&Aring;P Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We developed our proprietary SN&Aring;P platform to efficiently identify and selectively target vulnerabilities in the mutant proteins where
genetic alterations have eliminated or reduced the effectiveness of targeted therapies. Through the rapid generation of precise molecular SN&Aring;Pshots, we continually gain deeper insights into the structure of inhibitor binding sites and how
commonly occurring genetic alterations lead to acquired drug resistance to existing therapies. Leveraging these insights, we aim to predict the genetic alterations most likely to cause resistance to specific existing therapies and develop compound
candidates with innovative structures that are designed to inhibit the target while avoiding those mutations. Through this process, we identify product candidates that may have the potency and selectivity to, if approved, be used as important
treatment options to address critical unmet needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our SN&Aring;P platform is driven by our ability to rapidly and concurrently generate
iterative data from the following three key pillars. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Protein crystallography</B>. We have developed proprietary protein crystallography techniques that enable us
to determine the <FONT STYLE="white-space:nowrap">co-crystal</FONT> structures of newly synthesized compounds in target proteins in as little as three days. This enables weekly generation of detailed structural insights on the precise interactions
and conformational changes that occur when our potential product candidates bind to a particular target, creating opportunities to further refine the structural design. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cell-based assays</B>. We assess inhibitor potency directly in <I>in vitro</I> target-specific
anti-proliferation assays, in addition to enzymatic assays, to enable us to simultaneously understand target potency and cell penetration as well as target-specific cell killing.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>Our process
allows us to generate data on newly synthesized compounds in as little as two days. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B><I>In vivo</I></B><B> models</B>. Our direct structural insights and <I>in vitro</I> datasets are
complemented by <I>in vivo</I> pharmacologic data generated through <FONT STYLE="white-space:nowrap">in-house</FONT> animal models that provide us with bioavailability, pharmacokinetic data and anti-tumor activity in as little as five days.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g01h01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SN&Aring;P platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Together, these three pillars of our platform provide a molecular SN&Aring;Pshot for our compound candidates. At this time, we are able to
generate a molecular SN&Aring;Pshot for a compound candidate within one week. We believe that a sharp focus on efficiently generating these three key empirical datasets for compound candidates enables us to balance speed with the robust
identification of pivotal insights to rapidly and precisely iterate on the design of our novel molecular structures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Programs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is an overview of our programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g34h50.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our FGFR3 <FONT STYLE="white-space:nowrap">Program&#151;TYRA-300</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing our lead product candidate, <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> a selective inhibitor of FGFR3, initially for
the treatment of muscle invasive bladder cancer, or MIBC. One common mechanism of acquired drug resistance in kinases such as FGFR3 is the emergence of gatekeeper mutations. For example, the V555M and V555L gatekeeper mutations have been shown to
block access to a portion of the binding pocket accessed by first generation FGFR compounds, such as Balversa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (erdafitinib), the only currently FDA approved FGFR3 inhibitor for MIBC, as well
as Truseltiq<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (infigratinib), an FGFR inhibitor recently approved for cholangiocarcinoma. Because we believe the gatekeeper mutation represents a key limitation to efficacy and durability of
the therapeutic effect of first generation FGFR compounds, we have designed <FONT STYLE="white-space:nowrap">TYRA-300</FONT> to avoid interactions with the gatekeeper region of the inhibitor binding site. In cell-based assays and preclinical
xenograft models, we observed that <FONT STYLE="white-space:nowrap">TYRA-300</FONT> had similar inhibition against both the wild-type and the gatekeeper mutations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to addressing the gatekeeper resistance mutations, we have designed <FONT STYLE="white-space:nowrap">TYRA-300</FONT> to be more
selective for FGFR3 over FGFR1 to minimize <FONT STYLE="white-space:nowrap">off-target</FONT> side effects, providing potential clinical advantages over less selective first generation compounds. For example, inhibition of FGFR1 is associated with a
well-characterized adverse event, hyperphosphatemia, an electrolyte disorder characterized by an elevated level of phosphate in the blood, which is commonly observed in patients treated with these inhibitors, limiting their dosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have designed <FONT STYLE="white-space:nowrap">TYRA-300</FONT> to be more selective for FGFR3 over FGFR1 in order to potentially reduce the
need for dose modifications or interruptions due to hyperphosphatemia, which we believe will result in increased efficacy and improved clinical outcomes for patients with MIBC. We believe TYRA-300 has the potential to address additional indications
such as non-muscle invasive bladder cancer, or NMIBC, as well as other FGFR3-driven indications demonstrating resistance to existing therapies or for which such therapies result in dose-limiting adverse events, such as hyperphosphatemia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our FGFR2 Program </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our second
program is focused on the inhibition of FGFR2, initially for the treatment of intrahepatic cholangiocarcinoma, or ICC, a cancer of the biliary ducts. Acquired resistance mutations, such as gatekeeper and molecular brake mutations, have been observed
in patients treated with Pemazyre<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pemigatinib) and Truseltiq<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (infigratinib), the two FDA approved FGFR inhibitors for ICC, and in
other late stage clinical inhibitors, such as futibatinib.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>We are developing an inhibitor with the potential to address key resistance mutations, which we believe is necessary to address the
problem of polyclonal resistance. We plan to nominate a product candidate by the end of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Achondroplasia, RET and FGFR4 Programs
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our pipeline also includes development programs targeting FGFR3-related achondroplasia as well as RET and FGFR4-related cancers.
These programs are currently in early lead optimization stage. Our achondroplasia program is aimed at developing a potential treatment for pediatric patients, benefiting from our structural insights into the FGFR3 selectivity we have observed with <FONT
STYLE="white-space:nowrap">TYRA-300.</FONT> This genetic disorder is caused by a mutation in the FGFR3 gene. Our RET and FGFR4 programs are focused on overcoming acquired drug resistance mutations that are clinically observed to arise in response to
marketed or clinical-stage drugs in <FONT STYLE="white-space:nowrap">RET-</FONT> and FGFR4-related cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Leadership Team and Investors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are led by a team with extensive experience in drug discovery and development, with a particular focus on small molecule drug development.
Todd Harris, Ph.D., our <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Executive Officer, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
previously founded and served as Chief Executive Officer of Sienna Labs. Daniel Bensen, our <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Operating Officer, is a structural
biologist and protein chemist with over 20 years of experience, most recently at Cidara Therapeutics and Trius Therapeutics. Robert Hudkins, Ph.D., our Chief Technical Officer, has over 34 years of oncology and neuroscience medicinal chemistry
experience, including 26 years at Cephalon and Teva, where he was an inventor and team leader advancing new chemical entities into clinical development. Ronald Swanson, Ph.D., our Chief Scientific Officer, has over 25 years of biotechnology and
pharmaceutical experience, most recently at Janssen. Hiroomi Tada, M.D., Ph.D., our Chief Medical Officer, was a clinical lead for the development of a portfolio of therapies at Incyte, GlaxoSmithKline and AstraZeneca. Our Chief Development Officer,
Piyush Patel, Ph.D., with nearly three decades of experience, previously served as Chief Scientific Officer at CinRx and led drug formulation, clinical manufacturing and process development at Cephalon and Teva. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, we have raised $157.2&nbsp;million from leading investors in the life sciences industry. Investors with 5% or greater ownership are
Alta Partners, Boxer Capital of Tavistock Group, Canaan, Nextech Invest and RA Capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At Tyra, we do not accept that cancer patients with acquired drug resistance should be left with the devastating reality of limited or no
treatment options. Our vision is to become a leading precision medicine company utilizing our unique approach to designing and developing purpose-built therapies to overcome acquired drug resistance in tumors and provide treatment options to these
patients who have limited or no options. Key elements of our strategy to achieve our vision are as follows. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance product candidates for acquired drug resistance mutations in FGFR3 and FGFR2 through clinical
development and regulatory approval. </B>We are developing our next-generation precision oncology programs with a goal of overcoming the tumor alterations in FGFR3 and FGFR2-driven cancers that result in resistance and reduction of therapeutic
effect of first generation FGFR treatments. We are initially developing product candidates for patients with MIBC and ICC who have developed resistance to FGFR inhibitors. We believe this differentiation will enable us to expand into multiple
cohorts of <FONT STYLE="white-space:nowrap">FGFR2/3-driven</FONT> cancer including patients na&iuml;ve to FGFR inhibitors, tumor agnostic populations, as well as patients with other tumors driven by FGFR2/3 alterations. We anticipate filing an IND
for our lead product candidate <FONT STYLE="white-space:nowrap">TYRA-300</FONT> in mid-2022. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Harness the strength of our SN&Aring;P platform to rapidly develop additional next-generation precision
therapies</B>. We believe our SN&Aring;P platform has disrupted the conventional process used to discover differentiated product candidates, resulting in what we believe is a significantly condensed time frame. Leveraging our SN&Aring;P platform, we
have rapidly developed an expanding pipeline of product candidates since our founding in August 2018. Although our initial focus has been on a specific set of drug targets, our SN&Aring;P platform can be extended to multiple gene families and
therapeutic areas. We plan to leverage our SN&Aring;P platform to expand our pipeline with additional oncology and <FONT STYLE="white-space:nowrap">non-oncology</FONT> indications where there is high unmet need, with an initial focus on our three
discovery stage programs in FGFR3-related achondroplasia and <FONT STYLE="white-space:nowrap">RET-</FONT> and FGFR4-related cancers. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage the recent advances in the precision oncology landscape to potentially expedite our product
candidates&#146; development. </B>There have been multiple recent accelerated approvals by the FDA of targeted therapies on the basis of compelling clinical outcomes from <FONT STYLE="white-space:nowrap">single-arm</FONT> dose expansion cohort
clinical trials. Recent accelerated approvals have been conditionally granted in as little as three years from initial clinical testing. Although the exact clinical development and regulatory path for our product candidates has not been defined,
subject to consultation with the FDA, we intend to leverage the precedent pathways used by recently approved precision oncology drugs to inform our clinical and regulatory decisions and pathway to potentially seek expedited regulatory approval, if
we are successful in the clinical development, of one or more of our product candidates. However, we have not filed an IND for any of our product candidates, nor have we applied for accelerated approval by the FDA, and as a result, there can be no
assurance that an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
accelerated pathway will be available for us or that it will lead to a faster development process or a faster regulatory review. While an accelerated pathway may potentially expedite development
or the approval process, it does not change the FDA&#146;s standards of approval or increase the likelihood that a product candidate will receive approval. In addition, advances in next-generation genomic sequencing continue to help physicians and
their patients identify the mutations responsible for their cancer. We believe this may assist us in identifying and enrolling patients, thereby allowing us to accelerate the development timeline of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the value of our product candidates across multiple therapeutic areas through accelerated development
and potential partnerships</B>. We believe that our ability to generate product candidates with improved selectivity for the target of interest enables the possibility of designing and developing product candidates for indications outside of
oncology. Specifically, we believe we can apply our SN&Aring;P platform to targets, such as FGFR3, that have data validating their role in the pathogenesis of diseases, including achondroplasia and other skeletal diseases. We currently retain
worldwide rights to all of our product candidates. We will consider entering into compound, target or geographic specific strategic partnerships on an opportunistic basis, especially for programs outside of oncology, if we believe that such a
partnership can accelerate the development and/or maximize the market potential of a product candidate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Protein kinase inhibitors in cancer and the challenge posed by acquired drug resistance </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Receptor tyrosine kinases, or RTKs, are a family of proteins that respond to external growth factors affecting cell proliferation. In cancer,
RTKs can be constitutively activated though <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function</FONT></FONT> mutations or gene rearrangements, driving tumor growth. Protein kinase inhibitors are a class of targeted
therapies that can effectively block protein kinase signaling and cause tumor regression. These targeted therapies have delivered profound therapeutic benefits in the treatment of cancer. As of 2020, there were 55
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> protein kinase inhibitors for the treatment of cancer, targeting about two dozen different protein kinases. Despite the success of these drugs, they have been susceptible to acquired drug
resistance and reduction of effect, leaving patients with limited or no treatment options. In particular, these current or first generation kinase inhibitors lose potency in response to mutations that prevent the drug from binding to the target
protein, allowing the kinase to continue to function resulting in continued tumor growth. This mutation, and resulting loss of potency from these kinase inhibitors, results in the patient&#146;s cancer becoming refractory to treatment and the
patient regressing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g03h03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview of RTK activating mutations and acquired drug resistance mutations </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Development of acquired drug resistance to kinase inhibitors is common among protein
kinases. Acquired on-target resistance has emerged in nearly every validated target, including FGFR, RET, epidermal growth factor receptor, or EGFR, anaplastic lymphoma kinase, or ALK, KIT, neurotrophic tropomyosin receptor kinase, or NTRK, ROS1 and
mesenchymal epithelial transition factor, or MET. These key resistance mutations can be generally grouped into four classes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Gatekeeper.</B> Mutations such as BCR-ABL T315I and EGFR T790M are known as gatekeeper mutations because they
are found at a key location at the entrance to a hydrophobic pocket in the back of the adenosine triphosphate, or ATP, binding site that many kinase inhibitors access to increase potency and obtain specificity. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Molecular brake. </B>Activating mutations in the kinase domain of RTKs are associated with the development of
many forms of cancer. A number of these mutations cluster in a hinge region of the kinase structure, resulting in kinase activation by disengaging a highly conserved region referred to as a molecular brake. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cys mutant. </B>Irreversible kinase inhibitors, such as
Tagrisso<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (osimertinib), typically covalently attach to cysteine residues in the kinase active site. EGFR C797S and corresponding mutations in cysteine residues of other kinases prevent
binding and block the activity of these inhibitors. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Solvent front.</B> Certain kinase inhibitors obtain their specificity by interacting with amino acid residues
located at the opening of the ATP binding site to solvent. Mutations in these residues that lead to drug resistance are referred to as solvent front mutations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The rapid rise of mutations that enable tumors to become resistant to previous generations of kinase inhibitors poses a challenge to drug
developers, one that we believe will demand innovation for a long time to come. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial success of next-generation kinase inhibitors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Osimertinib is an example of how a next-generation kinase inhibitor can not only overcome the limitations of acquired drug resistance to first
generation therapies, but also demonstrate broader applicability across different lines of therapies. While first generation epidermal growth factor receptor, or EGFR, inhibitors, such as
Iressa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (gefitinib) and Tarceva<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (erlotinib), led to significant improvements in tolerability compared to standard of care
chemotherapy, on average, tumor responses last only six to twelve months before disease progression. About 50% of treated patients developed drug resistance due to a gatekeeper mutation at T790M. Osimertinib&#146;s ability to overcome this key
gatekeeper mutation, which limited the duration of efficacy of first generation EGFR inhibitors has contributed to osimertinib realizing sales of double the amount of the peak sales achieved by the two first generation inhibitors in 2013. In
addition to its ability to overcome the gatekeeper mutation, osimertinib also displayed higher mutant selectivity and other performance enhancements resulting in greater tolerability, safety and efficacy. When used earlier in treatment, osimertinib
nearly doubled progression-free survival compared to gefitinib or erlotinib with a better overall safety profile. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g43p71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Illustration of osimertinib overcoming gatekeeper mutations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FGFR gene alterations and cancer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
FGFR family consists of four highly conserved RTKs, <FONT STYLE="white-space:nowrap">FGFR1-4.</FONT> These receptors regulate a variety of cellular functions, including proliferation, differentiation and survival. Genomic alterations in FGFR family
members occur in approximately 7% of all human cancers, representing about 126,000 new cases a year. These genomic alterations, many of which lead to increased FGFR activity, have been found in cancers throughout the body, as shown in the figure
below. The highest FGFR alteration frequencies are seen in urothelial cancer, ICC, endometrial cancer, lung cancers, breast cancer and cervical cancer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g28u63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alterations in FGFR are found in cancers throughout the body </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Three FGFR targeted therapies have been approved by the FDA: erdafitinib for locally advanced or metastatic urothelial carcinoma, or bladder
cancer, and pemigatinib and infigratinib for FGFR2-fusion positive ICC. These inhibitors have demonstrated clinical benefit, however response rates and duration of response are limited. While patients may initially respond to FGFR targeted
therapies, many develop acquired drug resistance, ultimately resulting in disease progression and discontinuation of therapy. Decreased activity of erdafitinib and pemigatinib due to resistance mutations that alter their ability to bind to the
active site, such as gatekeeper mutations, has been observed. Gatekeeper mutations have also been seen in patients in a clinical trial treated with infigratinib while acquired-resistance molecular brake mutations have been seen in patients in
clinical trials of both pemigatinib and infigratinib. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach and Solution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our SN&Aring;P platform </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We developed
our proprietary SN&Aring;P platform to efficiently identify and selectively target vulnerabilities in the mutant proteins where genetic alterations have eliminated or reduced the effectiveness of current targeted therapies. Our SN&Aring;P platform
is driven by our ability to rapidly and concurrently generate iterative data from three key pillars. Rapid generation of crystallographic data, use of custom cell-based assays and <I>in vivo </I>models comprise the three pillars of our platform. We
leverage our platform to identify and develop product candidates that may have the potency and selectivity to address the liabilities that acquired drug resistance has created for other therapies. Collectively, our efforts to optimize and integrate
these three pillars in parallel have enabled us to condense our design cycles and more quickly develop high quality, differentiated product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rapid generation of crystallographic data </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have streamlined the use of protein crystallography for visualizing the interaction of our potential product candidates with binding
pockets of protein kinases. Through our proprietary methods, we can rapidly induce crystal formation and enhance crystal durability. Together, this reduces the time required to generate new crystal structures. We routinely generate <FONT
STYLE="white-space:nowrap">co-crystal</FONT> structures on newly synthesized compounds in as little as three days, a pace that allows us to continually refresh and, we believe, improve our insights into the features and structures that enable us to
discover compounds that are potent and selective inhibitors of our targets. In the last year alone, we generated over 120 crystal structures. The rapid and iterative nature of our proprietary approach also allows us to address known mutations and
potentially avoid future mutations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While conventional discovery approaches prioritize computational simulations based on a small number
of structures or structural models, we believe the ability to generate a large amount of empirical data obtained from many protein crystal structures is more informative and allows us to better design our product candidates. We are able to sustain
rapid crystallography throughput, enabling the generation of graphical images of protein structures with and without bound inhibitors that, when combined with enzyme, cell and <I>in vivo</I> assays, comprise molecular SN&Aring;Pshots. These
structures show the exact binding conformation of small molecules to our protein targets as well as the variations in protein structure that they induce at a resolution down to a single tenth of an angstrom (&Aring;). We iterate rapidly between the
wet lab and the crystallography lab and believe that the resulting datasets provide us with robust empirical data more quickly relative to conventional approaches as we seek innovative compounds that can potentially overcome acquired drug resistance
seen with other kinase inhibitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g41x73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>We capture variations in ligand-protein interactions by generating molecular SN&Aring;Pshots of many
ligands </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B><I>This figure shows several structures of the same protein, which has been
<FONT STYLE="white-space:nowrap">co-crystallized</FONT> with different inhibitors. Certain regions of the protein, shown as dark gray loops, assume different conformations in the presence of different ligands. The plasticity of the protein revealed
by these structures informs our drug design.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Custom cell-based assays </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Determining the potency, selectively and cytotoxicity of our compounds early through custom cell-based assays allows us to rapidly evaluate,
design and optimize our potential product candidates. The cell-based assays we use are a combination of cell lines derived from naturally occurring tumors and treatment-resistant tumors as well as engineered cell lines in which specific kinases or
kinase mutations are introduced to create panels of isogenic cells. By providing direct evidence of cell penetration and target engagement, we believe these assays yield more meaningful information about the potential of our compounds compared to
the artificial system of purified proteins used in standard enzymological screens. While we also assess the potency and selectivity of our compounds using enzyme assays, these assays primarily serve to provide concordance to the validity of our
cell-based assays. As a result, these cellular systems are our primary screening tools to progress our potential product candidates. We are able to run newly synthesized compounds through these cell-based assays in as little as two days, helping to
drive a rapid, iterative drug design cycle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In vivo </B><B><I>models</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ability to rapidly assess the potential of our compounds through <I>in vivo</I> models to determine their pharmacokinetic/pharmacodynamic
parameters in addition to their target-specific antitumor activity is paramount. We establish and validate the majority of our models <FONT STYLE="white-space:nowrap">in-house,</FONT> which allows us to rapidly test new compounds and to collect
actionable data in as little as five days. We feed this information back into our design cycle, allowing us to condense the traditional drug discovery timeline, prior to commencing clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A tight compound design, synthesis and testing loop </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our philosophy is to execute activities such as obtaining crystal structures, assaying for cellular activity and generating <I>in vivo</I>
data not as a set of sequential steps, but rather in concurrence in order to save time. Whereas more traditional drug discovery efforts may rely upon the availability of crystallographic and <I>in vivo</I> model data at monthly intervals, we strive
to generate this data on a weekly basis. We do not wait to determine if a compound passes a potency test in a cell-based assay before evaluating it in other assays, with the explicit understanding that there is key knowledge to be gained from
compounds that are not as potent as expected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g46h40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our synchronized and compressed data generation cycle time allows us to accelerate drug discovery by
allowing the execution of more drug design cycles in a fixed amount of time </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ever-growing understanding of protein and inhibitor
interactions, deepened by the crystal structures we continue to generate, provides insights that we leverage in product candidate engineering. We combine these potency and selectivity predictions with metabolic stability, bioavailability and
pharmacokinetics data to design small molecules with the chemical properties required to become potential product candidates. In a single weekly drug discovery cycle, we profile newly synthesized compounds as follows. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Generating a crystal structure with a target protein in as little as three days. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluating activity in <FONT STYLE="white-space:nowrap">&#145;on-target&#146;</FONT> and <FONT
STYLE="white-space:nowrap">&#145;off-target&#146;</FONT> cell-based assays in as little as two days. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Measuring tumor growth inhibition, or TGI, of newly synthesized compounds in as little as five days.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Taken together, the high-resolution structural data and preclinical experiments inform new chemistry designs that are
rapidly synthesized for evaluation in our next weekly drug discovery cycle. This process, enabled by trade-secrets and proprietary engineered assays, comprises our SN&Aring;P platform. Our highly experienced team of medicinal chemists efficiently
utilizes our platform to rapidly synthesize compounds designed to further optimize potency and selectivity, among other properties, while avoiding interactions with mutations which are known to induce drug resistance to other kinase inhibitors. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g01h01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SN&Aring;P platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Targeted Oncology </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Targeted oncology
therapies approved by the FDA in the past three years have received their initial approvals in as little as three years after their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> dosing began. FDA
guidance notes that the agency has at times accepted data from <FONT STYLE="white-space:nowrap">single-arm</FONT> clinical trials as substantial evidence for accelerated approvals of oncology therapies. Based on these precedents, subject to
consultation with the FDA, we believe that our product candidates may be eligible for accelerated approval by the FDA should they demonstrate appropriate safety and efficacy in our clinical trials. However, we have not filed an IND for any of our
product candidates, nor have we applied for accelerated approval by the FDA, and as a result, there can be no assurance that an accelerated pathway will be available for us or that it will lead to a faster development process or a faster regulatory
review. While an accelerated pathway may potentially expedite development or the approval process, it does not change the FDA&#146;s standards of approval or increase the likelihood that a product candidate will receive approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g57n46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Approval of targeted oncology therapies in the past three years has been granted in as little as three
years from initial testing in the clinic </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our FGFR3 <FONT STYLE="white-space:nowrap">Program&#151;TYRA-300</FONT> Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> a selective inhibitor of FGFR3, for the treatment of FGFR3-driven cancers
initially for patients with bladder cancer who are resistant to FGFR therapies. Resistance to approved and investigational FGFR inhibitors has been shown to arise due to mutations in the gatekeeper region of FGFR3. We have designed <FONT
STYLE="white-space:nowrap">TYRA-300</FONT> to avoid this region of FGFR3 and, in preclinical models to date, <FONT STYLE="white-space:nowrap">TYRA-300</FONT> has demonstrated similar potency against both wild-type and resistant FGFR3 targets. We
believe this differentiation will enable us to expand into multiple cohorts of FGFR3-driven cancer including patients na&iuml;ve to FGFR therapy, tumor agnostic populations, as well as patients with high-risk NMIBC. Although no head-to-head clinical
trials have been conducted, we believe the use of comparative <I>in vitro </I>and <I>in vivo</I> data from pre-clinical studies provides meaningful insight into the potential for our product candidates to improve on certain characteristics of
approved and investigational FGFR inhibitors, and helps inform potential future clinical development of our product candidates. We anticipate filing an IND for <FONT STYLE="white-space:nowrap">TYRA-300</FONT> with the FDA in mid-2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Opportunity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bladder cancer disease
background </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Bladder cancer is one of the most common malignancies involving the genitourinary system. Patients with bladder cancer
classically present with painless blood in the urine. However, because this symptom is similar to those of benign disorders, such as urinary tract infections, cystitis, prostatitis and the passage of kidney stones, diagnosis of bladder cancer can
take time as these other, more common, conditions are ruled out. Delays in diagnosis can lead to worsened outcomes due to the presence of more advanced stage disease by the time a diagnosis of bladder cancer is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An estimated 83,730 new cases of bladder cancer and 17,200 deaths are projected for 2021 in the United States. Globally, bladder cancer
accounted for approximately 550,000 cases and 200,000 deaths in 2018. Bladder cancer is classified into two broad categories: NMIBC where the cancer is restricted to surface lining of the bladder; and MIBC, which is a cancer that has grown deeper
into the bladder wall and has a higher potential to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
spread beyond the bladder. Approximately 30% of newly diagnosed cases of bladder cancer are MIBC. Of the remaining 70% of new diagnoses of bladder cancer that are NMIBC cases, an estimated 10 to
15% progress to MIBC. Whereas the five-year survival for early stage NMIBC is 96%, it falls to 6.4% for metastatic MIBC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FGFR3 is a
protein receptor expressed on the cell surface that stimulates cellular proliferation upon binding of fibroblast growth factor. Uncontrolled activation of FGFR3 has been implicated in the oncogenesis of multiple solid tumor types. The incidence of
activating FGFR3 mutations in bladder cancer has been estimated to be as high as 75% in NMIBCs and up to 20% of MIBC making FGFR3 an attractive target for development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of current therapies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Standard of care
and current limitations for the treatment of locally advanced or metastatic MIBC </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients suffering from locally advanced or
metastatic MIBC have limited treatment options and there continues to be a high unmet need. These options come with significant toxicities, lack of durable response and potential diminished quality of life. The initial standard treatment for
patients is typically platinum-based chemotherapy with cisplatin (or carboplatin) in combination with gemcitabine. Unfortunately, the median overall survival for patients treated with chemotherapy is only 12.7 months.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>Following chemotherapy, patients may receive immunotherapies, such as Bavencio<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (avelumab) as maintenance therapy or Keytruda<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) after progression on chemotherapy. Responses to immunotherapy are limited and overall survival for immunotherapy is 10.3 months on average. Alternatively, patients may also
receive other chemotherapies, such as Taxotere<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (docetaxel), Taxol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (paclitaxel), or Javlor<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (vinflunine) alone, however overall survival is typically no greater than 7 to 9 months in select patients. Recent Phase 3 data demonstrated that the antibody-drug conjugate Padcev<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (enfortumab vendotin) improved overall survival to 12.8 months compared to chemotherapy following disease progression after initial chemotherapy and immunotherapy. The relativity low overall
survival data comes with significant toxicities and we believe highlights the unmet need for therapies with greater efficacy and tolerability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Standard of care and current limitations for the treatment of localized MIBC </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients suffering from localized MIBC are potentially curable with surgery, which may include trans-urethral resection, or TURBT, partial
cystectomy (partial removal of the bladder), or radical cystectomy (complete removal of the bladder and nearby lymph nodes) depending on the stage of the tumor. For those who are not physically able or willing to undergo surgery, localized radiation
to the bladder is an option, but local recurrence rates are high, survival rates are no better than surgery, and few contemporary randomized studies have been performed comparing radiation and surgery in the same population of patients. TURBT and
partial cystectomy are reserved for highly selected patients with earlier stage tumors, often combined with neoadjuvant chemoradiotherapy for those who are willing and able to tolerate such aggressive therapy. Despite these strict criteria,
recurrence rates are high as high as 60% in some series. For the majority of patients who can have surgery, complete removal of the bladder and lymph nodes remains the only potentially curative treatment option. However, despite such a life altering
operation, recurrence of metastatic disease is estimated to be 50%, highlighting the need for adjuvant therapies that can decrease the risk of recurrence. There are no currently approved therapies for the adjuvant treatment of patients following
surgery for bladder cancer, though a number of immunotherapies are being studied in this setting. We believe that effective therapies that can reduce the rate of recurrence following surgery remains a high unmet need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Standard of care and current limitations for the treatment of NMIBC </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NMIBC comprises the largest population of bladder cancer patients, representing <FONT STYLE="white-space:nowrap">70-75%</FONT> of cases
diagnosed annually in the United States. Initial evaluation consists of local resection to confirm the diagnosis and establish the grade and stage of the tumor. The majority of cases are low grade lesions confined to the lining of the bladder.
However, a significant proportion are considered high risk for recurrence. Treatment of NMIBC is directed at reducing recurrences and preventing progression to a more advanced stage. For low grade lesions,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
local resection with or without adjuvant Bacillus Calmette-Guerin, or BCG, and close follow up are usually successful in curing the disease, whereas high risk lesions should be treated with
either adjuvant BCG or radical cystectomy. Recurrence overall for NMIBC is <FONT STYLE="white-space:nowrap">30-70%,</FONT> but for high risk patients, <FONT STYLE="white-space:nowrap">5-year</FONT> recurrence rates are as high as 80%, with
progression to muscle invasive disease in up to 50% of patients. An additional 10-15% will recur with metastatic disease. Following recurrence of NMIBC, few bladder-sparing options are available to prevent future recurrences and disease progression.
Those with NMIBC that recurs following BCG and are unable or refuse surgery may be treated with pembrolizumab, which was approved based on a complete response rate of 41% and a median duration of response of 16.2 months, highlighting the need for
the majority of patients for additional treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FGFR Inhibitors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients with genetic alterations in FGFR3 can be treated with FGFR inhibitors. Currently, the only FDA approved FGFR inhibitor for locally
advanced or metastatic MIBC is erdafitinib, which received accelerated approval in the United States in 2019. In clinical trials, erdafitinib demonstrated a 32.2% overall response rate and a median duration of response of 5.4 months. We believe one
of the key limitations to erdafitinib&#146;s duration of response is the emergence of mutations like the gatekeeper mutation. In addition, this mutation may impact the efficacy of other first generation FGFR inhibitors such as infigratinib,
pemigatinib and futibatinib. In a study of infigratinib and other FGFR inhibitors, the mutation that has been described in patients is the valine to methionine gatekeeper mutation at the V555 position of FGFR3, which results in a significant shift
in potency of all of the first generation FGFR inhibitors. Once patients progress due to acquired drug resistance, there are very few options available, representing a significant unmet need in this patient population. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g08h16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FGFR gatekeeper mutations block binding, resulting in a loss of potency in first generation FGFR
inhibitors such as erdafitinib </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Erdafitinib is a <FONT STYLE="white-space:nowrap">pan-FGFR</FONT> inhibitor and due to its lack of
selectivity there may be toxicities associated with the inhibition of FGFR receptors 1, 2 and 4. FGFR1 is expressed in kidney cells where it regulates phosphate and calcium reabsorption, and inhibition of FGFR1 results in hyperphosphatemia.
Hyperphosphatemia was the dose-limiting toxicity and was reported in over 70% of patients in a clinical trial of erdafitinib. Hyperphosphatemia and other toxicities contributed to interruptions in 68% of patients and dose reductions in 53% of
patients. We believe this is a key limitation of erdafitinib&#146;s efficacy. A similarly high rate of FGFR-related toxicities has been reported in clinical trials of other <FONT STYLE="white-space:nowrap">non-isoform</FONT> selective FGFR
inhibitors including pemigatinib, infigratinib and futibatinib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Approximately <FONT STYLE="white-space:nowrap">60-80%</FONT> of NMIBC has
been shown to carry FGFR3 gene alterations, the majority of which are activating point mutations. There are currently no approved therapies for FGFR3-driven NMIBC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients who have recurred following adjuvant BCG therapy. FGFR inhibitors have the potential to be highly efficacious in NMIBC, as demonstrated by three complete responses in four clinical trial
patients with NMIBC treated with infigratinib. However, toxicities associated with this <FONT STYLE="white-space:nowrap">pan-FGFR</FONT> inhibitor in that trial resulted in poor tolerability and limited treatment duration, and the trial was
terminated early. We believe a highly specific FGFR3-directed inhibitor, with minimal effects from other FGFR-related toxicities, could be highly efficacious and represents an attractive future market opportunity for our product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe the limitations of current standard of care therapies, as well as the liabilities of first generation FGFR inhibitors, necessitates
a solution that can address this unmet need and improve patient outcomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solution, <FONT STYLE="white-space:nowrap">TYRA-300</FONT>
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In preclinical models to date, <FONT STYLE="white-space:nowrap">TYRA-300</FONT> has demonstrated potency against the gatekeeper
mutation and selectivity for FGFR3. Although no head-to-head clinical studies have been conducted, we believe that these pre-clinical studies assist with the characterization of our product candidates and inform future clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">TYRA-300</FONT> is active in a bladder cancer xenograft model </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">UM-UC-14</FONT></FONT> is a human bladder cancer cell line which contains an
FGFR3 S249C activating mutation. <FONT STYLE="white-space:nowrap">TYRA-300</FONT> was tested in a preclinical mouse xenograft model using this cell line, as seen in the figure below. <FONT STYLE="white-space:nowrap">TYRA-300</FONT> given either once
daily, or QD, at a dose of 18&nbsp;mg/kg or twice daily, or BID, at a dose of 9&nbsp;mg/kg led to substantial inhibition of tumor growth in this model. We observed 90% tumor growth inhibition, or TGI, at the 9&nbsp;mg/kg BID dose and 96% TGI at the
18&nbsp;mg/kg QD dose. We observed 91% TGI with erdafitinib using a 12.5&nbsp;mg/kg BID dose in this study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g11j44.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TYRA-300</FONT> tumor growth inhibition in a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">UM-UC-14</FONT></FONT> xenograft model </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Antitumor activity in the FGFR3 S249C activating mutant UM-UC-14
bladder cancer xenograft model in nu/nu mice of various doses of TYRA-300 (3, 6, and 9 mg/kg BID, upper left; and 6, 12, and 18 mg/kg QD, lower left) and erdafitinib (12.5&nbsp;mg/kg BID) shown in both the upper and lower left. Body weight averages
for the dose groups depicted in the upper and lower left are shown in the upper and lower right, respectively. All doses were by oral administration. No TGI was observed for TYRA-300 at 3 mg/kg BID. TGI observed for the other TYRA-300 doses is shown
in parentheses; 6&nbsp;mg/kg BID (53%), 9 mg/kg BID ( 90%), 6&nbsp;mg/kg QD (46%), 12&nbsp;mg/kg QD (80%), and 18&nbsp;mg/kg QD (96%). We observed 91% TGI for 12.5&nbsp;mg/kg BID erdafitinib. Data points represent mean tumor volume (n=6 per group
except 6 mg/kg BID <FONT STYLE="white-space:nowrap">TYRA-300</FONT> dosing group where one animal was found dead at day&nbsp;7 of treatment where n=5) and error bars represent standard error of the mean. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In this model, we used a salt form of TYRA-300, and the vehicle is 30% hydroxypropyl beta cyclodextrin, or HP-&szlig;-CD, for both the
erdafitinib and TYRA-300 groups. Based on the results of this study, we expect to use a salt form of TYRA-300 for future TYRA-300 development. The salt form/cyclodextrin formulation used here replaces the polyethylene glycol 400 formulation we used
in the bladder cancer xenograft model utilizing the RT112/84 +/- V555M immortalized cancer cell line, as described further on page&nbsp;116 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potent inhibition of FGFR3 mutants including gatekeeper mutations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We utilized our SN&Aring;P platform to design <FONT STYLE="white-space:nowrap">TYRA-300</FONT> to avoid any interactions with the gatekeeper
region of FGFR3, which most other FGFR kinase inhibitors rely on for potency. In a bladder cancer xenograft model, we observed that we could obtain FGFR3 potency roughly equivalent to that of erdafitinib, by targeting other parts of the kinase
active site. Although no head-to-head clinical studies have been conducted, this design strategy provides what we believe is a key advantage in that FGFR3 proteins containing gatekeeper mutations, such as V555M, were inhibited by <FONT
STYLE="white-space:nowrap">TYRA-300</FONT> with very similar potency to wild-type FGFR3. Other FGFR inhibitors were at least <FONT STYLE="white-space:nowrap">30-fold</FONT> less potent versus FGFR3 V555M. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g10h10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TYRA-300</FONT> retained potency against multiple potential acquired
drug resistance mutations in FGFR3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g11k11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TYRA-300</FONT> retained potency in a V555M CRISPR mutated RT112/84
immortalized cancer cell line </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ability of <FONT STYLE="white-space:nowrap">TYRA-300</FONT> to maintain potency against the V555M
gatekeeper mutation, as observed in <I>in vitro</I> assays conducted to date, was tested in a preclinical xenograft model containing an FGFR3 fusion, as seen in the figure below. <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> at a dose of 12.5
mg/kg twice daily, led to significant inhibition of tumor growth in this model. We also observed inhibition of tumor growth by erdafitinib at a dose of 12.5 mg/kg twice daily in this model. We engineered a gatekeeper mutation into the cell line used
for this model. We observed 77% inhibition of tumor growth by <FONT STYLE="white-space:nowrap">TYRA-300</FONT> in xenografts using the cell line containing the gatekeeper mutation, while we observed 12% tumor growth inhibition in the gatekeeper
xenograft treated with erdafitinib.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g13k52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TYRA-300</FONT> tumor growth inhibition was maintained in the presence
of the FGFR3 V555M gatekeeper mutation in a RT112/84 xenograft model </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Anti-tumor activity of
<FONT STYLE="white-space:nowrap">TYRA-300</FONT> (95% TGI, upper left) and erdafitinib (73% TGI, lower left) dosed twice daily, or BID, by oral administration in the FGFR3::TACC3 fusion activating RT112/84 bladder cancer xenograft model in Balb/c
nude mice. Data points represent mean tumor volume (n=8 per group on left, n=6 per group on right) and error bars represent standard error of the mean. To test the effect of the gatekeeper mutation on tumor growth inhibition, we introduced the V555M
mutation into the FGFR3::TACC3 fusion gene in the RT112/84 cell line using CRISPR. Anti-tumor activity in this isogenic gatekeeper containing model was evaluated using <FONT STYLE="white-space:nowrap">TYRA-300</FONT> (77% TGI, upper right) and
erdafitinib (12% TGI, lower right) dosed BID by oral administration. The erdafitinib delivery vehicle in this experiment is 20% hydroxypropyl beta cyclodextrin and the TYRA-300 delivery vehicle is polyethylene glycol 400. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>High selectivity for FGFR3 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Designing inhibitors that bind to the <FONT STYLE="white-space:nowrap">ATP-binding</FONT> site and can selectively differentiate between FGFR3
and FGFR1 is challenging due to the near-identical amino acid sequence in this site. We utilized the differentiated approach of our SN&Aring;P platform to generate compounds, including <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> that
capitalize on subtle conformational differences between FGFR3 and FGFR1 to obtain greater than <FONT STYLE="white-space:nowrap">ten-fold</FONT> selectivity for FGFR3 versus FGFR1. In comparison, other FGFR inhibitors that are approved or in clinical
development such as erdafitinib, pemigatinib, futibatinib and infigratinib, have demonstrated low or no selectivity for FGFR3. The high FGFR3-specificity that we observed to date for our potential product candidates for FGFR3 also extended to the
broader family of protein kinases, where we showed that very few kinases were inhibited by our potential product candidates. Although we have not conducted any head-to-head clinical studies, we believe that
<FONT STYLE="white-space:nowrap">TYRA-300&#146;s</FONT> relative selectivity for FGFR3 observed in pre-clinical studies may address dose limiting toxicities of the first generation compounds, enabling higher dosing and potentially better efficacy.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g56t68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TYRA-300</FONT> was highly selective for FGFR3 over other FGFR isoforms
in a Ba/F3 cell-based assay </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beyond selectivity for FGFR3 relative to FGFR1, FGFR2 and FGFR4, TYRA-300 avoided off-target inhibition
of other kinases when profiled in a scanMAX<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> (KINOMEscan) screen. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g69w77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TYRA-300</FONT> was highly selective for FGFR3 over other protein
kinases </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phosphate levels in vivo </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In a xenograft model using a bladder cancer-derived cell line RT112/84 shown above, treatment with
<FONT STYLE="white-space:nowrap">TYRA-300</FONT> led to tumor regression at a dose of 12.5 mg/kg delivered twice a day. Treatment with erdafitinib also resulted in tumor volume reduction at the same dose in this model. Because the human dosing of
erdafitinib is limited by hyperphosphatemia we measured the plasma phosphate levels in male Sprague Dawley rats 24 hours after dosing. Plasma phosphate levels in TYRA-300 treated rats were not substantially elevated at 10 mg/kg, 30 mg/kg, or 60
mg/kg doses, unlike the erdafitinib doses, as seen in the figure below. We believe <FONT STYLE="white-space:nowrap">TYRA-300</FONT> may be able to sustain higher doses without inducing hyperphosphatemia. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g27q75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TYRA-300 did not elevate phosphate relative to erdafitinib </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Effect of a single oral dose (10, 30 or 60 mg/kg) of TYRA-300 or erdafitinib on plasma phosphate levels 24 hours after dosing in male
Sprague Dawley rats. Each data point represents the plasma phosphate measurement from the pooled sample of all 4 rats per dose group. Plasma phosphate levels were observed to be lower in the TYRA-300 treated groups than in the erdafitinib treated
groups. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development plans for <FONT STYLE="white-space:nowrap">TYRA-300</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently conducting IND-enabling studies for TYRA-300. In a completed 10-day non-GLP toxicology study in rats, TYRA-300 was well
tolerated at dose levels up to 20 mg/kg in both males and females. We intend to conduct GLP toxicology studies in animals of TYRA-300 using the salt form/cyclodextrin formulation as part of our IND-enabling activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to file an IND with the FDA for <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> followed by initiation of a Phase 1/2 clinical
trial. We anticipate that the Phase 1 portion of the trial will be designed as an accelerated dose escalation in any advanced solid tumor refractory to existing therapies, including dose expansion cohorts of patients with FGFR3-positive cancers. We
expect the primary objectives of the Phase 1 portion of the trial to be an evaluation of the safety and tolerability of <FONT STYLE="white-space:nowrap">TYRA-300</FONT> and a determination of the recommended Phase 2 dose, or RP2D. In addition, we
plan to characterize the pharmacokinetic/pharmacodynamic relationship for <FONT STYLE="white-space:nowrap">TYRA-300</FONT> as well as conduct early validation of a liquid biopsy companion diagnostic test to assist us in identifying appropriate
patients for our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are designing the Phase 2 portion of our trial to be consistent with the well-established
precedent of clinical trials of approved targeted therapies. If the data from any or all of these predefined patient populations are sufficient to support marketing authorization, we expect to seek feedback from the FDA in order to evaluate our
ability to pursue and receive accelerated approval in the United States. We have not had any initial feedback from the FDA relating to our plans to pursue accelerated approval in the United States, and there can be no assurance that after our
evaluation of the feedback and other factors, we will decide to pursue accelerated approval or any other form of expedited development, review or approval. We initially plan to evaluate <FONT STYLE="white-space:nowrap">TYRA-300</FONT> in the
following three populations of FGFR3-positive tumors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Metastatic MIBC (mUC) patients who have received an FGFR inhibitor previously and have developed resistance to
that inhibitor due to an FGFR3 mutation, such as the gatekeeper V555M. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Metastatic MIBC (mUC) patients who have not yet received an FGFR inhibitor where we believe a reduction in
toxicities and side effects, as well as the avoidance of the selection for the V555M gatekeeper mutations, have the potential to lead to improved tolerability, higher dosing and increasing the duration of responses. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any solid tumors containing known activating FGFR3 gene alterations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If TYRA-300 is well-tolerated, we plan to evaluate additional patient populations as adjuvant therapy for localized MIBC following surgery and
in recurrent NMIBC following BCG therapy, where reduction in side effects are a significant consideration for treatment choice and patient adherence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to select a diagnostic company to use a liquid biopsy companion diagnostic test to aid in identifying appropriate patients for this
clinical trial. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g55q10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential indications for <FONT STYLE="white-space:nowrap">TYRA-300</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>FGFR3 mutations in initial patient populations include S249C, R248C, Y373C, G370C and FGFR3-TACC3 fusions with a resistance mutation
including the V555 gatekeeper. FGFR3 mutations in <FONT STYLE="white-space:nowrap">follow-on</FONT> patient populations that are na&iuml;ve to FGFR therapy include S249C, R248C, Y373C, G370C and FGFR3-TACC3 fusions. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our FGFR2 inhibitor discovery program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently evaluating several small molecule inhibitors of FGFR2 for the treatment of FGFR2-dependent cancers, initially for patients
with ICC who are resistant to FGFR therapies. Similar to therapies designed for the treatment of FGFR3-driven cancers, resistance to both approved and investigational FGFR inhibitors have been shown to arise due to mutations in FGFR2. We have
designed our small molecule inhibitors of FGFR2 to be active against multiple acquired resistant mutations that arise during treatment with other FGFR2 inhibitors. Although no head-to-head clinical trials have been conducted, we believe the use of
comparative in vitro data from pre-clinical studies provides meaningful insight into the potential for our product candidates to improve on certain characteristics of approved and investigational FGFR inhibitors, and helps inform potential future
clinical development of our product candidates. We plan to file an IND for a nominated product candidate in the second half of 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ICC disease background </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ICC is a form of cancer that originates in the bile ducts, which are a series of thin vessels that transport bile from liver cells to the
small intestine. Diagnosis of ICC is often difficult as it is not associated with any specific symptoms other than dull abdominal pain, weight loss and elevated liver enzymes. ICC is a rare tumor, accounting for only 3% of worldwide gastrointestinal
malignancies, with an incidence in the United States estimated to be 0.95 cases per 100,000. However, the incidence of this disease has risen in the past 30 years. The median overall survival for all patients diagnosed with ICC is reported to be
16.1 months. The median overall survival for patients diagnosed with late-stage disease is less than one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FGFR2 is a protein
receptor present on the cell surface that promotes cellular proliferation and transformation upon binding of fibroblast growth factor. Similar to FGFR3, activating mutations and fusions of FGFR2 have been implicated in the tumorigenesis of multiple
solid tumor types. Approximately <FONT STYLE="white-space:nowrap">15-20%</FONT> of patients with ICC have genetic alterations in FGFR2, which are primarily gene fusions and activating mutations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Standard of care and current limitations for the treatment of ICC </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Currently, surgical recession is the only curative option available to ICC patients. However, only approximately <FONT
STYLE="white-space:nowrap">one-third</FONT> of patients are eligible for surgery at diagnosis. The remaining patient population with unresectable tumors are typically treated with chemotherapies. The recommended frontline regimen is a combination of
gemcitabine and cisplatin, which offers a median overall survival benefit of 11.7 months. Upon disease progression, patients with actionable mutations, such as FGFR2 alterations, are eligible to receive targeted therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FGFR inhibitors </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients with
genetic alternations in FGFR2 are eligible to be treated with pemigatinib, an FGFR inhibitor that received accelerated approval in the United States in 2020 for treatment following chemotherapy. In the Phase 2 clinical trial of pemigatinib for the
treatment of ICC, the overall response rate with was 36% with a median duration of response of 9.1 months. We believe a critical unmet need for patients with FGFR2 fusion or FGFR2-altered ICC is balancing the potency for the wild type and the
numerous <FONT STYLE="white-space:nowrap">on-target</FONT> resistance mutations that emerge in patients treated with pemigatinib and current clinical stage drug candidates. The most frequently occurring acquired drug resistance mutations are active
site mutations such as the gatekeeper and amino acids comprising the molecular brake. These mutations, as well as allosteric <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function</FONT></FONT> mutations, have been
observed clinically to confer resistance to pemigatinib and additional late stage FGFR inhibitors. We believe maintaining potency against these mutations as well as wild-type FGFR2 could potentially improve efficacy and duration of response. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g17b47.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Acquired drug resistance is common in patients with ICC treated with FGFR inhibitors
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solution </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are
currently evaluating several small molecule inhibitors of FGFR2 designed to be active against multiple acquired resistance mutations that arise during treatment with other FGFR inhibitors. In preclinical models conducted to date, our compounds
demonstrate similar potency in FGFR2-driven Ba/F3 cells to erdafitinib, pemigatinib, futibatinib or infigratinib, while reducing or eliminating the decrease in potency observed with N550K molecular brake and V565F/V56I gatekeeper resistance
mutations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g189651g57k04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our FGFR2 inhibitors retained potency against multiple potential acquired resistance mutations in FGFR2
</B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g03i80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tumor growth inhibition in <FONT STYLE="white-space:nowrap">SNU-16</FONT> and AN3CA xenograft models
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Anti-tumor activity of pemigatinib (1 mg/kg once daily, or QD, oral dosing, n=6, upper left) was evident in the SNU-16 stomach
carcinoma-derived xenograft model in Balb/c nude mice. SNU-16 cells contained an FGFR2 amplification. Pemigatinib at 1 mg/kg QD oral dosing (n=4) was not observed to be active in the AN3CA model (lower left). On the right panel, antitumor activity
of the TYRA compounds (10 mg/kg BID oral dosing, n=4 per group) was evident in the uterine derived AN3CA xenograft model in Balb/c nude mice. AN3CA cells contained the N550K molecular brake mutation in FGFR2. Data points represent mean tumor volume
and error bars represent standard error of the mean. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development plans for our FGFR2 inhibitor </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following anticipated product candidate nomination by the end of 2021 and anticipated IND submission in the second half of 2022, we plan to
pursue a clinical development strategy similar to that of <FONT STYLE="white-space:nowrap">TYRA-300.</FONT> We anticipate initially developing an FGFR2 inhibitor in patients with ICC who have developed drug resistance mutations from existing FGFR
therapies, including the V565 gatekeeper or N550 molecular brake mutations. We believe there is potential for an FGFR2 inhibitor beyond this initial patient population, including in FGFR-treatment na&iuml;ve patients with ICC and in patients with
endometrial carcinoma, where up to 10-16% of patients have FGFR2 mutations. Beyond these cohorts, we intend to assess the efficacy of our drug candidate in other patient populations with activating gene alterations in FGFR2, such as colorectal
cancer, melanoma, breast cancer, ovarian cancer, gastroesophageal cancer and lung cancer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g89h11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential indications for our FGFR2 inhibitor </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opportunity for a second <FONT STYLE="white-space:nowrap">non-oncology</FONT> FGFR3 selective inhibitor </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beyond oncology, FGFR3 is implicated in many other diseases, including achondroplasia, due to its role in regulating bone and cartilage
formation. We believe that there is an opportunity to develop a second FGFR3 selective inhibitor for the treatment of long-term complications associated with achondroplasia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Achondroplasia background </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Achondroplasia, the most common form of dwarfism, is a disorder of bone that prevents proper cartilage growth and development, resulting in
incomplete growth of the long bones in the arms and legs, malformation of the spine and chest and characteristic facial features. It occurs in approximately 1 in 15,000 to 40,000 newborns worldwide, and it is estimated that there are approximately
250,000 affected individuals worldwide. Achondroplasia can cause health complications such as restriction of breathing, obesity, recurrent ear infections and exaggerated inward curve of the spine as well as more serious problems that result from a
narrowing of the spinal canal in infants at the base of the skull. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FGFR3 is normally expressed in chondrocytes (cartilage cells) in
growth plates where it plays a role in bone growth. In achondroplasia, mutations cause FGFR3 to be overactive, resulting in deficiencies in bone formation, primarily in long bones, causing these bones to be shorter than normal. Because the mutation
in FGFR3 is an activating mutation, the presence of a single copy of a mutated gene results in increased activity and achondroplasia. Approximately 80% of cases of achondroplasia arise through spontaneous mutation of FGFR3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unmet need in achondroplasia </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are currently no effective treatments that directly address the cause of achondroplasia. Individuals may undergo surgery to correct
spine or bone abnormalities and to reduce the pressure inside the brain in cases of hydrocephaly. A more direct approach to addressing the short stature in achondroplasia is limb lengthening surgery. In
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this type of surgery, rods are inserted into the long bones and used to stretch the limbs. These surgeries are typically performed in younger patients who are still undergoing active bone growth.
However, these therapies have both a high financial and social cost, as well as potential for complications associated with any orthopedic procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opportunity for FGFR3 inhibitor </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that an oral, highly selective inhibitor of mutant FGFR3 may address long-term complications in affected individuals, including
spinal stenosis, scoliosis and respiratory problems, alleviating the need for multiple painful surgeries and improving quality of life for this patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our RET and FGFR4 inhibitor discovery programs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RET and FGFR4 are both RTKs that perform important cell-signaling functions and are susceptible to oncogenic genetic alterations. Both RET and
FGFR4 can lead to malignancies across multiple tumor types. In certain <FONT STYLE="white-space:nowrap">RET-driven</FONT> tumors, Retevmo<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> (selpercatinib) and Gavreto<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pralsetinib) are both approved by the FDA, however, drug resistant mutations have emerged. For FGFR4-driven tumors, there are no currently approved therapies. Acquired drug resistance due to
tumor mutation has been observed in current clinical stage drug candidates. This acquired drug resistance can limit drug durability, creating unmet need. We intend to utilize our SN&Aring;P platform to develop product candidates that can potentially
overcome drug resistant mutations and potentially improve patient outcomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prevalence of RET alterations in cancer </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RET is an RTK that is essential for neuronal and embryonic development. Activating genetic alterations such as gene fusions and point
mutations in RET are oncogenic. In non-small cell lung cancer, or NSCLC, and papillary thyroid carcinoma, or PTC, RET gene fusions lead to constitutive activation and oncogenesis. In NSCLC, 1 to 2% of patients who are negative for mutations or
rearrangements in other common oncogenic drivers such as EGFR, ERBB2, BRAF, KRAS and ALK, have RET fusions. In PTC, the most common form of thyroid cancer, an estimated 35% of cases in North America and up to 65% of cases in other geographies are
associated with RET fusions. In sporadic medullary thyroid carcinoma, or MTC, approximately half of patients have activating mutations in RET, whereas in familial cancer syndromes, such as MEN2B, germline RET mutations at M918T predispose carriers
to MTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of current RET inhibitors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The first FDA approved therapies for RET-driven tumors were Caprelsa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (vandetanib)
and Cabometyx<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (cabozantinib), both of which are multi-kinase inhibitors approved for MTC that has progressed on standard therapy or is symptomatic and in need of treatment. Selpercatinib and
pralsetinib are highly specific <FONT STYLE="white-space:nowrap">next-generation</FONT> RET inhibitors that have received accelerated approval in patients with RET-dependent tumors including NSCLC, PTC and MTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Both vandetanib and cabozantinib were approved in MTC without a restriction to the <FONT STYLE="white-space:nowrap">RET-mutated</FONT>
population. For patients with MTC with activating RET mutations treated with these therapies, secondary resistance mutations at the gatekeeper position V804 arise during treatment and can be identified at the time of disease progression.
Selpercatinib and pralsetinib address a key liability of the first generation multi-kinase inhibitors at V804. In metastatic <FONT STYLE="white-space:nowrap">RET-fusion</FONT> positive patients with NSCLC that had previously failed platinum-based
chemotherapy, selpercatinib treatment led to a 62% response rate with a median duration of response of 17.5 months. In patients with <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> NSCLC, the overall response rate was 85%. An overall
response rate of approximately 70% was observed in <FONT STYLE="white-space:nowrap">RET-mutant</FONT> MTC regardless of whether patients had previously failed on other kinase inhibitor therapies. Roughly similar efficacy was observed in clinical
trials with pralsetinib. Both selpercatinib and pralsetinib received accelerated approval in the United States in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although
selpercatinib and pralsetinib were only recently approved and therefore do not have a long history of use, the emergence of acquired drug resistance mutations has already been observed at the G810 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solvent front. Based on the observed history with other targeted therapies in molecularly defined subgroups, we believe the use of these drugs will likely lead to additional resistance
liabilities over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our RET Program </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are planning to develop a <FONT STYLE="white-space:nowrap">RET-specific</FONT> inhibitor that is insensitive to the V804 gatekeeper and the
G810 solvent front mutations. Our drug discovery efforts are driven by our ability to gain molecular-level detail and insights from internally derived <FONT STYLE="white-space:nowrap">co-crystal</FONT> structures of selpercatinib, pralsetinib and
other inhibitors bound to RTKs. Recent publications have shown that these inhibitors have liabilities at the gatekeeper, the solvent front, or other parts of the <FONT STYLE="white-space:nowrap">ATP-binding</FONT> pocket. Our focus is to develop RET
inhibitors that address many of these key liabilities, an approach which we believe will allow our product candidates to demonstrate antitumor activity in patients who progress on current-generation RET inhibitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our initial development plans for our RET inhibitor product candidate will focus on patients who fail previous treatment with a RET inhibitor
due to acquired mutations in V804 or G810. We anticipate that our RET inhibitor will also have potential for antitumor activity in patients with RET <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> containing RET fusions or RET
activating mutations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g21w88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential patient populations for our RET inhibitor </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Role of FGFR4 in cancer </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FGFR4
regulates bile acid synthesis and hepatocyte proliferation in the liver in response to fibroblast growth factor 19, or FGF19. Amplification of the gene encoding FGF19 has been implicated in activation of FGFR4 through autocrine signaling and may
represent a biomarker that identifies a subpopulation of hepatocellular carcinoma, or HCC, that may be susceptible to FGFR4 inhibition. FGFR4 gene alterations such as activating point mutations and fusions have been identified in rare populations
such as pediatric rhabdomyosarcoma and a variety of other solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are currently no approved therapies for FGFR4-driven
cancers. Fisogatinib is an FGFR4 inhibitor in clinical development. A Phase 1 clinical trial with fisogatinib obtained tumor regression in patients with HCC with aberrant FGF19 expression, indicating that FGFR4 may be an important driver of disease
in select patients. Results from this trial led to the identification of FGFR4 mutations associated with acquired drug resistance. These mutations included V550 gatekeeper mutations and C552 mutations, both of which were found to cause a loss of
fisogatinib potency of more than <FONT STYLE="white-space:nowrap">1,000-fold.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our FGFR4 Program </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our FGFR4 drug discovery efforts are driven by our deep structural understanding of the FGFR family including over 40 co-crystal structures of
FGFR4 itself. We are planning to develop an FGFR4-specific inhibitor that is insensitive to the V550 gatekeeper and the C552 mutations. We anticipate that our product candidate will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also have potential for antitumor activity in patients with spontaneous FGFR4 activating mutations at the gatekeeper (V550) and molecular brake (N553), as well as in rare FGFR4 fusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Initial development plans for our FGFR4 inhibitor will focus on patients with FGF19-amplified HCC, activating point mutations in pediatric
rhabdomyosarcoma, and other rare populations with FGFR4 fusions and activating mutations. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g88d38.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential patient populations for our FGFR4 inhibitor </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and
biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our team, and our development experience and
scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private
research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the
market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and
retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our
competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer
or more effective, have fewer or less severe side effects, and are more convenient or less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we can,
which could result in our competitors establishing a strong market position before we are able to enter the market or could otherwise make our development more complicated. We believe the key competitive factors affecting the success of all of our
programs are likely to be efficacy, including duration of human response and breadth of coverage, safety and patient convenience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There
are numerous companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist of small molecule drug products, biologics, cell-based therapies, and traditional
chemotherapy. There are three currently approved <FONT STYLE="white-space:nowrap">pan-FGFR</FONT> inhibitors in the U.S.: Incyte Corporation&#146;s Pemazyre<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pemigatinib) and QED
Therapeutics&#146; Truseltiq<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (infigratinib), each approved for FGFR2 gene rearrangements in cholangiocarcinoma; and Janssen Biotech, Inc.&#146;s Balversa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (erdafitinib), approved in specific FGFR3 and FGFR2 gene alterations in urothelial cancer. Both Incyte (NCT03656536) and QED (NCT03773302) are conducting global Phase 3 confirmatory studies in
treatment-na&iuml;ve metastatic ICC, and Janssen is conducting a global Phase 3 confirmatory study in metastatic urothelial cancer in subjects who have received 1 or 2 prior therapies (NCT03390504). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the confirmatory study in ICC, pemigatinib is being studied in NMIBC
(NCT03914794); as adjuvant therapy following surgery for bladder cancer (NCT04294277); in tumor agnostic cancer populations (NCT04003623, NCT03822117); in combination with chemotherapy in ICC (NCT04088188); and in combination with immunotherapy in
endometrial cancer (NCT04463771). QED has ongoing studies in bladder cancer prior to surgery as neoadjuvant therapy (NCT04228042); following bladder cancer surgery as adjuvant therapy (NCT04197986); in a tumor agnostic population (NCT04233567); and
in achondroplasia (NCT04265651). Janssen is studying erdafitinib in NMIBC (NCT04917809, NCT04172675); in tumor agnostic cancer populations (NCT02465060, NCT03827850), including a pediatric study (NCT03155620; and in combination with immunotherapy in
bladder cancer (NCT03473743), among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are a number of other investigational pan-FGFR programs for FGFR-specific populations.
Taiho Oncology, Inc.&#146;s TAS-120 (futibatinib) has completed a Phase 2 study in ICC, and is currently enrolling a pivotal Phase 3 study in treatment-na&iuml;ve metastatic ICC versus standard of care chemotherapy (NCT04093362); Taiho also has
ongoing studies in a tumor agnostic population (NCT04189445); and combination studies with pembrolizumab in urothelial cancer (NCT04601857) and FGF19 positive liver cancer (NCT04828486). Bayer Pharmaceutical&#146;s has an ongoing Phase 1/2 study of
BAY 1163877 (Rogaratinib) in urothelial cancer in combination with atezolizumab (NCT03473756). Isoform specific FGFR inhibitors such as Relay Therapeutics, Inc.&#146;s RLY-4008 is currently in Phase 1 with stated plans to develop their candidate in
ICC. Kinnate Biopharma Inc.&#146;s has a preclinical candidate in KIN-3248. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are two approved RET inhibitors, Lilly&#146;s Loxo
Oncology&#146;s Retevmo<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> (selpercatinib) and Blueprint Medicines&#146; Gavreto<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> (pralsetinib), both of which are approved for
RET-positive NSCLC, PTC, and MTC. Both are conducting confirmatory Phase 3 studies in NSCLC (NCT03473756, NCT04222972) and in MTC (NCT04211337, NCT04760288). Turning Point Therapeutics is developing their RET candidate TPX-0046 in a Phase 1 study
(NCT04161391) with stated plans to expand their study to NSCLC, MTC, and tumor agnostic populations. Boston Pharmaceuticals is developing their RET candidate BOS172738 in a Phase 1 study (NCT03780517). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are currently no approved FGFR4 inhibitors, but there are a number of FGFR4 programs in clinical development. Blueprint Medicine is
developing BLU-554 (fisogatinib) in a Phase 1/2 study in HCC in combination with a checkpoint inhibitor (NCT04194801). H3 Biomedicines has recruited a Phase 1/2 study of H3B-6527 in HCC (NCT02834780) but no further details are publicly available.
Novartis completed a Phase 1/2 study of FGF401 alone and in combination with a checkpoint inhibitor in HCC (NCT02325739) and a similar study with FGF401 is now being conducted by Everest Medicines in combination with pembrolizumab in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We strive to
protect the intellectual property and proprietary technology that we consider important to our business through a variety of methods, including seeking and maintaining patents intended to cover our product candidates and compositions, their methods
of use and processes for their manufacture, and any other inventions that are important to our business. We rely <FONT STYLE="white-space:nowrap">on&nbsp;know-how</FONT> and continuing technological innovation to develop and maintain our proprietary
position. We also rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> that may be important to the development of our business. We seek to obtain domestic and international patent protection and endeavor to promptly file
patent applications for new commercially valuable inventions to expand our intellectual property portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that we have an
intellectual property position and <FONT STYLE="white-space:nowrap">substantial&nbsp;know-how&nbsp;relating</FONT> to our product candidates and SN&Aring;P platform. As of September&nbsp;3, 2021, our intellectual property portfolio consisted of
seven pending U.S. provisional applications and two patent applications pursuant to the Patent Cooperation Treaty, or the PCT, all of which are solely owned by us. At this time, we do not own any issued patents, pending non-provisional patent
applications in the U.S., or pending patent applications in any foreign countries, and we do not license any material patent rights from any third party. Collectively, our patent rights relate to various aspects of our product candidates. We do not
anticipate entering national phase with respect to either of our current PCT applications until June 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We continually assess and refine our intellectual property strategy as we develop new
product candidates and improvements to our SN&Aring;P platform. To that end, we are prepared to file additional patent applications in any appropriate fields if our intellectual property strategy requires such filings, or where we seek to adapt to
competition or seize business opportunities. Further, we are prepared to file patent applications, as we consider appropriate under the circumstances, relating to the new technologies that we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent
applications we may own or license in the future, nor can we be sure that any patents we may own or license in the future will be useful in protecting our technology. Please see &#147;Risk Factors&#151;Risks Related to Our Intellectual
Property&#148; for additional information on the risks associated with our intellectual property strategy and portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property
Relating to Our FGFR3 Program </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With regard to our FGFR3 product candidates, as of September&nbsp;3, 2021, we owned three pending
U.S. provisional patent applications and one pending PCT patent application. These patent rights relate to the FGFR3 product candidates&#146; compositions of matter, formulations containing them, methods of manufacturing, and methods of treating
diseases, using our FGFR3 product candidates. Specifically, we have one U.S. provisional patent application directed to the composition matter of our leading candidate in the FGFR3 program. We expect any patents issued from these applications to
expire in 2040 or 2042 without accounting for any patent term adjustment or extension that may be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Relating to Our
FGFR2 Program </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With regard to our FGFR2 program, as of September&nbsp;3, 2021, we owned three pending U.S. provisional patent
applications and one pending international PCT patent application. These patent rights relate to the FGFR2 program&#146;s compositions of matter, formulations containing them, methods of manufacturing, and methods of treating diseases. We expect any
patents issued from these applications to expire in 2040 or 2042 without accounting for any patent term extension that may be available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Relating to Other Programs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With regard to our other programs, including the FGFR4 program, as of September&nbsp;3, 2021, we owned one pending U.S. provisional patent
application. These patent rights relate to these other programs&#146; compositions of matter, formulations containing them, methods of manufacturing, and methods of treating diseases. We expect any patent issued from this application to expire in
2042 without accounting for any patent term extension that may be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scope and Duration of Intellectual Property Protection </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the
patent term is 20&nbsp;years from the earliest date of filing of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the
FDA requirements or by delays encountered during prosecution that are caused by the USPTO. For example, for drugs that are regulated by the FDA under the Hatch-Waxman Act, the FDA is permitted to extend the term of a patent that covers such drug for
up to five years beyond the normal expiration date of the patent. In the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. We intend to seek
patent term extensions to any of our issued patents in jurisdictions where these are available; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions
should be granted, and even if granted, the length of such extensions. If patents are issued on our pending patent applications, the resulting patents are expected to expire on dates ranging from 2040 to 2042, unless we receive patent term extension
or patent term adjustment, or both. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, the actual protection afforded by a patent varies on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;product-by-product&nbsp;basis,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;country-to-country,&nbsp;and</FONT></FONT> depends upon
many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy
regarding the scope of claims allowable in patents in the field of oncology therapy has emerged in the United States. The patent situation outside of the United States is even more uncertain. Changes in the patent laws and rules, either by
legislation, judicial decisions, or regulatory interpretation in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our
intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our
success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect
to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our patents that may be granted to us in the future will be commercially useful in protecting our product
candidates and the methods used to manufacture them. Moreover, those patents that may issue in the future may not guarantee us the right to practice our technology in relation to the commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third
parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology. Our patents that may issue in the future may be challenged, narrowed, circumvented or
invalidated, which could limit our ability to stop competitors from marketing related product candidates or limit the length of the term of patent protection that we may have for our product candidates. In addition, the rights granted under any
issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies. For these and other reasons, we may have
competition for our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before any product candidate can be commercialized, any related
patent may expire or remain in force for only a short period following commercialization, thereby reducing any protection afforded by the patent. For this and other risks related to our proprietary technology, inventions, improvements, SN&Aring;P
platform and product candidates, please see the section entitled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to file applications for trademark registrations in connection with our product candidates in various jurisdictions, including the
United States. We have filed for trademark protection of the TYRA and TYRA BIOSCIENCES marks with the United States Patent and Trademark Office and certain foreign patent and trademark organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our confidential
and proprietary information as trade secrets, including through contractual means with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, third parties may independently develop substantially
equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants,
outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements under the commencement of employment or consulting relationships with us. These agreements provide that all confidential information
concerning our business or financial affairs developed or made known to the individual during the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of
employees, the agreements provide that all inventions conceived by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary
information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions
they invent as a result of the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. Despite these efforts, we cannot provide any assurances that all such agreements have been duly
executed, and any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our
premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies
for any breach. To the extent that our employees, contractors, consultants, collaborators and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in relation to the <FONT
STYLE="white-space:nowrap">resulting&nbsp;know-how&nbsp;or</FONT> inventions. For more information, please see the section titled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to retain
significant development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently
have no sales, marketing or commercial product distribution capabilities. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our product
candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not have any
manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical testing, as well as for subsequent clinical testing and commercial
manufacture if our product candidates receive marketing approval. We believe this strategy allows us to focus our expertise and resources on the development of our product candidates by eliminating the need for us to invest in our own manufacturing
facilities, equipment and personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to put agreements in place with contract manufacturing organizations for the necessary
quantities of active pharmaceutical ingredients, or API, and drug product for each of our product candidates, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">project-by-project</FONT></FONT> basis, based on our development
needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As we advance our product candidates through development, we will explore adding backup suppliers for the API and drug product for
each of our product candidates to protect against any potential supply disruptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of drug products. A new drug must be approved by
the FDA through the New Drug Application, or NDA, process before it may be legally marketed in the United States. We, along with any third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval
requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our products and product candidates. The process of obtaining regulatory approvals and the subsequent compliance with
applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development Process </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. The process required by the
FDA before a drug may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#146;s
GLP requirements and other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before
each trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or
GCPs, to establish the safety and efficacy of the proposed drug for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of an NDA after completion of all pivotal trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is
produced to assess compliance with current Good Manufacturing Practice, or cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity, and of selected
clinical investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for
use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate in the United States, a
sponsor must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s)
for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and
any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA,
within the 30- day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before
the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators
in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the
objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development
and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins
at that site and must monitor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which
provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or
other grounds, such as no demonstration of efficacy. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. The FDA or the sponsor may suspend a
clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if
the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. There are also requirements governing the reporting of ongoing clinical studies and
clinical study results to public registries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or
be combined: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target
disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain
early evidence on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2: The product candidate is administered to a limited patient population with a specified disease or
condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and
more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to
provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of
the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require,
or sponsors may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies, may be conducted after initial marketing approval, and may be used to gain
additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the
chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability
studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed
since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting
a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to
that listed in the protocol or investigator brochure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, during the development of a new drug, sponsors are given opportunities
to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to
share information about the data gathered to date, for the FDA to provide advice, and for the sponsor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the
pivotal Phase 3 clinical trials that they believe will support approval of the new drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Review and Approval Process </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are
submitted to the FDA as part of an NDA requesting approval to market the product. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources,
including studies initiated by independent investigators. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed
on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary
review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for
filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things,
whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#146;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act guidelines that
are currently in effect, the FDA has a goal of ten months from the filing date to complete a standard review of an NDA for a drug that is a new molecular entity. This review typically takes twelve months from the date the NDA is submitted to FDA
because the FDA has approximately two months to make a &#147;filing&#148; decision after it the application is submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may
refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the
application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a NDA, the FDA
will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission
and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA and conducts inspections of manufacturing facilities where the investigational product and/or its drug
substance will be produced, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will
describe all of the deficiencies that the FDA has identified in the NDA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required
inspections and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the NDA in condition for approval, including requests for additional information or clarification. The FDA may
delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the
indicated uses for which such product may be marketed. For example, the FDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may approve the NDA with a Risk Evaluation and Mitigation Strategy, or REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential
serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as
restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may
also require one or more Phase 4 post- market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these
post-marketing studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials
for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral
or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the
product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for
approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that
fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited
Development and Review Programs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA offers a number of expedited development and review programs for qualifying product
candidates. For example, the Fast Track program is intended to expedite or facilitate the process for reviewing new products that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet
medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent
interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. A Fast Track product may also be eligible for rolling review, where the FDA may
consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A product
candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if
preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints,
such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational
commitment to expedite the development and review of the product candidate, including involvement of senior managers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any marketing
application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and
approval process, such as priority review and accelerated approval. A product candidate is eligible for priority review if it is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant
improvement in safety or effectiveness compared to available alternatives for such disease or condition. For new-molecular-entity NDAs, priority review designation means the FDA&#146;s goal is to take action on the marketing application within six
months of the 60-day filing date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, product candidates studied for their safety and effectiveness in treating serious or
life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into
account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled
post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor
fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could
adversely impact the timing of the commercial launch of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fast Track designation, Breakthrough Therapy designation, priority
review, and accelerated approval do not change the standards for approval, but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no
longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug
Designation and Exclusivity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare
disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable
expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA. After the FDA grants
orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
a product that has orphan drug designation subsequently receives the first FDA approval for the drug and indication for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve
any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds
that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug
exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research
and a waiver of the NDA application user fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a
use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially
defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the
product to meet the needs of patients with the rare disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval Requirements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Drug products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product,
such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register
their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us
and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and
correction of any deviations from cGMP and impose reporting requirements. Accordingly, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program.
Other potential consequences include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating
to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical
judgment, legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many
patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of off-label use of their products. However,
companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA-approved labelling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing
Exclusivity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing
applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not
previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated
new drug application, or ANDA, or an NDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug containing the same active moiety, regardless of whether the drug is intended for the same
indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains
a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDCA
alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to
be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical
investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval
of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an
additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA and meets other conditions. The issuance of a written request
does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Regulation of Companion Diagnostics </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If safe and effective use of a drug depends on an in vitro diagnostic, then the FDA may require approval or clearance of that diagnostic,
known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion
diagnostics. According to the guidance, if FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA may will not approve the drug or new indication if the
companion diagnostic device is not also approved or cleared for that indication. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the
intended population. The review of in vitro companion diagnostics in conjunction with the review of our product candidates will, therefore, likely involve coordination of review by the FDA&#146;s Center for Drug Evaluation and Research and the
FDA&#146;s Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the FDCA, in vitro
diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design
and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance.
Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are clearance of a premarket
notification pursuant to Section 510(k) of the FDCA, also called 510(k) clearance, and approval of a premarket approval application, or PMA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years
or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety and effectiveness and information about the device and its components regarding,
among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled
clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. As part of the PMA review, the FDA will typically inspect the manufacturer&#146;s facilities for compliance with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the FDA&#146;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#146;s
agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#146;s evaluation of the PMA or manufacturing
facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA
approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If
the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA
believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with
post-approval requirements, conditions of approval or other regulatory standards are not maintained or problems are identified following initial marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for
the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#146;s manufacturing processes and those of its suppliers are
required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility
records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare Laws </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies like us are subject to additional healthcare regulation and enforcement by the federal government and by authorities
in the states and foreign jurisdictions in which they conduct their business. Such regulation and enforcement may constrain the financial arrangements and relationships through which we research, develop, and ultimately, sell, market and distribute
any products for which we obtain marketing approval. Such laws include, without limitation, federal and state anti-kickback, fraud and abuse, and false claims laws, such as the federal Anti-Kickback Statute and the federal civil False Claims Act, as
well as federal and state, data privacy and security laws and regulations, and transparency laws and regulations with respect to drug pricing and payments and other transfers of value made by pharmaceutical manufacturers to physicians and other
health care providers, such as the federal Physician Payments Sunshine Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Violation of any of such laws or any other governmental
regulations that apply may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a Corporate Integrity
Agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from
participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S.
Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate
for which we may seek regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare,
Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial
by third-party payors. For products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting
the reimbursement rate that the payor will pay for the product. In the United States, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover any of a product, the extent of coverage and amount of
reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own
coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a
time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or
obtained in the first instance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the price and examining the medical necessity and
cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit sales of any product that receives approval. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to
secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in third-party
reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, as a condition of participating in, and having products covered under, certain federal healthcare programs, such as Medicare and
Medicaid, we may become subject to federal laws and regulations that require pharmaceutical manufacturers to calculate and report certain pricing metrics to the government, including the Average Manufacturer Price, or AMP, and Best Price under the
Medicaid Drug Rebate Program, the Medicare Average Sales Price, the 340B Ceiling Price, and Non-Federal AMP reported to the Department of Veteran Affairs, and with respect to Medicaid, pay statutory rebates on utilization of manufacturers&#146;
products by Medicaid beneficiaries. Compliance with these laws and regulations will require significant resources and may have a material adverse effect on our revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Reform </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the
United States, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate
post-approval activities, and affect the profitable sale of product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Among policy makers and payors in the United States,
there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus
of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as the
ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. Among other changes, the ACA increased the minimum level of Medicaid
rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, in which
manufacturers must agree to offer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as
a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers who sell certain &#147;branded
prescription drugs&#148; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify
priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower
Medicare and Medicaid spending, potentially including prescription drug spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and
political challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to
the Supreme Court&#146;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The
executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the healthcare reform measures of the Biden administration or other efforts, if
any, to challenge, repeal or replace the ACA will impact the ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been adopted since the ACA
was enacted. Most recently, in March 2021, Congress enacted the American Rescue Plan Act of 2021, which, among other things, eliminated the statutory cap on drug manufacturers&#146; Medicaid Drug Rebate Program rebate liability, effective January 1,
2024. Under current law enacted as part of the ACA, drug manufacturers&#146; Medicaid Drug Rebate Program rebate liability is capped at 100% of the average manufacturer price for a covered outpatient drug. Other changes included aggregate reductions
to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect into 2031, with
the exception of a temporary suspension from May 1, 2020 through December 31, 2021, unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things,
reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed
products. This has resulted in several Congressional inquiries and proposed and enacted federal and state regulations designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although a number
of these and other measures may require additional authorization to become effective, Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.
Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are
increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing
systems and publication of discounts and list prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Human Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;3, 2021, we had 18 full-time employees, including a total of seven employees with M.D. or Ph.D. degrees. Of these
full-time employees, 16 employees are engaged in research and development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing
and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards. We value our employees and
regularly benchmark total rewards we provide, such as short and long-term compensation, 401(k) contributions, health, welfare and quality of life benefits, paid time off and personal leave, against our industry peers to ensure we remain competitive
and attractive to potential new hires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Carlsbad, California, where we lease approximately 4,734 square feet of laboratory and office space.
This lease commenced in the second quarter of 2021 and will terminate five years following the lease commencement date as defined in the lease agreement. We believe that our existing facilities are adequate for our current needs and that suitable
additional or alternative space will be available in the future on commercially reasonable terms, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal proceedings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any
legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources,
negative publicity and reputation harm, and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive officers and directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age as of the date of this prospectus and position of each of our executive officers and directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Harris, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President, Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Bensen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Esther van den Boom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Swanson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hiroomi Tada, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert L. Hudkins, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Technology Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piyush Patel, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Development Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I></I><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors:</I></B><I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isan Chen, M.D. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilla Kaplan, Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nina Kjellson (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Melissa McCracken, Ph.D. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert More (1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jake Simson, Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Siddarth Subramony, Ph.D. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rehan Verjee (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Audit Committee </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating and Corporate Governance Committee </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive team </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Todd Harris, Ph.D. </I></B>has served as our President, Chief Executive Officer and Secretary since November 2018, as our Treasurer
since February 2019, and as a member of our board of directors since August 2018. Prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> Tyra, Dr.&nbsp;Harris served in various roles, most recently as Head of Corporate Development and a
director at Sienna Biopharmaceuticals, Inc. (SNNA), or Sienna, a clinical-stage biopharmaceutical company, from January 2016 to July 2018 and previously as the founder, Chief Executive Officer, and director of Sienna (then called Sienna Labs) from
April 2013 to January 2016. In September 2019, Sienna Biopharmaceuticals filed for voluntary petition to allow restructuring under Chapter 11 of the United States Bankruptcy Code and ceased its operations in December 2019. Before Sienna,
Dr.&nbsp;Harris was a consultant at McKinsey&nbsp;&amp; Company in the Health Care Practice Division from September 2008 to December 2012. Dr.&nbsp;Harris currently serves on the board of directors of Primmune Therapeutics, Inc., a biopharmaceutical
company focused on the second arm, innate immune system. Dr.&nbsp;Harris holds a Bachelor of Science Degree in Electrical Engineering from Brigham Young University, a Master of Science Degree in Bioengineering from the University of California, San
Diego, and a Ph.D. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology. We believe that Dr.&nbsp;Harris&#146; valuable expertise and the perspective he brings in his capacity as our President and Chief Executive
Officer, his extensive experience and knowledge in the life sciences industry and his education provide him with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Daniel Bensen</I></B><B><I></I></B>&nbsp;has served as our Chief Operating Officer since November 2018 and previously also served as a
member of our board of directors from November 2018 to January 2020.&nbsp;Prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> Tyra with Dr.&nbsp;Harris, Mr.&nbsp;Bensen served as Head of Immunology and Protein Chemistry at Cidara
Therapeutics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from March 2014 until November 2018. Before Cidara, Mr.&nbsp;Bensen served as Principal Scientist, Protein Chemistry, and Structural Biology at Trius Therapeutics, Inc. from March 2007 until
February 2014. Mr.&nbsp;Bensen holds a Bachelor of Arts Degree in Biology from Point Loma Nazarene University in San Diego, California, and an MBA degree from the University of Southern California, Marshall School of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Esther van den Boom</I></B><I> </I>has served as our Chief Financial Officer since April 2021. Ms.&nbsp;van den Boom served as Chief
Accounting Officer of Artiva Biotherapeutics, Inc., from August 2020 to May 2021 and Acting Chief Financial Officer from April 2019 to August 2020. Since April 2013, Ms.&nbsp;van den Boom has served as the Managing Partner of van den Boom&nbsp;&amp;
Associates, LLC, and in that capacity provided outside consulting services to Tyra from August 2020 until her appointment as Chief Financial Officer in April 2021. Prior to starting van den Boom&nbsp;&amp; Associates, LLC, Ms.&nbsp;van den Boom was
with Ernst&nbsp;&amp; Young LLP, from December 2004 to March 2013, in their San Diego office&#146;s audit practice. Ms.&nbsp;van den Boom received a Bachelor of Arts in Economics from the University of California, San Diego and a Master of Science
degree in Accountancy from San Diego State University and is a licensed CPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Ronald V. Swanson, Ph.D. </I></B>has served as our
Chief Scientific Officer since January 2020 and as our consultant from August 2019 until January 2020. Prior to joining Tyra, Dr.&nbsp;Swanson served as Director/Senior Director, Biologics at Johnson&nbsp;&amp; Johnson, Inc. from December 2006 until
April 2019 where he ran the Lead Discovery&nbsp;&amp; Optimization group focused on engineering of antibodies, peptides and protein therapeutics. Prior to Johnson&nbsp;&amp; Johnson, Inc., Dr.&nbsp;Swanson was
<FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Scientific Officer at ActiveSight, the contract crystallography arm of Rigaku Americas Corporation. Dr.&nbsp;Swanson holds a Bachelor of Arts Degree in Biochemistry and Cell Biology from
the University of California, San Diego, and a Ph.D. degree in Molecular Biology from the University of California, Berkeley. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Hiroomi Tada, M.D., Ph.D.</I></B><B><I></I></B>&nbsp;has served as our Chief Medical Officer since November 2020. Prior to joining Tyra,
Dr.&nbsp;Tada served as Chief Medical Officer at Notable Labs, Inc., a personalized precision oncology company from March 2019 until November 2020. Before Notable Labs, Inc., Dr.&nbsp;Tada served in various roles at Incyte Corp. as Vice President of
Translational Sciences for Target Therapies from January 2018 until February 2019, and as Executive Director of Immuno-Oncology Clinical Development from May 2015 until January 2019. Dr.&nbsp;Tada also served in clinical development roles at
GlaxoSmithKline and AstraZeneca. Dr.&nbsp;Tada holds a Bachelor of Arts degree from Haverford College, a Ph.D. in Biochemistry and Molecular Biology from Thomas Jefferson University and an M.D. from Jefferson Medical College. Dr.&nbsp;Tada completed
his fellowship in Surgical Oncology at the University of Texas, MD Anderson Cancer Center. Prior to joining the pharmaceutical industry, Dr.&nbsp;Tada held faculty appointments as Assistant Professor of Surgery at the University of Massachusetts
Medical School and Temple University School of Medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Robert L. Hudkins, Ph.D.</I></B><B> </B>has served as our Chief Technology
Officer since January 2021 and served as our Vice President, Chemistry from January 2020 until January 2021. Prior to joining Tyra, Dr.&nbsp;Hudkins was a consultant at MedChem Consulting LLC, a company providing consultancy services in drug
discovery and medicinal chemistry, from September 2018 until January 2020. Before MedChem Consulting LLC, Dr.&nbsp;Hudkins spent his career as Distinguished Scientist III / Senior Research Fellow in Medicinal Chemistry at Teva Pharmaceutical
Industries Ltd. from October 2011 until August 2018. Dr.&nbsp;Hudkins holds a Bachelor of Science degree from Barton College, a Master of Science degree in Organic Chemistry from Old Dominion University and a Ph.D. in Medical Chemistry from Virginia
Commonwealth University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Piyush Patel, Ph.D.</I></B><B> </B>has served as our Chief Development Officer since January 2021. Prior
to joining Tyra, Dr.&nbsp;Patel was the Chief Scientific Officer at CinRx Pharma, LLC from January 2016 until January 2021. Prior to CinRx Pharma, LLC, Dr.&nbsp;Patel was Senior Director at Teva Pharmaceutical Industries Ltd. from January 1996 until
December 2015. With over 29 years of drug development experience, his expertise involves all aspects of nonclinical and product development of small molecules. He has authored several scientific publications and is a
<FONT STYLE="white-space:nowrap">co-inventor</FONT> on multiple patents. Dr.&nbsp;Patel holds a Bachelor of Pharmacy from the Maharaja Sayajirao University of Baroda, and a Master of Science and Ph.D. in Pharmaceutical Sciences from Temple
University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Isan Chen, M.D. </I></B>has served as our Chief Medical Advisor since February 2019 and a member of our board of directors since June
2020. Dr.&nbsp;Chen has served as the Chief Executive Officer at MBrace Therapeutics, Inc. since May 2020. Before MBrace Therapeutics, Inc., Dr.&nbsp;Chen served as the Executive Vice President and Chief Medical and Development Officer of Mirati
Therapeutics, Inc. from September 2013 until May 2020. Prior to Mirati Therapeutics, Inc., Dr.&nbsp;Chen was previously the Chief Medical Officer of Aragon Pharmaceuticals, Inc., which was acquired by Johnson&nbsp;&amp; Johnson, Inc. in July of 2013
and prior to Aragon, Dr.&nbsp;Chen served as Vice President of Tumor Strategy in the oncology business unit at Pfizer. Before joining Pfizer, Dr.&nbsp;Chen practiced medicine as a staff physician at City of Hope Medical Center and later as an
assistant professor at the University of Texas, M.D. Anderson Cancer Center. Dr.&nbsp;Chen is currently a member of the board of directors of Treadwell Therapeutics, Inc. Dr.&nbsp;Chen holds an M.D. from University of S&atilde;o Paulo and completed
his fellowship in Hematology and Oncology from the University of California, San Diego. Dr.&nbsp;Chen is board certified in internal medicine, hematology and medical oncology with more than 20 years of experience in oncology and clinical trials from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-humans</FONT></FONT> through global registration studies. We believe that Dr.&nbsp;Chen&#146;s expertise and executive experience in the life sciences industry, his
experience as a director of biopharmaceutical companies and his educational background provide him with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Gilla Kaplan, Ph.D.</I></B><B><I></I></B>&nbsp;has served as a member of our board of directors since March 2019. Dr.&nbsp;Kaplan
currently serves as Chief Executive Officer and director of Gilrose Therapeutics and as Senior Advisor of Medicine Development for Global Health. Before Gilrose, Dr.&nbsp;Kaplan was Senior Advisor from July 2018 until December 2020 at the Bill and
Melinda Gates Medical Research Institute (Gates MRI) and the Director of the Global Health Program, Tuberculosis of the Bill and Melinda Gates foundation (BMGF) from January 2014 until April 2018. Her work has encompassed developing a deep
understanding of the cellular immune response and how to harness it for host adjunctive therapies. Dr.&nbsp;Kaplan spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease, exploring novel
experimental medicine approaches that modulate the immune response for disease control. She was a recipient of multiple grants from the <FONT STYLE="white-space:nowrap">NIH-NIAID</FONT> and other funding organizations for her research.
Dr.&nbsp;Kaplan currently serves on the board of directors of Cerecor Inc. Dr.&nbsp;Kaplan previously served on the board of directors at Celgene Corporation from 1998 to 2018. Dr.&nbsp;Kaplan received a Bachelor of Science degree from Hebrew
University, Jerusalem, Israel and a Master of Science and Ph.D. in Cellular Immunology from University of Tromso, Norway. We believe that Dr.&nbsp;Kaplan&#146;s expertise and experience in the life sciences industry, her experience as a director of
biotechnology companies and her educational background provide her with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Nina Kjellson</I></B><I> </I>has served as a member of our board of directors since May 2018. She is currently an investment
professional at Canaan Partners and joined the venture capital firm in 2015. Ms.&nbsp;Kjellson is a Managing Member of Canaan Partners X LLC, the general partner of Canaan X LP, a Managing Member of Canaan Partners XI LLC, the general partner of
Canaan XI LP, and a Managing Member of Canaan Partners XII LLC, the general partner of Canaan XII LP. As an investment professional at Canaan, she oversees investments in in biopharmaceutical companies that aim to transform care for patients. In
addition to Tyra, some of the investments she actively oversees include PACT Pharma, Sardona, Inc., Tizona Therapeutics, Inc., Trishula, Inc., Vineti, Inc. and WellTok, Inc., on whose boards she has served since December 2020, February 2021,
February 2016, August, 2020, January 2020, April 2018 and March 2013, respectively. Ms.&nbsp;Kjellson also previously led investments in Labrys Biologics, Inc. (acquired by Teva Pharmaceutical Industries Ltd.), Tesaro, Inc., Eiger
Biopharmaceuticals, Inc., Trius Therapeutics LLC (acquired by Cubist Pharmaceuticals, Inc.) and NovaCardia, Inc. (acquired by Merck&nbsp;&amp; Co., Inc.), among others. As a leader of Canaan&#146;s Women of Venture program, Ms.&nbsp;Kjellson is a
vocal advocate for women entrepreneurs and investors. She serves on the board of Essential Access Health, Girl Effect and Life Science Cares. She has <FONT STYLE="white-space:nowrap">co-developed</FONT> an immersive curriculum for diversity and
inclusion in healthcare with Impact Experience, called Impact Experience: HealthEquity. She is an Aspen Institute Health Innovators Fellow. Previously, Ms.&nbsp;Kjellson was a General Partner at InterWest Partners, where she invested in life
sciences companies for 14 years and held positions at Bay City Capital, Oracle Partners and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Kaiser Family Foundation. She holds a Bachelor of Arts in Human Biology from Stanford University. We believe that Ms.&nbsp;Kjellson&#146;s expertise and experience in the venture capital
industry and her experience as a director of biopharmaceutical companies provide her with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Melissa McCracken, Ph.D. </I></B>has served as a member of our board of directors since March 2021. Since September 2019,
Dr.&nbsp;McCracken has served as a senior associate and currently as a principal at Nextech Invest Ltd., a cancer therapeutics-focused venture capital firm focused almost exclusively on precision therapeutics. Prior to Nextech Invest Ltd.,
Dr.&nbsp;McCracken was an associate and then senior associate at Third Rock Ventures, LLC from March 2017 until August 2019, a venture capital firm where she focused on scientific due diligence, partnership development and new company formation in
oncology and immunology. At Third Rock Ventures, Dr.&nbsp;McCracken helped build and launch Celsius Therapeutics Inc., a company focused on discovering precision therapeutics for oncology and autoimmune from March 2018 to March 2019.
Dr.&nbsp;McCracken currently serves as a board observer of IconOvir Bio, Inc., and was previously a board member of ImaginAB Inc. and board observer of Silverback Therapeutics, Inc. Dr.&nbsp;McCracken holds a Bachelor of Science in Biochemistry and
Molecular Biology from the University of California, Davis and a Ph.D. in Pharmacology from the University of California, Los Angeles. We believe that Dr.&nbsp;McCracken&#146;s expertise and experience in the venture capital industry, her experience
as a director of biopharmaceutical companies and her educational background provide her with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Robert More</I></B><B><I></I></B>&nbsp;has served as a member of our board of directors since November 2018 and our Chairman since March
2019. Since November 2016, Mr.&nbsp;More has served as Managing Director of Alta Partners, a venture capital firm. From July 2013 to May 2015, Mr.&nbsp;More served as Senior Advisor for the Bill&nbsp;&amp; Melinda Gates Foundation and led its Global
Health Venture Initiative. He served as a General Partner of venture capital firms Frazier Healthcare Ventures and Domain Associates from September 2008 to June 2013 and from June 1996 to July 2008, respectively. Mr.&nbsp;More currently serves on
the board of directors of Vir Biotechnology, Inc. He also currently serves on the board of directors of the following private companies: Affinivax, Inc., a biotechnology company, Qihan Biotechnology Co. Ltd., a biotechnology company, and Variant
Bio, Inc., a biotechnology company. Mr.&nbsp;More previously served on the board of directors of the following public companies: Achaogen, Inc., a biopharmaceutical company, Cartiva, Inc., a medical device company acquired by Wright Medical Group
N.V., Neothetics Inc., a pharmaceutical company, Sienna Biopharmaceuticals, now Sienna Biopharmaceuticals, Inc., a biotechnology company, Glaukos Corporation, a medical technology company, and IntraLase Corp., a medical device company acquired by
Advanced Medical Optics in 2007. He also previously served on the board of directors of the following life sciences companies: ESP Pharma, Inc., Proxima Therapeutics, Inc., eGenesis Bio, Utah Capital Investment Corporation (UCIC), NovaCardia, Inc.,
Carticept Medical, Inc., Esprit Pharma, Inc. and Oceana Therapeutics, Inc. Mr.&nbsp;More was a founding member of the board of directors of the Kauffman Fellows Program and previously served on the board of directors of One Revolution and The
Foundation for Innovative New Diagnostics (FIND). Mr.&nbsp;More currently serves on one of the governing boards of the Biotechnology Innovation Organization (BIO). He received his Bachelor of Science Degree in Biology from Middlebury College and an
MBA from the Darden School of Business Administration at the University of Virginia. We believe that Mr.&nbsp;More is qualified to serve on our board of directors due to his experience serving on the board of directors of biotechnology companies,
his extensive experience as a director of public companies, and his investment experience in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Jake
Simson, Ph.D.</I></B><B><I></I></B>&nbsp;has served as a member of our board of directors since January 2020. Since December 2020, Dr.&nbsp;Simson has served as partner at RA Capital Management L.P., a multi-stage investment manager dedicated to
evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics. Previously, Dr. Simson served as an associate, analyst and principal at RA Capital Management from July 2014 to
December 2020. Dr.&nbsp;Simson currently serves on the board of directors for Janux Therapeutics, Inc. and for the following privately held companies: Xenikos, B.V, AavantiBio, Inc., and DiCE Molecules Inc. Dr.&nbsp;Simson holds his Bachelor of
Science in Materials Science and Engineering from MIT and a Ph.D. in Biomedical Engineering from Johns Hopkins University. In his doctoral </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. We believe that Dr.&nbsp;Simson&#146;s expertise and experience in
biotech investing, his experience as a director of biopharmaceutical companies and his educational background provide him with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Siddarth Subramony, Ph.D. </I></B>has served as a member of our board of directors since January 2020. Since September 2018,
Dr.&nbsp;Subramony has served as Vice President for Boxer Capital, where he is responsible for conducting due diligence of public and private investments in healthcare. Prior to joining Boxer, Dr.&nbsp;Subramony was a Vice President at H.I.G.
Capital from February 2016 until August 2018 where he was a member of the investment team for the firm&#146;s dedicated healthcare fund, evaluating public and private investment opportunities in the life sciences and representing H.I.G. on the board
of Leiters Pharmacy. Prior to joining H.I.G., Dr.&nbsp;Subramony was a management consultant at the Boston Consulting Group (BCG) from July 2015 until February 2016 and served as a member of the firm&#146;s healthcare practice. Dr.&nbsp;Subramony
received a Bachelor of Science in Biomedical Engineering and Economics, summa cum laude, from Rensselaer Polytechnic Institute, an MBA from Harvard Business School and a Ph.D. in Biomedical Engineering from Columbia University, where he was an NSF
Graduate Research Fellow. He has authored several scientific publications and is a <FONT STYLE="white-space:nowrap">co-inventor</FONT> on multiple patents. We believe that Dr.&nbsp;Subramony&#146;s expertise and experience investing in the life
science industry and his educational background provide him with the qualifications and skills to serve on our board of directors.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Rehan Verjee</I></B><B> </B>has served as a member of our board of directors since June 2021. From September 2018 to March 2021, Mr.
Verjee has served as President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA, Darmstadt, Germany, where he led the North American biopharmaceutical business across the U.S. and Canada in addition to leading the
global oncology and neurology &amp; immunology specialty medicine franchises for the healthcare business of Merck KGaA, Darmstadt, Germany. Prior to this role, Mr. Verjee served as Executive Vice President, Chief Marketing and Strategy Officer since
October 2015, leading the global franchises of oncology, neurology &amp; immunology, and infertility, in addition to global business development, market access, strategy and portfolio management, marketing operations and the medical device and
services unit. Prior to this, he led the Canadian operations as Managing Director of EMD Serono Canada Inc. Mr. Verjee is currently a member of the board of directors of Massachusetts Biotechnology Council. Mr. Verjee holds a Master&#146;s Degree in
Molecular and Cellular Biochemistry from the University of Oxford in the U.K, We believe that Mr. Verjee&#146;s experience as a senior executive in the life science industry and his educational background provide him with the qualifications and
skills to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships and Other Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are no family relationships among our directors and executive officers. Pursuant to our amended and restated voting agreement, which
will terminate upon the completion of this offering, the following directors were designated as members of our board of directors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dr.&nbsp;Harris, designated pursuant to his service as our Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nina Kjellson, designated by Canaan XI L.P. and its affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Melissa McCracken, designated by Nextech VI Oncology SCSp; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert More, designated by Alta Partners NextGen Fund II, L.P. and its affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jake Simson, designated by RA Capital Healthcare Fund, LP, RA Capital Nexus Fund, L.P. and their affiliates; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Siddarth Subramony, designated by Boxer Capital, LLC and its affiliates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board
of directors currently consists of nine members. Our board of directors has determined that all of our directors, other than Dr.&nbsp;Harris, are independent directors in accordance with the listing requirements of the Nasdaq Global Select Market.
The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his or her family members has
engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our
board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of the director. In making these determinations, our board of directors reviewed and discussed information provided by the directors
and us with regard to each director&#146;s business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business and affairs are organized under the direction of our board of directors, which currently consists of nine members. The primary
responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and on an ad hoc basis as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws, which will become
effective immediately prior to and upon the completion of this offering, respectively, we will divide our board of directors into three classes, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I, which will consist of Dr. Harris, Ms. Kjellson and Dr. Subramony, whose terms will expire at our
annual meeting of stockholders to be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II, which will consist of Dr. Chen, Dr. Kaplan and Mr. More, whose terms will expire at our annual
meeting of stockholders to be held in 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III, which will consist of Dr. McCracken, Dr. Simson and Mr. Verjee, whose terms will expire at our
annual meeting of stockholders to be held in 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders to be held after the initial
classification, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. Our amended and restated certificate of incorporation
that will go into effect upon the completion of this offering will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of
directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with
staggered three-year terms may delay or prevent a change of our management or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding voting stock entitled to vote in the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership
Structure </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors is currently chaired by Mr.&nbsp;More who has authority, among other things, to call and preside
over board of directors meetings, to set meeting agendas and to determine materials to be distributed to the board of directors. Accordingly, the Chairman has substantial ability to shape the work of the board of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors. We believe that separation of the positions of Chairman and Chief Executive Officer reinforces the independence of the board of directors in its oversight of our business and affairs.
In addition, we have a separate chair for each committee of our board of directors. The chair of each committee is expected to report annually to our board of directors on the activities of their committee in fulfilling their responsibilities as
detailed in their respective charters or specify any shortcomings should that be the case. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The audit committee of our board of directors is primarily responsible for overseeing our risk management processes on behalf of our board of
directors. Going forward, we expect that the audit committee will receive reports from management periodically regarding our assessment of risks. In addition, the audit committee reports regularly to our board of directors, which also considers our
risk profile. The audit committee and our board of directors focus on the most significant risks we face and our general risk management strategies. While our board of directors oversees our risk management, management is responsible for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> risk management processes. Our board of directors expects management to consider risk and risk management in each business decision, to proactively develop and
monitor risk management strategies and processes for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and to effectively implement risk management strategies adopted by the audit committee and our
board of directors. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that our board of directors&#146; leadership structure, which also emphasizes the independence of our board of
directors in its oversight of its business and affairs, supports this approach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees and Independence </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Our
board of directors may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. Members serve on these committees until their resignation or until otherwise
determined by our board of directors. Each committee has adopted a written charter that satisfies the applicable rules and regulations of the Sarbanes-Oxley Act, the SEC and Nasdaq Listing Rules, which we will post on our website, www.tyra.bio, upon
the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The audit committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our consolidated
financial statements. This committee&#146;s responsibilities include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the qualifications, independence and performance of our independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the audit and non-audit services to be performed by our independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our
critical accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing with management and the independent registered public accounting firm the results of our annual audit
and the review of our quarterly unaudited financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and
regulatory requirements as they relate to financial statements or accounting matters; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board of
directors any changes to such investment policy; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and our auditors any earnings announcements and other public announcements regarding
our results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of
conduct and ethics; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating, at least annually, the performance of the audit committee and its members including
compliance of the audit committee with its charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are Dr. McCracken, Mr. More and
Mr. Verjee. Mr. Verjee serves as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has
determined that Mr. Verjee is an &#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq listing standards. Our board of directors has
determined each of Dr. McCracken, Mr. More and Mr. Verjee is independent under the applicable rules of the SEC and Nasdaq. Upon the listing of our common stock on Nasdaq, the audit committee will operate under a written charter, which the audit
committee will review and evaluate at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our compensation committee approves policies relating to compensation and benefits of our officers and employees. The compensation committee
approves corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of
these officers based on such evaluations. The compensation committee also approves the issuance of stock options and other awards under our equity plans. The compensation committee will review and evaluate, at least annually, the performance of the
compensation committee and its members, including compliance by the compensation committee with its charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The members of our
compensation committee are Dr. Chen, Ms. Kjellson and Dr. Subramony. Ms.&nbsp;Kjellson serves as the chairperson of the committee. Our board of directors has determined that each of Dr.&nbsp;Chen, Ms. Kjellson and Dr. Subramony is independent under
the applicable Nasdaq listing standards, and is a &#147;non-employee director&#148; as defined in Rule 16b-3 promulgated under the Exchange Act. Upon the listing of our common stock on Nasdaq, the compensation committee will operate under a written
charter, which the compensation committee will review and evaluate at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and corporate governance committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee is responsible for assisting our board of directors in discharging the board of
directors&#146; responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which
directors are to be elected), and the selection of candidates to fill any vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate
governance policies, reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The members of our nominating and corporate governance committee are Dr. Kaplan, Mr. More and Dr.&nbsp;Simson. Mr. More serves as the
chairperson of the committee. Our board of directors has determined that each of Dr. Kaplan, Mr. More and Dr. Simson is independent under the applicable Nasdaq listing standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Upon the listing of our common stock on Nasdaq, the nominating and corporate governance committee will operate under a written charter, which the nominating and corporate governance committee
will review and evaluate at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">None of our current or former executive officers serve as a member of the compensation committee. None of our officers serve, or have served
during the last completed fiscal year, on the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of
directors or our compensation committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, please see &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons
performing similar functions, which will be effective upon the closing of this offering. Upon the closing of this offering, our code of business conduct and ethics will be available under the Corporate Governance section of our website at
www.tyra.bio. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code. The reference to our website address
does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. We have included our website address as an inactive textual reference
only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board diversity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the
closing of this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors
as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for election or appointment, the nominating and corporate governance committee and the board of directors will
take into account many factors, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personal and professional integrity, ethics, and values; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience in corporate management, such as serving as an officer or former officer of a publicly-held company;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience as a board member or executive officer of another publicly-held company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strong finance experience; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversity of expertise and experience in substantive matters pertaining to our business relative to other board
members; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place
of residence, and specialized experience; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience relevant to our business industry and with relevant social policy concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relevant academic expertise or other proficiency in an area of our business operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Currently, our board of directors evaluates, and following the closing of this offering will evaluate, each individual in the context of the
board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various
areas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_14"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our named executive officers
for 2020, which consist of each person who served as our principal executive officer during 2020 and our next two most highly compensated executive officers during 2020, were: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Todd Harris, Ph.D., Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniel Bensen, Chief Operating Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ronald V. Swanson, Ph.D., Chief Scientific Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation earned with respect to the fiscal year ended December&nbsp;31, 2020 by our
named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Summary Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Salary<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Stock<BR>Awards<BR>($)
(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Awards<BR>($)
(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive
Plan<BR>Compensation<BR>($) (2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>All Other<BR>Compensation<BR>($)
(3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Harris, Ph.D.<BR><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,238,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Bensen <BR><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald V. Swanson, Ph.D.<BR><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,771</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in the &#147;Option Awards&#148; column represent the aggregate grant date fair value of
the stock options awarded to our named executive officers during fiscal year 2020, calculated in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic&nbsp;718. The amounts reported in the
&#147;Stock Awards&#148; column represent the aggregate grant date fair value calculated in accordance with ASC Topic&nbsp;718 related to the addition of a service-based vesting condition in January 2020 to common stock that Dr.&nbsp;Harris and
Mr.&nbsp;Bensen purchased from us in August 2018, as further described below. Such grant date fair value does not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the awards reported in
this column are set forth in Note&nbsp;7 to our audited financial statements included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for the stock options and do not reflect the actual economic value
that will be realized by Dr.&nbsp;Harris, Mr.&nbsp;Bensen or Dr.&nbsp;Swanson upon the vesting of the stock awards, the exercise of the stock options or the sale of the common stock underlying such awards. See &#147;&#151;Narrative to Summary
Compensation Table&#151;Equity-Based Incentive Awards.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent performance bonuses earned in 2020 and paid in early 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each named executive officer received $900 for a telephone allowance. Life insurance premiums of $112 and $169
were paid by our company for the benefit of Dr.&nbsp;Harris and Mr.&nbsp;Bensen, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Swanson joined as Chief Scientific Officer in January 2020, and therefore the base salary amount set
forth in the table above reflects the amount earned for the portion of 2020 in which he was employed by us. Dr.&nbsp;Swanson had an annual base salary rate of $257,500 in 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Base Salary </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
compensation of our named executive officers is generally determined and approved by our board of directors. The 2020 base salaries of each of our named executive officers are described below under the subsection titled &#147;&#151;Employment
Arrangements with our Named Executive Officers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Bonus Opportunity </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash bonuses, which are designed
to provide appropriate incentives to our executives to achieve defined annual corporate goals and to reward our executives for individual achievement towards these goals. The annual performance-based bonus each named executive officer is eligible to
receive is generally based on the extent to which we achieve the corporate goals that our board of directors establishes each year. At the end of the year, our board of directors reviews our performance against each corporate goal and determines the
extent to which we achieved each of our corporate goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors will generally consider each named executive
officer&#146;s individual contributions towards reaching our annual corporate goals. For 2020, Dr.&nbsp;Harris&#146; target bonus was 40% of his then-current base salary, and for each of our other named executive officers, was 30% of their
then-current base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The corporate goals the board of directors established for 2020 related to development milestones.&nbsp;In
March 2021, our board of directors determined that the 2020 goals were achieved as to 100%, with an additional 50% awarded based on other achievements of the company, as reviewed by the board of directors. The board of directors awarded cash bonuses
to Dr.&nbsp;Harris, Mr.&nbsp;Bensen and Dr.&nbsp;Swanson based on this aggregate assessment of 150% achievement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Incentive Awards
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our equity-based incentive awards are designed to align our interests and those of our stockholders with those of our employees,
including our executive officers. The board of directors or an authorized committee thereof is responsible for approving equity grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have granted stock options and issued restricted stock pursuant to our 2020 Plan and we have issued restricted
stock outside of our 2020 Plan to certain of our executives. Following this offering, we will grant equity awards under the terms of our 2021 Plan. The terms of our equity plans are described below under the subsection titled &#147;&#151;Equity
Incentive Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2020, to induce certain investors to purchase our Series&nbsp;A Preferred Stock, Dr.&nbsp;Harris and
Mr.&nbsp;Bensen agreed to subject 1,113,765 and 348,051, respectively, of shares of common stock they acquired from us in August 2018 to a vesting condition. Dr. Harris vests in 30,937 shares monthly for 35 months commencing January&nbsp;31, 2020
and 30,970 shares in January of 2023, subject to his continuous service with us as of each vesting date. Mr.&nbsp;Bensen vests in 9,668 shares monthly for 35 months commencing January&nbsp;31, 2020 and 9,671 shares in January of 2023, subject to his
continuous service with us as of each vesting date. If their respective employment ends other than due to an &#147;involuntary termination&#148; as defined in their respective employment agreements, we may repurchase the unvested shares for $0.0001
per share. These awards will vest in full upon the consummation of a &#147;change in control&#148; or upon a termination without cause, death, termination due to disability or resignation for good reason. This offering will not constitute a
&#147;change in control&#148; for purposes of these awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2020, our board of directors granted options under our 2020 Plan
to purchase 270,129 shares to each of Mr.&nbsp;Bensen and Dr.&nbsp;Swanson. Each option has an exercise price of $0.61 per share, the fair market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value on the date of grant as determined by our board of directors. The options vest with respect to 25% (or 67,532) of the shares on the one-year anniversary of the January 27, 2020 and January
16, 2020 vesting commencement dates, respectively, 5,628 shares monthly thereafter for 35&nbsp;months and 5,617 shares on the 36th&nbsp;month thereafter, subject to the respective named executive officer&#146;s continuous service with us as of each
such vesting date. The options granted to each of our named executive officers in 2020 are also subject to potential acceleration of vesting in connection with a qualifying termination of employment or a change in control, as described below under
the subsection titled &#147;Employment Arrangements with our Named Executive Officers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2021, our board of directors
granted options under our 2020 Plan to purchase 607,214 shares to Dr.&nbsp;Harris and 134,937 shares to each of Mr.&nbsp;Bensen and Dr.&nbsp;Swanson. For Dr.&nbsp;Harris, the option has an exercise price of $2.25 per share, which was the fair market
value per share of our common stock on the date of the grant, as determined by our board of directors, and 12,650 shares will vest and become exercisable monthly, provided that on the 48th month after the date of the grant, 12,664 shares will vest
and become exercisable. Each of Mr.&nbsp;Bensen and Dr.&nbsp;Swanson&#146;s options has an exercise price of $2.25 per share, which was the fair market value per share of our common stock on the date of grant, as determined by our board of
directors, and 2,811 shares will vest and become exercisable monthly, provided that on the 48th month after the date of grant, 2,820 shares will vest and become exercisable. These options are subject to the respective named executive officer&#146;s
continuous service with us as of each such vesting date. The options are also subject to potential acceleration of vesting in connection with a qualifying termination of employment or a change in control, as described below under the subsection
titled &#147;Employment Arrangements with our Named Executive Officers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2020 Fiscal
<FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the outstanding stock options and
shares of restricted stock held by each of our named executive officers as of December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Grant<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Exercise<BR>Price<BR>(4)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Expiration<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares
of<BR>Stock&nbsp;that<BR>Have Not<BR>Vested</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Market<BR>Value
of<BR>Shares&nbsp;that<BR>Have Not<BR>Vested (5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Harris, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742,513</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Bensen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/27/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,129</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/27/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,041</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald V. Swanson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/27/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,363</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/27/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,766</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">While none of the 270,129 options to purchase our common stock were vested as of December&nbsp;31, 2020, <FONT
STYLE="white-space:nowrap">one-fourth</FONT> of the shares subject to Mr.&nbsp;Bensen&#146;s option vested on January&nbsp;27, 2021, and thereafter 5,628 shares vest monthly over 35 months with 5,617 shares vesting in the 36th month, subject to
Mr.&nbsp;Bensen&#146;s continuous service with us. The stock option has an early exercise feature that allows Mr.&nbsp;Bensen to exercise the option while unvested and receive restricted shares of our common stock that are subject to forfeiture
until the vesting requirement is met. Our 2020 Plan specifically authorizes this early exercise concept and states that employees who exercise unvested options will receive shares of restricted stock with a vesting period that corresponds to the
vesting period that remained in the exercised option. Due to this early exercise feature, these options are reflected in the &#147;Exercisable&#148; column as of December&nbsp;31, 2020. This award is subject to potential acceleration of vesting in
connection with a qualifying termination of employment or a change in control, as described below under the subsection titled &#147;Employment Arrangements with our Named Executive Officers.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Dr.&nbsp;Swanson&#146;s continuous service with us, 33,766 shares subject to the option vest on
January&nbsp;16, 2021 and 5,628 shares vest monthly thereafter over 35 months with 5,617 shares vesting in the 36th month. This option was amended in February of 2021 to permit Dr.&nbsp;Swanson to exercise the option while unvested
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and receive restricted shares of our common stock that are subject to forfeiture until the vesting requirement is met. This award is subject to potential acceleration of vesting in connection
with a qualifying termination of employment or a change in control, as described below under the subsection titled &#147;Employment Arrangements with our Named Executive Officers.&#148; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents restricted shares acquired pursuant to Dr.&nbsp;Swanson&#146;s exercise of an option granted on
January&nbsp;27, 2020 for 33,766 shares that vested on January&nbsp;16, 2021 with an exercise price of $0.61 per share. Our 2020 Plan specifically authorizes this early exercise concept and states that employees who exercise unvested options will
receive shares of restricted stock with a vesting period that corresponds to the vesting period that remained in the exercised option. This award is subject to potential acceleration of vesting in connection with a qualifying termination of
employment or a change in control, as described below under the subsection titled &#147;Employment Arrangements with our Named Executive Officers.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the options were granted with a per share exercise price equal to the fair market value of one share of
our common stock on the date of grant, as determined by our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount reflects the fair market value of our common stock of $0.61 per share as of December&nbsp;31, 2020
(the determination of the fair market value by our board of directors as of the most proximate date prior to then) multiplied by the amount shown in the column for the number of shares that have not vested. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In January 2020, to induce certain investors to purchase our Series A Preferred Stock, Dr.&nbsp;Harris agreed
to subject 1,113,765 shares of common stock he acquired from us in August 2018 to a vesting condition. Specifically, Dr.&nbsp;Harris vests in 30,937 shares monthly for 35&nbsp;months commencing January&nbsp;31, 2020 and 30,970 shares in January of
2023, subject to his continuous service with us as of each vesting date. This award is subject to potential acceleration of vesting in connection with a qualifying termination of employment or a change in control, as described above under
&#147;&#151;Equity-Based Incentive Awards.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In January&nbsp;2020, to induce certain investors to purchase our Series A Preferred Stock, Mr. Bensen agreed
to subject 348,051 shares of common stock he acquired from us in August 2018 to a vesting condition. Specifically, Mr. Bensen vests in 9,668 shares monthly for 35 months commencing January 31, 2020 and 9,671 shares in January 2023, subject to his
continuous service with us as of each vesting date. This award is subject to potential acceleration of vesting in connection with a qualifying termination of employment or a change in control, as described above under &#147;&#151;Equity-Based
Incentive Awards.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements with our Named Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Harris.</I></B>&nbsp;We have entered into an employment agreement with Dr.&nbsp;Harris which
governs the terms of his employment with us. Pursuant to his agreement, Dr.&nbsp;Harris was initially entitled to an annual base salary of $340,000, which was increased to $350,200 in January 2020 and increased to $414,000 in March 2021. He is
eligible to receive an annual bonus with at a target amount of 40% of his then current annual base salary, based on the achievement of performance objectives as determined by our board of directors. Pursuant to the amended employment agreement with
Dr.&nbsp;Harris to be effective upon completion of this offering, Dr.&nbsp;Harris&#146; annual base salary will be increased to $550,000 and his annual target bonus will be increased to 50% of his then current annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Harris&#146; employment agreement provides for the following benefits in connection with a change in control (as such term is defined
below). In the event of a change in control, the vesting of Dr.&nbsp;Harris&#146; then outstanding unvested equity awards will accelerate as of immediately prior to such change in control with respect to 50% of the unvested shares of our common
stock underlying these equity awards. The remaining 50% of the unvested shares of common stock underlying these equity awards will continue to vest at the same rate as immediately prior to the change in control, subject to Dr.&nbsp;Harris&#146;
continued employment with us or our successor through the applicable vesting date. Any portion of Dr.&nbsp;Harris&#146; outstanding equity awards that remains unvested as of the first anniversary of the change in control will vest in full, subject
to Dr.&nbsp;Harris&#146; continued employment with us or our successor through such first anniversary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which Dr.&nbsp;Harris&#146; employment terminates, he is
entitled to receive amounts previously earned during his employment, including unpaid salary, reimbursement of expenses owed, and cash out of accrued but unused paid <FONT STYLE="white-space:nowrap">time-off,</FONT> subject to his execution of a
release of claims and compliance with post-termination obligations. In addition, Dr.&nbsp;Harris is entitled to certain severance benefits under his employment agreement, subject to his execution of a release of claims and compliance with
post-termination obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Harris&#146; employment agreement provides for severance benefits for certain terminations that
arise during and outside a change in control period. Upon a termination without cause, due to death, due to disability, or resignation for good reason outside of a change in control period (as such terms are defined below), Dr.&nbsp;Harris is
entitled to (i)&nbsp;a cash lump sum payment equal to 12 months of Dr.&nbsp;Harris&#146; current annual base salary plus Dr.&nbsp;Harris&#146; then target annual bonus, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the total number of
days elapsed in the calendar year as of Dr.&nbsp;Harris&#146; date of termination, (ii)&nbsp;accelerated vesting of 50% of Dr.&nbsp;Harris&#146; unvested equity awards as of his date of termination, and (iii)&nbsp;payment or reimbursement of the
COBRA premiums for Dr.&nbsp;Harris and his eligible dependents, or if COBRA is not available under our group health plan, the cash amount necessary to maintain his health coverage at the same coverage levels in effect as of the date of his
termination, until the earliest of (a)&nbsp;six months from Dr.&nbsp;Harris&#146; date of termination (which period will be increased to 12&nbsp;months pursuant to the amended employment agreement to be effective upon completion of this offering),
or (b)&nbsp;the date Dr.&nbsp;Harris becomes eligible for comparable health insurance coverage under a subsequent employer&#146;s group health plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon a termination without cause, due to death, due to disability, or resignation for good reason within 3&nbsp;months prior to or 18 months
after a change in control (such period, the change in control period), Dr.&nbsp;Harris is entitled to (i)&nbsp;a cash lump sum payment equal to 18 months of Dr.&nbsp;Harris&#146; current annual base salary plus Dr.&nbsp;Harris&#146; then target
annual bonus (which will be increased to 150% of his target annual bonus pursuant to the amended employment agreement to be effective upon completion of this offering), (ii)&nbsp;accelerated vesting of 100% of Dr.&nbsp;Harris&#146; unvested equity
awards as of his date of termination, and (iii)&nbsp;payment or reimbursement of the COBRA premiums for Dr.&nbsp;Harris and his eligible dependents, or if coverage under COBRA is not available under our group health plan, the cash amount necessary
to maintain his health coverage at the same coverage levels in effect as of the date of his termination, until the earliest of (a)&nbsp;12&nbsp;months from Dr.&nbsp;Harris&#146; date of termination (which period will be increased to 18&nbsp;months
pursuant to the amended employment agreement to be effective upon completion of this offering), or (b)&nbsp;the date Dr.&nbsp;Harris becomes eligible for comparable health insurance coverage under a subsequent employer&#146;s group health plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of Dr.&nbsp;Harris&#146; employment agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;cause&#148; means (i)&nbsp;any material failure on the part of Dr.&nbsp;Harris (other than by reason of disability) to
faithfully and professionally carry out his duties; (ii)&nbsp;Dr.&nbsp;Harris&#146; dishonesty or other misconduct, if such dishonesty or other misconduct is intended to or likely to materially injure the business or reputation of us;
(iii)&nbsp;Dr.&nbsp;Harris&#146; conviction or no contest plea to any misdemeanor involving dishonesty, theft, fraud or moral turpitude, or any felony; (iv)&nbsp;Dr.&nbsp;Harris&#146; insobriety or illegal use of drugs, chemicals or controlled
substances either (A)&nbsp;in the course of performing his duties and responsibilities or (B)&nbsp;otherwise materially affecting the ability of Dr.&nbsp;Harris to perform these duties and responsibilities; (v)&nbsp;Dr.&nbsp;Harris&#146; material
breach of any written agreement with us or any of our affiliates or his material violation of our &#147;code of conduct&#148; or any other material written policy of our company; or (vi)&nbsp;any wanton or willful dereliction of duties by
Dr.&nbsp;Harris. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;change in control&#148; will have the meaning given to such term in the 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;disability&#148; means permanent and total disability within the meaning of Section&nbsp;22(e) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;good reason&#148; means (i)&nbsp;the material reduction of his annual base salary (other than as part of a reduction in
the base salaries of all or substantially all our other similarly situated employees that is in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
the same proportion as the reduction in his annual base salary); (ii) a material reduction of Dr.&nbsp;Harris&#146; duties and responsibilities; (iii)&nbsp;our material breach of the employment
agreement (other than a reduction of Dr.&nbsp;Harris&#146; annual base salary as part of a reduction in the base salaries of all or substantially all other similarly situated employees of our company that is in the same proportion as the reduction
in his annual base salary); or (iv)&nbsp;the permanent, <FONT STYLE="white-space:nowrap">non-voluntary</FONT> relocation of Dr.&nbsp;Harris&#146; principal place of employment that increases his <FONT STYLE="white-space:nowrap">one-way</FONT>
commute by more than 35 miles, provided, that, in each case, Dr.&nbsp;Harris will not be deemed to have good reason unless (A)&nbsp;Dr.&nbsp;Harris first provides the board of directors with written notice of the condition giving rise to good reason
within 30 days of its initial occurrence, (B)&nbsp;we or the successor company fails to cure such condition within 10 days after receiving such written notice, and (C)&nbsp;Dr.&nbsp;Harris&#146; resignation based on such good reason is effective
within 30 days after expiration of our 10 day cure period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Mr.</I></B><B><I></I></B><B><I>&nbsp;Bensen.</I></B> We have entered
into an employment agreement with Mr.&nbsp;Bensen which governs the terms of his employment with us. Pursuant to his agreement, Mr.&nbsp;Bensen was entitled to an initial annual base salary of $250,000, which was increased to $257,500 in January
2020 and increased to $343,000 in March 2021. He is also eligible to receive an annual discretionary bonus at a target amount of 30% of his then current annual base salary based on the achievement of individual and corporate performance targets and
metrics, as determined by our board of directors. Pursuant to the amended employment agreement with Mr.&nbsp;Bensen to be effective upon completion of this offering, Mr.&nbsp;Bensen&#146;s annual base salary will be increased to $410,000 and his
annual target bonus will be increased to 40% of his then current annual base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Bensen&#146;s employment agreement provides
for the following benefits in connection with a change in control. In the event of a change in control, the vesting of Mr.&nbsp;Bensen&#146;s then outstanding unvested equity awards will accelerate as of immediately prior to such change in control
with respect to 50% of the unvested shares of our common stock underlying these equity awards. The remaining 50% of the unvested shares of common stock underlying these equity awards will continue to vest at the same rate as immediately prior to the
change in control, subject to Mr.&nbsp;Bensen&#146;s continued employment with us or our successor through the applicable vesting date. Any portion of Mr.&nbsp;Bensen&#146;s outstanding equity awards that remains unvested as of the first anniversary
of the change in control will vest in full, subject to Mr.&nbsp;Bensen&#146;s continued employment with us or our successor through such first anniversary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which Mr.&nbsp;Bensen&#146;s employment terminates, he is entitled to receive amounts previously earned during his
employment, including unpaid salary, reimbursement of expenses owed, and cash out of accrued but unused paid <FONT STYLE="white-space:nowrap">time-off,</FONT> subject to his execution of a release of claims and compliance with post-termination
obligations. In addition, Mr.&nbsp;Bensen is entitled to certain severance benefits under his employment agreement, subject to his execution of a release of claims and compliance with post-termination obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Bensen&#146;s employment agreement provides for severance benefits for certain terminations that arise during and outside a change in
control period. Upon a termination without cause, due to death, due to disability, or resignation for good reason outside of a change in control period, Mr.&nbsp;Bensen is entitled to (i)&nbsp;a cash lump sum payment equal to 12&nbsp;months of
Mr.&nbsp;Bensen&#146;s current annual base salary plus Mr.&nbsp;Bensen&#146;s then target annual bonus, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the total number of days elapsed in the calendar year as of Mr.&nbsp;Bensen&#146;s
date of termination, (ii)&nbsp;accelerated vesting of 50% of Mr.&nbsp;Bensen&#146;s unvested equity awards as of his date of termination, and (iii)&nbsp;payment or reimbursement of the COBRA premiums for Mr.&nbsp;Bensen and his eligible dependents,
or if coverage under COBRA is not available under our group health plan, the cash amount necessary to maintain his health coverage at the same coverage levels in effect as of the date of his termination, until the earliest of (a) six months from
Mr.&nbsp;Bensen&#146;s date of termination (which period will be increased to 12&nbsp;months pursuant to the amended employment agreement to be effective upon completion of this offering), or (b)&nbsp;the date Mr.&nbsp;Bensen becomes eligible for
comparable health insurance coverage under a subsequent employer&#146;s group health plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon a termination without cause or
resignation for good reason within 3&nbsp;months prior to or 18 months after a change in control (such period, the change in control period), Mr.&nbsp;Bensen is entitled to (i)&nbsp;a cash lump sum </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment equal to 18&nbsp;months of Mr.&nbsp;Bensen&#146;s current annual base salary plus Mr.&nbsp;Bensen&#146;s then target annual bonus, (ii)&nbsp;accelerated vesting of 100% of
Mr.&nbsp;Bensen&#146;s unvested equity awards as of his date of termination, and (iii)&nbsp;payment or reimbursement of the COBRA premiums for Mr.&nbsp;Bensen and his eligible dependents, or if coverage under COBRA is not available under our group
health plan, the cash amount necessary to maintain his health coverage at the same coverage levels in effect as of the date of his termination, until the earliest of (a)&nbsp;12&nbsp;months from Mr.&nbsp;Bensen&#146;s date of termination, or
(b)&nbsp;the date Mr.&nbsp;Bensen becomes eligible for comparable health insurance coverage under a subsequent employer&#146;s group health plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of Mr.&nbsp;Bensen&#146;s employment agreement, &#147;cause,&#148; &#147;change in control,&#148; &#147;change in control
period&#148;, &#147;disability&#148; and &#147;good reason&#148; have the same meaning as given to the terms in Dr.&nbsp;Harris&#146; employment agreement, as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Swanson.</I></B> We entered into an employment agreement with Dr.&nbsp;Swanson which governs the
terms of his employment with us. Pursuant to his agreement, Dr.&nbsp;Swanson was entitled to an initial annual base salary of $257,500, which was increased to $343,000 in March 2021. He is also eligible to receive an annual discretionary bonus at a
target amount of 30% of his then current annual base salary based on the achievement of individual and corporate performance targets and metrics, as determined by our board of directors. Pursuant to the amended employment agreement with
Dr.&nbsp;Swanson to be effective upon completion of this offering, Dr.&nbsp;Swanson&#146;s annual base salary will be increased to $410,000 and his annual target bonus will be increased to 40% of his then current annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Swanson&#146;s employment agreement provides for the following benefits in connection with a change in control. In the event of a
change in control, the vesting of Dr.&nbsp;Swanson&#146;s then outstanding unvested equity awards will accelerate as of immediately prior to such change in control with respect to 50% of the unvested shares of our common stock underlying these
equity awards. The remaining 50% of the unvested shares of common stock underlying these equity awards will continue to vest at the same rate as immediately prior to the change in control, subject to Dr.&nbsp;Swanson&#146;s continued employment with
us or our successor through the applicable vesting date. Any portion of Dr.&nbsp;Swanson&#146;s outstanding equity awards that remains unvested as of the first anniversary of the change in control will vest in full, subject to
Dr.&nbsp;Swanson&#146;s continued employment with us or our successor through such first anniversary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which
Dr.&nbsp;Swanson&#146;s employment terminates, he is entitled to receive amounts previously earned during his employment, including unpaid salary, reimbursement of expenses owed, and cash out of accrued but unused paid
<FONT STYLE="white-space:nowrap">time-off,</FONT> subject to his execution of a release of claims and compliance with the post-termination obligations. In addition, Dr.&nbsp;Swanson is entitled to certain severance benefits under his employment
agreement, subject to his execution of a release of claims and compliance with post-termination obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Swanson&#146;s
employment agreement provides for severance benefits for certain terminations that arise during and outside a change in control period. Upon a termination without cause, due to death, due to disability, or resignation for good reason outside of a
change in control period (as such terms are defined below), Dr.&nbsp;Swanson is entitled to (i)&nbsp;a cash lump sum payment equal to 12&nbsp;months of Dr.&nbsp;Swanson&#146;s current annual base salary plus Dr.&nbsp;Swanson&#146;s then target
annual bonus, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the total number of days elapsed in the calendar year as of Dr.&nbsp;Swanson&#146;s date of termination, (ii)&nbsp;accelerated vesting of 50% of Dr.&nbsp;Swanson&#146;s
unvested equity awards as of his date of termination, and (iii)&nbsp;payment or reimbursement of the COBRA premiums for Dr.&nbsp;Swanson and his eligible dependents, or if coverage under COBRA is not available under our group health plan, the cash
amount necessary to maintain his health coverage at the same coverage levels in effect as of the date of his termination, until the earliest of (a)&nbsp;six months from Dr.&nbsp;Swanson&#146;s date of termination (which period will be increased to
12&nbsp;months pursuant to the amended employment agreement to be effective upon completion of this offering), or (b)&nbsp;the date Dr.&nbsp;Swanson becomes eligible for comparable health insurance coverage under a subsequent employer&#146;s group
health plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon a termination without cause, due to death, due to disability, or resignation for good
reason within 3&nbsp;months prior to or 18 months after a change in control (such period, the change in control period), Dr.&nbsp;Swanson is entitled to (i)&nbsp;a cash lump sum payment equal to 18&nbsp;months of Dr.&nbsp;Swanson&#146;s current
annual base salary plus Dr.&nbsp;Swanson&#146;s then target annual bonus (ii)&nbsp;accelerated vesting of 100% of Dr.&nbsp;Swanson&#146;s unvested equity awards as of his date of termination, and (iii)&nbsp;payment or reimbursement of the COBRA
premiums for Dr.&nbsp;Swanson and his eligible dependents, or if coverage under COBRA is not available under our group health plan, the cash amount necessary to maintain his health coverage at the same coverage levels in effect as of the date of his
termination, until the earliest of (a) 12 months from Dr.&nbsp;Swanson&#146;s date of termination, or (b)&nbsp;the date Dr.&nbsp;Swanson becomes eligible for comparable health insurance coverage under a subsequent employer&#146;s group health plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of Dr.&nbsp;Swanson&#146;s employment agreement, &#147;cause,&#148; &#147;change in control,&#148; &#147;change in control
period,&#148; &#147;disability&#148; and &#147;good reason&#148; have the same meaning as given to the terms in Dr.&nbsp;Harris&#146; employment agreement, as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each named executive officers&#146; employment agreement contains a one-year post-termination non-solicitation covenant. Each of our named
executive officers&#146; stock options granted prior to execution of the underwriting agreement for this offering are subject to the terms of the 2020 Plan; a description of the termination and change in control provisions in the 2020 Plan and the
form of stock options granted thereunder is provided below under &#147;&#151;Equity Incentive Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Health and Welfare and Retirement Benefits;
Perquisites </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of our current named executive officers are eligible to participate in our employee benefit plans, including our
medical, dental, vision, disability and life insurance plans, in each case on the same basis as all of our other employees. Other than the telephone allowance described in the footnotes to the 2020 Summary Compensation Table, we generally do not
provide perquisites or personal benefits to our named executive officers, except in limited circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in a defined contribution retirement plan that provides eligible employees with an
opportunity to save for retirement on a tax advantaged basis. Eligible employees may defer eligible compensation
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on&nbsp;a&nbsp;pre-tax&nbsp;or&nbsp;after-tax&nbsp;(Roth)&nbsp;basis,</FONT></FONT> up to the statutorily prescribed annual limits on contributions under the Code. Contributions are
allocated to each participant&#146;s individual account and are then invested in selected investment alternatives according to the participants&#146; directions. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code with
the 401(k) plan&#146;s related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. <FONT STYLE="white-space:nowrap">As&nbsp;a&nbsp;tax-qualified&nbsp;retirement&nbsp;plan,</FONT> contributions to the 401(k) plan (except for Roth
contributions) and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan. Our board of directors may elect to adopt qualified or nonqualified benefit plans in the future, if it determines that doing
so is in our best interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The principal features of our equity incentive plans are summarized below. These summaries are qualified in their entirety by reference to the
actual text of the applicable plan, each of which is or will be filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Incentive Award Plan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
board of directors has adopted and our stockholders have approved the 2021 Plan, which will become effective on the day prior to the first public trading date of our common stock. Under the 2021 Plan, we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which we compete. The material terms of the 2021 Plan are
summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Eligibility and administration.</I> Our employees, consultants and directors, and employees and consultants of our
subsidiaries, will be eligible to receive awards under the 2021 Plan. Following our initial public offering, the 2021 Plan will generally be administered by our board of directors with respect to awards to non-employee directors and by our
compensation committee with respect to other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to certain
limitations that may be imposed under the 2021 Plan, Section&nbsp;16 of the Exchange Act and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all
forms for use with, and adopt rules for the administration of, the 2021 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2021 Plan, including any vesting and
vesting acceleration conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Limitation on awards and shares available. </I>The number of shares initially available for issuance
under awards granted pursuant to the 2021 Plan will be the sum of (1)&nbsp;4,537,850&nbsp;shares of our common stock, plus (2)&nbsp;any shares of our common stock which, as of the effective date of the 2021 Plan, remain available for issuance under
the 2020 Plan, plus (3)&nbsp;any shares subject to outstanding awards under the 2020 Plan as of the effective date of the 2021 Plan that become available for issuance under the 2021 Plan thereafter in accordance with its terms. The number of shares
initially available for issuance will be increased on January&nbsp;1 of each calendar year beginning in 2022 and ending in 2031, by an amount equal to the lesser of (a)&nbsp;5% of the shares of common stock outstanding on the final day of the
immediately preceding calendar year and (b)&nbsp;such smaller number of shares as determined by our board of directors. No more than 100,000,000&nbsp;shares of common stock may be issued upon the exercise of incentive stock options under the 2021
Plan. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
an award under the 2021 Plan or the 2020 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised or forfeited, in any case, in a manner that results in the
Company acquiring shares covered by the award at a price not greater than the price paid by the participant for such shares or not issuing any shares covered by the award, any shares subject to such award will, as applicable, become or again be
available for new grants under the 2021 Plan. Awards granted under the 2021 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a
merger or similar corporate transaction will not reduce the shares available for grant under the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Awards. </I>The 2021 Plan
provides for the grant of stock options, including incentive stock options, or ISOs within the meaning of Section 422 of the Code, and nonqualified stock options, or NSOs; restricted stock; dividend equivalents; restricted stock units, or RSUs;
stock appreciation rights, or SARs; and other stock or cash-based awards. Certain awards under the 2021 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose additional requirements
on the terms and conditions of such awards. All awards under the 2021 Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment terms and post-termination
exercise limitations. Awards other than cash awards generally will be settled in shares of our common stock, but the plan administrator may provide for cash settlement of any award. A brief description of each award type follows. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock options</I><I>. </I>Stock options provide for the purchase of shares of our common stock in the future
at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied.
The exercise price of a stock option will not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain
substitute options </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders).
Vesting conditions determined by the plan administrator may apply to stock options and may include continued service, performance and/or other conditions. ISOs generally may be granted only to our employees and employees of our parent or subsidiary
corporations, if any. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>SARs</I><I>.</I> SARs entitle their holder, upon exercise, to receive from us an amount equal to the
appreciation of the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR will not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to
certain substitute SARs granted in connection with a corporate transaction), and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service,
performance and/or other conditions. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted stock and RSUs</I><I>.</I> Restricted stock is an award of nontransferable shares of our common
stock that remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless
and until specified conditions are met. Delivery of the shares underlying RSUs may be deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted
stock and RSUs may be based on continuing service, the attainment of performance goals and/or such other conditions as the plan administrator may determine. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other stock or cash-based awards</I><I>.</I> Other stock or cash-based awards are awards of cash, fully vested
shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash-based awards may be granted to participants and may also be available as a payment form in
the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise payable to any individual who is eligible to receive awards. The plan administrator will determine the
terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service, performance and/or other conditions. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend equivalents.</I> RSUs or other stock and cash-based awards may be accompanied by the right to receive
the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Such dividend equivalents will only be paid out to the extent that any vesting conditions are subsequently satisfied, unless
otherwise determined by the plan administrator. No dividend equivalents will be payable on stock options or SARs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Performance awards</I><I>. </I>Performance awards include any of the foregoing awards that are granted subject to vesting and/or payment
based on the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively determinable. Performance criteria upon which performance goals are established by the plan
administrator may include: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net
income (either before or after taxes) or adjusted net income; profits (including, but not limited to, gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating
earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested
capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per
share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development, regulatory, commercial or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer
satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human capital management (including diversity and inclusion); supervision of litigation and other legal matters; strategic partnerships and
transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity;
investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to our performance or the
performance of a subsidiary, division, business segment or business unit, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Director </I><I>c</I><I>ompensation</I><I>. </I>The 2021 Plan provides that the plan administrator may establish compensation for
non-employee directors from time to time subject to the 2021 Plan&#146;s limitations. Prior to this offering, our stockholders will approve the initial terms of our non-employee director compensation program, which is described below under the
heading &#147;Director Compensation.&#148; Our board of directors or its authorized committee may modify the non-employee director compensation program from time to time in the exercise of its business judgment, taking into account such factors,
circumstances and considerations as it deems relevant from time to time, provided that the sum of any cash compensation or other compensation and the grant date fair value (as determined in accordance with FASB ASC 718, or any successor thereto) of
any equity awards granted as compensation for services as a non-employee director during any calendar year may not exceed $750,000, increased to $1,000,000 in the calendar year of a non-employee director&#146;s initial service as a non-employee
director or during which a non-employee director serves as chair of our board of directors or lead independent director (which limits will not apply to the compensation for any non-employee director who serves in any capacity in addition to that of
a non-employee director for which he or she receives additional compensation or any compensation paid to any non-employee director prior to the calendar year following the calendar year in which this offering occurs). The plan administrator may make
exceptions to this limit for individual non-employee directors in extraordinary circumstances, as the plan administrator may determine in its discretion, provided that the non-employee director receiving such additional compensation may not
participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Certain transactions. </I>In connection with certain transactions and events affecting our common stock, including a change in control (as
defined below), or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2021 Plan to prevent the dilution or enlargement of intended benefits, facilitate such transaction or
event, or give effect to such change in applicable laws or accounting principles. This includes canceling awards in exchange for either an amount in cash or other property with a value equal to the amount that would have been obtained upon exercise
or settlement of the vested portion of such award or realization of the participant&#146;s rights under the vested portion of such award, accelerating the vesting of awards, providing for the assumption or substitution of awards by a successor
entity, adjusting the number and type of shares available, replacing awards with other rights or property or terminating awards under the 2021 Plan. In the event of a change in control where the acquirer does not assume awards granted under the 2021
Plan, awards issued under the 2021 Plan will be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as applicable. In addition, in the event of certain non-reciprocal transactions with our
stockholders (an equity restructuring) the plan administrator will make equitable adjustments to the 2021 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of the 2021 Plan, a &#147;change in control&#148; means and includes each of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a transaction or series of transactions whereby any &#147;person&#148; or related &#147;group&#148; of
&#147;persons&#148; (as such terms are used in Sections&nbsp;13(d) and 14(d)(2) of the Exchange Act) (other than our company or our subsidiaries or any employee benefit plan maintained by us or any of our subsidiaries or a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
&#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, us) directly or indirectly acquires beneficial ownership
(within the meaning of Rule 13d-3 under the Exchange Act) of our securities possessing more than 50% of the total combined voting power of our securities outstanding immediately after such acquisition; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">during any period of two consecutive years, individuals who, at the beginning of such period, constitute our
board of directors together with any new directors (other than a director designated by a person who has entered into an agreement with us to effect a change in control transaction) whose election by our board of directors or nomination for election
by our stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease
for any reason to constitute a majority thereof; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the consummation by us (whether directly or indirectly) of (x)&nbsp;a merger, consolidation, reorganization, or
business combination or (y)&nbsp;a sale or other disposition of all or substantially all of our assets in any single transaction or series of related transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other
than a transaction: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">which results in our voting securities outstanding immediately before the transaction continuing to represent
either by remaining outstanding or by being converted into voting securities of the company or the person that, as a result of the transaction, controls, directly or indirectly, the company or owns, directly or indirectly, all or substantially all
of our assets or otherwise succeeds to our business, directly or indirectly, at least a majority of the combined voting power of the successor entity&#146;s outstanding voting securities immediately after the transaction, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after which no person or group beneficially owns voting securities representing 50% or more of the combined
voting power of the successor entity; provided, however, that no person or group will be treated as beneficially owning 50% or more of the combined voting power of the successor entity solely as a result of the voting power held in our company prior
to the consummation of the transaction. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Foreign </I><I>p</I><I>articipants, </I><I>c</I><I>lawback
</I><I>p</I><I>rovisions, </I><I>t</I><I>ransferability and </I><I>p</I><I>articipant </I><I>p</I><I>ayments. </I>With respect to foreign participants, the plan administrator may modify award terms, establish subplans and/or adjust other terms and
conditions of awards, subject to the share limits described above. All awards will be subject to the provisions of any clawback policy implemented by our company and to the extent set forth in such clawback policy or in the applicable award
agreement. With limited exceptions for estate planning, domestic relations orders, certain beneficiary designations and the laws of descent and distribution, awards under the 2021 Plan are generally nontransferable prior to vesting and are
exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2021 Plan and exercise price obligations arising in connection with the exercise of stock options under the 2021 Plan, the
plan administrator may, in its discretion, accept cash, wire transfer, or check, shares of our common stock that meet specified conditions (a market sell order) or such other consideration as it deems suitable or any combination of the foregoing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan </I><I>a</I><I>mendment and </I><I>t</I><I>ermination</I><I>. </I>Our board of directors may amend, suspend or terminate the 2021
Plan at any time; however, except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2021 Plan. The plan administrator will
have the authority, without the approval of our stockholders, to amend any outstanding stock option or SAR to reduce its exercise price per share. No award may be granted pursuant to the 2021 Plan after the tenth anniversary of the date it was first
adopted by our board of directors adopts the 2021 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors and stockholders adopted the 2020 Plan in January 2020. Our 2020 Plan provides for the grant of ISOs to employees,
including employees of any parent or subsidiary, and for the grant of NSOs, SARs, restricted stock, RSUs and unrestricted stock awards to employees, directors and consultants, including employees and consultants of any parent or subsidiary, and
nonemployees, <FONT STYLE="white-space:nowrap">non-consultants,</FONT> and <FONT STYLE="white-space:nowrap">non-directors</FONT> to whom an offer of a service relationship as an employee, consultant, investor director provider, has been or is being
extended. Once our 2021 Plan becomes effective, no further grants will be made under our 2020 Plan. Any outstanding awards granted under our 2020 Plan will remain subject to the terms of our 2020 Plan and applicable award agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Authorized shares.</I></B> Subject to certain capitalization adjustments, the maximum number of shares of common stock that may be
issued pursuant to stock awards under the 2020 Plan will not exceed 4,685,476&nbsp;shares. Shares subject to stock awards granted under our 2020 Plan that expire, are forfeited or otherwise terminate without being exercised or settled in shares do
not reduce the number of shares available for issuance under our 2020 Plan and will become available under the 2021 Plan after it becomes effective. Additionally, shares used to pay the exercise price of a stock award or to satisfy the tax
withholding obligations related to a stock award become available for future grant under our 2020 Plan or, after the effective date of the 2021 Plan, the 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Plan administration.</I></B> Our board of directors, or a duly authorized committee of our board of directors to which the board
delegates its administrative authority, will administer our 2020 Plan and is referred to as the &#147;plan administrator&#148; herein. Under our 2020 Plan, the plan administrator has the authority to, among other things, determine who will be
granted stock awards, to determine the terms and conditions of each stock award (including the number of shares subject to the stock award, when the stock award will vest and, as applicable, become exercisable), to accelerate the time(s) at which a
stock award may vest or be exercised, and to construe and interpret the terms of our 2020 Plan and stock awards granted thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options.</I></B><B><I></I></B> ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan
administrator determines the exercise price for stock options, within the terms and conditions of the 2020 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on
the date of grant (or 110% of the fair market value for ISOs granted to certain major stockholders). Options granted under the 2020 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The plan administrator determines the term of stock options granted under the 2020 Plan, up to a maximum of 10 years (or five years, for ISOs
granted to certain major stockholders). The plan administrator will determine the effect on a stock award of the disability, death, retirement, authorized leave of absence, or any other change or purported change in a holder&#146;s status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan
administrator and may include (1)&nbsp;cash or check payable to us, (2)&nbsp;subject to plan administrator consent, a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of our common stock previously owned by the optionholder,
(4)&nbsp;subject to plan administrator consent, a net exercise of the option if it is an NSO, (5)&nbsp;a combination of any of the foregoing methods, or (6)&nbsp;other legal consideration approved by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless the plan administrator provides otherwise, options generally are not transferable except by will or the laws of descent and
distribution. Subject to approval of the plan administrator (i)&nbsp;an option may be transferred pursuant to a domestic relations order and (ii)&nbsp;an optionholder may designate a beneficiary who may exercise the option following the
optionholder&#146;s death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Changes to capital structure.</I></B> The plan administrator will make appropriate and
proportionate adjustments to (1)&nbsp;the maximum number of shares reserved for issuance under the 2020 Plan and (2)&nbsp;the number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards to
reflect any increase or decrease in the number of our issued shares of our common stock resulting from a stock split, reverse stock split, stock dividend, combination, recapitalization or reclassification of the shares, merger, consolidation, change
in organization form, or any other increase or decrease in the number of our shares of common stock effected without receipt or payment of consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Change in control</I></B><I>.</I> Our 2020 Plan provides that in the event of a &#147;change in control,&#148; unless otherwise provided
in an award agreement or other written agreement between us and the award holder, the plan administrator may take one or more of the following actions with respect to such stock awards: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assumption, continuation, or substitution of a stock award by a surviving or acquiring
corporation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate the vesting, in whole or in part, of the stock award; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for its termination if not exercised (if applicable) at or before the effective time of the transaction;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel or arrange for the cancellation of the stock award, to the extent not vested or not exercised before the
effective time of the transaction, in exchange for such cash or other consideration (including no consideration) as our board of directors, in its sole discretion, may consider appropriate; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terminate the award without compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to treat
all participants in the same manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the 2020 Plan, a &#147;change in control&#148; is generally defined as any one or more of the
following events: (1)&nbsp;a sale of all or substantially all of our assets or similar transaction, (2)&nbsp;the sale or disposition of 50% or more of the combined voting power of our outstanding securities, (3)&nbsp;a merger or consolidation that
would have the same effect as the foregoing clause (2), and (4)&nbsp;our stockholders approving a plan or proposal for our liquidation or dissolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Plan Amendment or Termination</I></B><I>.</I> Our board of directors has the authority to amend, or terminate our 2020 Plan, provided
that such action does not impair the vested rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. Unless terminated sooner, the 2020 Plan will
automatically terminate on January&nbsp;6, 2030. No stock awards may be granted under our 2020 Plan or after it is terminated. Once the 2021 Plan is effective, no further grants will be made under the 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted and our stockholders have approved the ESPP, which will become effective the day prior to the first public
trading date of our common stock. The material terms of the ESPP are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ESPP is comprised of two distinct components
in order to provide increased flexibility to grant options to purchase shares under the ESPP to U.S. and to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> employees. Specifically, the ESPP authorizes (1)&nbsp;the grant of options to U.S. employees
that are intended to qualify for favorable U.S. federal tax treatment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under Section&nbsp;423 of the Code, (the &#147;Section&nbsp;423 Component&#148;), and (2)&nbsp;the grant of options that are not intended to be
<FONT STYLE="white-space:nowrap">tax-qualified</FONT> under Section&nbsp;423 of the Code to facilitate participation for employees located outside of the U.S. who do not benefit from favorable U.S. federal tax treatment and to provide flexibility to
comply with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> law and other considerations (the <FONT STYLE="white-space:nowrap">&#147;Non-Section</FONT> 423 Component&#148;). Where permitted under local law and custom, we expect that the <FONT
STYLE="white-space:nowrap">Non-Section</FONT> 423 Component will generally be operated and administered on terms and conditions similar to the Section&nbsp;423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Shares available for awards; administration.</I><B><I> </I></B>A total of 380,000&nbsp;shares of our common stock will initially be
reserved for issuance under the ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 2022 and ending in and including 2031, by an amount equal
to the lesser of (A)&nbsp;1% of the shares outstanding on the final day of the immediately preceding calendar year and (B)&nbsp;such smaller number of shares as is determined by our board of directors, provided that no more than
10,000,000&nbsp;shares of our common stock may be issued under the ESPP. Our board of directors or a committee of our board of directors will administer and will have authority to interpret the terms of the ESPP and determine eligibility of
participants. We expect that the compensation committee will be the initial administrator of the ESPP (referred to as the plan administrator below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Eligibility.</I><B><I> </I></B>We expect that all of our employees will be eligible to participate in the ESPP. However, an employee may
not be granted rights to purchase stock under the ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Grant of rights.</I><B><I> </I></B>Stock will be offered under the ESPP during offering periods. The length of the offering periods
under the ESPP will be determined by the plan administrator and may be up to twenty-seven months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The purchase dates for each offering
period will be the final trading day in the offering period. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. In <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions where participation in the ESPP through payroll deductions is prohibited, the plan administrator may provide that an eligible employee may elect to participate through contributions to the
participant&#146;s account under the ESPP in a form acceptable to the plan administrator in lieu of or in addition to payroll deductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ESPP permits participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible
compensation. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period. In addition, no employee will be permitted to accrue the right to purchase stock under the
Section&nbsp;423 Component at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the offering
period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of
our common stock. The option will expire at the end of the applicable offering period and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period. The purchase price of the shares, in the absence
of a contrary designation, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date. Participants may voluntarily end their participation in the ESPP at any time
during a specified period prior to the end of the applicable offering period and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation ends automatically upon a participant&#146;s
termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A participant may not transfer rights granted under the ESPP other than by will or the laws of descent and
distribution, and such rights are generally exercisable only by the participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Certain transactions.</I><B><I> </I></B>In the event of certain <FONT
STYLE="white-space:nowrap">non-reciprocal</FONT> transactions or events affecting our common stock, the plan administrator will make equitable adjustments to the ESPP and outstanding rights. In the event of certain unusual or <FONT
STYLE="white-space:nowrap">non-recurring</FONT> events or transactions, including a change in control, the plan administrator may provide for (1)&nbsp;either the replacement of outstanding rights with other rights or property or termination of
outstanding rights in exchange for cash, (2)&nbsp;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (3)&nbsp;the adjustment in the number and type of shares of
stock subject to outstanding rights, (4)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering
periods or (5)&nbsp;the termination of all outstanding rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan amendment.</I><B><I> </I></B>The plan administrator may amend,
suspend or terminate the ESPP at any time. However, stockholder approval will be obtained for any amendment that increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the ESPP or changes the
corporations or classes of corporations whose employees are eligible to participate in the ESPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We did not provide any cash, equity or other compensation to
<FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors</FONT> in the year ended December&nbsp;31, 2020 with the exception of our independent board members. We do have a policy of reimbursing all of
<FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors</FONT> for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reasonable&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> in connection with attending board of
directors and committee meetings. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option&nbsp;Awards<BR>($)
(1)(4)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>All
Other<BR>Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isan Chen, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,821</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,256</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilla Kaplan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,160</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the aggregate grant date fair value of the stock options awarded to the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director during fiscal year 2020, calculated in accordance with FASB ASC Topic 718. Such grant date fair value does not take into account any estimated forfeitures. The assumptions used in calculating
the grant date fair value of the awards reported in this column are set forth in Note&nbsp;7 to our financial statements included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for the stock options and
do not reflect the actual economic value that will be realized upon the vesting of the stock options, the exercise of the stock options or the sale of the common stock underlying such awards. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Chen was granted an option on January&nbsp;27, 2020 to purchase 115,417 shares. The options will vest
in 36 monthly installments following the date of grant, subject to Dr.&nbsp;Chen&#146;s continued service. 61,392 of the shares subject to the option are compensation for Dr.&nbsp;Chen&#146;s service as a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director and 54,025 of the shares subject to the option are compensation for Dr.&nbsp;Chen&#146;s consulting services as Chief Medical Advisor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Kaplan was granted an option on January&nbsp;27, 2020 to purchase 61,392 shares. The options will vest
in 36 monthly installments following the date of grant, subject to Dr.&nbsp;Kaplan&#146;s continued service. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2020, Dr.&nbsp;Kaplan held options to purchase 61,392 shares of our common stock and
was the only <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our board of directors that held unexercised options as of that date. As of December&nbsp;31, 2020, Dr.&nbsp;Chen held 80,151 shares of restricted stock acquired pursuant to
the early exercise of the option granted to Dr.&nbsp;Chen on January&nbsp;27, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents fees of $6,438 per month as compensation for consulting services as Chief Medical Advisor pursuant
to a consulting agreement entered into by Dr.&nbsp;Chen and us as of January&nbsp;1, 2020. The agreement has an initial term of one year and automatically terminated as of January 1, 2021 pursuant to its terms. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, our board of directors has adopted and our stockholders
have approved the initial terms of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program. The material terms of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program are summarized
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will provide for annual retainer fees and/or
long-term equity awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. We expect each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual retainer of $35,000.
<FONT STYLE="white-space:nowrap">Non-employee</FONT> directors serving as the chairs of the audit, compensation and nominating and corporate governance committees will receive additional annual retainers of $15,000, $10,000, and $8,000,
respectively. The <FONT STYLE="white-space:nowrap">non-employee</FONT> directors serving as members of the audit, compensation and nominating and corporate governance committees will receive additional annual retainers of $7,500, $5,000, and $4,000,
respectively. The <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will also receive initial grants of options to purchase 29,000 shares of our common stock, vesting over three years, upon election to the board of directors, and
thereafter annual grants of options to purchase 14,500 shares of our common stock, vesting in substantially equal monthly installments over the 12&nbsp;months following the date of grant (or, in the event the next annual meeting of our stockholders
occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the annual award will vest on the date of such annual meeting of our stockholders). Awards to our non-employee directors will also vest in the event of a
change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Compensation under our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will be
subject to the annual limits on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2021 Plan, as described above. Our board of directors or its authorized committee may modify the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time,
subject to the annual limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2021 Plan (which limits will not apply to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director that serves in any
additional capacity with the company for which he or she receives compensation or any compensation paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director prior to the calendar year following the calendar year in which this
offering occurs). As provided in the 2021 Plan, our board of directors or its authorized committee may make exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the
board of directors or its authorized committee may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the decision to award such
compensation or in other compensation decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and
Indemnification </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On the completion of this offering, our amended and restated certificate of incorporation will contain provisions
that limit the liability of our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any
breach of fiduciary duties as directors, except liability for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will authorize us to
indemnify our directors, officers, employees and other agents to the fullest extent permitted by Delaware law. Our amended and restated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bylaws will provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. Our amended and
restated bylaws will also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of
any officer, director, employee, or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered
and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by the board of directors. With certain exceptions, these agreements provide for indemnification for related expenses
including attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that these amended and restated certificate of incorporation and amended and restated bylaw provisions and indemnification
agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#146; and officers&#146; liability insurance. The limitation of liability and indemnification provisions in our amended
and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation
against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards
against directors and officers as required by these indemnification provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under
the Securities Act may be permitted for directors, executive officers, or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since January&nbsp;1, 2018 to which we have been a party in which the amount involved
exceeded or will exceed the lessor of (i) $120,000 or (ii) 1% of the average of our total assets at fiscal <FONT STYLE="white-space:nowrap">year-end</FONT> for our last two fiscal years, and in which any of our directors, executive officers or, to
our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation,
termination, change in control and other arrangements, which are described under &#147;Executive and Director Compensation.&#148; We also describe below certain other transactions with our directors, executive officers and stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales of Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Simple Agreements for Future
Equity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Between October 2018 and March 2019, we entered into various SAFEs with certain investors pursuant to which we received
$3.2&nbsp;million in exchange for our agreement to issue the investors shares of our convertible preferred stock upon the occurrence of subsequent financings of our convertible preferred stock. Dr.&nbsp;Harris and members of his immediate family
collectively purchased $505,000 of SAFEs in the aggregate, which converted into 81,903 shares of our Series A Preferred Stock. Mr.&nbsp;Bensen and a member of his immediate family collectively purchased $120,000 of SAFEs in the aggregate, which
converted into 19,639 shares of our Series A Preferred Stock. Dr.&nbsp;Chen purchased $100,000 of SAFEs, which converted into 16,366 shares of our Series A Preferred Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series A Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2020, we sold an aggregate of&nbsp;2,848,486 shares of our Series A convertible preferred stock at a purchase price of
$8.25&nbsp;per share pursuant to agreements entered into with investors. In February 2021, we sold an aggregate of&nbsp;2,848,486 additional shares of our Series A convertible preferred stock at a purchase price of $8.25&nbsp;per share pursuant to
agreements entered into with investors. Each share of our Series A convertible preferred stock will automatically convert into shares of our common stock at a ratio of 2.5974-for-one immediately prior to the completion of this offering. All
purchasers of our Series A convertible preferred stock are entitled to specified registration rights. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for more information regarding these registration rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes purchases of our Series A convertible preferred stock by related persons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares&nbsp;of&nbsp;Series&nbsp;A<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total&nbsp;Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alta Partners NextGen Fund II, L.P.
<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,212,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P. <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,343,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackwell Partners LLC&#151;Series A
<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,406,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Nexus Fund, L.P. <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,250,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boxer Capital, LLC <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,211,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MVA Investors, LLC <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">788,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaan XI L.P. <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,000,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:8%;border-bottom:1px solid #000000; width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alta Partners NextGen Fund II, L.P., is an affiliate of Alta Partners, and is a holder of 5% or more of our
capital stock. Robert More is a Managing Director at Alta Partners and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RA Capital Healthcare Fund, L.P., Blackwell Partners LLC &#150; Series A and RA Capital Nexus Fund, L.P. are
affiliates of RA Capital Management, L.P., or RA Capital, and RA Capital is a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
holder of 5% or more of our capital stock. Jake Simson, Ph.D. is a Partner at RA Capital and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MVA Investors, LLC is affiliated with Boxer Capital, LLC. Boxer Capital, LLC and MVA Investors, LLC together
hold 5% or more of our capital stock. Siddarth Subramony, Ph.D. is a Vice President of Boxer Capital, LLC and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Canaan XI L.P. is a holder of 5% or more of our capital stock. Nina Kjellson is a General Partner of Canaan
Partners and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2021, we sold an aggregate of&nbsp;3,874,793 shares of our Series B convertible preferred stock at a purchase price of $27.4337 per
share pursuant to agreements entered into with investors. Each share of our Series B convertible preferred stock will automatically convert into shares of our common stock at a ratio of 2.5974-for-one immediately prior to the completion of this
offering. All purchasers of our Series B convertible preferred stock are entitled to specified registration rights. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for more information regarding these
registration rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes purchases of our Series B convertible preferred stock by related persons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total&nbsp;Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alta Partners NextGen Fund II, L.P.
<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P. <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Nexus Fund, L.P. <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,999,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boxer Capital, LLC <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">713,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,577,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MVA Investors, LLC <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">422,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaan XI L.P. <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nextech VI Oncology SCSP <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">729,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isan Chen, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:8%;border-bottom:1px solid #000000; width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alta Partners NextGen Fund II, L.P. is an affiliate of Alta Partners and is a holder of 5% or more of our
capital stock. Robert More is a Managing Director at Alta Partners and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P. are affiliates RA Capital, and RA Capital is a
holder of 5% or more of our capital stock. Jake Simson, Ph.D. is a Partner at RA Capital and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MVA Investors, LLC is affiliated with Boxer Capital, LLC. Boxer Capital, LLC and MVA Investors, LLC together
hold 5% or more of our capital stock. Siddarth Subramony, Ph.D. is a Vice President of Boxer Capital, LLC and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Canaan XI L.P. (&#147;Canaan XI&#148;) and Canaan 2020+ Co-Investment L.P. - Series 7 (&#147;Canaan 2020+
Series&nbsp;7&#148;) together hold 5% or more of our capital stock. Nina Kjellson is (i)&nbsp;a manager of Canaan Partners XI LLC (&#147;Canaan XI GP&#148;), the general partner of Canaan XI, (ii)&nbsp;a member of an investment committee of Canaan
Partners 2020+ Co-Investment LLC (&#147;Canaan 2020+ GP&#148;), the general partner of Canaan 2020+ Series&nbsp;7, that makes investment and voting decisions with respect to the shares held by Canaan 2020+ Series&nbsp;7, and (iii)&nbsp;a member of
our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nextech VI Oncology SCSP is an affiliate of Nextech Invest Ltd. and is a holder of 5% or more of our capital
stock. Melissa McCracken, Ph.D. is a Principal at Nextech Invest Ltd. and a member of our board of directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with our Series&nbsp;B financing described above, we entered into an amended and restated investors&#146; rights agreement,
amended and restated voting agreement and amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement, which contain registration rights, information rights, voting rights, and rights of first refusal
and <FONT STYLE="white-space:nowrap">co-sale,</FONT> among other things, with certain of our stockholders. Pursuant to our voting agreement, certain of our stockholders have the right to designate member(s) to be elected to our board of directors.
See the section titled &#147;Management&#151;Family Relationships and Other Arrangements.&#148; The foregoing agreements will terminate upon the completion of this offering, except for the registration rights set forth in the amended and restated
investors&#146; rights agreement, as more fully described below in &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reserved Share
Program </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At our request, an affiliate of BofA Securities, Inc., a participating Underwriter, has reserved for sale, at the initial
public offering price, up to 3% of the shares offered by this prospectus for sale to some of our directors and officers and certain other parties related to us. If these persons purchase reserved shares it will reduce the number of shares available
for sale to the general public. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered
into employment agreements with our named executive officers. For more information regarding the agreements with our named executive officers, see &#147;Executive and Director Compensation&#151; Employment Arrangements with our Named Executive
Officers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consulting Agreement with van den Boom&nbsp;&amp; Associates, LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;23, 2018, we entered into a consulting agreement with van den Boom&nbsp;&amp; Associates, LLC, or van den Boom&nbsp;&amp;
Associates, to provide (i)&nbsp;a resource to assist with finance department and administrative oversight, or Oversight Resources, and (ii)&nbsp;resources to assist with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> accounting functions, or Accounting Resources. Services provided under the agreement with van den Boom&nbsp;&amp; Associates are billed at hourly rates. In
April 2021, Ms.&nbsp;van den Boom, the managing partner of van den Boom&nbsp;&amp; Associates, signed an employment agreement with our company whereby she became our Chief Financial Officer on a half-time basis. Following the date of her employment
agreement, we anticipate that Oversight Resources previously provided under the consulting agreement will be provided to us pursuant to Ms.&nbsp;van den Boom&#146;s employment agreement and that payments for Accounting Resources under the consulting
agreement during the year ending December&nbsp;31, 2021 will exceed the lesser of $120,000 and 1% of the average of our company&#146;s total assets at the end of the last two fiscal years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options Granted to Executive Officers and Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted stock options to our executive officers, as more fully described in the section titled &#147;Executive and Director
Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Officer Indemnification </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things,
require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146;
fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive
officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify each of
our directors and officers to the fullest extent permitted by the Delaware General </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation Law. Further, we have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our directors and officers against the cost of defense, settlement or
payment of a judgment under certain circumstances. For further information, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted a written related person transaction policy, to be effective upon the closing of this offering, setting forth
the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or
relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end
for the last two completed fiscal years, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related
person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances,
including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions
described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of June&nbsp;30, 2021,
as adjusted to reflect the sale of common stock offered by us in this offering, for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our capital
stock; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to
securities. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Except as noted by footnote, and subject to community property laws where applicable,
we believe, based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each individual or entity shown on the table has furnished information with respect to beneficial ownership. Unless otherwise indicated, the
address for each beneficial owner is c/o&nbsp;Tyra Biosciences, Inc., 2656&nbsp;State Street, Carlsbad, CA 92008. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The percentage of
beneficial ownership prior to this offering in the table below is based on&nbsp;30,115,139 shares of common stock deemed to be outstanding as of June&nbsp;30, 2021, assuming the automatic conversion of all outstanding shares of our Series A
convertible preferred stock and Series&nbsp;B convertible preferred stock immediately prior to the completion of this offering into 26,228,089 shares of our common stock, and the percentage of beneficial ownership after this offering in the table
below is based on&nbsp;39,115,139 shares of common stock assumed to be outstanding after the completion of the offering, assuming no exercise by the underwriters of their option to purchase additional shares and without giving effect to any
potential purchases in this offering, including pursuant to the reserved share program relating to this offering. Outstanding shares as June&nbsp;30, 2021 include 1,512,699 shares of unvested restricted common stock. These unvested restricted shares
have the same voting rights as unrestricted shares of our common stock and, therefore, have been included for the purposes of calculating beneficial ownership below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See Note 2 and Note 7 to our audited and unaudited financial statements included elsewhere
in this prospectus for a discussion of our outstanding restricted common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Shares&nbsp;Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage of<BR>Shares&nbsp;Beneficially&nbsp;Owned<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% and Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alta Partners NextGen Fund II,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,924,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital Healthcare
Fund<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,986,454</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Boxer Capital
LLC<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,986,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,409,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nextech VI Oncology SCSP<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,893,582</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Harris, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,759,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Bensen<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Swanson, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isan Chen, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilla Kaplan, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nina Kjellson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Melissa McCracken, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert More<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,924,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jake Simson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Siddarth Subramony, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rehan Verjee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors and executive officers as a group (15&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(11) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,890,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,924,046 shares of our common stock held by Alta Partners NextGen Fund II, L.P, or Alta. Alta
Partners Nextgen Fund II Management, LLC is the general partner of Alta. Daniel Janney, Peter Hudson and Robert More, a member of our board of directors, share voting or investment power over the shares held by Alta. Each of the individuals and
entities listed above expressly disclaims beneficial interest of the shares listed above except to the extent of any pecuniary interest therein. The principal address for Alta is Four Embarcadero Center, Suite 2100, San Francisco, CA 94111.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 4,047,120 shares of our common stock held by RA Capital Healthcare Fund, L.P. (RA Healthcare);
(ii) 1,496,613 shares of our common stock held by RA Capital Nexus Fund, L.P. (Nexus); and (iii)&nbsp;442,721 shares of our common stock held by Blackwell Partners LLC&#151;Series A, or Blackwell. RA Capital Management, L.P. is the investment
manager for RA Healthcare, Nexus II and Blackwell. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the managing members. RA Capital Management, L.P., RA Capital
Management GP, LLC, Peter Kolchinsky and Rajeev Shah may be deemed to have voting and investment power over the shares held of record by RA Healthcare, Nexus and Blackwell. RA Capital Management, L.P., RA Capital Management GP, LLC, Peter Kolchinsky
and Rajeev Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the entities listed above is 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 5,698,359 shares of our common stock held by Boxer Capital, LLC, or Boxer Capital and
(ii)&nbsp;288,095 shares of our common stock held by MVA Investors, LLC, or MVA. Boxer Capital, Boxer Asset Management Inc., or Boxer Management, and Joe Lewis hold shared voting and dispositive power over the shares held by Boxer Capital, and Aaron
Davis holds voting and dispositive power over the shares owned by MVA. Each of the individuals and entities listed above expressly disclaims beneficial interest of the shares listed above except to the extent of any pecuniary interest therein. The
principal business address of Boxer Capital, MVA and Aaron Davis is: 12860 El Camino Real, Suite 300, San Diego, CA 92130. The principal business address of Boxer Management and Joe Lewis is: c/o Cay House P.O. Box
<FONT STYLE="white-space:nowrap">N-7776</FONT> E.P. Taylor Drive Lyford Cay, New Providence, Bahamas. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)&nbsp;3,936,595 shares of our common stock held by Canaan XI and (ii)&nbsp;473,396 shares of our
common stock held by Canaan 2020+ Series&nbsp;7. Canaan XI GP may be deemed to have investment and voting power over the shares held by Canaan XI, and Canaan 2020+ GP may be deemed to have investment and voting power over the shares held by Canaan
2020+ Series&nbsp;7. Nina Kjellson, a member of our board of directors, Brenton K. Ahrens, Joydeep Bhattacharyya, Richard J. Boyle&nbsp;Jr., Wende S. Hutton, Maha S. Ibrahim, Guy M. Russo, Tim M. Shannon and Hrach Simonian are managers of
Canaan&nbsp;XI GP and make investment and voting decisions with respect to the shares held by Canaan&nbsp;XI, acting collectively, and are the members of an investment committee of Canaan 2020+ GP that makes investment and voting decisions with
respect to the shares held by Canaan 2020+ Series&nbsp;7, acting collectively. The address for Canaan XI L.P. and Canaan 2020+ Co-Investment L.P.&nbsp;- Series&nbsp;7 is 285 Riverside Ave, Suite 250, Westport, CT 06880. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,893,582 shares of our common stock held by Nextech VI Oncology SCSP. Nextech VI Oncology SCSp
represented by its General Partner Nextech VI GP S.a.r.l. Dalia Bleyer, Rocco Sgobbo and Ian Charoub have shared voting power as Managers in Nextech VI GP S.a.r.l., the General Partner of Nextech VI Oncology SCSp, and Alfred Scheidegger, Thilo
Schroeder and Jakob Loven have shared voting power in Nextech Invest AG, the Investment Advisor of Nextech VI Oncology SCSp. Each of the individuals and entities listed above expressly disclaims beneficial interest of the shares listed above except
to the extent of any pecuniary interest therein. The address for Nextech VI Oncology SCSP is 8, rue Lou Hemmer, <FONT STYLE="white-space:nowrap">L-1748</FONT> Senningerberg, Luxembourg. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)&nbsp;1,696,343 shares of our common stock held directly and (ii)&nbsp;63,246 shares of common
stock issuable upon the exercise of stock options granted to Dr.&nbsp;Harris that are exercisable within 60 days of June&nbsp;30, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 527,981 shares of our common stock held directly and (ii) 284,180 shares of our common stock
issuable upon the exercise of stock options granted to Mr.&nbsp;Bensen that are exercisable within 60 days of June&nbsp;30, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 270,129 shares of our common stock held directly and (ii) 14,051 shares of our common stock
issuable upon the exercise of stock options granted to Dr.&nbsp;Swanson that are exercisable within 60 days of June&nbsp;30, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 192,783 shares of our common stock held directly and (ii)&nbsp;9,363 shares of our common stock
issuable upon the exercise of stock options granted to Dr.&nbsp;Chen that are exercisable within 60 days of June&nbsp;30, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 28,231 shares of our common stock held directly and (ii) 70,755 shares of our common stock
issuable upon the exercise of stock options granted to Dr.&nbsp;Kaplan that are exercisable within 60 days of June&nbsp;30, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 7,262,526 shares of our common stock and (ii) 627,790 shares of common stock underlying stock
options exercisable within 60 days of June&nbsp;30, 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following description
summarizes some of the terms of our amended and restated certificate of incorporation and amended and restated bylaws, each of which will become effective upon the completion of this offering, the investors&#146; rights agreement and of the General
Corporation Law of the State of Delaware. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation,
amended and restated bylaws and amended and restated investors&#146; rights agreement, copies of which have been or will be filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the
General Corporation Law of the State of Delaware. The description of our common stock and preferred stock reflects changes to our capital structure that will occur upon the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our authorized capital stock will consist of 500,000,000 shares of common stock, par value $0.0001
per share, and 50,000,000 shares of preferred stock, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2021, there were 3,887,050 shares
of our common stock outstanding, including 1,512,699 shares of unvested restricted common stock, and 26,228,089 shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock in connection with
this offering, held of record by 86 stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have
cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters
shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended
and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital
stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend
or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See below under &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and
Bylaws&#151;Amendment of Charter Provisions.&#148; Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred
stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of common stock are
entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no
preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights,
preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of our
restated certificate of incorporation that will become effective upon the completion of this offering, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board
of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The purpose of authorizing our board of directors to issue preferred stock and determine its
rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate
purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Upon the completion of this offering, there will be no
shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2021, options to purchase 2,586,835 shares of our common stock were outstanding under our 2020 Plan, of which 609,601 were
exercisable as of that date. For additional information regarding the terms of our 2020 Plan, see &#147;Executive and Director Compensation&#151;Incentive award plans&#151;2020 Equity Incentive Plan.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately
following this offering, holders of 26,228,089 shares of our common stock will be entitled to certain rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to an amended and restated
investors&#146; rights agreement by and among us and certain of our stockholders, until the rights otherwise terminate pursuant to the terms of the investors&#146; rights agreement. The registration of shares of common stock as a result of the
following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Registration Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If at any time beginning 180 days after the closing date of this offering the holders of at least 50% of the registrable securities then
outstanding request in writing that we effect a registration with respect to at least 50% of the registrable securities then outstanding, we may be required to register their shares. We are obligated to effect at most two registrations in response
to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten
for reasons related to the marketing of the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If at any time after this offering we propose to register any shares of our common stock under the Securities Act, subject to certain
exceptions, the holders of registrable securities will be entitled to a notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing
underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If, at any time after we become entitled under the Securities Act to register our shares on a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the holders of at least 25% of the registrable securities then outstanding request in writing that we effect a registration with respect to the registrable securities of such holders at an aggregate price to
the public in the offering of at least $5,000,000, we will be required to effect such registration; provided, however, that we will not be required to effect such a registration if, within any twelve month period, we have already effected two
registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Expenses and
Indemnification </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us
related to any registration effected pursuant to the exercise of these registration rights. These </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders
(not to exceed $30,000) and blue sky fees and expenses. Additionally, we have agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any untrue statement of a material
fact contained in any registration statement, an omission or alleged omission to state a material fact in any registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the
indemnifying party of securities laws, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each of the foregoing registration rights terminate upon the earlier of five years after the effective date of the registration statement of
which this prospectus is a part, the closing of a deemed liquidation event, as defined in our current amended and restated certificate of incorporation, or as to any holder at such time as Rule 144 or another similar exemption under the Securities
Act is available for the sale of all of such holders shares without limitation during a three-month period without registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects
of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our amended and restated certificate
of incorporation and our amended and restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our
incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including
transactions which provide for payment of a premium over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are
intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of
the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals
could result in an improvement of their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ability of our board of directors, without action by the stockholders, to issue up to 50,000,000 shares of undesignated preferred stock
with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in
control or management of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Meetings </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or
president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for
Advance Notification of Stockholder Nominations and Proposals </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated bylaws establish advance notice procedures with
respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of
directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of
directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. For more information on the classified board, see &#147;Management&#151;Board
Composition.&#148; This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to
replace a majority of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our
stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock entitled to vote in
the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors.
Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our
preferred stock may be entitled to elect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be
&#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or
the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and
associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or
other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or
proceedings under Delaware statutory or common law: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers,
employees or agents to us or our stockholders, creditors or other constituents; (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of
incorporation or bylaws; or (4)&nbsp;any action asserting a claim governed by the internal affairs doctrine. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any
liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Our amended and restated certificate of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest
extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant to such compliant. For the
avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a
statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. In any case, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules
and regulations thereunder. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of
provisions to be inapplicable or unenforceable. Our amended and restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice
of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our amended and restated certificate of incorporation is inapplicable or unenforceable if it is
challenged in a proceeding or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock
and the provision prohibiting cumulative voting, would require approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock entitled to vote thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws could have the effect of discouraging others
from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the
effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock will be the Computershare Trust Company, N.A.. The transfer agent and registrar&#146;s address is 250 Royall Street, Canton, M.A. 02021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common
stock has been approved for listing on The Nasdaq Global Select Market under the trading symbol &#147;TYRA.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and
Indemnification </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For a discussion of liability and indemnification, see &#147;Executive and Director Compensation&#151;Limitations on
Liability and Indemnification.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in
the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on
the number of shares of our common stock outstanding as of June&nbsp;30, 2021, upon the completion of this offering, we will have outstanding an aggregate of 39,115,139 shares of common stock, assuming (i)&nbsp;the issuance of 9,000,000 shares of
common stock offered by us in this offering, (ii)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into 26,228,089 shares of our common stock and the related reclassification of the carrying value of the
convertible preferred stock to permanent equity upon the completion of this offering, (iii)&nbsp;no exercise of the underwriters&#146; option to purchase additional shares of common stock and (iv)&nbsp;no exercise of outstanding options after
June&nbsp;30, 2021. Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is
defined in Rule 144 under the Securities Act, whose sales would be subject to the Rule 144 resale restrictions described below, other than the holding period requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The remaining 30,115,139 shares of common stock will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the
Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized
below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements described below. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, we estimate that approximately 30,115,139 shares will be available for sale in the public market, subject in some cases to applicable volume
limitations under Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, of the 2,586,835 shares of our common stock that were subject to stock options outstanding as of
June&nbsp;30, 2021, options to purchase 609,601 shares of common stock were vested as of June&nbsp;30, 2021 and, upon exercise, these shares will be eligible for sale subject to the lock&#150;up agreements described below and Rules 144 and 701 under
the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we, our directors, our executive officers and holders of substantially all of our other outstanding shares
of common stock or securities convertible into or exchangeable for shares of our common stock outstanding upon the completion of this offering, have agreed, subject to certain limited exceptions, with the underwriters not to directly or indirectly
offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of or hedge any shares of our common stock or any options to purchase shares of our common stock, or any securities convertible into or
exchangeable for shares of common stock during the period from the date of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement continuing through and including the date 180 days after the date of this prospectus, except with the prior
written consent of the representatives of the underwriters, and certain other limited exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the applicable <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. For a further
description of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, please see &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the
restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, we have entered into agreements with certain security holders, including the amended and restated investors&#146; rights agreement, our
standard form of option agreement, our standard form of restricted stock agreement and our standard form of restricted stock purchase agreement, that contain market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions or incorporate market <FONT
STYLE="white-space:nowrap">stand-off</FONT> provisions from our equity incentive plan imposing restrictions on the ability of such security holders to offer, sell or transfer our equity securities for a period of 180 days following the date of this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, certain of our officers, directors and significant stockholders may adopt written plans, known as
Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a broker may execute trades pursuant to parameters established by the officer, director or stockholder when entering into the plan, without further direction from such officer, director or
stockholder. Such sales would not commence until the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by such officer, director or stockholder in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate Resales of Restricted
Securities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a
part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s
transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately 391,152 shares
immediately after this offering; or </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in our common stock on the Nasdaq during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Affiliate resales under Rule 144 are also subject to the
availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller
must file a notice on Form 144 with the SEC and Nasdaq concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not
an affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell
such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the <FONT
STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701,
any of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration
statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period
requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The SEC has indicated that Rule 701 will apply to typical stock options granted by an issuer
before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to file one or
more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under our stock plans. We
expect to file the registration statement covering shares offered pursuant to our stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public
market without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion
of this offering, the holders of 26,228,089 shares of common stock or their transferees, which includes all of the shares of common stock issuable upon the automatic conversion of 26,228,089 shares of our common stock immediately prior to the
completion of this offering, will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable
without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares
covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reserved Share Program </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At our request,
an affiliate of BofA Securities, Inc., a participating Underwriter, has reserved for sale, at the initial public offering price, up to 3% of the shares offered by this prospectus for sale to some of our directors and officers and certain other
parties related to us. Shares purchased through the reserved share program will not be subject to lockup restrictions with the underwriters, except in the case of shares purchased by any of our directors or executive officers. See
&#147;Underwriting&#151;Reserved Shares.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_19"></A>MATERIAL U.S.&nbsp;FEDERAL INCOME TAX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSIDERATIONS FOR <FONT STYLE="white-space:nowrap">NON-U.S.&nbsp;HOLDERS</FONT> OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S.&nbsp;federal income tax considerations applicable to
<FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holders</FONT> (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> means a beneficial owner of our common stock that is, for U.S.&nbsp;federal income tax purposes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign corporation or any other foreign organization taxable as a corporation for U.S.&nbsp;federal income tax
purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign estate or trust, the income of which is not subject to U.S.&nbsp;federal income tax on a net income
basis. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships or other entities or arrangements that are
treated as pass-through entities for U.S.&nbsp;federal income tax purposes or persons that hold their shares of our common stock through partnerships or such other pass-through entities. The tax treatment of a partner in a partnership or other
entity or arrangement that is treated as a pass-through entity for U.S.&nbsp;federal income tax purposes generally will depend upon the status of the partner and the activities of the partnership. A partner in a partnership or an investor in any
other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This discussion is based on current provisions of the Code, existing and proposed U.S.&nbsp;Treasury regulations promulgated
thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or
differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holders</FONT> described in this prospectus. There can be no assurance that the Internal Revenue Service, or the IRS, will not challenge one
or more of the tax consequences described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> holds shares of our common stock as a capital asset, which is generally property held for investment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This discussion does not address all aspects of U.S.&nbsp;federal income taxation that may be relevant to a particular <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> in light of that <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder&#146;s</FONT> individual circumstances, including the alternative minimum tax, the Medicare tax on net investment income or
the rules relating to &#147;qualified small business stock,&#148; any U.S.&nbsp;federal tax other than the income tax (including, for example, the estate tax), nor does it address any aspects of U.S.&nbsp;state, local or <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;taxes.</FONT> This discussion also does not address the special tax rules applicable to certain particular <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holders,</FONT> such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pension plans; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension
fund&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes
(and partners and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or
other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons that hold or receive our common stock pursuant to the exercise of any employee stock option or
otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">investors in pass-through entities (or entities that are treated as disregarded entities for U.S. federal
income tax purposes); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This discussion is for general information only and is not tax advice. Accordingly, all prospective
<FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holders</FONT> of our common stock should consult their tax advisors with respect to the U.S.&nbsp;federal, state, local, <FONT STYLE="white-space:nowrap">non-income</FONT> and <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;tax</FONT> consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on our
common stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As described in the &#147;Dividend Policy&#148; section above, we do not intend to pay any cash dividends on our common
stock in the foreseeable future. Distributions, if any, on shares of our common stock generally will constitute dividends for U.S.&nbsp;federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as
determined under U.S.&nbsp;federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder&#146;s</FONT> investment, up to such holder&#146;s tax basis in the shares of common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in
&#147;Gain on sale, exchange or other taxable disposition of shares of our common stock.&#148; Any such distributions will also be subject to the discussion below under the section titled &#147;Withholding and information reporting
requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussion in the following two paragraphs in this section, dividends paid to a <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> generally will be subject to withholding of U.S.&nbsp;federal income tax at a&nbsp;30% rate or such lower rate specified by an applicable income tax treaty between the United States and such
holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> within the United States, are generally exempt from the&nbsp;30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> satisfies applicable certification and
disclosure requirements. However, such U.S.&nbsp;effectively connected income, net of specified deductions and credits, is taxed at the same U.S.&nbsp;federal income tax rates applicable to United States persons (as defined in the Code). Any
U.S.&nbsp;effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> that is a corporation may also, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a&nbsp;30% rate or such lower rate as specified by an applicable income tax treaty between the United
States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> of shares of our
common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or a successor form) to the applicable withholding agent and satisfy applicable certification and
other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;holders</FONT> are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A
<FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> that is eligible for a reduced rate of U.S.&nbsp;withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely providing the appropriate
information to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on sale, exchange or other taxable disposition of shares of our common stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> generally will not be subject to any U.S.&nbsp;federal income tax on any gain
realized upon such holder&#146;s sale, exchange or other taxable disposition of shares of our common stock unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
conduct of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in
which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on our common stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30%
tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital
losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed
U.S. federal income tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition
(or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market, within the
meaning of the relevant provisions of the Code, and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the
five-year period ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a &#147;U.S. real property holding corporation&#148; only if the
fair market value of its &#147;U.S. real property interests&#148; (as defined in the Code and applicable U.S. Treasury regulations) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other
assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax purposes, or that we are likely to
become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup withholding and information reporting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> the gross amount of the
distributions on shares of our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Non-U.S.&nbsp;holders may have to comply with specific certification procedures to establish that the holder is not a United States person (as defined in the Code) in order to avoid backup
withholding at the applicable rate with respect to dividends on shares of our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> will comply with such procedures if it provides a properly executed IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8),</FONT> or otherwise meets
documentary evidence requirements for establishing that it is a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder,</FONT> or otherwise establishes an exemption. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holders</FONT>
subject to withholding of U.S.&nbsp;federal income tax, as described above in &#147;Distributions on our common stock,&#148; generally will be exempt from U.S.&nbsp;backup withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding will generally apply to the proceeds of a disposition of shares of our common stock by a <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> effected by or through the U.S.&nbsp;office of any broker, U.S.&nbsp;or <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> unless the holder certifies its status as a <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;office</FONT> of a broker. However, for information reporting purposes,
dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;office</FONT> of a broker with substantial U.S.&nbsp;ownership or operations generally will be treated in a manner similar to dispositions effected through a
U.S.&nbsp;office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;holders</FONT> should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns
may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> resides or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an
additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> can be refunded or credited against the
<FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder&#146;s</FONT> U.S.&nbsp;federal income tax liability, if any, provided that the appropriate information is provided to the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding and information reporting requirements&#151;FATCA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S.&nbsp;federal withholding tax at a rate of&nbsp;30% on payments of
dividends on our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations,
(ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S.&nbsp;investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Such withholding may
also apply to payments of gross proceeds of sales or other dispositions of shares of our common stock, although under proposed U.S.&nbsp;Treasury regulations, no withholding will apply to payments of gross proceeds. Taxpayers are generally permitted
to rely on these proposed Treasury regulations until final Treasury regulations are issued. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> may be eligible for refunds or credits of this withholding tax.
An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;holders</FONT> should consult their tax advisors
regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our shares of common stock, including, without limitation, the process and deadlines for meeting the applicable
requirements to prevent the imposition of the&nbsp;30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc., Jefferies LLC and Cowen and Company, LLC are acting as representatives of each of the underwriters named below. Subject
to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of
shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have
agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the
nondefaulting underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters
against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering, the public offering price,
concession or any other term of the offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount
and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Without&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>With&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at $3.7&nbsp;million
and are payable by us. We have also agreed to reimburse the underwriters for certain of their expenses incurred in connection with, among others, (i)&nbsp;the review and clearance by the Financial Industry Regulatory Authority, Inc. in an amount of
up to $40,000 and (ii)&nbsp;the reserved shares described below in an amount of up to $25,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to 1,350,000
additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional
shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reserved Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At our request, an affiliate of BofA Securities, Inc., a participating Underwriter, has reserved for sale, at the initial public offering
price, up to 3% of the shares offered by this prospectus for sale to some of our directors and officers and certain other parties related to us. If these persons purchase reserved shares, this will reduce the number of shares available for sale to
the general public. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares offered by this prospectus. Shares purchased through the reserved share program will
not be subject to lockup restrictions with the underwriters, except in the case of shares purchased by any of our directors or executive officers. We have agreed to indemnify the underwriters against certain liabilities and expenses, including
liabilities under the Securities Act, in connection with the sales of the reserved shares. Other than the underwriting discount described on the front cover of this prospectus, the underwriters will not be entitled to any commission with respect to
the shares of common stock sold pursuant to the reserved share program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or
securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of BofA Securities, Inc., Jefferies LLC and Cowen and Company,
LLC. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lend or otherwise dispose of or transfer any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file or make a confidential submission of a registration statement related to the
common stock, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership
of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to securities convertible into or exchangeable or
exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing on the Nasdaq Global Select Market, subject to notice of issuance, under the symbol
&#147;TYRA.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common stock. The initial public offering price will
be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us,
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenues, </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the
offering the shares will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions
and Penalty Bids </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from
bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter
repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in the European Economic Area </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus is not a prospectus for the purposes of the Prospectus Regulation
(as defined below). This prospectus and any offer if made subsequently is directed only at persons in Member States of the European Economic Area, or the EEA, who are &#147;qualified investors&#148; within the meaning of Article 2(e) of the
Prospectus Regulation. This prospectus has been prepared on the basis that any offer of shares in any Member State of the EEA will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for
offers of shares. Accordingly any person making or intending to make an offer in that Member State of shares which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for us
or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation in relation to such offer. Neither we nor the underwriters have authorized, nor do we or they authorize, the making of any offer of shares in
circumstances in which an obligation arises for us or the underwriters to publish a prospectus for such offer. The expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the EEA (each a &#147;Relevant State&#148;), no shares have been offered or will be offered pursuant to
the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State
and notified to the competent authority in that Relevant State, all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus
Regulation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&nbsp;2 of the
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who initially acquires any shares or to whom any offer is made will be deemed to have
represented, acknowledged and agreed to and with us and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each
such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have
they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior
consent of the underwriters has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, the underwriters and their affiliates will rely
upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the
expression an &#147;offer to the public&#148; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an
investor to decide to purchase or subscribe for any shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus may not be distributed or circulated to any person in the United Kingdom, or UK, other than to (i) persons who have
professional experience in matters relating to investments falling within Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;); and (ii) high net worth entities
falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &#147;relevant persons&#148;). This prospectus is directed only at relevant persons. Other persons should not act on this prospectus or any of its
contents. This prospectus is confidential and is being supplied to you solely for your information and may not be reproduced, redistributed or passed on to any other person or published, in whole or in part, for any other purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the UK, this prospectus is not a prospectus for the purposes of the UK Prospectus Regulation (as defined below). This prospectus has been
prepared on the basis that any offer if made subsequently is directed only at persons in the UK who are &#147;qualified investors&#148; within the meaning of Article 2(e) of the UK Prospectus Regulation. This prospectus has been prepared on the
basis that any offer of shares in the UK will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in the
UK of shares which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for us or any of the underwriters to publish a prospectus pursuant to Section 85 of the UK&#146;s
Financial Services and Markets Act 2000, as amended (the &#147;FSMA&#148;) in relation to such offer. Neither we nor the underwriters have authorized, nor do we or they authorize, the making of any offer of shares in circumstances in which an
obligation arises for us or the underwriters to publish a prospectus for such offer. The expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law of the UK by virtue of the European Union
(Withdrawal) Act 2018, as amended by the European Union (Withdrawal Agreement) Act 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any invitation or inducement to engage in investment activity (within the meaning of Section
21 of the FSMA) in connection with the issue or sale of the shares may only be communicated or caused to be communicated in circumstances in which Section 21(1) of the FSMA does not apply to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All applicable provisions of the FSMA must be complied with in respect to anything done by any person in relation to the shares in, from or
otherwise involving the UK. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to the UK, no shares have been offered or will be offered pursuant to the offering to the public
in the UK prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of shares may be made
to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within section 86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each person in the UK who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and
agreed to and with us and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the
case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired
by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an
offer to the public other than their offer or resale in the UK to qualified investors or in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in the UK
means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the
offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering,
us or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority
FINMA, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under
the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying
any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be
illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized
financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission, or ASIC, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or Corporations Act, and does not purport
to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (Exempt Investors) who are &#147;sophisticated investors&#148; (within the
meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act
so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares applied for
by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act
would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must
observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only
and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors
need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or to or for the account or benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or
indirectly, in Japan or to or for the account or benefit of, any Japanese Person, except pursuant to an exemption from the registration requirements of the Financial Instruments and Exchange Law of Japan and otherwise in compliance with all
applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; shall mean any person
resident in Japan, including any corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus has not been and will not be registered as a prospectus under the Securities and Futures Act, Chapter 289 of Singapore (the
&#147;SFA&#148;) by the Monetary Authority of Singapore, and the offer of the shares in Singapore is made primarily pursuant to the exemptions under Section 274 and 275 of the SFA. Accordingly, this prospectus and any other document or material in
connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether
directly or indirectly, to any person in Singapore other than (i) to an institutional investor as defined in Section 4A of the SFA (an &#147;Institutional Investor&#148;) pursuant to Section 274 of the SFA, (ii) to an accredited investor as defined
in Section 4A of the SFA (an &#147;Accredited Investor&#148;) or other relevant person as defined in Section 275(2) of the SFA (a &#147;Relevant Person&#148;) and pursuant to Section 275(1) of the SFA, or to any person pursuant to an offer referred
to in Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA and (where applicable) Regulation 3 of the Securities and Futures (Classes of Investors) Regulations 2018, or (iii) otherwise pursuant to,
and in accordance with, the conditions of any other applicable exemption or provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is a condition of the offer that
where the shares are subscribed for or acquired pursuant to an offer made in reliance on Section 275 of the SFA by a Relevant Person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an Accredited Investor), the sole business of which is to hold investments and the
entire share capital of which is owned by one or more individuals, each of whom is an Accredited Investor; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an Accredited Investor), the sole purpose of which is to hold investments and
each beneficiary of the trust is an individual who is an Accredited Investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts
(each as defined in Section 2(1) of the SFA) of that corporation and the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has subscribed for
or acquired the shares except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an Institutional Investor, an Accredited Investor, a Relevant Person, or which arises from an offer referred
to in Section 275(1A) of the SFA (in the case of that corporation) or Section 276(4)(i)(B) of the SFA (in the case of that trust); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section 276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing
Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a
<FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the
underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Latham &amp; Watkins LLP, San Diego,
California. Certain legal matters related to this offering will be passed upon for the underwriters by Sidley Austin LLP, San Francisco, California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements as of December&nbsp;31, 2019
and December&nbsp;31, 2020, and for each of the two years in the period ended December&nbsp;31, 2020, as set forth in their report. We&#146;ve included our financial statements in the prospectus and elsewhere in the registration statement in
reliance on Ernst&nbsp;
&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc189651_23"></A>WHERE YOU CAN
FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under
the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits
and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the
contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other
document filed as an exhibit to the registration statement. Upon completion of this offering, we will be required to file periodic reports, proxy statements, and other information with the SEC pursuant to the Securities Exchange Act of 1934. The SEC
maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.tyra.bio. Upon the completion of this offering, you may access our annual reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not
constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock. We have included our website address as an
inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><A NAME="toc189651_24"></A>Index to Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audited Financial Statements as of and for the Years Ended December&nbsp;31, 2019 and
2020:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_3">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_4">Statements of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements as of December&nbsp;31, 2020 and June 30, 2021 and for the Six Months Ended
June&nbsp;30,&nbsp;2020 and 2021:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_7">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_8">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_9">Statements of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_10">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin189651_11">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of Tyra
Biosciences, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of Tyra Biosciences, Inc. (the Company) as of December 31, 2019 and 2020, the related statements of operations
and comprehensive loss, convertible preferred stock and stockholders&#146; deficit and cash flows for the years then ended, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted
accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These
financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over
financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of
the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our
audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our
opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the
Company&#146;s auditor since 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May 28, 2021, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except for the last paragraph in Note&nbsp;12, as
to which the date is September&nbsp;9, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_2"></A>Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and par value data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simple agreement for future equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.0001 par value; 2,000,000 and 6,223,046 shares authorized
at December&nbsp;31, 2019 and 2020, respectively; 0 and 3,374,560 shares issued and outstanding at December&nbsp;31, 2019 and 2020, respectively; $27,840 aggregate liquidation preference at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 50,000,000 and 50,000,000 shares authorized at December&nbsp;31,
2019 and 2020, respectively; 2,820,560 and 3,050,781 shares issued at December&nbsp;31, 2019 and 2020, respectively and 2,705,779 and 1,829,377 shares outstanding at December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_3"></A>Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year Ended
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of simple agreement for future equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(943</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,650,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,542,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_4"></A>Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Series
A<BR>Convertible<BR>Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total<BR>Stockholders&#146;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,602,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of shares of common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock upon conversion of simple agreement for future
equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,848,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incremental vesting conditions placed on previously issued common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,461,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of shares of common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">585,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,374,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,829,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_5"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operations:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of SAFE commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable, accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of simple agreement for future equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series A convertible preferred stock, net of issuance costs</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from early exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for financing lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash increase (decrease) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reconciliation of cash, cash equivalents and restricted cash to the balance sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease assets obtained in exchange for finance lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease assets obtained in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred issuance costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred stock in exchange for simple agreement for future
equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_6"></A>Notes to Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Basis of Presentation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Tyra Biosciences,
Inc. (the &#147;Company&#148;) was incorporated in the state of Delaware on August&nbsp;2, 2018. The Company is a precision oncology company designing and developing purpose-built therapies specifically designed to overcome therapy resistance and
improve the lives of cancer patients whose tumors have acquired resistance over the course of therapy to currently available treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has devoted substantially all of its efforts to research and development and has not generated revenues from its principal
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From
inception to December&nbsp;31, 2020, the Company has devoted substantially all of its resources to organizing and staffing the company, business planning, raising capital,&nbsp;developing its proprietary SN&Aring;P discovery engine, undertaking
research and development activities for its development programs, establishing its intellectual property portfolio, and providing general and administrative support for its operations. The Company has a limited operating history, has never generated
any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable
future as it continues to develop its current and future product candidates. From inception to December&nbsp;31, 2020, the Company has funded its operations primarily through the issuance of simple agreements for future equity and its Series A
convertible preferred stock financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As the Company continues to pursue its business plan, it expects to finance its operations through
a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, there can be no assurance that any additional financing or strategic transactions will
be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it may need to delay, reduce or eliminate its product development or future commercialization
efforts, which could have a material adverse effect on the Company&#146;s business, results of operations or financial condition. The accompanying financial statements do not include any adjustments that might be necessary if it were unable to
continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2021, the Company received $23.5&nbsp;million in gross proceeds from the sale of the second
closing of Series A convertible preferred stock. Additionally, in March 2021, the Company received $106.3&nbsp;million in gross proceeds from the sale of Series&nbsp;B convertible preferred stock. As a result of the financings, management believes
the Company has sufficient capital to execute its strategic plan and fund operations through at least the next twelve months from the date these financial statements were available to be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the
Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASU&#148;) promulgated by the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation
of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of expenses during the reporting period. Accounting estimates and management judgments reflected in the financial statements include: normal recurring accruals, including the accrual of research and development
expenses; fair value of simple agreements for future equity (&#147;SAFE&#148;), common stock, convertible preferred stock and stock-based compensation. Although these estimates are based on the Company&#146;s knowledge of current events and actions
it may undertake in the future, actual results may materially differ from these estimates and assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash
equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to
significant credit risk due to the financial position of the depository institutions in which those deposits are held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Reporting
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company operates and manages its business as one operating segment. The Company&#146;s Chief Executive Officer, who is the
chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. All long-lived assets are maintained in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Option </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
has issued and entered into SAFEs with investors which grants investors with the rights to future equity upon the occurrence of an equity financing event. As permitted under ASC 825, <I>Financial Instruments</I> (&#147;ASC 825&#148;), the Company
has elected the fair value option to account for the SAFEs. The Company concluded that the terms of the SAFEs were at arms-length, and the cash received by the Company at issuance of the SAFEs represents fair value. The SAFEs are recorded as a
liability on the balance sheet as they give investors the option to redeem the instrument for cash upon a change in control. The Company records subsequent changes in fair value of the SAFEs in the Statements of Operations and Comprehensive Loss.
Debt issuance costs related to the SAFEs are expensed in the period incurred. Refer to Note 6 for further information on the SAFEs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of
Financial Instruments </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value,
and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The carrying amounts of all cash and cash equivalents, prepaid and other current assets, accounts payable, and accrued and other current
liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash
equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. As of December&nbsp;31, 2020, the Company had cash and cash equivalents balances deposited at major financial institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Restricted cash
is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash for years ended December&nbsp;31, 2019 and 2020 was $0 and $0.2&nbsp;million, respectively, and consists of collateral
for letters of credit related to the Company&#146;s operating leases and are considered a <FONT STYLE="white-space:nowrap">non-current</FONT> asset on the balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property
and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to seven years, or the remaining term of the lease). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company capitalizes costs that are directly associated with <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds of the offering.
Should an <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statements of Operations and Comprehensive Loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be
generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value
exceeds its fair value. The Company did not recognize impairment losses for the years December&nbsp;31, 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and
Development Expense </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is required to estimate its expenses resulting from its obligations under contracts with vendors
and consultants, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the
periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The
Company accounts for these expenses according to the progress of the preclinical study, as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through review of the underlying
contracts along with preparation of financial models taking into account discussions with research and other key personnel as to the progress of studies, or other services being conducted. To date, the Company has had no material differences between
its estimates of such expenses and the amounts actually incurred. During the course of a study, the Company adjusts its rate of expense recognition if actual results differ from its estimate. Nonrefundable advance payments for goods and services,
including fees for process development , are deferred and recognized as expense in the period that the related goods are consumed, or services are performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of external and internal costs related to the development of the Company&#146;s SN&Aring;P
discovery engine and its product candidates and development programs, including employee related salaries, benefits and stock-based compensation charges for those individuals involved in research and development efforts, costs to third-party
contractors to perform research and development activities, and associated overhead expenses. Research and development costs are expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses
in the Statements of Operations and Comprehensive Loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has operating and finance leases for office and lab space and equipment. At the inception of a contractual arrangement, the
Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If
both criteria are met, the Company records the associated lease liability and corresponding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset (&#147;ROU&#148;) upon commencement of the lease using the
implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating
lease or a finance lease.&nbsp;A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is
substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if
the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term.&nbsp;Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating
lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and
their corresponding ROUs are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the ROU may be required for items such as initial
direct costs paid or incentives received. As the Company&#146;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay
to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in
which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space
leased by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Operating and finance ROU assets are reflected in ROU assets. Operating lease liabilities and finance lease
liabilities are reflected in leases liabilities, current and noncurrent in the accompanying balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and <FONT
STYLE="white-space:nowrap">non-employee</FONT> stock option grants, estimated in accordance with the applicable accounting guidance, recognized on a straight-line basis over the vesting period. The vesting period generally approximates the expected
service period of the awards. The Company recognizes forfeitures as they occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of stock options is estimated using a Black-Scholes valuation model on the
date of grant. This method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#146;s common stock, risk-free interest
rate and expected dividend. Options granted have a maximum contractual term of ten years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which
represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is based upon the historical volatility of a number of publicly traded companies
in similar stages of clinical development. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rates used are
based on the U.S. Treasury yield in effect at the time of grant for <FONT STYLE="white-space:nowrap">zero-coupon</FONT> U.S. treasury notes with maturities approximately equal to the expected term of the stock options. The Company has historically
not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Valuation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to
the absence of an active market for the Company&#146;s common stock, the Company utilized methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants&#146; Audit and Accounting Practice Guide:
<I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I> to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company has considered the fair value of the common stock
as of the grant date. The fair value of the common stock has been determined based upon a variety of factors, including the prices at which the Company sold shares of its convertible preferred stock to outside investors in arms-length transactions,
and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the progress of the Company&#146;s research and development programs, including their stages of development, and the
Company&#146;s business strategy; external market and other conditions affecting the biotechnology industry, and trends within the biotechnology industry; the Company&#146;s financial position, including cash on hand, and its historical and
forecasted performance and operating results; the lack of an active public market for the Company&#146;s common stock; the likelihood of achieving a liquidity event for the Company&#146;s securityholders, such as an initial public offering or a sale
of the company, taking into consideration prevailing market conditions; the hiring of key personnel and the experience of management; and the analysis of initial public offerings and the market performance of peer companies in the biopharmaceutical
industry, as well as completed mergers and acquisitions of peer companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant changes to the key assumptions underlying the
factors used could result in different fair values of common stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company records convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain
events that are outside the Company&#146;s control, including a deemed liquidation event, holders of the convertible preferred stock can cause redemption for cash. Therefore, convertible preferred stock is classified outside of stockholders&#146;
deficit on the balance sheets as events triggering the liquidation preferences are not solely within the Company&#146;s control. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it
becomes probable that such a liquidation event will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Commitments and Contingencies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the
amount can be reasonably estimated. If some amount within a range of loss </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the
Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December&nbsp;31, 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income
Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax
assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the
financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in
income in the period that includes the enactment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets to the extent that the Company believes
these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable
income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount,
management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As
of December&nbsp;31, 2019 and 2020, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#147;more likely than not&#148; to be realized threshold. Changes in the valuation allowance
when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
records uncertain tax positions on the basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process whereby (1)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the
technical merits of the position and (2)&nbsp;for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, management recognizes the largest amount of tax benefit that is more than
50&nbsp;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are
included within the related tax liability. As of December&nbsp;31, 2020, the Company had no accrued interest or penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances <FONT
STYLE="white-space:nowrap">from&nbsp;non-owner&nbsp;sources.</FONT> The Company&#146;s comprehensive loss was the same as its reported net loss for all periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic net
loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock
and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company&#146;s potentially dilutive securities include convertible preferred stock, unvested common stock issued
to founders, unvested common stock upon early exercise of stock options and outstanding stock options under the Company&#146;s equity incentive plan and have been excluded from the computation of diluted net loss per share as they would be
anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#146;s net loss position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the basic and diluted net loss per share
(in thousands, except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year Ended
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,784,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,958,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: weighted average unvested founder shares of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,278,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: weighted average unvested common stock issued upon early exercise of common stock
options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,650,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,542,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the
calculation of diluted net loss per share because their inclusion would be anti-dilutive. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,374,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">991,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested common stock upon early exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,970,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#147;JOBS Act&#148;). Under the
JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of
this exemption from new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, the Company&#146;s financial
statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases</I> (Topic 842), which requires a
lessee to recognize a lease liability and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases with lease terms of more than 12 months. Additionally, certain qualitative and quantitative
disclosures will be required in the financial statements. Companies may adopt this guidance using a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial
statements. The Company early adopted this guidance effective January&nbsp;1, 2019. As a result of the adoption of Topic 842 the Company recognized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets
and lease liabilities, on January&nbsp;1, 2019, on its balance sheet. Refer to Note 9 for further information related to the accounting for the lease commitments under Topic 842. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</I>. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and
complexity while maintaining usefulness. The main provisions remove certain exceptions including the exception to the general methodology for calculating income taxes in an interim period when a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">year-to-date</FONT></FONT> loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income based franchise taxes, eliminating the requirements to
allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes
the enactment date. For public companies, the standard is effective for fiscal years beginning after December&nbsp;15, 2019 and interim periods therein. The Company adopted this ASU on the effective date of January&nbsp;1, 2020, which did not have a
material impact on the results of operations, cash flows, financial condition or related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major
asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such
assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;1</B>&#151;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical,
unrestricted assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;2</B>&#151;Quoted prices for similar assets and liabilities in active
markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;3</B>&#151;Prices or valuation techniques that require inputs that are both significant to the fair value
measurement and unobservable (i.e. supported by little or no market activity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#146;s financial
instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Included in cash and cash equivalents at December&nbsp;31, 2019 and
2020 are $0 and $4.7&nbsp;million in carrying value and fair value of money market funds based upon a Level&nbsp;1 fair value assessment. No transfers between levels have occurred during the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option for the SAFEs. The fair value of the SAFEs as of December&nbsp;31, 2019 was $4.3&nbsp;million
based upon a Level&nbsp;3 fair value assessment. Changes in fair value for the years ended December&nbsp;31, 2019 and 2020 which are reported on the Company&#146;s Statements of Operations and Comprehensive Loss were $0.9&nbsp;million and $15,000,
respectively. The SAFEs converted to shares of the Company&#146;s Series A convertible preferred stock on January&nbsp;6, 2020. Refer to Note 6 for further information on the SAFE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Liabilities measured at fair value on a recurring basis are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Fair Value Measurements
Using</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>December&nbsp;31,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>for Identical<BR>Assets
(Level&nbsp;1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level&nbsp;2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Significant<BR>Unobservable<BR>Inputs&nbsp;(Level&nbsp;3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAFEs </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of all liabilities measured at fair value
using level 3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Simple<BR>agreement<BR>for
future<BR>equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of SAFEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value reflected as change in fair value of SAFEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value reflected as change in fair value of SAFEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion into Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized $8,000 and $47,000 in depreciation expense for the years ended December&nbsp;31, 2019
and 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued and Other Current Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and other employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued legal and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other general and administrative fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Simple Agreements for Future Equity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2018 and 2019, the Company entered into SAFEs with investors. The SAFEs granted investors with rights to participate in a future equity
financing. The SAFEs contained a number of conversion and redemption provisions, including conversion upon an equity event, and settlement upon liquidity or dissolution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
events. The Company elected the fair value option of accounting for the SAFEs (see Note 3). The issuance costs related to the SAFEs were therefore recorded as a general and administrative expense
in the Statements of Operations and Comprehensive Loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;6, 2020, the Company entered into a Series A Preferred Stock
Purchase agreement which resulted in the conversion of the outstanding SAFEs into 526,074 shares of Series A convertible preferred stock at a conversion price of $6.11 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders&#146; Deficit </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under
the Amended and Restated Certificate of Incorporation dated January&nbsp;6, 2020, the Company had a total of 16,223,046 shares of capital stock authorized for issuance, consisting of 10,000,000 shares of common stock, par value of $0.0001 per share,
and 6,223,046 shares of convertible preferred stock, par&nbsp;value of $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company entered into the Series A Preferred Stock Purchase Agreement dated January&nbsp;6, 2020 (&#147;Stock Purchase Agreement&#148;)
whereby the Company agreed to issue and sell, and certain investors agreed to purchase up to an aggregate of 5,696,972 shares of Series&nbsp;A convertible preferred stock, at a price of $8.25 per share, in two closings. In January 2020, the Company
completed its first closing and issued 2,848,486 shares at a price of $8.25 per share resulting in gross proceeds of $23.5&nbsp;million and incurred issuance costs of $0.2&nbsp;million. The Stock Purchase Agreement granted investors the rights and
obligations to purchase an additional 2,848,486 shares of Series A convertible preferred stock (&#147;Future Tranche Right&#148;) at a price of $8.25 per share during a second closing which would occur upon triggering of future milestone events,
provided that they occur before January&nbsp;6, 2022. In February 2021, the Company completed its second closing and issued 2,848,486 shares of Series A convertible preferred stock at a price of $8.25 per share for gross proceeds of
$23.5&nbsp;million and incurred issuance costs of $5,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determined that the Future Tranche Right did not meet the
definition of a freestanding financial instrument as it was not legally detachable. The Future Tranche Right was also evaluated as an embedded derivative and the Company determined it did not meet the definition of a derivative instrument for which
bifurcation would be required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company&#146;s Series A convertible preferred stock has been classified
as temporary equity in the accompanying balance sheets given that the holders of the convertible preferred stock could cause certain events to occur that are outside of the Company&#146;s control whereby the Company could be obligated to redeem the
convertible preferred stock. The carrying value of the convertible preferred stock is not adjusted to the redemption value until the contingent redemption events are considered to be probable of occurring. The Company&#146;s convertible preferred
stock has the following characteristics: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company shall not declare, pay or set aside any dividends on shares of any class of capital stock of the Company unless the holders of the
Series A convertible preferred stock shall first receive, or simultaneously receive, a noncumulative dividend on each outstanding share of the Series A convertible preferred stock equal to an amount as defined in the Company&#146;s Amended and
Restated Certificate of Incorporation. No such dividends have been declared or paid through December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Preferences on Liquidation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of the Series A convertible preferred stock are entitled to receive liquidation preferences, in the event of a change in control,
at an amount per share equal to the Series A original issuance price of $8.25, plus any dividends declared but unpaid. Liquidation payments to the holders of the Series A convertible preferred stock have priority and are made in preference to any
payments to the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After full payment of the liquidation preference to the holders of the Series A convertible
preferred stock, the remaining assets, if any, will be distributed to the holders of the Series A convertible preferred stock and common stock, pro rata based on the number of shares held by each holder, treating for this purpose all such securities
as if they had been converted to common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Conversion Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares of Series A convertible preferred stock are convertible into an equal number of shares of common stock, at the option of the
holder, subject to certain anti-dilution adjustments. The conversion rate for the convertible preferred stock is determined by dividing the original issue price by the conversion price. The conversion price is initially the original issue price, but
is subject to adjustment for dividends, stock splits, and other distributions. The conversion rate at December&nbsp;31, 2020 for the Series A convertible preferred stock into common stock was 1:1. Upon the effective date of the Forward Stock Split,
the conversion rate was adjusted to 1:2.5974. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each share of Series A convertible preferred stock will be automatically converted into
common stock at the then effective conversion rate (i)&nbsp;upon the closing of the sale of common stock to the public at a price of at least two and a half times the Series A original issuance price of $8.25 per share (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the
Securities Act of 1933, as amended, resulting in at least $65.0&nbsp;million of gross proceeds to the Company, or (ii)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of 60% of the
outstanding shares of Series A convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Redemption Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of Series A convertible preferred stock do not have any redemption rights, except upon certain liquidation and dissolution events
that are outside of the Company&#146;s control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Voting </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holder of each share of Series A convertible preferred stock is entitled to one vote for each share of common stock into which such shares
of Series A convertible preferred stock could then be converted and shall vote together with the holders of common stock as a single class, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2019 and 2020, of the 50,000,000 authorized shares of common stock, 2,820,560 and 3,050,781 shares were issued, respectively, and 2,705,779 and 1,829,377 shares were outstanding, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The voting, dividend, and liquidation rights of the holders of the common stock are subject to, and qualified by, the rights, preferences and
privileges of the holders of the Series A convertible preferred stock. The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Common stock reserved for future issuance consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>December&nbsp;31,<BR>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,765,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options granted and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares available for future issuance under the 2020 equity incentive plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common stock reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,168,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has issued 2,820,560 shares of restricted common stock at a price of $0.0001 per
share to certain founders of the Company (&#147;Founders Stock&#148;). The Company maintains a repurchase right whereby the Founders Stock are released from such repurchase right over a period of time of continued service by the recipient. Any
shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest. Unvested outstanding Founders Stock as of December&nbsp;31, 2019 and 2020 were 114,780 and 991,178 shares, respectively.
The amount recorded as liabilities associated with shares issued with repurchase rights were immaterial as of December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2020, in connection with the issuance of the Series A convertible preferred stock, the Company&#146;s founders agreed to modify
their outstanding Founders Stock to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the 1,461,816 modified shares of common stock became compensatory upon such modification. The
total compensation cost resulting from the modification was $0.9&nbsp;million, which will be recognized over the vesting term of three years had a measurement date fair value of $0.61 per share. For the year ended December&nbsp;31, 2020, 487,260
shares vested and the Company recognized $0.3&nbsp;million of stock-based compensation related to the awards. As of December&nbsp;31, 2020, the total unrecognized compensation expense related to unvested Founders Stock was $0.6&nbsp;million expected
to be recognized over a weighted-average period of approximately 2.0 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company adopted the 2020 Equity Incentive Plan (the &#147;Plan&#148;). The Plan provides for the grant of incentive stock
options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Plan was amended in December 2020 to increase the total number of shares reserved under the Plan to 1,633,530. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Options granted under the Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their
date of grant. The exercise price of each option shall be determined by the Board of Directors based on the estimated fair value of the Company&#146;s stock on the date of the option grant. The exercise price shall not be less than 100% of the fair
market value of the Company&#146;s common stock at the time the option is granted. Most option grants generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three
years and early exercise is permitted. The vesting period generally occurs over four years unless there is a specific performance vesting trigger at which time those shares will vest when the performance trigger is probable to occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A summary of the Company&#146;s stock option activity under the Plan is as follows (in
thousands, except share and per share data and years): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Exercise<BR>Price&nbsp;
per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contract
Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,734,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(129,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2020, the total grant date fair value of vested options was $16,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of employee option grants for the year ended December&nbsp;31, 2020 was $0.48 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liability for Early Exercise of Stock Options </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain individuals were granted the ability to early exercise their stock options. The shares of common stock issued from the early exercise
of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary
termination. The shares purchased by the employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash
received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheet and will be transferred into common stock and additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital as the shares vest. As of December&nbsp;31, 2020, 230,222 unvested shares issued under early exercise provisions were subject to repurchase by the Company. As of December&nbsp;31, 2020, the Company
recorded $0.1&nbsp;million, associated with shares issued with repurchase rights in other long-term liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized stock-based compensation expense of $0.1&nbsp;million in research and development expense and
$0.3&nbsp;million in general and administrative expense for the year ended December&nbsp;31, 2020. The Company did not grant any stock options during the year ended December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option pricing model to determine the fair value
of the employee and nonemployee stock option grants issued during 2020 were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,<BR>2020</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$0.61</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate of interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.3%&nbsp;-&nbsp;1.5%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.6&nbsp;-&nbsp;6.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">92.9&nbsp;-&nbsp;97.7%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the unrecognized compensation cost related to outstanding employee and
nonemployee options was $0.6&nbsp;million and is expected to be recognized as expense over approximately 3.5 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2020, the
Company granted 102,863 shares of employee and nonemployee performance options. The options vesting is contingent on the achievement of a development candidate and also include a service condition of four years from the achievement of the
performance condition. The Company determined the performance condition was probable of achievement and therefore, the Company recognized compensation expense of $16,000 for the year ended December&nbsp;31, 2020. The unrecognized compensation costs
related to outstanding performance options was $31,000 as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate
tax rate for the years ended December&nbsp;31, 2019 and 2020 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected tax benefit at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,960</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent items and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The tax effects of temporary differences that give rise to significant portions of the
deferred tax assets and deferred tax liabilities as of December&nbsp;31, 2019 and 2020 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets, net of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets / (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty
surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation
allowance will be reduced. The Company has recorded a full valuation allowance of $3.0&nbsp;million as of December&nbsp;31, 2020 as management cannot conclude that it is more likely than not that certain deferred tax assets will be realized
primarily due to the history of losses from inception. The Company increased its valuation allowance by approximately $1.9&nbsp;million during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2020, the Company had federal and state tax loss carry forwards of approximately $11.7&nbsp;million and
$3.7&nbsp;million, respectively. As a result of the Tax Cuts and Jobs Act of 2017, for U.S. income tax purposes, net operating losses generated after December&nbsp;31, 2017 can be carried forward indefinitely, but are limited to 80% utilization
against future taxable income after January&nbsp;1, 2021. Of the amount of federal net operating loss carryforwards, $11.7&nbsp;million can be carried forward indefinitely. Unless previously utilized, the state net operating losses will begin to
expire in 2038. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2020, the Company has federal and California research and development tax credits of
$0.1&nbsp;million and $0.2&nbsp;million, respectively. The federal research and development tax credits begin to expire in 2038 unless previously utilized. The California research and development tax credits carry forward indefinitely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#146;s NOL and research and development credit
carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRC Section&nbsp;382. If ownership changes have
occurred or occurs in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from
deferred tax assets with a corresponding reduction in the valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Uncertain tax positions are evaluated based upon the facts
and circumstances that exist at each reporting period. Subsequent changes in judgement based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustment may result, for example, upon resolution of an issue
with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes a tax benefit from an uncertain tax position when it is more likely
than not that the position will be sustained upon examination by tax authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes to the
Company&#146;s gross unrecognized tax benefits for the years ended December&nbsp;31, 2019 and 2020, respectively (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions related to current year positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to the existence of the valuation allowance, future recognition of previously unrecognized tax benefits
will not impact the Company&#146;s effective tax rate. The Company is subject to taxation in the United States and various state jurisdictions. All of the Company&#146;s tax years from inception are subject to examination by federal and state tax
authorities. The Company&#146;s practice is to recognize interest and penalties related to income tax matters in income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company had no accrued interest or penalties related to income tax matters in the Company&#146;s balance sheet as of December&nbsp;31, 2020 and has not recognized interest or penalties in the Company&#146;s Statements of Operations and Comprehensive
Loss for the year ended December&nbsp;31, 2020. Further, the Company is not currently under examination by any federal, state or local tax authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The CARES Act provides sweeping tax changes in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Some of the more
significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending
certain provisions of the previously enacted Tax Cuts and Jobs Act.&nbsp;As of December&nbsp;31, 2020, the Company has not recorded any material adjustments to its income tax provision related to the provisions within the CARES Act. The Company will
continue to analyze the impact that the CARES Act will have, if any, on its financial position, results of operations or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Leases
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had operating leases for office and lab space in Carlsbad, California and a finance lease
for equipment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents the balances for operating and finance leases ROU assets and
lease liabilities (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company paid cash security deposits totaling $17,000, of which all is
refundable in November 2021 and is included in prepaids and other current assets in the Company&#146;s balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The components of
lease expense include operating and finance lease costs. For the years ended December&nbsp;31, 2019 and 2020, operating lease costs were $0.1&nbsp;million and $0.2&nbsp;million, respectively. For the years ended December&nbsp;31, 2019 and 2020,
finance lease costs consisted of $4,000 and $9,000 in amortization and $1,000 and $1,000 of interest expense, respectively. Amortization is recorded in research and development expenses and interest expense is recorded in other expenses in the
Statements of Operations and Comprehensive Loss.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Maturities of lease liabilities, weighted-average remaining term and weighted-average
discount rate were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>December&nbsp;31,&nbsp;2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Operating<BR>Leases</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Finance<BR>Lease</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: amount representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (years)&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (years)&#151;finance lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average incremental borrowing rate&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average incremental borrowing rate&#151;finance lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019 and 2020, operating cash flows included $0.1&nbsp;million and
$0.2&nbsp;million of cash paid for amounts included in the measurement of operating lease liabilities, respectively, and $1,000 and $1,000 of cash paid for amounts included in the measurement of finance lease liabilities, respectively. For the year
ended December&nbsp;31, 2019 and 2020, financing cash flows included $8,000 and $17,000 of cash paid for amounts included in the measurement of finance lease liabilities, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2020, the Company entered into an operating lease for office and lab space in Carlsbad, California (the &#147;New Lease&#148;). The
Company paid a cash security deposit of $21,000, of which all is refundable at the end of the lease term and is included in long-term assets in the Company&#146;s balance sheet as of December&nbsp;31, 2020. Additionally, as part of the terms of the
lease agreement, the Company is required to maintain a letter of credit of $0.2&nbsp;million which must remain in place until 2023 at the earliest and is considered a <FONT STYLE="white-space:nowrap">non-current</FONT> asset as of December&nbsp;31,
2020. The New Lease is expected to commence in the second quarter of 2021 and projected lease payments over the life of the lease are expected to be $1.5&nbsp;million, with a lease expiration of 60 months from lease commencement as defined in the
lease agreement. The Company has the option to renew the lease for two additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">thirty-six-month</FONT></FONT> periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. License Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2019, the
Company entered into a license agreement (the &#147;License Agreement&#148;) with Emory University (&#147;Emory&#148;). Under the License Agreement, the Company licensed the exclusive, royalty-bearing, sublicensable, rights to certain <FONT
STYLE="white-space:nowrap">know-how,</FONT> patents, and patent applications to pursue the development and commercialization of certain inventions and technology for the treatment of disease. As consideration of the license, the Company agreed to
pay an upfront fee of $0.1&nbsp;million, which the Company immediately expensed as research and development expense in the Statements of Operations and Comprehensive Loss as there was no alternative future use for the license. Under the License
Agreement, the Company agreed to make future development and regulatory milestone payments of up to $0.2&nbsp;million, commercial milestone payments of up to $0.2&nbsp;million and sales milestone payments of up to $0.5&nbsp;million. The Company also
agreed to pay 1.75% of the net selling price of all royalty-bearing products that are covered by an issued patent included in the License Agreement. As of December&nbsp;31, 2020, no milestones had been accrued as there were no potential milestones
yet considered probable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Within the terms of the License Agreement, the Company may provide a
<FONT STYLE="white-space:nowrap">90-day</FONT> written notice of termination. In February 2021, the Company provided notice to Emory of their decision to voluntarily terminate the License Agreement as the license was unrelated to the Company&#146;s
current technology and was no longer relevant to the Company&#146;s product pipeline. The license agreement was effectively terminated in May 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Employee Benefits </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
offers a 401(k) plan (&#147;401(k) Plan&#148;) for all employees who have met certain eligibility requirements. Under the 401(k) Plan, employees may elect to contribute a portion of their eligible compensation, subject to certain limitations. The
Company did not make any matching employer contributions to the 401(k) Plan as of and for the years ended December&nbsp;31, 2019 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Subsequent Events </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2021, the Company issued 3,874,793 shares of Series B convertible preferred stock at a price of $27.4337 per share for gross proceeds
of $106.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement on March&nbsp;18, 2021 to sublease office space in Carlsbad, California for
general office use which commenced on March&nbsp;22, 2021 and will expire on November&nbsp;30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2021, the Company
effected a 2.5974-for-one forward stock split (the &#147;Forward Stock Split&#148;) of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#146;s preferred
stock. The par value of the common stock was not adjusted as a result of the Forward Stock Split and the authorized shares were increased to 50,000,000 shares of common stock in connection with the Forward Stock Split. The accompanying financial
statements and notes to the financial statements give retroactive effect to the Forward Stock Split for all periods presented, unless otherwise indicated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_7"></A>Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and par value data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs (including related party amounts of $0 and $53, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable (including related party amounts of $0 and $60, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.0001 par value; 6,223,046 shares authorized at
December&nbsp;31, 2020 and June&nbsp;30, 2021 (unaudited), respectively; 3,374,560 and 6,223,046 shares issued and outstanding at December 31, 2020 and June 30, 2021 (unaudited), respectively; $51,340 aggregate liquidation preference at
June&nbsp;30, 2021 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.0001 par value; none and 3,874,793 shares authorized at
December&nbsp;31, 2020 and June&nbsp;30, 2021 (unaudited), respectively; none and 3,874,793 shares issued and outstanding at December&nbsp;31, 2020 and June&nbsp;30, 2021 (unaudited), respectively; $106,300 aggregate liquidation preference at
June&nbsp;30, 2021 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 50,000,000 and 50,000,000 shares authorized at December&nbsp;31,
2020 and June&nbsp;30, 2021 (unaudited), respectively; 3,050,781 and 3,887,050 shares issued at December&nbsp;31, 2020 and June&nbsp;30, 2021 (unaudited), respectively and 1,829,377 and 2,374,351 shares outstanding at December&nbsp;31, 2020 and
June&nbsp;30, 2021 (unaudited); respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to unaudited financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_8"></A>Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(unaudited) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except
share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative (including related party amounts of $0, and $118,
respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of simple agreement for future equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,414,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,139,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to unaudited financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_9"></A>Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(unaudited) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except
share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series A<BR>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series B<BR>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In&nbsp;Capital</FONT></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock upon conversion of simple agreement for future
equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,848,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Incremental vesting conditions placed on previously issued common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,461,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of shares of common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,374,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,538,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,374,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,829,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,848,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,874,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock for stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of shares of common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,223,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,874,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,374,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to unaudited financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_10"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(unaudited) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six Months Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operations:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of SAFE commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable, accrued expenses and other liabilities (including related party amounts of $0
and $52, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets and lease liabilities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series A convertible preferred stock, net of issuance costs</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series B convertible preferred stock, net of issuance costs</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from early exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for financing lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash increase for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reconciliation of cash, cash equivalents and restricted cash to the balance sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred stock in exchange for simple agreement for future
equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(including related party amounts of $0 and $8, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset
obtained in exchange for lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchase of early exercise liability in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to unaudited financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin189651_11"></A>Notes to Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Basis of
Presentation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Tyra Biosciences, Inc. (the &#147;Company&#148;) was incorporated in the state of Delaware on August&nbsp;2, 2018. The Company is a precision
oncology company designing and developing purpose-built therapies specifically designed to overcome therapy resistance and improve the lives of cancer patients whose tumors have acquired resistance over the course of therapy to currently available
treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has devoted substantially all of its efforts to research and development and has not generated revenues from its
principal operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From inception to June 30, 2021, the Company has devoted substantially all of its resources to organizing and staffing the company, business
planning, raising capital,&nbsp;developing its proprietary SN&Aring;P discovery engine, undertaking research and development activities for its development programs, establishing its intellectual property portfolio, and providing general and
administrative support for its operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from
operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues to develop its current and future product candidates. From inception to June 30, 2021, the Company has funded its
operations primarily through its Series A and Series B convertible preferred stock financing. In February 2021, the Company received $23.5&nbsp;million in gross proceeds from the sale of the second tranche of Series A convertible stock.
Additionally, in March 2021, the Company received $106.3&nbsp;million in gross proceeds from the sale of Series&nbsp;B convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As the Company continues to pursue its business plan, it expects to finance its operations through a combination of equity offerings, debt
financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, there can be no assurance that any additional financing or strategic transactions will be available to the Company on
acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it may need to delay, reduce or eliminate its product development or future commercialization efforts, which could have a
material adverse effect on the Company&#146;s business, results of operations or financial condition. The accompanying financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited financial statements as of June 30, 2021 and for the six months ended June 30, 2020 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;) for interim
financial information and pursuant to Article 10 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-X&nbsp;of</FONT> the Securities Act of 1933, as amended. Accordingly, they do not include all of the information and notes required by GAAP for
complete financial statements. These unaudited financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company&#146;s financial position and the results of its operations and
cash flows. The results for the six months ended June 30, 2021 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The balance sheet at June 30, 2021 has been derived from the financial
statements at that date but does not include all disclosures required by GAAP for complete financial statements. Because all of the disclosures required by GAAP for complete financial statements are not included herein, these unaudited financial
statements and the notes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accompanying them should be read in conjunction with the Company&#146;s audited financial statements for the year ended December&nbsp;31, 2020 included elsewhere in this Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1&nbsp;filed</FONT> with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting
Policies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s significant accounting policies are disclosed in the audited financial statements for the periods ended
December&nbsp;31, 2019 and 2020, included elsewhere in this prospectus. Since the date of those financial statements, there have been no changes to its significant accounting policies, except as noted below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company capitalizes costs that are directly associated with <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings in other long-term assets until such financings are consummated, at which time such costs are recorded against the gross
proceeds of the offering. Should an <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statements of Operations and
Comprehensive Loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Commitments and Contingencies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the
amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than
any other amount the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December&nbsp;31, 2020 and June 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Parties </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Transactions
between related parties are considered to be related party transactions even though they may not be given accounting recognition. Financial Accounting Standards Board (&#147;FASB&#148;) ASC 850,&nbsp;<I>Related Party Disclosures</I>&nbsp;(&#147;FASB
ASC 850&#148;) requires that transactions with related parties that would make a difference in decision making shall be disclosed so that users of the financial statements can evaluate their significance. Related party transactions typically occur
within the context of the following relationships: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Affiliates of the entity;</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Entities for which investments in their equity securities is typically accounted for under the equity method by
the investing entity; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Trusts for the benefit of employees; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Principal owners of the entity and members of their immediate families; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Management of the entity and members of their immediate families; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Other parties that can significantly influence the management or operating policies of the transacting parties
and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company previously entered into a consulting agreement with van den Boom &amp; Associates, LLC (or &#147;van den Boom &amp;
Associates&#148;), a professional services firm contracted to provide resources to assist with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
day-to-day accounting functions. Services provided under the agreement with van den Boom &amp; Associates are billed at hourly rates. On April 16, 2021, Ms. van den Boom, the managing partner of
van den Boom &amp; Associates, entered into an employment agreement with the Company whereby she became its Chief Financial Officer. van den Boom &amp; Associates is considered a related party under FASB ASC 850 from the point in which Ms. van den
Boom became a Company officer. During the date of her employment agreement to June 30, 2021, van den Boom &amp; Associates rendered contracted services totaling approximately $0.2 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There were no other significant updates not already disclosed in the Company&#146;s audited financial statements for the years ended
December&nbsp;31, 2019 and 2020 to the recently issued accounting standards for the six months ended June 30, 2021. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of
those accounting pronouncements have had or will have a material impact on its financial position or operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for
each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such
assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;1</B>&#151;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical,
unrestricted assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;2</B>&#151;Quoted prices for similar assets and liabilities in active
markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;3</B>&#151;Prices or valuation techniques that require inputs that are both significant to the fair value
measurement and unobservable (i.e. supported by little or no market activity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#146;s financial
instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Included in cash and cash equivalents at December&nbsp;31, 2020 and
June 30, 2021 are money market funds with a carrying value and fair value of $4.7&nbsp;million and $124.7&nbsp;million, respectively, based upon a Level&nbsp;1 fair value assessment. No transfers between levels have occurred during the periods
presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">None of the Company&#146;s <FONT STYLE="white-space:nowrap">non-financial</FONT> assets or liabilities are recorded at fair
value on a <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. No transfers between levels have occurred during the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>December&nbsp;31,<BR>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>June&nbsp;30,<BR>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized $12,000 and $49,000 in depreciation expense for the six months ended June&nbsp;30, 2020
and 2021, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued and Other Current Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>December&nbsp;31,<BR>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>June&nbsp;30,<BR>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and other employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued legal and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other general and administrative fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Simple Agreements for Future Equity (&#147;SAFEs&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2018 and 2019, the Company entered into SAFEs with investors. The SAFEs granted investors with rights to participate in a future equity
financing. The SAFEs contained a number of conversion and redemption provisions, including conversion upon an equity event, and settlement upon liquidity or dissolution events. The Company elected the fair value option of accounting for the SAFEs.
On January&nbsp;6, 2020, the Company entered into a Series A Preferred Stock Purchase agreement which converted the outstanding SAFEs into 526,074 shares of Series A convertible preferred stock at a conversion price of $6.11 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders&#146; Deficit </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under
the Amended and Restated Certificate of Incorporation dated March&nbsp;5, 2021, the Company had a total of 23,085,506 shares of capital stock authorized for issuance, consisting of 12,987,667 shares of common stock, par value of $0.0001 per share,
and 10,097,839 shares of preferred stock, par&nbsp;value of $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company entered into the Series A Preferred Stock Purchase Agreement dated January&nbsp;6, 2020 (&#147;Stock Purchase Agreement&#148;)
whereby the Company agreed to issue and sell, and certain investors agreed to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase up to an aggregate of 5,696,972 shares of Series&nbsp;A convertible preferred stock, at a price of $8.25 per share, in two closings. In January 2020, the Company completed its first
closing and issued 2,848,486 shares at a price of $8.25 per share resulting in gross proceeds of $23.5&nbsp;million and incurred issuance costs of $0.2&nbsp;million. The Stock Purchase Agreement granted investors the rights and obligations to
purchase an additional 2,848,486 shares of Series A convertible preferred stock (&#147;Future Tranche Right&#148;) at a price of $8.25 per share during a second closing which would occur upon triggering of future milestone events, provided that they
occur before January&nbsp;6, 2022. In February 2021, the Company completed its second closing and issued 2,848,486 shares of Series A convertible preferred stock at a price of $8.25 per share for gross proceeds of $23.5&nbsp;million and incurred
issuance costs of $5,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determined that the Future Tranche Right did not meet the definition of a freestanding financial
instrument as it was not legally detachable. The Future Tranche Right was also evaluated as an embedded derivative and the Company determined it did not meet the definition of a derivative instrument for which bifurcation would be required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2021, the Company entered into the Series B Preferred Stock Purchase Agreement under which it issued 3,874,793 shares of Series B
convertible preferred stock, at a price of $27.4337 per share, resulting in net proceeds of $106.1&nbsp;million excluding issuance costs of $0.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020 and June 30, 2021, the Company&#146;s convertible preferred stock has been classified as temporary equity in the
accompanying balance sheets given that the holders of the convertible preferred stock could cause certain events to occur that are outside of the Company&#146;s control whereby the Company could be obligated to redeem the convertible preferred
stock. The carrying value of the convertible preferred stock is not adjusted to the redemption value until the contingent redemption events are considered to be probable of occurring. The Company&#146;s convertible preferred stock has the following
characteristics: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company shall not declare, pay or set aside any dividends on shares of any class of capital stock of the Company unless the holders of the
Series A and Series B convertible preferred stock shall first receive, or simultaneously receive, a noncumulative dividend on each outstanding share of the Series A convertible preferred stock equal to an amount as defined in the Company&#146;s
Amended and Restated Certificate of Incorporation. No such dividends have been declared or paid through June 30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Preferences on
Liquidation </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of the Series A and Series B convertible preferred stock are entitled to receive liquidation preferences, in
the event of a change in control, at an amount per share equal to the greater of (i)&nbsp;the Series A and Series B original issuance price of $8.25 and $27.4337, respectively, plus any dividends declared but unpaid or (ii)&nbsp;such amount per
share as would have been payable had all shares of Series A and Series B preferred stock been converted into common stock. Liquidation payments will be distributed ratably to the holders of the Series A and Series B convertible preferred stock and
have priority and are made in preference to any payments to the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After full payment of the liquidation preference
to the holders of the Series A and Series B convertible preferred stock, the remaining assets, if any, will be distributed to the holders of the Series A and Series B convertible preferred stock and common stock, pro rata based on the number of
shares held by each holder, treating for this purpose all such securities as if they had been converted to common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Conversion
Rights </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares of Series A and Series B convertible preferred stock are convertible into an equal number of shares of common
stock, at the option of the holder, subject to certain anti-dilution adjustments. The conversion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rate for the convertible preferred stock is determined by dividing the original issue price by the conversion price. The conversion price is initially the original issue price, but is subject to
adjustment for dividends, stock splits, and other distributions. The conversion rate at June 30, 2021 for the Series A and Series B convertible preferred stock into common stock was 1:1. Upon the effective date of the Forward Stock Split, the
conversion rate was adjusted to 1:2.5974. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each share of Series A and Series B convertible preferred stock will be automatically converted
into common stock at the then effective conversion rate (i)&nbsp;upon the closing of the sale of common stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of
1933, as amended, resulting in at least $75.0&nbsp;million of gross proceeds to the Company, or (ii)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of 60% of the outstanding shares of
Series A and Series B convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Redemption Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of Series A and Series B convertible preferred stock do not have any redemption rights, except upon certain liquidation and
dissolution events that are outside of the Company&#146;s control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Voting </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holder of each share of Series A and Series B convertible preferred stock are entitled to one vote for each share of common stock into
which such shares of Series A and Series B convertible preferred stock could then be converted and shall vote together with the holders of common stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock
basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2020 and June 30, 2021, of the 50,000,000 authorized shares of common stock, 3,050,781 and 3,887,050 shares were issued, respectively and 1,829,377 and 2,374,351 shares were outstanding, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The voting, dividend, and liquidation rights of the holders of the common stock are subject to, and qualified by, the rights, preferences and
privileges of the holders of the Series A convertible preferred stock. The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Common stock reserved for future issuance consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As&nbsp;of<BR>December&nbsp;31,<BR>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of<BR>June
30,<BR>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,765,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,228,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options granted and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,586,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares available for future issuance under the 2020 equity incentive plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,032,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common stock reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,168,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,847,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has issued 2,820,560 shares of restricted common stock at a price of $0.0001 per
share to certain founders of the Company (&#147;Founders Stock&#148;). The Company maintains a repurchase right whereby the Founders Stock are released from such repurchase right over a period of time of continued service by the recipient. Any
shares subject to repurchase by the Company are not deemed, for accounting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes, to be outstanding until those shares vest. Unvested outstanding Founders Stock as of December&nbsp;31, 2020 and June&nbsp;30, 2021 were 991,178 and 741,534 shares, respectively. The
amount recorded as liabilities associated with shares issued with repurchase rights were immaterial as of December&nbsp;31, 2020 and June&nbsp;30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2020, in connection with the issuance of the Series A convertible preferred stock, the Company&#146;s founders agreed to modify
their outstanding Founders Stock to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the 1,461,816 modified shares of common stock became compensatory upon such modification. The
total compensation cost resulting from the modification was $0.9&nbsp;million, which will be recognized over the vesting term of three years had a measurement date fair value of $0.61 per share. For the six months ended June&nbsp;30, 2020 and 2021,
243,631 shares vested in each period and the Company recognized $0.1&nbsp;million of stock-based compensation expense for each period related to the awards. As of June&nbsp;30, 2021, the total unrecognized compensation expense related to unvested
Founders Stock was $0.5&nbsp;million expected to be recognized over a weighted-average period of approximately 1.5 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company adopted the 2020 Equity Incentive Plan (the &#147;Plan&#148;). The Plan provides for the grant of
incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Plan was amended in March 2021 to increase the total number of shares reserved under the Plan to 4,685,475. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A summary of the Company&#146;s stock option activity under the Plan is as follows (in thousands, except share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Exercise<BR>Price&nbsp;
per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contractual
 Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,088,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(876,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,586,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,574,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2020 and 2021, the total grant date fair value of vested options was
$14,000 and $0.4&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value of employee option grants for the six months
ended June 30, 2020 and 2021 was $0.48 and $2.67 per share, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liability for Early Exercise of Stock Options </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain individuals were granted the ability to early exercise their stock options. The shares of common stock issued from the early exercise
of unvested stock options are restricted and continue to vest in accordance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased
by the employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for
exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into common stock and additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital as the shares vest. As of December&nbsp;31, 2020 and June 30, 2021, 230,222 and 771,153 unvested shares issued under early exercise provisions were subject to repurchase by the Company, respectively.
As of December&nbsp;31, 2020 and June 30, 2021, the Company recorded $0.1&nbsp;million and $0.5&nbsp;million, respectively, associated with shares issued with repurchase rights in other long-term liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized stock-based compensation expense of $0.1 million and $0.2 million in research and development expense and $0.1 million
and $0.3 million in general and administrative expense for the six months ended June 30, 2020 and 2021, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The assumptions
used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants issued during the six months ended June 30, 2020 and 2021 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six Months Ended<BR>June
30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stock Options:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$0.99&nbsp;-&nbsp;10.75</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate of interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.4&nbsp;-&nbsp;1.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.8&nbsp;-&nbsp;1.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5.8&nbsp;-&nbsp;6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5.8&nbsp;-&nbsp;6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">92.9&nbsp;-&nbsp;97.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">98.9&nbsp;-&nbsp;99.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June 30, 2021, the unrecognized compensation cost related to outstanding employee and nonemployee
options was $4.6&nbsp;million, and is expected to be recognized as expense over approximately 3.6 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Net Loss Per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six Months Ended<BR>June&nbsp;30
,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,864,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,668,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: weighted average unvested founder shares of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,405,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(882,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: weighted average unvested common stock issued upon early exercise of common stock
options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(645,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,414,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,139,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the
calculation of diluted net loss per share because their inclusion would be anti-dilutive. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six Months
Ended<BR>June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,374,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,097,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested common stock upon early exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">771,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">887,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,586,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,774,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,197,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. License Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into a license agreement (the &#147;License Agreement&#148;) with Emory University (&#147;Emory&#148;) to
obtain rights to certain <FONT STYLE="white-space:nowrap">know-how,</FONT> patents, and patent applications to pursue the development and commercialization of certain inventions and technology for the treatment of disease. In February 2021, the
Company provided <FONT STYLE="white-space:nowrap">90-day</FONT> notice to Emory of their decision to voluntarily terminate the License Agreement. There were no milestones payments met or paid in the six months ended June 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Leases </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2020, the Company
entered into an operating lease for office and lab space in Carlsbad, California (the &#147;Carlsbad Lease&#148;). The Carlsbad Lease has a lease term of 60 months from the contractual lease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commencement date. The Company has the option to renew the lease for two additional thirty-six-month periods. As of June 30, 2021, the underlying asset was made available for use by the Company
and therefore, the Carlsbad Lease is considered to have commenced. The Company recognized an initial right-of-use asset and lease liability of $1.2 million, respectively, for the lease. The initial right-of-use asset was calculated based on the
initial lease term of 60 months, as the renewal options were not reasonably certain of being exercised. As the Carlsbad Lease did not provide an implicit rate, the Company used an estimated incremental borrowing rate of 7.5%, determined as the rate
of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In conjunction with the Carlsbad Lease, the Company paid a cash security deposit of $21,000, of which all is refundable at the end of the
lease term and is included in long-term assets in the Company&#146;s balance sheet as of June 30, 2021. Additionally, as part of the terms of the lease agreement, the Company was required to maintain a letter of credit of $0.2 million which must
remain in place until 2023 at the earliest and was considered a non-current asset as of June 30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents the
balances for operating and finance leases ROU assets and lease liabilities (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The components of lease expense include operating and finance lease costs. Amortization is recorded in
research and development expenses and interest expense is recorded in other expenses in the Statements of Operations and Comprehensive Loss. Components of lease cost for the six months ended June 30, 2020 and 2021 were as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of ROU assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Maturities of lease liabilities, weighted-average remaining term and weighted-average
discount rate were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2021<BR>Operating&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending December 31,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021 (remaining six months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: amount representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (years) - operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (years) - finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average incremental borrowing rate - operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average incremental borrowing rate - finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cash flows for operating and finance lease liabilities were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating Cash Flow Activity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for finance lease liabilities - interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing Cash Flow Activity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for finance lease liabilities - principal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure on cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease assets obtained in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Subsequent Events </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the purposes of the interim financial statements as of June 30, 2021, the Company has evaluated the subsequent events through August 20,
2021, the date the interim financial statements were issued. The Company has concluded that no subsequent event has occurred that requires disclosure. The Company has further evaluated subsequent events for disclosure purposes through September 9,
2021. Except as described below, the Company has concluded that no subsequent event has occurred that requires disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward stock split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2021, the Company effected a 2.5974-for-one forward stock split (the &#147;Forward Stock Split&#148;) of its issued and
outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#146;s preferred stock. The par value of the common stock was not adjusted as a result of the Forward Stock Split and
the authorized shares were increased to 50,000,000 shares of common stock in connection with the Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the Forward Stock Split for
all periods presented, unless otherwise indicated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (the 25th day after the date of this prospectus), all dealers effecting transactions in the Common
Stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold
allotment or subscription. </P>  <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>9,000,000 Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189651g56o91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BofA Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Cowen
</B></P> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount&nbsp;paid&nbsp;or<BR>to be
paid</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of
directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional
misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our restated certificate of incorporation provides that no
director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General
Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director,
officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or
completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall
have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such
person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation provides that we will indemnify each person who
was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director
or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such
persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and,
with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our restated certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an
action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a
director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against
all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in
good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be
liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been
successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain
circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to enter into indemnification agreements with each of our directors and officers. These indemnification
agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising
out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of
claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In any underwriting agreement we enter into in connection
with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain
liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding unregistered securities issued by us since our inception on August&nbsp;2, 2018. Also included is the
consideration received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>(a) Issuances of Securities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1. Between October 2018 and March 2019, the Company entered into SAFEs with investors for an aggregate principal purchase price of $3,214,467.
The SAFEs granted investors rights to participate in a future equity financing. In January 2020, the SAFEs converted into 526,074 shares of our Series A Preferred Stock at a conversion price of $6.11 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2. In January 2020, we issued and sold an aggregate of 2,848,486 Series A preferred shares
at a price per share of $8.25 for aggregate cash consideration of approximately $23.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3. In February 2021, we issued and
sold an aggregate of 2,848,486 Series A preferred shares at a price per share of $8.25 for aggregate cash consideration of approximately $23.5&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4. In March 2021, we issued and sold an aggregate of 3,874,793 Series B preferred shares at a price per share of $27.4337 for aggregate cash
consideration of approximately $106.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing issuances of securities. The
securities described in this section (a)&nbsp;of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D
promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All holders of securities described above represented to us in connection with their
purchase or issuance that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear
the risks of the investment and could hold the securities for an indefinite period of time. The holders received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a
registration statement or an available exemption from such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>(b) Grants of Restricted Stock and Stock Options </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since August&nbsp;2, 2018, we have granted to certain of our directors, employees and consultants (in connection with services provided to us
by such persons) options to purchase 3,823,557&nbsp;shares of our common stock with a weighted average exercise price of $2.15 under the 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since August&nbsp;2, 2018, the Company has issued 2,820,560 shares of restricted common stock at a price of $0.0001 per share to certain
founders of our company, or Founders Shares. In January&nbsp;2020, in connection with the issuance of our Series&nbsp;A Preferred Stock, certain holders of the Founders Shares agreed to modify their outstanding Founders Stock to include vesting
provisions that require continued service to our company in order to vest in those Founders Shares. As of June&nbsp;30, 2021, 741,542 shares of Founders Stock were subject to such vesting conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The restricted stock, stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of
Item 15 were issued pursuant to written compensatory plans or arrangements with our employees and directors, in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities
Act or the exemption set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering. All recipients either received adequate information
about us or had access, through employment or other relationships, to such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of the foregoing securities are deemed
restricted securities for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item 15 included appropriate legends setting forth that the securities had not been registered and the
applicable restrictions on transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Exhibits.</B> See Exhibit Index attached to this registration statement, which is incorporated by reference herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Financial Statement Schedules. </B>Schedules not listed above have been omitted
because the information required to be set forth therein is not applicable or is shown in the combined financial statements or notes thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exhibit Index </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521268272/d189651dex11.htm">Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521268272/d189651dex31.htm">Amended and Restated Certificate of Incorporation, as amended (currently in effect) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex32.htm">Bylaws (currently in effect) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex33.htm">Form of Amended and Restated Certificate of Incorporation (to be effective immediately prior to the completion of this offering)
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex34.htm">Form of Amended and Restated Bylaws (to be effective immediately prior to the completion of this offering) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex41.htm">Specimen stock certificate evidencing the shares of common stock </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521268272/d189651dex42.htm">Amended and Restated Investors&#146; Rights Agreement, dated March 5, 2021, by and among the Registrant and certain of its stockholders, as
amended </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d189651dex51.htm">Opinion of Latham &amp; Watkins LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex101.htm">Tyra Biosciences, Inc. 2020 Equity Incentive Plan and form of stock option agreement thereunder </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521268272/d189651dex102.htm">Tyra Biosciences, Inc. 2021 Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521268272/d189651dex103.htm">Tyra Biosciences, Inc. 2021 Employee Stock Purchase Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521268272/d189651dex104.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex105.htm">Amended and Restated Employment Agreement, dated January&nbsp;6, 2020, by and between Todd Harris and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex106.htm">Amended and Restated Employment Agreement, dated January&nbsp;6, 2020, by and between Daniel Bensen and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex107.htm">Employment Agreement, dated April&nbsp;16, 2021, by and between Esther van den Boom and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex108.htm">Employment Agreement, dated January&nbsp;16, 2020, by and between Ronald Swanson and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex109.htm">Employment Agreement, dated November&nbsp;9, 2020, by and between Hiroomi Tada and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1010.htm">Employment Agreement, dated January&nbsp;1, 2021, by and between Robert Hudkins and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1011.htm">Employment Agreement, dated January&nbsp;18, 2021, by and between Piyush Patel and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1012.htm">Second Amended and Restated Employment Agreement, dated August&nbsp;18, 2021, by and between Todd Harris and the Registrant
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1013.htm">Second Amended and Restated Employment Agreement, dated August&nbsp;18, 2021, by and between Daniel Bensen and the Registrant
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1014.htm">Amended and Restated Employment Agreement, dated August&nbsp;18, 2021, by and between Esther van den Boom and the Registrant
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1015.htm">Amended and Restated Employment Agreement, dated August&nbsp;18, 2021, by and between Ronald Swanson and the Registrant </A></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1016.htm">Amended and Restated Employment Agreement, dated August&nbsp;18, 2021, by and between Hiroomi Tada and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1017.htm">Amended and Restated Employment Agreement, dated August&nbsp;18, 2021, by and between Robert Hudkins and the Registrant </A></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1018.htm">Amended and Restated Employment Agreement, dated August&nbsp;18, 2021, by and between Piyush Patel and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1019.htm">Office Lease, between the Registrant and Fabric 2656 State, LLC, a California limited liability company, as amended by Addendum dated August&nbsp;5,
 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1020.htm">Form of Indemnification Agreement for Directors and Officers </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d189651dex231.htm">Consent of independent registered public accounting firm </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d189651dex51.htm">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1863127/000119312521252729/d189651ds1.htm#sig">Power of Attorney (included on signature page)</A></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery
to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers
and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in
the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The undersigned hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) For the purpose of determining any liability under the Securities Act, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California, on this 14th&nbsp;day of September, 2021. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TYRA BIOSCIENCES, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd Harris, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Harris, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons
in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd Harris, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Todd Harris, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(principal executive officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Esther van den Boom</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Esther van den Boom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(principal financial
and accounting officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">Isan Chen, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">Gilla Kaplan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">Nina Kjellson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">Melissa McCracken, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">Robert More</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">Jake Simson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">Siddarth Subramony, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 14, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">Rehan Verjee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;14, 2021</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Todd Harris, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Todd Harris, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-fact</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d189651dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">12670 High Bluff Drive,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">San Diego,
California 92130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Tel:&nbsp;+1.858.523.5400&nbsp;Fax:&nbsp;+1.858.523.5450</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">www.lw.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="17"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g189651g34k57.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Abu Dhabi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Milan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Barcelona</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Moscow</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Munich</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Jersey</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orange County</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Doha</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paris</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">D&#252;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rome</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shanghai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Washington, D.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;14, 2021 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tyra
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2656 State Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carlsbad, California
92008 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Registration Statement No.</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;333-258970;</FONT> 10,350,000
shares of Common Stock, par value $0.0001 per share</U> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as special counsel to Tyra Biosciences, Inc., a Delaware corporation (the &#147;Company&#148;), in connection with the proposed
issuance of up to 10,350,000 shares (including up to 1,350,000 shares subject to the underwriters&#146; option to purchase additional shares) of common stock, $0.0001 par value per share (the &#147;Shares&#148;). The Shares are included in a
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act of 1933, as amended (the &#147;Act&#148;), filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on August&nbsp;20, 2021
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-258970)</FONT> (as amended, the &#147;Registration Statement&#148;). The term &#147;Shares&#148; shall include any additional shares of common stock registered by the Company pursuant to Rule
462(b) under the Act in connection with the offering contemplated by the Registration Statement. This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under
the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related Prospectus, other than as expressly stated herein with respect to the issue of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter.
With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law
of the State of Delaware and we express no opinion with respect to any other laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set
forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company
against payment therefor in the circumstances contemplated by the form of underwriting agreement most recently filed as an exhibit to the Registration Statement, the issue and sale of the Shares will have been duly authorized by all necessary
corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated
shares provided in the General Corporation Law of the State of Delaware. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>September 14, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page 2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g189651g18c86.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be
relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under
the heading &#147;Legal Matters.&#148; We further consent to the incorporation by reference of this letter and consent into any registration statement filed pursuant to Rule 462(b) with respect to the Shares. In giving such consent, we do not
thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Latham&nbsp;&amp; Watkins LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d189651dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated May&nbsp;28, 2021 (except for the last
paragraph of Note&nbsp;12, as to which the date is September&nbsp;9, 2021), in Amendment No.&nbsp;2 to the Registration Statement <FONT STYLE="white-space:nowrap">(Form&nbsp;S-1</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-258970)</FONT> and
related Prospectus of Tyra Biosciences, Inc. for the registration of shares of its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 14, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g189651g01h01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g01h01.jpg
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M.#.+N(^)+B^L=-6:PBM[6ULY&OK"(M%''VDA[.6Y21 ;J:XP&521@XWKWMZ
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MI',1YCNB9\&-'_!E?\&#PWZXW*8VC]<[ <WM7AN\]AVV-B>SQVO];^K7V_\
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MM>-NGYSLPQV5'U2]B=CW!5FMHRV>XC;SJ[_E*^A$9;_!?5S&-WFBX6T.XBC
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M_=+0O_XC3_DZO;<__,S;G_\ :.]?V#I_BQX__P#.MM_ZWOO_ *%/^4YZ!/\
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MQ4 P6",B41W7J%K<_P"*7U8QRQ7$/#=FTL3HR2QBV6":X21& ="L44@=6 (
M((ZUXLX=U/3C^5@-16YMKFPO/21K26EU!-'/;7#:E+J%KI\L$\;/%*DMQ<VY
MADC9E?F4HQR#7YMM>6:_4BFE*:4KNM^#PQF0R/M?=)CH"SMQK-VY.^T(GMKX
M]&R-QI<39C\E;VV$4HF?0FVEA/Y6N>^C*&27C;13&#]$;V:1@#A8UL+H,3X!
MBRQY.W,X'?70_P"4Q=6UKZ%>,EN&7-TNBVMNC$9DN7U_2Y$5 >K1I%).0-PD
M+-W5W9_"9]&^JO5?K=TW3TWZ?;LWE%?IL-:W;P>%N6\91>>Z,Z8JR.6A8XO'
M&0&)C%ZY7Y A*/28G7/?2QH>L:SQ!I:Z7IE[?<NE!'>WMY)(HV-Y<D++,%[&
M(D$$=HZ[$&NAOR4^..#^#N N*).*.)=&T,R<4&6&'4+^"&[N(UTG3U+VMD7-
MW=*&!4FW@DPP(.XK571/\'S[:>'M)RF/WVGH.)F#;!5-^Y2,R8SQZSC]BMOX
MZT4CQ#*V0R]42#E;?7E>OCZ!Z-./('6:+4%X=YL,Y34IA<$><>G&2-SCJLLZ
M#&QWVKE_'GY2?H)OH9+2YX>D](94,D8FX=M/40=\_P IX@2VNH0#]66VLI2&
MPR;8:O9+HMTSZM[ HA7ZE]?,UU>8">Q2;NS-K[<KUSD>)DKU15[/Y&5S,R+K
MN7DV%$$8P'*8[ST'2=:TV,+JO$D^MD+A5DL+2U53XF1!)<RD?M23DL0"0!E:
M\/<=\5<&<1W!DX5]'5AP4IDYG>#7=7U22503@"WG>WTZVYACF2"R 4956+?2
M5PZT;MW_ (C<_1K9?3[-[>VW?ZE[OW)@[^=W%MBUNZOCZ6!V!N;>(S7P]7<>
MUR:^S8P*Z<L/*K%*[!.[&RN%GCKU[J<-WH5AIEQ;6DFJWMW;RW%U9O>K%';:
M;=WPY8$NK,LSM;B/)F 4,6P<8.7 NC<-WFD\<Z[Q)8:GJEOPKHNE7]MI^F:M
M#HLES/J7$FDZ&1+?3:7JX2.*/46G"K9L7:()S(&++K/=G6+JQTMJ=7-K[VL;
M)W)NG;O07?O6GIMO#;^WLKMS$Y@=DUIK9;";FVE?W-N)]>YBLMD-O61?C=QG
M6RV*R+0A>/M4VDWY5YKFLZ0NLV>H-875Y:\-ZCKVEW]M;36L$_J"E)[>[LI+
MNZ9)(9I;5PT5T4FAE(Q&\;$\JT?@C@[BZ;@S5M BU_2](U/TB\.<"<4Z)J>I
MV>J7MB=?E$MG?Z3K-MI.F1RV]Y9VVI1&.[TL36=Y:HQ>YAG0)?\ 2OJ/GMV9
M_:B'^U/[/V]FY6N-VWL#:.TL96W7?&,4V_;H8^U7ZT[AM(?C@!EFV[]SER0K
M4K)-K)"#8G/1]4NKVYLE;C'AK4#,HD?3;*QA2\E'8M*\<3KKURZM$ 7=O59,
M)&Y9%&2M'&'"VGZ+IVL2)Z(?25H*6DIMX.)-;UFZET:W)O$MH+BYBDX#TR&2
M.Z+)%#'^=( TL\0260\JOA6W>NO4_=F;RDXC?G2"GO3$[TR6&?[,>X\2[;N_
MYV]C=S/Q/P[LS&]*5I^XK^ 2.Y,?E:>T+.U;)6:U%*6H9&0+1M>(M7O;B;L=
M1T..^AOI8&X2NH6MM3-M%=M#D7L]_$[7,ELHNHYH[!K1BZ1@%3VE?=U/T>\)
MZ-86GKO#W&TVA7FA6M]%Z6-+O(]3X;_.5UI,=YOHUEH4\4>F6^I.=+N;.?7(
MM8B6*6Y=TD3U4;"W9U\W!M++=>*48C'9RSLK='1_9/37"@3L<W-[IZKXG 5\
M92S62[[4#3C<>=4ZS:KU%LJ8=%CPU6+ !W_2O.)+JSGXCC$$5P^GW>AV&DVX
MYHVN+S68+98HYY<O[ NK@,[*BE(%? 9@,\;T?T<Z;K-EZ.[CUVZL(M?TCC;7
M^*K]@ETFGZ1P=>:E)=SV%J%A)G.EZ<Z112S,LU]+%S/%$S<N2TF]?ML[AVJ>
MXMW],-_8S,Y6I0W=MK$;8?L')[9HY!;A'/;6RF6WUGCSM3$W82JUA\ECO>>7
MI$Q^.L5[JXHNVXVXEM+JR-U?:1J45Q-''>VD%HVFS6D<H8>LV<T^HW)N8X9>
M4/!+%VT\?,T3K(!$?DSKZ.-5TS6%TS1>+.'+NPLYKG1=5O=6CXCM-5N+9HR=
M.U>TL^'=.73IKRW[22*]M;KU2RG"QW,<L#>L)A/27VA]Q;FWIU6V+OK%XS$7
M<9N_JPKI%EZ2W)Q^\-K]-]TY+:^7Q5D7V7=V[ML/IT<CED)8F,AA,W2R-2HE
M=/($OY^B\3W5W?:SI^HPPPR0W^MKHL\898KZSTF\FLYH7#,V;VT,<<LRJP$L
M%PDJ(HCDQ]_C+T9Z9I.@\'<0\/7=W>P7>B<'/QI93M&]SHFK\4Z1:ZM97D1C
MBCY=$U:.>>ULI)%<VU_87%K-.[3VP;>/1/>&6Z@]'>EN^\\-,,WO'I_M+<V6
M#'I97HCD<W@Z.1N#30UUAB:T6+#(0ICW&"X$2:<Q)3R+0+V;4M#T?4;@(+B^
MTVRNYQ&I6,2W%O'+($4LQ5.9SR@LQ P"3UKK_CS1+/AOC;B[A[3VG:PT/B36
MM)LFN762X:UT_4;BU@,\B)$CRF*)3(ZQQJS9(10<#9^OK5Q.FE*:4II2FE*:
M4II2FE*:4II2FE*X,:M*S:Y@*4L9(V,,06 Q\R,RF!$8^N9F(C4,RJ"S$*H&
M2S$  #J23L!YFLD1Y&5$5G=CA512S,3T"J 22? #-1_O&7^F/JNN1/RL%'E:
M,<^HGYEXP;TG',BZA7O#QQ,\043-/;<VT,;2?US[$7O[1MW7P:%91\ZV/5A'
MO<31P=YC'TMQML5[*,\L<BGK'<R6[=? U8NLO)A)=D)AX\=V.PE>+%E<G$3"
M[=IX/\)9Q,0NT:<2,27=+1B.1J9V)*-*0_?%:ISNN>@DD96Y01TD*6XW)YAM
MC82) @D2VS&>ES?R]E$V#NT,*-'SLIW:)9+PX&.0YWM7BFB'G[0XW#K5R0Y#
M-69R>0 1 B)<,?8@*Y ,&:X5D;J^.9\#F3&,&"Q#M7$-N%R1+<N9Y\8)*AF?
MV" "0%FE&-N09-71E[AO5X3=7KOA3;6,0M;9B2 &Y(XRTH)(5N>UMVSCZ3 4
MUT[ZL>W=[-?3 K-.[O*QU#SM?O$L)M<@S4&:^0*N^*4U=M5[*&_"RMF+%&S!
M04P12 \<'UGTA\*Z27CDOI-5N%R#!;$3*<;%'6+DM%=&V*7 C?.3DX%=V\&_
MD\^E/BWLIX-#CX9T^0@B_P!7#6!4-N)8^W[;59894W66RCN(B" 5&3GSYWO^
M%&ZM;OMCMOHMTYH8#S1S5Q\/1=W'G[4>LJ;C<+AHIA2N<^I5BLYVL4#QV$)%
M$=:ZAZ6]:O7%IH.F1VP<E(AR/<7#]2##!;\G9OWE.TN$ZC!%>E- _)(X-T2$
MZIQYQ1<:AV*B:ZY)(-+TZ([<ZW5]?&=KB#&PE$6G2C.>8$"L"'HM^$-]HEGB
M;TR.[MO8G+!W/K[US<[&Q[DM+U99Z?[?0&>LK@>Z2LLVC8B!@O$=W3/=\X:#
MZ2^)FS?RWMM%. 66_G_-Z.I/UGTVV47+@;DR&Q8#!RV:Y$>._P F?T9+R:#;
M:+J=[9MB.30K#_""YC=!LL7$FHR-IT+$X B76XB21RQX&V\=D?@D#%07>I_5
MR*"![9M4MK8>NGP>)CNE67R]FPMJF<P"SL8JFU9?$Q!SPN>0:?Z%V"B35]9$
M*#':);0J.7IN)IG92K9P"\4; ]4Z \ U_P#+.!=K?A+@PW$A)$,^KWLC]ID'
M >RL8HW1TP698KR='&RRCZ]=P]B?@\?97VB"27T\RG4*^N!XS&_<]DSI$4>L
M]V-IEBL182V([EL3M[(*F)$?'@9,M<WT[T9\(604KI<^J2K_ ,XU*YF$1/7]
M%'V,+J1]5EM)E.PY\$FND>(?RE_2]K3.&XFL^&K9LYLN'=.M%G Z#%U.+R]B
MD3HZ/J=LV<GL\@ =G-L]+^F6RB&OL_8^RMM.KS ^3V%LW XJRL_G*[^6KT8<
MMTQ' W'6<2UDP;.[Q..SEEKI.E6!Y+*PL+5U(!CTNPMH'!P,K+.L?,K'!Y9&
M>V8@$YYL8ZHU7BWBO7P9-;X@U[5(Y1S=MQ%KNHWD3*#]>WLY9RCQ@_6@CBO$
M4%5 Y<\VPDXY\LARZU.@R(X&U9EF7R\K.)B1FT]D#6:L9F!CS&31R7$#(#,'
M]-86SS*D<3;@2.6N+CE(QCM'/T; =!SSIOC! P>-274?*8VEFN%.YAB"V5D'
M!SD0QKF5&(!)[*TDVR2&.1?>ZJS/6X3\C,_E1>;+4%Q^3,T5PK'001Z"8U!/
MZY*2F9FWU=&_2EYO$2MS(<=,Q*%AR.XB,'.^<[UK^N2IM ([8#H8%Y9!GJ!<
M,7N2#WJ9BO< !M4@  L!6L!6L(@0 !@ $8]($1&($8B/2(B(B-7 !0%4  #
M    '0 #8 > K69F9BS,69B268DL2>I).22>\FN6IJ*:4II2FE*XF , EL 6
M+,9$P,8(#&8XD2$HF"&8])B8F)CYZ@@,"K ,I&"" 01X$'8CWU*LRL&5BK*<
MAE)# CH01@@CQ%1WNJLO]YF_'3'Y,46^&@>?RIBBP6XZ2*/0C.H1_7!041,4
M^KQKO$7A/=V3<J#Q/8L&AR>\F,GOSG>MGUR5OTXCN@3DFX7FD;'0&X4I=!1W
M*)PO<01M5D_'.\27,JT[Y\1$VJ\GB<O !'$"-I!]MAK!]"B+&+1S$Q,0!=H5
MM"^2Q2.8X [1"UO<!0,8[1"0[$=0&@0;C&#@7QW,?*(UEFMU!)$,H6\LBS'.
M3#(N8D4[Y,5W)T.[#)MF>&Z0J->)$1C 8S<E)31,QY[4T[@PL;+8B8$[ NS!
M#$B1=QS/?@<-A&?<GV8+V)6!8;A8I/9YR,X+A[GER#OT:U>9,S)'LJGFN]+G
M9&56V9YX3S&)#U6)H[$,05! QR\Y!E2)[QR.,B/F==I9G%3QZB'AO6ZQ4K+'
MGQ9"IBT@,$$6(@5'$X:/KVT'3=&-S;^2X<,\:*/K$1P( ".? !K'*S?5-K==
M?9E1;&[ /UFYHW2*:5S]0-->2%L$Q'+*>"ZT0$6*U:N]1S)#=VW:B@36=WJQ
MU&; TK(JF"B9==O$11VQ5F#,(Q5, .D:.IR1+92=CS')PS0EQ$X4Y^M++DY]
MC!(K)I<L8Y99(W7"F#5(?6 BX'L)<",SQ%Q@X2"W"C'TNP8NP+C>T64LG92,
MR"<G7/%9JN$S'TPV%5P>D!*8\$U8RO!=PE%KNCN)@2,,&*=U799T-O=(,_6#
MJ@9 "?9*P)DD$2=Y<S0(25GM(Y#AGM)5N[&1@/T9B:5HY&(_2![N3EP08<'E
M'UA L"2^Q9H+..V:V?0O)8TQ*?XU[QB[V,*)\)+\Q+(XG\5@>V(,0!RN\D2G
M ,=VBSP$'QEYB2S'ZJM<YS_1XP 4,S"2..*X9?:$NG2-:W2D9.UN$'*J#Z\D
M=ER;CZ8G)/+RYU(B?+7<>/'H[!O*]26$^G$8IR#%9M+XIBKB;'9W=Y68^D+4
M\C)^I+"!T>U<RQ ?ZNRD*6.^$MWQU[3J:CM%FV[6"Y.=X]0C%O.S=<^N)(I9
M4&P,UY%S=!#]45Q% 6).TE5#)S)=K[>*<>(RHR,1RAII?'C.XD2<M]['@,QQ
M*(F!&("AR9%6&?)]J2W8V]QD#ZC%6]ML8Y@\L('0IL!4M(8PL3O<VH S'#>(
MMY9X;?M$5X_HTZA&CM[EB#D2;DFLJT\&"E60GQRY[<?G*\5[#)"/552V@$"T
M B)AEE:LO',0?B%$\EFKN&"K-ECGZ&Z0([8ZK'(@0, /K.J7 Z'F(.36\2,A
MD>V^C'6YL)#+$H)V>>&1I"C,=TB9[(XVY!C:_G)2CTR%5U.(^=@8\U1GC\HO
M,H&30D(F))U^O1'Y\<P)3%O;%=IHWBQ^O]>+;J>T7=% W+3)$!\#5'JHDWMI
MHY^_LC]%<>0[*0XD<X.$MI+ANF<9%6>X=O[?WOMO+;:W!2K9O;6Y,;9Q>6H&
MUGE<EC+RB3:K&VJU3)1821+.5.&2 IB"XF=8W-M;:A:S6MRB7%I=1/%-&6/)
M-#(I5T+(P)5U)!Y6&0>M7:;J6I:!JEGJNFSRV&JZ7=17=G<*B]M:W=NX>*54
MF1E$D;@,H=" P!QM57;VV]O[2P]+;^UL'B=N8+&JA-##X3'U<7C::H]>RO2I
M*375$SR12"XDRF3*9*9F<K:UMK*".VL[>&UMXARQP6\:0Q(/!8XPJCSP-SN<
MFL=3U34M9O9]2U>_O-3U"Z<R7-[?W,UW=3N?UI9YW>5R!L.9B%  &  *FM7U
MH4TI32E-*5BV8R>T,E?;T[S61PUG*;EV[EK+-I6[=?WAEML\KQ67L1C29%E^
M-YOA3LN$)7RZ0[N8/MTYY;&60Z7<2P/-=VLSFR=U[6>TVAG;LL\[1?2"-V Q
M[6,]<?7LK36[6V3B:PMKZ*TTO4[.)=9AAD]6LM6PUY91>M!3%'=8MVGB0MS8
MCYL8(S^6WVL_9;W;[-'4&]C;-.[>Z>YJ[9L;#W;X1,J7\:9DY>'R%D!\)&XL
M2J8K9"JWPCM"J,G55-*RN1\B<9\(7O"FI21.DDFF3R.VG7N"4DB)++!*X'*M
MU"OL2H>4OR]LB]FXQ^N'H;]+FC>E7ANWNHIX+?B6QMXHN(M%YU6>VNE 1[VV
MB8\\FF7CCM;:9>=8BYM)G%Q$X/5+7#J[AKD &TP6L"8QA""U@,F9F<P(  C$
MD1$4P(B,3)3,1$3,Z $D  DDX &Y)/0 =Y-0S*JLS,%5069F("JH&2S$X
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MD02LK 9,$P9@!XA7Q,@.RJRL80!E8VK*7( :[MUD1SA+RU*(6(&<<\8:WE8
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MH89OJHX;ZW4XCF  =206[*0 MC+PE<$V*)8D=K>07-KLTL;)D+T&;BV8L8V
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M,E(CUE_7D'^9!& A_P LP/,H)B4ATF6>SCM=Y@);@=+?.8X3_P"DE3EI%_\
M)U(Y6VG961[=N4M31@:&.KPZSQXG@"9""X:13-K(6BAIKAS(,B:R'6[;(::U
MV#!Q!/,L6(H4#OC/(&P!S$^W-(0Q7G()YF#R2$,55RKD DEQFYN92D6>7M"H
M)<J!B&VB!0-V:\H")R00*8U=HE:,-6K4?#9YJTSS=V1D?'(.Q: +U)5)$D<5
MDE/'?,&RP^!7YFP_PE]F218;G=NTD[F(P$!&"L2Y/9J>_=G;;G=^5<5RS\R]
ME$G8P9![,-S-(1GE>>3E4RN,GE]E8TRQBCCYWYK_ %;6O32E-*5BFXM];-VB
MRNG<^Z,%@7VUF^NC*9*K3>VNHH!UH4N8+(II*8%]LABL@IB&M"9CF<$] 3\*
MC('4@?&J.9ZA[$V\5$,YN_;F*+*4XR.-B]EZ2//T"D8&[3DW1%BJ4F,#85)J
M+N'@I[HY8/@?E0L!C)Z]*O\ &;OVKFBQHX?<>#RLYFG=OXCW=E*=P<G2QKTU
MLC9H%7<P;:J%BPA%TD2?E6N6M_AD41,8/A3(VWZ]*I9+>NT,.C*V<KN7"8]&
M#N5<=EVV\E52&.R-Y";5/'6I-D>'?MUK-=]:E/XTY5A!K40M7)3@^!ID>(J,
M=U/Z=5\+6W$_>^UTX*Y<;CZV69FJ 46Y! $Q]"+!/A8W4 !D^H<C83 EXBQX
MG3!\#\J<PZY\J^T.IO3O*8K+9S';VVO=PV!6AN:RE;-4'4,6NU)Q6._:!\IK
M#8)9BF6F,,D9@.9CC3!\#\J<P.3GIUK*FY7&)L8VHV_479S$OC%(*PJ&Y+RU
M8KECR0=W-GP:@E99*H.!3$LG@/745-<BR6/'(KQ!7:T91U)V25CY<$7&8^N]
M%5]T*_=XA5DV;59#'0,@#7J B@C&)4J&W'O3:6T!JENC<>&P,WI9%(,GD*]1
MUOP!@GE60TX<\*XD)V&* @0)"3B 2B98/A4$@=3C-7%C=.V:F"'=%G<.$1ML
MT*M!GVY2D&&97?(BARLE+_)M6\B$$$MQ0XR$%=Q$,2P>F-_"F1C.1CQ[JC*7
M4+8V1P^3S]+=NW[.&PGIF<BO*5)K8B9$3B,H<MB:!$!"P!MPJ360L") H*9P
M>F/QY>-,C&<[5RP'4#8^Z;C,=MO=VW,YD$UYMMH8S+T;ET*HF*BLS52XG^7%
MA@LGPN5"PP C@B&)8(Z@CX4# ]#4Y4S6(R&0RN*HY.A<R>".HO,X^M:2ZYBF
M7Z_FZ09"NLR;4*W5GS%<7B$N5]('<,3.HJ<]?+K6*XGJITUSN21A\-OW:.3R
MUEAJK8VGN#&.O67+@B8FM5"S+GM 0,B4D#,1 RD8$2F)P? _(U',"<9K(YW)
M@(Q#]P3F<;&#K':78RTW$>[TG1NMQUP&6^_P0*M?0ZF^".)794:2X,9B(P?"
MF1C/=51.>PEBME+B,MCVU<'9O4\S8"VB4XJUC0AN0KY%G?VTVTU$+;(6)625
M$+3B%D)2P?#KTID?+.?A5[3N5<A4JWZ+U6J5VNFW4M(.&(LUK"Q:AZ6#R+%.
M48L68S(F!"0S,3$Z5/6KG2E-*586*,,9YJLSREV!@?'$.];P'U!5U'<$6DC/
M/9R:["8)D5K"/%9)U/%ENT0]G+@#F R' SA95R.=1DXW#KD\CKS-G8BGY5[*
M5.V@R3V9;E:,GZSP288Q.<#F]EHW(4RQ2<B 41<F[!8_(UQ39[?$FN1R:W"L
MAF+6/LQ"R9"6=APP(3<ILE)M77(T&> 99<PS(%?'-R$Y#!3M)$^%)Y3@\P"R
M1L5+!"4)S*/;D7%M*7BSR]JJ\K(7!!AN(LN$+KS*48O#.H=4:55D"\?%L8ST
MLDRWCX^5R8[K-,?JB\(Q$OKA\O/+'Q%+[2NK(%V,A+F>'](2\('Z4_7C'^=
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M5ULY2"Y/239()SW"4#V8)#T[90(6/*9EC/:7!^RA=CC(XRPM3VQ$RT([ZMV
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M+E\#9LF/=6H00P0B0Q(^/;("$UU (>Q9"ZR:5LKC9EY&+&*'!9<<[D92($9
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M9U#*V%"5;=(>Y-N9;+SDKF&S%VG5NW;YIQ[5.3+'Q(UE-$-2  5Z@YZ'S!W
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M5KF:Z23)=VTLB WL"9%E"FP>)'M*)"];7,2B8*I6.+GCMH0Q,Q:-"1&IY99
M2"S X:*,@@C'260'V#F-#VH<PY(%M56610UPZAX(64%8T896XF4['F'M6\+
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MXW;&T\]N01P^_+6:MY"SA:)WPQLIL;*PZZBK:4O$LAXUF:S!7'DGPR27& 2
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M1YF(&+%>2@%WU!'$+.9X$+*XY\M8+B(GZ%T^ 7<O)T8-VL7U\#G38"51W'.
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M*K"GK4@!(8K;1L 0\JX)E93D&*#*DJP*RRE(RLD8G"W5AR:%63\/A:A6I%=
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MB)+(<KS*7B9A'+(#4KO3>K0SLGL9#%.0X1DUL&258K/"),)-9P:F1!&LIB9
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M:X_6$5EOL'$K2?$@9.!WU!( R:PG_",?V [[QK_V.LN0^(^W[JQYQX'[/OK
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M!U*M'*H+!)4=.8\N:M:_-"UY&?2I:EC,=/R%+8@FV,?'/R&!@[5(8F>U$64
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MU(@ + %K 06L1   8$  8@1 1B(@1$8B!&(B(B(B(XU<         !@ #8
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M5R,NQ%:LF2+B(%:4)"9G@1C@06L?2!CB!CB(^K5I*QH2<*B*2=L!549.PZ
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M&K.?:GM,$6<I/4\J![*<@%@BH[-SSBOE?E.>CA.!^/#Q%86YCX9XW]8NG2%
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M)<ME%BI#:V/OY)*W/#=C:*2/LQ[(P05)RPR<Y!QO@[YQ[Q6G(LL<@D/M;[,
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M&C8[%X7 >%R!T+Q,CX[N;! .U7>K*III2FE*:4II2FE*:4II2K/(6#K4WN5
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M?0OQ]R/2%68J.GYE-?(]M<5C'R^+(1CS(OF(+.8GCNB4WLM#)^S((V_L3$(
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M3"\=PN>BHQ[";'F[R6N1WB//ZN]Q>KE:IVJX% ,:A@*9//T3I&92V./6"4V
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M+<Q^3;A-P7\;<MKMMFRSI_B>FFZMA;65!F@2;E+=O.6,[DU_ %>WG,CV-;X
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MVZ^IG25MQE_$[5RN2LX-K2[Y0NGF&XFZL2YF!79F:=F%#PL'^9,8@G'S8XR
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M#QK4&ZMVW*VX<Q7L70G$4W4ET!K;B?@& #<1CKCY$J2USD&-=:80'8R *6$
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M -Q:OO!B[NAX7$XVZ;2L-J^*],M>_3C\64_KFQEA_P"X8_T:+_.)?]# <?\
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M;?P^+PE&<?B733Q-"KCJTM*UFA)I)J*2LFD(B),D9.8$8F9@8B!)/4D^\YJ
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M(T)_VA5T_H0^0'RF;2ALQ]*=A3+2V'$1'?"UA4)<\1 ]L-(>T1]._O,['TN
M@!&D0@8))#\Q\2.5=_'! \AWT1\0WJDF6*WD4G( #QE1M[(.6R._V@6R3[1&
M +6.@V6X]=R8Z9_/&-LQ'^CSD_\ ?JK\TC_+G_LQ_P#KK8_PDD_\C3_MV_\
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M87/SDVI!AS/Z9(IF?UZ]'VW\W@/C%&3[R@)^TU^<MZ,7ET.Y;B9!_921E4?
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'*:4II2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g189651g03h03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g03h03.jpg
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M 0$! 0$!_\  $0@ T0)0 P$1  (1 0,1 ?_$ !X  0 !! ,! 0
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M@_(4I\LK?T<C^J+_ ,OC0]!^0I3Y96_HY']47_E\:'H/R%*?+*W]'(_JB_\
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MZW)^J/Q^IJCMR459V#&6%ESYC35^(Y,$9<QQEVWSG$<SC+.,9S].<8\O/FZ
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M[EVYU%?]>ZR"L:L5,UVSZRM<ZQL5CVP/6:IZLN;.IMJ@YSSJ*&Z3:S9 G.P
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MN5 6Z#0DN!LC8TBH5Z?<22!]^JUAW*+]IB2EN3IN4DM(X;KY;  )]!5W^O\
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MEK)N!7 5J:B(C057"* ,PT0S @:!!((&]Z!!V.IWT\^M055@054@G9! ()
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M].@KRHZSK=8W%^MU^DKWHYO,Q=1JD%&XYV:WA?[)F+(%QFQG8+T8[N\SB?\
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M_%QXC_M&G(OI^\_QI\BJ/S$/[?\ %QXC_M&G(OI^\_QI\BJ/S$/[?\7'B/\
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M!5BI[J2#L:.P='8/4>QJ_4A@&'9@"-'8T1L:(Z'W%2/(J:H'M7<9=>]:;[O
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MJ;^X[)_, C\:ZO!KT'HFD=/=<[@UJM"]OVQ4X=Q-M;M2DU>)#V9>#M<G6V+
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M4XI3BE.*5K<\?G0>B'Z?N^S];U6AH-NU:\K;BXM:6J2K7-@K[NQ5I+(=O-(
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M92V)M)ST7*HO;FHRG=)),);+6MQP)PI),3BUBR>B*XL)A.C6DJ\RA"5/^YL
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M91AZSG+*9F#2(<TYE).>:)F9V9V.V8EB?4D[/_Z\JO%54544:50% ] !H?\
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MMM?*BK>G%*<4K3K^#GU?6MNL/$+4;5KU)LM41G1Y3K;^J1N$93P[OF,3RI8
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MF_PQU48S_67/NO\ BDK;7RHJWIQ2G%*U)?@QO^L/B"_\?1_OV]\N,I^I;_\
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M3Z)5OB>\_M']7K%7Q[?YT_8W]ETK_D76^=>/_HD/_P S_P UZY<A_2Y/9/\
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MN!U-_P!JG6G^\#3?^8ZWFN;_ %4O]V_^$ULA_P!;%_>)_B%;F/PF7_8%K?\
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MXVQ_^XI_ANZV_3IO^$7'_P!CQ_*/$?\ 66_[B?\ ^G3^07%/_P .3_QMC_\
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M*UUG:4#(\B,Q5FS$]<U XX%">:!\'KVQ,@G B[HH3R0!(E58],XSSBR1R#J
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M>PLC'H::L(NP;%?@L5=:C6XH$+8P*\ L--;-;AKZZN00 MF>H"1-_P!8#KH
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MH+ZY?^S*G[U=<>0]S]%IYGV'U:L5N\>OK0-TQM]6J9RML8"E9X7A(I*]L 8
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M5M/MZ'.B4P=&JM4U[5=7C;L;(CC6568U5XV\FNI&[6L&7;#XX;5>!6,)#/\
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M-Q]3[%UTVG,=>[\C9MZ^3\03-2TTJQ)7+6'LHMS2<1=P##$<_C+,2P9>>4F
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M4R5==.<LYS*<TEI2EG/]>92D+.<YS_ISG/GS48(&.S#$2>Y,:$_F174M[>J
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M22#L[CJ#T9AU Y0>_<+T'H.G:H-I:L #;6Y !4 PQD!3()BH!7H#*HE('0R
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MBX>Y<,X "@A57L-G9/7J23W/GH=JM;6UBM(Q'$   HZ * %'*JJJ@*J*!I5
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MWL?<:[UQ<08%I'8 [*Z W]Q(V=>NM'[Q6RT0AA&,(1P$(4("$(<8P&,8XXC
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M%6UVQ4 Y,$E/$\L6#]D7"8Q#)'VZQZ1YAS\-$]MBXVYY)>G*%,?WEB5;I]P
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MYR5UTXI3BE.*4XI487ZY0^S+;[U2\GR/N/HU1YCV/U6EM^2B^TZ7]\H<#O\
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MUHGS(.NF_/H>NSORK.ZMKDJ>NKZBM7@I75:2M=7J"\_;521 -95<?JS*7H"
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M\&M!LU$D%J6-BL9%EHV%)$E96/R]AA,3&?@U1C98)A#)\KE6[;B_DGC\/D5
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M8QI(ZHK/*^-R21RW6'NI9)H8[BSN,CCLA7V-]$(FQ^05Y<=*YD5HP&N,?<,
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MQ@\;NWX[Q4^1&+-GE8+N*>RM,BLUO;^'B+O)7M_C\=;W\D5Y*KO>W6/E2![
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METEP\)C>>.XFBE9XY&0U)44%-0!PO35RU<'"M<E@:T<QCA6I2%75H,8S+/\
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4I7D?_(7?[(S_ ',^2O<>X^M*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g189651g03i80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g03i80.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4;V:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3 Y+3 R5#$Q.C(S.C(W*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 Y+3 R5#$Q.C(S.C(X*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP.2TP,E0Q,3HR,SHR."LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$R,#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%E045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$W4F0V9BMA-'8W.#9B<6QK
M.$IN4"8C>$$[0EI$>5I&;S=)3TI2:$@X3'!593%D*W!L<VID<E,T4'I(=$Y2
M,#AA=').;7=A-%IB<3!-:4)M:&ML1$PV9%EX5G9T2T)4<'-+66UL,R8C>$$[
M8G5,1#@Q26)I0T<Q,5<P5#$U6D1/6C-74FU&46552W1#3T$T,7!(.%%(:FIS
M=39,:%@X>&].5V=L,5!58D=$4F<U.6-%;TA996]31B8C>$$[56U*84)L;W97
M=G982%ID,'5I9R]--DU#0S(Q;7<R:F-N,5I23DE::DQX4F%T2%AI<$EI4&EW
M2C9N1'-U-FEB<C@S2#%186-,-G=2,"8C>$$[9VM9>3%H-'E3:FQW5D9+;5-O
M86QA<4)X.3EY-TDS4CEH-60O37584S5,9E5T6E-/.&YV4%AK=6]72C11:4XO
M,U590TIX1%-C4&M++R8C>$$[4TQ#9#!-4$MV-7!4=TXV;79R0DU+0TI69&U(
M>$\S375W5F$O0W$P,B]A3D].04U.:&%,2U!*.6@U:G,W5S546$QL<FU6<%(Y
M6$QY3"8C>$$[26945D98;%95:G!Y644P-V9E5$5Q12]W2E%E=%$S,"MJ,S!/
M;GEE;&9Y,CAQ5VMP4$AJ37E%4G1896Q'<&E&64MU:B]!2G=P6DI$1B8C>$$[
M<61S1T5K8DM:5S5S1E%H;35V-EI:9S=60D9E;$(T-4]W>#-6+W%(-7E%,$=P
M5T-Q-%%%<V=:;%!.3U9+4G)8-&569G<Y:'-N9%I9828C>$$[4BMB:5AE;F97
M=%1T;G1"3D4R;VIL5GI$1DMP2V]21TXR:E@T=D5K-#)%8G(U=$LO3FU/4TYB
M3%5R65)V2S5U<$IM5U5K17)2;VQA128C>$$[96U+5G!(=4(T-#=*,U)T:F%F
M;60K;6](=F)U,"]1-FU1,T559D@Q5W!Z36%Q9E-(14@T060V9U8S<FIS=39"
M=#E++TYY0DE963E2="8C>$$[1$=K8D=74U5M5U(U951-=GA.2#EN:GA4=#!R
M:G-U-F=)+WIP:W5*3&8Q-U=,,&]U475U35AP4T\S3&E&*T%T5F4O=V=F<DHR
M4G5I8B8C>$$[2'DW*UIC;'%O=F1A4T<W1C5,8W9*1WAK:DUB4DHV8TE4:6YW
M0U5.=%AP9W-*,U%S6&Q0.# U67!Z3C5G5T(R0W!B4G$W=498;7I->B8C>$$[
M=GA5;'1G3VTT4&%L34YH1D9(5V5G+VUC-GI-,VU"8DAL27A31U-'2SE016]"
M>34X26%F1C!7;3-V,T9H3S9A:E(O3R\Q37A(>D1'3"8C>$$[:6=P8T,P:G)8
M9U998V9S+V)O=U P64Q#;UA63DHO34),5&I:-C!T,4Q)231Y1$)(0G=90G55
M=UID-F-Y=DIF-5%A8C1147%69F]$."8C>$$[,D)*1"]U66=+4G-O2C5M<#1M
M06,R2'!N;4A%8FYH=%1K9'IH<TQU:4QB4V9Z2W0W<3)L3C9K:T,K;$9,8GE4
M97-35$UR5%1&+U-H0B8C>$$[56]R04M254)T:E5#9W-,=7IZ27!D:7)S5F1I
M<G-69&ER<U991G%0-5<V5&98;'AC4F%T9$QF>5-36$5O-6]16C,O8616545!
M54%!1B8C>$$[2T1P:W5*1DE#2#AN9DQ$>E)N.4TS13EZ-DMT2#AC1%9&86E2
M5DMN-%,Q9DAW=SAA3T9'9CAQ83!5,V,Q>3)P6'!E850Q0G9&5DMS9B8C>$$[
M:%)U1E(X3$5#;E$W-$]*4$-R>2]L6%EY5V1V64YQ3GDY;D%J:CDU=VMK3%!+
M2E=.6$1+3U9!1%)E=S8W9W9%=$XR6#53-DAA6$-Z2B8C>$$[93-H;WAK96IQ
M:DTS=TU$-FE+<G)35U Q3FHY<DAI5VQA,2],1%-,5'I"8C9X0F-3:&]895)O
M5S1K2&Y+,'=!24%)061X.4$Y.&5*828C>$$[6FQK575X5C)+=7A68DEX5D-W
M-UEQ;V97;CA":7)V<E0K07A6,S%P+T%9<3<V,"]G359D.6%F=T=+=2MT4#1$
M1EAF5VXX0FER=G)4*R8C>$$[07A6,S%P+T%9<3<V,"]G359D.6%F=T=+=2MT
M4#1$1EAF5VXX0FER=G)4*T%X5C,Q<"]!67$W-C O9TU69#EA9G='2W4K=% T
M1$989B8C>$$[5VXX0FER=G)4*T%X5C,Q<"]!67%O5U1)3E1V:U5I;%592TM!
M5DLO169V-C1Q,W%C14MX0U99,45R5#)W6G=!1TDK<THQ4%A&569I<B8C>$$[
M<U9D:7)S5F1I<G-69&ER<U975"]!3C R2W-E,5,O,5<R=4].<F%R8U)#3#%0
M,F=3=V16-#%!239.6#9-;WDU2GA/=W-5-6UN=S1P>"8C>$$[.55U13-85'51
M3FPU:#%P-WA)3')3,U-.;EE036=B6DM54G%(*UHY=78Y=%5.4D\V35A*>39,
M0TE'55II-C5E9E@U0F$S;3(Y15133"8C>$$[;S%Y,TAJ5F%-0U%15'163S%+
M9E X4BMB;"]-4#0K0U(R8D,V.%-0,F9R5W U>75(0TUM:UA,>'E!;%I&1$9E
M.4YW=F-I;BME-DY95"8C>$$[+T-5;G-U274X:V)(-#<Q5S$X,%@X,3E&8G9P
M33A-8VMG:6%29S%&3E0X9&5.0W9W-%DV;5)K0G=L:&LW4&A'0FM-:U-13"]:
M>C5O5R8C>$$[1'IJ<3!H4G8P2DLP56M1;%)O>3=61%<V5$-H.4U$6C,Y3G9F
M-E)M9%1Q<E%3+VU88TYC1T5A0F5J,%9,,V\T;FQ#=D%S=DEC841L428C>$$[
M9F%),G%E,DAH5S-.*UE/<E-4=V969$=D-T\T4DA&,F956D5$;6YQ16]J5E%E
M=W@T5G1L1V<V<$QQ96Y,9'DR-71P0S=O.%)Q849(2R8C>$$[.5-&4&)F8G)K
M4VQ-359D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ*S%M9#E3=D5,;&\P
M.4U)=&%G9D1V5'<S=TLS<78K.'%F."8C>$$[>$9T+S%%4C1Q:DU69&EQ1D]P
M,G=V9G%F1U5Y554X,6EK95 T>31O6D95<4ME;6$Q3S)+<F)A.75R<3)T-31R
M9F=S=U(S37)C84DX9B8C>$$[4&MG05ES5EEH94QC92\P<7)B>E,R=F)+93)N
M=7!6339+4%5H26I-8G)U2&DV;&9I,RM);D973U,O;'=(37!8>D1Q>4Y)5TML
M8F=$:"8C>$$[5F=Y.%%&,C0X5D$K43ES;'A)<&PP369P47!(>F%49V]8;35Q
M>E5&2W-E-5!F27!8-'%S;B]U;7A64W0T:V135T946$9647=1:G%+9B8C>$$[
M4V-69#9%2C9$.%1I<FAB=V=50S=F331Q-S9V1B],*TIX5C,Q94PK6#A4:7)V
M<3A8.'8T;D989E8T=C5F>$]+=2MR>&9Y+VEC5F0Y6"8C>$$[:2]L+T4T<3<V
M=D8O3"M*>%8S,65,*U@X5&ER=G$X6#AV-&Y&6&96-'8U9GA/2W4K<GAF>2]I
M8U9D.5AI+VPO131Q-S9V1B],*TIX5B8C>$$[,S%E3"M8.%1I<G9Q.%@X=C1N
M1EAF5C1V-69X3TMQ1G=I;W=#:6=P:7$R,$-$54QZ-&E:4&=,03E!0TYQ8FXY
M47A6039J6E<Y;&)P8R8C>$$[4U14>7-T>&)5<'E)+W9K540P64965RM:43EV
M055+0VI:3"LV83%A94,R6E%O:W%S=UI:2V]A259J5E=,0BMV545$=&=7,FMK
M:FYU628C>$$[564X+V9E;3!V,5)A=W-Y*V]J23=)5#9O-%4T;F5H<6%J=&A7
M=VDT;W)E2VE226MF0D912V=!;VDQ0TQ19G-J96U"2SE1;U5"2T)10B8C>$$[
M>$$V53=5>%9V1EAC9T-"6&,Y0CAS5E=R3D5X058Q6715<E%G,4%.1%0U66]T
M9&EL6E X03-467%L,2]%.&QG9E1J.5-22D5:1F]4=B8C>$$[5V@R,W)S8U94
M25)X9S%#9T=G1E%/>3E".49C5F-I2VEQ:6EI<4M+4%E507A69&ER<U9D:7)S
M5F1I<G-69&ER<U93.$EG,7<P07$P028C>$$[66LW;6]B:G18<'0T67%I5W-O
M>DMS9UIW>7-'<%=O3D)3:')8,BLT94=+<G)74C-J6FU.4TI*1BMH6D=59F=-
M5E9C5E=1=5AH4GHQ6B8C>$$[4514,T9C5E@T<3=&6%EQ-T953F1F8DAY>%9:
M84DO,38W;4E)4U%Q1C5!:C=!2VUM,4M9<3=6:"]O,&4Y2UA&='0T+W8P>%9'
M67$P528C>$$[475*0V],<4-Q=E1C0G%%9T@S-&I&54YC859P9'I+6F)I>F=M
M;$E!36MK84UX039#<$)/,6-B4G=H<4A39$QG-&5H6G=W*VTS3E!4:B8C>$$[
M5DM.>$LQ*T5$<WAW,F=2035"4S%Q>&EN,#8W55<O<79/:7))<6YI>FA4=%9G
M2S=64'8T66=O>5)S1F@Y.35D369P,C!(;'52:$YX928C>$$[4U9,=C1E6FIQ
M-G5$,$%,<TLX:%=M5T-8;31C<UA14BLQ13)M;7I7,7A(93)F;#DW95=&;DMH
M<&UA:D)U2#)A<G-63S%!4CDR-$HX,B8C>$$[8UE58D5785<W>5-14GE3<#95
M:F]R4$=46&EX1E-T9F)+,TQ(2C O.3 R2U5T,456,'E1,#9/:')T=#A12&5U
M2W!Q04%!04M!8D%$1B8C>$$[5W8R:#AJ:7)E2V]:63=G-F<P=W538EI9:$=B
M44)#;VPU8VDU4$AM1'AO2V-Q93)+<65R-E9(<61Q<T1Z5%<O0U):1FQG8F<Y
M5C)),R8C>$$[0D)$2U-P0D=%1E=.>&9L=UEZ1W<X>#9W6&I)2EDS27%30U-3
M9F@W.&TK.#1E2D9->'E+6%EQ-T9867%G:50K;5%V1D]0;V-U6$5C*R8C>$$[
M6$MN,G5V5$958FEQ:%IF,TQF.$%'5V(O04I/=&EQ<DI)<V-B4U!S:4%S>$%*
M,D%Q9&AV:7%N6D)X6G=#46AP4%14;7EG<7!0159)528C>$$[;&E"-U9/2W!$
M<E!K;4A5-W57-4=Q6#EM6FU6-4ER96)H1V5#:%9(1V@R<G8Y3T5&1DEV469,
M6C!I831K+U-6-69#-%9"-F0S2C9I;R8C>$$[57)6;$9"47155BM72DMP>F=3
M-T953F1F8DAY>%9%-'%G<BM#95%Q9E=264]C0D5B0V@U<$]R:S@V+W1!8U%T
M3W9F1E5B:7%K.7A':R8C>$$[-GA-=U5S:GE53F9S;U9"3F5M,TU9<7%+4U1Y
M1$%O44].4' S<E@U67%H-V$W171X8W<X9U1%=TMG2S1006IJ.%)9044K;VHO
M04=E,B8C>$$[2W$W=6MC8E-3349205=::G-!0G95:S1Q-DIY.&%S97!!2C))
M,S<W2&-F5&EQ-T9867%S;B]U;7A63#<Q1F5X25IG:6E24U=)<E1F,B8C>$$[
M1%EQ;45S,&-1575A8VI284%K:S!*;T%+.6AI<E5D>$1)=T-/1TI5<T(S2S%P
M>4$X4$$T<75K:U-/3G!(3D511FU.0V1G2VY967%S="8C>$$[9W!J.598-6EB
M.31'-&AA:'0Q<G186F%$-DU65F-69&ER<U9D:7)S5F1I<4-%86I71V-S07AH
M,E-M-4A,<E=L3S-J:7%,37-A<T5:=R8C>$$[1T]W56M63F%N*T)X5E-S=C=L
M=BM-<S,O04-D8D96.#%#63!O+W=!5$$X:S)P>"M,-&I58DAJ5#-R:7$V3D%K
M86].=V]#:79S2UEQ=28C>$$[>%8R2W5X5C)+;V$V*S)0;&ER1#,O3G9224Y2
M=G)+-W1:-'I:>E1W:#0K3#AV<7IM3C)917!W0F)I1BME.4M:3&A286IB9FY8
M-5-L:"8C>$$[:FME2S=J3$E(8T-.5T-M;%-.;7%D.75M+W=!<V5!<GA,5R]/
M<GEZ1T$X,79C>'=L431K;VI(:2](:%9666M%:'%K9&@T,7@T1C1K5"8C>$$[
M9B]M;&]&=$-4<45%:U9T2D)#-T97:F%5;35I:FMO26=W:TM"2G8W>6Q+:&@Q
M1S=W<F%!2#5N*U%O5BMU;4\X6&<V9W%50EE0>%EI;R8C>$$[1&XY;5!R,#,O
M=T)A:G=L1FA.9%0O3DA29$MV-W$Q,4-#84PV=3A%64MC6D=,>GAM5&E653!5
M<%-J+T8Q<#0T.$MB54@O3U!Y:V=C1B8C>$$[3'9N1U%R>"MK=DE%9S=F8G!T
M4VY8.$LT.$I7,&(U62]-9E-F365U5&%8<#A%;T9V03 P:SAV1F9I4U52;$%O
M3%8R64YY<FE9,&],3"8C>$$[36EL,DMR2B\W<'-64RLY:6%7>&%*5DQ--W)3
M9TI!-"]&=E%(8F)&57E+<65O0BMF,UEQ-$MQ,$-G04%(65EQ:'139VMU<D]E
M,&EF,"8C>$$[,VYJ6D,O>$%Q<D1I849A1E1V<V4S6&5L35922TM%4E5&4T9!
M04I*63=E2DY39G!X5E%V<FEE,V=%:TU"=4A,;VYP9SA4.&)"83%O9"8C>$$[
M:%=P.7-H3U)!,D9T;4M!:V%*<$LQ.'I42&U8,'$X:E%2=$EJ<VUX2W%'-'-"
M57%4=4]N8DM0>D(O;6QZ1&]2=%4T8RLY9G S;4M3.28C>$$[=GIA;E1R;3-5
M1F=*-55)43AA-V<K.4UL:GIM57$T4T=/8E)I14],:FEF24IZ;5$T3'-69&EQ
M0D-Y3G)":S1.-F%1.$]:1S-,:T<R4"8C>$$[,#1Q:D1&15=$1D9,03%";TMG
M-S<O=T1$2$962WDO=5<O=T--<S,O2C%S5E=22UIR<UAD45EK4F\T2T1Q1TML
M;4I)0C-+1&I486TY5"8C>$$[55564E=+<%1Q4&UB5#E0:VQJ=45M<D560DM*
M>4(U8V%5;V8X<UI2:S%%66UJ8FU99$1024%9,78U+VIU43EX-3,X=G=24GET
M33=2>28C>$$[.'5"5D=**T4P,TA59E1K1')-66))9&PU<$5I=5AM;65L-G):
M-FYA+U=R4FDP6$IK<7=+;7%M:#)/6%DX;VU,1&DU.5!,1DQH;'I2928C>$$[
M5TY+1W5V=&HU67%W6%9H*UIS16QX3%DR5G1C2F,S9'E);S%32&UL=7-V1T5Y
M;'5.96-D5S<Y<3 V6DE5:F1$=5!Z6G0W;C!N:70U228C>$$[6D=J451145%3
M8U1X:4Q/,TIO<4MV3G=$4G0Q<%%#:EED:V)P=VYL8GHR<R]*+TUL=3A)0VHP
M9C!D06]0141V=5)U4#@V64Q#84M-=28C>$$[=DPO;7EA5S1A4%A);V]P0U!Q
M.&8Q2T8O5%5337=3<F9A;W!64EAW<F=S2VLQ.6-F;5!(9FTP<TY09W59<F(P
M<F1R=6%/3D9M2E)'.28C>$$[96=)*TAL-G9)3'-/9$)U1&@R6&14:G9V>DY-
M>E!C-E-H:5AI-%))-V0S851I0S!22FQJ+T%(9$]66E!T8W%50D=(6F0P-#AS
M,C)Q828C>$$[:3=N>E)P8T@Q-U1N43(Y>C93,$UR0FQK84TW9V=Q1F5O+VUP
M*WIG4&MR2U5G9U)U4U)Q<D=T5T%!3S5Q96U24W9X5C)+<DHO-W!S5B8C>$$[
M5U=V,D0X.%96<U974WEX>&IK-T%!06YC9V10;FEO1G!D639Q2G1.=4PT;TAM
M:45N3D5$2TM2;&EQ0C5K:')T,4HR<69$2R]&0D))-B8C>$$[3C4P.&A-4FQT
M9&5F4#-)<%)Q3#-02FUJ:71#;$)%05=L-3%R57989T)48FI1+U!#3TEN>5%E
M05(V;5@R9DQN*T]3;&1P3F)A9$1&1B8C>$$[965K.%II:DXQ8T976FQ"06-S
M5T9#-5=P*V52;4-),$18;5=736E5>51'-W999EHX4#!*8W-V;6M'6FUU8D9W
M<V(X;S%*57AU1D9$>28C>$$[24]W4#AW-S531&PS,VDU4FIP.71P."]N*U!*
M53!M8E@R,4M29%)U-U)R86HK:D)!87E%:'1U5F8U441H>%-N>&5O:6U/;VIH
M.$UC128C>$$[6F-7,6LX:SAZ2V1E-T9867$W1EA9<6LW-G)A44),9#5O:U=7
M935385(U:$550VQN8FI4-'5D0T0R;TXV:EE'37!X:GI.3FU01$]D."8C>$$[
M24IP379R8TAQ2D-H1'E/=DY%5VTV0F=R34]G;W9)5G@T:&1).$TQ6C5*9F%A
M=E!C6&1K;D\P159Z05I3:51L<%-3<4UP4D=20U9O5"8C>$$[.4<K,U1+;S53
M4T]7-#<S2GEA8U)J22MQ-'ER-F1U=DTR5D166DY913%W3%!53%-&458T<%!X
M2E%(:E=V>BM,<C=:1$M:,F%K1WI4:B8C>$$[1E$T;WE0=2M+1G9M.#%#2TQH
M3' P8S-&+U9:>65*1E14:GE&4E0W<VA--64K3&1I1VYS-UI#3FLW,&QR>')*
M5&1T03 O2C9T8D5M4"8C>$$[9&EA0W9C9$1M5&EV:#-R-$]"<4)(:3E.,34X
M,%IL:E%H<G(W62M72W%D<%!-,2]D=WE31FA#5C1I9T%!8U9!-E8R*V5+;VE#
M2V1&028C>$$[;&U-<$<U8FEQ,3ET=3)+<75+=$MX2F-(.6LP2#-!+WAX5G9&
M6%EQ-T9867$W1EA9<7-N+T%,<'-65U=V,D0X.%96<U91:G)A4U116"8C>$$[
M57-"339),W!-63)::U=1<5='=TY$.$,Q*U=.2T,Q97@R1C=B4&)88TQ447EG
M<7E'3U1O>6M':$%Q<&]4=4UJ3T%K2TQ::7EY>'E%;R8C>$$[;6E&2T\S=&]B
M=C9Z2$IC<79P1T57+S<P=R]%+U!N=TE0>#%.3UAH9T=/:EE:4WIK>#130GIU
M-C,U5E8Y>3AW,FHR8U9R3TIB:$EV5"8C>$$[*T]62$Q-,%)"5FU)559.5G%F
M2$0T64EO-V\X66E2:TYR=FPU;T)F3&9L>$XT-U=22#1'4#%&131B:58T:U8K
M5DUP+TMW-VY)4&%/628C>$$[.'HU.&<S6658=$%S3"\V+V$R.'%82C5696MX
M<GHV,4)"=W<P,$EY-&AZ4FPQ*UA*1&=K9E0W:S-&,4511'AK,SA9-4(O=T%A
M-64T828C>$$[*T]62D4U;V%R56IC14=Q;6@R4'5-5EA9<3=&5G)Y0D-G2VLX
M,C0Q03)'>$Y7.$)T5#4T<6A.37,W3T9*6&AG:FIE4V5:-4=25E5S,R8C>$$[
M<79U4T)U9'IG-%)D<W5-:U9E=U8P='94:S52>4UK65AI3&-C9E1",D%)1D]1
M;T9P445$,G)G16$U2DTW1S0S-RMV-"LQ4F@K=$Y.1"8C>$$[-G-C16IX255U
M8FA3>4UR<W%S5FI1<3-W='0K,SDK04$R3'(X9FIV6FMX;S!:8SEH*W,Y+W=5
M<C=Y+V\Y*S=T9#(T;&%3:&-K<TLP-"8C>$$[,#9(+T%#0FM*-$E3,TE:-'1:
M;'AI;VUQ+T@V54I.-4PX=E124GA35S='2TMV<' V:VQ">4Y34CA8:FM$<$U:
M-DXP93 X,%-31'5F228C>$$[2FQP*VXR96Y1+U9R5D-I35,Y0U=B9EEF84YE
M,4%-=7@T>$%52$9Z6C5:1&-U84I:,55Q0V0R3D8K9$-F,41*=%-(=79T:C59
M<7!7<B8C>$$[3614=D9Q2TE%-TM#95,Q,TE513 W8C1Q:FI886Y4=FER<U99
M=C5J93=H<VYL1W1V<%5Z>E1.1DPV851P=U=)<VDX5E%B1&=R+T95,"8C>$$[
M-4Q5,4=3071R;DU21FMS9G1.8G5R9E59<%IV3T@Q:3%3648W53)20FM1.5EU
M4D=X<'AO,S Y>FMU13EZ6"M::#-S,3!N>DAP3W%Y>28C>$$[4E=5<&ME2E9D
M9U9:9FAB-6I);4I$6D1,1UA*33AI,D]X5C)+=7A66E O9$YI<7DQ*W=F;FEQ
M=&EQ,'%427)6;T%#0TXY-C Y-F1V1"8C>$$[1E8R2W%6>$,X;VHT>4Y'5618
M2E@Y;T$W<699:D952'%'<T=Y=6QI83%M;6E+<7AL:55T47,U6&9O2T1Q5'EW
M9TET5S V+VHQ1S$Y9"8C>$$[27!954Q55EI6-$UA54E954HR3TI3<C(P3%%W
M<D<P:E-S2S%K8G%35%A!<7!I<3).0W%G13%B8FMD-E9!<'15;D96,DMU>%8R
M2W)9,28C>$$[6E9O>F-J56UV>DYF131Q=7A666530U8Y,R]A5D)8<T]G-CEA
M67%K.%!M:$=-85-71C)S,&Q$>%=0:W1'8FI513A344MG;F)B1%-,5"8C>$$[
M:&\R37E30GE&44U#9S9.>7 Q*U9-0U8K2W%-.79,3$I'>7I.1W%'<DMV-UAX
M2S%$-V9$5#9C5E=86#)X.'-653=22E!R.35)=U!":28C>$$[9U9J,S1G.4YH
M:7%)9TXR5DAR<6=B8FM%2DDW,4E*2#1F:FEQ;'%6,3E7=%-Y<W%Z4W-S34)9
M<4(V<W)"12LP4E=H3E-"=E1O0V1S228C>$$[4DDP;S-7;'-Y,FMD<$E)27)E
M5D=C16,V>&]V16]/5F%C;$A%-&=S6E)U<5-Q6%%F3D14=$M.5VA:,6I):&M.
M=$=#1TQ!.%125#A.0B8C>$$[-"]2:W5)3E)X>G9N.6ET1F\S;49B>4=D.556
M;S%:1$Y#<V9%34)X-6IB>&\Q3G4O:EA"65--8S=U,"]Y3&4W1EA9<3=&5FLO
M.3 R2R8C>$$[;U9*6%%56'9I<2\V>DPW67$W-GI,-UEQ-S9Z3#=9<3<V>DPW
M67$W-GI,-UEQ-S9Z3#=9<3<V>DPW67$W-GI,-UEQ-S9Z3#=9<3<V>B8C>$$[
M3#=9<3<V>DPW67$W-GI,-UEQ-S9Z3#=9<3<V>DPW67$W-GI,-UEQ-S9Z3#=9
M<3<V>DPW67$W-GI,-UEQ-S9Z3#=9<7-E4FY.5S=9<28C>$$[,6%+9C!N978K
M=S-P:%-"=%5,43<K3F-64C)+;U,P=4DW-R]366DS;TM7:FER5&DO1C9'46)M
M<6MR.$HK6C9%655$9$8T175X5C)+=28C>$$[>%8R2W5X5C)+<EI&-4E6.&-6
M55!Q<F9Z1$989E97+VU'2W4K<70O34U69#E68BM967$W-G$S.'=X5C,Q5G8U
M:&ER=G%R9GI$1EAF5B8C>$$[5R]M1TMU*W%T+TU-5F0Y5F(K65EQ-S9Q,SAW
M>%8S,59V-6AI<G9Q<F9Z1$989E97+VU'2W4K<70O34U69#E68BM967$W-G$S
M.'=X5B8C>$$[,S%6=C5H:7)V<7)F>D1&6&965R]M1TMU*W%T+TU-5E8P:FI1
M:V]O57-A<U%!2VYR=FEQ:&4R8U8T9VAL3')'<DI)=U)U26-!;7-B9R8C>$$[
M9F%2=6I+4E%J1D)204%!;T)18FYB>$\U>%,S:7)S5F181EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867%T:VI$.&%K:FEW66-34E=N62M)>%9D:7%N3GI%
M8G9'3U5I;S-"2S=%,'%+:C9-5E$X9"8C>$$[,V9'5EDS<WEO<4$P;DU5;U)U
M8690=%A&559(14DK5D-X-4U74$EK-VYW<C!'2W5K5&Y'>59+.&=2>54P27%+
M5D)X5F-!04%",$<R-28C>$$[<69V3TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMV.$$O.6L]
M/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY-:6-R;W-O9G3"KB!0;W=E<E!O:6YTPJX@,C Q-CPO<&1F.E!R;V1U
M8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C
M.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/E)O8B!7:7-H;F]W<VMY/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \
M9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @
M(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E!O=V5R4&]I;G0@4')E
M<V5N=&%T:6]N/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%10
M9SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=$1I;3IW/C4Y-2XR-S4S.3$\+W-T1&EM.G<^"B @(" @(" @
M(" @(#QS=$1I;3IH/C@T,2XX.3 V,C4\+W-T1&EM.F@^"B @(" @(" @(" @
M(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X
M;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\
M+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R
M86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N
M8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS
M93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!4
M4&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L+4ET86QI8TU4/"]S=$9N
M=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI
M;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%C93Y)=&%L:6,\+W-T1FYT.F9O;G1&86-E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N
M=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3
M=')I;F<^5F5R<VEO;B W+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC
M;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA
M;64^87)I86QI+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI
M;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R
M/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&
M;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O
M;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L+G1T9CPO<W1&;G0Z9F]N
M=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @
M(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3
M=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R
M;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C)%,3%#.3$Q0C(P0D5#,3$X,3<R1#,Q0D%$
M,# R,$0W/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z
M9&]C=6UE;G1)1#YX;7 N9&ED.C)%,3%#.3$Q0C(P0D5#,3$X,3<R1#,Q0D%$
M,# R,$0W/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,D4Q,4,Y,3%",C!"14,Q,3@Q
M-S)$,S%"040P,#(P1#<\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F
M.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C)&,3%#.3$Q
M0C(P0D5#,3$X,3<R1#,Q0D%$,# R,$0W/"]X;7!-33I$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C)&,3%#.3$Q0C(P
M0D5#,3$X,3<R1#,Q0D%$,# R,$0W/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,D4Q,4,Y
M,3%",C!"14,Q,3@Q-S)$,S%"040P,#(P1#<\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C)%,3%#.3$Q0C(P0D5#,3$X,3<R1#,Q
M0D%$,# R,$0W/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3 R5#$Q.C(S.C$W*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HR1C$Q0SDQ,4(R,$)%0S$Q.#$W,D0S,4)!1# P,C!$-SPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TP.2TP,E0Q,3HR,SHR."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP
M34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA
M<W,^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E
M;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_P  1" $4 E(# 1$  A$! Q$!_\0 '@ !  ,! 0$! 0$!
M          4&!P0#" (!"0K_Q !4$  !!0 "  ,$! <*"P4( @,$ 0(#!08
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MQM7W?)7"G!.[C.#BY1]N];1WL>/M]OC\_O64K;VSZ_MM?EV;"D#;4)>&K9U
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M(V:UM6]D<5G0"SH3"-#UE #N5AN9<J20&4 D9*C.-PY7*GT)E)8')&UE.T,
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M:68-F:6\KFUE&!=V<E[&.$^%ET84/2#!0MEE6W]X@KK&>QL*UY%/5D0P53K
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M#: 9N3+OQ?7-@W&#&VY6EBJ_.,'519XZ'&48G:ZEO*&PU35XR% <@MG<PW$
M#/<QX#<X8 !D95RQ7*V"P\,3L!QC:IV\EL#M)JV]CJUL,_C*@;9TP).-S'>
M(LSL^077G:+LOVB>GO: SQ5G6ML W&4(1W52T6OK$+'*O@[PIPQH;O.YP:@
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ME "C"L 3N.[[V ,!2099+7'+J/N\*IP2'5B222P)"[5QRN2<DXQG.5]C+15
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M-/DQB8AZ^S=7ARJ,#8<E25*HQ()*G;O/; !(P#R6(DBEB4W,I\/@, 0S  @
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M7EU/C\]-;7.7G"@K9\W:V,E<XRQH)JX48":G,FFKI AH!7CN@ACC:WO@#>V
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M(OCGHG6/A"WH_B]5NU^[3#0UG3WZ&C2K1U76:QUUIHZ[=TCJ>E72ZN[[&_\
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MU>!">',CI(VMCDK)HXX(O.QR^F5$=)+&C7,*9X.\^\?U_P#OK_#Y0/KG\O\
M8]CZ9Y^<_F@O3*8_-00U\90=S:DUYY;REBD 9%3V-E HPK89'&3DR K%Y7/'
MBBB261TKI?1ADU5#;N<$#(]CR!R?0<R68KMXR"<'Y<$\#U/$RH+M^V,K7'?!
M AYHLQ8;N8,B0^&?Y9KZVAL4&A1XZ-ELCVWB15Y37J/)[B0I804Z^Z,LU@'&
M3WV9XQNR1[]ACGU&>,R!82,X&<;L<CRX!]1W.>/0XYQ+KG=W-9R&K8USX1_A
ME5=UZU0MG;E(!<66@KQA3A 0R9VFP)0K.3+#'[LUQ:C>"*(LY,LFWL<\D'.!
MR I..>WF^O$I7+=QQ@$8R>"6'/SX^DO5;9"6PC#@7R2#OE*@\9AB@YF3A%3@
MEPRBF0CE0R0%CSPR,FA8Y'1JJ(K515D@@X/R/YC([?(RP0>1\Q^1P>_S$[N9
M-CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB1-[_)!W^I_WV<1,EXB.(F@:]*M
MPPD-_>,J*0Z=P!,<L5>P8Z>2&8F* VPL1R8@1WQ"SL8Z+W.>0I\$4)K)Y(8I
M-'R&3W^GX>OI[_28?3)P#P>W\3Z=CV]Y8*F*NAK 8:F2.6LB%AC DA*<;$\5
MC$;"L9;Y9WD,\B)Y9732*]/I5[OQ\P]SGOZS1V&.WI)#B)&75Q79ZHL[VW*'
M!JZ@$JRL"RB!A!QQ0X7SS2S$F3#BP,:QB^,I,\,+?H625C?%R "3@#)/  [D
M^T$@ DG '))[ >YF(]<]S]8OZTZ](BV-*:27A\T0/24AP^IT<[&TXC'H)092
M2\M;%S7L<Q?AHIC7.3P8Y_BGC;(P9@5(PQ'(*@'/J3C'XXDJRE5((((&""#G
MYC&<CYB6[]T*_M&-?E>L]<</*K4BMM7[AU_5(B_2Y2@=#.FZ%\B>'CY\._S*
MO@Q55'>7,#U8#Z<G\,>4_P#5-R?0$_P_///\)\J[&R[>LO:WZAJ)NP>M,-4V
M/76[C*SE&^KT^Q9&XNO?,^EN=1G@II";"86IGCA^7E 8RF.]8<SP\S.P1? =
MQ78VUU'B8(K7.>&()&3R!DYR1CU$\;ZNE=;3I#J],EUU5EE>E-M8U-J5_>LK
MJ9O$9%P=S*I4!6R>,CZG)Z=REN(4/KYKWL%YD$\)2;B[.M:DA9V/8KUR84E9
MC1'M1ZHV2LSH$L:?3%(QZ(Y..XCMA><C Y'T;[W\9[, ]^<\'/8@^A';^$Z^
MG^LZ3I_KC+==Y\"E !SM<T:1F?JUI:LNPE>^>RLX:QQ1SA);,V28XF-2Y_\
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M?,9 %[<0:2ZLL/7[^ >*Z*0@@NS)Q<H$]>.5[O&L(\%*&OOD,(*\[*;FPS[
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M%T39E;9[-?5'557U8'>;P;(G@BJCD_S<LC"+V^\QX^B=_G(!R[=_NJ.?J_\
M"6[D2XXB.(GRS[9&$([-Z*O<&%M=-@[#1V^>'"N\IYGV;D!LHK>R&F&8?5O,
MK8Z2OM+&Q%99 K(-7O59U:QT,O?3-LM5BJL &R&[=B!S@X.< '![SAJ%+U%
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M!/L,RK=47T6APM.1%1/S"5DEGF79^0PH^2J7*VIN=C@<4<%6GRMF@K(BX5/
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M1B4,>WT/-'5.&-"*;<R-94N%-#)::L!0\DE;&]NPSZ?EW[\'COP>.).]??\
M7/ISCOCD<]L'.<29K+^GN938:PZ(N6OD2,IC&R-5GFE(@9-'ZK&(0+).(8/$
M8.LHDI 9D$<SIA2&1X01C(QG^OSP0<=\$'U$T,#G!SCO_7X'M[2/R/\ )1?]
M9]M_ZSO^:W<?NI_V+,7L?WG_ .]I9^3*CB)EVILA=#HLMBQ5FD?#JXKS11/&
M(&]*LQ(8&G&G&(GA; 4V/5V/7\1"#/D:\6RFC1[7,E].U! 9O])4?5\J>/3R
M[\9]I#$$JO\ JW'TX3#?]VW\#-1Y$N.(CB(XB.(CB(XB.(CB(XB.(CB)$WO\
MD'?ZG_?9Q$R7B(XB;AQ$<1'$3RG@@*@F&)AB(&(BD@('GC9-!/!,Q8Y89HI$
M='+%+&YS)(WM<Q['*UR*U53B)Y @@U@8]?6ABUX <38! 01X1 Q8&)X,A'&'
M9'#!$Q/H;'$QK&I]"(G$3JXB.(GG+%$1%+!/%'-!-&^*:&5C9(I8I&JR2*6-
MZ.9)'(QRL>QZ*US55KD5%5.(G+6UE;3!05M17@U5<*US1@*T0<$(9KWND<V
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M^P8> =CLUDG.;!%'$USOBFT3S*V-K45W@B)XJGCX(B?B3F$DJN3GS-W^B30
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ML$,Z6%%HJQ*IY:".KET+K&I%;F8[A+ 'X'+H5K(KSWL=*AYJRM\?,G6^F.5
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MKFN\_I*TE(6>[TQ!_CG^MHDJ"/I@=_Y9(_3Z30^3*CB(XB5C(_R47_6?;?\
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M9FQO!("Q[Y(+F:M8=8)%;ZA69B X4C4C:<8S<7*\ XXW+G]WC/$A:&"J"5W
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M[#Q]916=A9V9N9,,E+(MH34(-Q?>S%K3D^;BQ-HQFQ0N/\WE8D<9 X'1Z&.
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MHZ>F]?X56!5WO/I^O[H/'!ZWH^IZ7J>1J>;T_5D\GC_B^=WA^->"2>Y)^L8
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M+G)679A5A$O8DIQ)MR%H#*JU%".?G)R\X$<.7?55GEE#T3'8_1X?3XQI*D#
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MU>L3[5ISJ:DIJJTXMZD.G=,-H34VZVMJM?<^-!8HJ.X&?3X4\I(8A) L@,Y
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MFZO2$@0N7RCS7=B]B(I#_'<G 7)P"2!Z L "?J0J@_03,#).!D@ GU(&2!]
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MDPY%"%(NXLK.45,Y)(3$J0OF5XL9$X(HY)@/H-L&SRS#A]?#'N3RPP!SQN
MXP3QG&<X/;U/'Q#P" .%[GL3MS\\#)&<8X[]P+%C^PBM-$5/-22PK&($6E>"
M_P!ZL0%*L+RO46SCF45L<KFTS+"%R-B5PMA"ST7)$A)&,FT@;AW(R> <!3P?
M^;'X?/ I7)SY3V!P.2.2.>W/&?H?QFC F06(0=@,KE&.%','5[%C>L!4+)XE
M>QW@YCEC>U7,<GBU?%%^E.01@D'N"1^4L'(!'8@'\YU<R;'$3CEL!(#0Z^69
M&&'QE2B0^215FC"2)2G(]K%C8D23P^/J/8KE>B,\R^*)N#@GT&,_CV_2274.
MJ$^9PQ48)R$QN)(&!C<.Y&<\9G9S)4<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1
M'$1Q$<1,8-_CA?\ 29_[5_$2V8W^$L/Y@W^U-Q$O?$1Q$<1'$3+JK"8H'MS6
M[H+)Y\3:VV0RP5KK1ZH2+0V0+SKX= CK1D:%$BQQ456R.*1ZHUHD+?I;'&C.
MA9C6J[CM#-A<\#A3G'U)G,*HL9MHW%5RV!D\L._?L!^4U'G.=(XB9GK>GNN]
MSJ<WL]10.LM#DT1M,4EM=!#-;&0I@K;&L L1:RY2N.<X^J2W#.^%GN<8![N0
MYTB_)UO0^F=0UFEU^KTQMU6BP*'%^HK3"N;$%M55J4W^%83;3XZ6>#82]>UB
M2?U?1OC;XF^'^D=4Z%TGJ(TO3.LDG74G1Z&^TEZA1<=+J]3IKM7H3JM.!IM8
M=%?I_M>G HU'BU *,=[\]EG.=OX'29:O-LZVRO8*J!Q1VALBO-#57 %M",VV
MM1M+95PC7!(Q@(\!5,J.\\E,\R,,X'X?Q)\'Z7K?3=5HZK+JK=0M*E[-5<^5
MIOKN5!=>FKMJ0&L 5HKT'N:#8*[*_P!M_9U_:YU/X+^(NF=6U-&EU6ET%FLL
M%.GZ;I:=MFKT.IT;VG1:.WI6EU5Q&H+-J+;*M=QM37+0U^GU%]Q?3=CC,Y04
M-;VGV&/#1YK-T$(*%YNSIH?EZG JFR"17^8M+2*$SW%)BHEM?,]9IEB>.Y[5
M9]'0="MT&ETVFJZQU-5T^ETFF6L/I+:%^RT5TYK&HT=MRK9X>YU-V3N;:4)&
M/SW7?CC3==ZIU+J.J^$?AFU^H=5ZIU*S4&GJFDUUG]YZ[4ZPK>_3NK:32/91
M]H*5.-'M45UAUM"D-7?9AZ<[ Z4Q=_G.P^SB.T;.UU]IH ;2<6<?X< ; '"T
M)KBYR2G/GG&E/GA]7W,.8IPX3%8Q\\_F^$>A=2Z!H-3I>I]7?J]MVMNU-=S(
MR^%78J+X8-C.Y+,AL9=VRMG*5C +-]+^UCXW^&_COKO3NI_#7PG5\):71]%T
MG3=1I*[JK/M.HT]ES^.11534%JKM335OL\:]*A;>0S+77]!V]>RVJK.JDD=#
M'9UYM?)*Q$<^)AHTHSI&-=^"YS&RJYJ+]"JB(OT<_2WU"^FZDDJ+JK*BPY*B
MQ"A(!X) .1/YMHM2VBUFDUBJ';2:FC4JC$A7:BU+0K$<@,4 )'(!XF>7/5-)
M=?"Y")U:55=<ZCKH<SW,9Y"":86C#=:I(]/,PVM'J3(0F-7R,AO;:)',C*G;
M-\R_HVGU'A%FP]/2]7TM;/#0OX>K33H;LGD65+2ZU@<!=1>N0'8-^ET/QAK]
M!]J6JO-.K^)^D?$]E'CVK5XW2;=?<-&57AJ-59K*'O8C<7Z?HW*LU-92HE^S
MIC3G' $F7$>8/0DR:AKK ^H(2_+RSL5+:-T-8:+=2!,SA%D,/0$D$5D!=Q8E
M-8Z.2 4?PO\ "VAM-E;V7C26;[&TU5MM#?:7T9T#7?:J;4U!K&E>U4TK.U*/
M?:X!!1$^U3_:=UW3C3ZBJG1-U;3>%0G4=5IM/K:STZGJXZ\FD/3=71;H%O;J
ME6EMMZC557J[*M%I:BP9;+;9JXZE*O&U 5CKC[*DB87/I*FZCM;>.^NSX!QB
M+T.0C1-BH) XXIYL]2#"EY?.V):VU?1ML@ZXD3T7]%?4"BNW6V6T*';54Z@7
M7#4ZBU41]166U073&L!FTM"I9I-+:_C5:?Q4J=/!H?C*KIYUM^FZ-I]+KW:F
MOI>LT+:/1-T[0:>RVVOI]ZU],9^HI>SUU]2U]MU/5^IZ6D:/4]0.EOU-5T*_
MHAA,EQ.?K"")]7+F9==)#3CC-LW89*A<:ZL8ILR4S@9:0.6Y5RV++ITQK((Z
MF.09H? _#H<WM;K&9M8=*=:5H1!<>GBC[":AXC> :VTZ-?\ _:+\N%%(*;/>
M/[0VJ71)INCUU5]'3JJ=%5]=9:=(.OG7?WX-6W@5G7+J4U]R:$ :5M"$H-C:
MQEM-V@=<8=V HDH6DTI(\2"M@?3Y^6@\Z#!PAK,=')=7*%F3,'B60B-PC/P?
M*D'AX*GTNE]//3=,--OH=5V!31ICILA*UKS8IOO#N0HRP*#TVS\W\4=?7XCZ
M@>H^%KZK'\4V+KNI)U+:;;[+PFG9-!H330C6N%K87-SDV>DT'GTY^;CB(XB.
M(CB(XB.(CB(XB.(CB)^)(XYHWQ2L9+%*QT<D<C6OCDC>U6O8]CD5KV/:JM<U
MR*US55%147B)BO0W4G7/3V3N:+K7)U62JK+;;"S/#JH$B84?#?&TK")557/5
M6U]2%!%"CD'&CB; )".,R."/K;8]C NQ8A% S[;0?U)_WYG*JM*U(10H+L3C
MU(.W/Y ?+VP)MO.4ZRM7>5K;F>*Q;(547PL2PA:*GD8+;C1>9TB#22213BV=
M?ZKEF=47 EC423>6>0%TS(Y&>2_1U7NMH+TZE%VUZJ@A+U4$D(259+JLDL:+
MTMH+>8UE@"/JZ#J^JT-;Z4K3K>G7/XFHZ9K4:[16OM"FU55Z[M)JM@"#6Z&[
M2ZU*\UKJ!6S*V!]::KVFTVG:PG:O7%+-AZG1#A=7V>1LJ*&[T%%ZEBQ]J:-9
MZA@KFR!PU)149;J,H8\XL84,N&!6"_G.DZSXM^W]93K'2].W3J=4M?2+=%;I
MEU&IT^ZT>-8ENL"$&M:'<6?9G2RQT5'"E:_Z)\5=(_LI/0OA"_X0^)]?7U_6
M=,LO^+-)UK2]0LT'3>H;-*PT=%NDZ2UH*WOK::FI'4*;=/IZ;;;Z7LWW==_[
M5'7.5[=Q?2VFK=A0ZW:T1^@&*LJ@*&@I@@6W#W?&[9EK+'&V5E%92(96QV=6
M-%'%*<>+#(LC+U/QATO1];T'0=75KM/K=?I[-2C6T(--176+S_CW"X@!AIK3
MXE(NJ10&LL13N''IW]D7Q-U?X+ZY\=]*U71.H=&Z%U#3]-MJTNMO?J.NOO.B
M4?8-$VC1V*-U#2KX&J;2:NUF=-/I[K%"-MA6ZQ -4EZ;LLJ'1N*'!;<E:&H'
MJE-+?Z8H:6,IC U*)D_ ''2;U9G_ (,;'.^CGWWZCT^NG[39K]&FG+K4+WU5
M"TFQSM2OQ6<)O<\*F[<QX )GX2GX>Z_J-9_=U'0^L7]0\&S4?8:>F:VS6>!2
MNZZ_[*E#7^#4OFLLV;$7EF EI145$5%145$5%1?%%1?I145/H5%3\2\]G?M/
MCD$$@C!'!![@^QE$N\0#?ZL2YLQ:TZH^2M;D;2L,&;,ZQBTQ^7F<V5',6.01
M J0P0B.1WF>TQC&HK/4\/G:CI]>IUB7VI592=!K=%=2Z!C:NKLTC'.1@IX>G
M='!Y(< 9&<?H=!U_4=.Z/=H=);JM/K?[^Z-UK2:NBXUC3/TG3]6K!3:P=;OM
M&OHOJ=1A30S$AMLQH[V?#RZ((!-+(ZPCQMC47TY)9Q4>VO;.XJ[2R^:SR&37
M)5-<BU[Z,R<,T2YKJN>**HG&0$*.#X5GPU:^FKJ&K/BKH;:=2SO8XZAJ+KZ;
MK1K;&4ZA]/>E1T]C5V)J*J65:&055A?W.F_M)TU'4;]3_=2C3-US3:WIU=5.
MGJ;H/3]+HM7I-+_<^FK9-#3KM#;J5ZA37=1=H=5K*W?6UVG4ZAK+5F^K-50:
M:\U";6=Y&R4FQUH,8=.\>2Q"O23LS5UQ!6?GG=2B4%M996S//;+>SUE7F4!(
M#97N@3UZ3HVLTVKU&K_O!BVN+VZZL)04:U-0UFDIJ9]*S&A--=;H[;+=VH--
M.D%;(*RL^/U3XNZ1U'I73^D_W#6M?0Q5I>C:AK]<MB:6_I]6GZMJ]373U&NL
M:^[J6CTO5])I].4Z?7JM7U8ZBJ]M2+)2X.C]69 (^R7)TMD:8,M^1GK ^4("
M&ON.L[.N,Q=?\L4L-(T*LZXK\J#1/\Z"!"4UV9HKBT$/ALO"O0-;8J&TZ.BZ
MRQ?M+:6RPUU+7?TFVI]!5]DH6@5T]+KT=>G.=E:T:BS57W)8MOW;/C[H]%MP
MTHZSKM+11:.G5=2TVG2_4/J=#\5Z34T=<U7][:^S7F_5?%&IZOJ.HC:;M1=K
MM#1TS0Z2[3/I?!W1FN4.P$\N&<S0Y+28RQC=/:*'GA;C)]69$2ZI@O@2_%R(
M(>NI[9U/.101P$6@X$5S.T)]D3'_  ]KO#M3'3L:K1:K0VJ6N->F6_1=&T5>
MHHK^S?X[J.EM>:';3!6N2M;VV&U^@_M Z-XVGNS\0 ]-ZSTOKFF9:](+^IW:
M+K/Q=UJ[0:[4?WA_\*MW^)Z]$-=75U%K*]);J6T%9U"Z6KZOC9Z<<<?G?)Z;
M&,\\CO-(_P K4;YWN^CS/=X>+G>">+E5>?LP, #). !DG).!C)/J3W)]3/X\
MS;F9L*NYBVU1A5R2<*,G"C. ,G QS/WS9,<1'$2)O?Y(._U/^^SB)DO$1Q$N
M'8RQMJ:U\S1I!H[J!Q,!25,K"(EK[)C8VAW=E5UISVSOAF]WG)<Z-D3S((G3
MBQN92]SW[<8SGN/8''Y26. /KSZ^A],C/]'TEGSSH74=4Z"..&%0H%BBBA"'
MC8SR)Y6LAKB"P8FHGXF"$SP-_%'(YO@O,/<_7^O::.P^GTDNK&+X^+6KXIY5
M\6HOBU/Q-7Z/I3_N_%S)L_J(B*JHB(KO!55$1%543P157_/X(B(GC_F3PXB0
M&2_R5S/]7Z;^[AN4_P!]OWF_4R4^XO[J_H)8.3*CB)4[%K5V>7<J(JMI-9Y5
M5$54\2,OX^"_C3Q_S^'X_P#/RA]QOWE_1YS;_P"VO]VS_P#XELY,Z1Q$<1'$
M1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$Q@W^.%_TF?^U?Q$MF-_A+#^8-_M3<
M1+WQ$<1'$3*9QM*N^]:%+A(_BRR0S/G/7-)D/D8F!!YX&3-JEL4WRPD/C]-+
M]XJQRQR_"HWHSIQL].WRW;MV?;.-GK]W\9S\V_C=WX[[=NS\L[OQ]N,SK%9L
M?FZ\\)\UZORYE?.JB6GD\GQ/8^FC4]]\R/1WJ^=5545%C\J(J.51V[1][[S>
MWLL>;<?N_=7W]WEC\FT^L9?]3MO^>Y/D_P!7\)7G_P!/\9XDKNHAB)8%S!4\
M4$LD(R#V<2D2LC<Z.!)7G>2-9GHD:2/_  6*[S.^A%X\G^K^$>?_ $_QGZA^
M>'Q1/EDS$,CXV/DA46T>L3W-17QJ]IWE>K'*K5<W\%WAXI]"IQY/]7\(\_\
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M.TZO>=3_ *'H/_$MC_TIQA/VF_Z1_P"<W+_LK_U'_P (]YU/^AZ#_P 2V/\
MTIQA/VF_Z1_YQE_V5_ZC_P"$X*VXTME!*1'1T4;8K"TKU:_2GJJOJ[(JMDD3
MRY3P\DL@CI&(OTHQ[4=^$B\$(/\ ,WI_E'J,_MP"Y_RKZ_YCZ''[$[_>=3_H
M>@_\2V/_ $IQA/VF_P"D?^<9?]E?^H_^$YYS];$\5C,]23M((]&5\>F.1HL?
MNY$WO$OFRJ*L?J0QC^#/%WJ$1KX>5'*C"<^9N/\ 2.>?3S_C],S"7X\JG)Q]
MX\?,^7M.CWG4_P"AZ#_Q+8_]*<83]IO^D?\ G-R_[*_]1_\ "/>=3_H>@_\
M$MC_ -*<83]IO^D?^<9?]E?^H_\ A/6CM"+48J0H2$(@2R/K9H1RWFPJ\$AT
M/JQD2!@O<V5$1_E<-&K%56>+T1'KC #&#D$ \C'?Y9/ZS5).<C!!(X.>WSP/
MTGI>_P D'?ZG_?9S)LR7B(XB7G;Q2SC5C8VV,?NMBAWO (M^2JJP,P11G/RL
MC;\1\C3%E2<9(QGLA>*7*Z$AXT]+_7;_ 'X/X^^?22WI_P#OL?;D?A]/63U!
M*^6K%\\)D2Q,;"CCFGLF(1C&^,Z,MYI;A&.<KF(MKZ9SG1N?(Q6.CDDP]_\
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MJZ=(OW/8Z%\+7%D^;77>BJ#9[-AI]&$CVNIF05XK#QXVSSQ.F.)4A!(NBJI
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MBR*^$X.4\3P]Z"B)@D+&\T<$S?>!FO6:'QA*%E3U&-\8R8)$_!FC5V8( )!
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M/N .<  DSL@[WH21%D@S>NFLVPEENH(:V"6Y0$ V\I3+! 6%K.\<?34).=?
MR-UI\0+K?+7.8;&O,-# X+(!P-V3MR0I SC@[6#<X& 3GB!<I[*Q/?:!S@9!
M/T# KQDYQQS-5S5^+J**NO0XWPP6$3WH/+,)-,--#-*,2*0\$@H=I(I,,PY$
M*3+*//'(.3'"3%+!'S92K%3SCUYY]0>0#VG56# ,/62)5> =&1":"&7$9#&,
M7$4-"1&4/$^22* ADK'MGAC?-,^.*5',8^61S6HKW*N D=B1CMB" >X!SWS.
MF**."..&&-D,,+&1111,;''%'&U&1QQQL1&L8QJ(UC&HC6M1$1$1$3F39^^(
MCB(XB1GP6F^)?&?A-9\81OE2U]P%^)>7T?=_+[]Z7O7E]W_>/#U?#T?WK_$_
M!YN3C&3CVR<>_;MWYF8&<X&?? S[=^_;B2$<4<+?)%&R)GF>_P D;&L;YY'N
MDD=Y6HB>:21[I'N\/%SW.<Y5<Y57)L_?$1Q$<1'$1Q$<1'$1Q$X@:VNJX7CU
M@ 5= ^:0A\ (L D+YY?#U9WQ#QQL=-)Y4]216J]_@GF<O@G-))[DGTY.>/:8
M !V 'KP,<^\[>9-CB(XB.(G#7U=94Q2055<!6PS3O)FAKQ!PXI29$:V0B2,:
M.-CYY&L8U\KD61R,:CG*C4\-))[DGTY.>/:8 !V 'KP,<^\J.XN[VKGQ==0%
MTH!6HU<]&2?>59EN(&&-C=?IG21A!7>?D>1*1G1A6O?8MBCA(F<L,DGI^6D5
M2'+ G:H8!2 22Z+W(;]HGMWDN2-H! W-C+ D ;6;L"OMCO,N#[]8QE:,;GI[
M4R=-&',;G?>9:^PL<W6;*\]6I8^ H5@FAH,63=489MW\6F'N:7T!;"NFFNH^
MIH/)# #"G#<$!BB\]CE6?:Q"XRI]<"<_&Q@%23YAQV)4,>._#*A903G!'?O+
MA1=NUM_I:BC#JBVUU\PY]+H'2NDK[5!WZ.4*4&> :6ND@MJC-$WM?%+:0VIE
M26)8A51=;'8G 0U152Q(RN-R^H^[G/.>"P4G& W!(. :%@+ 8X.<'/?&['IC
MD*2.<D<XQG&MO8R1KF/:U['M<Q['M1S7L<BHYKFJBHYKD54<U45%1514\.<I
MUG"RIJXS6V4=;7QV+!&@,/8&,PU@+7(YH32FQI.T1KD1S1TD2%'(BHQ%1.;D
MXQDX[XR<9]\3,#.<#/;.!G'MF2',FQQ$<1.*PK:ZV$E M0 K,&96+,%8"P&B
M2K%(V6)91B8Y(9%CE8R5BO8ODD8U[?!S45-!(.02#[C@S" >" 1[$9@2LK0(
MA8 :\(. &*2 *$02 >(.&56NEA%CAC8P>*1S&.DCB1C'JQJN15:G@))[DG/?
M,8 Q@ 8[<=OI.:]_D@[_ %/^^SF39DO$1Q$NO8,2/J IE(#@42V@(:EA/# '
M,JB'#^E,Z:]SJ.^B=98VQV;)$FBC?Z4K&/:E+W/S&/ZX/Z26[#Y'/]<C]9.Y
M8IIN=IBFHQ&S@0/1(VJV-/%O@OI>)UHCH_%%].1ED?%*SRR1%D1/9*Z3W/\
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MY$5CX QHW(]'?1"Q4\%3QYPW'D9^\03\R,X/\3^<^AX:[D;'F0%5.3P& !!
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MIU%K>#6%NU-A"@6DG<>>6?=CB(XB.(CB(XB.(CB(XB.(CB)C!O\ '"_Z3/\
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..B(XB.(CB(XB.(CB)_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g189651g08h16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g08h16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5B):'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E5N=&ET;&5D+34\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@
M(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^
M1FEL92!.86UE.B @(" @(" @(" @(" @(')I9&5R,3$R+F%I)B-X03M5<V5R
M;F%M93H@(" @(" @(" @(" @(')R,3$V,#$T)B-X03M,;V-A;"!4:6UE.B @
M(" @(" @(" @(" Q.2U!=6<M,C R,2 Q.3HP-CHP,B8C>$$[15-4(%1I;64Z
M(" @(" @(" @(" @(" Q.2U!=6<M,C R,2 R,CHP-CHP,B8C>$$[4V-R:7!T
M(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N
M.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R
M:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E
M+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P
M97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A
M<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I
M86Q-5"8C>$$[(" @(" @(" @($-O=7)I97).97=04RU";VQD350F(WA!.R @
M(" @(" @("!#;W5R:65R3F5W4%--5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG
M(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @
M(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C
M>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @
M/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P
M,C$M,#@M,3E4,3DZ,#8Z,#DM,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 X+3$Y5#$Y.C V.C Y+3 W
M.C P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E
M/C(P,C$M,#@M,3E4,3DZ,#8Z,#@M,#<Z,# \+WAM<#I#<F5A=&5$871E/@H@
M(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3
M-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4
M:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$P.#PO>&UP1TEM
M9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*
M4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=)
M;6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV
M9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[
M05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"
M055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$
M07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W
M8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!
M04519T%B045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%
M04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!
M04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'
M06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[
M571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P
M=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L
M85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP
M<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%
M1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA
M4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z
M=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7
M<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[
M*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!
M44%#15%-4D%$.$$Y531Q-T95;3%N>F@U8S!7-E<Q,28C>$$[3S<K<GIU9VQ6
M4%1L97%%;%%A;W)$<7!W9TQA02]W0U9M*U-0*W)L+WE1=5 K<6500U57-R]L
M6G9K:B]Q-68X04I#-"\V<#0X2E<P8B8C>$$[<&YN5'DQ<6MK:V5N,UIU2DEL
M.5(P5T=93G@U0F%G1D)88SES851A:&5F;48U4',W<5<Q=4Y1-%1W35DU53E+
M6G%-<&]25E5)4#!9."8C>$$[2E)A:B]W07)..&MF.5A,+T%*25A(+U902&A+
M,FE,2'HO=T-5<BLX:7,W5R\Y4S5N64I%;G!43%9J,G%Y05DX2E1B24U#=7A6
M,DMU>"8C>$$[5C)+=7A6,DMU>%8R2W5X5C)+<EI:0D=H8SE":7%7;E9,<S!A
M3S%D,%E65FAX,T(K;D-R6#94=B]!4&QJ9C<Q+W)J4TQD*VLW+W=$-28C>$$[
M63,K.68V-#!T=2]39"\X03AS8B]!2'(O049X<&)D*VLW+SA!-5DS*SEF-C0P
M='5'<5@U-E=B+V5V.6-A5S-F<$\O.$$K5TXO=E@K=28C>$$[3DQB=C!N9B]!
M4$Q'+W="-B]W0F-A5S-F<$\O+T%/5TXO=E@K=4Y,8G8P;F8O=T1,1R\S<B]8
M1VQ29&YE=$]74C!-8VDO854Y9#DK,B8C>$$[0DMU2C1384(Q*SA9<3):66@Q
M9%(Y27A6-7HU-C!J5F(W>EAB6#%L<'@Q0S!I=%9I96A11&U*2D=.3U(X1T=4
M2$I"4U$K6%!-5&DS5B8C>$$[=DQR3$9&2&-*3'=-4$YJ4'HT;FMA+S-98U4R
M-UEB47!1*U<O3E595D)O2F16:61!1SE!:T]70FIE=$XK25)14C,S.%1J659D
M+V@W>B8C>$$[=&)J;' R:WE7.&MK36-&,%0V1$)H17%!8U)487)*>5!J6$=W
M<4-V9%5V6#%3>G-B>E1!*W-24W5T-&=33&Q02D]344-!<$9F:D9-5B8C>$$[
M5$\S.'8V-T9(8BMV-5IA5C19,FID=6-).50Q4W!C<U!%9D9W<#!R:F%66%-F
M3&UV+W O4EHS,&@W3T-Y2TI.3'EI;W=604,W8V%(:R8C>$$[4T0K2'53,F@V
M=VE!1#)Y0U8Y2V1-0U=G,5-2,T=+=#1Q-T9867$W1EA9<3=&6%EQ-T960RLO
M,VQK*U)X5D,R2"LX3G8O=T%9:R\T:28C>$$[34M'2'I7+S5Q>E@P<E<Y,V$R
M,6=B<3573DI647EI04]207=O:D1D845!-RM09TIB23-3-C1T=GII:&UH:6=U
M25IP<FA36C=R.3!B928C>$$[37%G;T],2GE(>%9P>%AF=FIS=3=5;6=F;3@Y
M:&-W:E9O1FUN8T5.-FI!<CA64U5D67=5031J665/*TYH1S=03D985E4P=3-8
M5EA35"8C>$$[54%P.61O+W-K,4Y/9U56-#!R44%6-EI%<VM82#EK+TYV,6Y&
M5TQE84Y..#E83W!3=&]6.49B5T5L:UEI:FMH+W).6DM-=G=0>$9(2"8C>$$[
M>$QV541#2U%K3VY7;C5Y+U4U3%DS34U5=&UQ45%Y,TAP=4II<%5E;T<T3S=!
M<#%,-VLO8T1S:F1E+VPO.#)21&)2<'$P5$Q'5F5C*R8C>$$[;U$U9%EW3FU-
M6G%'87168C1F8D=W;F1N.6=T-G1H8DQF36HS;VE16%1X-TE:46\U;&$Y=59A
M6D9+,GDO-#9D,2]S4"M):D958UEK028C>$$[2DDV-'%P3$-R35)4661C5E8P
M:59244-G>%9D,"M70DLQ=5$S5VQF9D-H6C8W:C=38F5)4#EC85-W2'E0<'1V
M9F5:3E@X,%0P35IU6B8C>$$[;SE0-65(26=Y9CA!02]#4'!Y4C=K0FYK8VE3
M+TAY0D(V04=T0FM68DIQ.4(R>%9656UN5$%L9%59<71+,4YC54Y(9W8R;4$K
M6G=Q<R8C>$$[83AG53 U<E@U:D=K<7%S1T91831&8GA6,DMU>%8R2W5X5E%V
M=CDU6E!K8U9134US:U=M,C=X=W9C3C9A1# T>6=B-TDS+V5-:2]J:"8C>$$[
M46Q'<"MC4#!F9C)D<$Y94U)V9$UO<$Q*17)K4$EK43E*56%4,5=$4U9+9V=G
M8C1A47E,06QJ9FPW>G!"<D]P3EI2,B]P:U)35&AH2R8C>$$[<FM+:F]N0U)1
M2W!*.&1753E-2D-,6DIG4W1J*WEF;3,V>FEQ6#9V<5=O5VQR9%!A86).9'EW
M>$TX4E5X.$A93%5,5&XV<#,R,E-V:"8C>$$[:$-T95A.4G9D43 P6$8U14DU
M4%5D1EI5:VE74D9.1FM73U@T,$1E1%EL5DAZ42MU9E4T24Y%;5-'+VYN4F54
M;$YO:%5Y1VIQ+U%E0R8C>$$[:S1H0V-G54%"3F%D>C,K-T%L1%=8+TA5=78X
M05EF.$%%4FEQ6D5623ES0U<V1$951')L-V573VLS3C-:5W)8=#%%;TU6<W1A
M<U-13R8C>$$[:6=K,$)R46)N0T=-:E%96EEF;35:1GI"<75N>3)S>3!$;45I
M54$Y>7E-235&*UA%-4QG-VUK86=D4E1,=$<X>#9(<D-V*VIB=$HR:B8C>$$[
M04UK9GA*26]047-J:%A!*VI):U4S4FM*8VPO;4,T;'1T2'5P64%48T905'1G
M3W!M;$EJ:4@P=7=X0U904SE(:3!V4V)F5#1I4%1T-"8C>$$[=VAB>% W5&8W
M2FE4:'16:5)3;6IQ>%4O<SA6<68T1$%Q26AV23$R;'%J:G)553-X5DDW-WIW
M,7 U=71D0VMT06M&,'%H3'1M3F5C;B8C>$$[3&@X24A1<VY$<C%W.$\Q<T1K
M<5A#>4XW:&LK,FYY2R\R-$MB1DDS:W(O0V\Y361Z,4].25=-,%-I<D=T97!0
M6$-Q-DMZ17 U=#A+9B8C>$$[<W%/<"ME0S%2:4MQ2T9'=TA406QC4T(Q3DU6
M9&ER<U9D:7)S5E5,-R]E5U0U2$953%EF-W<R+R]!0FE4+VE)=V]1*W9-13!Q
M-&M$328C>$$[:S9,+T%+339F8D5Z9D1%13963$]1=$]H<E$W66A502MQ96)E
M3$EM:'@K<E%H6D1D;UDK6%IQ8U$O1W9T6$1S:$UD1SE"=$UT6DEN828C>$$[
M6&Q'0UIP4#=X;4E(378Q;S-)9D5/>#)W1DM.>%9B2#EK+TYV,6Y&5C)+<V5-
M;793-FQF>6%-8F(V;TI&:FLK=&5O43%X1W1*5VI+9B8C>$$[<V=C55 K57!W
M;U9D4"]386$P1')"9TTX='55<VIB.'A';U8K57DO1V$X;4AP;C5,-T=Q<659
M16]A>2\T-FPQ+W-0.$%I27A633A#6"8C>$$[67$W1E5*<4=L85AQ369P,SEP
M1F1)4'-I5D9E;&9#;S(K:D-G9TAM=TQ23%A3+TQN-6@V:$A*36QL66960V)B
M,7!/2S!L84HK4$IZ,B8C>$$[84XV8C5);31U4$-01&M)2$MM8BMR6F%O,71,
M83--3GIA,CAN<74P5'))0S9Q46<K1V\R3&-V;4)K6$I25'-84$1T,WA1<4MG
M07A6428C>$$[=3=F,4=6;#)D9G50=&E&964O;79:=$9:,E=S>'0V13EK+T)P
M5S(T06XQ26Y*.$5K5"]H<VY%=5!Q0G-*1&]Z5%-.6G0Y83!I>C%',"8C>$$[
M<$I(95%P2V]1.&=/47%6<5 U5'1K6$E"=$AX,E-5<DPX5$AS0U%".3)#,')X
M8G=*=45&97A/+S8X54QL96UX>%9T;5=M2W%354QB0R8C>$$[=4MO9T-G=TID
M:7)S5F1I<6AF9C=Y>69)-'%H8D0O94<S+S1X2B]X15E52F0U<6AU>G!F,7$P
M86QX65-#-U)#2W$T:D(U0FA1,6]R1B8C>$$[9T)V54-M14MS;3@S84MM:TYF
M<F111B]1.5IB67EX."M26&M%3D-A1W5X>'!#>GDY;S!Y-EI$3'%-<R\Q,F-M
M-&U26EI95E9P1TPX9B8C>$$[5&I:54(K3#0O1G$T:W%N,D)+,E W2BMB9G)/
M2W)S5EEX<%9Z2G!'<S9L<&MW;6US,DEV8E8T-#5:=4%U1V)K:F5M<F-F:E9U
M4'E*3R8C>$$[-7=O8DMF<'IZ1U5M5U9.3S R2EI)-%I&:VA-:W-W6E)*>%E)
M4T%!>3E.:4YJ=5)I<DE,87IT<EE-244T8WI6='EA:V)D>6-#5FQL+R8C>$$[
M>#%,<B]99CA21TMP;F=3-T950G)U=F%6;T]L5#9R<71W='1:5S8Q:VMB9G)S
M1E5$9&U9-T%$<FER=V)Z4"]Z:WAR17,W42M7<D-',R8C>$$[:%DP:FQV03!K
M>$@X-5)75D4K6'AF4$972#,Q>'%'<E=S;#4U=W9*-S8U,4(Q:VEJ<4]587!Y
M;U946E54-'I25D=7055.,T5L27EN-B8C>$$[3VE"<TY(<TQ3.6IU9$,Q<30P
M=2]"06EK06%.-FYA;DI#=&$K1T1H0C9S=D9Y4C5X939F;$8K6G0Q<C$Q9"M7
M=DU$25!-96YG<W,V9R8C>$$[270Q0W!!36=58D(Q<4]12&I59#9227!U:$E3
M1F@V;&=:;U159%4P>E0P4U,O=31B4EI'-%)T4$EK45IU=D93-494-UEO95DK
M6C<V-R8C>$$[+TU,550U83!Y;S!58C--*R]&;$(O=FYP5#119C=T9C)J=CA!
M2WEQ1S=J1U)N2V\X;F]0;&)Y=EIE6$Y-3VXR:W-K<U133DM7;#0Q<28C>$$[
M=T,P05%+;T9&2&)R:T-B8C11-%)14FPY<3)L,D)16#DW0F%E<%@P+UAL4U!L
M5'<U:U9X6D5O8B]!0E0U6$A85TQ,+W!*:2\U<7AP2"8C>$$[14\Y2%<X.7)D
M=TIC5S!Q5'=30W-C,%1",%EE2W-T46-5<FYJ1DU644=S95ET13!/,T4R<#-A
M5S1B*S=1,6%2+SE33F%U,S!$1W)16B8C>$$[06,P<%0X,&9*1$-P=C-4>$17
M.7E+9E0V9$U00U=!>E$W,#<P5%@Y1S%Y>DXW<$XP;#5B0GI'6DDV-T]!0U9)
M24)";U%C:3)!9V\O1B8C>$$[3'-654PW+V575#5(1E5"1&-E:'!L=DHV8GDO
M=31X=VE8:S(V:G1H46M(;4AZ4$-S;'9P8W1R36E8-TI(3C9H5TM2;S-L4TIK
M:5$Q328C>$$[:&(Q2TU&,T,Q3T5"1$MM:E(P36)Q1U)H>%I#2V=G-T5%645S
M5SAO*V%O8BMD3DI332]U64AK:FQA5EI(16-5:7AO:WEQ2W)+030U028C>$$[
M+W=!8TI#1U9917)9+W-N-70K<S1Q;"MS87DK;5=T,61.67IZ45=S5%-T3$=9
M=4I#<GE/>&-0.$$X3&A!5D0K5G)Y,W8W4S4Q0T]0:B8C>$$[3&-81&ED:$ES
M>4TP5DEX-E5I:%$P65910G0T.38T;%9N;5151'!D>G Q-4)A=F0S9#%-8D)9
M;WE10W)O,'A:*TM3365(;T5I9S)Q928C>$$[,6-1:%!C0U5.6F8X9%,V+S)(
M+T52:7%:-$5U>%8X-68X-4IE84IB:GI(8658+U5+,D=M=W)D5'AI=$AU2G%H
M86IV=VIP>"\Q:FER>B8C>$$[3'E:6G=85W-V3&-X;&U#33EV13-2;51C035/
M03-A3E1):4]Y8D<T;'9,:'!P>BLX8S<K0VIS0C=$26LR,EDT0TEO2U9Z1T5/
M>#-88R8C>$$[164R0FU286-A6F5Y5T@U9V55+TUK3&5L1F-8345.-TM0<W%S
M:D-#9FUF1&<U>6,Y.3-',#5Q-&YO*W-%9$I%1&]W6D=&5EI4545E>"8C>$$[
M1U%C;#1(*V1M<'1Q,VU+2W=M:D5),'$T:6=S1V%207)Y5$)*2&MC=%)&5VY%
M9D5D<58R>7E),G1X33!I6F-+4#AT95=036QN8GE08B8C>$$[*UIT3V=M=5=%
M:VM53BMW,W!10G9457%A93)*239H631P1&M64'IP<2]W0UE':&%9-%1Z3F)T
M3DI10T=#-5-A8V]E<%)7:59X.#8T-R8C>$$[1DHT-#AY1T]E5D(U9'563W K
M6G!T5'5D5%IM-6DS34)&96Q7;&UL85)Y4C=#;G9H;SE'=FEH+T9:5&I78GIY
M0VUN>6TS=$Y7;FMC8R8C>$$[0D9*3F)22V5F=R]A5#%M-SEL3U!Q45!#-D%R
M+T%-=69,,S5Q-EA:>G1P8V1X86%F8TAM:T9X-DMG="]-<U4T-4Q59%=#:FQG
M,F)1328C>$$[;&)-;S%,+VQD:5=--U%%=DM&2E5+3$ET-SA10E5M;E1"-E4O
M=F9*9S-L5V923'%E-G9F3TMA:&18.%5N0C=D4GA%:$$S.5=34U):2R8C>$$[
M<68R2W)4,S=3,S9.5GA"=5A.35!-;'AO*W1A6&,R9FQZ>3,V3G<T;TQM07EZ
M>4MO24QF=6]15D96,C-9,'AQ=5I36F<O5$9-4'EX."8C>$$[.39$-5<P6DY#
M=DQ'-&IU:DLX=#%C>#A8-7E/86-M:EEO-F-55E9O065M4DU35WE'84U24C)E
M>E=T,4)D,G-.,6)V-FM&=VEY=W5+:B8C>$$[:VIG37 S,S-">41K<75+<48Y
M+W9,2CAJ:7%$<U=B-FQB+T%4*S94=R]L2'9H47)':D9735)*53%5;FI516EM
M,B]H:7)F3G8U1"M(.28C>$$[8U979TMP2E=+:$Y34T]09G(S.7-66&,R+VM0
M-&8Q>%9B1S=C5#A"-G0T94HY.%988S(O:U T9C%X5G!+26]226EQ<4M+;S1G
M065W<B8C>$$[:7):2DY#67EA8FHW3S-B>'A6,TYV-40K2#EC5E$Y:6$V;F1B
M52MX<V8Y55EL53!W2F1I<C56+U!I2S-N+TY7.45B1FI(0F)#9%0P128C>$$[
M;G!!:6XK=TLT<7@O5%EZ8E1W>GAI:E)S1T@P65%A3$=C94E%22]69$UU67)Q
M4S5T66YK=%IJ-FE&0514;4]88DI3:C%$4FAY9T-I9"8C>$$[=VA,2S)M=G!Z
M16%X4GAJ;%!+,G=24C%*<F=%8F)-;5E21WE&;3@R86A,<G1J;W9L-59%36MS
M9'1&1U5$;5)P2$-!;79D;4]332LU<28C>$$[:'!W4F-U8C,S5V9Y879V<6-Y
M849R:E=6=S0O9'59>D<S6&]:65=1:791:TIG-#)1=U9Y2E,O>78K5$TX<40O
M13AK<4YA:%)!24IK8B8C>$$[,5I#4UI*2%EQ>E4V8V5H-C%W;5AC:4]$8VU4
M2EI0>6\X=71S8G$X6"]:46XO:552=V-:5"M79S-:9FLU-5!J=69R1C4V.2]4
M6EEP5R8C>$$[5DDO;5)#<UI9+TTP.7-427-O-$EH;&M0;#-Y+T)%<U5/;5=K
M8U-#:6]S15E!*V=,:U<R9W)1-EAP54UG;&AS-$EP1BMY-E)O<D0U128C>$$[
M0W5"55A567!A2D%X5DQB:E%D0W5R,S8U8V%F8E184D%";FMI4C,R,D<U0D\R
M1FI1=$UK4D5126EH55555E%+04%E04=":VAR-U-D3"8C>$$[,4%+="]:=UA9
M6#=);FI34VYY-4$T;TET16]I4F]S8V%H15%"55)244%$64%!67!B>%91=G8Y
M-5I0:V-6471H+W9$8B]!4$=*4"M):B8C>$$[0VA)=DU8;'98.50Q3T\U<V1E
M;3!Y,%=!4E!A>$Q5331L-6U3=%(Q6&(V4$%N0T-H:3$Q*U90;5<W=%1B,TAM
M6C-J.5@Q-&M+4TU)-28C>$$[0WIU>%AL3'536D0X4C,W-4QI0TM22R]L<C5M
M5S8P-F1F33!G1F=O5D4T4%)34GAC<%=4649A9D-D:E1F0GA*<#9*:U5R62]S
M;C5T*R8C>$$[<S1Q>#=Z5#58,4A6.5(P>3ES9%-A=V%W.5E32T%X.5):=W%N
M-TQ*46=!-%%536(P-SAS=DY.;$,P169M:5))6DHQ;6Y216M(36-E3"8C>$$[
M2V8S;F-!8CDK+U%994E)<%5H+TQB>DI(8BMM9DUC:D]H1%<W1EI$-F)C*U1-
M=C=Y=%0S.&4K4$5M;F]30FQ25EIU8D%!335!1E0T,"8C>$$[1U)3:#=,+VIQ
M6%@K=R\T:4U65$I7<F=39W1A,6EZ,&946F11=D]8;U)C45%G-4U3-T)604<S
M56Y#0F)'56A%5UAZ2"M:348Q<DAN-R8C>$$[561C,"LQ;65X=E)!>49L05E'
M3T));4)513DT.%!!5W-A:4AE;'-&;F-1,G(S37<Y15)K2W%306AM63EG1#=9
M.$]Y4FU":T%.,$I0<28C>$$[9'IB,65#6F]M-FYI840W<T%*1$]73TUU65DO
M<DAM+UAB>$1P;VU$3$E2>EE+07@X06506#595$UT8V-%46)$,D0X:&9Y6#%'
M,S%/2"8C>$$[>F(U:G0S='AB+TAP;&Y-3TUR>45513AQ2&1&5#EH5'989F%G
M<D9U9E$K2W151TMR1U94=&A1<T%D3S%2:7):;%DW0F-65VM39&56328C>$$[
M5E<K=45.1UIA+T]M2W)*8G-6-&<Q8G='*TMQ5%184V9'<V9+;E5%.5(Y,DMO
M;7EV23=K3GAQ1U1:,&)Q1&E5;VY!<G-69&EQ:&9F-R8C>$$[>7EF231Q9W)A
M6#!T36AK-$TO1TI$=U%662]#3V=W;U,S5G9.0S)&;6)G,F-O2F1),4YX4S-I
M1%-.>$)E5G514F9E;45"57@P;E55,28C>$$[3%,W6%5%4F\P=6]K;59(-F=/
M2R\U;D%64F5+=7A68D@Y:R].=C%N1E5$938U85=K53=V1F-U649:;59,861G
M94%*;W)C3TAB<E=M1R8C>$$[;%5F3%=V<')D;$QC<D5S6'!3*VMF5&M784YV
M,V%307!);T%B85%!*T1!:G1I46A.<T-867%H<DPO:G%86"MW+S1I35940W9&
M=F)&5R8C>$$[<&]B931H84=E3EIO6$9(:FM537!(=4152$%L:&YN:CAR9$HQ
M,U(S:#!H63E&,5=-*W!A,V1S9VE1<T(Y:5I9=T]33CDT-FIW2C1I=R8C>$$[
M3T]*-E!N9GI*-6$O35A26FI"<FUM,V-I4D=I6%5A=&-7-7(S5U9!>3<K0F]F
M8D5Y2E1(2$=024E$>6(K6#-N3'I/=W-T23 R5T,R.28C>$$[4U5Y6#$P<GA7
M,%E-<#56:UEF15%7*WET5SES1$HY42M1=GEZ.'0K5#E+=#=E,G0T<FY5:W$Q
M>'%S:V%E=DI),S)I1V]74F5Y<41S4"8C>$$[13%*5EIB:7%(=4QX26AS0S4V
M1VY19E1H<%9%6$8Q2G5)4VEF>D5G;C=T<U5.+W8K<5-68BM6>"]3;4MQ:51Y
M56\V8U<Y:E59<75$:B8C>$$[<65V:&ER<49Z=G-01$9896U7*T9.:#!,9C!X
M5EHK:C1"=711,V1Q-R]4:F%7,E-3359*1$PP<C!X46=B:T<R=31R=$YL2D-Z
M1"]*3R8C>$$[,51I<6(T175X5C)+<48Y+W9,2CAJ:7%&<U X065',R]!3TU3
M9CA21T9#<S9)-FQ(54UR0VI+4E5%931X5FI6;$HU:%=*=C!82$,K;28C>$$[
M3DI)8DPQ5DI94FQZ4VA%:UDT5G%9-D0W2$A#:$XY3'9B=59P<F$K4D5V64]$
M<TDV:%=J:TAW<T%3,5!I5FQ0>&9S,3<T16\O1E9S9B8C>$$[,E0X,B]78U98
M67%K9#=F;E,Y5G!$8E0S544P2$]A,G15-6U*,65I4'AQ=%!61$U$+W%F4$-H
M5W-F3556,61X,GHR5C-:=$QY.4HW<28C>$$[25)Q>DM/4E)4>4HU8V%T,#9!
M-#!L3G-#;V%Y+S0V;#$O<U K26I&57A:86I!;&%O64XP,G=O5DU#6%EQ;#)G
M9C=W>2\X>&PW+W="4B8C>$$[:W5+<&EC5E58.5IY5BMY=FE"46Y#<3%O9#0Q
M0R]#1T)0,%EO5GEO=TI5;FEQ86=954Q3:FIC06ME1TMR9U0O2U(Y1TMR=W!0
M6%E9128C>$$[<G=!0E%D359D:7)4045&4TMG.6-64S970V1M15A%;$]8,G%B
M538T54DV24]O-&MF0T]H.$U#5E1&6%EQ;U@S*SAS;GE/2V]7=R\S:"8C>$$[
M="\X06I%;B]!0D5954MK,%-Z479%>$E74E-R1E-63D=&3FE.=V-663,U83%G
M5U9R4'!E<'DO-E)P<WI7-GDX4U$X64%:1%)145!H628C>$$[8F1H5'980U98
M-F)B4S9V<3DS<61Y6F\W5T5M,7-%4U-31W%!9W4U-$9E45EQ0U!P0C9$1D1)
M;V\Q:FI73E-X5E)11FU:,BML;4I**R8C>$$[:S1%=6HK>69M,S9Z:7$W1E5G
M=#=I-7,O3C%Z83-!-7=A;$5S,6Y.5&1406]6-&EF1'$S9TLK3%EE:4=V36MT
M>&,S*VYA5EHO0F-V2R8C>$$[=# Y>'@U96Q(0V$X:"]R8FIW+UI0,G-1<6(R
M,$8W2$E7;G5V6%%G,%0P,5-H<4M';W=*9%IF.$%(575V.6@O>$59<6UE0DQS
M5F1I<28C>$$[;F-Z:3-T<%HR5FY71D=K2TE/5&M+2S!59'EE,DMV2C=4+VY)
M2'EB6E%#0U<Q=4)02F-K:4\S275)-EA-,&)U-&Q):D(T+U<V,%5%9B8C>$$[
M0U%#975&5E<P+S5Y52],-F8Q2&%/*VII17%2=W8Y6$QL,64S12]);W U1#EP
M86(Y2SE$9U97:R\U>4XO3&U/,E,U8S-O:6-+>3!T*R8C>$$[4F\X2FXS5E=*
M5VEJ=CE&4E5H5C9F1$E:26MK2TY'6%5-63-P>5=O<GAA:$EQ4%DT<75X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>"8C>$$[5C)+<48Y+W9,2CAJ:7%#=&YA
M4%196%=.<%=%4U5J5&E'4'=J<'E+<CDU=V]3,U=D8S%3,7-';70Y3VQJ8T]I
M=$Q-<7I):4TQ1V-X,B8C>$$[>GE3='A(65E114EJ>7A(36UG,E181511,V,P
M66UU:V9:+U=L+V531FAT46PR2G R-EEL53!W2F1I<3)0-THK8F9R3TMO4S4Q
M>E)R628C>$$[>4Q09E%2=D98,4EZ279-53-P>')Y<C=5>'!5<3 R6%1F360U
M3&5Z46PT<E9&:&ES-W%*86]:9W-X;$E02E0V:65N>#A!1#1N1'E1;B8C>$$[
M5G1P=6Y7<D8W5S%H9UIH4FUI:E9#4C1%<4)G4VE-5E$Q;"]X,4QR+T%'2"]!
M0D59<6UE0DQS5F1I<6IE4&-2,F,W,GE#5S533C)G:B8C>$$[3W=:=W!+<61X
M,4]+=DU:.60O3V)H1D=N;$]Y17I81&MZ;UEY<5%2=7A,14Y0=3 S1E-"+VQE
M2S1643%H<B\U,CA"9%A0;$<Q4C,T:28C>$$[3W=5=SA)9T%6-65P-F]A<$%R
M-T$P<#1+=E$O3$YN361+5V)5=$UT<D15-35(93EH9U9E0F1#655F670Y<4I6
M-VYB8D%Q9%EQ-T98628C>$$[<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%P
M,T5F<5%S;FE+67%L871Q14UA4DI!<DQ';U5-4V0V0VYH:%$S.5HQ3"]!2EHQ
M+W=#0R8C>$$[4#E-5F0Y6C%,+VQN6"]G:B]41EAF5V13+W=#5V1F.$%G:B]4
M1EAF5V13+S5:,2\T22\P>%9P6CE307 Y6%AQ5#EO.7I8=WA6>&XQ128C>$$[
M9V<R>45(66=K+S!X5D1A9F%T<#!"9W-.3V=T65-X8WAX1&=P63E4440R<&IA
M;W(V>G%8+T%#>G(O=T%%9C99<3<V>'%8+TQ/=B]"2"8C>$$[*VU+;VI4-$IV
M5VMU2E9#=$I3<6IC8D-M0DM0>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2R8C>$$[=7A6,C)+=3)X5C(R2W4R>%8R
M,DMU,GA6,C)+=3)X5C(R2W4R>%8R2W8O+UH\+WAM<$=);6<Z:6UA9V4^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS
M=&%N8V5)1#YX;7 N:6ED.C(R,34W,C)&-4(P,45#,3%"1# P1CDQ-#8R-D5#
M-$8X/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YX;7 N9&ED.C(R,34W,C)&-4(P,45#,3%"1# P1CDQ-#8R-D5#-$8X
M/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X
M0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.D$V,3!%-#$S-3DP,45#,3%"1# P1CDQ-#8R-D5#-$8X/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.D$V,3!%-#$S-3DP,45#,3%"1# P1CDQ-#8R-D5#-$8X/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E
M;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@
M(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z044V
M,3$P,D9!-$4R14$Q,3@W,3-$,C X,3A$13-",C@\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#@M,3E4
M,C,Z-38Z,3$M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C(R,34W,C)&-4(P,45#,3%"
M1# P1CDQ-#8R-D5#-$8X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 X+3$Y5#$Y.C V.C Y+3 W.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI
M<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU
M<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O
M(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT
M/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@
M(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS
M<&%R96YC>3Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*
M(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @
M(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM
M.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^
M"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*
M(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!4
M4&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D-O=7)I97).97=04TU4/"]S=$9N
M=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI
M;'D^0V]U<FEE<B!.97<\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP
M93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXY,CPO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/F-O=7(N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1.86UE/D-O=7)I97).97=04RU";VQD350\+W-T1FYT.F9O;G1.
M86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y#;W5R
M:65R($YE=SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF
M;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I
M;F<^5F5R<VEO;B V+CDR/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP
M;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^
M8V]U<F)D+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M3F%M93Y!<FEA;$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S
M=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14
M>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z
M=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O
M<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L+G1T9CPO<W1&;G0Z9F]N=$9I
M;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @
M/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P
M/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O
M=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO+W=W=RYE>'1E;G-I<RYC;VTO
M;65T82]&;VYT4V5N<V4O(CX*(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E
M.G-L=6<^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/D]P96Y4>7!E("T@
M5%0\+T5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/@H@(" @(" @(" @(" @
M(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/D%R:6%L/"]%>'1E;G-I
M<T9O;G1396YS93I&86UI;'D^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I
M<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^,#PO17AT96YS:7-&;VYT4V5N
M<V4Z3W5T;&EN949I;&53:7IE/@H@(" @(" @(" @(" @(" @(" \17AT96YS
M:7-&;VYT4V5N<V4Z1F]U;F1R>3Y-;VYO='EP92!4>7!O9W)A<&AY/"]%>'1E
M;G-I<T9O;G1396YS93I&;W5N9')Y/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CXW+C P/"]%>'1E;G-I<T9O;G1396YS
M93I697)S:6]N/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N
M<V4Z2V5R;FEN9T-H96-K<W5M/C \+T5X=&5N<VES1F]N=%-E;G-E.DME<FYI
M;F=#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E
M;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^,C4R-3DV.3@Y,#PO17AT96YS
M:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3X*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/C(U,C4Y-CDX
M.3 \+T5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/@H@(" @(" @(" @(" @
M(" @(" \17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^07)I86PM
M0F]L9$U4/"]%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^3W!E;E1Y<&4@+2!45#PO17AT
M96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I&86UI;'D^07)I86P\+T5X=&5N<VES1F]N=%-E
M;G-E.D9A;6EL>3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E
M;G-E.D]U=&QI;F5&:6QE4VEZ93XP/"]%>'1E;G-I<T9O;G1396YS93I/=71L
M:6YE1FEL95-I>F4^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93I&;W5N9')Y/DUO;F]T>7!E(%1Y<&]G<F%P:'D\+T5X=&5N<VES1F]N
M=%-E;G-E.D9O=6YD<GD^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O
M;G1396YS93I697)S:6]N/C<N,# \+T5X=&5N<VES1F]N=%-E;G-E.E9E<G-I
M;VX^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I+97)N
M:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K
M<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]N
M=%-E;G-E7S$N,E]#:&5C:W-U;3XS,#(W,C8Q,3@R/"]%>'1E;G-I<T9O;G13
M96YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/@H@(" @(" @(" @(" @(" @
M(" \17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^,S R-S(V,3$X,CPO17AT
M96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93Y!<FEA;$U4/"]%>'1E
M;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT
M4V5N<V4Z1F]N=$MI;F0^3W!E;E1Y<&4@+2!45#PO17AT96YS:7-&;VYT4V5N
M<V4Z1F]N=$MI;F0^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93I&86UI;'D^0V%L:6)R:3PO17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN
M949I;&53:7IE/C \+T5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ
M93X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O=6YD
M<GD^36EC<F]S;V9T/"]%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/@H@(" @
M(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CXV+C(R
M/"]%>'1E;G-I<T9O;G1396YS93I697)S:6]N/@H@(" @(" @(" @(" @(" @
M(" \17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/C \+T5X=&5N
M<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3X*(" @(" @(" @(" @(" @
M(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^
M,3<Y.3DP-S W,#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#
M:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E
M.D-H96-K<W5M/C$W.3DY,#<P-S \+T5X=&5N<VES1F]N=%-E;G-E.D-H96-K
M<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z4&]S
M=%-C<FEP=$YA;64^0V%L:6)R:3PO17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C
M<FEP=$YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI"86<^"B @(" @(" @(#PO17AT96YS:7-&;VYT4V5N<V4Z<VQU
M9SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N
M9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_  !$( /4"4 ,!$0 "$0$#$0'_Q  ?  $  00# 0$!
M        !00&!P@" PD* 0O_Q !J$  !! $# 00#!0P4"@<' @<! @,$!08
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M@[T3_*4=B?\ UVQ_XA;H_P#!.G[+C_P_^3/S)\W#_%X.]$_RE'8G_P!=L?\
MB%NC_P $Z?LN/_#_ .3/S)\W#_%X.]$_RE'8G_UVQ_XA;H_\$Z?LN/\ P_\
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M)[_[H?43D_\ !<W\6F1N[Q/JF=V_P'HGO_NA]1.3_P %S?Q:9&[O$^J9W;_
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M<9!.RJSM;<>^+-K$J[N4[DJ2::LGLJD0(5.BG#3LN>ZZM]Z?*<=G((<!0$5
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MM13_ /BX]GK_ %#[,_\ A?A']AZK\S$_B/\ ]3O56@;AW!/\7'L]?ZA]F?\
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M!3UX2.@'''B".?M<:@/!,#6QM[^_BG>)HXW TKV@UF:S)F%;$B'^2%+:4GN
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M=YJ/?B]]1! )Z<@\^P<<<>/V>G.K!T"")'ZS6_EVH&S6L:&!Y3/NVZ'FU*'
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M5K>3R7E$VQGY\0S,#J@#<-136_:%7#'RV- B35P@7[K10=JVN AD$=P*/!
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M*5]ILI4W'%GD#SF90(Z4I]$&*7*JM*6U%"0 $!/=B=&[+B_0 '7&1P:#6YF
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M_,PS$#Y3B0 T-ECR 7%K:9FN#02))#A-&A2T'#Q!))&(T"22Z'LDQ+JPYI)
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MMM:209!!H+Q,>]>"JYT"A$S'L'S63*TM,(#;2$---A*&FD!*$H0E/="$)'
M2 .$@ !/  \]4>*V,B9O3W7QW*I)(J;\IF=:2!NCR@*<2H*'(//M^(^S6:@'
M*9,U%+6[^"_=%+R#$<>>BCY#9ZCD<_1^?Q]-6!@BAH"!&I)/JH-9=H3'&P]/
MMQ5ON.2(Y6XPXMLG@D#GNJ_TB4D%*C]"!R#P >O4\Z1-P+D5O F/MPNA.4G*
M8'Z*@>M+EPA"9@:21PI2&60H^/(!*"I)XXZIXXZZJ65I01SKN/LJ<YUKR)'D
MN46-))6LR'N\YPI:B^XHN=#W2KE?*BD  %7>*1T! U;*!I:;^,Z;HFL<E62=
M^XP/=S,BQ*N:L;>05EQQQ2 D !:U*')XX/7GP /''V>=4<6TB.)CV%HP&3,V
ML>.O@I?5%=-$31$T1-$31$T1-$31%&6WTH[]:>_F:(M)]P?S9XM^ZO'?PC"U
MNVPY#R6#KGF?-;5ZE0FB)HBU!W<R6@R7?;;[;O*[:%18)M<W@^\.6JN'DPXF
M4YYF>:SMN^SSB[ ?"$SX47/:V\RJ6ZRHH@YK0[9QG%]ZR6T=F C#<YH)<_-A
MMBI#6M#L4T_PD-J(+2_<L7D'$:TF&LRO,ZN)+<,;H#@3?Z@T+;[6*V31%A#M
M"8]1Y;MP_C-AD\##<DN+[&T;69--4/2T^\%=;1[K;2= 92"_-?BY/60GYM:Q
MQ[YTC=M7RB*Z3-.M,,EKI#2X '.!JPB'30Q0T)%#!N J8@#FQ(!D9"='@RT]
MXJ-1(LK0V\[46*YE@V(Y188INE$L[S!4Y=;0\<V<W;S>@@RX+DNOOJ>HS#$<
M*N\:R*7&N*VQ8I8=/:S+/(JT5]O4PI4&T@O/R["+7$ L(#LH)>QI,U!+7.!:
M((DD0#()D%5;BAS6F'R6R88]P$2")#2#4$""21! @RLH8SNUC.67D/'ZVEW.
MA39U$WD3,K)MFMV\.HVX+H:4F+,R3+,*I<?K[U(=2',9G6<?(FE)=2[5H4RZ
M$5+"T$DL@'+3$8XSP#7$D?X@,O%7#P3 #K35CVB.9: #P)!X+)VJ*R:(HI[\
MO*[]JKG^ET6IT/,>3E&HY'S:I74*4T1-$73(4^B.^N,RB1)0RZJ.PZ\8[;[Z
M4*+3+D@-/EA#C@2A;P9>+25%8:<[O<)%I-V.=PZ6RI?F3MHUE&W7S"IM-Z]Q
MK"S9C1TWFX-MF5UAV[6,0&VI4I]M[8O+**JVLFULHI53XY'P-IAR5$EQY"M\
M=A!D06 AC(T8&AS'&@_O 2\$7=G.]88+A&4SG(+WS%7%Q#P*G^[(#(-FY!N6
M[^L%NFB+1#,MR8UWVE=LI>U]1*L<RQ[<+*=BLO6_)8@T.:;:HPJ#G>Z5@U,:
M$M_T6R>7' 6(]M)@.1SF]U<;:0'H<W*;FPK.AK8PGAY :YK<1NI#@XM8#N^8
MW/0&<H#S(;!P<\'$;E!)#BPZ MRYGGDPY:D?42P07$C8*ORO?MX4ILMFL%@*
ME6%@S?"-O3,L!3UK+4%5;/@E6U,+WYD3G79[<B L50@)A,.)F3#-+<7,C#K#
MW&@B<,"360>N8BD&LSHM)?26-O7KV&A^FO@L@8599G:T:)>>8K3X=?F3(;72
MT>5NYG 1$04B-)3=O8YBJUNR$E1<C&I0(Y2 'W^]R*N#0>JXN&\MRGNEWFK-
M+B.L T[@<WC \E=NJJ5KI9?GNWG[&I_P;#U1]AS^Q5FW[OYFK:^C^E6OK?\
M6UDME.:(FB)HB:(FB)HB_"0/$@?*=$7'TB/](:*A> 8B?"O<OPNH'GS\G72"
M;"54G/N$;S>>S@O+_P!UJP)S+NR?+S&$VE=EL[N!A6XC(#??>75KL'<+R!*%
M=X!MN-1Y=+MI!4%)4W5<%/>[JD]W1[PS:6 Q#SD)W ZS^H'A'S_Q1LS=JZ$V
MUL9G8&&<9H(I+()K,[S:=%Y.]@//T;<]OG:.2X^&*C>_!\PVNL'"2E@6+]4S
MF]"IP] 79%[@R*J*2#^2VX:2>'%<^MTNPOP0\?3AO#1O(BI.@(,]E*$U^#^
M=J.#TEM&R'Z7X3XK$NPS ,6FD7-"."^J;7S:_7\[=_GZ*CL5345\Y=:VR[8I
MARE5[4@E+#DU+"S%;?4%((96^&TN$+20@J/>3X@+B;:K-SR>&^MU X]1P<3Q
MRCQJO6XN%0U<*K9>>X,B4J(PEIR;+4A(#LV:XE<J8^1WGY3SSRR5N*)L9<XD
MTDSV$\;\%-@10DS/  6Y^SHN,R0M*%'D=1T4?C'G[!T///'/ YZ>.H !,7U\
M_3[U4.FU@+#W?OWJU&4*ES5/*/>0@AML<]#_ -X>77Q/QC515Q)L"8]^/=%
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MERGB&VQPI1ZJ4>>[STY /R\>/EU/MJ2<Q U&LTXBL=L3,J1%9[!O.ZRJH-2
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M@$D#?KR"FD("!P/'S/F>NLE:KSN T]B]UST6@  @)HI5.^@*3R>HYZ@CD'D
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M;H(F1'$5TI*W:/4$>W6:V+(J*UMP[Y*XI0E'/=YZ\<\GV<_CT4$EVEMP.O\
M14LAD%*N..#T(//B2>HU(,$%3)-Q!$&8J1-J\:[N"A&6QZ5220G@\=>?%74?
M>]OMUL328/A:"9W>*J8:Z]B(X\/,<Q988WY[5&P79AH6KW>G<FAQ!R8TZNEH
M%NNV>79'Z'A"T8[B-2U.R&Y[CI0T^_"KW(D-3B%S9,9KEP49AOQ7$,:7$R8
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MPMAX0["L_P#T%T1_%VD[I>*> 72KW%JW!_(NUQ?!/'4.[05#BBKGJH*3G37
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MJ?H2.!Q@_8-GQ(^68WP:R;6)XWUO,0O2P/B[I+9H&.TXAJ,N(PB2+B0)UH>
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MI/!"V\DRXWMZA1*0HJ38@E0!/4#CB?CXV)(?BO<)F"XD#D),=B^AV?8-AV<
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M<!^:#?MG?.1\U2)$7:YS(*"1+B[>PK3-:Y/S55E:U(A4F%UCC^.SKC/;OP6
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M##3!#A<"LCBLMZHKIHBUTLOSW;S]C4_X-AZH^PY_8JS;]W\S5M?1_2K7UO\
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MJQ+-\%"^3R /:.>I)Z#G_;]G3WYJ5B')9"$I4KH%@J[BOT2/#PXZ@].>1UY
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MW)E_/:=6Q=Y%;1PRRS*+UFT1-$310XP)B5^$A()/@-%F7$TH.V]+39="G_\
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MDQXEA#D.M!2&I+*R%B1$B9C6#!C@2#Y*#,&(G21(GB 1YK WO;VNOJR[./\
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MN0VTV> OQZ\CIUZ'J3X=-4RDF3%+;^!M$^"1%9!Y&OEY^"MJ?-*CZ)KE:U]
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MQ^[F)4D*G9<M"N\T3W[]ZKQ,S[W(/W5C:^;*AVO9%S7*XT9[T3-QMK?89N!
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MX[^$86MVV'(>2P=<\SYK:O4J$T1-$31%JUN\E.[&Z."; LI$G%Z<5.]&]B>
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M_88XU$0HHJL&OMM(Y 5(U+^NUN)J>H__ #@4=_YM@DZO#]RC#ZCG8>@ZS/\
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MXVE*>2>\I6#B22-Q,(XB2#--UK#?;WR%R.1B0">O'3A)//7XN-0"1NWU'LJ
M1! )$ZNB->[Q4?(CGND%//'EP>G3SY'@?C^+6C73NG6PGPT'O=&43$TI!O/E
M,$^>ZMLV$!#J3RC@GGRXZ\]".?(GR\N.1YC4D9A6A\E%C2L'O_0J*9A@ \**
M3X=T$@HX)\ G@@GQZZ@,B:FM-WK/O5"Z=&CD%S<:EL<J0M3B> I+:^>]QTX*
M23X<@]".GMZD 0X5!)X'WZ<%((-"-U>&MKG3W6HASFW?@/)2%CZ)*_HD]3Y<
M^?3Y?L<:EKIY[N'OW"@B.6G'C&[W*FFV8KH^$D<$^'=/CP..O'Q^SCX]3&Z)
MWQ_10JI,.&G@D<*'_=)^3KSQX?%J.L/PQVCU5P"10=O5WUX^/HJ@>KCX*$\J
M  Z \ =!UYXXX_Y&IRNCK6T-C.F[F#%T%+'2:Y= ;$3W;IJBEI0.5'CQ/GY>
M/R?9U*HNEEAZQ6H)4IJ,D\+='/PCYMMCD<JX)[RNH3T\3P#1SP+7I&NM??%6
M:V;VK['N%.08$:N8]!&04I*UNN*4>\X\ZL\K==7P"MQ7 !)  2$I2 E*0,EJ
M! A5FBE-$31%^*2% @^?WOC^QHH(GWNJNI#G7N*/4<CGP XZ ?'SX@^?(XT6
M9;0D::?<<._B5&7]2FYK7H94&W>CL9TIY]%(;Y+:O;W5<J;< ZEM:@GA7!U+
M3!![U8/!B;Z[EA-BPDQ778<E):D1W%,/-+\4N(5PH#CQ'0%*A\%2?A#D$*.]
MU8ZS;[*W\JDI=C.+Y'T!Z> 'P3P.OMX^,ZAXS-+1J(D^R@$<^<ZS>G-7-B+#
MU)#JY;"C&??KH2)"T<=UT^@0I+<IL\H?2CO$(4X/2,_##*T=Y0.1:01-C%=*
M_I55)O!J.!MKY&;BUBLX5TPS8P=4$I<22AQ*"2CO  A2>>2$J!! ))'4<GCD
MP1!O-)"EKLP5?J%9-$31$T1-$31%&6WTH[]:>_F:(M)]P?S9XM^ZO'?PC"UN
MVPY#R6#KGF?-;5ZE0FB)HB:(M&.SAN-7,YYF-#F5?-A;M[K;B;P3\HL7U,*J
MZZ^VEN:O&*'::"Z7#*1[R[,OX+F^+%34>-F5!:9'GL&)%?G7D:-OBMZK2TRQ
MC<, :D/!<7GGB9FF^4PPF@G'#<,S@1#G.?/-A#0WL9E</Q EX%3&\^L%LFB+
M0OM"[EH>W2PBOVRI';W>C:C<G;S'L>#T]JKQ[+9.[U;<R]S-H;>V:CV4^MC4
MVS%*-Z,FL6Z6U8Q[WGV\ND0+6<(]5(Z,-G5<7F,-['$F"2 P@,>!8SB'Y8J)
MEXD3*PQ'=9H8)Q&.:!6 [.#G83>C!G, Q#3!B%L,O*.T$$2BWL[MLMQO'H,R
M(A6^-TA,G)W7ZY%C1/+&RJS%J84=ZT>BY$E$E^>[ B,+H(*;%Q^OSC#_ !ON
M1_=B@K!_O!4TD:2:F*WG$KU&VD?VAJZDCZ+7KK%A-,MTK]O*IZJ3?UT*GO)%
M=#>N*JMM'+NOK;1R.VN= @W+U;3/6L2))+K$>Q=J*MR:TA$A=?#4X8[=#$F#
M(DP2()&A(DQ.Z3&\JXF!( ,5 ,@'=,"><!2>H4J*>_+RN_:JY_I=%J=#S'DY
M1J.1\VJ5U"E-$31$T1:L9N^SNMOYA^VA>:5A6R[E)NON"EQ:!'N]R9WKR]E\
M(4%E*93E"*Z[W<MH;9,JML:+;&>MM42T).S>IAN?^]B2QO!E/F.X3(8)$$%X
MN%D[KX@;^ZR'NXO_ '&\8@O.XAALMI]8K5-$6O/:-QNXDXO0[AX5$,W<W9W(
M4[@8/5,.(:FY@S"K9\7.=MXW>4CUEW<# 7\CHZZ.ZLQ8F2G'LA?;4J@96UIA
M$!Q:ZC'C*X_ADC*_7Z703%2):+K/$!@.'U,.9HWP#F;_ .39&Z8)LLC8ONKM
MSF6.XUE6.YIC<^DR^HAWF/2DW$!I=C7SH,>R:<;8=D(?2ZW#E,NRHZVP_$*^
MY);;6"!4L<TEI:008(BQLK![7 $.!!$@SH5<$3+<4GO0HT')L>FR+$.FO8B7
M5;(>GA@N!\PFF9*UR@R6G0[Z!+GHRTX%\%"N(@[CW*9&\=ZN#4*5KI9?GNWG
M[&I_P;#U1]AS^Q5FW[OYFK:^C^E6OK?];62V4YHLWY;")G=P5.\@ =X=#SU'
MMY)ZZ*!+A&X2+:4 \?+M@IL8J1\$%0Y'D/ <GP^7P_V>.M@X&FIFGZ[]:?90
M:S(@TGW6G:*ZF0!#Q'0TXIM:NZ0L'J3_ *7@!QX=2/CX]NK>EOUM[XJJNF)(
M)4D*\%]/:223W3Y <>'R'PYUDYL5';;EPUW2-5=I$P)KI86[23W<X4IJBU31
M$T1-$6MV<_\ Q2=GG_Z9=HS\(;&Z*=#S'DY;(Z*$T1-$47-M:^("B3(#1(]C
MG4>?=4E)!/Q _BU8-)M&^XTX$JI(-+S2GK0>/D5C2P12R)[CT!@*+A2M0#?"
M0L_1D#PX4>%$'CE14>[U .@; J!/+]$K!J!0]G;-MU)B]5)UU2@J#A1RYSSP
M.J0#U 'D/;QY=2=7  O01-(528$".)XQ6>)@CCH:%70(P91U 3R/ <>(!Z$C
MQ \!X=-5#@3337T4M,P!$16:]FF_CZV!ES@7&#"$@J=>0D('4J*>5@ #KSWT
MIY^4>'(U8W/ FN^MT:-;3%-T B_;I&[>LL0(YB08<4GDQHL=@GVEEI#9_FZY
MS4D[R4+ :UK6BJ]0H+*4F>S]%TO-I4DJ/LZ_'X#K\G&BJV20.XZ@U/\ 65#2
M8P4"KCD>SIX]2$]?+G^_XMFNGL\>.ZNZX0B!! !OV#C/A;< ;P3T1?\ G8_C
MU*T<<\\$\#GCV<\?+QU\-6((,=X->-^'Z4408G?RTI[[UUB2A22T\"A8''=(
M ( XXZ'@\'KU'(X/CJ)XP>,2)]TO6BB-=%$3H*EJ#T<_#//*0H!73KXCKSTZ
M>TZHYLS B--#Q&G/W-FNBAL=8K6-^E*T70U8^JCNS/2,\'CTCGT'L'*U<)3R
M/+D\>WJ= Z/J!FT_8SY#NWR1-B-3 T[+UIH-U  I)NZK?T4QA2CP.%O,I//E
MPDK'B.#X>'!\]7#A%QW^M5'6'X@!S\Q12<2<99+4%*WSSP5-I"FAR/$O %L
M#_OCCC[<%XWS'EP]/)1#MQGQKO\ OS$W"FF*EQPA4U8[OCZ%L]3\2W.G3IU2
MCGGR6/#52\Z=YO[]PKAF_N][^?Z3J$);2E"$I0A( 2E( 2D#P  Z :S6BY:(
MFB)HB:(FB*ADGT:TJ//"@0?9RGC[1X(^T=2 3;W[^_-4<8BL5N-.8U'NMES2
M^>Z.@5\9YY/70B#!I_3AO5 &S!D&8I$;M9*PEN1&$*W@VB$A*)["F)''@7HR
MD!"S[5J:<2CG_1:' Z'G1EN1]\[[AWB5HTS.O9I[G4K'#R%W%E7T[7)]:>1Z
M90_ZN.GX<AU7'DAH+X/3E12D'O* U+@2T@7X'O\ 9[E8F 2;>_?:M@4U[+D=
M#2$<-A*4=P $!*1P  !TXX'!\N .=3$S)D'0Q]H/*JP -^-Y KVE<J]BRB2
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M?GNWG[&I_P &P]4?8<_L59M^[^9JVOH_I5KZW_6UDME.:*(&X=P31(&X=P7
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M[#9Y0RT@^U#:$G[82-))N24@;AW!<E--+/*VVU'GGE2$J//MZ@]=0I7(  <
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MOK(2LDO,9Q:FI**/(A^^MWD>1TU6Q*L*NL1*>M;6M@R[L8729:UK8S.=,":
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M),<RJN8Q\9FM=$QF:#$WB08F!/)8W_Q/>R1_V6NSG_X([9_\,:M\_'_C8O\
MN/\ 55^3A?PL/_0WT43E.RTS!\AVDS;L^87MU4HVHH=R\)1M2A+.V^'V&%[L
M6V'Y-DR\<E8UC=O78WDL/+<#H;R-WL;=KKM$S(8=A*KI-FBVC@_,'MQ7..<M
M=G^MV9@<&S+@2"'$7I2AB%!9E+'8;6C('-R?2,KRTDB 0""T&U9(D3*NC9S
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J_1$]71[!]K^_1$]71[!]K^_1$] CV#[7]^B+L#:!X)'3Y3_+HBYZ(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g189651g10h10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g10h10.jpg
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M8G*RTP<THK$6)#5#5'-T@K.TP>)UE*/"X?!C559DU/'5_]H # ,!  (1 Q$
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M-=J]@\:H*+GF!48IHI?&H:@^HV5!%VJJ=]+':]DD=S8C C)<!M8U>$E;*:0
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M&_?;[]NN+2\IB^'C##QAAXPP\88>,,1%IT"B([$MJ#JZ511:W(^"U%99V%2
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MQ6DZ10H,"--[Z@YO?R%=,8M-])M:I@Z& 2T-S]DG1-ND;DFKUFLY[8CT]/.
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MI&Z)5AG%8*#SQ3SY6_.ES/LN/%(&K-7;F(-E4(DQH3<60F1:YC$62<R26;0
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MA.EJO2U'8T?NZB[! +R7) C787O'IL618M18L??T/0@FW?R=<^_82F_PPD_
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M2;BF#CEC;[;0$P0SQR1ZPS2JS*SN&4D$:SL0:.X-'[QL?+$JD3*&5$*L 0=
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MVV9U]FQT& F,Q@@EG5JL$(K!6!VV+>(%?/PE6/1@-X<.00%1ENBI9@64C?<
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M9)M2C HI<>]"Q$A9P";%Q;1[[C$;C_[I!MMITR0Y+-9Z!F='SO"[S$<:R^.
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MC(BU'@%@BQ\?6/:**;77.Y'O?GSYUYO@W#,R<S+FHM0S$V4S69+32(A?AZU
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M[-\$RD4V7X1E/:A(#%PG+Q\-,KY7*/IERTDF8OYSVB!',O(P_)O<M+7JZET
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M/+*@I\<PQ2GEEF*2/5< MPTK;=5"Z9JGC1:YU4F+]T>84:2Q>S*6-2.2 %0
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MB/S6]6\*\>F[M/!Z.&-3&Y\RWI9-KV7:Q,/=$EQ4ZWT+<-$W3]$;[+*=LHJ
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MQ<=YD\>-C,Z;%M'#:E)#V;$K:/2./))II$Y,^8XX],RR[9UTUU]FN.24 2R
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M\U/^K3?WB[\?XH=Q^OIA9[']/7#YJ?\ 5IO[Q=^/\4.X_7TPL]C^GKA\U/\
MJTW]XN_'^*'<?KZ86>Q_3UP^:G_5IO[Q=^/\4.X_7TPL]C^GKC3.TR6RP"C6
M.GAV 8$X=H$.[7H&L ;,/.V1&(L1Y$\8YPN=]\CEQ:Z$09WVS%)K[V?;(L73
M58HUJ%CL:'3[,00#5I=&Q84T>XL[''BUK]>>ALU[RDK7(#N0:9R"U55UB&WF
M#T@C#E9C%SS0GR"QBBZ#2%Z2[0:#0:Q9TUACQJ!(JGJNE%A7W;;?RP(!NTN^
MMA3==+L[UC=Q2[011P0*"H888](H88LK(XHHH]<:1QQQZ':Z:1Z:8QKIIKC&
MNNN,:XQC&,8\BO[0_7TQ-_V3^GKCT^:G_5IO[Q=^/\4.X_7TPL]C^GKA\U/^
MK3?WB[\?XH=Q^OIA9[']/7#YJ?\ 5IO[Q=^/\4.X_7TPL]C^GKA\U/\ JTW]
MXN_'^*'<?KZ86>Q_3UP^:G_5IO[Q=^/\4.X_7TPL]C^GKA\U/^K3?WB[\?XH
M=Q^OIA9[']/7#YJ?]6F_O%WX_P 4.X_7TPL]C^GKB-6<F;(@^,KS-?\ .?\
M3MN!G'_DI/S?Y)VV?;_ZO9_Z?.+.@<M/$!X_/5V/93CU>$,1/)2,WR)V!2_G
MIOXG4?K?V8A'QY?L1/\ ;#_%^>;I'TU^#_MQ]!K;ZF3XQ?YN'QY?L1/]L/\
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ML616)!)4$D @7Y['<?<>G3%D^4Q?#QAAXPP\88>,,/&&'C#$8M/^\Q_^D_\
MTI/.+/?T:?W_ /[3CUN#_P"L2?\ 4G_&F(-YYF/HL/&&'C##QAC\S[<8SG&/
M;G&,^S'M]GMS_P &/;_P>W_C\8#KOL/,]:Q6G,[-:+)'=-+<$F7,Z_=S4$(*
M,DHX(4"-#76HT&S$P<*9B5'EM+J4;\@!%-+C/P X8==-<^%P+/Y_/+Q0<1BR
ML$^3XK+DUBRDDDT4<*Y3)9B-3/*D332#WAA)+R859KT1JH&/JO:KA7">%MP)
MN#3Y[,Y7B7 (.(OF.(10Y>>7,/Q#B>4E<9:"6=,M"PR:&*#WC,.B$<R>1RQQ
M$^3WBYOF<ZSH,!:%XP0Z6936#JC&BDA4;'X%)D@:PVNPY9;JI2UR]D,R7UUH
M.21 5NMP*9!MCSO9[BO$\Y.T'&4DR>:FR@S^6R$O#ERC+EC,(W9<PG$<Z9CE
MS)!#/'/#DLPDCI(8!'*F/8]L?9_@?#LK'F_9N2+B.0RW$6X5G>+0<9;B"/G1
MES-"CY-^#<,&57.)#F<SE9<KF>*922*.2$9LS02 ]AI/]5!_\S?_ +63S]'R
MW]!']Q_Q''XCQ#_7)_[R_P"!<;7S?''CSS#%M+H1M%'F>*.6&.;.FN98XI]H
M=YHM),X]_2.;<<?>737;&LFT$.V^,YBTSK&E2P8J-0#*&H:@K%2R@]0&*J6
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M@H4AH:Y>T9KU39T<I7OW@BE?#8K($#!8+'\#,CQFPEF(WEDO(PTFZ_N@71)
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M0G8H[(O/4'Z*[;8TA+):2*P8U]L37F))23X0$<\V;>R3=DVBD&R";!4@[J"
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ME_P+C:^;XX\/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88>,,/&&'C#'/O\
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MK6C;1K%0(*P%-JU4M]A.  HC&D7L6+$$U\TL"% KII/4DFZ(R,-DMKIC5D*
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MFL\\.5FDS\X]Z"29V00H6ZG2?ZJ#_P"9O_VLGGWF6_H(_N/^(X_(.(?ZY/\
MWE_P+C:^;XX\/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88>,,/&&(R?45#(
MN8TF>Q:33YTSOJ%<+<L%QG2/2/7X0*UX(%!C.NFN=\0#QXDDSM+OC:7???:P
M<@4 O\T0GXE23_,XJ44FR#?]YA^@-8P_J(B^TVS^/[Y_4GD\QNR?EQ_MQ'+7
ML?Q-ZX?41%]IMG\?WS^I/',;LGY<?[<.6O8_B;UP^HB+[3;/X_OG]2>.8W9/
MRX_VX<M>Q_$WKA]1$7VFV?Q_?/ZD\<QNR?EQ_MPY:]C^)O7#ZB(OM-L_C^^?
MU)XYC=D_+C_;ARU['\3>N'U$1?:;9_']\_J3QS&[)^7'^W#EKV/XF]</J(B^
MTVS^/[Y_4GCF-V3\N/\ ;ARU['\3>N'U$1?:;9_']\_J3QS&[)^7'^W#EKV/
MXF]</J(B^TVS^/[Y_4GCF-V3\N/]N'+7L?Q-ZX?41%]IMG\?WS^I/',;LGY<
M?[<-"CI8_P"\WKA]1$7VFV?Q_?/ZD\<QNR?EQ_MPY:]C^)O7#ZB(OM-L_C^^
M?U)XYC=D_+C_ &X<M>Q_$WKA]1$7VFV?Q_?/ZD\<QNR?EQ_MPY:]C^)O7#ZB
M(OM-L_C^^?U)XYC=D_+C_;ARU['\3>N'U$1?:;9_']\_J3QS&[)^7'^W#EKV
M/XF]</J(B^TVS^/[Y_4GCF-V3\N/]N'+7L?Q-ZX?41%]IMG\?WS^I/',;LGY
M<?[<.6O8_B;UP^HB+[3;/X_OG]2>.8W9/RX_VX<M>Q_$WKA]1$7VFV?Q_?/Z
MD\<QNR?EQ_MPY:]C^)O7#ZB(OM-L_C^^?U)XYC=D_+C_ &X:%Z;UVU-ZX?41
M%]IMG\?WS^I/',;LGY<?[<.6O8_B;UP^HB+[3;/X_OG]2>.8W9/RX_VX<M>Q
M_$WKA]1$7VFV?Q_?/ZD\<QNR?EQ_MPY:]C^)O7#ZB(OM-L_C^^?U)XYC=D_+
MC_;ARU['\3>N'U$1?:;9_']\_J3QS&[)^7'^W#EKV/XF]</J(B^TVS^/[Y_4
MGCF-V3\N/]N'+7L?Q-ZX?41%]IMG\?WS^I/',;LGY<?[<.6O8_B;UP^HB+[3
M;/X_OG]2>.8W9/RX_P!N'+7L?Q-ZX?41%]IMG\?WS^I/',;LGY<?[<-"_;^)
MO7#ZB(OM-L_C^^?U)XYC=D_+C_;ARU['\3>N'U$1?:;9_']\_J3QS&[)^7'^
MW#EKV/XF]</J(B^TVS^/[Y_4GCF-V3\N/]N'+7L?Q-ZX?41%]IMG\?WS^I/'
M,;LGY<?[<.6O8_B;UP^HB+[3;/X_OG]2>.8W9/RX_P!N'+7L?Q-ZX?41%]IM
MG\?WS^I/',;LGY<?[<.6O8_B;UP^HB+[3;/X_OG]2>.8W9/RX_VX<M>Q_$WK
MA]1$7VFV?Q_?/ZD\<QNR?EQ_MPY:]C^)O7#ZB(OM-L_C^^?U)XYC=D_+C_;A
MH7[?Q-ZX?41%]IMG\?WS^I/',;LGY<?[<.6O8_B;UP^HB+[3;/X_OG]2>.8W
M9/RX_P!N'+7L?Q-ZX?41%]IMG\?WS^I/',;LGY<?[<.6O8_B;UP^HB+[3;/X
M_OG]2>.8W9/RX_VX<M>Q_$WKA]1$7VFV?Q_?/ZD\<QNR?EQ_MPY:]C^)O7#Z
MB(OM-L_C^^?U)XYC=D_+C_;ARU['\3>N'U$1?:;9_']\_J3QS&[)^7'^W#0O
MV_B;UP^HB+[3;/X_OG]2>.8W9/RX_P!N'+7L?Q-ZX?41%]IMG\?WS^I/',;L
MGY<?[<.6O8_B;UP^HB+[3;/X_OG]2>.8W9/RX_VX<M>Q_$WKA]1$7VFV?Q_?
M/ZD\<QNR?EQ_MPY:]C^)O7#ZB(OM-L_C^^?U)XYC=D_+C_;ARU['\3>N'U$1
M?:;9_']\_J3QS&[)^7'^W#EKV/XF]</J(B^TVS^/[Y_4GCF-V3\N/]N'+7L?
MQ-ZX\I>>UN?7&L\EGFUQGWL:RWN\R:XV]F<>W&-['G&,^S.<>W'Y_9G./*L0
MPIDB8#<!H8B+[[H<:(6B),4DL9(HE)9$)'8E6%C'A^3.I?\ )6#^-;K_ %#Y
M73']3!^1#_EXTY^8_P"DYG_YB;_,P_)G4O\ DK!_&MU_J'QIC^I@_(A_R\.?
MF/\ I.9_^8F_S,/R9U+_ )*P?QK=?ZA\:8_J8/R(?\O#GYC_ *3F?_F)O\S#
M\F=2_P"2L'\:W7^H?&F/ZF#\B'_+PY^8_P"DYG_YB;_,P_)G4O\ DK!_&MU_
MJ'QIC^I@_(A_R\.?F/\ I.9_^8F_S,/R9U+_ )*P?QK=?ZA\:8_J8/R(?\O#
MGYC_ *3F?_F)O\S#\F=2_P"2L'\:W7^H?&F/ZF#\B'_+PY^8_P"DYG_YB;_,
MQ,5R\54$.O"Q/@4;7;2'!)99\^-=M]I,_$+/G)+GS[V^WLVGGDVQCV:8SC37
M77$T!T"J/(*H51]RJ !_(8S+,Q+,S.QZL[,S'[V8DGMN>FV,WQB,/&&'C##Q
MAAXPP\88>,,/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88>,,/&&'C##QAAX
MPP\88>,,/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\
M88>,,/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88>
M,,/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88>,,/
M&&'C##QAAXPP\88>,,/&&'C##QAAXPP\88KOK]S,YQR7J/0UX8S$^A<ZNUS!
M7F[2Z!G&5>M,W@P9>\&VLVHQ,P.D,^T.VLNL6^^8]L;XQG%D4,Z*=@S*I(ZT
M2!BKMI1V O2K-7>@36.-^3^K]W;>@<MJQ5U].?5E?0TEB:V7?A%F9MK!QX=%
M2C+?&^OR_P"FK8'#6"S0=:5L6897S-+2Y20!C,M)3HP^AX %<A94*E0HE J2
MVTTAI3>^K8$:0;K;&"3EF0:HG# EN6262E+6PMO#MILT=1 HWM.KSZVZ%6Z/
M:[,DJ/1F;M#6ZM<4]7L5!N=,,M=/MEL5U .UI/I=!\R0I#/;#;L!I X' >9U
M\+%>NU:"$9JF79F52R %BI8,K!652Q4T:NAMO1WHFCB6S"A6(5R0%8 HRVK,
M%#"UZ6;/0]P,2Z#U24P,ILK9QO[#9,W6XH$-*H% O%@NFJFD)Z@TLICM!$LF
M)@VK7UR2#O&L?P4OT@]0H5\I3Y@.O(@P-L1072A+,ZA;<L!1O^MI:AUH$G87
MBPF7>P2=3*%56+4H%V*VJQ9Z D"[.-LN]5?'7K>NJZPQLUM'L*N@N/I^KT>V
MNZX@ ZB;.NH,EL:!J-]:WN_-&G@EB9Q0R5W$>Q%LU0B9Q/FI@D4$L M%Q3,H
M)*;OI%^*NXZ]%LXD31D@ LUA3:J2 '-+J-;6>M]/ZU8FG1^TT[F3)(A;BVVP
M6:PK7CQ95J'3;'>;'O7:QNLBL5C(55M>?.(E4D.DX<A1.(MS6+0!4IA8,RH0
M]JI&S@D:0 0"S,JBVNA;$631.W0 DT-\6>14(!LD@D!5+&EK4: .PL?>2 +.
MV*FYCZCI^P=YLM+I X)?):YR'G'10;IO7K+O)=".G;.#49:*PRS U\!)"F7#
MR0!$KV#=V7(YQ#*LUK9\$NCP\N)6:Q(TCH4M?"$H&QNQ))^P#;J3C-)3)*RJ
M 8PB,&H^+79%'H  .A%G<CICFJX>NBV5LGLY@EG]-1S+E?3+M24G B[0X#[Y
MTB"HM]  5M55BNV9,]MN<6<Q5<.&E&!%,91XI]X0MIS1]ERRMRAIFIT5C+0Y
M2:AN6.D4JGYQ+;#[<9OF"O,\45HS*(B:D>NFD:MRW0#31/GYX[1F]1_,8+QM
M1)2;'@J&W+>=F6?6HV*2@K^C-P@SUM"-O,2_>N0V8N-BO$T'^>V"T>'@UB8Z
M*S&#*)>?DOIU[5I+A=0UE :+!;NMCY;@$@5OC?FIJT^+YP0G2VD,0"%+55FP
M+!(L@79K$'SZM.?6"F&VVFD.A5N,41F@LURY_?%M/MM7NE^1TD-[5FD*F/#H
M<\EMI"OU'EC+%D-5-VH," G!DEN0X;2U7X@0KJ65E4M3"]JK?[B ;Q4S*5)6
MQ\T@LK:65F"VI'6[V\Q8)%'&FZ'ZT:#5N:]FOM5KMWN&_*J'U:X+,[4VVJ*A
M>2^1F3([4L2WC="6HU@4V;31<T.WTWWU61,[*H#<HE)QL4IEW9XT8JNMXU/B
M4LO,W4E;!W7<?;2D@L :OF%5'<!FT+(P\+!6Y9I@&JNNWQ(VWQ8C+U,\Y3OE
M2)LOZ&MPP>4&J'O#>;W$>L5BX=0V0Q4>HVI_(IPO3OW)EJK2V07>66!.T?*E
M[TE849%'F@A<J6!0[.P&M=15+U,!=D *Q^T*2+Q<S(" 0P%JI8HP4,]!58UL
M22H[ L+(O&G2>KWB+L^<;Z7LB55$)T@L>WV>D6RN4AG^2"8^+I8ZFV-E(R=@
M14(U;,IC@<G:&<58UE73&Y4-= I.7D Z*3:#2K*6',^9:@V-6U6/,75BX$\9
MO<@ .=3*0IY9IZ8BCIWNNQJZ->D/JQY7(!J1,#TI<V-/K"^MU!MRR]J[K=)+
MH#8FM7FJ%:/20,'0S)74+6T,ECTBS6EU:=G6[1 ,O(ET<A_[! #$L'4JND@-
MJ8&@064#Z18!;)Q/.2NC@[4I1@S:@2-((L[ WVHZJK&QN7?DPWIOZWWN@19=
M;<YYYUFRQ(K$N;(#!K9RU/8IFM2M2<^ !VE/ ?U\A.X#G@@*BQIO,+O)!*,3
M*6(F:.)MM;QK8HC2Y%,IZ$$&Q@THY3RKOI5S1L'4@-JPZ@@BB.HQSW8?6G85
M7'/3K<PJ4G)Z%U/JU/YETFI2G'9 H&0^H)^.=C<AS:>X88)4NB.T];1[%>Y\
MY/9$!1>FP\TN,ZKEP9)5+'0D;.C;6W@,D8K?=D!)KI1'7&1S!$<3!06=PCB]
MEIQ'(>YTN0!WL>6^.@[-ZF^;H:1%<P96S[5HS[)7*RI"3-L&O[7PX+H95W1Q
MZZ@3RA_+R<PMD C"<?88[Y."0#YO!@FL^*PN7TFA0C9B2-EE*:3UW^>IH;[[
MXU,R!=5DV7  !W:,.6'3;YC;G;;$36>L'GFM,I-KM*+H"+2PTF@W.U$#<^N;
M2N\[%Z!O@1/M:K% DU##$F81DYUGUQ(0(EU%L;@16E/$-FL<N^IE4J:9U7Q*
M&?1UTK=D@?K8!)!Q43II5F#BU5CX&(75L+->9_G6Y !&-&F]85;,>6*.T#1\
MWK5,Z1VFFO6=P762/5BBXY32+4WM"IGHL&5!1"B@FLVXY^9HQE<<(X9)9Y$/
MOV.7;2"OC9DB8!2NQD;2%(N[N@*\[O;$"<%B"-(5I%)8'<1BR0: ^TWT%=;Q
M,)O5[QT!8T/>8Z%6C59% BQ5[%RZ_*[HU%ZE8=JGS]E7ZA,AR_?!66R:2(A]
M%0)1Z]O'LL<@K6&8QMZ<B2Q6D@Z_$'4J.6NIP6NAI7??8C<$[XMSXP"3J%:=
MBC!CK;2A"U9U-MTL'8@;8_-O5YR/ 8.T(W13; 6SO*HJA@<SN9O0$T_-(:^5
M>YG%3'4R,AA*\';:F9O/#H3AJ-9D<B#5MEA#KER)-_F 4I#%U"G66"TUU9*M
M]VDW58<Y*_K$VP*A6U#16JUJ]K7I=ZA5WB9=@[%^3[GB*UU=-';;!?++0J1S
ME&P+*KH#:R])=+DZ"9Z?,N+/1HUD)\K^PS?1)349.K/A$6%-<CA2Q''J<JQT
MA S.1N0$!) %T2:H;U9LFM\6=]*AE&HL551T!+$ 6:V&]DT2 .A.V(K%T_I_
M+(+0U]1:^C:TA8KKQ:+H7+Q['+])6>Q6(>K!<TVYL>79+HQM;)PR1C5(VNR-
MA[66U^BOHM(U@$%:3H1](B+:R6U*^G8*NHOK%*% !U T5 NR#M&MTU&4+I !
M#)>Y)K1H-L2;721>HFJ!J_@CU;<F%A!@G'Z%K:C[L3SF+G.O-KC+T:*YP4PG
MH<:@BI0JI#XH#:4++907^?;62%.LIGTSK"*9L,Y$G]C3HUZ]:Z-.K1>JZL-X
M:ZWM6XMSDV^=J+:=&AM>K27K35[J+OI7GL:T@'K=X >B.M&S:Y+*V)SE_P!5
M$=O>:WQ$$^IM/9H$EV,KNK5 (4X.ICJT(%-C4BC;,1#6<.HXQ<6D\L4^[2ZM
M-*3K$9 =#3,"5#42 &"FB=MC9&*^\15JM@-)>RC"U4@-5@$E2PL=>UXET/J?
MYO.&USA;TB.QJ7=>03<_(YE=1^ADF6U8T=5<D2I3)]&.Z=TH1/CX7LNL"8#"
M!^&Y.6LT;8$.O)?;=-)!(;6NBE(# M=6"0*ZFQ0((NPF0W\ZP5&DHP:V!*[5
MT(!WZ;&R"#C7 ^K?CK,NCKE\]T*:7N2ZZC*XN?7#Y^K1<UN@O/>D&]!AW4ZZ
MT-70K>7"IM#:S[KU@&VVI.A<X<L$\LF"0:B=("Z=]2TVM2Z!-_$74$J!N?OV
MP$T9*@:K;5MI;PZ#I?5MX0K;$G;^6^/(+U?\3*4'/"6-N2KXZRMN=>V?\\NR
M<SH%4=V!)4T3OG"PQ'&RND;JSV>JH5RU,).[E8VRJ1R*XHK,BE8#EY+TTI.H
MJU.IT,%+$.;I:56))->%M_":CGQT3; :0PM6&I20 4%6UEE  %VP%;C&WXSW
M7/6G/<A]:T[1+^3WA-4@U[JO/4-O)^<Y=1[TPU;U]Q#"5&=&RM!@2S8&+<!L
MKA6L%Q!HYL1<\21:!%N"9%+$@@KL[H*(\J7?S!L>6)CDUF3PD!&"@$$,? K&
MP:K=J'< $'?%:T?UN<]L7.JA=G]8Z F;62J.KZVJ*&B7.YLJ?1DKDQ03;W^R
M:OYG@KNTPDL0!VP41C^<)QK7U;'5,T^2N^7979 RD!@@9F"AF(!H6>O\]@19
M%C%%S"E5)# E2Q4*Q(4&K( L"]AW-T-CBX.H=?Q4$?([#58U%E4]0ZIR^DCL
M?F9)0=ZYT,SX>K]40))B,G? 6\1:[?;;<6?677?;&^F<>42/49 U@I&[5YZD
M'0W]O7SQJST$(HAF1;^QCU'\NF(?>O4NCY?U/H%7O8\@-(I?,^!6R%TF3O[)
M9#[/W/L/1N0J4$%?0B,CV$>[JKUF$")6N(.W)=&9DTDBBBQI982Z(R[LSRK1
M(50L4:2$DD@#9C=FMOMQ1I@CL&V54C-@$DM)(T8%"SU  H>?;'WMZNN38% U
MU#Z1-9&-SL//(J /S&Z$] ANM8JR^\-4)E7@4R&!R:TMLKM0[$C;1*2A/&81
M,LP[YSB/=Y-_F:0JOJ+J%TLQ4$,37S@5[V*K#GIL/$6+%=(1M095#$$5L=)!
MWV((-XP$?K2X/8%FSP-M;A4<]-!Z D<.N=W9 %:JB59*]4"G%8RY1@SMHDEF
MME<4.X8X(R0)VX1&8909M2O).7E4Z2%O5H(#J=+46 -$U:J2/(UWP&8C(NVK
M2'!*L-2D@6MC>BP![6,;/HOJ=K-(Z'2N:K4+^TOG_7:WRJS_ $6J;R0U&6T\
MUM'2E;;>6!82.UQ*MKX\<HL1 V@H93-I.7KHA+%F) S(SEE4"-G6R/%I=4(Z
M[;G[=P!6X.#S!75 "Q+A6H'PAD9@?MO37\R?+$0Z!ZUN=U&C](LZFNWULTI_
M(^G=<J"QU1[A4E/3TG+AQ,/Y:K8FB#>&18(>V1?/LMP]I($+36U@ M$(\QFL
MIEG9T4E0&D2-B&5BA<[:E!NR :\K&DD$@8ALPJJQ 8D([J"K*'"=:)'0$B]N
MAU $;XGF?5+RX=L$F8XN*^?!-%4V=I/1+7BM4"S](%2ETVIWVQ85[*ZM87,=
MCKV<KF)&FZB.P5^>P;J1WJF8RG)>K%'YY4:AJ=4)#,HNR!1Z==+5=&K<Y+ .
MK<J"=)I6>M*L:H$V-CW'<8C<'JKK=BZ[RSF](5O&JF]VGIM<+N3.IVE55V&.
M:5FR&N9Z/9RP1D5BP!:4>J(R6(B2 V#8@]'LQ!AV/CMR"L;NQ *JA"AE+#6P
M U+=BU-UU'G1VQ7G NB*"0S."Q5@#I5B=)( /B%?:+(L;XQ?4'ZCW7*P.Y$U
M)*D<2\)]/9O8[/N]E-B$D=O"K"/SNN12!3PYU&+'H=X9VF7;;YI>)K6,#:^Z
MYWG@F*)7,88D<V81BJV K6QOMK0+Y'Q=L)92@D*@'EQ&1KNK-Z1_/2Q)\MN^
M-5SWU/JIT5LN%P[5Z<.GUI"754(X_II-=W^QXMUS;_0U6KI"=18KD::TM1^<
M UY8$%$661$7/MM\D$9..>$@JJQ3(Q#'Y:E&E1;&RJ !1N230_F,0DP(9FDA
M< J/D6+G4QI00+-L=E W.^-BU]7]%#?U?'Q=T-3'QV+3KT]V3/JS:.8%<HH:
M3H!0S>OGBPF0[DU]ZO=Q2:C&CMD#%4T0SG"L!9I@R[D':V/+Y84A@X=R@HC;
MJ".HH@@U6),Z@KY+\IKU @IH4-N/N-^=@@BP1B6\F]06G6.N=0H(%6LM<4<_
MYQQBX1[76IV:EVHAKT]_VD P4E-8PPMMU(J?G%=/6FA12?YVY;K&,L3-64N
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M5HEZ)'=#64-QZ=\R=/31[/3P6'.4S2 ">OJ:[)8;$,/:;.V^22R'QZ1Z[R(
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MZAC\Q@P)WK=66U==@VQV*C&9BW5E8J0I1B!\]:(%BZ!5CJ5MR-QT8XYV4_\
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MYVRE#N-%.!L2)Q71BDC2-[.M^ >U#<H7&DP,BW))%"E'0NI97&EM!!4$==+
M@@[BKV%$;WHZ,6#HX1@I4ZEU@@D'H&6B"-C9&Y!!QJ^$^G)+P8L_9#8V3I<5
MS+CW-X!VP@^K#73D\%SCR_/8BRQCFL+1/<9S3AAE:T1>0-MJ)IN.1I"(EE,M
M6 #KD;;IXRNP'D%TT-R2.N^Y1Q"*Z)(*HN]7X PLD=2;WVQ%F_I-2-:-T.NQ
MVLI5<++V*V=RH72E248:R<MOCMUAZA.4>\=+LU@23XV5N YBP [A6S7%=:#C
MK&Y<6;"<AD.D%5C6)D)V= *(.VQ(W!HZ2 1N!B#""K#40Q=I%<#=&/0C?R\Q
M8# D'8G$)#]$B<7K,G2=V7*RXF74U79G9+#@%3<]/Q=@=%IYH-7ZC8WSO-9I
MQUK5PV4(+:HM[K6MR"@:YT!=KJM*6V]X.C13@B,QBI6":3=:D &I@ITGQ!3Y
MKU!I[N.9KM#;B0W&"^H43I<G921>ZEAT#C:H\F]!\H,EHW*Z370?K&)5!CM*
M!R87G(5L8UGJM)Z=M>^H5M)=9Z3:^GG9I7T%BW52J\Y$&BL]J-WKY<; -<NL
M<S=>!C1)&J365!1DTHQ76$&J]+,Y\(%^>(&6^=;@77S$"!B'5]3J&TL_AK4H
M3JVVXKT?>A#ZS,>RD,NCHE W7>>=MH#8ZA\K"H=HLFG9 B5T#SL!B.WZTWJC
M>A"$^[6V$//Z6W*F@B*<-C"-RY"H&9TB,!">6\;@.^I5Y9!(C!74@<CQ#4PK
M8#I0Y8-S+8 2*ZG0F@G6*MZ;2Y4?-.A3MN2;OWM7HGLE]O$-ZNW5*98'..D\
M4ZIJX*XT67:*Z\Y$?SMP54^;O7?578W.^96QS0R&D]<3IB+*)/:W\;*[V(<T
MV(X,PJJ56-E&B2.N8*(DUC4X$8UNH< ,3I\(\((!!LL7;4[@G7&]Z-P4*DJI
M+G2C%;*@6"3XB"09HW]&E=L?.ZOS*Q7!@;74VOJ.#=;!*(EYSQ1ZC%G15#D(
M:?9B9HG)KX70BL!G9B98.F712R""8(VTAJ,P0[.%W/)JS=&$H1Y"[*#;:@?/
M%S "@0L2 )0=J)$H8'>]JU;'?IY8UM[])UXZRLKVW6^M4OH+RA6*KV&A+'7#
M02>3P%(JW>:DX*O/-F5^:G7)O<DE^8ZNCU]WJ0*QBBJ3*IIZ\0J8?34K.J:@
MD94.&#D2'7N58:7"@*%*#2"K'=@2;%5:!G UR*Q0J4'+\ I64ZD+DL6#&R&7
MHI %;SY;Z9@ /3-TCT\1.:VISTVI]6KS6P4GFE;H5;3F]3 >@$&H>?5P@<2-
M?7AW$(Z\5M8&]A9BK!\V&W-6<Y#7>AF/.26B=#1D!G9R1'1 +'?>MZ  O8 ;
M8N(0(GBL#6K@E5"@%P02%'D+VLDFMV)LX@K3T5IF-DO]@TOC"&*WVSB=M0IY
M$(Y"^B&<UZ%RWHO084>-6D$DNG:'?(:@78]I=HL*&HNS:")EOO*-+<9DA472
M/"LBDWNP='1;V_YL2,!W&VV*G+@LS:CXC&0*V72R.U;_ /.%%+=COOCQ']'[
M_+A.&QZX*3S2JW[U!WRK5$/GF ;-"3ZBEO5A[*!8+M-<V CF.LL>L.2:F0OI
M]?VC6#ZK7\+TR2!T$]X%$B/QE(D9B]CY$QZ2%"BM0C 8%CON"!8+D&P"_@5I
M&"Z?%<H<,"VK>C(2*4;;&^HK.T_]S^L-VKXZ"V=@IUA^!SSGE%!;NN)E.6=,
MFYM%D98VY9"WZT>EH6MD@&6RW335.[>M&.&QJ:SU[4Y4-7KKF@K%EC86[L0)
M  VLV0]1VU&])L "@0:)-&RS, #(II46S&204Z%?E*6]M0HDFZ8; 6/;?1.'
M>C;R%9NB324JX6CM=D@2J:MA;9%'Y=.;$T*SBYM4UD8 GRJ#"/K#7#,50' W
MP]53(5IKG)_E%S)0+I0:E$8LFP>4^M?#0J^C#4>XKIB[9<,6MO"QD- 41S$"
MMN20:(L>$=B#UQO#O2U;KE9U][ZGUM99[FF;<3V3F5?F^],0C5SCO4A.JS@D
MI"[W;"BK'>70D(KRP:.QE*P41?\ 0=2#^"?HT@3*JZ4C(4B2[?42TD9C!O2
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M@-O'T(5I7A%MKL[,V982D0#0*YG4CV29%5G7ELNHLS,I!TD$:=0W)-:2"2H
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M3N[)\E3(QB%D*'"M\H"% 913$%F9B I JRVQQ17^4M7'-->)D+)X"";#&U!
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MNMRRP"9+)C;24G3KU1_(HU::B+^%*J[:V YE]=5&ZL8YM+_+,MW;Z?$VJ]-
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M5,&;9L<6T:M&)M$0DFL6;,^8@YBP-)DE)-.-(G++)EE((FEFDWWVY)?Z66@
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M8A?-".2+*%.%Z7XAPOB[#LM)_JH/_F;_ /:R>?I66_H(_N/^(X_#.(?ZY/\
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M^.2_V?'#^(0_1?X#UQDC6S4K,^(ETV/EQIBI/?(BQ_N4&OO;XU]F,^W?./\
MQ<9]F,Y_TYQY!B85=;D ;^9Q=,[&^K2K>!&<W7S5Z^?7?&-]=H/U<1^^A\GD
MO]GQQ3^(0_1?X#UP^NT'ZN(_?0^.2_V?'#^(0_1?X#UP^NT'ZN(_?0^.2_V?
M'#^(0_1?X#UP^NT'ZN(_?0^.2_V?'#^(0_1?X#UP^NT'ZN(_?0^.2_V?'#^(
M0_1?X#UP^NT'ZN(_?0^.2_V?'#^(0_1?X#UP^NT'ZN(_?0^.2_V?'#^(0_1?
MX#UP^NT'ZN(_?0^.2_V?'#^(0_1?X#UQDS6S6"$6?==-[A>DDD6-2(L[8UCD
MS%M[^/9C&,YVQ[<8QG;\WY\^S/YO($3$D"MC1WQ=L[&JHQ5JD!*]+I31O?;?
M&-]=H/U<1^^A\GDO]GQQ3^(0_1?X#UP^NT'ZN(_?0^.2_P!GQP_B$/T7^ ]<
M/KM!^KB/WT/CDO\ 9\</XA#]%_@/7#Z[0?JXC]]#XY+_ &?'#^(0_1?X#UP^
MNT'ZN(_?0^.2_P!GQP_B$/T7^ ]</KM!^KB/WT/CDO\ 9\</XA#]%_@/7&0)
M;=#"(A8ETV))M_<TSO/%KK[?9G/^5G&-LXQ^;_@QGR#$X!)JA]N+IG8Y'5%5
MM3&A= =^MX\,W6'7.<97$>W&<XS_ +O#_IQGV9\GDOY5\<4/$(02-+[?8/7'
MY]=H/U<1^^A\<E_L^.'\0A^B_P !ZX?7:#]7$?OH?')?[/CA_$(?HO\  >N'
MUV@_5Q'[Z'QR7^SXX?Q"'Z+_  'KA]=H/U<1^^A\<E_L^.'\0A^B_P !ZX?7
M:#]7$?OH?')?[/CA_$(?HO\  >N'UV@_5Q'[Z'QR7^SXX?Q"'Z+_  'KC$;.
M)6JV*> ';2/0[,6?B$1XVSOB#.^?9C73./=]V3'Y_;_I]N/9_P /G!GTTH@<
MUXK%#5Y'[1CWN!3B:65XU) C*G4:-AHR?(]QB,?%*^RZ_>-?Y?GF4GTS^#_W
M8^FM_H#\?_MP^*5]EU^\:_R_%)],_@_]V%O] ?C_ /;A\4K[+K]XU_E^*3Z9
M_!_[L+?Z _'_ .W#XI7V77[QK_+\4GTS^#_W86_T!^/_ -N'Q2OLNOWC7^7X
MI/IG\'_NPM_H#\?_ +</BE?9=?O&O\OQ2?3/X/\ W86_T!^/_P!N'Q2OLNOW
MC7^7XI/IG\'_ +L+?Z _'_[<6FASME0%G?7W-LQ[^W7&WO>S/Q9/S>]C&/;_
M /K[,>>OEZY,=&Q1WJOZQ\L?*Y^_>Y[%'4-KO^HOGMC;^;8Y,/&&'C##QAAX
MPP\88>,,/&&'C##QAAXPP\88>,,/&&'C#' 9O<.S*(O4??I5CYE4N-D=C^@
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M*E]9.BJ#*JZ2SJ#>JS;5V)VNHS!)^9LVG0!J)LJS,&I2=M) I>UU9KZ0>N>
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MO)0;0-]WTL&TCQ40:HC'O(R70PY(F/"B'U@(*VGD*@CAU%$VTU*)S+M)C3$
MVTD>I$V=OAP[;Z8DVUSMKC,42: )-@51NST'WGRQ8RQA=1D0+I9]1=0NA" [
M636E20&;HI(LBQC2OKE6:TO$:.&X@X;"=:,OVCDP3*PD:L %@608!_BS&1;E
M,@OB3#Z210038)GWC'UVDQ9(W<E54DJ&+>5:06-DT :4['J10WQA/G<KEHTE
MFF14D:-(R#J,AEDCB3EJMLX+RH"R@A0VIB%LXWLAD46^VFVA6=M?9[<Q@FRZ
M?GQC/^3)$/O'M^;/Y_=VS[,^W&?9G&<8K7W?$>N.F_O^!],:P.!&NT-C7J=
M8V1I;%C&&A)&T/8'YQL<>;K !IJ4:9MC&Q94^))R,XQF:3?./).HU9N@ +8;
M = -]@/+MB-M]NNY\)W)ZD[;WB$5_E?&JG@S%5Y/1*SAB>H:,,5_FJE-@YF@
M8QN$+$S"Y"-@H](WAA:*"Y_?(6L8HS@Y(2=-9<6+R-6J1FH$"Y+H$40+;8$$
M@]QL<0%C6]* 603259!L$T.H.X['?$RG!KI)1YQ*,<@UJJA1-#)Z[-*4R2#R
M'S#ISR)%^TQBJ"9HSEA7D;R"12,3]](==C",R5\6V_0V/$-CW&_78;_9B?#O
MMU%'PG<=CMTW.WVXCZ2B\SK+F2QUOGM7K]AE5C(Y7R2AAJG,J4(9>$&GD: )
MASMU8@:A4(,OVGR) ,L7P10Z1!#:126=A1<D7=%[%[[T35[G?[3WQ " V% -
M582C7:P.FPV^S&LK/.J96@9UNP9UC#UZ3;^JI8[0A&:[U2V7:Q/+6W(K4^M?
M%G!Q"]L]C+5F$2&.@(71J^-ME=@80>2S$W8!T*AIJU*H"@'Q;[* 1L#0VO *
MH%42-3.+4FF9BQ(\/=C1Z[]<9I7/.5&LK&X-YM42V]Q72J+<U*Y\ 0RM*F>,
M.*978SI4FY3Q=-$O CE"9RE#21@AZ;Q9U&AQI&J2E&LTIM1KV4[[J-5 [G<=
MSWPTI9.@6PICHW8=B:W'V''C!S3D8LM8G&Y?2QYJ3F7:F30<Z6Q2U+:<W+*?
M:L21H]=T.9F.VQ\N561,R&YR5O[T^<R>3JD\7C;Q?.\?SMJ\7BWVVW\L-*"J
M0;=/!TWO;;;??;SQ$]^#\;%,4&U>C)Z!*MMB.XG_ % H:*K;VAE6RB&"8:S%
M@57# ]<&T(^E,0CF!3R&1XQ*5N-,6,3/,DH@MJM2OB<G2#L2!JH&MMP=L5Y<
M=@A=-,&.E--D=+I;-'?KB[?GX/\ DS?_ .&L?POF='[/B/7&EC[?@?3#Y^#_
M ),W_P#AK'\+XH_9\1ZX6/M^!],/GX/^3-__ (:Q_"^*/V?$>N%C[?@?3'G,
M2$1#*.0,3.//')#/!,I/EAFAEUSI+%+%N)MI)')IMMI)'OKG7?7.==L9QG./
M%'[/Q#UPL?;^$^F*M"XOPA8J8H5O%N;+T;<P!BV3!<I0B*FC!5MMNK.8KH*[
M&&:8MWWWV *)AEG#VWVV'WCSMG.;EY2;,C$BP"9-P#U%ZO/SQ31$!0C4 T2.
M7L2.AK3Y>6,DKD?$S@MUIO(.?&+I!%@$@!7,$Q 4@*6=F4F"W%EK^\&PBDET
MY(6#;1YA G;,YA=(I#RMI6N4;B1@=]^9WH'^MY@ 'O0[##1&>L:G8#^C\A=#
MYO06:[6>YQN"Z+S,\>80[GM7-%)B,'(&+H@9(\\#%.OKK"&:&9-O'+$=7U*I
M&9'OKMH4G6+UD^NX00T$<:G'1SY?U^Q)'GY$DCL23YXG2GT!Y_U.X /EY@ '
M[ !C!AYCR ;:L[#\LI$&U*FF(INT/.%<6U2((88;D3UG.B+7*&:=KC#.:55D
M3>5AC!N^VQ.,2^3JD.JW;Q?.\?SJ%#5XMZ&V_EMAI3;P#P_-\'S=[VVVWWV\
M]\1BK<#X34J$OYL#RNI'U4,"O!FANN?*V>UB)K"Z-8J>6G,U?Q"_L6D&F\DK
MH^"0S<D@J?7?3:>3&9:25F+F0ZK)!#U6HV0OBV'V#$!(PH70"!6Q2[T]"=MS
M]IWQ:BD"N(8R8D2(9+$9*+.9&IKDJZ,J<%2M0A3$Z!KX=9Y0T29.E%DEQON.
MI5+5T.= P188J'4>IOKU8'J23U/F22?M)/4XL*'05]RD>0';L /N &-M\_!_
MR9O_ /#6/X7R*/V?$>N)L?;\#Z8BMO-AW60XQH7C/SL6?\H _3'_ )$C_AW&
MUQ[?S_Z/;[?^'V>S&?-H13'I\T^8/F.QQP\0WA6OK5Z[?U'[UBMOF8_T2/NA
M?\GSIQX]'[/B/7#YF/\ 1(^Z%_R?&%'[/B/7#YF/]$C[H7_)\84?L^(]</F8
M_P!$C[H7_)\84?L^(]</F8_T2/NA?\GQA1^SXCUP^9C_ $2/NA?\GQA1^SXC
MUQ!/R=<Y^.Y(VIJJ22P#LA&^)4TTT10SDO1@Y@U'E@W'%C<,8HF3;4.(?#-E
M%"P.^.9%'/KISI:4<QJ4@KOT*C2I/<JMJMWI4D"@2,< X5P\-.WNF7)S"R+-
M:JP99G$DRA22J":0"64(%$LH$CZG 8(>=\[@$V!UJ"Z4:01Z#/&6J*.V*'L\
M0@]AP9*9%/,;,Y& "$8E%R3%$ABP"239&CUBQ)FE)U<Q@;0BC5&.RE 4!I))
M4"@#OUQ(X7D%31[I RE9T8.%DUKF@BYC67+%VF5$61W+,R*$+:16+003#C:'
M01QE8BB1'01:_*'2YUTT@UTTQMOM#OOGV:ZXQF23;.<_Z=]LYSG.>>3<H?\
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M9&9[U,Q,]8EQ96H\8T)_R1BL9]H1F,?[[W_T9S!C&V/_ $ZYSCS!/G2?WO\
MTQZ4P^1RW39'\Q],_;O_ "QI?F8_T2/NA?\ )\TQS4?L^(]</F8_T2/NA?\
M)\84?L^(]</F8_T2/NA?\GQA1^SXCUQ@,Q53D*5<U!R>#-O!)**2"5)#)N*1
M$6/MMIF'V9S"3!#-IG_@DCUV_P"#R02IL$@[[C[11^()!QG+"DR&.5$D0E25
M8@@E&#J2+_JLJL/M QH9:;2I[#FUS5H.6P;;ZS;LI%A.TFY6J[9/H?)#F+(T
MC/1/MLHT:;P[,-%.<K=2< _[AY82R!- =M'2K\M6JN^G4-6GIJ\57OC!N'Y-
MLQ[VV7A.8ZF0A22PCY(D*WI,HA^1$I4R"+Y(-R_#C$5\^Y\EC'B5U, 2,5D
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M(Q%FY,N07>;-EB<;U?P2W:VUJLE4T^)<6@H3'>VYC-Q+3S/R\]AZNRKG-?\
MP7MDC%;$=(T8<A$U9T$BUK;SY6303%?UH<W'RU;5(6#RKR[!$@&4R\"O.-7]
M=E9S6O?F+>^K'1%[/YP9R6(PY(1/E\A(<Y3ALG(>/\9XM+EN&?)'4,JLT$"%
MSE0H]VGTD)[L-L5Z9V,%8@KJB*BYG:\[8T1RW+#)&+JKAHVE9%=(I_RRHC=A
M:9<S#33Q&3H22&-;JIGT_%JKQ#M49Y3(7;FTLRRJH((D55H0R$L-,=@U6L /
M(-&]XT?V7E7*C+PC(%IN&R</FF='5LI-+,TK\2R>F)C)FCJ0D.T#-)ELH_/
MATG96?TY.'!%NE&L $B_-E3O.?(2,3B#J5Y%UTZ3?TC1C\BUQ%I;;GM$4$5
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MK,V!]3M5<L&5*QP6T$6.023@QM)L>RK1N@!8 62 "RZO"Q4G3>H ,K"R*L$
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M)8VA.8D@DSC%XH$YJ!7E%VZ@RJ[IX* B!8IJ57ZO:+H<6UG".B56AT[5QQH
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MDS2FPN%K)=K&(H;+@%]D6PN\V]YDLFE\5V/$+LJ:M6!%%011!Z@D@UB/=XZ
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M),.,_6OYC'_AOZP_Y>6V57_@KRG.;E\JET=:HWKO^DN[UZ3H^CH_JZO%C?\
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M%)+/CQ[VJ;CO#>%\+?AN6RF7X$!E^"M [F7*<.>%/>\E.[ >^'-<01^+-F)
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M!XQH/F3SAB#3B<QQZ[$&&3SE%39WG(FDEWWWSRO/-([2/(Y9V+,0Q LFS0%
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MB3;Z PGBQM(+QS^^+CCAI9X,F"0,^? A&+M)192U[$W S!<;&*9#K#/RE9-
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MF,"I/I_LPE:YP;9;>)!>^>56EJ*M\I7X9T=?W0"$QL070L3>+>WZFQL"%,S
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?CE1)$/5756%$ XS?(Q?#QAAXPP\88>,,/&&'C#'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g189651g11j44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g11j44.jpg
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M 0,1 ?_$ !X  0 " P$! 0$!           &!P0%" ," 0D*_\0 01   04
M @ &  (&"0,"!@,!! $" P4&  <($1(3%!46(2(Q05.3U!<C-391=':UMB0E
M83)Q&"9"D:'1"2=2Q/_$ !P! 0 # 0$! 0$            ! @,$!08'"/_$
M $H1  $$ 0,"! 0#!@0% @0#"0$  @,1! 42(3%!!A,B410R87%B@:$'%2-"
MD;%2<K+!%B0SDM&"\%3"X?$7)34T0U-D<Y25TM7_V@ , P$  A$#$0 _ /\
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MJ[K665W -)965;DF8:EJZRACG_#\1UK9E:JMN&V%!$#04R%KPUKG.D>TEPW
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MK$6F<K<[=EVFCI#28K<8>O;,0\>.6&;'%[BZ"F1N(/EO#=[G-8T.&S<XBRX
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M[_$I]'VIOK/' &+T%M,#UO;5XZUN9T,D]SHM?HM5/3"C1D>O,9L2T:V<JRE
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M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X11+<V=U39>QL:
M=2+(>2M3S;5F7D@E?/:@C7-I%25\PY]S-3T\Q]M!4 RH99RA,"%9+//'$^\8
M:YX#CP;[AMFB6MW$$-W.INX\"[- 6J/):TEHLBNUT+%F@030LT.35#E1KJ'4
M:C7Y-+?5U\U>8X@*(9"L_:9<LB-V>HB[-Q-)<O6Q%<#I"KVGAFF@$C/$K![
M6!PI4))%IF-8_:TV*)X<'5ZG >IO!MH:XU=%U&B"!6)[GMMP(Y Y:6GY6D^E
MW/#B1="P+'!LVES):IPB<(H=OO[KF_YVB_W^KY9GS#\_[%5?\I_+^X4QY563
MA$X1.$3A$X1.$3A$X1.$3A$X1.$7R][(V.DD<UC&-<][WN1K&,:BN<YSG*B-
M:U$57.541$155?).$54.V5YN7.$ZQ8-'2.5T9?9UJ,\B@1J+Y2-Q%9ZX)-J7
MZ?T8KKWA,6*Z5I,%II20#LZ[3:&\OZ]F T?_ %'^4?3YC[-ZK/<7<,Z=WD6/
M_2/YC]?E'N[HJ1\-/A'ZI\.V\[KUN"FU9-MNM&*/9IH[D6Q$KPU!#U2A5$(E
M76OC@6QTA+5ELY;0[V!16-,;YD?(TFGDE;$U^VFM)&T$=RWFR>S>U=3PLX<=
MD+I',+K>>02"!WH4 >I/4D_5=C\YUT*D;#P\=56<W:1)5$4A7<)F5L=@1!<6
M@\K;'$3ML<J?GUA*8F<*IM DVL'DJ&C>YJS#[\I)SS299-!-(-@W?],.#; /
M#Q3@;'((]/-^FAT 5/+9ZN/G(+N>[38(]J//'%V>I*PQ?#AUM"!9!%MTEQ+=
M5"4UQ97&DLC;&P%36KMO-TGN1C HV^5'CB50M?6@ ,BJZX$.OAB'9/G/L$4*
M-@ "AZ=OY\>]GN3:CRF\]38HDGD\[O[^W ' "T=EX3^I+*LN:)S->!G]-06&
M>U6?J=G>UE1J!3AM*)$7>C"$QN,L*X?67$0A#9(631MJ&6D-DW/4#:R1/(*/
MIL$%KBT$MK::!(Z':..>]59N#"P@CFB""+-&P1S]@XU^7L%.<KTEB,9LK7:T
M"WXI=H7J+):1V@L9,N%;[:VBOMA;AT7NH,X_07<<EK.\UQL-<:?<2T4-3]Y<
MM.JZ1SFAIJAM%T-Q#1303[ <<58 NZ%6$;6FQ8Z\7P">2:]R>>;HDU5E8^(Z
M9H\?I':1)Y#3*JT[BDQ[_5/"ZGH.]=GE^S=[3GQ),X6RE?OL]\NF-2 =U90?
M#IXXWOB++,.D+A7N(]WU,37,:1[>DT?<\HU@:;]B^OH)'![A_P!PX]APON3I
M6A;N[SL"LU'8-#::>\HM%HZFCUI8.:N[3/T='FPY3Z5898'QST><J:T^&-\4
M98XR^XB222/<\UVP,+6$-!:"6@N )+C1^[B1[)L%EP+@7$$TX@$@ #CIT "C
M8_A@ZHC, :8)H;O)TQM[8T'6-_IK:ZZPHC-+5W='=(#BSYYJV>K(IM+?U06:
MM4L<M15]J0)GZ2J@C&9!/G2<\@.- O#0'FB"+<.;!:#N%.)%DE1Y3.X) )(:
M7$M!-@\$T00XBC8H\ +7_P#PD=&!"6PF5R:=>)>7MW=V1'6Y"88F9NFS8&2T
M=(R7/1!)!G[FCK0X9ZV!D:!GP#WM3-77P@=F-/GRFMSM]  ;QNJB2T\]P2>>
M_0V+">4P7M&VR2=OIZ@ ].Q _KR*/*W$GA\RE.7=WV#G-R^BEJM''CAY###\
M5A=1I,Z%FC-C1X[WX H;20"L 83%%/!!(Q;CX7UI6HTAMG'FN-!].%C<: <Y
MH=NVEW4BR?KTNPUM/+ LMX)NK)+6D@ D#WH?WZ6;MW(Y>GP^4S&+ST#A:#(9
MZER]&,]ZRO'I\_6C5-9 ^1419'0A"01N>J(KU:KE1//RYFYQ<YSCR7$N)]R3
M9_57 #0&CHT #[ 4%(>0I3A$X1.$3A%S^!N^PI>UC<H73SQTB68<8\:XR_BK
MHJ!L&S^59-WSB5SAA\Z!XVS:+$GR(5MRLXVJ<8(;<B])CC$(>#ZMIL[VWNME
M#RZW <O;[<;KHAIP#Y/-+*XL4-CJVT^SO^4GAKJ'/-5U*Z YS+=.$3A$X10[
M-_V]V#_J>M_X1DN6=T9_E/\ K<JMZO\ \P_T-4QY563A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1:VRN:BF0%;>UKJI+2R$IJU;$T8)+"W/<Y@-4$I,L2%6)K
MV/:(%![A)+FN;#$]45.2 3= FA9H70'4GV ]U!('4@6:%]S[?=?H=Q4V!EM7
M 6=>:?0E#@W@(A@Y)=,:77B6PH=J-#(^:O*)JSP;* <MD4LP!HAD;'#DPR/$
M$42" >02.HNK'OR"/N*2P; (L=1[=^?;CE83=5F'URV[-%1.JFWK\NZS;; .
MKVZ6+3.Q<F>4Q"%'2\CV+791]4LGSF:1KJ-T"6:**C:ZZHW6ZJ-[=NZZ]MOJ
MOIMYZ)8J[%75V*N]M7[WQ7OQU6<7;50!E77G60 9]X20'2A%&#CEVY8@)-F4
M+6#RR,F/(&K0C+">$5DLD((A)4C6P02R-439 ) Y)KH+JS[<D#[FE-CWZ]/J
MLHDD8(8@PPB 002"4DHHF6. 88:"-TLY!$\KF10P0Q,=)++(YL<<;7/>Y&HJ
MI'7HBK,+O'I:QTR8H#MSK,S9*YT:9(?=9B73^XRM^YDB^@99K:^['4?]UDB^
M)[D=<BFO:T9%D2YBD#=QC>&_XBQVWK76JZ\??CJJ>8R]N]F[VW"^E]+OIS]E
MCY_OSHS6 W%GENYNJM'6YVG=H;^QHNPLG:@T= Q$5]W;E@VTX];4,1R*ZR,D
MA#:BHJS(BIR3%*T@.CD:7&@"QP)/L 1R?H.4$D9LA[" +)#FFA[FCP/J5NZ;
MM?J_19>[V]#V-AKC&YEA\FDU=;JZ(S.YZ.K!99V;[VY@.?7U#*^LDBLC76!
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M#31W.:['S>>+$T78=]W';WR[/L6?J7M+(Z/<Y$!+&UDPE=JKS34J5MZ Z@U
M[+!OR\A0"X*@FL;"6$.<318YPI@C #6>8QS6N-#>6AIL$$&OF.XU!CE( %AP
M'+B\\NV.!<*)VV2*(Y]P !=M0]==GU?AA[GSEV-J3K"X.NKBAQMM<"Z30K@X
MJO,I?X4.*LM]2,'+K656PBK<^/L==!'+J(VPVU>,5'FL_GOC,T9&T "BX @;
MK=3C8;>VV\[6\-'!(W&^UPB>#=FS5@G;0MHY/6CQ;NO'!#1N,_X=K*_M]YI]
M1M]47F[CN.T[;PG7H$^'CQ!9*T%1%D=)8'CXMG8*%PV,#[-:J;=-J5(&$4JK
MD#5XDD&4 ,:&M!# QSSN+JW$N &XLJN+#+JZ-\J1&3N)<ZBXN:T;=O(X)].Z
M^];JOLJIP'3'>$'2.-ZZO:7=$7?70/0=U#3]D[KJRRZ]T-ETQJ<9?66/H)L'
M7D:"I&NXL^2RAM-.%8"ADATL]HU?:*9/=TD7F.>"VGF46UCVN:)&N <=QHU?
M(!%V:^E&L?L:TAUM$9I[FEI+"TD#;9%UP2#7'"Q.UO#_ .(WO'*=[CRVE1CZ
M/>5#WTG7O9.9Z\TVITEK7YS>"U.=O-5U#8X:OKL917=[D#<*[4Z3L^[#LLPR
MSTA$@$Y]):S'+%$Z(UN+#R]CGM:!N9;@V0/)<0';MK6"G - (L'QR/;(+#0X
M$!K@TDFG4+86TT$MVV7'@[KNEG]D>'#N'<@;G$*+0.EU&BV/8;NR&F05.=L+
M#3>#&S\-S<J_.K8WVLJR5V5E]@^.1MU3A]="01LU%AHT2M:9-&TM?SPUK-E6
MX;<D37=!I](KL=_:N3#HGN!;QRXNW=C<)CJOF')^OI'6^%8H>0W$_8V=T]AE
MR\G;;?Q*#]G14#SJRW+R6(R7AE9U3H+72F9\NRH$(T-H%#GQ(:^TL$^'ILG/
M.L!X]D+4Y[F[" 0X-A++Z6YTV\!H-'CYN@Z._.X#MP)!!=('58-!L>TDD6.:
M Z]Q^7;?.=;IPB<(G")PBK+MFW+J,B?+%5P&B2,8IYYRYF6MJHXBA'PO, T]
MI5!V*F2J@H8\4LLWS'PK'&Z98&2:Q %XYH]@-P)L$&BT$BAU[5=\6LY20TTV
MQW/I('3LX@&^WU[*/=#H)+E[RR&1D<MOK##3Q8AL[7#AG0TU#6.'@I\V04/3
M>8]<,02$?+]I,;.593M:.>*G+3WN:.S6 #EQL;G.^9P&[DD CBJ'4%5AHM<>
MY>;%-%$!HJF\#H..M\J[N8+9.$3A%#M]_=<W_.T7^_U?+,^8?G_8JK_E/Y?W
M"F/*JR<(G")PB<(G")PB<(G"+S2:%TCX6RQNFC1'21(]JR,:Y$5KGQHOJ:CD
M5%151$5%3R_7PBUM[;LHJ@ZWD",L(P(??D$K_A_+DC1[6R+#\\P 15B8Y97I
M*7$JL8Y(_<E5D;Y L@6!?<W7Z G]%!-"_P"WW49UFO)JY@<YG 8K?<W@[YZN
MG(E5@=4"Q[8B=)J"1EE<!GJV5Z1O=$KB[@[VZBG;.7,Z0>6MNR331U/<GV;?
M4G]!R5#G50 MQZ ]A[NKH!^IX"H#H[PK]4]0]P]L]KYT ^7L?;LA&UEX0>0E
M<63H7U^KU1-11>MXU-%H=-#%;D!I.:P)T40==**$QT$FTD[Y(XXS08WY0!R-
MMM;9[TTUVOJ;)6,<$<<DCV@[W?,;X.ZG.H=K<+KH.@H+KOG.NA.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A%\2N>R.1\<;IGL8]S(6N8UTKVM56QM=
M(YL;7/5$:CGN:Q%7S<Y&HJH1<EUMI'?=STXMM7!TUE77Y]C") -UTRT@LFYN
MT1]6=HJV[L+>R);6&S&FU0,;+641&$F1QU49:OZR"V%Q%D.: 23)1;O;3@PM
M  L !QMH/3U57*#NE (VD.NOX=@[3P7 EQX-D#DCKQ:ZWYR+J3A$X1.$4.S?
M]O=@_P"IZW_A&2Y9W1G^4_ZW*K>K_P#,/]#5,>55DX1.$3A$X1.$3A$X1.$6
MJ.N!*XVH (86Z>[)G#"= )// DXXDQTC2IXF.B$111R)6/G<QC_9D:U5>B-6
M0+!/''/7^R@FJX//M_NMKR%*B&[%@-S)D!,+9XG%5"NC<BJB_P#> 47S\E1?
M)6JY%3S\E:JHOFBJG+,X</S_ +%5>+:;^G]UZ:7:YK(H'#;GJEC8I(VGH*T4
MNWT=RZ#T),VFSU7"7;V31DD8\R84.0:O@<I1\PHK))F&L<ZZ' ZDT&C[N- ?
MUY[(Y[6]3R>@%EQ^S19/]..ZXAZ)TWC*V_='B"SO:.8J>J^L0M LV*UM-54Y
MU\1'%,.%3A5$]C9W58<398^*JM+*WMJ \>M+B03Z@>:R2"OZ)1CMCB,;B]Y'
MJ:2:[DW0!%.L  B^MFK/-$[(?)*)&AC+]+@!?!  %DCEM$D@_;GCH3?>&?J_
ML;/0T>NSE1MIFZ&CT)%KV4/9;LV<BFGE>Z.&0RY!EK("1B[()E;53!9\*"T/
MC'HTAG=#S)DSV&VDMX(IE-Z_D;HT;-DUU6KX8WBG-:_D$E]N/%^YXNR*%  G
MCLN@(((!8(1AH8AQAXHX!QX(V0P000L2.*&&*-&QQ111M:R.-C6L8QJ-:B-1
M$YEUZK;IT7KPB<(G")PB<(G")PB<(G")PB<(G")PB<(JQ[7CL),O(Z!]-!6"
M$!6=F;9Z2+)F54U+9 75+<4UR?47E$T^LMJ\<J,#0@)36$C(A[ J$-2(Y]82
M \<$N-AH#=X=N!:YI:"UU%I(MIW#J!=$92WM[ 6"27;"*(((<06V"+IPH]#Q
M:Q>GCJRVSEG=UY&M/(N- 05<6VQ@HX["WLAZNHK(C0"<H*)CK.F945]4"!9Y
M)DM,5\*7U$3VC+)ZS,"'!I# &M :UFZFBR2"'_Q [<22)*<+Z!M)$06EP+SN
M<22^K)H"QM]!%  %GIX][5L<Q6J<(G"*';[^ZYO^=HO]_J^69\P_/^Q57_*?
MR_N%,>55DX1.$3A$X1.$3A$X1.$42"&&9N=$2P>!A,N8R+92&Q1MGE:EGLFH
MV25&I(]$;%&U$<Y41(V)^IC?*Q^1O^9W]FJH^=W^5O\ =ZY2\7W9W<3.J-(!
MX5*:OW?8-5<UX>JED"@L*:BSZ2D078@MC8SAYH_6CF?7PFY_YY5E4U$UA8'
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MC@RF3C5K"'"AI'"Q$Y@]^XFN&V2U@Z-!)- =..YZGJ5O&P,:!U=M <^N7$
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M]LK/"1=]@2CS13QKJ*Y$DAD9*Q53$Y)%1'L5S55%_)4\_-/V\AW 9?\ A/\
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M@1TO[=C?0\$>X[A0(/J.CKV"0!65H,*C@'W(8\=1 +?K6:BPV #"H8:N-E?
M-=VMCZ1J1M; M84ZK6/XT(J07,A))H=ZY)VV T]3S8'>^>53RP*Y/;=P!NIQ
M<.@XHD].W"W><Z_JL\DK'%&70Z5-3GJX6XC G'JZ"CF,GJZL=D 0ZD(.\U[7
M&'*4;/&,$DT[Y!UED@O)[ <EQJ^2>IZFOL..JEK /KP&@$"@T=!TYKW/*^\F
M*,'==@0"#P"PIJ*YR0CQ1P1(YV)R2N5(XFM8BN7\U5$\U7\UY#N0R_\ "?\
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MV5/SB[$T-:0L9&=C<GZ,^)SYL+H=-Z%=%J+P=^9G<M%5:2OO[C^&+_G(X'^
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M0@3(C2Z.%BK(V^P@6XAOT/S'[-ZCZ%VT'L53??# 7?4<-'W=T^X;N([A<?\
MA4ZB[^'V?=AGB9[,SG;E'#V$.=@Z0(\RP IKH-Y1!%J92/KZNJ!8.#)G8Z6F
M)AN(Z"VJYR:QU8>$XH[HGDBV1"%CHSL]1( )'M=DFS9)XL$78/'/!'-ND,SV
MO;NM@!) /-&J  JJ'-$<419[]L:FOM5"4^!TRUQT-D'Z9R(/9-'1Z0S?]/+%
M[GH1[T]N7W(G(Y4?&Y.<H)%UW!'Y%=1 /7[K8\A2G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(H#BS?L+;L
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ML<@:XECQW8ZG#N%U9.#FX;<=^7AY6*S+A&3B/R<>:!N5CN)#9\=TK&B>%Q!
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MF[(:UFSM?I=1-5;%^&<%2TLJ$&7<6;#UDTHDUK+5U[*5M&;&5#?6!P-18/\
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M</2AGG&_>7P7EG3@3K7_ .E?_G7G_O,Z8#_R>SXBIATTVS[2?YJF*PD;?/\
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MZ(B)7>N*5CT1W.6?0-%R8)\>;3,-T>3#)!,X0,;,Z*5CHW@9#0)VDM<X!S9
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M*>5%YOG>6SSMGE^;M;YGEWNV;ZW;-W.VZOFK6WQ63\-\'\1-\)YWQ'PWFO\
MA_/V[/.\G=Y?F[/3OV[MO%TLWFBP6&37@&R"3& AES 3H4#*2-#/($2C58A
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MM@>WRC$'A],Q)-C(\V7S5Q:# )-ZOAPJT7N( )) )/)ODT/]N/;GW*!C6DN
M )%&O:R>GY_V4NY563A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$151$557R1/S55_4B?XKPB_&N:]J.:Y'-
M<GFCFJBM5/\ %%3S14_\IPB_>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?/J;ZE9ZF^M&
MHY6>:>I&JODCE;Y^?I545$7R\O-/+A%]<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*G^X@FS
M4L%@>-F3J.LC)4NOU%->Z<*RN; JKKLS6Q9>H(]FW(L+0GX4+IZJ[L1B)QV4
M@"F%/=S: G<0TN#C5%CFL(: XO)>?E :+/J:" =QH+*8 MLAI:.H<"ZR2 T!
MHX))-"P[Z"RMY@ZG!Q1%6^'S,^5'FDD +!3):#K\<F9GQR'%RY:VJZ"(N=&O
MCCAO5J997,^0% >K&%0-B1TA($C]YZ@[VRD#D5O:YU?5MCL2.A4QA@LL;LO@
MC8Z.^G.TAO\ 6O<7U6S["#./Q&K&K#;8 ]U!:O$FHWI':/GA"FEB&$E2">>.
M0N1C1E>&V,]K954$@8KVIXZ,H.;=$6+OI5]_M]>/>PK/%L=1(X/3KTZ?G].?
MJJ8UJ;C\:2$4+KM#(!0 Z@!(;UT);9L7HO=LX[!LC<F+4#WIH:6E=;"3VI%G
M40SM/'=/GQGZMV51JB3?2AZFT*^:R :(-4:JK*Q=OW<;N@JMUGTF^?EH$BP>
M;%^RU4B&>N?T-[$_ GU,ZC)Z=DEXFZ_"@SHG>7E]][/FDZ^;T^L_&JJY%^X\
M^../DW7STK99_+H1?-[1[)1Y^<,KMN!W[1_ZN"/8C=QUX%QEW&YHZ6ML#PZ
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M3DZ*C"+AIJ&IFBK*7(;'= UK)/JV$GPGW\EM+;SV)9 HPY(C%MDD[V@EQVL
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MB<NG(KSK4&JET0>5N2\S6/N-]8=89TZSNX!GAP5>DVU6=5TQT+B(Y0H6Z,M
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M+F;V-8AAI[!],9.3.(8+7N(EN>S>YSO.(<\N/0EP$^+(UKKD%C9 ]G).W<
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MNGV&FTJU]Y/M+,"NBL=%8RTXCYHW2F0$*-&.022:-?Q!5C^=C6@D!H%C:":
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MK^Z^N.B^JETW9>AL<]56NES]#62U MD99FVJF?=.#%AJT4AK?JJ:S(GFD?%
MR*!6.>Z:2"&7?'C?))3&AQ#23NJ@*JS?U(I<N8YK82'/<S<YH!87-=8.X@%I
M!Y:#?/W7AUY3:'MKR[:NKZ"ORVWJA"<0-E+$QUL3UB>V"SSHZZ)1P"\R/IA7
MB:33CT$<6DL[-]8,;JAJK/UN?$LYS(?0UN^1I]1>!L;(.#3+(>6FV@O] %TP
MD[UR&#+S7O,TOPV&>&1XTC_B<F+L9,EH8[%CD%.,>,?B'>ESLJ,;H!96$ZTQ
MN,U.]O\ /]?4&5LM-9AREW]95401NB%97B.E<656R/L9W?<?9&$+:,AF((+0
MIWO2.<Z.LLTDD<3'S/D:QI]#G/(8=Q H.]/R;0-MT!7"C TS"PLO4,C'T['Q
M),J5A=D110,?DL$;2XO=$3(X^?YKW>:&ESGAWJ-D3R]K2K4*$40P<*2*SJ+!
M9B0I#F.;4V8MHV!(8CJ]S73RAQQK,LSDCC<_RB>Y6JW)C@TV02-KA0(:?4TM
MNRUW2[JOS7H3Q/E8UK'M81+#);F&0$0RLEVT'QUN+ +W&@3P3TW/*K9.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A%7O8XU##30:6ZQ@^V?F#Z\P4"4".S)KX3
M+2N"M;NN#F%-8\^FJY";6)60,(?&%*-$8"PF4EFL1=N+6O,>\$$@U=-):TFQ
MPXTT\][HU2SD#:#BS>6D$"K(L@%P%'D#D<7Q0(NUOLKJ:S85+;FGBL8P'S20
M0OLJPRKDG]IL:NF'A-AA?.+YR>VTF)'0NECFB:]7PR-;1S2PT:NKX(/]:[_3
M[*S7!XL75UR"/Z7V^OO:DG*JRK6\[.J,]9V(UD&7%55!@]79W?NB)"/:ET$N
ME'%C =.AY,#JQD37F0PNC::5$.QDD8]B0#<,+@*ZGD#GI=7?3K^GY70R!I-C
M@&B>.NW=TZ]..W*P).T_:DGKY,I<IH1 Y[@JA0JJ4B*@'JQK66T0KY:!O>GR
MX:EH*2I*MVKA_6E<W[59\OON%70/(!<217Z63[*OF'GTG< 35CY:!N_SH#W^
MG*VNRN:H_(K,,>*]I\F9+$8LT;)Y8#+BH(&>D#W-F1989&2-:K$=Z7)^7(:"
M'#@\7?'L#:LYP+>HYJN1?)%*Q.45TX1.$3A$X1.$3A$X1.$3A%KK:U"I*\FT
ML7SQA!L20B0<,T^5D:O;'ZT%KQRBY&M5Z+(Z*!Z11HZ63TQ,>]L@$FAU^X'Z
MGA02 +/3[$_H.5'M;LA<R,!$.$1=Z2^DD%R^7#<D%C=&,C;)*Z1T[?35U%;'
M)&3>W1L;1*<5S5E;*9.$"7+6DWR !RYQZ ?[D]@.3]K*AS@*[D_*WN?_  !W
M)Z=UQ;TEX(L'A.\>\>V]+:E[JZ[.D;-H<?H P;7$UMKI;$#;W4H,%E!.3<0@
MWC$&R\]M#&744ZR#R?*)G<4SIDR7NBCC #0SHX6'$-!:+KI8/JKJ?8+FBQFL
MED>XEY?\S746VX[C]Z/RV.!]5WZ***"/"&$- &(-&V(<46&,<>")B>3(H8(F
MLBBC:GY-8QK6M3\D1.<A)/)-GW*ZP . *'L%[\(M'4U)5<;H"R#XS&7=K'9Q
M0L#^*H+8ZROJFCK+\F?Y7_3UHSUE5D"K,LSD8C'L9')-AHKH*Z]>2?;CJH Z
M_4W_ +?[+><A2G")PB<(G")PB<(G")PB<(G")PB<(G")PB\Y8HYXI8)6^J*:
M-\4C?-S?5'(U6/;ZFJUS?-JJGFU4<GGYHJ+Y+QT3JJAQFER5)>&]<5&)*QY@
M5G8M@"J<W/#2&U\3G/'TC[ *N&#9%:1HU92#/TUL'N&4HQSHB2-GM>X"1SP^
MP+)<-P/^&B2>.P';L.@R:]K3Y886FS0#31'^*Z Y')/ZE7%S%:K0::_AS52Z
MTE&G,<X^FJA1!W0QR$6-_< 459"Z8A\< \+[&R%:03*_T#P+)-Z9%8D;Y:-Q
MKZ$_DT%Q_0%5<[:+^H'YD@#GL+(L]E"8>UJ^>7VXZ:Q>E>6*%II&3U[X\\09
MK[3$#^MS252QC6[IK.69PGZ8]4*ILL;9Y(PG6V'W'/+>O(VAQ^W!'7OQVM4\
MT>QX^;IZ?46CZ&W C@].?HMSF-\!HU>YX)5/!-2U&FJR;*8-L5EG[V8V&M.1
M8YWJ(1(X)7S@$HV4>,L'S>^6:6$<6$?7DM-7PX<D?7[CV/YV:\.[4*#@2>K3
MT/T^QYY"]LK/ 3=]@2CS13Q+J*Y$DAD9*Q53$Y)%1'L5S55%_)4\_-%_7R'<
M!E_X3_J<I;R7U_B_^5JFW*JR<(G")PB<(G")PB<(OADD<B*Z-[)&HJM5S'-<
MB.3];55JJGFG[4_6G[>$4 V%MG*_2]=P7-I1 6!-_;25,%H?7"'%)!E;UI3J
MR$R:,@E873B_)^&V18DDA=+Z6JU>6:'$.H$BA= D=15U]CU]BJN+06V0#9JR
M >ANK^XNO=5SI.[K"V+BS72V=BWFCL(/=#OK&>>NP00CY'#_ 'LEE#&XV_HQ
MY4=*EE3QQ9ZV44^GJ=1/IH(Z2?9D'!?*[RXVFB:MQ-7L:V_G-CTGEMAS@UEN
M'!DYXC>W'QHSE9DC=T<+7;6M87%OG3R4X0X[2#<I!W[71P-FGVPNB>[\/M;L
MNM[(/N@RM[CT]E8Y\XTC64[OP72D0W K6AXC%!G#AYL,8<HL*.R0LO56HT[V
MZ+0V\?M00RV8-D'E-,;!N  <-[K'5[RT@G@<!H:*H =3/PTY@/GS1S9+BTN?
MY1&.SU ED,/F;FM L;WROD<;<YU;6-ZFK*VOIJVOIZH$.LJZH$2MK:VO'B#
MKP 8(Q@P@A(&LA%$%'BC@&'B8V*&&-D<;4:U$3G))))-DDDD]23R2?NN\
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M9H2!GRPN:GK]39:=I!ZU]Q^HHCZ*'#<".E_8_H;!^J@0?4='7L$A"LK485'
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MVZ;C]B&CNZ^#7EWONI.G\IO=LNH3>ZVFS5M<:<^NMZ?1]A6XU&$18."9$$K
MJ"L$<DLX=0*%2Y2GEF)+CKX)""Y"-X\>>:2*/88VO>UK2]KF1C<:NR!N/U!+
MG<#GA>-GZ[IFG8F;EG)CRY,3'FR)8,66.;)<V!A>YNQCCY0%<N?LC99)( 6J
M\.OB.QG:7467UM1G.Q:H!WSJ.( C(ZC7S#K0D* K/O,EGCJTR!L;(V032((2
MY&/C(&;-%(YU\O"DQYWQE\3R UV[S(XR0\6+9(\.![\6*((/(7)H7BG#UO3(
M=1CQ=0@;(^6,Q#"R\O:Z%^QU38F/)$YI/RV6.X(+ 05>$?8]#))'$VKWJ.E>
MR-JR=7=DPQM<]R-19)ILI'#$Q%7S?)(]L<;45SW-:BJG/Y#^?5#Q_P#S$'Z?
MQ.?RM>P-3QR0T1:A9( )TK4VCGCESL0 #GDD@#DDT+7-70OC&%[XN>TJ:CZH
MW@Y/7&B%ITBC^D]^P%-)N1H9SW7-I0@4EC#)2S(95$GS/B2:)T<\RI.P?MRM
M..*V!SLB*I6%Q)WT" TTW:U[G@AW#@T=#8'%_,Z!XS9KTVJPP:3GM=IN0V$-
M'D;I&O=.T&0SS8\<$K3 0^)TA+=S:<[U;=?XF^V?$?EX^KY>G>B;O0K9[1XV
MD'MK)SR1H!HZY]9#*G7>UF$#J[=2K1A-IH2S*<!]6U;"K?'./)).#!A/,XR,
MIC=L8+"UO'.[<1Y\0+G- ;36 ..[TNX6?B?5_$N*-+.C:!/D>;FEF2V:4ES6
MM$1B:?W;G%C(YM\H=+DO?!&8AYD1#FD]226/9ZRS-AR&&:.DLC1YY>P;UQ2P
M(]4CGE 9UJD"3JSTR.#9:K&K_.'Y[6_UZ<(;!Q<LM\6!"RK[@$SW7:]OUV]E
M]29=5MVW"P VR&N=J.07[;-.=&-,V[JH[!-5^GS!\RY<\+-AXL;7-[EO;N3Z
MZPEDS;GOHWPUT,T9<<SBEOG.KLOH'0EP!VC(8 CC+2$XIGRHYI)F#CS+VYS<
M!KXOAY)I6^6-PW=*K9ZGLL$MLD!M=" +(7RWA23Q;+BYXU?$T[ E&?(8"(FN
M#P[?\1_#Q<G:]K)0UK)'RM>X;VN+MK2NI'U794S71R[7)C-<U$26MZ_LH2XW
M>E$<YDEEO[81?TO4YJ2 O1/T4<CO)WKXMT K^%(?<.F;1_[86D?U7U1AU-P(
M.=B-!'6+3I&O' Y!EU"9G6R+8>P-T;Y<R/0G887B>[-WEYX@-/=9&^S5>R#
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ME9)\L!LD@>T/:US'.&TNVA6'2=-=44=/34U?UQCV TE15TM>T[/U5D=#74X
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M>+EB0YR0[&VKV5=F:6:34V5O^%JO22=@@_ZA>YXCV1!P+(B,9\+MHL%@!D!
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MNC]'H5JJBHJ*O,K-W9N[N^;][ZVNT,8&[ QH96W8&@-VU6W:!55Q557"^0
M*L."OK A*X 5GMB@@#0AAC1^:N]N 8=D<,+/4YSO1&QK?-57R\U7@DN)+B7$
M]2223]R>2HCCCA8V.*-D4;!3(XVM8QHNZ:UH#6BR30 Y*R^0KK$& "">2\00
M<9YL[RBWP0QQ.))?_P"LB=6-199G_P#U2/\ 4]?)/-?RY))-62:%"R30]A?0
M?0*C8V,+BQC6%[B]Y:T O<>KG$#EQ[D\K]*!"-]CY@8I?Q9V%#?*'B(^.5%Y
M^V3![K'^S/'YKZ)H_3(SS7TN3S7@$BZ)%BC1(L>QKJ$?'')MWL8_8X.;O:UV
MUPZ.;8-.'8BB/=97(5UAAUX%<R6.O!# CG(E+GC#&A%9,5.J+,3*V!C&R$3*
MB++,]'22*B*]R^2<DDNJR30 %DF@.@%]AV"HR..,$1L9&'.+W!C6M!>[YG$-
M !<[NX\GN5F<A73A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A%4^$P^'SVT[4O\[B<CGM!>:0!NAOJ+.U55<Z)\F<I
M+ET]]9!#0EVLZV-L>4LIDLCG3$22O]4SWR.T<YQ;&TN<6AIH$D@>HC@'IP %
MFUK0Z1P:T.+N2  3Z0>2.O))5L<S6B<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBJ7M$:2?ZI2J^]
MLZ1M;J(WBT EJ<6S33 "MS!;X*>.4N)(&MN&!V$C&BU]M/7$R3CD-%F9I&:N
MB ;;R:'IYW=>/:QU(NK6<@O;P2!NZ6?57I/'/O1Z ]:7CK8]JS%0L*FHGS,'
MR3#W$1FO+?9-/IFG/<\:5@KF.L$E<U8F(U851$_2_/ANS?\ S59KITYKKST1
MV_9V/ N[N^+Z?53;T[?][E?X%O\ S'*^C\7Z*WK_  _JGIV_[W*_P+?^8X]'
MXOT3U_A_581\^^$@CE&'S)TCS:T9T$4=K&YD!EB*&48KG3N18ZX6>:PF8B>J
M2(5\;7-<Y')(V'NX<'V["Z_/HH.\=FGD>_<U?Y=5F^G;_O<K_ M_YCD>C\7Z
M*?7^']4].W_>Y7^!;_S''H_%^B>O\/ZK665CM:YU:U4RTOV-F/6HJ1VS/:<1
M'/(DR^<SO6C?8\E8GI5?5Y^I/+R60&&_FX%]E!+Q7R\FNZV?IV_[W*_P+?\
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MA@AOB3#S'EEP!KJ(]Q: [TN/4BJYV@U?1Q( /4\\"BLC)0<2WU#B@;OC<1=
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BPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g189651g11k11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g11k11.jpg
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ME);3UB$B(S$V07:U&"15"3)1)3-&=++_Q  ; 0$  P$! 0$
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M^?RAYS16:5G6U4NQXD_E5>R3778'Q('>MO,(B62A95318(!RKU9O0"^_4^X
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M%?#WGXG6\:>G*BL4->5#L[BB<U.]7?I%9O5??:K+HGMG1F]H<7,N)AH%(L-
M>[W%Z"8C;)V"20"4*/*_)"M:2) E8$FE(9%0J1:E4"A>K]1Q!L&[OXFY,2D
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M6M-1.5W$ME5K+FTH'2WI*!@>!/L9FMUC1:^C+1-96:04(Q>.M,0LP&A(KB.
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M:Z9WTQOG&,XUSOK[<X]['MBQ86Q9!(%BR!5D#U(%BS[K%^HU(5BI8*2JD!F
M/$%KX@GT!;BU FSQ->AU[\G4:>--/&FHN786@Q$L$5)M)\<><8U+$)IVH\V,
MZZ[9VBU-M@96,:YSG3/QAHL^]KMG7&VGN[;6 '[2CY$-_P#12/\ /5"Q!_\
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M6Y-^F_UC_P!33[3N/W>W'^:HG^;>.(_;7Z/_ "Z<F_3?ZQ_ZFGVG<?N]N/\
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MB6789!D8FR96Z[?%O,./AY&=BR_TEQ2KDXNS>(MRPH)#B8_A9I%P]SG..<V
MQ3PY&X3K)O[<T[96F90*P[I5@6(;79($0P]>(V9VM;E7SULIQFW*J':%'Q@F
M#*V)%<-L3I:FX'V*T;V]837LGB^S<LCQ1@SO'!+OF9CX>X9J8L:8;^?N,)@V
M7(QA_6./M&?C\HII]QQ(%W'&QMNR4,@R=RQY,,S1\[9</P'NN)#D9<'A;;<K
M<=GVN3<)9=SC&+L^4,OQ-A9E;-F>(MISN&1C8NS9^6^S9V?O.%((FPMDRXMS
M&/-V[Y^IZ_!-/&FJI[Q=F_-.'=EZ-7X@9G] Y3T2[)(6<,Q*V5O5:@X>K8F
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MH4,-IIF7BCH8[IS!:)#PZZ9' DB>-\3C-3;>2M.3RH&.@SQQGVPY/M,::BE
MKZCL@>FJ^<UJHX]AR2$D<>RR@=+VMAK-]#TL^NMB+ZI+UOV#;G6 :ZUG^^K7
ME0E3$Y[T]8R:I0 4S"VW9;U(R<SFDV]/2GL[>TJN\>K&5*EF50F:NC <3O)7
MR^=D?V?.^2$ DD!2G3CD10/I9OL ZD2MSXT#[?"@KW77)N1]F@+)'P%7?6KC
MYWUN[-W_ %FH7I(@7V3G%9J=ISHE&LZ]?OFV#V[>5$%FUAKS[>IKQ-5^3BZ@
MC#!JMO+,/7+5BEM6'J^"CHH$;*20Y8=E2?9*]^S?$D-? ^TO5V"#JZNQ+JP
M**IZNNP; NBP!%<@.)-@=@@5Q5O4G>#*H.,_0U>7I=L4<">\W7*(FP:)\J[L
M$,+\V4*6R9,=_N\=I>BM;; "?O-I2:VO;^Z'.UTCQ9HD!L%N ,@>Z+ Q_P"
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MXQY#M---N@R,>:#S,?#AQ5$T_P"K;OX?\#;7+XUQ9!X9B?#S/'JX.$<R%,S
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M&PIN)&0K&R@C@BO&I6ZQ20O&60WR:P2_( H+\P@O71KD1\.O<!V- L0_* "
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M2 K2<5.L'%DRR'WIZDFEB 8D$$L  'Z)_-?J3ZDV"1#X^@ MG)4 @@*2;46
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M GXF_P# (_M>*/R^H^^G-?C_ )'[:?4!/Q-_X!']KQ1^7U'WTYK\?\C]M/J
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M;_P"/[7BC\OJ/OIS7X_Y'[:?4!/Q-_X!']KQ1^7U'WTYK\?\C]M/J GXF_\
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M_A],0XN)L.!L>=%G;MB[MEXV9MTN;%O!=L-XG;&7%D!EEL,?BA]19[FYQ5F
M2CLR)>GW.@35-)969G15*BIW9]3IKHR1:I)0HE$&BD1ZVR0< *$K9Q_"8$&_
M)A,*8GC2;)W-<%(]JG=M^W/9WV_%SIY-ZQ\;;]UR]L;=)\3\(T2XR#&CR\CG
M-%''CSJ5F>7RXIM-Q_HQQ\'8WW62;Q!B1IX2V+Q''O&?M.+!X9S,W>=@V[?(
M]BQ=Q.>L[YLC9LVWX7E8^1+D9>*W/&BQ_/GQK0H'1G=EM5LI]C1*$SBL):P]
M('3O)W.0M;//8(=$3'8A6LCF:J]$6DA9Z?=BF(W/P/"3'()[Q7>V?>\K.W#<
M=MS<3&QLG Q<#+=,;*?),0SWS%&).7QX%?(QQB!I)L4SXKF;@KJ8P9/DO$?A
MC VO9]FWO;-PS,["W;.W;;XI,W CP?/.TQ[:[;CBB+,RV3#S&W!DAQ\Y<7.B
M7'\R2)EFJ&)<X[=73ZF[8-DNM,$KN#&(J$%49'@"G;6][3414D>@L ^YYK.N
MM-RQ%T7P O\ 9CQF377)$O.V3Q3AS;?E39.*-L3"\R:/#BQY1Y.VG<LO;,21
ME$:H9I<C"R#)'"O&+I>Z+MVO%'@+<\?>,#'P\X[[+N?D8TNY9&9 QR=[&R;?
MONX1*S322C'@Q-SQ!#/DOYDYY,>)/E))M.W51CL1A-N9O %<551(:LE+<9&0
M85;]:<Q@!:CADC_/A-=9Q]1#\@[[^[$?OC5-)AECW#Q5MTW/\,92D6YX^VOD
M38^0F*TLFY#;9TCG2-T$T60'01S>2S4LQ'X5A/KDMX"WC%\K\<L"R3[)F;U'
MAXN9A2[A'!#LAWS%DGPY)X9?PV1AF.0SXPR%6WQEY9R?A=?&/U <_E&#(TQ:
M,Y;QHB:T-FIO-#+8NLQ4@2%K7!MA-9#ES O32+::3 ^ZV,H MO$O!8!%3U'C
M#9RD3@9Y_$KB28*?U?E>9N,&?(8L3(PD,?*6&:0!2S<# )(I,E889HI'NW]'
M'B1)9XF_JD?@FW"+=)1O&WF#9\K:85R-QP]SE$Q7'R<:$LX1?,7*:+(APGR<
MC'GBCEF.G53:EQ7OXK+Z/,QU1Q"?23_KF]CWLN:;BMX2XAR=EWBUXV0;"_#^
M'H=KOMO/J)IL5CH#?=O.UKNW*<8SS#%6,X\WXLYISOZL&#^%X^;^*_K'_P"Y
MF.N(E!)<1@R#CGPIO WU_#W#%_')C'/:;\;C?U>-L&U?UX=T.>9!CC _J8C<
MA-SY''( C,Q$1K\GO2L:R3K"EQ:E2(MKIY,[Q>Z7O-)V.G;-G2[Z-E=OMK.J
MUX_,0&7O-],<"'2D+S9X=E<C'D2>+L>/.:"2&3&QXX,*:1\N'*AR@\__ +4_
MB8?PI@)#0#PVSQ2%O(R8Y6>&5E\@S?21?T=YDNU1Y<.5#FYDV5N>/%'M^3@Y
M. 8\4^ A@Y7X[\4H:/+;QM'%/"L?XO"FQTBR8(W&6N+F2^H&C::!%S$FI ,$
M;$M][.D?)RX:U)SV[]!!L( NRZ7>80U71VTT?S?RFVD2YF)-I$XB$7%:-XPV
MD"*1Y)<2'S"^0<_%R\:1<%MFW;>8LV*,PLS12X^TY+J91&0L$\;!<E8X9,$_
MHW\0%LB%(H,_(\H188VG<-NSH9-U3Q+L'AK(VW(F&4BI-!E^(,.-O)\Y6?)Q
M)D9\%YLJ':,^VU=,G)<M4=] A ^H2LABZ2]')6@*UZ]J8T+VF&T"^2U!:@R0
M8',G,,)W*6!B3MEC4$'T3^*,#&QI,K(Q=WA2'SFG23:\M)((8(8<B6>0L@B\
MH0Y$3*$D>61S)!'$^1!D11>/$\![MG9L.#B9_A[(?)_#)B2P[]MTL65DY>5D
MX<&)"(Y6G\\Y&'D+(9((X((5BRYYH\/+P\C(E%(N<=SWMN\$$48=>M.4()44
MN\F&86]:K=@@8[:R119@VEU?YBQ#_M^S2#23.^-I-M-/=M6Z+N9W$HBK%A;A
M^#BD5BPGB.#A9B3T57AR&9Q"=T$!NV('*W_8FV,;,LDCM/N6T#<<B)T5#B3C
M=-TVV3&!5W$@0[=S,GLVTC*!2AFG/G6U\_J"=0N)/.^<WB_")=[')2JL[M<B
M*(O8(AH)7U\[4\,0C0,_;!TH(I& 8OE)<$EXA&VS%K+F:.R+R=5)KD0+JZLT
M/A[]5=N*LU7Q!->E@=FOG7I\=<_#>JG+>]6>AUZDP,S8K_2J;SEG-:OE5?1%
M[4RY+NA6&&6"OGRJ=.9G<OZ?&R7C1/?J4-<53Y-6?:'2-?J8:17+4"K,XXV4
M(XE!Z]EPZ$7QJSZUK/S;8JJ]\E523TU\N1Z'7'BW79- ] ]3SC73.G]!>=$7
M76@4.H+J!:C:1*=5^FV&[&L["$HK+W;>-<VY30X!4VZVR:8U.V9S'8-$V@RJ
M^!-@N.LB(@7B[,6 :B@4!22!V';OKL57S.IC=V+\E4!6*VK$DD43T57KOUN^
MO344O?J;UI%)Y1?9*7EBAZ;U\BC;E:6# T*'F\(O1+%CK^TN4T_U!7K0*'B]
M3H_<"WA5,Y8M6\LB_$AMDAY-(O*BD?/TNV]@>7Z]$LW&^^QZ=]0TO%4;C8=^
M/KZ+[1Y^G?LKRKU[J['>94/5!6+'T7IM%9*IT0M+M3&LU=Y\P2S^VWV8K35M
M>#LKQU46*]I7'5:M:$>$DX[+K5+HQ%DB^H0!:0T+*B.#?);8>G&R HN^^096
M]!5UJ5E!9E(H*:!N[H62175$,*[NKZNM:^'UA\RT4WRR,UEV JM(= A9L,%.
MLC,)DA+Y51.L2VJ3Y15G"D 1)>@X/D3I/JA\D,&RL4TAC %I/X=R54%2S#TY
M#H\V0+Z]DE3V.A[ZJ]1YZ4Q(8!3Z\3V."O?IT*8>OK[KU][OZO.85)/?F 0M
MLL9E&079MH,%5+&&ILC*A)0G[VO([,4I^CEL!E+(!E-(/*0/HNW-*BV)W4-1
MPRX[DJ#Q'(J#;"U#&@Q6[J['[^O>-#.@#&F/$,12FF*@$@&J]"/_ $#5GVGL
M].I[Q76VPMPG=-*BXO6 4=&MEDF K**+7+ QIJA4L<A%?-RBJ@5.^-F[1L8,
M L!+FVDQ%18V8$@K08)995MCZ59'5=D^@'9.KM(JD AK*EJ"DT!\:![)Z ]2
M>AJH"_6#0IG2=,A6.#/GP[IEJR<KWB<"KNJ1<N15,^OO,AH7A.AAVO74QZ\P
M,<I;G;"T4@J"-SJ:!<8[422.BM 42P978$65']PBB0?4^[NAF6PH!-\K)Z *
MLBD$T>SS!'N/0L7U<-%[50NBMY4M9,;[D[J2;"F(:5UXE76NM!-<)"[)4&+4
M 4.QHQFD@P\IRV6;3X#)*TTUV3OT3!C1HV06:]0#1!*L185@#8-7T?>"#V"!
M=75C0OT)%@@$ T2#[Q?_ '@CH@ZM?S/5]/&FGC33QIIXTT\::>--/&FGC37-
M/2O5)S_EL%S"M0KE%<*T@?6%#5[*)LD@OJQ.2,! RJMJBU:5DU66<P68.S&P
ME?5H(W0VR5Y;G3(^VR0N]%:*D@%@;XDV:8&C= UU3$4"=9M*J<KL$ D ]<@/
M>#Z5V+[L>\#5//O6S+7 JQNQH=?V9-6%U%=@17BRA[K]::]YPGV6+P7W*DMG
M%M;6'I"\\9-TFL\O4BQ+Y9S++$E9J'IEQCW=,:I:]D=\@Y!-.5XC@1:,_P *
ML$#,SU7LCLM8Y&_9*B@"H-GD#3!1\Z(.K;/]1!-0O%@KW3:@!4*RGK;^XRV9
M5:IKB?7*FKOZ.C)+%TY(IK,(-!470=P9<4!V+(_'"J=3N[&SR(,U%[H%01<E
M!1BS$A>)4+;%"Q"$M;%:XD<1;,H6^0NYEXL0PH $D@\N(Y!07 'LAKL=GH,3
M5&KZJ5I3W>M)K;7I"IT5@"C9IBRP#%LIRLC.VP+&,-A ,9&(R&^&<!)/!%L2
M"0,3KIC2;7S)E*DJ?4&B+NC[QU[QZ'YZT4A@"/0]B_A\?\?=\M2+R-3IXTT\
M::>--/&FGC33QIJA[WUFV4J_5*M?=\"UKEN?+JPH8PW86&[/&Q2ANY:EUJB:
MI"1#:]5!%P\ME;O[?5Y Q)6)T() RX+9WJL:LK-SHJI8CC[( ( !:QVU]  V
M:'J36;.P8#A:D@ \NR2"20M'H5V21[SZ#N"@>J9;7LVJ+M2 #G6U5.K*DYE5
MWS;IU;%LUGK+FSP<^;/%E.1X!Z.$.H&"WK0H3,5NSMM 45QPX?W1.EWMY!:O
M+//ER(##@Q56"\P"3:=^MV.+6 %)U7S@"P<<>) L'F+8$A20!3>ZJHDJ 26
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M%/K*0*05@-ED#FYN=/B30*,9)()9<6#S#D!)GER9S$4QL=8I&F;'C!R<@R/
MBP LC.$E,?TVR['A;MB9KMN<V/FXN)N>;^'3;FFQ(<7;<$90GW+<7RL:/#3<
M,AAMN L$.=+)G%(IHH3/BC(\6>['5FQ5Q7,D%F3V%BM3PM-W7R["1FPD,TWB
M!4863C3P+M(!)C9V+E1M/H=B!5"Q.BU#(C+SY,3*Q86@1H,F6.!9C/QE,LA<
M$1P")E98@$,C2SP%O,"PK+(H1FT;!C;MMFZ9:;A-'G;;BY6<^(,#S,5<7&6
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M::>--/&FGC33QIJ*F?\ .]>_[5N7_EZ+YXI/]HXO_0L__P ?;==B#_8&Y_\
M7&Q_^2\0ZE7GMUQ]/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g189651g13k52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g13k52.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %, DX# 1$  A$! Q$!_\0
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M[D#2,69R'$*@E3$@(+2!0205<'QL* 3EI&E558MVL0@TJ@KZA(!]1B#VIL@
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MI-U -CCZS-9^6>C#ZR&1UU4BZ92?U*XBVGGUS^7TX_3( ,7S]I(+,&)[_4+
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M:(/:=E&"Z;SVG>M-HE3Y )&LQS#<;#6_R[&BPT&!.U'YAK>U\!AX) ).873
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M1LD;D5KV*J.8[]G(B\JK*X)5E8 E25((##P0=$Z(/N/<?7+O')&0)$>,LJN
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MVYQ#Z1&5C+SU"R7?7'4)T"]AUDR,I\ONI(PS7$[)LJVA'Z;V+LG*'&BQ#4I
M-)/4NG.0T0-; 52_)]+=(<QQT_/MRO =.(MODEEIA9T_?JHFD::-B;YAC].U
M#\/$L4++ZD_R $]WT_\ $S\9NB>I*70D?2W7GXCSR\1TY)5Y=IN-LGX!IS4@
MCIV$6+A$MV38XNZ.0L26;B,:],>NVH]?/J+'RUMZA/2_9CAYU[:G0UOU9<]Z
MA*FNI:AWZM 7VG5NDS@M_P"4D;#X'SS GD*Q*=%4J<9T6MU+TKR]OJ+I:U#T
M];E@I65+ST>6=:=016$LL9Q/06956*-Y0*YC]1(VB1N\CMZGX<_BUT5Q/X??
MB?Q-W\1>#J7>:XYUAH\WTK _,<LUJE)QD*T6H<Z].622Y82IOD5L&"Q8CLR*
ML?>LE_\ >06/L>JNQRH[3J[0^_(6<;A,U@-#V?I72/8V-@[M8S9_8^ A?$$T
MC :LYH[I903!R&1R-]7R72%KDJ=RJZ\-6-JM+$)+E"Q,\9*;_>7IKPF],J-.
MT=9954EHRK@$?+>GOQ@X;IKE>)Y2&7K+EDXODJMIJO!<Y0KI859@H6MP5'A)
M*GQ0=P]>.SR,E620*D\<D3,K?GI0'J*SH;KR*LDW5:Z$.\8@66Z;>(!&K-7?
M>[V%ZG+:NS>Y\BOD2>TTDAAT+XK&84-YBPMGISI67B.'X^DW(5$>*$L3Q\5)
M:VK#O94(;L%JX[*)@LKRRDO*KDA22,K^('XL4NK^K>>YF/IWFY8[=TQ*G43\
MXW(@\?##QCM.G!W.-X:%96I&:O#5@5(ZTL2!G4*<Z:0C5N8Z04GN?X6JO\IU
M7TA5-\(WW(OLNZZOE1J_XJ>YB*COV<B>%YW?V=,/_P!=65&MZ$?'D?PVO%,/
MY'Z>^B,\/_I+5;YAT/2EWXV\_-Q$_J1-U;"PWO7D?X9_/7U_;J&JZ^Q+=3V;
ML\7#^OH$@DMA.I]622<VGL'C,CI<(8+.$HJH\MM]83.CJ)XX7#L^8ELT/G.J
M.CN2ZAI5JU/G[,<E>[%8<R5*DJ^GIHRX41<<OJ0=XFC)=W#+^[57TP^E?A;^
M+G"="<UR?(<M^'E">M>X.Y1C$?,\C3?X@/#8BKM(;O4;M!>])JEA/2KP=D@:
MQ))$#&W]:J>19JBKF=*L[I:X&1TRS0D+,L@T3EE4@=$'G615]ZS0(D,OGWQ(
MC'-YZU5**$+%R@"EV&F8J-%F'T+:V1]SGREI!,S2B)8!*QD$"$LD(<EA$K$D
MLL>^Q2220 =GWS8\G*Y'M49=U]!9GY^*KGM AI"XH;F4N$"2(9JS$,DD"BF(
M9(Z!CTA5L;F_*K/?X9Y7FK<DGBK32UEA:6-#(%G9UC*H.Y@3&K,"5![=#7=K
M?C>=+AX*%GD:E?DGMQU)Y5A=Z*0R6%>4]D3*D[QQ%1(RF3; ]G=V[;64G%V[
MN0J;$F6V,K+"P[0HZ]^$BSI]G-7_ *QL04N8LYIB2J_YJJOCSCC=(1?P#E00
MU.6U/N%4^.E!MN".;Y".#CWGHPR2\O7C/'"K),T7QTD?KK5MN\7=#&*OJ6FL
MJKJL-.YM/46O'/[U^B^G[%WGX:?.VJU;I+D+ ZA?DZ]2.S^PZUCX%^4XJ&&U
MZ=RRW*"#BX^-DEBDDN<OP^IA6>_8HX&:[ZL;;:LS9]551 _J?M2GL9HHM2"1
M0Y[K&WU%*5M"[2SHHLK:5)-C15%><+5W;B:DW5 12/(<"=&F*IU'+/?%62"$
M1_&<Q7E8"W&U:MQ$]R![[RRUQ4FA>6M!%(D,Y:&2Y$"6].09L<K^'5:GP3<I
M6N7'L?LGI"]51VXB>/D>2ZLI\1>AX*&I4Y!^7J7(JO(7;,$UN@L5R#A[+HL8
ML5VS?=6]_P"3[#H)+(RSS%#;2Z$>BK*>3554KK6:_JJ_29$ .>62!2+T^CN
M [2I'CFF TP=[4P_:;7?-)L\1U+2Y.L97FIUYC:2M# ;D),S688K=*)&)7NL
MR5[$4<T**S1VTL0KW>EL\[J[\..9Z:Y%*L%3EN1IKQDO(6[R\/<1:B<;<L\7
MS5B:-%D]/CJ]^C8GJ7)71+'$S\?=D]$VNQ=!)WCK8I]!028^D9K\Q^I;*S!G
MN;JOJYZ/+9:AOSWU\]EFP[0EY5KH(<U4725?Z>MV 6.CKRR(!GT[=8]070UJ
ML:-<7:GQ4LL;3V(X6KTZ=:S(8FEJ1S.7FLK5@G$/PTPCEM1NRH8,Z2_A_P ,
M\?&<BO-WVX7EOV75JV(J-"S;CO\ +\OR7&UA9BJ\K/4B6&IQK\K=H&Y^TJ36
M*O%V88I)5NF9X?M@K8Z  9M*,)G-'#V&_-'H=/);>_K35561N4N:]X<8PR6E
MA8$E5BB&D?7# 8A;G$'LC%W^/YEKUF-1 B5;2\H:DGJ,9R>)NPT9_7B[ BB:
M25WB[)&[4B^<EI %X7/]'1<'QMF4WI9N3XN3IE>5K^A&M+MZKX>YS5$T;(G,
MLIIUJT4-L301&2>RQA CK,\L5;W[(1>Y^N%I!HZZV;F[:>R,32/&CS6WW]WB
M,<9]^HSMM5UAUI!1$7*QZ,NG$D*,K:" AS7V5Y4Z8ZD+V:T,<""*859WED%L
MJM2_R5CCZ,GJ059H8I)EKO/VVI($+O%75B#+8@ZY_#E8N.Y*U+?E>U2/*4XZ
ML!XM97Y7@.G*'/\ -P_#W>3IV[=>H_(14>_BX;LRPPV>2DB7MJT+LUTW<U'F
M;PS/OSFON# STJ7S4P%3('+;NR)F\_&0D6-W6_\ 6$R59:V[YI61 1I72 O,
M;9FU 5COV^=KU+#UC5NSR)((28(X2C3FE)R/HJTMB+YA2AFG+$","(QEQ+)#
M'+PN*Z&Y#E>/@Y)>4X2C!/7-P1WK-Q9THCFH.G?BWCK4+7[H\S:ITEC1GLL;
M2V$@:I7NSU=7/WQG21#)J"JN[+YZ?1EY.R(%@#H=9<9V>KJR: (K[4MH(:NB
MNZR@:MC4!QDGO+;6O.8 4^/"W455D=JT-B;N@M/2E9%2O<GJM#$]:-P[3))\
M58BJCU8$#RF01&01.1MQ_A[R<4T*<C;H5?2O<9!S-6.9YN1X>CR<=NW%R4\7
MI)4FKCC*%ODC\+=G:*NL!M+7:Q$K8V9[]H-#7S/%J;>XN!=?=XB>KS4(IR2:
M"B9>V=E7C$6!M9"^>IS-/#=VZR21P12V85(!/8WTJU;:U>HZUF-BD,\\Z7K'
M'M%55)-V:XL2RQ*TDD2]\-2!;$VR%!EC@B:6PWI#+ROX<\CQEF-9KM*E2FX2
MAS\=OE7FKZXWD#Q]2K9DCK5[;B.YRUV2A2[5:1TJ6.0LQU>-06SK][WD91B8
M&RR5$^[!W.$TN_%4BFVEJ:E=208PD$%U9A\[JK(*2RAU[/GLBPEKJV45D,SY
M9BQXWXN2Z@DK)QTM.N9X^0XZWR2=T%^:01UUH/'&8N/JW)8S*MWYI7C,410*
MQ+.H.UT[^'\'(3=1U>9Y%:%CI_J'BNG)O3O<%3@-KD)><AGL"WU!RG#U9UJR
M<*WIU89Q:M),SHJ1PR.OE7=S:G6:.'.Y"AR_S3SF20F7%\5.!-7B];=0[QCH
MC:(*P@GD(G[26NC+$4H%XM4P^!Q"&)$RL7/6[ML5*-:IW,TA62>R[1-&G%<'
MR(*O7CD5BS<QZ0="\92 2*6]3M%[70O$<-Q;\GS7(\L$CC@22"EQL4=F.S-U
M3UMT\P>#D;%:2-8H^D!9>&80V%FN-6D$9@+M/.N>RTW;_AGJ?Q!,F5SFIB@:
M7]QC([<V_I+.M^S\ Z%2TU[F;%B'10Q#GUI]25%##)+/%'TN+Y;]HGM:'T7:
MG5N*O?W@"=[%>:+N[5[V@L5)1Z@55DBDA<*&+JOG.I^E?]'E[X[GQL2<ORG$
M/(8?0+-2@XZ_4M^EZDIA2]QW+5F-=W>6O;KW86DD1(W:U>=C/(967<4\D'7E
MVV,*&Q>:7G*E 9:N*YD*;=:>FJ'Q 5I$X@A%RYASOP3CBPZ\>Y0 FP+%"AG(
MCRPC<B^=:#'>^W6D8[)T3VC7S:!)78 )S',=1MXWY4:UW;VP&@-@$^?&R!O6
M_&\UW2V:CRF5*J8JBWIXFVSY(X+NFH*8Z6-M=6BQ2N;06EO&;%% -$' 6<8I
ML< L8#61@A!M29W+N&)!^7^R6(]V)_, 02220!K9W[DY$2]BD:(\^Q4+] /H
M3OP -D^PUX RWN8<RXXQF#9!LL IQ))S!F2M3S, 7."4SV.;(GQ%#/CFB]RM
M1K_8]/>Q7,=Y:Y460='Z'^.01L:V1_ Z.:;$I[<9D4\JOC,4">5555?%4(GE
M57]U5?ZU7]U7]UY+_G;^\W]3D)^1?[J_T&2?E<MCC&.,8XQCC&.,8XQCC&.,
M9IAB3WWMH'-*&ZO'!JR1(XQ)HS&2F26$<Z$EN.EA(9Y"1T38@A7,23VO?*K?
M<[71Y39F1F0Q+'"Z (PD!<R!NYS(58?N]J!&I'=HDZ\[TL58<?4F1)Q9DL6X
MIF::-H&2%:SQ^E"($DC;5@AR\\H8J"JIO0U>S-(!K*^48-#72ZC(BOC^RP;X
MF%::K@2?W/8]'I'*^-'1HB.5KG.1?Y'M<LC<:?I8JG^5F+''$BQ)KS_J'*?_
M ),N9+>;&:.0,W<1D%$5.-K7["X&D? 6\4I LU4$12)%-!>ZA8"Q!2H'+_/U
M%8-<Z&)'1RR4K1GJ0WG2<@&=X:,1O3H2KE'"5(7!TRV+95T1U/YH8EGLJ""8
M I[AZ"#@6BBBN<W9'"TI562$2Q&?E+L3J723C^)$D,TL4BC<=RW+1XR0AD6^
M90(C_,O7'A1_])QTW7:(?L*TV"X8ISK7,C(#U\'\M)LR!18Q2IK.S?2U]>Y!
MM$5^0'C+NB(2WA!Q22A/\\_1QL=3\?U5;Y27XNI3L+\'7C,=1A&P@1%+RR2*
MG9>/J+Y$\D9DU"',:_1(/Q9-#\+NH?PSXOIRF.)Y3F*$IY:],+/*H\ZBY++(
M(:]:L\WK<*%KR%>ZE7L"L&M-$M@_UPY[+/C>1?<2ZR#&ZJ?!0U1.W'SUP1D1
M+QLSJ8S20 3RTH5K]<D2=E>98,'%+EA)AEA@E?,QWN8B+9>WN7NV%V.XCW"[
M\D;^H'ME6[NUNW7=H]N_;>O'^><C%>L2)SHM'F\9?;7(Z;]+TF%K<_0Z W2'
M:./KLWM?L$VT?2U^@EBJ:;.W.+R( <%$DX?8,&GK- ?7UHAMC09Q7^C,%9=E
MB2 NN\1IK?;Y+!F))\IVD#?@XC-KR%+*=   [![2[$ZWXT5&M>&!!/VQJ+U<
M7-BYGY3%&4U;H]V^GPU[,-$A1-*/VGU-B"J[1Y(JV%M*2[C [4!8\V4UR0V=
M3?234448-4)H9:N =!P2$VP_7L=MJVM%=H?&MZ(T3L]H3'ZJ0"Q"G7T[E&B-
M@@Z;[^X/V\_MWZQR:@# ZXGKZQ'R.[R >RSM<&;7Z;7:>LW!&7J^K8H*>A,F
MM,]:6ESHH1K\ JDN XHYF-SMO?EUUP(% K[+*''<KE&V"JJ5#%_)\, %^4@@
M_P"T!L8,VNUB/E9>X:\DAB O@>WD^?<?8G66\/W@=?X/&:"LR]OEM#L>T@.L
M4IMC3W-9)5DBZ<\'2VJ"VX%!;3 RYF@O+G)$'U=9-8S$4<5K65\TYP V/TP&
M8%@RJA?:D'8[00/!8 ]Q 8;\>='V.7[R5! *DMVZ8$:\Z)T='V!(V!OQXRHU
M[T[A?V:'U*ECUM!9;*VQY&,W$>3MK/-?IG187OO=''5H('9+_P!:5HB=05&:
M#NYKS#V1%C;Z"X(R(E.'G77F3TH^PR:?2A^Y>X!NX/$@!)3Y3^\[B.UAH =Q
M).L?J/W!-C;$=K:.M%9&.O.F [ -[!.R>T#6])4>IKL09N$V.OS&>R6![9RG
M6N[K+2OJ#]):B5%ID^K+;5SI4YJUM]?HRFW>ENNN8739&H=0E'==W<;-!2_J
MA];'P\2M*(_^T#L'( 4NZ]T:EB0!L1QH>YF)[5*[&D&7-F9UA$C,8TC B5BS
MB-&;U72->XE5,LLC$*H7O?O(+,^7UN^Y[O+]F]79G-8RZ[&S>]ZQ[5VI#<7%
M03WL,^.T'2M?G[$<K2:W+5#<^2!V)<)8,8XZP(,?1R"(.+ <LU4C#(Y9@C(\
M:_-O7S"0D?*K'>T&O8:WDLY#J "P97/C1.U* 'W UICO_#.3NH_4'W'V;;9K
M:CX[*6)Z!^GV+315/3.GE^KC>Q>F^GNT^S;1O<+MNZNHR,LG8&GM<_B5I=%:
M6P]-1T3!#3]!'<P3)2II,9S%'\0$EC2R?2]<(LTB)$&,?J&-BH+#O502S'6M
M9ECY/D6I_L\7+7[/::.PU 33BD9VAC+6#!ZOH>N%.ED,9D[0$WY!%MZ7U %W
M/9%?3I3UUCT;,;D:+6NTG7M[)9?-KZG;$5LUG6VYX.EK2;+54.;S^3JDZRO!
M+(EUK^4M*];C-E"UEJ0SP/%/'','#=T4@CDB<(R'3(RM&X /<=MX(! )!Q7O
M6J-F*U2LSU)X6#16:TDL%B)F5U+1S1.DL;$;4%-$AB"=')/!VUJ-+>;0G!Z/
MKOK_ *XZICP<90G9>0TE&7HJ^]KQKBR/G,L+K)S]?9Z.KG=FLR27D[5[=146
MQ9<!U8)'42RL,<21QA#^4JBQ% D:I\J(JJ"I T#I2 $T!KWRDD\L\LLTDI=V
M<R2RS%WDE>0]\DDCNW<S,Q8EV)+/MF)\[A57W9W>M;FKJ>QZUNF=F:+OO)9'
M.BY"_H['*VO6 G9]QF+N^NI-U=P:#+EC]<0Y[5*/0Y\J&XUE(57G"L1:\JYC
MB\@!P46)F/<"&[_3# #M&F^?:^3X4[W[C%WOX.U/<7 ':1V]O>1L]QV"%[3X
MWLC6MZSL7'7U9LLQFMS6"N''V.8SU\*I$+(STK+6O9<5PICVI[E<*RSE7X5<
MYD,TY*QHBRO5VLR!)'\+W_D9@!M@A;M!;W*J68J"= LQ'N=[(E=HDC+N8E9Y
M4C+$HCRK&LCJF^U7D6*)78 %Q'&&)"+J3\97'&,<8QQC,.Q(^I7G%_.&+]4,
MDC[-C+\->/\ #"^3YSIO<WX@X?;\A,ON;\<+7O\ <GCRD@;(&B=D#0]SY]A^
MOV_7(/@'V]OK[?X_IG)?7C1+CLV&X2LUUD(>21<#V&0LDT'3(9S5UUHEM^H[
MK$XZX*E-L=EIRA*VHO-?5PV5]&]T,8H-82!MR[6(CN0$:4AQVSD?(".U9'4:
M$: E@A(77U8'5C\R[TY!V05.X0?F.]E$8[+-H N S;T  1V!S3S;SY<]C5:C
MG-:KW>UB.<B*YWA5]K454]SO"*OA/*^$7C&$<URN1KFN5B^UR(J*K7>$7PY$
M7RB^%1?"^%\*B_P7C&?S&].'6W9U;O>^I=]D>_'TS-; !E4*]0M@;$$&T_0V
MB!8D8:WP_P!#-(#9U93Q;"YM'/855Q>97@O6#S7&<YSUJQ?BO=+/0AJ2B**>
M*S6E;D'+S;GA2R\$7HB)(3W+)X>0J-Z98OIG4_1_0W&\?P%C@_Q,K<Y;Y6HU
MFW2GXJ_53@$$-0K2N2T(;TYNFS+;4(U<CTJZ.2 T4DW63A8Z=_QS67J)S"R+
M_(1L9/8[&^?/C^?"K^S6QHW^'\_,U/X*[S^Z\ZYY54/;8X^]"?THR6@=_P"]
MQAMJ/\2-?IXSR2=,O.I:CSG 7 -[[^:K\2PU]DZB7B';?T"*Q/MKZ9PUZ?KB
M/_\ %YZJ$;ZE>Z-2Q(W+!C?T,=8Q4RP:&K'(?5 $!ZX.67)RN;E(VB82B64&
MP(*B:V*)RMY57KG@.3OW>$JI:-[B WQ.J5EQ+V2K!-Z*P1R6']*:1$E$D:$,
M=J&0%E]5RWX,=<=/]/<#U?R9XJ/A^J2B\:S\YQL+0>M7ENUC;EN3P48A9J02
M35VBLR@J DI25DC;O$<_0F>Y*?2][VRHJ_N7@^N\RU/Z_P!OUGA,A[FI^R)X
M557S_']G>.FO*+*=0<;R$NOJU2:F/X[Y&6GO_#[^WV\K)TW)7&[O/=/U=@$=
MG*U^6]S]1T_#RQ!]_!UKW]M;XIR>7]0U1ZWNW=RS0=ADYD[KJG! I]'U]';9
MB-L N21J>^IUV8R=H6,^,XB!F1T$5Q)8EVZ$5R!USX+?57FZK7IJ2=.<M'?A
MB62S>^#KK!+!J-D2/D!.R6G!E5?AHW=D,4NE/I@MVINC[R<!0Y9^ONEIN&MV
MI(*'"CE[\EVO>+SI--8X1J2S\;"Z57?X^>&&*1;%3N<>LPBBO_2(Z>YO^F<K
M%8=:Y_960O9-.D+K;]=];'L@2@TZE$14-_%0E3BJYD8Y,M9J-*"&$26:0@B#
M0V+.7U!QW3/4]2&MS)GKK#9BGB%HR<1+M.X3A)KJUUG5:K6&*Q]X[@&!&NX>
MG_#SG?Q$_#?F+G)=(_!W9+?%VJ-EN,6OU=4"S>D],SUN%DY"2G(_))15))Q"
MW:S1.K=W8>R\K#5%C@35'57IP'5U<*]2HNQ ;2^'E:)&L:%L%ZO(0PJ%Z*V:
M1^ED61['/_(2*]9^=:"KTR>TUH^*D*A=.D-)Y"%  9I.YI&;0!+OMB?+><\A
M?Y/\1AZB\C9ZKA5GD+0SV>7AKJSL3(L=<JE>-"S$".-5C TJ@+H9R_\ ]'&/
MV0[K7LE@]1T)CYY.RSG/GPQB;827S5 N]I0^<W1T;!!IW2QT@Y&@!>VND58@
MF1^V:?5Z9K=*U:UM>F%I_#O=G:S\#;AM*9"Y,'?)'/:[/]6,?;"64)Y[8UV=
M]C\3^1_$KDN4XF3\1Y.9:_%PM*+COVYQ=KBI%KK$JW?1KST>.];?(+8,MI8Y
M6G(0R6)2JE?Z#PT7:TT[5M.Q,I$(CD5T6;ZV+JS'-1RJK%+O]]KAD]S?:U7-
MKFK^SE;[55/;Z7<?T1O_ *G!_HB_U_GGS/3_ %=?\$U_5FSD7TL]-=D8B\]0
M!)'JCL>S"+WLE\T QM<-=0Y4H)]PXP:S"/N#_J'V,-A70E@U,U- /%1!)#YA
M?]<?!#>XRVTZT1"\E>=XKHBE+%+("@I)[A74+X&M:\?3.ER'$]0<='QTG,Q6
MZ\-VC%9X=K-<1)/QK,[1RUSH&2)F=CW;WW$DGSD<]0O2?J+V/J ],FKIKGI>
MZH,CH7S:BRN<!7 V\(8ER!:2,$%NB==:E2PUT4\M4M#?TCH+M?N20AL;]V+=
M2>JBE)&D21BY@03LO<[1LC%55D#GL)#AD?2%A[,1G$DX^:P[3K4K641(5M3R
M48YWAABLI8@W.\<K0*ME$DC*21 S*A\LHSI+N_JX+8=/=BY[M#NC3462NLC;
M Z2XC;B\S25 L\"HX]TL>=2RC"'E2-7A&7Q49<2O#(>0R=S7:LUZOQ\4EVP\
M%>O64S2S3N4CCC3RQ=V8*HUXWH'9T/) SJ4>)Y#F[E?B>-K6^0Y#D)4K5*5*
M$S6+$\ATD<,,:,[L3Y(\@ %F(4$B"^F[J?H[KSHCKW-Y[M(O?Y*KJ[&.LU17
M8MO7T]PTR_MK ]T%)6WX-"'$-9F&@-%^D\P2,:.O.))G$5_-=.<X[D(4Y"M=
MI/5L M#,DT)C95)C.G8[)5E*.#HJX96 8$9OW.C^H>%OV.$Y#@^7K<I0<16J
M4M.R+$+R(LZ!HHT( DBD26)EVLD+I(C,C*QLQU3Z6WSL=.)TC8&-=_(D-3&7
M!WR*]O\ *24M3"EE61&^7JY9'2>/*JY?WQ?MOCMZ'+4M[]ENP$[WK\JR[WO0
M]O?,W^AW4NNX],<V%UOO?A[RKH G?>]<+H $D[]AOV&<[>KC9^DK)8#()V=U
M</N<S-NZI*>MR^,J5'"M(13)I+!2+$>NK)1V5[2V2@BD336B/:')$HLD\D?"
MZ@Z[XWIBM7N3?&6DLV%JCX2,L%#*TC.7F:*-@J(Q54=F=@  !MU]UT!^"G4O
MXD<E?XFB_$<7-QW&R\G(>6M!"X22."*%8:D=JRC233(KRRPQPQ)W,SLX2*3^
M@@<L$P@LPS%C&E&@E'C6)8%C@DB:Z)BP.:QT*MC5K5B<QJQ^/8K6JWPGJ58.
MJN-Z=0PV"#I@"-@Z(.CY! (/@^<^5RQM#))$_;W1.\;=K*Z]R,5/:RDJR[!T
MRDJPT02",R>6RF>)$$)0\XI#$D@)AE@GC57-22&9CHY&*YJM<B.8YS?+7(Y/
M/E%1?"\JRJZLC#:NI5AY\JP((\>?()'CSEXY'ADCEC;MDB=)(V !*NC!E;1!
M!TP!T01X\@C-&S)YZ.#)BLK6-@P\\).5C^<I4J)A\]9Y6%\;EG5Q"LH+FRKD
M0UQ+584Z9R*3'#/'KBE6"TD$0[>/97ICN?\ <,M6:D"I[MMJM/-%^\+>'+'Y
MPK#H-S')-)S$K6F,G/QO%R[>G%_KL<G)U.8=7 CU%W<E1J6MP"(AH1&"(F>-
MM#;=68&\J6T=IGH2:QEKK+IH[3;,=Z6&Z?H'[!ZE"FP&.&T*ZF^;95[IUKYH
MK!\""MA@%C@UI^'XVQ *\U57A$UV?M$DJ'U>1-DWCWI(K]MKXRR)8^[TF64K
MV=JH%Z-/J[J*A</(5.3>*VU/AJ)D,%25?ANGEXU>$7T9H)(!+QHXCCC5LB,6
M8WK+)ZQD>5I)+^FZ/\K97:UT"V5Q35^?M)W+(Z,^GJI[8FN!)%<]0Y(Q)KVW
M6)[H/F]AY$3I'0N1C=OX6OZTMCTE,T\$5:9CLB2"%IWBC=">PA&LS]I*]VI7
M7?:=9ROVG?\ @ZM#XF05:5ZSR52,!0U>]<CIQ6K$4P43H\R<?2#@2=G=6B<*
M'!8P5W2?6T@#ZZ6C.FAD=XE(GU.MGM)A/Q3J1:>>ZFO7W$^=?4O>!)F93GY^
M2![VR5CE<YR\\\!Q1B,1KR,I\%FN76F9/1^']!IVL&=JIA)C-1I#69208CO/
M0CKWJE;(M)R%=)%'R1Q\1PL=1)OC!R O1T$X]:,?)K< L+RR5UY)) "ML  "
M356#RE)?&:6KJU%MC8SXGR(?9S!"LMB@CKA*FH(-EJ*1;HZN /NWTX +[D\2
M VS<45&V5-N'CJ=>P]J&'LF<2J3ZDK1H)WCDG$,+2-!7^(DABDL&".,SR1I)
M+WNH.<FYU#S%_CX.+MVQ-3@:LZJ:U1+$S4H;%>B;EV.!+M\4*]JS6H"]8L+1
MKSRP5!#"Y0QX'J+'#)5_:#G.?1G23U"_?LP((Z\?3$ZO/4UH!7'#5NAKLC:D
M(_,0W@9S*E88R!61G2%%DZL?"44$/?&TAKR%H?WDT:B-;;W:L$L44B168J4S
M;J+8200]H=0)"[MT['6G.2_%B&>.NO(5UCNCX:I9D:S+Q47#\G>J6+->6UQM
MGFJD7;RS\?/7:YZCQ2LU=888I*9A\K8'2V1E1%,;/:NNY9U(-:K[1V4.P[BU
M9&2V-'+E;$VH^-&)#\4ZD?']QD9+-J3CZ<LAED@5I&F-@L6<$S&E)QY?08#?
MP<LD&M=NF+:]33CE0<_R]:NE6"Z\=>.F*"1B* A:@YBOSXA!:(MK]KU8+O<6
M+]\8B[O09HFK.IZ#S5;LXM-(6015U;)5SF8B?:"5U05-;Y.]0R2-MU+6SD"V
M>-J2()@*>G(L7N)GU<^G/?$;#RH>FZD5Y;9=VAA#?"U 9DBA=IJ5CU"!.8F9
M):,+*T<$+RDNUUK<A$B^JN?B+REK@WXE88X[=MD_:?+.M2:S=A2ES''^@K&B
MEJ..:ISER*1+-Z[%5411\-%Q-=7@DS=3TAFK<1B9M4R5JA[#);01US-).B0Z
MN&1'*#?TI\!3OUG>.^^%9BD3P3LIK3\GFOGHI\EO@*DR 5=4YO4$AF0SL6^6
MZIWZ=F"17/Q]@^HDJLRL()?5J]U=L'$=?<K2F8\H#S50UFKI4G%%%C^?AW0@
M6..O5Y(E_8?'CX>>I-'')&UZI\)ROI\A'OI.I,:148ZH)9?>W"YO])T-A6:S
M3YBU922"4HA@1AV3MZ*4Z"P;GJ>8P8GY!9" 89601N:G-EN%HO#1A<6?_A]7
MX.O+#=MU)A79*Z21R24IZYD67X6!I%?:%HU8*-9STZSYR*[SEV)N.WU#RG[8
MY&M;X;B>6IM?6:]-!/!7YFER"5I*QY*ZD$L/;,D=AT,C YY3=,]=2.'>+2G4
MD@LBO&DR^GUF1EA8N<S.246.7+WE1(VO_3N-S%9^,1WX_P"*G%F^K]E99I:M
MP/%DJ4KR5RAVIIV[E(J/A:E+L!J6(#Z7PM"G#Z6_2[8$/9W;8WCZZZG42+-?
MKWUE7ME7E^)X;FDD;]I\MS/K,G+\?=4V?VGSG+6_BR/B>^],GJ^EV(LAS^)I
MLU9E6%5!$)"[/YO)U5:)!&-7TN;RR6<E96A0L\HB_;NK*6:9%C22!:\58O%>
MR:79K4(*DKR0JJ+\-5IPPHJI%7JT_5,44:CV^>>5F;P"OI)V_N@S<SDN>O<K
M5AKW)'GD')<KS%RW-(TMF_RG+FHMNU/(VMCT:%5(XSW%9/B9@_\ K)1)AS>S
MB97/:KL_+B;FLT4T*!6D$0_TW#9JP(/^,L69\(M5K?=16+F(ULDL)L<C(XD=
M,QJ3,B5,L/=ZBE1LCS_: '@C9*?,/XC,<G:4(;V.A_9._(^C>#_CD.Z#$@#H
M=/%7C1P4RZISZ>1:W$TYA RT%"A+SZ_"*M5'+'8M,@AF+^*QG%C@=(,P1H<Q
M-[))9>[\W9\WEV'YFUHR>?;1\>-D^=[ K -*P'Y>[QX0?0;\)X]_OYUKQ][W
MYKYFQQC/E_\ B._U7?[EXQD;Q7]#<E_9FA_NH3EG_.W]YOZG*I^1?[J_T&2;
ME<MCC&.,8XQCC&.,8XQCC&.,9$:]"/UOIT>9/*.E#E)(0WQB) ,^0K3QRNBD
MC&86_P"3Z[7JA!,S6N?)[$:SV-9KI_WF?Q_^AK^?_KL_X9OR_P#AM+_S?(?^
MEQ^<Y^K7U#0=$Y_'RP86[[$/O-KFXIJC.GL%-JA@+.&W$,):VLMYGNM"JI]=
M5".%&CL2&E11GP2#JCO*=8]4KTU7I.O'3\I+9NUXV@K2A)(4#^HDC 13L3+)
M%Z4*%%$SAU$JLOGZE^$'X8M^(W(<Q%+U#1Z8K<;PU^PEWDJQF@N3/":TM>(M
M:I(JU8K*V;LRRRO5B:%VK2+*"+T3.7FL1"=A92ATTZ,E'QE%(770.@>Q5;#J
M;GR/;74KT5%)JQ64E*C7RUMB!>1,^U-W_A;%SYKLI2!M,M"N7C4J0?EMS_+-
M.?([H4%>#WBECL =[>#_ &G0X?<7"U4GO)W))SG(+#9D#@Z+\12_>TJ*J1^Z
MMS&_>VJ6JMCCW;TDUQ5J59D28/K)@5.)3.97Z+5AA"_A\;%'X^2BSH*0K76F
MR="GQQ@NC=495DT=MH(C)65^8ONK%%%!&BK&D<: +%#&H10H&@ J@!(Q]  -
M^RC6V7SEBS8N3RS3SRV+$SL]BS/(\TKR-Y9WED+/+*Q]V9F(/ECO0.159RHR
MVORU33#.@&CQ^YGFFFFE+/L#I[[!2%VEK8$OE,L[4^=\A!]D;-,661))+/*]
MSE7FO(2UN$G_ /I[/Z  25- #V 'L /;-V$!>)N ?_W#C/U)/PW+;)/U)/DD
M^YRS^9\T,<8RO[+J;JVXS\>3M>M\)8Y>&ZM-)#G#<G1$4<6AO"[4^[O(ZJ4!
MP,=O=&7MX3;V+($+LYKJW>=+.MD;\]@[@]P=@V@.X,=Z&@!O>]#0U]M#7L,J
M40CM*KV[)UH:V=[.ON=G9^NSOW.9[NN\ _ZOOP^0=]$V:R"1V;IE0.Q(M*B\
MG/%10E0<R:ZH**WE)B]DTEI2U)[WJ57!RPN]_P#:;VU^8^VB->_MHD:^Q(^N
M3VK_ +(^_L/?>]_S /\ $9I(.ENGAH+04?JKKF$:[;8LN!X\5G&0VD=Q&R&U
MB/B2M1A<5C#&R(V*=KXR8V-9*US41.3ZDAUMW.CL?,W@CV(\^#D=B#>D7S[_
M "CSOW^GUS-(ZPQ+LM68VJH@<Q04E[3Z:D!RX85)#47M)IA]<+8@#BB_4CF(
MO8'EVJ/&DCN&FV4%FPJ*R-;-'>W<6)V2""6\[!4KK_ >WVT->PQVKH #0!!&
MO&B#O?\ /WW[^=YKI.D>FI0KRMEZHZXDK]+8#VVA"?BLXX6\LQ)SBA3[6!:[
MXSBQB;.T(@G);))%/9V4T;FR'ENFGU)/'SM\HT/F/@'7MY\>P_D/L,CTTT1V
MKHG9\#R?)_XG^9^YS?7G7>#TH1-;H,?G;FO+K:FGG!L:D(H1]51'NM*:O:/+
M$Z*,2LL7?="@B8QD!+(I6(CH8E9 =P=AB#LGP3[D:)_Q'@Y)53[@'V'M]CL?
MR.;[\'2I85UNE16):U%784=39H *A]92VT]03:U%>9\7V JRR)S]"0> -)&*
M9-25,I$4CZX-T,;.B-G1()&_!(WHD?4C9T?IL_<Y.AL'0V 0#KR =; _0Z&Q
M^@^V8><R65QX;Z_)9J@RX$C:UD@6>IZ^E$>RFHZK,U#'CUPXT+FU6;HZ3/US
M7,5 :2GJZH9(@0!8(A9F.V8L?/DDD^26/O\ =B2?N23[DX"A?"@ >/ &O8!1
M[?8  ?H ,BC.H>O5[#L>U"\U56>X.AHX![VTK:TXZE9GPK2O!=0F3!*=5R.%
MN;*,A\)2J]"YVQ_$R>=LMO4?L";(4;\ D ]Q!.QO1]AKQ],CL7N[M MX\D>1
MK>M?S/\ /-E?]8];ZK05&LT^!QNAU% H:TFBN\S36EY4_CCG6=<E?:&AS&BI
M76;W60"0S,0*Q<IPJ1%_SW(#NH*J[!3O8#$ [&CL Z.QX/Z8*J2"5!(]B0"1
MYW_7SD<7H?J$:'7KGNO<?B[;=5.@I=+J<3E\]F-;8!:F60C0?)HJRKBLG$6A
MDKSRB9)I)I++V62O^]'$0RWJR?+MV8(055F+*"HT/E)UX'C7V\>WC([$&]*%
M+ @LH 8[\GSK[^?X^??+4$%&!%&!"'A$##'A%$%&C9".,,/&V& >"&-&QQ0P
MQ,9'%&QK6,8UK6HC41.8_?WR_MF1QC'&,<8QQC,8R*0@,J"%1FS3#3Q1.,&<
M8&DDD3V1J4&R<5Q0R.<BSC-)'=/%[XDGA5R2-D'1!\^"#X.C_@='1^QT=?;(
M/D$>/(^HV/\ $?4?IE&X#KB@K=)/>5NZ@*LJ,LP*[R?7S*C(82"SEAF'F9>8
MVGFL2GV4"RR2Q-OKHTB*=L9"-66-)'9Y)6*!3'H, 5>3;R%01KMD8 =O@#Y%
M /D>WC,,<:AB1)LJ2"J:1 ?8]R+OS_>)^X^^7WS7S/E4]B4A=Y8Y\6#+%6<'
M\\X[2#25$A= *P^K*46G%M+FL46VM)!6*E\+',13C!O<,R8J>!D>1"%#'NT?
MHOGR='R2 ? W['6R?/MF-QLK\I/T)&B0-@^ 2-$Z\M]!_'-+C,GJZLL]\4$&
M<*6EC L+4V 2V@TE\W26EA+?.$!MAR2?DKB'>TBPG#+C=:,'6)[0'PMEF4Z_
MM#>PHV.T=H&MD??[>/'W.556'M\OC1) /<=D[UO['W/GSKZ9-\5%80D[6.T,
M'/-;K8_F*%!?702HN1RCHT8&\P]T7LB5D;E4J7Y'-=(GL1Z1MHVCK0T->Q._
MJ?KH99-_/L[/>?.M?1?IYR<\KF3(U68S(4M[=:>GRV>JM)I/A70W]=35X=S>
M?71&P?EK,<>,RP^%$3XT*FE1OA%3PJ>>:L5&E!8GMP4ZT-JUV_$V8H(HY[';
M^7UI5422]OT[V;6=2USG-7N/H<3=Y;DK?%\7ZG[,XZS>LST>/]4[E^"JRRM!
M6]0DE_11.[9W[Y)>;6<O'&,@^^ZVPO:-0/0]@9>EU=0)8C6PH-W7B6, ]B*R
M6.$N%A4,S8IDBGG@<]B-=)!-- ]70RR,?S^2XKCN7@2OR5.O=A259DCL1)*J
MRH"%=0ZL W:S*2-$JS*3VLP/?Z=ZHZ@Z2NR\CTYR]_A[LU66E+8H6IJLDE68
MHTD+M"Z%T+QQN%8D+(B2+J1$9=T3ELR:QD9>>I"61L;'$V>J!D^)C&^R-L2O
M@58DC;X2/XU:L:(GL5OA.9WIU) !)5KN  !W0QG0 T NU^70]M:U],T(>6Y6
MNS-!R5^(L2SF.W83O+';%P) '[CLMW;[MGNWLY2757I7Z4ZBI;6BS>(I2 [6
M^*OI%N!I;N:"<B&$:,<6>])M2!X!AH(X8V#S0L<U%>]CI'.>[@\/T?P'"P35
MZO'UVCFLO9/KHUAE9E50J-9>9T5$4* K*#K9!;9/O.K_ ,7.N^L[]3D>4Y^]
M'/3XZ'CD%&5./CDCC>21Y)H^/BIQ2R32R/([2QNRD]J,$"J+1BZSP(SXY \I
M4 /B>DD;ZT=:US'IX5'-<"X=47]D_K\+_7SK+Q/&H04IP1D'8,2^D0?O^[*^
M_P!?O]=YY)^JNHI5=9^8NV%=>UULR_$AE^Q$XD_Y^_W.4AT_Z1.L^F3NPS\Y
M8;2:7L310W]@C]==U;Z]HLEK*'6AE9XNF,F$@?<GJY]@0:20KH7$32O@C<G
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M&,6\>*=Q+(5(A9,D;2'0#.E1B/1%>H\7N5%_D(G*02-+#%*RA#)&KE0Q<+W
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MV@%!CPI7ABCS6$;S!"2L@16 T#OR3LD'MV=:^71WX'@^_P!/MC+N"=D:]@0
M1O0V3YV->3HCP,FE1KK!M:2VQKK.]+#N]%2O/S]6CAYV4UC()$1/"XM6C3OC
M5L)#(I)(G&#&+&V%B-@90J-^X4$*=,3]1]- [_Q^FLR!CKV+$%AM0/H?KLC7
M^'UWD@Q*^<9D5\*GG,4"^%3PJ>:H1?"I_4J?P5/ZEY#_ )V_O-_4Y*?D7^ZO
M]!DGY7+8XQCC&.,8XQCC&.,9X%31CC$3S/2.*&"665Z^?#(XV.>]R^$5?#6H
MJKX15\)R#Y!_@<LGYE_O#^HRJ&7A.CJ\]D<B<^&8W/4YNATHGE4S= 2%'\:
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M-O?=VD$$DL/8#68N-I6KUB5((YF:/CN6E9*\3S,D0XRVK2/V D(I927T%4D
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MV9BAU UZ6F146*O;FAIAC.7GCN2\&O.D&,0B-JZ5RT'JB42-.H98O28,'/=
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M6MV68/1,1183V]_>Y54.8N$Z%^+Y;J3B^6O)6;IW@X.8:2C8XIX;GQ7*]/\
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MJH!^@7CDIAAKQJ3O)'N2=G#=0",J>.X3@>,"_P"Q0;E'8CR',G4$_,,CCWW
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M^0SE94UTRCV]52:6GS3=.) 6GXF1ZUI[\_(2%I5CC>S:_:'KV!JI803LO(/
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MT: !ZE2"5HJXY&TE>NTC001NJ11HL402X;__ .2&_P#.\W_Q#6<[=K_LT_\
M,U/_ ',6>*XW_O$G_D.5_P#R7<S=\V<T,<8R/D?TJJ?[/Z'^\<QS6?\ [Y!_
MY:W_ .K2SHQ?^$W?_F/%_P#MN8R0<V<YV.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9$\W_ )5W7]K(/^#<CR3[+_#_ (G*
M)[O_ 'S_ $7)9R,OCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQGR_]F/5?X>UW^Y>,
M?\? _B?8?XY#*"UJZ#!YDZ]L@*8(;-T3"#+4L>O&@>E8*SV33ER0Q1O]Z>SV
MO<CO=_)\>[]N8[%B"!7FFFBAA!),LLB1Q@$^"78A?.QKSYV-9L4Z-V[-'4IT
M[5NVPTM:M7EGL,5'S 0Q(TA*Z/=I?&CO61W0=@V9N>O9.M,Y::B[CI;2:CL3
MP7T6._*MKB)JB4VZOB:/\G3$&,@C(+RWYE8XGJY70M\RLY=CDII:]C]DU)KE
MD03&M))&:](S^DYKEY[+5_6@DE"JST_7^4D[ \CTW'].TZW(41U7RM/A^.-V
MHO(P06%O\TM'XF-;XAI<='?%*[#7,CQQ<P: +J-!S\AH+H/<]SZ/IL?3^H'9
MXWJZR?>7(+;.IGRLI9-;#)"@)3[BSN=#DP#$G^^,@*UA\L@HXA#U@FED8[C]
M,?Z6\AQ2MU 8^,O&>=2M2"&2TT *^E(6>2W5B;9D4+Z$FT6-CHL0?8?B6OX5
M\%U7)'T MCJ3A12I2F3E+ER#CH[S"06:Z105N*Y.S$$6O+ZHNUPDTD\2B145
MA:0T^(L"(#:/.;3M>ZA9&\&YN0[HW.I*CT^.UK[S7+58*")DZ-DGFQ:2F,C:
M]P5=.YC8%]&O$U5=9; :S,GD279GM,K@]W<D+,T,#[ (,,,(!]NT9\\DZHY1
MH9:U)XN,JS=P>#B*D/'+)&P*^C/;@1+MV$*2I6[;ML1ON+'.7_1KGMWH>MMF
MG=G3M!Z>L^!OM 5-B<O7LQ]%MX)8QI"3=8V:QL+(RFHYXI:>".*S"H=#7PM@
MLA;*O&?%/AXNCQ?"UIUXZK4X^)K5J>7T4$,?<)67U6+10#:QJD?<5*J(P4;M
M((W^J><ZCZMY2C)S7*\MU!<CXSC*=4W9C<L=IK(Y@A6.S<)62=Y+ C#K(SSD
M30K*&!L'6>I'&TWJ3ZFZORV&L-:=?8;0B9G4T#ZZ/)CQVI<'L%'-@$+<M96R
MXE1+.PKW*+4CV#GJ*4D;XT\K>ZNIQ=5<5Q%?CYN0GNTK!K<A"\9K S.Q95E"
M2,T:-29;$T;%85?N*R:('TKA/PGYBS^%_575O(<[4X&CPW,\>O(\#<CL+R;"
MM$H$CU6FKQQV98^8$E"I819+CP=BRP=RL;0[GZA([DZOV>7[2O)AZ(^IF-_3
MV'6 &$0BG)'O:PB>_N*^PL;4X,JMB8D\85+5SPS3M)H99/AEBZ?/<(_.\1?I
M\O99:TD+2?#<=VQ!&@=;$+-9L1RRS21O$HV(Z\+J6[ZQ/:P\WT-UI'T1U;P?
M+=)4(Y.0KW(X/VESXDL/-%>BDX^W%'QU&S6JTZ\\-IV,;6+]R.1(S%R*+ZB/
M9O5W6.2ZEQ6>Q.0"=#64%0%5Q&F?#/<6$8D:-81:GQP0.,)>OE57XXX8F^V$
M:& >.*%G6X?B:7"T*M"C&5BK0QPB23M:>4(  \TJJGJ.?OH*!I454"J/*=6=
M5\QUESO)<]S4X>UR5R>X\$'?'2K/,Q9HZ==I)!#$/ UW-(YW)+))*SNU@R?_
M  Y/]1W_ /RO.FWL?X'^F><3\Z_WE_J,U>?_ ,@TG_E%;_\ 90\PU?\ NU?_
M / 0_P#IKFWR7_B-_P#\[:_]>3/,;^D-O_Y51?\ W-]R$_[U/_\ @:W_ .W9
MR9/_  VG_P"<Y#_T>.Q?_P#R(W_G>;_XAK.1:_[./_S-3_W,63QO_>)/_(<K
M_P#DNYF[YLYH8XQD?(_I54_V?T/]XYCFL_\ WR#_ ,M;_P#5I9T8O_";O_S'
MB_\ VW,9(.;.<[,.P%F-!+$'L#*F<F"2&&SKV 2' 22-5K2A&6@-E7/GA54?
M&TZO,&5R(DP\K/+%I*C21NB2O"S*56:(1F2,D:#H)HY8BR^X$D4B;_,C#QF>
MM+'!8AFEK07(XI$=ZEEK*5["J03#,U.Q4M+'(/E<U[,$H!/9*C:8<J!Z/M.@
MZ^I-V-M#-P>7N#\090[ ')UE7,[2=AS=:8^R@,R&1HCQ9**_FSY]LU\A41]%
M-I8XQULG4KP?'I:YBKQM?D%OOR$DG(/Q[UKT5*&)C<Y,\51E62C1K2(:]EJT
MDP)<25FM +ZOH-']>FXOI#D>I+_3\O!0]/UX. K\_#R/"6>:MVT7BNFDZJYN
MK)!S?-<C7F7D.-CY*O2*I$]?D8^*9I15%];&F*V/:E%MK2O-V-\7G<WVUUC@
M3]19B]= 8R,"RPG5][H&:2O"R+]:-9ZNPT5P%1GUEG7T@&FT6; F)!JQIV/U
MGO\ ,5^0FBDO6'JU>;XCC9+DR<7%1$<W'<18LBU%'2-U9KLMJ>.M)%-%7CN6
MJD3-' C [T/!](<AP-.S!PG'P\IRG1G5G4<'$U)^I[/.-8J=0]6\?QIXNS8Y
MI>%EJ</6XRC8Y"O:IV;]CBN,Y2Q'%8N2QLLIZ[[ET]C=7C]%1:>SJ->#+N.J
MQ J.M@+(R(UVM'.+7>"@WGC0T!V!V19-J0ZT98;6[ A\UE,%##N<7SMN6Q8^
M*K6Y8+L9Y#ATCKQ*[TDL&NR1::,R(M:3C;[M,WK"3D+$0_<UXPO)ZFZ&XJK0
MX]>,Y#B:EWA+"=/]836.0M20Q<W+0^/CEM?NIUK2OR-?J/@H8J<8J-6X&A9<
M?%W[$CZ$[L_0P;>QS479C)<M9W&=9/L18,6JX6(B[VH5Q631S43QLQ,^YJ\]
MA*\;<P:(ZQG=86(9T-A 3!#KR<O97D):J\L&J2SU0]U%H[XX-8OQSQ,K5BM1
MC/#6XZ).16U)*QDE219%=5Z-?I/C7X"KRK]*E.7JTN3:/A)I.> Z@>.CP,]*
MVC1\@)>604+?)]0V9>GY.+KU8UK5IX'K212/Z=<]J;31:#%QW&E8\JTOZ2AD
MR; *,>/08XWI<C<?X38HFU[;X5UEK(I0XBA;&/,1# 34T5<MG,A+)XOF+]JS
M0$]H%YK,%8TQ'746:+\"_(?M8 1"RGJW08PZ2K4"QF!8O6;N%.I^D."XSC>=
M:CQ;"*IQM_D5YEK'(2OQO-P==Q<!_HF[&T>.F^%X9DG>*6JW+--82^]H4T])
MO#L[M7>4@6AO*FXE & M.U@:FE"=AH;22YP]?0!92O,AV+H'V^<N["+075T)
MFEFW!#+K,B9^-1(C9%KR_,\C7CM6()C&D<O,QPP1GCEF:QQ\=:.G$ZWNTS5;
M$@M3V$J=W(MZ]6.J#&KG,O2?1_3O(6.-X^[22Q+8J]'SW;]@=0R5$H]06.1L
M<Q9@?@PZTN4H5FXVC0EY4)T_&:/+3\DPF>!1:F\[,UN;OAZ>ESU"6U!>MGV$
MEQ;GB2PF=D]@IUX' .P&L-9)#4&3,MRYGO:XH<62OACBD+8<'V.2Y:Y4L+#7
MK5I!V\5ZAGFD0B3E>3'&1JHCBD!6&1A.[$@NJ&)0"XD3R'3W2G#<IQ\MV_R7
M(P$S=4K62E2K3H\'2W3?^DL\DK3VH&5[L*-2A15(BEE6S([I"U>>N8?4R5 0
M$MU49FNBA.+JK>J70$_J8Y:O(:?4V>FRM5)7L=99EI&:GHA7SK%+)81VR2D0
MRT[1K'EKU8ZM'Z\%2,+(\,\/Q+_%R>E1MW);=.%H@9:H:JU=2W:3()@75H.R
M3T[?A3%)'/\  W>5LO)7AN4K@XV+]E5_B^:XGB:O%<Q<6R15Y4Q<K'R$RQAT
M6LU(I$Z7C+5Q*;O#;9XK5Y?8Q5D]QGK/+U<.EOB!*6EL)[<C!T&AL1$J0FP_
M@,18Z)]GHYC'BF+-?Y^NA02M)2V'I#U!?JO;J7A"T]:6I"MNR\<%>5YFXZM:
MD3T(^WX;CY;1FM,_8_=9K1+V1/ZR9;W0/ \E#P_+<&]N.CR=7E[DG%\?'/?O
MU8Z,747)<96G-R<O^TN?K<6*G%QPB6 1\;R5I_6M1?!R['7]NZ&RZ]ZRT]3?
M5N374]J:3)6]I2:#*LJ2JC.UO:D,,U7J=SF[BC@!MK#'U-D,:12).5#*T 9\
M3RT>N6]S5J3C>)M0V(J9N<Q:I3RU[-,0O#6AY@*8;?(U9ZZQS2T894D:N'=3
MZ:$%_.MPO1?&UNI>J^)N\=:YC]D=(<7S-*I?X[F#<AN\G:Z0D=+?$=/\I1Y"
M2Q2J\W<JRUXK_IQ.ALRJPA[1!*WN+8VSLF-<]CORE58"]:C76GA@P421D6%M
MZE:N\L1;FTH;++FBW\_6^3:)>!U\5';B#Q6^9 J!;UT#N9#SMZPU1)N5-."1
M>)2:VJ<:--+-U5#8E2>:M-3D2RW%4^RQ'$*\R*)Z<<"6.W/16NA^$ICF9:72
MXYBY6EZIEH<2\O4;%HZU/\++?'U9J-/D:G+UYN.CZIYEIN/GLMR%*:1J7+6;
MLW'"07-UIO-%;WU%6F7J:RBMX.U1ZS1()5PK? 8/6YVOH=5"^F$!KI8K '0F
MU-J=7014MJ96U%I1@UPA\L<W?XGD;4]BO%)8^,K3+S"PVNR%39CXZ[5CK7 :
MZ1Q%9([,D$TD2"":2*":O'$DI#>%ZJZ>XREQ_(6H.//#<A2DZ0DM\69KCCCK
M/4/#<G9Y'AW6]/8M*]:QQD%RG7LR/?IPVKM/D+%J:LC)T3ST^?,\<8QQC'&,
M<8QQC'&,<8Q_]/\ ]_[N,9"L@PQANW:>0,24FMB^28020*!R+D,FL:,&F,/D
MC5L?M:]7%2>]Z.>B1M<D;+-KY= @:^IV?<_H/Z91-_/OW[S[#7T7Z;/]<FO*
MY?'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC*][9PZ=E]:;C K8F5/ZMSEG1_D0"G!
M%"J; Z-'L*:.6L3'+XCG_P"JD(^!\L;H9&O5B\[EN.3E^,O<9+--7CO5I*SS
M0$"6-9%[2R;\$_=3X925) .\]!TIU!+TIU)PG4D%.IR$W"<C6Y&.G>4M5L/6
MD#B.4+\R@D;61=M$X6102@!Y.ZA]'8>4Z_P<57V_V936M30L:%84A6.+@8+8
MVMGH&(._0X,RT#BD9<(/*(&4%%%%!"R-%G8\N;S'&=#P\/4IUJO-<FDU&-XD
MLB+C7+!IYICVQVJ-MH4#2E0D,RCM5=DG9/TOJC\:K75_+<OR/*]&]-2U.8L0
MV9>/-KJ2!8S#3JTD+S<5S?$Q7)6CJI(\UNG*WJ.X4+'V(LMTGIZ[;D:995'J
M1[/,,'J;ME?5O)BKHI[ BH-$K72-%-%IR)!S)X2(VV *"+/%$^5T36K(WHV>
M-ZA%:S'!U%+(9*UB-%;CN.CG$CPNL316%B7TY%D*L'T@V!LJ-D>=X[J+H#]H
M<=/=_#ZO (.2X^Q*Z=1]16*)KQ7(9;45GCY;,_KUI:ZR1O%N9BCL%1V"J:=Z
M6Z8]2>0ZSI'WVJVA6UKKC2N270"=5:;805!TM>\(&$[1V=_+" A YY<+1^S!
MT:\Z1)J=&I#\7"Z5XWJ3C>%CK\G:YVQ+\38D*+;X?XU(F*>FG^OIR<+IW"1U
MWR,; R$%%':5]K^*G47X?]1]9SW^E..Z%XZH>-X^!9)N'ZP/"368EG,TI'!3
M],7(9^UZ\,A'3UB-Q"&$[.&[[U"OMY52 B;NF[M(D.DC%DGSCZ*Z'#]WM9)8
M6SLYE:>LK 6^[Y'M$T-U/&U'(K)$:KG>HBC1F6.:]U%%)(P18[56,J2Q"J#9
MXBI/5C'D$O+-$@&RQ"AB/E]FU:@BDL5N"_#^U6KQM-+9XCEK E"1@N[)Q?5_
M*<;RDY[5)2O2JW;+G211NY0-Q?Z#]EZ=LYUUI#+JWV!?R=G7[Z8GM7/+8L#)
MBKJ*6<FF=3PWE8#8J+/627QI$XIRF/8C?8*K'2<K@^B:'1<#5>1OQ69;-RS;
MJGEYZ$31@,D7?6C>Q(A>14BDEE1O5+,H=(CI6]#U9^.W,?C=;7E^F^G[W&5.
M+XGCN&Y1>D>,Z@N13.4EM"'E+-;C(9$BKRV+%:M4G4UD6)VAFM ^HO8UWZN.
MDJ[NOKGKYVF^<O69/0G!74 TR9T1I!L2!,L;"5D31GS.RMU"DBL=$*YK/MRC
MLG:YWLEHV9S'R$(AEI116(I)4L1-\[/692BJ6$BJ$8,P8=O=X!^;7R*QU5PG
M'3OTS?FMU><OV:%JO5GH68@(8HN2C9;$DJ1M7DF:56B1XR'$1+LFXBV[[7]4
MG1&6ZYW5TG9F/T$E5G273T^9T%;?7;FV90N>%D;654YAK1_RMN +,4^!HHSR
M(U)FA8ON3%Z+<@):-22N]F:"941IT4#Y&5G<KZCJB[^8A&.] #9&;DW,4^F4
MK]0\Q'>BXKC[M*6>:"E)+(_^L1E(H%D,$4DTI&D5YXU]V9U521,L;ZC.E-CF
M\]H NRL77MOJ:OMH:NZTM337(L)P[)HXC:JT*#L!I$1RHWYQ8TE9[9HO=#)&
M]V=H98I&KR*/7CT)$C;U-'0]B "5/NK%5)!!(&]9HUN6XZ[2@Y.O9 HVU]2O
M-9 K,R$D .CL0D@T0\8=P&!"LZ@,=[H^Z>J<[F[S3']AXUU71U)EL;*+HJP]
M[1!8G/>Z,>NG,+(<Y?;''&*-/-)(]L<44DCFL6?A[#D)'"[2/M8U(*!VT=+W
M, HWH[).@ 2? .2_,<1622S9Y*I%6K 2V95E68PPJRAY#%"7E?MV-(B,[L0B
M@LP!T?7_ 'EU'I<-D;^M[$R#@+>C$G!4B\$ (FC%DFJ9WH!9J!9QI'8UYH;F
MD@P2-(&FA=&V2-[4YTEFOQGI4^1LU:=N*&$25YK4"N 5 5E!<=Z,5/:Z@JWL
M#O/1T:MOJQ)^<Z9H\ES7#V[=IJ_(4^-NM Y$K,\;GT?W4T7<!+#(1)&?S  @
MF.47J#PUKVMO,8,S2DF9NCIBR" ,[^:%G%9)&YDX8><LKS6K%.Z^9**7:Y.G
MK[$2.8RI,L0Q92W:$?)-\999^.YA:;11BMR'[,FDHW#$WS+3EKM//,P,Y.WJ
MQ(Z*[PO)'&SGNS<! W%4((.H^CYN:BLV'Y/IT=44:_.\.EF,>E)S%3D$HTZ2
M,E)5[8^2M30RS0PVXJ\]B*$5_P!\^L+J;K+/4MB:5:6+2ME454X;!+_/G!3#
M^^T^T4.;G"#?K"*&V8B!X<+Y48K(/LRL<))U8JUWET[>/JR;BDCE<\@MSBE8
M1MWJ(38H2/,Y=1\HC6,'7?*NP&\?R?/]/=$.DW4?*5V6XEFC$O3S\-U9)%)/
M$\4K6UH<]7@I1K"[GU'LR6&!/P]64AGCN"?U XB"<B#Z6FG4>:6!9!:J F.5
M89'1N?#\1ZR.C<K5<Q7QQO5JHKF-7RB4:>P&9?V9R+=K$!EAA*L 2.Y3Z^^U
MM;4D#8(\9N)#Q<D<<G^DW3RF1%<QO9N"2,L 3'(HH$"1">UU!8*P(V=9YIZA
ML2Y41*C=N5?X_'C;4A$_?POE1V3(OCRG^*KE7]O'GRG L3?7CN0'\88O'\IC
M_EO^6/0X_9 ZAX-OMVV+9!^VMT1[_KK]=96Z^JWJLGU!X'IU*37-V6OS9IE3
M;FUIU8#6Q3-M2TJK"M+DA*;,?%GI24)0"49C?I+*0SPJP;T?'S3P#E#$L:1!
MXM2RNEA59E#@0JKQ%2W8=M*&( (! &_.V>L.+I<LG1PM6+%J^8K:/5IQ2<;(
MZ13-$7NRR0W%D2,3J!'4>%6+*TB][E>ON8\ZN:F_O:G+T=SI;XR.NI,_56%U
M<'RMD?&%658LIIQ3XX6232-@%@EE6.&.25_M]D<;WJUJV1&=E1!W,[!5 ^K,
M= >?'DGZ^/OF&Q8AJUY[5AQ'!7BDGFD()"11(9)'(4%CVHI.E!)UH G0RG!/
M43U:=$OTRK4SZZ6\UA"#0&V*5$E''0ES1'RU\90;32Y=1F(J@04@HRT/O0!@
MHI26EM%V#1F7P50#:E=L &[B^BH/GP8Y"Q( 7L9B1X)Y"=4<;)\R36'8+.)?
M3AEE,(A2 .DKQ=Z;D6W5CBC5W,QL1Q(K,'5/@7OO'N6(?15%UGYK3;DXD,>P
MJ"G?8M&Z$+*5;#'3##Q*;97!08K0@76C@QGP6A$Z43XK1PTG(;L[)!Z8E?17
M6O3[V.MG85%_,VN[7:H[AVA'U+65H_76U4<W7H0!TE!$GQ2UHE[NU CRV)0/
M3B,G8']9V$+"4PRG]38IE-7VUEC%J7FT.@T<$'Y"S)CI*6JS=EIPI=%.W*12
M@.M*P"#Q'2"Z#XOEE6/[7P01E9FX_3%5<-V,D8/8HVS.L9$?[SR 3KYC&/ !
MUYUH1=5EX%EEJ-$9X+%LKZTS+'%!6EMQM;;X0%6D1/'HI9T6)7N( >4:'OK#
MU]??2 59!Q([KYSP[FJM*(32KG':&LM5K#I*2PAL5%N,Q/3RS%10#?&\<R(B
M8.4)Q>!>/+D*RQ=LQ3U-"-_SB,J94V"=HRD;V=#M.B/'0GZJA@4R1/9,M3X@
M5Q+\36#?"O:285)?2D "6:\D9(")W-ZH8HZL\NA[4SA.1TNUBJ[.$[)U[$L:
M.RK)ZF]0DZIK[NHJH$L!X'K'>1V58T"?P@R$DJ.:T4\$\02IJD3HI["7VBRK
MVM\@<A_F!WI2I9EW] 1L$$[ YN)N/MV +(6H%EFIRK)#(9W@26 ".0*"\R3(
ML<A'@N4?L=9$76,TIHVL[#H:WKJ%;NLK<!LY#[+2 !4NEM=')9Y<FW@F=#8S
MTU7EJ_(,0RWGJX;RR'KR6@9LF2&NDM\24:R S@J#:LO)+I&=O6@@AC23M8A?
M6:)8HQZ>E 52TF^[MV9NH.6F=^-,$C_LCC*L-,O:A@BDJ<C?OSV81*B-,*->
MR;5AS85I6+S"&J1Z8EQ3.V['_!O2;JNQ#[FROM!+1AU-?/H[BMG%!NKD6/4!
MVN9PVCT-CEK"MIGZ7.V8>+EDLZZQJ)?JA_=^6+.*R&9XVD"A45BS"-6WI66,
MK)*B"1'?M93+\C!O)(SG-S5A>,KWHJ;RR6+#P1P0R6IH63U9HFMI+5HV+$E2
M>O ;$,J4B9X9(0542;&KT>HZGJAL?VIIQ33R;/-EZ^OES9&OU.9%KZO+R$WV
MBAIH8@JB>*LSEN<C;X_+@7AE>Y!H166#QJQ- \+7GO?$&%FL02!$$L\J1"5U
MDKHWPAG-3UV1WB]7TV=58CU.T;'?'7EOCN!CI_%K'0Y*HUF5J7'P6;+5(6K<
ME.@Y9:"<M^SX98(;0KM/#"[QAEJB9S&V;?=K=8WP1E'<"ZYJQV(0N@##I=34
M7.8(?>5(5.7<F4JAVU'%969-6X(H<MCYP_L$$_'75]P\/8GXSXJ)HI5!CD[6
M#1V&@=RA$NXIH9(Y0R&,%NQU)T%.PP5M"AUA'Q=M+-5IELUV>&6*SQB7HZZS
M_P"IJ+M*[7LU6BG%K40GAD73M, GHR21:',=Q]<4T^@PI-4RDK<;57FG#A;/
M8:HL_*U=YJQK39GQN")L$ALC*F(R"P*+M+#1VNH#@'F.LB)EDM%Q*5JT$,$8
M,(8(J.2VII.V5@TDKN\LS/*[S22,7+"221B6).&SUL_(<KR-GD9W2XL+V7F@
M 7NH53/565*U*"&*I2BAIUX:=>!!"(Y*U6K$ BH);J.VJ8#!ZG6U^>F.*RFB
MSV2M*#4#'9N02WN+',#0QG2MIKTIH8(6P!M&DUE5;L*'<]M<TA9FO6XIAY8X
MG["LB%U90D@*HLA&@64;VC* S+VDG>O.8I^?->C:O5UL>I3M0U98)VGILD]J
M2FC=[+%/(%$=J&5GBBF]55 0/\IRLF=^PR2I>#X6H-U,-/LZ>&2#8VGX>']-
M;;J*B;7"%6.-"MZX*[F[1K+*S+)R%98K^F18TK[ZK?06T=_V7$)Q.6(D$4<*
MN4VR0RK/.RH@E:)=M6'?Z;?O-1"1]PJB:8ZSMM0-%*\;0M8N7'@2T5@ENTI^
M)XZ)Y9VH1VW58N:<P_$U@:H-HUH&2\\\UJU/:=G^J(,=K,R#272Z$?/$R4NB
MGT-2V2XREKK<Y8#'F9[-DRB6(^=T%0;$56@EU]V*!!!#9 V4=A$:NOIF6.0L
MO9WCN0(Q"R+'(I >0 J71E^8AD))T1H[$7+2_%K2MU8X)_B5K,8++6809J<M
MRM(LCUZSE)%K6(7#Q(\<Z1A1)'*)!<W-7.WCC&.,8XQCC&.,8XQCC&1/-_Y5
MW7]K(/\ @W(\D^R_P_XG*)[O_?/]%R6<C+XXQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M1S6VY5%GS[()D+S(E#'&4EDD@L,]@>+7QE%1Q20R2"B/*0HF..:%[X(9&MFB
M54>VR@%@#[?7Z> -Z!\^3[#P?/TRK'0)'_6SK^0]SFEIM43)7F)<0$&F@W=_
M3/*H:6S)$(;4FO@B(= .MBX.1\+HHYXI27M^Y"4D3O8SV,$#?CV(!T2-C8_P
MW_+VUD*QUY!)!*D@>/'U_3?V\Z\CZ9B8W2B1Y#*L6NT3E9FZ-BJS-W<C%5M8
M*BJQ[ 58]JJGEKVJK7)X5JJBHO)<'N;V_,?J/N?UR%;Y5^5ORCZ?IDD_5 ?^
MC=)_LS>_\ARNC^G\Q_SRW=_NM_+/ C8U@D;920M%%&^<49KW9F^\+.:3"&+$
MG@!5]TQ4\,+/ZO?(WRJ)Y5':3[:^I]Q]!L_7[8+Z]PWT'M]SH?YY[_J</_1N
MD_V9O?\ D.-']/YC_GCN_P!UOY9JZXS-U(TP=;F[<(0@B8J<<?(W+(92"'>Z
M::1B5_M<]Z^$55141J-8U$8UK4HL2*"H5>TDD@L&&S_>)\   #V4 *   ,RM
M8E9UD)<.H 5D4(1HD[^3M^8L2S/^9W9G<LS$F"VF9ZBLMWG=99X.6?;U%-;B
MY^PDQ-LI8U,Z5D5O' J5GQM'66]]A$:^$E_)RH]DB22> ATA17D2 [#UHYF2
MK(7[B3+65Q#(3Y)+(=D#NV575&DC>S'=EJ59N2AU\-RL].O-RM54[0%J\E)&
MURN@TH413+V;81]@DE[Y+<5^ T%'89J\P2VV>M8$&LJ0_K\PFK.'26.=L104
MM0X>9K)XHIXT?&JQSQ131JV2-CFS#&M9E>NJ0.OE6A[(V'\"FB/<@_<$C(Y!
MVY6&2MR?J<C7F $L-TM:CDT01WI,SJQ! ()&P0"""!FUJS<U25H%-39BRJJB
MK%A!K:NNQ=H'7@!#,;$.(&&/61CC#PQM:R*&&-D;&M1K6HB<NVW8NY#,Q)9F
M8%B3[DDG9/\ ',<"I6BC@KQ^A!$@CBAA01QQHHTJ(B:55 \    9']+'UYV%
M2:3&:;*6&@I3H'4FBJB<E?-:^(P08WZTDT($)$,BC$"%0SBSQSP/=#-#-'-&
MUS+QO)"R/&W8RGN0AAX()&];T?.P01H^01HG->Y4J<A7GJ7*RV(+"&*>.1?S
MHP!T6!#@^Q5E8,I 92& (T.<ZXZ6R>;I\C1]3BP9Z@%E#J0#,!96[A!YRR#Y
MV?<N*T\^9TQI91<TA!4LLI!$LKWN>]RK=[%F1VD:9^]SW,1(%V0 H.E*J-*
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MH?RJ?,:JJ^X^BJ ?OK9\^<O+PG&S!5D@9@HLA?WTPT+<LLT_Y7&^^2:1AO\
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MOD9;'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,\"A13AB C1H#
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M<8QQC'&,<8QQC'&,<8QQC*S[(U-QGAP8*62(68H:VL3K!]))H'@55,P-QY+
M'7>;"B2)AS)7''6ZQP+&R**KM92&PQY8D#D[\@: '<%VS'2C?:WU'L%\^?*Z
MWF.1BN@/KLDZ[M!=$^-J/;ZD^/L<W^>"V8$[XM!?T^CKWP.? 7!13Y^W&)1\
M?MB)CCLK*NL!YHW3+\D4%1,&Z&-CHK#[+Y!*L4(':K*?J"W<I'W'@$']/FW]
MQKS*AP?F8,/OKM(_D2"/Y:_7(>=O=0QVC&"RGS&TVW%S,$0[R;=RU,^4"TWY
MPZ$*.%8G2-)0:,2.=S(WSB,D*6=[XDGM7QMM IW>=#SW%=#S]->_UT?&078;
M^7V?MT-L==H.SK^/G[?<YJRNV2X1!K40"MLJFUL \]2312GBS%W)^8 T@=@4
MR<=7A4DZ%3C20OB=8"L@@(?\KRGC"R(]G1V" 6/L=*&[=#[GZ_;]/&1ZAUO0
M() 'T\D;\_I]A[_XG63>LVD?U)_S@Q41X=O<4\ZTM1>W(<SZDI(D+8M< <\-
MA0\H\_UBWJ^&9\XS)RT&?.ZI7S\I&M CN(!\_3R1O1W[98-X^;>P2#H$CQ]?
M .@1Y\_\,F0A8YX@IPDK9Q#1X"Q9FHY&S#DQMF@E:CT:Y&R1O:]$<UKD1?"H
MB^4Y0C1(/N/!RX.QL>Q\C,CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9Y3R/A@FEC@E*
MDBBDDC&@= V<E[&.<V"%Q,PXS99G(D<;B"(($>Y%EFBC]SVA[^^OU.]#]3H$
M_P @3^F/\_\ K]<Y]G[P6ONY*NU/Z8%(@L'UI&:9W37-V\)<:L]]<E599RLJ
M'W[?DCCDII[P,:.9[6_FI(U9(_8$ *]P$Y&M]WH'T_U/<')[?KW=N]?V1FN9
MM'1,.]Z[/6'?O[:*@=W^[O7^]G0Z?NB+X5/*?P7QY3_P7PJIY3_P54_S*O-?
M-C(/M=-9Y>$&P'"$*JT*&BM9)7'.('C)L 1?E_ZJ+*+7 "ASGV)]W:3Q !H#
M")*SR>A(MT4-L;(/T]OL?U\G>AH>?._OE'8KHZ!'U]]^X'T'@ '9)\#ZYI<]
MV)+8S/=:U_U@S*2/1U2U8]C;&,KI+HJG:,>&&+.3(;XC",>\0=88_M%#R,:R
MN4PN637L?(/:=G0WK>P3H:]QY._ ^_B%<GW'@KW#6R=;UH@>2?8^!K)]57-?
M=0SSU\LSVBDN#)C)"-KR1R6PP$_#.)8#BE1.4<D>=GR0M1\4T<C%<QZ*M""/
M?^/@@C^8V,N"#[?0Z/@@@_J#HYM.1DXXQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&5?W-,:/US>2@
M/*CG:9FOD>(3<BO:"[54C+-29<ZR2_=6_C7%I;CTB):EU2F"5\D14\4K,L&O
M478!\/[A3Y[&UX;Y=[UVEOE!T3L YCE_(?)'E=D$CQW#?MYUK>]>2-@><Q^G
MW"NSM@HD@4D?YJ9'*"9M3HD?]$#RCY=U_P!JMD]OM58QO^H(U6N9_P!9<3Q,
M"&&QKY1[]GW/_P#+\?S\_P"&LB+V/D'S]"Y'_P#W_0>,FQ^3S]DI3BJ]%E,L
MH;><D<DP$Q;."LCI8S8C0B!RQI_Q$;:Q[AIHOE!=*+*CX9YF24#,-:/L-#P#
MXV3KR/N2<N54[V/<[]R/(&M^#X\>/&8?Z#R'NE5*(-K)@&UKAFK.P%@K0AZU
MOP5[9D!%);7!B (>,/$<@8HXJ$_!#&QKO;V[C[[_ ,=D^_O[DG7MO'8O^R/;
M7W\:UX^W@:\9NZVIKZ4! *V!1QF.)G5KIIR9I2"I9"2B22BI9BBBB2)9)R"2
M9I9YY7NDED>]RKR"23L_]?H![ ?H,D  :'ZGZGR?<DGR<UF*_H;DO[,T/]U"
M<E_SM_>;^IR$_(O]U?Z#)-RN6QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S2S
M6L\5^!2M"1\)M7963C_LM;\'XTBO&D@47XE=(Z5]F,YDB2M:C4F]R(K&I).O
ME)W[$#7\03O?^&1OSK7C1._X$>-?XYNN1DXXQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&>4ZSM@F<-'%,2V*11XIYGCP2SHQ5BCF(C@*D@B?)
M[6R3,&(?$Q5>V"9S4C<&M^?;ZZ&SK^&QO^&Q_''\/^OZYRS;8V^OYK"DFR_:
M@]8=8:FRAJ)K7J(?(5=OLPKVNT%E'IHI+?83U)46FOW"#S5-K8!_DU>E$R,2
MO!K]L.J@,'A+!4&]3%R(R"J]A"H&^5=G8![?S;))U2C-L=LNB6/;N(*&;>SW
M[+$?,VO!(!_+X '534\-:GCQX1$\>5=X\)X\>Y?W=_\ 5?W7^*_OS4S:S16^
M8HKZ<0FVKV%S!MDBB<LQ,+9!Y98)Y0C(QYHH["OEG%&GEKSV$@R3#PRO'=)&
MQR2&(]CK_G]Q]C^H\Y4J#HD;U^I]O?1U[CQ['8SZJLU1TA!I=77QB3V#O)+V
MR3R)[?G)*^ :.:62,(3[9A9?TPF#B*6423\/SSRR/%B=;.]?_8?X^ !L_0 9
M(4#>AK?\?U^_ZDG^))^N:_-_Y5W7]K(/^#<CP?9?X?\ $Y5/=_[Y_HN2SD9?
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC'&,<8QQC'&,<8RKNYOO?X.;S\?&9+.AF:=(P*&[+D4%NJI'6BD YMC]!
M9UC:U"W7%33?'8VU2AM:).-*4TB+-!KU5WKV;W[??L;6B_R@[UVLWA3IB#K6
M8YM^FVO?:_[7MW#>POS$:WL#R1L#WSPZ?B%ASM@T2(*&-;F9SF@YW:YJ)7*"
M GN>%NI9;6:141$4D9R .:C86-^S"2JIM]XV2?E'NR,?<_6/Q_@?/^!&1%K1
MUK6_LZ^=?[_G[>WC+8YAS+CC&?+_ /$=_JN_W+QC(WBOZ&Y+^S-#_=0G+/\
MG;^\W]3E4_(O]U?Z#)-RN6QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8R,E?TR
MI/[,ZC^]<ARP_(W]Y?Z/D?4?P/\ 5<DW*Y..,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQGG*K6Q2N=+\#6QO5TRJQ$A:C559565'1I\:>7^9&
MN8GCR]%;Y3C_ #Q_EG,O7]OL+?6P03;N[T>=J]9KPY9BK+K6MDLGUI5^"R J
MBIJB302U4$ZQR5C8K$)Y@HU9<J./72("NU(J*F^P*Q2,Z"R$+L*=ABW;W:]_
M!T25]_.:R%V8#U"RAF^L8WHL/R@=Q'V\Z( /@9T]S5S9QQC'&,A64,$*N.P8
MQB8)Y!=C!"2R*5DCQYDQV218IFM55CD3POECT1W[+^W*K+'(65)$=HCV2!6#
M&-_?M< DJVB#HZ.B#[',CUK%=8WG@FA2ROKUWEC=%GAWV>K"S "2/O5E[T)7
MN5EWL$9->6S'F /9"E&GU\*D?9K?K?:20,R&!/MQNEA^ J:",4ORQJK)]2:;
MX5\-F]CE1%QK*CO)&.[OB[>_:.J_.-KVNRA'V!Y[&;M/AM'QFQ)6FB@KV'$?
MI6?5]$K/ [GT6"2>I"DC30Z8CM]:./O'S)W+YS/YDS7S#98 R'35L98[[ :"
M(D@)LS%*A'G<YL,\L"+\C(I7,>V.1S4:]S7(U55J^*"6,R-$'4RHJNT88%U5
MB0K%?<!B" 2-'1U[9F:M86".TT,JUI9'BCG*,(I)8P"\:2$=K.@92R@DJ&!(
M (WF<OF''&,<8QQC'E%_@J+QC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8QQC'&,<8QQC(5N@\S)3.L]--:!05<D?U;*@-T%??P$V! X(X=3
M/EI8KXLBU-E""CI@D)2X*<((\$QZPQ+>,MW:71WO88*5( ))(?Y? V>XZ[1L
M@C*/V]NVV /JI8,-D#0[?F.SH:&]^Q!S0=:1XBR'DT67LM)>DR#!02V.NL]7
M86HPEO65>A%@%&U4JNK!+"N.J3I&U(HHASFP*2LY8;DAM+Z@/:X51L^$" ;!
M93LI[D$$?,20/T(RL?8?F4LQ\>7+$C8!  ;V!!!\#SEJ<Q9EQQC/E_\ B._U
M7?[EXQD;Q7]#<E_9FA_NH3EG_.W]YOZG*I^1?[J_T&2;E<MCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQD9*_IE2?V9U']ZY#EA^1O[R_T?(^H_@?ZKDFY7)QQ
MC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,QC7AQAER6+AF5[!I
MWG/-6)H; VQ/<2XMT_B%HS8$>LZS*D21(]9/Y'GDC>QK>]C6O??TUKSO[8.M
M'?M]=^VOUS@Z>!OZ[-J>OKVJ"WPFCVAE1#1W?I_;3S5GXG0R9:BIZ9T<^^B-
M&5]#^IX;*L&;& -K'PV<T"U$9&^/,8:16,95 2RV-@]R][,W_9:UW=A!/GLV
MN^XYHG7J=L9 <,Y&C!K6CVJ!HOL'7<" =!O.M#.^4\^$]WCW>$\^//CSX_?Q
MY_?QY_AY_?QSGYO9^\8Q_P#O_-_NXQG\I>@?4%MA-9W\'LNY>N;6GK>P!@\Y
M#79JTU-J CGZ"K1I+8"<E9&-?6YNM C/M[C0%-EJ7(]SABPBR_E72G/\I>Y/
MJ>*]U)T_Z->^HJ>I$J"-3)9A[5'=QO=N.")1ZDUB3<+-V^FRR/\ J#\5.ANF
M>"Z:_#2WPGX;_B$UJ_P,C<K\+/+.]B40<==]:0+%U)Z6I[]F23T*?'U@+<4?
M>L\;UXNEH.\837>Y-AVA:)[_ &HW"]$6)4:K^[O;[IZK8*JJU6^%^1%_9%_K
M5.>X21Y"3_I#%*-D?_#Z<,B[]];]/D"3H_?S_CH_#I?1K@ ?AYR%<Z!)Z@Y*
MY7.MZ[M&?@ !W#SXT//D:V.3>E^P !O5'ZG)Q>S?49HRHF>^;+LP 1#*E(]#
M5C2O&#LC- *Q::21M17I/CLTL=(27)&K$C5$^=],V8I.MNKH1S_/,4#%HYZ(
M^&A$=J)&,8;XT?NMB&N3QU7==G93H:/Z*_$KC[=7\%/PFN-T#T,L4IA$=FAS
M3?M&V;'&6YD6?M;A"/BE!N\@%ZBY/7(Q0HP8MXZ_E[=;$OE=EV'7N1/_ (6D
M"Z,I)&>YOEJSP7-AGB&?LJ.]JI$JIY_;^M/HC3UE.FZKCA/^S9CIQ'9'@,'X
M^%MCW(!'C_+\\1U^4F53%^$UZXK'P_&3\G9!"GSVO%U'<C^FMD/Y]LYRH.QN
MS:GU1=E7=AW(ZQP8_76=+"R%G2,)IZ[[D>;B%LGOBNL]U])\A1%C,,7E^PC[
M(\BW=!]$B,4\<;QE*UR*];\OZG5E-N,3BJLD,5FO;% =ZU0D@;LJT%)=I62:
M"\6E:;M[6[943[)S5#I]_P %.D37_"7FH^IINJ>3KW;'&7^(;GG6 \H\T)B%
MGD^:=4BBJ12U;G"B*O%2]821F6O-+L_4;ZC^PG== 3=1&X#0Z&+;9^*R9>T9
M%(+%6M&N#O<*N@ORL^=*XZM$;-]*_)*8&XAK!9&SME;GZTYOEJ?%UVX6YP')
M6)+\"N8Y(61(4CFE)*2W)(PQDCC]Y>\IZ@5#\Q73_!CHWI7FNIN1BZQX;\0>
MFJ,' WWB2U4MPS2VI9:M5>R:OQ$$\B)!/8/[NJT*3_#--,@*+)T*[U$7HAE1
M5F9*CD(M/QD3+%A_9U=5RN/CA<TR"RMNFA<N^!WR+/%'%KIXG0HGM/?'Y(YZ
M6/EN5D6)EXJ&9'1&::.;E$B"%59I>^7A%K^DH)??Q;)V#?JD;;/F]GICI2M+
M9AFZIM4YHI)HH:5FITS):DF1W2*F(JW6LE]K+LHB[?V4DWJ'7PH8B/.8O3]Z
MP]^;BK>S['!Z5:<5O[P&M6/N_&9F-H""5EBYL#;K0Z!MJD,UBL0BB6 B?2:.
M[ZL<#QYI_&=*=7\W<XZW8NT^'G9.1G3N@YNG72*)DCE 8S6+8< NZQ'U8QZ:
M#Y>T!F^Q_BG^$_17#=0\5Q_#\SU=32?IZE-Z5[HOE;T]JU'-/5?TDJT.)DB;
MLBB:T&J666Q*P:4R%HH^E&>I R90U^IBAV%SQ,:X'<Y#4(L4CT:CXOQ&KAGE
M7]_/A@SO_!'+^W/4Q=0VYV5(ZM5B3Y%>Y4OD+O1(6M;#G0V3I2!K?MGR^ST'
MQ%&*26URO(Q(L?<C<AQ/*<$K,0>P%N1XHQ@,WA?WODD+L$[')WIW]46_&M.Z
MI=CK>J=Q[NPJZ#.U;KNEZC0!]F[4-G%FN-)04L)I[QZ(2(>C-_*:>%0RR;!\
M8\L9)'B^E.J>7>7J)[-CBN46+D8C%&LD7#"NLS7%<33V*L"%V^'C18)C+:5E
M=I6"NK-]F_%+\,ND(*WX>0\;1ZGZ7DM=/6EM6)Z]KJY^1EJ)Q4D8I\?Q_*79
M513?L32W::U>+=)8TK1L\3QQ7GOO5%V50=B='T(/2VL?1[:XE'T]G3Z',Z*D
M' (+#KHC67%")?5TH(39B+5)#;;+$20BRLEC9$OR,[O)=7<K5Y/I^O'P-TU[
M]ADMRPV:EJ!8WD2$.)JR68F2,,TX,D]-RJ$,%7YAXGIW\)NEN1Z:Z_Y&?KOA
MEY#@:*2\34N\;RO&WY;$4,]IX&I<C-QUI+%@QQ4^VO2Y>-))E*,S@(TYW'J]
MPF?R&MO*RMV$T^?HK&SCL%RIQN<64*!\DD46CKG&9PPV!&.5 &6[&O(2(8PJ
MOAF<7%T[_6-.OQU^[!5Y)UIUI)6L"A-+21E!^5KL(DIEPV@(_7 9RB.\8?O'
MF.#_  BY:_U!P'#7>4Z<@EYGD:]2/CFYZG6YN6.1@6D7A;9K\NE<H"[V!0<I
M ))X8;#1>DT'QGKEREKUKE-:9D=UH[.^K"3?KYFFHXY)&"WMQ1/EDKC],.2,
M_P">GFDG@"_+#QI(Q@A]@J2/9BX?JV;DN%I\I!P7.<D+"/N3CZ$;1=\<\T#*
M_?958W!B[GCC:8*&7MDD\D9NKOPMH=-=9<QTQR/770W33\?+ 5K=0<_-%:]&
MS0J7HGC$/'2//"ZVO3AGFCJ-*T4OJ05R IE6>]5=MJ24C"ZAW],%(KOC-N.O
MN\#28V_Q8LH=#TT?4O>YOAZM@TSX?"I\9,B+[DW(>H.1G?1X&[33S\]NMRWJ
MKKZ-##Q+QEM?1;1&_9B/.<NWT-TW3B#Q]=</S$WC]UQ%_I<UI"1Y*7+?5<-A
M4^SR<8K?>-<YP]:7>>[I\%DS*6Y[+S#O\(-0)-)F^G-;C99Y9P+*<$>6V['2
M..[B9,*Z1M34@0)9RM0*QG$AGB<OB.O>H>1@XVF]>QRM0GDX8V-7@KM'N+1S
M&-3/RFEL@,G<(((U]<CTY6C5U.?;/P*Z Z?O=1<Q#>H=*\JIZ:N3Q)RO6_#\
MT(TCLU([$@H],=TG'N4E"M<NSR&FI,]6.:2-QG]2JV2:6N E(=(Z>0(629TP
M_P!29TSX(W2.E%]S_K2*]7+(/[W_  N\Q^YWM\K]?B+&.,MLL40L63TV[BH)
M[DV>P[]TV>T^-G6?DFRJ+8L+&%$:S2K&$E]9 @D8*$FTOJJ% [9>T>H--H;U
MF;R^8<CFNDO(,[:DYP^LK;8028P<JWJ";L!&BL=/-%-7B7%#/(L\4;HHY&64
M/P/>V9T<Z,6%^I>:PM2=ZLD,4\<;2(\\+V(_D!8JT23UF/< 5!$H[2>[3:T>
MIPR\?)R=.+E*]NU2FF2"6&E=BH6"9B(T=+,U'D8T$;LKLIJOZBJ4#1EN]:'@
M[#[:"I.MB"1\CI+#MZEK0<X76TEC0@9?;6%)/K%DT )FMMR;C+"Y(/06\RUY
MU;9/)R?XF%SR-4#+4>>7D^:CK\4SK2M2\W!%%5>&O+6CJ<A+7:Z6LQ279VGI
MQTH[4[>E)%,7I>B"6N1M!]#DZ:Z,L7^J(X9.:XNMT7>M6.4AM\A6Y&QRW 5K
M\?#!>-LP<+2BI<Q-S5CC*,8LU[541<S\8X6+A["7=)0=XZ]VO8)I%IQ,M%J^
M[ K4PC)6% "!D.J+?9U7YJKUYNU/%T-Q'-14?YBB#S+"4%/N[.%!:^@(F=KU
MNH+QNA+?PZ4Q=Y^.9VI2UHXZ/#3WX?B(;LE^5+4X:M7]>M'4#]LMB9>R*LY.
M_P CT!PHX5IN+%Z?F&X?H*>G!'S-;D9[/-=8TN"N_ V^$@X&O-QE%DY'D!2Y
M&QRIA,U>A4<S6>1BC$KZN[Q=J*8YFT$3/ZN"WKX8:QE#IPQX:S5UD5[F'V;2
M0S2*^&N26QR-[H#'CTI>AR6@L G" 20"P[G$=0?&02"^GPUQ9XPL0KVXU$-R
M$6:AE#I(T2Q RTK%ERM=[5*U+'V1%47C=7= #B;U<\%,>2X>2E9=[;<CQ,\C
MV^'MOQW++5,,\$=E[12KS7'\; );\/&<UQE:<365EE>)S]Q=DBEZ3,3OQ<.D
MS86GTJVY6?M8:.XS>>QU#=BK7@0;(QS!=#=6I\53?.OI9FT='8/-S0Q\?N73
M;G.522U3;X!;56.W:,[UIEKSU:U&O80Q1K?D(2S8FD6&P;+,*]>4R5$D .=F
M/HCI>:'B^6C'.R<7RD_$\5\%#R5*3D*/*\ESG(T)A:L2<'7#2\90IUGN<>O'
M(C<AR%5:_*RUF($\Z^[/T6MTM6PX6J%H-/!VH^IJX038=!1/ZOVM'CGNN+"6
MT($LX[UUD19?S%14+4HZL"\V*D2%IT>-Y>S=M0B1(4KVUY@PPB.1;-<\1?KT
M3Z\AF=)5L>LTH[88##N)/WO>7'GNI.DN,X7BK;5YKDW)<3)T@+EM[$#\;R"]
M6\#?YQ11K)4CFJMQPJQ5=R7;HN$6I]51&D.0^/O'5F7>=:/5B#YLX?&:"TLE
MI'6#!\_V1V5?8O)"$SNUM,75V3*VE@D.GKJ38)^:MF/+KZBEKIB2]%>H;DEB
ML%A1:LB4;,TOPYE"5N4Y6S0IH[_&0O%*(JX,CQ5[O^L3*7C@KQ,S]MN@.'@H
M<F9;D\G*5Y.>XVI5^/6J9>2Z6Z5X[G>9FBC'"WH;=4VK\BUXK-_A#\!298;-
MZ_:CBAG6K[E(SNB.SX6(M+Q0[=,^VPCN*>O%FN%Z^LNRW0)&7*I+!8LW363)
MBUA<Y+1:T2$>> LLRMZ-WG6JV9*T="6P4G^&$@G@B1I_V;+RW;IR7""I7F[G
M[2?5])%5@[O%Y[A^AH^3XROR5CGZG'B>D>2-9Z5ZS*E$=25>E0_="GI-,_*7
MJK)"' -06II)8Y(88+6B?W^RT!6;/9HQC+ZLT\6%M;4D%1[34T-G09B&IM*8
M8QED% ;K-+75@DT<ST+@&-*?(##+62GZQZD$R;JU) +,-L<=-,\16:W6EK5%
MAF@202QB2Y;BB0AB'59')C4Q&3H#\.&J3A.3Y6$MQUKB7Z@ITXK DJ<1R-3D
M>6>Y4O2P-5GD@X;BK-N:-XU,,DM>)4L.EM*WAD^_YM +,)#F";/10;:^Q/UH
M9A\\*6;2#:J_)*'9=E/(CK8LUGXHQ+255#O=!.0/7NBJ@3[0**?4C649%IO+
M:6_8H=@9:JO) ENRSJ+#EA"*M95CF)*6++LD6H8I9H\O,?APG&S),_+15.,D
MX#CN>]5TEY.6&"_+P_&Q0R-Q\(C:V_*\D[34T'K\?QL<4MD/<L5J=B1'=DVU
MZWK1F7,I<D-ONO[WLLF^UM=)<#U%+2"XN?\ $*$+>T Z61";6 T@^:U>*'74
M-M[19UGC+"VI.4FL#BA4>"DO(\;8Y5[-R(SI!!72@WH%$L5E$K?'K(TC3%$B
MK3Z0EA)'RZ_2U/CSU4W+07N9EZ<ZDX_I6+CN&LK2ENW^0FYV/XT3S<?R4AJQ
M'@9((ZZ4UFFM<C2W-&(V@L5@O=G8Y55O-*'+AQZWJ[KQNLNJR6@NC5VEA3[7
MN+,7?Z<O8]:(RBJ-&+U<.;DI2:C23"I?03%NN(V-BEX_^D'*/#R=N,T%BXCB
M_C9H6K3R&_+!?YVI8^%L+=C%>"VG#K)29H+10659S. %;UO^@72\-OIWBYTY
M^2UU;U,>&HVTY*C ."K7>"Z(Y:C^T^/;A9VY"[Q<O5TL',I%<XM)CQTD<(HL
MQ=.D,CHBKLG95I\<+#\AL"\[/(,Q\8Y Q5-1ZZDD:R225R3Q9S4TXEB[W_'+
M:C'301P02101>JI6GL/>BD"B2C>>JQ0$*R/!7NUR 23W"K<@24[(,RR,H52%
M7Y=S/&14(N#MUW=J_-\)#R<:2,K212PWN0X6^C,JH/3?E.(O35AV]R4Y:Z2-
M)(KR/,N;V</*R[B*B#Z\NII1FDHXS-CQHC;R4@4DS44H8EG7#9B<72FW%05/
M#:TE=GBAKVRMPP@*B>&P('D;EA&Y%&]>&_V=>$;P2X*!3[,6!4*26! .8YB!
M&Q(V/E_VOJP&QVZ8D>X"D$D  [.:+HJC%H,D4 -*>2D=G% I5KC^R,<?+"#3
M5-<##('V?8V=Z9 %7ABA"% S14T8\# AAF%"FOEM88LX) '@G0DBD&RQ).XE
M50222006/N3K64@&D(\GSK921"=  >)26.@  1\OT'G>75S!F?'&,P[" @D.
M>$4V6OG>U/89#"//)%[7(YWMB+BF'=[VHZ-?DB=X1RN;X<C521K?D;_3VR#L
MCP='[^_]<TF)14QF115]RIF*!%541%54JA/*JB>$3S_'PB(G^;DO^=O[S?U.
M0GY%_NK_ $&2?E<MCC&.,8XQCC&.,8XQCC&.,8XQFKM[:"F'@)(',(80>!7-
M:$.I,C)[$F,,9\K$<U60*1-%')+^Z1K(USD]OE4D#>_;P"?/Z?\ '()U]"?(
M'C]?XZS:<C)QQC.5M)ZG>I\_ZI,1Z=[$ZZ;V1H<E;3 10TSY:&-UJ@UT"(9;
M?8:^$P@#*GRQLB"(%191HYRX)9/CYG6%S \H [ PWY\^/!\?;;CWU]=9@,\8
MG6$D]Y4D>/'D;'G[Z4_3.J>8,SY%]MJ1\/CM3LRZRVN0\GG[?1F55"/"9=GA
MTH$]B6-4AD$B1&6$@X\J""*3$XJ?V01N621C5LJEF500"Q"@GP 2=#9\Z'W.
M0Q[5+$$@ D@>3H>? ^IR V7?O65/;V]=;7T0(%2!DR4T;EB)H[0_6U6BT8]%
M3O E+L3[:GQ^>_6VB8RN:%48^XJ+^8UP#SY +")R!H>26&O8CM(&SO0T6/:/
M.RP(U[;IZB[(W[ >?H>X$Z'G>P!L^/ (.\TU5ZE^J+LZZJ:Z]BFNJ34MR\E3
M*74BS6*KK\MC'75.:39Q5%G51V.TS!;XQ;%]Q]"]I'-JG&7M('8R87&B1X9>
M[?DZ^5FT0!L'2M]->#YT"0]1/(WY!UKP/J%V"3K6V'U^H^XSVD]2_32688 ^
MSK#12*^ZM2KL<@=*:MK:B(.6"P(((F@G,K=&XQ1\G:4PUI6:,L0P:K,(F@5B
MO1DUOM/N !]23OQ^A77S D%=C8R?43QY\$$[]AH:\^?H=^"-@_3)F3VICVY:
MIUU4>N@K+[2U./IXZEJ*:7I+73QY)]5((8X2<$NCM_N-TPAK(#<_!473[$6*
M6L)@;7TV[BI&B%+'?L%"]V]C>P1KM/L=C1\C)[UUW [!/:-??>M'[:/OOVRJ
MT]3]#)>V61&Z\[%*VPM_1Y^MQT7Z 9<W<^BS_86MKI63$;V&FSLR93K'4:,R
MCVUKE].#5OS[BZ.(K2TPI5O1.@W<@71)8]WC113X[>X_,Z@%0P)WHZ4D4]7R
M0%8L" !M?.PQ]^[0\*202"!K8&QGSF/5;UULM+69C-U^EL3+\;#&YN5!JJ-M
MV%N,SD-O 7&&ZW6UK!ZC%;"/3'/NZ^M<>!F=M'0,N"\P:.Z6@=02Q UW ^_C
MM9E]]:.V4KH$D;7>@1@2JQ  )V%(/CR"%._?>@K;\^^F WK+*V7<O7_7NSRF
M+VM_698G99?;ZFHN=!;4M'GU'P=K@JFTJY3[:S"D=<F2=A59=8&*,2R8*MNI
MB)Q7"CQET6-V5F4$A652 "3MPY!T ?'R'?GW(]_I9G5656('<&()( ^4J->?
MJ>[Q_ Y2>5]9.*UJ9T^OPG84&7T5KTW01ZLR;KF,*OO>\\CUYK\36ET,?84N
MT,5@O9^5K[PVAS%S7U9LED4XJ6BJ;&Y'RM79=@LG<!(W: _E8F=6(;L[1YC8
M@$C8U]2!F,3@ZTK:)0;VO@R*K*-=W=KYU!(&MD_0;RT;?O7,U';U'TY)4W95
MY=N$@;:C39Y*X4TZBTNDA&6M)OA]780BU68FFN;.GSMC54C[C/ML#8HS39:W
M&(F,9DV-#Z>=D @$[UVCRPT"03HZ'@;R%P'":.S]?'V)]M[/@'9 (&QOZZ][
MSN1E=K[?)T77V]W#<K-FQ]Q>Y,;-D5V2(U#8B01" ;3256BO3@:8D+2W(.6I
M+LD'/G!D11EV!4%9($>U#%T7N#%0Q.SV_P  0 2"H)(V1]!YP7T2 K-K7=K7
MC?\ $@GQY.@?'ZZ!@8?JEI9AG61_6?9M-2'$=F 9&],APQP6YN>JFZDO14&?
M#S^YN;X6[.I\3J[W.B:2FH8;6OHS&*4*?\(4MC"=@!T8ZC+ =P[!)VZ+$J!H
M%E!()T3]O.5]3[JP!+!2>WYNW>P-,3O08@$#P/?>=+@'A6H 5I6E0FUUD(,>
M :-(V4<L(R%A I0\K55LD)$$D<L4C55KXWM<B^%3F(@@D'P0=$?8C,H.QL>Q
M\C,OD8QQC'&,<8SQ(G:,/.2]DTC!X99W1CPRDD2-B8Z1S(!X6OFGF<C5;%#$
MQ\LKU:R-KGN1%#R=??[^W^.#X!/V^WOG)^-L+NT[?)G_ %?#%7G6K[.&JO=9
MLJ+3&U@T>^?'2P]0ZJEJ$ B& T&8")F%C^EXQWZE=)+<6,T<.VX40@=GD#1*
MHC*"?3\^LC-O95R-^?G*>%4;U5),OYO!.]%W#$#O\>DX77YE!T-;7N]R<ZVY
MJ9M8XQCC&?STZ&]/O=N2W'?EE9=O!40M[V /+13YC'94PQU8QEK>*"7%?4$P
MM8%-!IZR=:^K^5C#1YBFF-F*.;/\]Z7Z:Y[B.1ZAM7+],Q<C<[Z2Q5$8B 2V
M).YE7T#!LS "!6DC#!Y/+N6/W[\2_P 1NA>K. _#_CN)X#E5M=/\.]?FFL<M
M/&K7FK<=7"H\GQHNLHINQNR1PV#$\-<@10HB]>Q9GLP81T,7:(9I?[>TRYP-
M81X\)_\ F&IK?/QN\_Q7VN9_X>$Y[,P<@3_W^(#["DO_ !L'/CXO=/C_ /4-
MH_QYI_\ AQXSES#=,^I>L[K[TU!O=H(>=UCJE<NJ8J6SC@2,D>>!(JJVC#J
M_P 351$TGFMN;A2E)8=8.0N-&KY'B."ZBK]1]0WKW-NW'7O2-.*O"@E0AU:/
MQ:J2UHA7A5ZS>EZWK]XED*2*!GU?JSK?\/>0_#S\/^%X;HN./J#A!:'+V+]V
M9ZTP:.6.QM^,Y2KR,[7[;Q<@ALBF*HA-:!987)R\HNN.WI/\L]QQWGA47V,S
M5CEVN\>/".?DM93RM\HG\KV.1%\JJ)_#QZX<>K']]?Y68?8V8(!_.C5ID?S^
MOT&?*#S_ *>_A. Z:I^^B*-SD-;W].;Y'E5\;\;!(T/.<F9OTT]I4OJT[&[5
MDQ0)=%=8\2N"UKNZM+007Y*A9(-0A1:NJN.P*"TADI2IK ZVNKRK,@'8/$WW
MVBSU_ @Z)XF#J&]U$L_(?$7:L==HQ?G!1E$*._?&D-GYTK0_,U^4EFD[H]$
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MIWMVLO@!F5R1L':AP -'6OG.QKZ#6OK;L!96/GM5E .M:8J=_P 1VC^9RO\
MJGTO=3=2BN95TD&CM/P^.H(--K*S.V.H#I\7U5C.H0*X*\#I*XP4,[.8D,ZS
M&A>R":ZMKP@:,4(R$ :SS/(?)T-L>U=A26D:0D@D@Z9CK] /<C9JD2(/ V=
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M4M1'1Q:C5S0(94XF.>&,AHC(55(+?:%"30D5U"Y_UZH0D:^T?M"FJ*G26"@
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MBR)36B:82VCU6>TLUZ/16HUE-F;HG.WC!_D\U]T'%!,4#(LD;&R/@:1''))
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M2P@"Q#H03+X^8LIT;4>69.J>\@PETI)$GF2>61ZJY=R"M7JH8Z\,<*%B["-
MO>[?F=R!MY&]VD<L['RS$^<Y%[D;_)S"QR%RQ<F5%C1[$KR^E$GY(80Q*PP1
M@]L4$02*)=)&BJ !C$?TJJ?[/Z'^\<QRK_\ ?(/_ "UO_P!6EF2+_P )N_\
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MS4)<;?':BDQF;T.&T"!Y\2JASEO1=>XX N;/5E%I/-.\^+016EO?'6EA.XT
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M*._JV1QQ1L1K(XV,1&,8QJ-:U$:U$1/'/7V0%BB50%5;%-550 H4680% &@
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M#_6"1VEOI_L_/H?Z1\G%"SS15F;LM3R!.XB"!*W44\*PDA3-(#PZ!_5$8()
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MHWDH=U:&*!VKCD:4?.<6EJ'T5A/Q=&9>0B%=["P%BEHUK@,.2,35=+73:[.
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M\E7*Y;,8P,4\=PID+"!WOA>^*1%5CGP31D0N7PJ+YCFBCD;^_P#C,3SY3]N
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M>_ZY-^4R^.,9X"BCA#Q"BQ-@'A;[(HF>4:QOE5\-\JJ^/*JO[K_7QD  #0\
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M]Q';W'1WH'0.MC6_<_7-D3WICP]%:YLD6UC+IV&3FSLGS14<(-7HJ'.6]F6
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9CC&.,8XQCC&.,8XQCC&.,8XQCC&.,9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g189651g17b47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g17b47.jpg
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M8KSQT7*\Y)9;:3L9.9$\_.9>0T>OU6QG"/.Z=3..1R+K# YR)",R9]*LA8U
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MB*,IQ=2@KD]4*,QGK3(ZZ2([-:$(J%1B[+6^OK+;EY<.M9D_TH'$U\HER7R
MBLL%Y4_EM0JW$XAH]&0(FLMR6IU,M)2P0F LY^&9D/1(;C;J(/N<I3<:4ZM.
M6I$(/_A-32Z5.4M2CD\)1!LXY?'-8*R/_$0U.MQB0MX_PJ\/.5KX-^8/2.LA
M3]+[RR+@=*FB[STCD-C'0HX\1TWE02Y'J?-W&BQVFH35LYS9!.P]I%--M/.!
M257.Z9DMD)DY5^T]GA"1+2O8,(:D5MA.421S:[9Q;B^8GA69Z&M*9*.IQ*I3
M@A1*!)C\8I2>2/CF.YQY+=Y[;1?#KF=)LE<K?8.Y^/[_ 'OKO6"53B&XU(I
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MI?92/*>31.]<E[A?IG7VP@N_5BAWSG'2#P@0+N\.2B\.#J[9:79I@6'8ALR
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M,-MR4A-ZR/"@ZO&2!ORYBJ[&>YJ_"Y8/K]2D#!QZS$.LV!H\4*R^4!.N3HM
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M/"T@$/RT#%.M5'DD*N"!YVQ57G=F)0;9U#GU;M(EZ_PRQ95?$T_XH2(78Q6
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MX<<5M3D$MW.^[ZQAQQ>7Q\PBG^T2[??(']@S+=_AC\,TV_XI?')%</VOSO\
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M7U1H;;KK;;DN2B/(F*CQD+4E3[Z8D25*4TUI;FH\:0_M.FF7%)?]NN,Q[]@
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M ('@_P"),]'YG[9__%_7_P#\YP?.W9?+5_H/S9S;\:/*#F7E=2C-]Y7JQZ!
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M>-WV@^(?G7H?]_X^2]I_A]?^SJ?EQ\H[/]/H_P!V'YL?IFO&[[0?$/SKT/\
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M)!R$ZSV> HS>YN)TDEVZ6IJ6 =TO3H)*HV/#D&O-!(!O(L+LK=.$0ESSQ.U
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M#Q+?/;Z38FF;2%=V7#&Y/%;I RILQ],\@+Q:.@,]1F3;N(Y'%ZWSWF0.+/O
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MUA=D3_B$-O&^2\P[S*:MW;TP:,[9*7^JXW2?4WWSM*LG8$0$"CKGR+X;=")
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MMXZ!%BUX%#X-T4^0X2[3+7U<OT(.,8-LV&M*)SN=UBO2K2\5>2)&JET@O6D
M[0&I%TPU.^;)18Q=SZ6!Z7=&!%:1HFI$Z^M%L9D3DP[B3C(E( -.2PIFR.;+
M8ANO_"E2-QX5\[NE(.HT9&]&4+%^//&^;$973ZT-JLFFV2@3[<I'*^>-BH8Y
MNUT&L1K&0<9MI%=U(2E/#$?HK7KVLC06.T3C(X86ZNI,(*[B1'OSOF,Y4=TV
MG"[(^,Z$)1>=_P#PX1[X&UBO<C76,;ZNY>._+FIC\I+_ -B#R"_\JC/_ '77
M\O\ H[_G>S_YW_TRRO;_ /E-?_)_[C/%CGV>?)9Z?OD5G3#/B/V)ZO1($\^U
MV:V.@X)6:^.%S3#?,^>J&1"1"-#(28$"3-TPS,FQX$Y^+'6X^U#DN(2ROYG]
M-5\JT;4/0QM"T/2:EH66UT++\\^A_1%_)M6@7TLJ%H7T<*%YHOQYR^>.<7ZA
M\9\AH_9@\BFD"!KB/69O4ZV<FW7=GZ50]-6N<5##CW/!HTJ!ASA$,6U6HK!+
MYK (HBFBM)?'"RD?AU-2%:7H^\!J0V)M",NZ"DU'F[:W-R>%,[8:<KU-YMMA
M-D.ZY1I>&()Q5%T 9*_&7]$+F]PKO-9M#+QJ^:J=53N<>!GG[%6J/6N>ZA<[
MC%+JPAJD-IJ(P*$Y_::-#C(*R^IG;CT(<]&!&]P%QK;)QE,D62EP)4IL[FD;
M9=Y649=-A&+R&3I;H2(;>&(6DK(QCW+?5X*BQ.=S)O.P[.3.G&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9&;A^U^=_O1?Z6
MQEH>L?7]SE9^J_5]YE*YMF.,8RJ^E\-XYV6/'C=6YA1N@)AH4W ?M5:%%YPY
M"U;4M TE*C+(#DK4I6UZ@RH_K[4KUO3Z=^F\-34T_4G*-]=J@^\Z.4E"$_7C
M&5=+!R,<X\6O'+D1)!OFW$^;U$ZWZVF3XNK"_C\=*M;2M$4Y)8D%HK;B5;TX
MU'F--N:]'KI5Z->B9ZVK,J>I.1Y,FOATR(Z6G!N,(CYAS\>N7WF>:9B#H #:
M1,T!9@@BQ@B3:&B(4Z-AEQ,]IMUM]MN:-(,R(<IM#[33R$/LN)2ZTVXG6EH2
MK4BQ1BHG1%$]R<Y""4@CU$L?J<B-6X_R2C$]FZ3RWG-/,[C.PMEZM2*S7R>X
M;ZFUOQ-SQ(R)*W&>6RRIUC;OLG%--J6A6T)WJTM2<BI3G(ZU*2E^=+D$(1;C
M&(^9$'XAEBY3+8QC-F1A()#YXYU^7&;(0Y4)R3 DNPIT=$IAQA;\*8PI+\26
MTES;D:2RI+K#R4.MJTM&MZ'#?EY]/KQG$C@G@?XT>-5SG=!Y32IXRVSPLL X
M7,V>P61U@=/E1)<Y,)LW/F,PY,MV%'0_-80B6J/[:-[;3$F2V[OJ=IUM6)"<
MKB(T!'DL.@7UZ9CIZ&EI+*$:4JU7CKXM>![?MSF'F&;9QS[SXF>/?DNS!3V7
MFPFU$!3"HPJP-228&SCHRG%O>Z1[%7YHPLL>E]QQ](N5*D#/;N./;A[<<6I6
MNGKZNC?HYL1Y3A%\Z1+]M7[<SU-'3U:WQ%.C:)]8C7L>/9D&X?X#>*7CS86K
M?S7E<&-<(VG$PK38BQNV&!>G4*:6L,NPD"$0)(4RMUA<T1$A3G8[ST=V2XPX
MIO=M3M.MJFV<[C^Z!$??0+]:Y73T-+3;C'O>:JGNOI[ROAG,7,,VQC&,8QC&
M,8QC&,8QC&,8QC&9$/\ LL+_ (QA?TEK(ET?<_=DQZGO/OR_\PS?&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC(-TBEU7HM/)TF[A(=C
MJEC>%P#8,@EQ4(E#V6@O>[R--.-.;1[5IM?ZAQ._61KZ\O"<].<9PDQG%N,C
MJ-5Q]3E9PCJ183B2C(IB]$]N<:_H\O"G[.M _P#Z"G]YYT_.';?XC4^)^&<_
MR+LGT&G\,O[E'%^6<- SZOR6E!Z+7R9=T]/%A$2$1I1A^%!'/$'=27Y"]ON0
MAL&.K>EZ3[.,WZ$ZWK>]X:NMJZ\B6K.6I(-HRZA:U[K5^O-M/2T]$8Z4(P%M
M(\"T%^^@/JRS\RS3&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,9&;A^U^=_O1?Z6QEH>L?7]SE9^J_5]YE*YMF.5KV7H
M>N2<DZ9U+8G1[7.J):KKL)LA\)T7U60LPQ\-V3]R(_#]3/=/=]S?A\WW;3GM
MO=7_ %/9JOIP])J0A=;Y$;JZMJZLOXF4G+9"4ZO;%:NKKPNFOAD:A>1_%R <
M\<C75M4.MS:\.)QW@5GBFG)5O=6Q4$!ZY*"LV&QM6YUIY%3DUT64BV;<>3\#
M>GZC/[;ETM00V\HIR)W>96C1MOO6E>-8])"EW=$.B-O0!+5\*&_"\^.>1_&6
MP@L^JX+5$,%CH.(/;K=M>LS12K:2NTQB=-: KMP357:6S(LL@R$@10$63#EE
MWH<:9%=>>BU+3;R O>C52]6I7M=WA2V\%N/20H=W#?@WQUN-;BO&PKQK-2A]
MPK-FX14.]6AR!1ZU9:8#N,U,LK\3AAV3K,942"T3;@PG"[[\F7&@CDQ1K4HK
M,D1HL*$Y*DLL+2TY&I+3+DQDQX*6NK7-=+>>#JXC,EIQU'NC$ERW5^%T7Y''
M+X9H.^2G%6!,<P_<EL(E69ZF,AWJS;V;?\[V0;EFW5W:*X 3=(Y]^O-_&X0B
M0 :GSQ;C$V"Q(CR8[CKT6I=;>A=[H[:6KW7MJ^%NAX:<CTL*O=X[:IW75UMK
M==<].3G)BWU&G3N:3>L@B>[%3(M=,65N<'BS94F7"!LS'"$9@=J-HDDG&?@2
MH$D6]#;(Q"+#T"5%9ELNLHC9(F03;)0YKBZIOI7(W=5STRVXVLAL!>/9U]M\
M4E7?%7E7!O*[CDVK4JR&C\NN+M]/JUSDCIE=MDO50%VU;D07)NI*)7EP*@*E
ME8I <,/VIP$'-;'RIHR5(A(V]J[H:FZ40O;*4;&)N8]=MO>:IJ-I99>4-:%"
MM6#5+0]-U"!8TM#2C62*;Y)<5@3;.->NJ'9U/,HK1V+! 6DF\U:72?PANICD
MC0<OX];G)OJ^SJH'9.P+AN,DTC=C7V9:Z^BU';W?6++0XJ]S;Q&N=S1[<MZ2
M'/>Z-/"\W5%'+?@6]&J3/Q^F5XFH&/L$:[)(P2I@\ @10]>M9H^^6JB6E6N)
MNJB04VT,[JGMV46E]\.U&KCSJ&#3T%Y6F]SZ'4M-M("VQ"I>KRH=ZN[S;X7C
MTD*'=8J%"JG#P%\/5JCQS<TKN]+Z!TRT<VK#DHHJN\^YYT:+:8<:=)J]A!]$
M6>6-<#&VX7P>6TS"%CIK,ADF\DJ@L^T.;=<KYSW.):4H0)2XN4X,6MPPJ[+O
MS.G%<]2T=2,IR@<L8QE?@DKJGH]/MXZ-:,SR1XK"G6<:]=FW)U/,IK1V+" V
M@BZU:5D]B$5,<D>$E:/6YR;K7LZJ!V3L*X;C)- W8U]F6L:.HD4CQ(LY#BKW
M-O$?\31X7>/20Y[W1IX7FZHHY;\"WHU29\(^2?%!042?EW9"AAF-8IK*H("T
ME)HZ!3YS0NWD+*)&!)A:H#ZD3?9&VF?:X(:'72#B81EZ%)]+6AI:BH1Y*ZL2
M]Q<05"3(Y"-J=+R'5@ LN$7HM$6E:+B#PW5/#SFE,\A>>A)UJBV,V-:2%N+=
M5#1ZFU:+Z>,-IYS2>B32$VNUNIR" WX<,N4>7-<&?.(%#KSP(Z0L<*2<="B1
MI2=M'4MW,8 [Y0 92!MB]:;L!JV?21+MZ-&VY+W8RN@XXEX653?-&%B>5')I
M%GNP1TPZP%IU0Y?<6KBV/,3J]:(767I+-5BU:7 %R&3TXFMP"P$A"'R!&RSC
MJ8 2#*DC""&I]#.HH6RE..WQ&'6^> YM:JK>*R#5@LB^ A+=S23]6FN5LH+N
MRO',XYY*\5:$P"[EP>2@F?+U2$'W5;E\[GK2!@,%3%:W1M5[=S:L$ 3)CEG@
MSP%LCL4\V3;C+@JU(R/1:EIMZ WNCMI:'=>VK$NZOC)])"KOQ8U3>X+3;5C7
M-5=9^R/DKPX6/KI:5T$8H7: #-L'$84$T3A0ZJ_,V/19[+*&#);-,KB2*7AS
MYVX+!"XQ&+-@29;4N#,98&CJ-FUN+M10=QX%O>:YJ-M<],>D@4[BDL?"O-?V
M3KS*CA\G,_"[7R\C=5\]AVR._:4E)X!$?0\PD1*L8F \4+5<?:7!R*L2M8D;
M'E3BE7'FI-@&Q(<U^:.8;ARE-0Z<R.]CW:&[+I:%+L%X%*?!QOBRVWS:=&K+
M4NJ4!LNRGCART\IE\8QC&,8QC&,8QF1#_LL+_C&%_26LB71]S]V3'J>\^_+_
M ,PS?&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC(+TF[
M57G-.*7>[FXE<J=<=%SSAR?[7W,;#^+06/>'_8-O.^I[5YM'^C:6KUEZ^KT>
MG>7A">I.,(193DU&)U7*SG'3C*<TC&)<I/0,XS_2)^$_VB:+_P#]O^Z,ZOF[
MMO\ #S^,?S9S?+NR?3P_ZOPSD#R;M?*^Z )]IY)=1-ZKXLP\ GE _O?NT4PQ
M"@D7A[GO<:*Y[=N$2@R%>JA2/9R6_0O:O6UKGUM#5T)$-:#"3'<#7,52^%\1
M/JS?2UM/6BRTIDXCM4OAH:YKP3+1S+-,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QD9N'[7YW^]%_I;&6AZQ]?W.5GZ
MK]7WF4KFV8Y5?<^?S>K\8ZMS$;.B"R'0N>6^F024]#SL&!+L@&<(8ERVXZ5/
MN1H[LM+KR&4J<4VE6D:VK>M9II3-/4A-%(R)(=6FZRFI'?"<!K=%+\K,ICK'
M!NA6J\76ZTJWPPJ+.$X&$D FSMIIDPV*Y/9NT&K$"D7JG-JL]-CV%GIP?< ]
M54NF(SU?EPGV]0"3F]Z0U8QC&,HKM=5NHR!F:8.V7=E6QLD5SYF4EIR92D2J
MS3 M+(,U&1R#N\.>/;D"YYXQ]6Y784= K!Z@%+=L[UUMP+8I]]G@&ZCUU/)B
M;NOG*4D'[>0LU1/\K'HW-(K=1=A4N8N;(K,R3%2(F>M'4-DB1&H<Q(CNAZ0Z
M%1"1/P]6BMU-Q'2E!W#%E<REDA&>QZMJQ8?^:VZ\+-C>/UAC^,_-.-(LH1-S
MYDCD1H8?V+E+JI&V<AMU9NPQJ<'0^Q-17#1.LLCYC3#^IP^#,7*A;7,B,:53
MTIZ6>I3MGZ02P2.I&47FJLN^E-4\.6]&FG&%EQV(U0L)$CB^BE>-'/4S%@^
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MS?U#LO*;XU5UU+H=0,R+H C6BKBHYX<@\8 2H[\ELE%K[\AHW[!#467[SIR
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MWGEQ$'1T<5-EAW@<I<UMMG;;B[>AGXL15(C+F21C/NI93&<45!LK(]+'GB2
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MQ.QQ"0IN)-T4';C/.ZFQO:SZ.?[D^J>J]2[.G4IL\*?+&^'/?CP6]XX'HO/
MV<^W-N[VWC##2Y#W7>8,L-PH1%;SM^JC;2!Y'>DCYZW%EM(3"GJWI,*5M6F)
M6]ZTPXYO>L>CU/HY]4]674ZG3J>.1Z2'[\/ZC\<WQ#K?*1+AEHKTWGHQVNKA
M-V!LA=*W"<!+):VH<@RB22;4,7/3K>X29NF-RM:WMC3FM9!";50DW=5%;KK7
M'->-9+.!=SB55W(XOI?/%^&?IOJG.MS(HZ3=JJ-)$)IJ"*&$K("AD##E??>C
ME71,-PC[P0CQ%1W5ON1D+5':0I4E#.TJ2ELGX17@6A:OI?'%XWQZ;@;0%.:Z
MUSSFQF]EY=$IT_H#%ZJYFF"C(<"5LM?.BC@862-%PH:,T2)#9DB#!3&D6 5)
M).2I#21XZ2DA*]G%]#FY(39$=J2101% 7B_<UYO&0S@19;AB(*(@J'->\OR.
M<_:^Q\L:;1+D]"I4,5(2'V..3+97(X0PLZ@HZ,9#DW"FHY!^2V&(N--L*5MY
M$5]4?VR6']M/1S\(27FPC*RJN^/:?$QOA^]&N*=Q3=]&_8YJR>P<DA).+F=2
MYS$16""1%E5)N]9837BJY$^(@8<4Z31H205+%%(J84_<>2J0-GLZ:VY#D);>
MCU&JA-LL[LN3CDXY.3IYGGD[X%W./#3WCA\GGA]^2R!8Z\4>:CC#P8C(?T84
MPQ *09;SR:\40#L"FFH[[BW- S3B YC:$JT,*+0/F^PEJTSNJ)U$JKL?$L^)
MR>9R9(CT1Z]'R:?@\/D\9F<C)QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&0+
MI=%3T6J*K7QF97WV;)1K8.,08T.9(@F>?7FN7X&YN)/;=B2HSABLP69L=Y'H
M>A.2&T+:<4AU%H2V2W5?$HH^).+!]W$FGSRLX[BK3F,A*ZQD2.O'4+R@C7B7
M L!F/82O4K])+S+@.O5O=0L5 @6FQA"/.I0)]T$)B#@,:*+%<NJE588E#"KB
M0$>5(CR(UKG3+0_J:Z&TA&B+"/6P2>[EMY9REPG-#<0CF;HBVRE:DEXY1C7!
M1TB1]W)2KF\I7BN/IULYO9?T1KH:B\NU!36Z^1<B)$Z;%\SL7)Q[+\..EL:W
MINL'O?)4Z$-B&R-@CKE3"[H5R+7QZ6NRC..R)O54Z\S)O/7UCHJ T%EXCHD9
M1=R[.AX>JPYZ^#?%-^-<$:Y5PZ!93$#I1^RDYLJB]P\DYE."L#P\$:+8-=ZZ
M8X;C3G6(?OAER=.9&3(\V6\E\:H;I,3U7)Y)^7,]1!@ ;M/2)*JM:< KG@JR
MO;Y "$+=R\QU-2N#@=25CYV\WX?%=F*\'ZL$$"1(OHMVA*!00-=#&6=#$6<7
M4*U E#@XR!:T,)LL0@Q'FRMR-,E44HBMYQ)&@RXSCD=<O:9*K&/-J?LLEM6/
MJHUXFX\)F1Z  "250-%@"!?6^?/:O[/-9*:EXA4ZI$XA"/:;,0:$DUR 44A[
MA*4/%ZJ/8*A&$/3Y$=^?,;BP^SV!QM:7XL32A0A:!S<^59B-AK+7E(J@LYJR
MW=IROWWIG6WEYZ!)HQ&[>.@TUW9QYOEXF^/ATM5PT/PLJ,(F$G-W>W.1A$P5
MMV [H;M@@)$D:F?CC)"&X[<7;N[#6'I?Q)V'(D,P3LV/%0P6&5P\%E[1)$VQ
MYOSX4D+\$^L.:48] %=YX;>G-(GVGV^=),@7C3& 4BSTR)T2UIV<!<XK PY$
MCB0A4$!Y6TQ%JT)J17XPJ3(>EP8S<2QDV)0\K+1(FJ S*UOX9H55UKD+"+3.
M2-HNIZW5>G6)S7%[N;L:5$@E(LA$>!"'3DKE\7KY5Q7[I7C*$I8.\ &+A9"D
M3H%&/4DZ\1:&KEI2=OW7N@++PY*(VG$S(L_L]G'H;F*FHD0809R4MV<S.E3T
MM9DQEMB,9$BK#B.G&J]IIQ>*Y7ZD=(B2"2DHHW7C*<K^,T]P>V]A5O& ?2Q8
M-FK68=5SM4,MFJV;J?-:%5F-.NUR?52\2S! HJ+ M$0V*FM;ENR=Q"D><-&R
MX)*-N.MMV9:S)60R)%2)3G)>=Q2ME/3PY;P:0!M=J-Q2,2N$; +$3KS8<YC7
MO#+E\J7+L$]^:4OGNM=F NAE158F6RK74%U'I/8I-U R]!&HX^18[MTTNY8:
MY$C1ZN0 0H-:4*2']M'6.T3."B-RN(M2BPAI[6UO;&!M6Y"K=Y5T(-K;)"I(
M62)3GN./%FV=*HJLL\WQ,:3>M!.#8S(6QG.I ^O"#L5@9*<K-K!4"K<W0S$@
MSHC\.>%*UBMR!QF%.0N4_$L1E$">-EZ&SA]#4K:,1"#!.2QE*5V/496>'!8\
MW=TQM%%F3OCA(QCQ9T2--^;F!O51E *E0)YJS%[H:JO8JH;=*'VX2-%'>BV.
M7S4P-^'CH\2"/""ZWTPM$K@^.TM0] T0J;))S6IDZ;,97*=!$EIR*/#9'>-]
M56!N?&WH<!CQ&UDDQM\=SMJC@ E0>PNVW(_^E;A.CJH,G]&MA.+S$97Q/)$3
M!]:WJG1ZM;Z)<PKY93 IAVXSV)G-ZJ$>G$W8K[];8(Q];;.EI]A>GTSWJA$W
MJSI>]NC*+5O=*FH'C3R%9'HBHC)=E;+#N@Q2_P!Y[H6^%^*N8\GXECBKMK>E
M='M"GKX#M59M[N@M0941!]"J'/*;T&/ 8B XT$1*-#^64Z2(F1X;B@$Q@JOV
M1-DHIEB373;4#NHQYEPQE.4'E5IG*R^>.E<PZ0WWGO"/$>DHQC(Z461.?#GK
M>;,KX> RTN(3?Z#;6RE>M%ALU)DQ6!@QNNJMACHYBP0)N@;0B;8&)2^H6")&
M?ED(TB+%@!%;4_,U895CD[0@FR-($AMNB )=AZ@O#=O^':]"/63PK'H5;)>E
M7ZZ6^SJVMF@>%1*=R^T<THUSLE3W8DM(C6T9'!L6$%IJO5ZKZ=$IA#( N)*T
M'KS#4>3#@0UC7GU/B=0%18&HU'4W3C.425=8JTW*4N>;ZR\WVWS=B&V+$DE^
M( G <'0X/+CPK(C"\8HPY(G0Z^EA/PT97V'&0]<K$.%)-T>5=9]!L>H;T"8V
MU. D;HLH5:=5*;M1*NU^265ZJK"S8)=:[N(VO55"6W<6)U(T=-HH>%1Z+I4D
MJKH.6-[7IQ5\^='MO:BO%:!!'!A\WH%@([C*EQ+1-4*"M$;X%FV>JW.9'M!!
MUF7/F'2%CK#KA.V*E+,3QEEL4)Q29:@9,'+K=:B'3:6U%(RB,3@H)>K56'M&
M/1=.\OG87(L>6NMG+U<W'/Z.J^<:MM1*&Y$:L]IH-JL4B'"AQD3ZS.\@+/U6
MXVE4$D]M[1#X>Q=1X<8F7$0RGYN((+8TLM)BL)2V:D9!WM.<0MXEZ(A&-G%7
MM5I\:\+Q&.^$HKQ.,KKPWRFM?'B_+)/ \;J,/MW0K5&+7N"WT.36YTP'7+Y;
M*./"3P,JZ$IK@2513%:+MPK,=OMCL]@$S2,T9+M!&:=3&;FR5+15U9,8Q2+L
ML%B242(#N$[I$"@H \,L:424FY&Y%"3$$M:VH\LE1OE7QR(G/#WF)(Z8LH^?
M<()<J]7RNT&[?:;Z$39*W?QW181R57KX<L N8N27%1!TV-IF-MD$N7""20LA
M],UJQVB8 U19W0@TP85< Z#=^+UO*NA!67-M>LLRR1*ZDIX5[#I63MSA0EWB
M-FX2[8";M5L=!,T+4EP>$U*&1+ *)#B\R)$:@-"?4>=)O2(8;<%(07';CB1\
M%@6PW&37TKZ4U=IN);JMIIL.M^]NUY6\MZ,]&Z=NUCMZ%G'/A7U51TZ9%!WB
MY5(L>G,/$(@]--NCMMC,T:ETWG@XJPO0$EH 8%5P2W!DP/GG3J%=GI;33!.6
M6H]>A2I;H9J9 ERZTG=PNZ.UW2E-.I8K9W92C72I2>M)'HC@N@;[L8QOIPT=
M+(R\[B%U8PD)X6 @^FICG3;V6/PU5B6-.&%P2LE@M2Y],)ULE+^*(G226D3Z
M&"EEH4B:F),<>+1AJ HN0-'";/:%*V1#O6%EDB0A5!Q-I"^BVVM31KG>K8V\
M\Q1/'SB7Y\U7AM3?A&#L6IC1CJW1)D4@CI,F7&6H-J)LSU,/UL)92<<1J!\V
M8WK,=A/SF$H *(;(CA#<@J^ 9? OR=I8U6G K976Z@P8EWN__&'K!2\6WAT"
M76<N62\%=\F/%5^VIQ=AX%9(3GB&#L)E^X$;]:E7N18F;8]8(C4(3#<.L!9%
M3;<^#A=#%,C]T]_X(Y"ADHKKTAO1MV:LFX^Z[$==B;2$=M;:>>+W=6^=W-MT
M=WIDNB+NW.[K?0NJZ%?L\45Y]<LACQUYMN?R*::##;4GBO.Y?/:9&L]?K)-F
M(T^]0'F+(RS\&9B"K%!UST:W$D@8HF+&1.G(C1&&M16V,W5G^LI3TDMTJ4OU
M[.O([VQOH98THW!0=D-D;#CU>3CA[ITRMK/X>56UQ2 4G<3^JLH)U<'7Q#0:
MHZ)5\;V"NW*N6(&JS+!K,EZD*8O1J?7*U.=]A&(L!GS$LX@/ ::N:\H\D3=<
M%5ESZ-BQ:NB3M!3J6%7E71)",G;4P*."9(D75IWN!Z(=:R37GQ%X5?4C(A*A
MU@6&!TZ]54 % 5BM"8=;G7LM3S,NZ5GW<3KX!<A,ZF#WQ1H:EEUMU]]R2F1O
M2-:B.OJQNI*LHR5E)4B2-KSS%)-CDNCIR1VA44  JV+N..)#$Y,R83@C[=@N
M!VZ]%M%Y<N0X:,EK5KYF&!,(/)&2Q@VN62CS )FN@6),&5,E @D@?!+D"I">
M9T0E/N+<AU2HD($-JISN&[%20B\U;= !DFGR[I,K ?V:JJVL:8G'0:5MR,E_
M%("4DE=M7:R01=B+?%[(*V*J99@J]#Z]TKL@6/\ _KX,K&1"'V#JUFA2XDN'
M/8,CHH-D@VMN*4:,V-= [HH4-R*_5PTWHG*0&[*;KPJ'2%]9!;2AOO3F=1XN
M;X<T>V\> \2H%;G K"-Z5;]VNK$]EJT2(-0C @(ZL*>K+@Z&$,[(O) [K]F-
M,L!ME]QQA*9[X%4,@Q8 B)+KJ,6$6+U.B\CRE<W$;JT*;5<@T:1)-ET\-=3H
MWQ2\7U>**"=<O\<JCR>367JZ6.RFJH,)B!S110YU;T,C4N8T[>YKT2!#]J^R
M.Y8$?2MEN.VN5,G;VREA,1B/2>K*>ZPN2+5]=TY>*^,WSZ&6CID*I]6PX.C&
M,?#V1/PS Q?%'G@&A Z;2-(HA48[7'"]XJ@<57[7=DU]J:TEJZ&*ZP$+&6IR
MR,N?*3HG&V\15I<O<L<^2&$9]--DREWCFHR5C&_W1L.AX=/)I(-*)$B<)5R
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:8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g189651g18c86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g18c86.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M%?\ BO0]+\/0:]>7ZQ:7.$:.<HQ!#_=X SS]* +;ZSI\=[I]HUTOGZ@K-:J
M2)0JAF((XZ$&@"C=>,-"L]:&CR7CO?[D5HX;>27RRWW0[*I"9S_$10!N4 %
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M^!)(_F0WLQW#I@P-0!E?%33=1U;6O"UEI-V;.]E:[6.<#[I\@\9[9Z9ZC.:
M+VDZC87OPJU2RLK#^S9M/LIK6XL"/FMY%C.1[@]0W?.>N: ,;6K5+KX/>"[6
M>'S(I)M,22-AU4E 0?PH SM$MM1T'XI>'/"=XLDMKIGVN33[EAG?;/'\J$^J
ME2OY4 7_ !#J,7AGQC=S^%=;$^L7MW"+S0FB\SSB=H+J0,QX0YSG'% '<:G8
MZQ)=7_V0(8IA"T3-.5*LC99<8. 1WH FTS2KN+6[S5;J8J9^$MT<LJC;'G)[
MD%&QQ_$?6@#;H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g189651g21w88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g21w88.jpg
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M P$1  (1 0,1 ?_$ !X  0 " @,! 0$            &!P4( P0) @$*_\0
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MN]Z0TO>MC;3@9,,@ \DHP SX]OW'_-8BX@)P)8R?@,"?GP#\<U> 1@DB&)(
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M)2=FZGU6RQ8U;UY#0-+(A?#V L)>Z_U7FI7VD[T?J6^V(#?E(R F1"45=^L
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MI)&P!R R.&4X(!&1P1Q7R-I?7MA<)>6-Y=6=W&6*75I<2V]PA8$,4GA=)5+
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M*'/0 Y$2?+$B%)'?<=FP *P7ERPR25;@$ \>>1[Y'1([AXT3;Z@Y)8$\)M.
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M536W%)Q24=QWDW'N+*K%<$YD4C."1G!.<9''O6SQ9C1(\#MM&R@Y Q&P(4D
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M'VLH%2*2.-ANW,77:"XQZ<#)8 MN;!XQ@V9%\$Z1%WJCLHD*"1S:C^1/5?(
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M):(:N!.H*"YY8;588N ,K\!9%M5VLQM6/LTG&R:1XF :CG$L#QWLJ!,1N!.
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M$G)'N:&-"<E%)#!P2 3O P&S\@  'SCBLA$4RHP&X+<'5X"'W5ZTBF5O<9$
M [@*BW]F[;J\/L9AO<; (W#1&T1 GP0$_9@'L8U\HQ\."[-NRQ.YM[9).6Y]
M1^3R>?/)J0JC;A0-J[5P -J\>D? ](X\<"I+E:M3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*\]Z7RSHX-JE.?KI_QJ
M'XTQ_4I'A;M@UMFJ7V:ZO'GIYE%B/(<0I$9QRC3=TY'+I5H=U LT 4T[OW/C
MN]K2)M5PV&G,8FQG<HC([A(^9'"N/.2#7$L;[BA7T0"3L[@ K&0?I@8]HD+1
MG^0?:J#J?+;[' 5:1BJ[VFX0O.ZEXM+N0/3*:7"V6!?XSV2$M4ES7E$6J)@W
M+O"5R!58K0X2"W=RIJ2K-0C8GH-MD3&!Q]FD0E@6B5G:?:8V!5NY&RB20Y)1
MF8*ISL"AF.Q1G.81QM(61@BP;Q(N&':E5MD8 &X*NYLC<6*J [9%2+K_ "7N
M74Z#Y(3=2ID<;S?H=BZK?H3FEZ=N%(O5@E1.$<WYI1IAJG;I4T<^IJV4RXWR
MNT>SLU:0/MTG2;#(.11<4AM58Y(HW@#.1)&(T:1-K1A>Z[NNX,."K*K.NX!0
MZ@'-3)'+(DQ5!L<R.$?<KD]E(U.S:V?4K.$.TEBAR,5N +Q2V3@,/('6Y=$(
MGR>?6SH5>K+LX82W;J=!Q$$I53N+,C3RA ):"AHV GXZT56QQ)PH*"@X6)E'
M"37^;NHI("[PN]49L#TL2?4N'!(8E@58$>"2.*Z>TQ );86V,X7<?4HQZ6RI
M&0 ""I!QX!.:F/&>'1'$0OLBJRY2H(R"@F)J'?%0D:0N,.&U&&7L9?S#CL;)
M62+'!#L$8A1$:^J'B"P&X\I$L[,5EF,O+*-P)P0?"'D(>.=IY!X/)SGC%HXA
M%PI.W R,>6'&_P#8D  CP< C!R6\ZIZ+\A9&6ODO7*]U^$F9WG_EI#SL2T#V
M9\V/L!U8M!7)V%WNQ6QNA6LDJ6"CE\\(Y-0P8FGZ4) !6=A9PX$KV@P (&:-
M@KVQ!/:P5#*)"$5=ZC;G?W&RWDJ<9'$PF)D*K("4N!@"3.XJQCRY8(QR!L[:
M>G(&[YN"U\YOE/N1\5'#=IEN&/->.%EZ4%&6?I=LLDXXZUY%QG2UUY\>8D;H
M>;Z@#X),](K=.>4;+5D8K2H<[4N<+(9K(C $F(3?KK&2L:JO,)CW9 4 +W0C
M-X8CG@5H4=6( D,/Z#. 78MQ,'V\EB=W9+A>2 >#D@S"B<HM=A\/^]<QKP-M
MI4YT62\HPJ&GHKTT/960>@6N\N4N0GS9A\JR--R8$M'$K.E"'["R"3I\]Q4L
MV]O*/(HN878JRH(-^P KE0NX*!Z>,'@<9\8%76-C;RQKN0N9PF\MN =W*DD^
MKD$'G+ ><G-=*<MW4[Q:N3 \YY/9H-JJ)<]1\WZCQ8**IW/" J+=(9<A!=>D
M"!X<PQ]Z5BZ0$GE)MD016Y"87I\:*..VB0L:+)OD4AL[7CER[^M2,Q@$@8!8
M[PO(&,G@P3([1;(V&S\D>(!4(1QZ9#@'DA!L+#!/(!R(SXQ\D*7)AUVVUOH]
MFI"/&VI<SO$=W"H.0<?4IZO3;+X?)J *7$Q(MQH*0S;"F=DU.7X(H2$IP:^A
MV1HDAI-KB3C<K1J_?:1#"P8L&!S(YR2KY"X&$()8A%P*B"/G:P=D["QN)4P%
M*GB-,@;DP6R27! 7UMSC-4.LV/E4)XQVV=HEQ<@>?@>0-5L%>J]/F;'/UDN]
MV463ILTBG5T$Z<=C5 5HV!25%QA*(UNUA/F:$AG3CA:NRR&X4.NYS"REF"AM
MBD.-S$+Y;/)&2O&:LH,8A8HVU.\I55)*[F!4[ ,XPI' .-P]LFI#R;QAGT43
MEY-FEV*C-Q].B!I:+%K@&KU6AOA29#7.A[["S ;1-,#9EDQL_5)R,N$<Z0U*
M[KDM$,FBOB1)<#>^T;AN.#N.QCP-^PC\N,AAM/C<#XI' =B;L*=HR-HWKYPF
M]3@J,X*D,,YP1FMM^>4"N<SJ<54:P ("#'!@LOK%&;$^T31(T*-=E"66]J1H
MLQD!A3V]*5K_ &)3K>])UO.9W:1BS'.<X]\ DG'^,UTHBHH50 !\>YP!G^>*
MF^4JU,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE3WT"=^.$_2]].*4
M] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3
M]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4
M] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3
M]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4
M] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3
M]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4
M] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3
M]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4
M] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3
M]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4
M] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3
M]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4
M] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3
M]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4
M] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3
M]+WTXI3T"=^.$_2]].*4] G?CA/TO?3BE/0)WXX3]+WTXI3T"=^.$_2]].*4
M] G?CA/TO?3BE6GBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4JO_7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3
MBE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B
M?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O
M-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4
M]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7
M$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W]
M.*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^
M)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^
M\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI
M3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY
M<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?
MTXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7
MXGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'
M[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3B
ME/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?
MEQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-
M_3BE/7XGY<1^\W].*4]?B?EQ'[S?TXI3U^)^7$?O-_3BE/7XGY<1^\W].*4]
M?B?EQ'[S?TXI57XI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*UHANX=$M2ILFG\*E;##0]GL573+_ .H--B4F
M&5N5(BC'4 RCHYC+:GAU*1IQOV>ZK7NK7K7O;^*MNI]7OS<OIW2UQ>6UO?7E
MB+C^K:;;B22RN'MY&$4[I(H+(2,KX/!/FOVC4?IETAH0TR'J'ZHV6DZCJ&BZ
M1K9T_P#TEU%?FWM]8L8;ZW1KJQ2:WD98Y0K%'!R.54G:+[C)8ER#CY2Q@-U8
MX@5AV1BC9, S446[K7OA.28KGR!2VU[^'IX=S;3N_P#+>]ZWGU<$[M:PSWD0
ML97C1IH)9HI.Q(PYB:>-C%(5/&Y&*M[5^57UA"FIW=CH]V^NVL,\J6E];65U
M;F^@C/IN4LIT^Z@5U]1CF42(/S J/WB]C4I5)2\ [(ZNM[@Z.,M@AME(3\X-
M)$M2+FU(<T^PPF.4E3+>T+<^*G:7$Z3OV\>J:JFF'3 T33#4]5M=+0HX41/=
M),ZS-D'>BB$@J,$[@0>*]?IGI:;J4=2F.Z2S/372^J=3S++$\AN8],FLX7LT
M"LG:EE:\4B1]RIVV!0DC'S1+Z+>!;86T"Y%MU.]6^CD;));=22[49)<<1)I6
ME#:6!R]HV\AE?O*91_A;BMZWO&E:K'JD=_(L30+8:IJ.F/O=6#MI\YA>8$!0
MJ2%2P4Y*C@DTZHZ6GZ9GT&W>Z2^?7NE^G^IH1#"\9ACZ@LUO(K(J6<RRP!A&
MTBX65N51<XJ;,F"$,()8*&>&<WK2"&7VG&%[VKW-:0ZA2FU;VO\ V:UI6]^]
M_M_\?\9Z:R1NH=71D;@.K*5)SC 8$@\\<'SQ7S<EO<12M!+!-',@):&2)TE4
M!=Q+1LH< +ZCD#T\^.:YO?1[_P /WD^_[OO^Y[VO?]SV^[[WN^WV^[[=ZU[W
ML]GM_P >WVY;(SC(SC.,\X\9QYQGC-9[6V[]K;-VW=@[=V,[=WC=@$XSG'/B
MB5H7K>T*2O6E*3O:5:5K2D[VE2=[UO?L4G>MZ5K?^=;UO6]:W@$'P0>2.#GD
M'!'\@\$>QJ&5E(#*5) 8!@02K %2 ?8@@@^""".*X72Q!W6&'RAV7B5;0,RZ
M\VVZ0O7L]J&&UJ2MU6O;KVI;TK>O;KVZ_P Y5I(T959T5G.$5F4,Y^%!(+']
MAFM8[>>5)9(H)I(X%#321QNZ0J?#2NJE8U.#@N0#BOIXD89"W""&!VVF]NN+
M>=;:0VUK>D[<6I:DI0WI6]:VM6])UO>M>WV[R6=$!+NJ!1N)9@H"C@L22 !G
MC)XJ(X9IF588996=Q&BQQN[.Y&0BA02SD D* 3CG&*Y$.(=0AQI:'&W$I6VX
MA6EH6A6M*2M"T[VE25)WK:5)WO6];UO6]ZWD@A@&4@J0"""""",@@C@@CD$<
M$51T>-F1U9'1BKHZE65E.&5E(!5@0000"",$5P/F!BZ]XDH8?7Q&VO:^^TUK
MXKOM^$U[7%IU\1WV;^&C_P R_9OW=;]F5:2-/SD1/4%]3*OJ;\5Y(]3>P\GV
MK2*VN)SB&":8['DQ%$\AV1_[CX13Z$R-[>%SZB*Y7GF1VEOD.ML,M)VMQYYQ
M+33:-?\ BI;B]I0A.O\ U4K>M:__ #DLRHI9V55499F(50!Y))P !\DU2..2
M9UBBC>61R%2.-6=W8^%5%!9B?8 $U^((8<900A]E;#FD*;?0XA3+B7-ZTVI#
MFE;0K2]J3I&TJWI6]ZTGV[WK ="H<,I1L$,&!4@\ A@<')( P><\5+0RI(T+
M12+*A8/$R,)%* E@R$!E*@$L"!@ DX KY9*&)^+H<AA_;#JF7],O-N_!>1_Y
MV7?<4KX;J/\ W-K]U:?_ %UK"NC[MCJ^UBK;6#;6'E6P3AA[@X(^*F2":'MF
M6&6(2H)(C)&Z=R-OQ>/<!O0^S+E3[&OOXS7N)<^*W\->TZ0Y[Z?<5M>]:1I*
MO;[JMJWO6D^S>_>WO6M>W>3N7 ;<,'&#D8.?&#X.?;YJO;DW%-C[UR63:VY0
MHRQ*XR-H!)R. ,FH/4KT/:YWH,&U'NA+H%E&K9)+K[;K<BX1 Q4]HME"6T;'
M;0U*H'VVXIQ6ULK<][25:3KR]/U5+^[U>U6)HSI%['92.S B9GM+>[[B  %5
M"SA,,2<J3G!P/IM>Z7ET+2^D]3>[CN5ZKT:?6(84B9&LTAU6^TLP2,783.SV
M+3!T" +(J;<J29:F4CG!236312!1$NJ(>&(:?0U\%&UN)6II:DI6E.O;M"MZ
M5K_'MU_G/0$\)1Y%E1TC#%V1U<+M&2"5) ( \>:\ V-XD\-M);3PSSLBQ1S1
M21._<8*A574$J2<!@"*@=8Z.BZQ7/K'6("0.K=Y;-*(DBC8L$BL@LQA1P#\E
M'**>>,=D2&& -"QKA+H:RD$D;T,TXO7E6.LKJ=OI%Y8VDTMEJJR2-,\D$3V4
M2P22Q//"9&:1IG58>W SM&T@=_0K$?5:WT<W3=]U9I&MZK:6VL=,/;0Q6<%M
M>W4.M7,M[!:W45G>""*.WCLX99;HSWB0I<+ T,(,SHM6'LL31.@]DCZ,VWM[
M0FWF_F=M:W[-NZ8][XNV];_QM>D>[[?\>W/7[D>_M[T[FW=V]R[]OC=LSNVY
M]\8KY'[><PFY$$WVX?MF?MOV1)YV&7;L#XYV[MW[5^/FABIVLHL89"5MMJ6^
M^TRG3CO_ ,I&U.+3K2W/_MIWOWE_^W6\/)'&,O(B $*2[JH#-^(R2.3[#R?:
MD5M<3D+!!-,Q5W"Q1/(2D?YL BDE4_O8<+[D5]$%#",J(+(8%81[/??(=;89
M3[V])3[SCJDH3[RMZUKVJU[=[UK7^=Y+ND:EY'5$&,L[!5&3@99B ,D@#)\U
M$,,UQ(L4$4L\K9VQPQM)(V!D[40,QP 2< X S4-Z':I2HTR:LL! .6DX"--.
M%":-#""2@4 D]1\B<2^W\*+8:&VM]0+9I[WOM,A!ONNZ]WS=8OY]/TVYO;2T
M-_+##)+'$LL448"1/*99I9'7; BIES$LLS958HW9N/HND="L=?ZCTW1M5U5-
M#M;N]MK6>Y>VN+FY+3W4-J+6SMH8GWWTKS!8A<O;6L>UY+FXB2,[I-"'.2D-
M$23J$-NR,6 <ZVW[WPT.%B-$+0W[VU*]Q*G-I3[RMJ]W6O;O>_;O.VVE,]O;
MS, &F@BE8#. 9(U<@9R< G R2<5XVIVJ6.I:A91LSI9WUW:H[XWNEO/)$K-M
M &Y@@+8 &2< "LGF]<-,4IBE,4IBE,4K2+RT\F>F<7N7!N6<6YG!=5ZAW66O
M0L)7I^S;JX8T908 *>F3W)+;:V&=(&-TY[Q;C+/PAB/<4MS6DZZ[:W259I)9
M#%'"$)8+NR7) &,CX]LURW$[Q-%'$@DDE+X#-M&$ )YX^>,_!KN<2Z/YMV6^
MB17<O'#G?->?N1\D\9:JWU>.MTH/(LC^_&"-PPR]NNM&$?\ 2>?UKV#I_P!Z
MO\9$L=JJ$Q7#R/D84Q%!C/)R2? ]J1/=,^)84C3!]0<,<^PP"?-;HYRUU5H/
MT?RB[#9>W6KQY\3N94^_6WF<5#R?6^A=-LLI7>9T0ZQ#;-@*CK5? /FYZRR8
M.E&.M@>XU')9>8>;?=&DMQO8EO&L*S7,C(LA(B2-0SN!Y;D@!0>.?/'S7(\\
MC2M#;HKL@!D=V*HA/*KP"S$CXX!\^#B3>.'E!<.GRW9>6=>YN/S#NO"5QB[9
M Q<NY8*=8X6P1;TK7;349I; Q#L;(#M(45'DZ=*CFRXY3Q2R"WQ *SVZ1B*2
M)S)#-G:Q 5E(.&5AS@CV^<''BIAG:0RQR($EAQN4'*L",AE. <'_ #C(R<\#
ML^&OE 7Y$>+T)Y"]%"K% 22]=G9_0A[XU:A(JH3LK&NR1,A-$K4*,V!&[-.(
M*)2PQ_U5[4AI/^%U;]BX,"%G_#;QZB6 .,#]S@5:WG,T F<*F=Y./Q 5B,Y)
M^!DU&/'7RFZ/Y2=,M$YS6@Q,/XF5=XN#B.LVUJ;'MG5[("I\8U^@0>G@10JL
M*9I*79>79)<TV-L?;")8PZ,KEI[>.WC4.Y-RP!,:XVQ@^ [<Y;'L,<GX&32&
M>2=V*(!;KD"1@=TA'!V#(&W/N<^,><A=\,XZZZ8I6O%![(8;S'K?1[F,VL3F
M70?(6)='KXGN%$53D%[N,)'::8./TR1-D0-<8^.XX8$(7)+6YK0+#FD-;R1
M/$B>9(X6RQ_NE52? \ M\$@?)K%)"8Y';^QYA@#^V)W4>3Y(7GGD_ \<-P\F
MJ=4#QXA57O=AF3H;CLQ%Q->CZ\Z5)J[C9[94:5&#NRUFB 6#T3%.D=3CTB8#
M$18A0)BI1YCY]8!+=G!.Y% ,H)8MQV55F/"GC#C&,DX/'C,-.JG&UV.V-@%
MR>ZS*@&6 SE3G)  P2<9QB!?*B#D4!1\1S#JDS=?C]$38^>1HM#<M%.$Y9,Q
M4#;I*;+(OPU2.%3(SL(U CU>S6&4LJ9-I<-'E:"E_LV3;D9)DC"X3:YW@.9
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M%()3(&E/,#HE=6666:6Z=,(E/?<??65IK1VU%JJ;B0MNX!$W>!QX;C  \;0
M !CP,>*MV$V[3DJ8NT1G@KSD^,[CD\Y_QFL:WXNUD^6%L5WOG1>D60(ZBN"S
MEN(I;9+<-STZ<DH6L+!K%)KD,]%2$A8I4ZRF.QBK%/$.CI)G$"1\:*'/W# 8
M1(XUP_"AO+@!FRS,<@* HSM4>V228$"YRSN[>GEBOXH20N%4#&6)8XW,?+8
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M*#82V&P6\(V88Y\%1 S+!!35%@+ G< 1NX(/L0O_ !GS@$@>U6><(0-I()4
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H,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g189651g27q75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g27q75.jpg
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MU#N9X5%Z]I9G' CO:0J=QK&NC1?*]<Q+B.$SWFX4SQB.XD^0HP!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%=:EQAKNF;GR?O53-:27/+5U
MKU[L\9I(\P$!NLZK6:A7-J((A()A!WU52+(4PD@U\ICIIHY(HGM@99R2Y3[R
M1FWSCW%BY"C & , 8 P!@%<\3<7ZYPUH5/QUJ<UH10T96P%ARW1(YEDZ79-D
MM]IL$G(%$!@>QEE=%L&1@L:QB-@BD=+(Q\TE;ER1*%!8V0HP!@$0Y!TFGY*T
M3<^.]@D.AH=ZU:^U"YEK)HAK&.KV*K*J3W@$3CEP0&,%+E<--,*1'',C'O@E
M:BL<633Y!YIKF;FAIA-<HJ77@'3/!HJFNI@GDO;(0X2K#A"&<1(R.)CYG0P,
M65[(HVND5SFQL14:AYMOF%DDN1ML 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & 0'DWC?7.6=,M-'VEUK!664M:9%84-H327U/:TMD)<4MU26PBI
M.!:55J"(:+,B20O?#V"X"1)9QY:G#DC4_6G5%?:!X>Z32]V_TD7N^<E\K[T/
MKQ6J4FP\FW5'82:QKM@8*=:5VO56K:UJ5 #);$@5[K2UDJ2;HV,* >6R]-W(
M9$Y1"7'+_.2*E)S+;7,O_(:& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MA\1:M8BW;KN6+]/M6;M%+MW5G154B$6G./"M(VL?<\O\7U++JKANZ9]GO^J
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M]BVUMFQM1*]B+.RJK6.KLV*+]F_=P>'K=QXBJWB[*QN&M7E57=LWJZ:-WB]
MKN+V#Z2>A5.-O[9V_P"B-CTSQ#]#L;Z,U5X/ 8WTIHQ6Q+6*QU[ XO X7;&/
ML4V5LZG$[)Q?\#;1Q6#KHM87&8.S=NNY6\UEJ^S:;XN-AVD!P,=GP+QM:TH>
MT.CFOJK1[#A>6UH!N\0U"?5B[]-M+8YAO)*_:QY9(.E@R/R^55=P>,P'IKB<
M;;=I7O1S95ZQ1BW2\39V?=V#5>PU&_7%;N4;2JQBIJI2;QM-3I_XB4?4483:
M^R=N?D8V9LC$+$583\HGI1@\=>V2JK>SL7Z08;T[HP6T;OJ[3=KU%[T<HV0Z
MZ+LT4['NT4W/_#55SIK=KYN%?&B5O#$7D^ /4O22&,8EY!8P\$<8D<7^V.<B
MD,F_TER74E)Z94>[:GVG8_'UGSAOIO8/IY7M%)[75&"W'6D\13=I]'=DU;(]
M5EO*I;6=]X?=S^VN\Z5ZUUG=P+HM^G?Y"K7H^VO1.Y>VRKU%FJK^#[F&K_*%
MZ5V_2W[6E_PZK?\ %6C 4X_UOLK8].$]9&&5L_2T59U%&4I&H4L$*DHWIY4G
M[;>\C>G5/*DGFZ=%Z=.G3/U:C>W*=^-_=IWHTWH6]$<)D_EB[ZOUMWU,^J]9
M7ZK>G>]7O/<F<YW8F<Y._-'&, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# ,*R)F"KCS!Q9#B! BB8 HEZ2F30022Q"Q+T=TD(>QL3
M%\J_6>GT+^3+2DZJ4W";2;Y)O-]VIQW:JJ+5RNFEUU46ZZJ:%K7532VJ5UJ:
M275GYR\8\K\W6=?Q-N]O<W,HO*M!LMC>"[!L?#Z:O*]NAW^T0?Z,-<H'?' -
MAI=Q7@UY59;NLIWT3+A^VQ,OQX9X?9OX?"TO$6J::)L5VU2Z*,3OJ;M%O_CU
MUKU52NTU-IT[JWG3ZN:91^;[+VOMR];V/CKU^^Z-KX?%7+]&(Q.Q_LM48#$8
MI?P7AL.UC[=S WK=%NNU>=RIV%>>,7VBFFI2G1+/DZ\!\-5%L/-.\,?SGQS;
M<I;/LD FB@6$5[4ZEH1];Q[ICVZ>X.JJBF;1;;":PL6SO#X-5)=#8PBSVT:\
M=U6*7C:Z,+:C"WJ;%NANZUN57+JJO7?^)-52]730H:IIWU*;5+.W@+FU+]'H
MS8Q.V\<GMW9M[:N*Q--& MW%B+.$P%=K9V":P;HM6JUB[N(K5=%R_<IPE3IN
M*FJ\B%<=[-L+=4U;0=8W3?\ 9;NVY!\5>SV2<9"\:TMGN%92<[7=:F[6>Z;J
M8%K6M:]$?=-*GJ-6J#K2Y+MP7 M$I*HP:PY;M%'K+EZY:LT4TVL#0O7N]53;
MJJPM-7JJ;5I.NNMJG=WKE2II5+ENJI-='9V*Q'V3![/PN.VAB;][:'I9BKBV
M73LRQ=QMJQM_$6ECKN.QU=&&PV&5R^JZK.%LW+M^N]0Z%18M5TUZ?3]@VWD&
MQX:Y+O=XNC+X/P]^+.5L@\>F%U=E)H/)ND:P"62@^LO!+=L $=<3L!-6H@E@
M35 RU$=6#/8BV.KE%NS]HL4VJ50\9@%#]8JJ?6V:ZZDO;E;E6\J)EI5/>WGN
MNGKX/$XS:->Q=IW\=?KQ-'HYZ75*JE8*NU<>S]IX+"VZZMW#.W7]HMTVZL15
M:W*+E5JAVE:HJN4W,,6YV:NK^8N0X=MLG7I7AF\'MLZN(KM3EHG%[ 9M41<\
M=.[7$8V(!XYTM= QZ"BS;#:I)%,QE-'4[5%NIX6R[:W%CMI4RJKBJBA6X6]O
MS[4I5<6J*8CVG5FF]BK5K;>T:<9=>(J]&/0Z]ZNJWA'8W\17BE54K/V:$K;H
MK=JF=VBK$7I37J59MW9-NY1$%Y>Y)'Y0V,>+C?Q%:QHVO:3!6ZE\)%ZE9;!Q
MC57%;?-FUV6_L2#1=OM6C'0WP<U8^$"8)&3L,D,ZMNW8;P]AV*'Z[!W+M=UU
M7/6*Y31?=%5#5:I2I=NENG=>]-2J;327L8G&;5HHVQM.G:N)I6S?23"X##X&
MFWA/LE>#NXK9=F]:OJK#58BY571C+N[<IOT56G3;=$5*MUQI2;K>.7..*TO>
MC=.GBYR\6FNA6M )K=?=D5-,VM8'0U<IU.8"A\XT'4JSFKC;F<$8UT949SX[
M ?<46K%YJRKJ^R;/K=-;N.A55INJNK=J56ZFW%*J5*J:4;N3ZSJO8[;&S;5>
M/N8*I;=]+L-;NX>C#6[]5JS395&'M57+-=M7*J:?:NU6Z[U5%-<5*XU<I]7>
M'_:;_:=,NOB&Y7:)M8Y$Y#TBMV]XX(TNVTFH[58TU9=DLJQPZJ0_LC+66A56
M(+7F6=:86,,.R;LQ]#&6Z+=VG<H]6KEFS=JM2WZNJY;555*WFZDI>]2JGO*F
MI)GUOH]B\1BL%?\ M%]XMX7:6T<#:QCIHH>,L8/%7+%J_4K5-%IW(I=J[7:H
MHMW+MJNNFFE50KQSJGNC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & :V2FJ);8:_EJJV2]"KS*D.ZD!%?;"5=B0$785HUDZ)3(*\XJMKB3
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MM6Z*<J:***$J:*4M*:4DN"-CF3D& , 8 P!@# & , 8 P!@# & , 8 P!@#
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M*4^,9J/BR)N8<:3E//J3'(:& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8!H=J_FQL?[!N/[O(RTZKM7F2K1]C\COU_\PTG
M[(K?W*'%6K[7YBG1=B\C;Y"C & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MQ-.*PWK*[-5:HN6ZJ+M"I=5NY;NT47**E3714E52IIKIJIFFI-V9G">H, 8
MP!@# & , 8!7W*8$=CHMS#+,Z!@\U+:*_P!N)MAU6EOZNX;%8UP:M*+IB' M
M@O(X.LB4\ASVL?Y?(ZTZKO7BH,U:/ZX_7R9#N-K4EUKO6Q6I%<E;L^T:^%32
MT@]@ZF/M(==  +FK"B1XIK."5\(P4UX\4,2<H"<9O2()LK[5&22>2XZQKP[^
M1$]6VLVDHG5=O^G(C_%TLE?>T%/0WEML-;/1; 5MP=]K533V.H6[; (@2$DB
MOJQ#!+&R.,LXBJ>XM+R<MH[K,$EH@KY2+5Q;A.5$<5X\HS@4\$G*SG*(Y=\\
M)9<._K;IJ-][.VN=+[1:^J]R>2R- _;#.ZL"BL>Y2?-V^VDB)$K?/YG(OER4
MQ*F=5';/'H6J8<1HYGE'F;K7_P PTG[(K?W*')5J^U^9:=%V+R-OD*, 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'E?8
M!;!FY':W2DU\YEGS!HNXS13U5I'M,(H$NKE74T)/;]NGUN#7ZTX>'8T);$UB
MD:6X-QDJSIM:3GDFNG&)ZR].QF'K&3]I//7@\ND<<H4HD?(YM*7> 7K=MN]>
M*J=;W&JI)Q=7K;:LL;=EW60VE.GOE/;*59OL* &%E17B!V5J+&^2GLUC2=<B
M66B>:RG.(URT6>KTXAO.9:A-++*>4O+AP7>79KI%F7KU$5<AQUUR335A%M7Q
M(J1 V<P,$AP<:*YRI&*4Z6!B*YRHUB?67\JQZN.9I:*>1#*A=@7D&?W]E.V3
MX-9Z;VB0V1BL][=W.^IL<;D=YO+Y$C14Z>;S+UZ9IQNY3][CV=#*G>SC[O#M
MZEF9@V, 8 P!@# & , 8 P!@# & , 8 P"G>:.!>+_$!KH.L<HZ^Z\K:JR;;
MU<@UC85)]<>D$@TDHI]:0,0D9 TTD)(TKI19T[4DD*SCC2P]C#8J_A*W78KW
M753NU)I5)J94IIJ4]'JL^#9XVV]@;+](<-;PNU<.[]NS=5ZTZ;ERS<MW-UTM
MTW+=5-454MTU4MNFK)M;U-+7F+\&5X1__9FQ_/.S_P"?SN_PSC_^91^RH^1\
MO^;#T0_F6)_KV*_O!^#*\(__ +,V/YYV?_/X_AG'_P#,H_94?(?FP]$/YEB?
MZ]BO[P?@RO"/_P"S-C^>=G_S^/X9Q_\ S*/V5'R'YL/1#^98G^O8K^\'X,KP
MC_\ LS8_GG9_\_C^&<?_ ,RC]E1\A^;#T0_F6)_KV*_O#U9P_P +\=<$:C\$
M<94/L-"^R*N2HI#3K(L^V-B&@(L#CK$@DH@AXP88K.LB10C"CP0QQQQHW.CB
M,3>Q5SUE^O?J5*I622II3;22222EM]6VV?5[&V)LW8&#^P[+P_V?#N[7>K3K
MKNUW+U:IIJN7+ERJJJJK=HHH6<4TT4TI)(M/. ]88 P!@# & , 8 P!@# &
M1_;?YJ[-_5^Y_NXG+3JNU>9*M'V/R,G7_P PTG[(K?W*'%6K[7YBG1=B\C;Y
M"C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# (7^D3^Q?^.9K\'ZWP,_C_5^)-,R:& , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , X1S55R(Y%5J]'(BHJM54141R
M)]**J*B]%Z+T5%_(N :#;?YJ[-_5^Y_NXG+3JNU>9*M'V/R,G7_S#2?LBM_<
MH<5:OM?F*=%V+R-OD*, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# .%<UO3S.1OF5&MZJB=7+^1J=?RJO1>B)]*], Y
MP"%_I$_L7_CF:_!^M\#/X_U?B33,FA@# & , 8 P!@# & >7O%U'XC)>)_+X
M8GPLW[XCJULO*^ACM':J@]A[@VCDV94IF6'N'M+I5(<V=:UI[0G>K6)KN]L_
M['Z__P ;_P"5N5;L[V[ORHWMSVHW=Z.$Q.1\KZ8+TD>R4O1=TK:'VFUZV'AU
M=>$W;GK%8>*_X*N>L]2ZMYJKU2N;CWX3_+/T7\+U_O[K_P!?PY_F<]N=@?\
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M%:B_]'#AZOM?F5:+L1M\A1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M:_!^M\#/X_U?B33,FA@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M5, AGZ1/[%_XYFOP?K? S^/]7XDTS)H8 P!@# & , 8 P!@# & , 8 P!@#
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M5J^U^8IT78O(VN0HP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P"N^4'0LU=CE9=/L4OM=2@77TJ?<V;$^Y#93.C6^DAH_3J8Z-
MAJ6LC19 WSQ-52'P(M6O<YF8B,YC,S5IWJ.WAJ1/3]2V"UMEV#=H]H#MPCZ@
MM'6<FE,#MHJD2_'J 1Q-6*M'!!4I%[9V4O?*B-/L+"+N%D "H#%6^"B,^;UC
MGV$2;SJF<GJH<3&FD>\O#,FSR);+"G)]C:.(HD-BYCTL6/7YH6KR21$ZAHJ+
MW"DM5E;*)IC!B9;PZE;5EPDTPNSDK?!J=."+M::/[KSU6K?CUG)\##UU7WEE
MH]$O#I&:XDIY6?JEW=UUF7M^B1-U[5MU;7UVV:Z'L](=9CW-2/<,C(+/&K5L
MZLZABJ+&M#6780FDDQ1>C6>5)%,QDGFUHXX..[.9T%42G*RG*)GFM8[M2]M9
M+(/UO7SBJQ*4HRCJ2R:=&=M*D@@ >::L1GE9VT D>X7R>1OE[7E\K>G1,/5\
M32T7#)$/J)[Z?D&9;VLJJR1NFL0=E7=E73)6+=KW'32%45&L#FN\J-8R,A'H
MJN5[%:C7:RW<OY7*.':R9[V?\GG/'L19F9-# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , JWE,6+8:5FHBD4<UT<=26H^O7UX50![%755
MT&98 2%A!G'2P20C.9,P$4ET,KQ'&1*-+VB*LG/;UCAIWF:L\LLXU<3V/MCZ
M:,711@=3,)J;*@T_3+2\D$;7UE#NMGM)UUZ6,Q\TCQ;37M?)%C C>KTD&B,B
M='-,\F09L#%EK;?%N.B43V!)++)-\$VVRW,R:.%1%145$5%145%3JBHOT*BH
MOT*BI^5, ZHQQX8V0Q00Q11+YHXHXF,CC=U5WF8QK4:Q?,JKU:B+U55_*JX!
MRR"&)\LD<,4<D[D?,]D;&/F>U/*CI7-1'2.1J(U'/551/H1>F!"Y&DVW^:NS
M?U?N?[N)RTZKM7F2K1]C\C+HOS'3?LJN_=(<5:OM?F*=%V+R-KD*, 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , JWE,6+8:5FH
MBD4<UT<=26H^O7UX50![%755T&98 2%A!G'2P20C.9,P$4ET,KQ'&1*-+VB*
MLG/;UCAIWF:L\LLXU<3V/MCZ:,711@=3,)J;*@T_3+2\D$;7UE#NMGM)UUZ6
M,Q\TCQ;37M?)%C C>KTD&B,B='-,\F09L#%EK;?%N.B43V!)++)-\$VVRW,R
M:.I8(%F:0L,2D-C6)LZQL69L3E\RQMEZ>=(U=]96(Y&JOTJG7 .'C#2(Q)!X
M'I'+WXT?%&Y(Y_,KN\Q'-5&R^9SG=QO1_F<J^;JJK@'=@$+_ $B?V+_QS-?@
M_6^!G\?ZOQ)IF30P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# (9N).KR $U^U:Z9LE:@\)D]>S2;G<1)6O*:'&C0ZZFMHR"V2R]QXT4<A
M< O<-DB8(R2=M4\''#5+XD<<5/<W\#5\?#Z%#'8II&F2:DV-1T.[_'=SH3S%
MF[JQ*Q;FAI)+1(^R[NN@]4@O6%LRQ=Z%'G/%SWS\6%'!1W->>I8^0HP!@# (
M]MW\U-G_ *O77]VDY:=5VKS)5H^Q^1F47YCIOV57?ND.*M7VOS%.B[%Y&UR%
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 0S<
M2=7D )K]JUTS9*U!X3)Z]FDW.XB2M>4T.-&AUU-;1D%LEE[CQHHY"X!>X;)$
MP1DD[:IX..&J7Q(XXJ>YOX&KX^'T*&.Q32-,DU)L:CH=W^.[G0GF+-W5B5BW
M-#226B1]EW==!ZI!>L+9EB[T*/.>+GOGXL*."CN:\]2Q\A1@# & 0O\ 2)_8
MO_',U^#];X&?Q_J_$FF9-# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M8JO"VJ;56-5J[A5<HOXVJEXK%JNJ[4\5=O5.[<=6\ZO_  0G('ZZ-2^6[O\
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MW333>LMJ[1^TF?O!_"@P!@# & , 8 P!@# & , 8 P!@# & 5]R=&41J<P<
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MCI'*Y;+YOQ)"Y+P-_D*0O](G]B_\<S7X/UO@9_'^K\2:9DT, 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#S]RTT\^Z]+4A13SZ]IEGMMD
MXO;=YUZ(P 0MT4%2##J-S5P,.+?"8Y]O91'($UH\; R62/2'=*RSXN%DGGUE
M:=YBK7+@I>;62>F1:.F45'5UL5C1MN60WH=<>]EQL>P[!(R-X[IQVQK?6MIZ
M1S6E/29 UA;.Y&+-W.U$K,O6'&7))>21I:2ISYMOS;)AD*, 8 P"/;=_-39_
MZO77]VDY:=5VKS)5H^Q^1G4OYFJ?V8!^ZQ9!3HNQ>1L\%& , 8 P!@# & ,
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M/:_1]_US,U'[Y[E$BCZC[/Z6-9WH9<^Y(=[?UE;%%Z'TKA4M/J1O?,V9:_\
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MQJ"@T@S3.K17D2Q2O%Z.F8R7JS)[$/[TYQDHZ3GXFO:R^[PG7OCX&%')R;Z
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M_C_5^)-,R:& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MW<OY7*.':R9[V?\ )YSQ[$69F30P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8!"_TB?V+_P <S7X/UO@9_'^K\2:9DT,
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M++(E^M:V/K0AD,9AMF99V95S;VMDHOKK.S+;#$\B=@(H04+8A1A 18!!!X8
MQ!H48YS'2/-S\"I1YOJR19"C & 8Y8HYPI()D+"!#!YA2H)$563#D1NAGA>B
M*BJR2)[F.1%1>CEZ*F!J5?'Q%4/$D%LK_9;=8*8"@H"S9ZEAFL5]7:5]W7.J
M9@J<1I!XMM3TION-U':DSRTU>A3ID:2A6MY\EK+Z]LSS?B9W5QEY1V)=A,M;
MUB'74M9G6-A<VE[8-L[BXM$!:681$"'6"QI#6A5X HH=> *,,,*'"Q/)(1*L
MQ9))$T;GI'^O'M*E$YMSS^H)-D*, 8 P!@# & , 8 P!@# & , 8 P!@# &
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M=$3 Z0>:&5Z(\Q,^1FX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@T"%.9T\CB$B:DZMZ=$\JR^96]$1.G3IF#D[3(P!@# & , 8 P!@# & , 8
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M45<@A1$*.7 C<7&FC0BFB,UX7MV$M<07-).;,?*34+,M46EG,4^QB,K6D2Q
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MPQ9XI(A,! )!L#Y(CG!2#H:V27U:3+(]7-Y\^$=Q72GJN,]Y(Q*FK JX:0(
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G:-BMRVW]>]\WU9I)+1?7P[B49"C & , 8 P!@# & , 8 P!@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g189651g28u63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g28u63.jpg
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MN:7458SF1FGY'1AL'AMDK9)86VM<8#57=>R> DBK:%/"5(QW]1^>H_\ 4>=
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M";;]@W-JT2<RZKJ>?)"9^EHS'RY,8RNOB-!4W<EB"RNP#3'"CA%=G=U8NNH
M($P@&=B=6HGVL$ $;YZLHDO>)WEH]Y<VD5G:6<L*6LH@=WN6N@]U(^DM(D9@
M$4<3$P!DD,J2%E"U13>L73)IJ7+YNK_PR9',&="8W5=JU.4UH$/8AO;M)A[*
M3LC/VE'2G=9Y*G#K-S2:&"@MKY9M3.MO34<E,L%%)=Y#;K@L3RV;FLL993HY
M;.-!!(=B2A7(7L[,<[XTTX[,)DAB3UZ&%N&037J03J+IKZ.W<W<3Q1M9P1JE
MS'*(WES,=<<>C$?,E'HQ[)W6]/T,>QT]IH8Q>F.B;\=MC*R1(KG1Z3O82\L6
M>R-G@BS&SE'"4[[HYE8*C6M]JJZMPBJ!I4#Z65=O!1$0/AJ./?67@-W<W+RB
M>9Y0.'\-E&H@XDFFXDLCC8;NL,0/=V!YYS_67=.HI?1UT!VIH)';#4:UOIPS
ME\?<%.AG-([>[0Z^ZWM[T@B")?>97#[$FYBC^&R(DH.(>5T44KY&Q)$IN9HU
M[*J9RH Z")'<*!YZ0/CFLMI?S1\"X9>2'GS3_JJ&1I&(+&^O+6T>0D#=D$YD
M V#%0"0#D1[4^J7LZ7>:W!]>XW E%9(;U&W!EIK+Z^@$FJ>@0O3V1\K"/2UI
M<KK73']W2U4ROEB&HHZA+-6VDL;Z8R5@32K.SC481A0"<RF;?<C91%GQ.<;=
M1BFXQ=^LS6UK!;,85XK(SS22 %.&KPPZ0(T;+S/Q H<D",)K[9!1O*D]66YU
M1V<T='C,:%UQ;]P=4]-&B7>DM8]_!;=C8;%[HO0AC#U?T:<2KAV@E4!0R/89
M:@"S[%;44)T-'))MT4$%V+B*24$*-&$9D .3G?3DMT![&">U2/C5Q,T4L=O
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M@%?76-6R)&UIPY4)XYI<$C)P@D/L0MBWCD=F,;%"H&64.3VB% P@9B#WC&,
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M_0$TP=7<4^?I'E5C \M7W=>=4E"TID-1%>2"CUMD<%5@7=M<5U2.0D5<&,V
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MN#<"4T-PKBHR8HH9)[OL_.V/'O\ A5>C8^L/F1U^S'E5F9[_ )3;[_XO2?\
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MUMM#RII9)2B=K99>N,I&01!"B986ME]A)-F3,V3MM\_>,[#Y[^?3SJ,G?IW
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M%GB]A+Y6JZ)@[_=[9G2M171MC5RO:BJU%1//(P?#IUJ^I< ZEP>AR,'W'O\
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MQ#!H)XGQMAT9&*N"K#&Q\",@C&Q!!!!&Q%7M[F"[B6>WE66)BRAU.VI&*.C
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MZD?_ #:?X(/2C_&N"_VJ\_\ Q]/\5_ZAO^<74_\ M'J/^">/U[9_4N/ZD?\
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M 7 NV%=,VK,BF'):,W/)<JS-I9M#>M$KN 3*KB,L.APQ4[YTG<5RK;@$\=O
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M[S9LS-%ZF"K#M6SC:M/7[.Q/[#Q(/9H!P)=C5["/+S4Q-VEA+@ZU&.:RLO4
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M(.IJ:\9J.F,/.G8.- SRJ-;[Y9&^^21S8HF>Z25[(V.<F=W6-6=V"HBEF8]
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M>*.[\R*6Q2W,4[\)'K$BH\I2U>")7+. \I 6K:R-EI"];!\]I6:"@L.M<O<
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MC/G/1^P9)9+0UN(FK-'];;559CWML\Z+(&1!,*%#&0V+EW6%%"X0N\CCLIK
M!Y9"ZS*&31J8#9SD$$[5K6-QQ:\F>;F70M[?A]I)F>X%M*\F;X-,;:+AS0W?
MK @AD)$UHA1E9(U#A:Q^:N.V4S&IBLKVPHKJ3IFIUE%.62W:.LK-XLI-O=TT
MAF:S;*JQ!_:JL[/EMN!Z^PLZ:R4(D)K8KF76W,D>%5E]9:-](Y>E00%5L.^I
M3G4'&DL%9<@^SCM)^-^IWBS7$MM<MP""]MF=QQ RS%&:>XMR]I:<F:+LPRVK
M^L)%+-;R\MX\+/(NP-M9!0EO=M#LL5,E)E<Y \JFIJXO7-RT^C/T-U=W(1(H
M&<K6:6HEM86,EG/+SJ5 H-F28VFL:11*2/HQ( 7D?VF81ZPBHJJP)=M#!2=E
M#ZR5 UC:XGQ&6-)";^2R=A;65HI>W@B>^]3:[ENKBXN(W2*UA%W TR@%I'M>
M0D<SR"WESO=&QVM51LK<"+;VES6Y\K;:.XSP]*Y!*BF#**J@V1W=@..J;&\
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M<3^QG^GUOM/]0.G!17*IV?ZXB(C\^WV^\/1Z>'W)^:K\;.UTK7>6HE^V2/\
M2%E3SG'+S&+.,]0'G(]^4C^YV\M&#U _<_T2^C /,])KN/.#):\*5AWC,=U>
M+[CJM8B#L1<@CV#7</SS5?NM.*5HC^R*X K:^G&SM0('3F]?:&IV:QQ,5\SZ
MR*,RCN/;X1?$(H5TZV*5?"-@K'2*OZ"(O6X+,(KT*QP)D:+?IJR'7XDKI'FU
M?G'Z4N&/Q#T5EFB4M)PRZ@OR ,L8562WG_T4CN#,_@L)/=@_.[SV5?+U=Y?[
M&[WKD"NK%Z?OK^LJ-3D[JW)H:ZS,@"=<YZ\*?<.?5N)DB:86%<%VR&ACJ^:
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M%&C"33, KK6*Y)+L81ZT9#[*S!!DD6\31Z\L,K,W\ZC%1'D A!$&E!([3+I
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MJ.!VP2!KEAVYB50D>S&AQMO^VX).W15P=S7S]^EOC\EUQ6'@,,A%KPY(Y[I
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MX_)P?TBM[1W(L>,.EC/&3V1<.2+*8#IK6=A"2< 13R$Y(6OI.RW[[Q_S,_\
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M&D$9[[&OI9QZ$9JM:XO1V:LJ,S7Q>51/>=?'5P<:)]_=,U$15\)P.HSXU+'
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MAY<=\C#LJ?W4.?>_BM?0'Z)/1[U:RN/2&YCQ-?:K6QU#=+.)_IY5R-O6)T"
M]=%OD'3)OVJ\\_7[+7RM>I&[FT7?_<UK.]TBR]E; 6!SE\J@-7>&5=<Q?/\
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M//M6-7*OV\(QMGRS]H&_=X]/C4'VO])?N)_/GYFO1OGDW)WJ)9$1+';;'?\
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M==R?[%%3-:#W5H'L\OG+P],/(J?N&BPZ8XMC5_\ Q%,"5R?_ (3/'YKSS?I
MV]JGE*Q^/+ ^YJ_=_P!#$ $?'[HC=GX? I\ BW<CCXZX_P"K7;[SS=?N-.*4
MXI3BE.*4XI3BE4-ZENY!.BNGM5NW20K=,'2FR(DWM<AVKM62PU,?PG?:>$+V
M3W!T/EJOK:PU&K[_ &HN[86IN[F.+!T ZY3X1J1D9[BQP@/<6!KS7I;QY/1S
M@5YQ'*^L:?5[%&P>9>S!EA&#[2QX:>1=LQ1.!OBOEQ--+L3"[ \F8PX\F<TT
MLB1TI!194KYR29Y7JKY)IYGOEED<JN>]SG.5555Y[H         #  &P  V
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M!:"P;816%L 4XY9A33A+6QKBI6/\RUI3@51!V0LCL;B0D$Z#A0F.6@!08PI
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M9Z5D;VA_HYZ]Y;'XY^&=JVNR_P"_G8_^N8/_ (>8/ANB?NG_ &VK'#_.7?\
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MF#X;HG[I_P!MJQP_SEW_ )PO^Z6M5_Z@5>?D,]D(?:L^^[)Z[RKF.\+[ZO\
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MR4TL()$8BTE9SO&I[66,6-:E@-6- /13A@-Q5H>'\4E1'O'X@)UGX,AT7TZ
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MY1TM:A?HD/9Y9Y_523VP-1)))Z'!H>&7L@+.W$=4EOZ1-)B_NT'/]>C_ %.
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MQ'3_ "O#=I];W<;_ "B.8!<:</#:+PY?R:_+:Z[8]/UM<J>//C@=?@?XX^)
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M3C P1G?(P>GG53*@_:!&,Y!!&!G.^<=U<_*]]Y?656:M!MPE4NP>L>:K+W2
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M)V##_.R6Y#&2.-&5^:2%90V-F9&R"NK8J3L"2N"!DX&$<8A6SOKNX@FM?U>
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MG.:AJ]-8HJNLA+P:;3V5FTAKM1?05!&H 2>DK\\U:>T#J@4J'P554!"Q]>/
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MMI QL02HSO[7D:S=AZD<$#G<U=Q1W%F9IK(*L&HZNIM"S8IV]C]?]7:-ZO:
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FXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g189651g34h50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g34h50.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6#U:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<S-&@U,#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S,T:#4P+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,CDS-S0Y)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" R-BU*=6XM,C R,2 Q,#HQ.3HP,28C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" R-BU*=6XM,C R,2 P,#HT.3HP,28C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C>$$[(" @(" @(" @
M($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @
M(" @(&<S-&@U,"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!24C$Q
M-S4W,B8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3DM075G+3(P,C$@
M,3(Z,S Z-34F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,3DM075G+3(P
M,C$@,#,Z,# Z-34F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C
M>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC
M('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L
M:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@
M8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M
M96YT.B8C>$$[(" @(" @(" @($%R:6%L350F(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @($--64LF(WA!.R @(" @(" @("!";&%C:R8C>$$[)B-X03LM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,S1H-3 N86DF(WA!
M.U5S97)N86UE.B @(" @(" @(" @(" @<G(Q,38P,30F(WA!.TQO8V%L(%1I
M;64Z(" @(" @(" @(" @(#$Y+4%U9RTR,#(Q(#$X.C(U.C4R)B-X03M%4U0@
M5&EM93H@(" @(" @(" @(" @(#$Y+4%U9RTR,#(Q(#(Q.C(U.C4R)B-X03M3
M8W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E
M<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!
M<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M
M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE
M=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O
M;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @
M("!!<FEA;$U4)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#35E+)B-X
M03L@(" @(" @(" @0FQA8VLF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z
M(" @(" @(" @(" @(" @9S,T:#4P+F%I)B-X03M5<V5R;F%M93H@(" @(" @
M(" @(" @(')R,3$V,#$T)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q
M.2U!=6<M,C R,2 R,3HT-#HT.28C>$$[15-4(%1I;64Z(" @(" @(" @(" @
M(" R,"U!=6<M,C R,2 P,#HT-#HT.28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @
M(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F
M(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ
M*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS
M=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ
M*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[)B-X
M03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C>$$[(" @(" @(" @($)L86-K
M)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<S
M-&@U,"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$Y,C$P-"8C
M>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C M075G+3(P,C$@,3 Z,C4Z
M,3$F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C M075G+3(P,C$@,3,Z
M,C4Z,3$F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL
M=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z
M(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C
M:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS
M(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[(" @(" @(" @($%R:6%L350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($--64LF(WA!.R @(" @(" @("!";&%C:R8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,S1H-3 N86DF(WA!.U5S97)N
M86UE.B @(" @(" @(" @(" @<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z(" @
M(" @(" @(" @(#(P+4%U9RTR,#(Q(#$P.C4Q.C X)B-X03M%4U0@5&EM93H@
M(" @(" @(" @(" @(#(P+4%U9RTR,#(Q(#$S.C4Q.C X)B-X03M38W)I<'0@
M5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ
M(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K
M)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N
M(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E
M<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!<FEA
M;$U4)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#35E+)B-X03L@(" @
M(" @(" @0FQA8VLF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP."TR,%0Q,#HU,3HQ-RTP
M-SHP,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$
M871E/C(P,C$M,#@M,C!4,3 Z-3$Z,3<M,#<Z,# \+WAM<#I-;V1I9GE$871E
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP."TR,%0Q,#HU,3HQ
M-BTP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R
M96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @
M(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIH96EG:'0^,3 T/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K
M6DI29T%"06=%0DQ!17-!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML
M3D$K,$%!04%!04)!0DQ!04%!045!)B-X03M!445S04%!04%104(O*S1!1&M&
M:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='
M0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%4
M17AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(
M>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G06%!14%!=T52)B-X03M!
M04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%1
M04A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G
M8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%
M1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I2
M5&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P
M5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7
M-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E
M66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"
M455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO
M8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X
M9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-
M5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F
M2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K
M<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9
M<3=&6%EQ-T9867%W)B-X03MJ52]Z9#AU-F)Q9'AP,7I:,S1M="]7+V5#2U P
M,T9U5T1M3FUK1E)736EV:FMH1DA%9U(K95!L9FI023%N96E+1C%I2'=W.#)D
M;&1J)B-X03LX4'$Y4#-D06$W;D1W1DA%>5AY+S4R,')83E)N<TQ32V5/84-)
M5',P<7%%2T9Y;7I)>C<Q6&1446IO9'=126M*=&M'0DQS5E-0>DPU)B-X03MW
M,'9Y-G%M*U-6>3A5:S!A>$)#5U=*:T1H96)*57%*3U(O>5%4:$%T0DMA86)F
M=S9H<#%R9G=H;&AU-&MN:E8V0F=S:6AG1V]32VEU)B-X03LK*T),8VXR>FA1
M<WA6,DMP4C5H.'I71V=147HS>5-V1DY-<T-M1D]:57-+.&U7;TY",W!5*S)%
M0D-Z>78U<S W>DIB5#-&:DA01VQV)B-X03M+65A%-D)A<T)8-%=5=6@K5F%J
M=4)55E-+549/:G-+-$5T8S O;4@S-'%O6"]W0EEE>'5%<S55:79':61B85(V
M1E9L2VYG>#)B64XW)B-X03M9<7<V5%(O>E14,49I.'@R<S1.9E1K:VAI:4DO
M9'5".$MW4V8W<TMN<61H.4=3,E)U>6)163EA:',U13%U-FAU8G-Z4TY(2D-/
M2VE%)B-X03MT5TY32TQU;S(O:65U07%M6$Y0-6@Y*T)+26A)2V)'=4)++T98
M67$W1EA9<3=&6%EQ=R]79$XO34=3*W9:=$TQ*S-G=&XR<W)*-#1G)B-X03M)
M-D=,9#5$1$MX<4),=%1R>#,X2D-K8G!0639F*V-&>F%P3&,V-6(R37),3GET
M,U<Q9#%C5D5&5$AB>4I1;F1Q3CEM;F5U2%I'-U W)B-X03M&-6QS<F1B>6%/
M4SA72D)C=6A!5G!!;S5L96UX8G!T:T=41CEE<V9Z16TQ4S1L,%A7<D\R,#EX
M1TQE,VU61UIA8U!52E!O=6%M:E4K)B-X03M).64S85%P0E%5*VQF;6\Q-TA,
M2')T;4E%47$P9DI!5UDX<6XO955Q2R]$>'%$>"]Y="M4<VID:R]L=5!7-V)4
M+U0Q,BMI=F(S:T-*)B-X03MO*TE&1$=V2F9H4T5B4V,V9D0Y;6YF055H3F96
M:2]N6#=X9U-W8E8Y32].0V)5-WEB5&1C<W)E>DPO-VHT;F]3:UI+,41J,$=&
M9FA.)B-X03M#959+-4E5:F1$>390*V)9=G)I4TAZ1%IF5FYK+V-"*T)947%7
M-&AL1G)X-6(W.&5V:G1H,E)U>D1163E5='1.:6HQ:2]J=F(K:6UA)B-X03M:
M1E)&-6-11T,X46Q2>4))4$5D8VE5<&HV<U@X-B]E34-71F%N<#,U;5!,33)N
M-CEA4F\S<6U&6$5614Q/9E1"+W="1V-S<7AG9#8X)B-X03MI9'E.<VQS:F11
M<SE-+TYL6G!'=2]-1FDX6DY),%)9>%%60D(O=T(U<3%'.5(S1S%62C5+-TDS
M6F9O565R4F%287@V=E!(8S9K<55U)B-X03MR:455:F1Q.59&13=E=W=&:T5N
M.#!7+VUY82]T1S!054E,4S)J-698635U2DPQ2SAE3EEP93%E-"MN0T=*4TM,
M5&9Z5#EE0FXQ,GDY)B-X03M*16HY9&5+34AC9F)O;W0P2V<O-B]8*U=T1D]Y
M-W!L-5IT+T]L=F5G82]Q358U8FDQ*TUX:45)8FQP;7!W2WAX4%)9;$9A<E-P
M-SEG)B-X03MA54EN>DI$-6]U2'1J;T8O8C)I;UI0<EEM-&YN5D9%9D=S8W8R
M5W)8<&E&4U%A8BMA9VUU0BMN3$EW;&HY5EEH3U%114%C,49S4&I))B-X03M&
M4U$Q2S$R-E5/>3=P<C5A2&TV3%9.5&HQ,C53-'-%15$P,F-E:4]D95A-,&I6
M1T)(=SAU47!8-T\R07%N5V]M-FMT=4YJ3VM.>#9K)B-X03M2-711:C Q:U5Y
M<G5'*S%'1U5B9F0Q=TI20FMJ<79X1'(T:G=/2V]'.5A5,S%45'!,5S5J:C V
M27EN55EI5C5307!324M$1W@R9F5O)B-X03MD9G W1D-/36MF269%3V@W:C)W
M2E-Y,70Y5&HX=S,Q,TQD23)L>GA23$)B*V]Z1EI%1S="0V]62S%.84UE5S-3
M;351;G-"0FIQ1%5E)B-X03LR4EI*4#5L:CAY>G=X2F]&-V)78WE->&UA-$A,
M:TMC46=(1G5.3U)E=CAY<4M52G=H0EEX3G!F-7$R-G8Y6#%Y0S51,T1-;%=G
M5U0P)B-X03M83DXK9'%6<7!.9'1L039.54M*8DDS86934'ID1D=I.'<R06ME
M9#-M2E5C4%,K14EK86U"=4Y!<')V,S8Y.&1L,U)E;U=(-7!36#$V)B-X03LQ
M;')E;G<R8G9+8D)'448P4G$K;4AR0S(V-V50,#1.:S=Q34=K+VUO<CAP9DU&
M;7A:-4AC;T5#,$-K4DQW83-F-%-1=&5,0V=R=7A.)B-X03MC9&MB<W$X=7)R
M14=J,CA7=3-C3C-Q<3@O<D4X1D9J87)S56]/2V1%;U!S:D%5:&I(;4A59DU-
M5C-Q2#%(>EAP9&U)-3 T,G1Y.$-')B-X03LR:31+3TUJ1DAB:S=L:E)H-%5B
M<4U)5D)35"M:-')I3SEU4$YL<&5A6D$Y=3-/,UI9,D%L2'!G=6M%37%S:S!G
M96Y-.%9P6&5L34MS)B-X03LY<TY8,')5968V4'993'HP<65R-D5Q4SAE5F50
M3&=44W1$5$E5;&=V;4A54$]-4&U+*VIS+TYE:C)D<T-N,514<G%71DIK3DDR
M65-!)B-X03MW<R]X2TA053=%9E)-57A+0W,Y6#@T<G%L<S$S-3 P9CE'3$I(
M3F-)2F)F;3ES97%P2CE8:E)I9E1E<$90;WAO9'EO<7@Q4'II*W0R)B-X03M9
M;#@S84Q,67DS4U9T23595$Y,0UA,96Q(4TE&;EI*27=+2'<X9#-:6'!'45I-
M93@Q965.3#AT1D)F=UA-9VM4,45A0D9C1E$S1GIU)B-X03MY+UE,2E@O5U=L
M9#9%0S!%<&)P,S5K1%=M169L+U-,:3EL0T=36DHU26)926Q854=P851K96%C
M864Y8U!#='-Z1E-!4TM(=4UI;#)+)B-X03MS8S$W>C-O*VEA,5HV4F1X5'E8
M3C9%36)12VMG6#%(2T1K9V8Q96\R-&]A.7$W,$E#3%-I>2].8E0U<C)#,75,
M2C K<W5);W!96EDU)B-X03M61&U6:T)C;C!G<45+1'ER,7%V,FQ/2&A7,F1:
M1DQ(=%,X,#)L;F93,GHR3V]Y=$=11$I"63--<UIQ069H9$5+=#$W6DE"0DM'
M+WAP)B-X03M:9CA!5G0Q8B]U2%AF+U901VM7-R]';&PO=T)7,U9V*S1D9"\Y
M53AA5S)H-3!S<70O=4XQ6'(O,6)R=G<O=T--94Y,871P,VTR>78Y)B-X03M4
M5%1K<S<K0UHT;6U$,TYP3$%N1D-!4E=13"].-%4K;D=L=$]Z,'=*9&ER5&16
M*V8X1&ER94MT2#=9*U(O:&ER94MQ.%@R34-5;3@P)B-X03LK8CE/.'1X5W-L
M-T1034QU47A20S-66%!)0W4T6FMW9U=G;&IQ+VY2-6%E3#%K<S<U;VE&*TU,
M8FUJ3VIU:7-O;4Q+5T549%(K0G)H)B-X03LT0VII4D4S-71E6#=C4DI08EA)
M;6QI=%I1<6E,,#98:U-Y<BLK95-/4#1!-$1&:5!A=2M00VTQ;7!F;3DU9# K
M-6QT-7)/*TQ1<6I-)B-X03LT:FE69C-K87E!9DA+:$(T=4LQ03-X-%9T6'9F
M>E4X=E=C,7A&2D)D2#9S05A93$-"=7%.5#0U5DEA:V=Q<D%%2#1307I+1V5&
M8EI()B-X03MO3W17=70V5D1Q5G%R<$)/6$-">6A0-W0R:DIR1S!I1595,$EB
M05%L5#%$>3%O96],3W0U84-D8FE4,5IG>DY2;CE%,B],6FA4.3!E)B-X03M/
M,WHV-#)T2F9(*UAV:S9*;6505$%J=4]%:DQ*2T-Y9D(X1$50=6XW<&9H3S-T
M=6%V1555:DY#.'$V1&]*;4]L5VAT>F-C4DU42DI))B-X03M4=W)X+W9'96XR
M:C!X2G1.2515=GDK.&\V;G%C=7 S=6YM82MN-"MR3#8P>6AU2VA&<7%Y2W5Y
M:G=X-&EI;$=8.',O23AS145%;6PX)B-X03MO<F%0,&]6.6%F-%5Q-7 O96(W
M>70Q+V=-4$56;TMW+TPO>6M,,DLK*V]-8G%#9C9Z1$E:-7IX;#4K<%916DM!
M8SDK4#)F8D):5VU2)B-X03M64&AG4S9P.$U69%4K1TMU<69$1EA64&AI<G%N
M=WA6,50T67$W1E502U0V:#)**S=#:%IY4#AP+T0K=4MU-4@K52]H+UA&5VQ9
M,6(T)B-X03M4,3EV064K2W0X:B]!0VXX4#8T<31S869:4#1F,7A6,TDO>6XX
M4#8T<3!Z1W$O0V5V=#1(,WA6=FMF-50K2#EC5F%,2&U0:%!1*TAT)B-X03LW
M-'$S>5 X04MF=R]R:7%):%!W9$M917(V*S)+=7%F1$985E!H:7)Q;G=X5C%4
M-%EQ-G X3599<G)0:S-73#9E-FUT4$UD-5ET8WIR)B-X03M+<V%L,FIJ4D56
M46MA<DI(4W!$13<P3F9S,4%/4T)24VY9*U-D6G1.6&AU>#5L=F)I>FIE3C-S
M-VAP6D]1:FHT8V51;%9F:4Y787%')B-X03MU3G)43'-I;#54-7)M<S0O3F5P
M4GDK97(S4S5754MD3FEG=3-307E1<GA)6D@Y4' X5W=(6'AY635C;4I11CEQ
M5VU08W!D4V5F3#)+)B-X03MZ;6I%,%E-1C9Q5$QY3F8W=59#2V5I=TE65BMK
M,4I0=U98<&%0<71J8E%E97)Y07I*8C)6=' T='(V3TXU16A7,B\S-&Y$;DIU
M,C1))B-X03MA=GA";$IW9D)8<3EH8GDR,6IB5S!S>EA-<TU34GE81#$U4TUI
M9T8R<5<S66EV6$E-:VPX,5AN;F$R2V8T8W-B82M6:S5/2C(T1E=6)B-X03MQ
M1F0U238X=W=)4&)I,6$Q6$-+455T,#(O=T1Z6'5E275T3S R>5!(:S=3=3=$
M;%9X>%@P<%I4+T%#2&5M,6-/>3=O<E=.42]-3TA5)B-X03LU23E,,'DP=4Y/
M<6=I;60V4V8W<CE4:W!L:C(K2BM0*W(P-E9!<%905&)V.'HW:FDQ,UIA6F%!
M1U Q56ME47-14W9Q0TUX=DM.;#5B)B-X03MT5#1T='=/5$A:9#)46#5U4EDS
M0G115&1#2B]1030Q36Y%.&%C+V@V*T\R4E-X3S$Q1#AZ;&MT27!T370S9T@Q
M9&)U-5EX*W%145)/)B-X03LO0EHQ5&QS<#1J659.0V-L<VID;6524W@S53E8
M.'A16#!S5G)O3#-D=7!(<#-!=5E)=RMW2BM&>GE'*S(K4T-%3"MN9DYN+U5S
M4V8Y)B-X03M*;'0O6$=G:#,V9#@R9CA!57-39CE*;'0O6$=G<4TP3%5T6G9*
M<GAD4S!L=$U71FM%1$Y.2$XV9UI+=#EJ<'A/2E9.<T-82'!I<G-6)B-X03MA
M8G%V>B]G8U9B>%9O+V)(>5 X041&5SA65C1V<UE%<U,O34\T<S=E3WAL=69-
M8R]L.$%Y.$1!<G8V>%AH27=:53=+:4U"-W0Y0FQ&)B-X03M"66,O,4U79C%T
M4'I"=F\T5FM+4W5)<C4Q36M4*V]E2WE3>4YX-'EP2#%)63 S2DY-;#A%2W1H
M85(R=#9.3U!N=2]A*VUN6D=1,G0P)B-X03M'85(U631L-6QM86A$43A!5TY+
M2'<K,%!G<65A3#5,,39E0TLK:C@U,S$U6C-&<DES4$I*57(V,75):VPS;$1!
M;V9J1E)Y<C-",W=%)B-X03LK4S W+VQ7+VUV,5I82&Y3*U9*1%99,45X0T1M
M<F-16'5(3DM*5')89G9J>$1U5VQT>BM7;FUI67%2-7IV5EI'3$DU4U%S<$Q3
M1W%N)B-X03LQ>%$X2D]',UEF8SA1-VQP-D9V:U=3;$QD5SA,>%)Y>7!'.#=C
M255D9W!D<58T<40Q3D)88D966&9W>%9,8FYY,S5E=7)P<G4U,'%Z)B-X03MN
M=3(K,6-345)026%$:G4W2U<V0VU',7!A,VQF>3!Y2D<R:U=42D5O4TY$8GA%
M2V],14MO-#=$.30S,VYX>'1&3&PX=&585FU%-C94)B-X03M::6-3*W5*4D)%
M2$5P3F95-6-A.#9J-UA81S P;5<O:&=6,B]H:7)T+T1&6&(K1TMU,SA-5F1V
M-%EQ-V9W>%8R2V]E6&PV:&]".2\Y)B-X03MM1D-Y<BM!*R]W1'-X5C%8.$(Y
M+SEM2W1+6'$R=S8K4'-08D97-G8T1#<O-TU68U,Y3V<K+W=$<WA6,5@X0CDO
M.6U+=$U8<75W-BM0)B-X03MS9F)&5S9V-$0W+S=-5F%*9FU.:#!09C5E,DMT
M,69W2#,O,EEQ:4EA.$XX0U9'.3 S5#<U5E<Y=$EB<%5R=T4V3$E">4A&<6-G
M8595)B-X03LP3TMO6657=DQW:CE)859::5!M6D]!9VDT.#)89U=P>"LP5C)R
M-%EB5VQK6&PW>7HY65=A3%1,2#9X87962D5H:35X4U8Y5%EH87$Q)B-X03M8
M-6946$<Q<$UO65EO26MH:&I72TM-0E5J44)6541O04%+05E&6#<K1TMU,SA-
M5F57*V,T=DE8-E9V;W11*W9P93-&,T=B<6%";U9J)B-X03LY6#!9:$-H:VY)
M:6I"4FU+;'%(-%I.-F1::3)*<%<X;S9*-4=V+TU%<W5K<&97,7A9>4MZ47IE
M;5E83G!W:EAI>$5J,%@T9'=W-58V)B-X03MK5D=*2E505$UG>5ER<E=M+VU$
M4'$P:C9:<71V8395-U)I3TAG;VUJ4E%V<4YY:VAU035E<B]$=%-I;FPY;T=1
M<$<V569O8C@U>3AH)B-X03M/=3)!4FY5;V]69&Q"3E)V83EW4G1U9F9'=VID
M<'1++T]8-GIW:3%M,#E+3EDV>7ER15))95HU-TIB8V=E23A!0E=G<5%7>'-,
M=6Y()B-X03ML2%0O04UX3%<Y;&)Z4'%D<F97:&AP16QU;U9H3'IR>3)H:#(T
M8F1C5%A22716.#-A6#5X=C-J:C!3*VET3$YO,E<U474P37!9,6]Y)B-X03M3
M<D9->3 K1VQ+931A=4%5<%-T.4@O3FXQ,4MA-5II14=P0FI3<$%K2C0O-WHY
M,&]08C-P>4IS3'5Z;DEP9&EQ4F$U6BMB<&(Y6DY()B-X03MV;V)E>D9V27)1
M4W%#5$]A.$=$96TU2'-D=W9D2#994E-%<'1D22]--7(Y5&1A-6)25TE704]S
M8V-C<FPP465S84<S:"M'4FA13%AA)B-X03MT82]$>%DR1C-:;FM5<$1F>"MB
M1&53;3!U3$)B878W<%I96FUC0VXW4E=6469U=V]19'A$-2M):CE'-C!W9G9%
M36XW:6-(,'=W-3!R)B-X03M)*R](+V)'2%I$24U#5VPV=#@O-$1&5SA68V5M
M2W5X5G!U<2]0*T)X5G9&5VHY<V9)+W=X5G9&5F5,-T="3$10>DU4>3))3$MF
M5WAE)B-X03LX65)-.$)S;E)#3TAP>5!8;7DX:5)'049&5%-P<'1Y5U551C5V
M3$XK5F%J-%8Q<%-G3$\X47-O95125'5W8W%05%=T6#).04].0C%Y)B-X03ME
M-TA:3G9+96IE44Y2,55A4%IY87=K=D\U155K:G=H1#9B4DY*>4UA+T0X55$T
M*S-8.6M!16Q)<&Y'9V9L9&]':#9T8F%P85A.-4I0)B-X03MA<7E22DY+:G!2
M-&QH3E%%52]:561$*T=237)307I$27!D:7%X25EK85)K54DP<F,U4V]!3$U&
M0S%B8F,X5D$K47A6=V=I17AN0TM*)B-X03MM54DP=$)Y2W%347!A;&%!<V1S
M5E@P4&II<5)A=#4S.'(V4SAI86AF96<P8DUJ:C U5V]Y27)S4&=2=6EY2V9P
M=V=&1G%&>"M9;FLK)B-X03LR9U=E8E5#<U1T26M:.4-C;&I&-EIF:4)'4U)3
M9$-#3FE$559'4$-6=$XY23%F5#E8<U5V.5!M33%R25=#4T9':G%567%F:&16
M8G%0)B-X03M$16A+3F]F2$%R<4AX>%8Q1#0T<39H.&-69%$K3TMU;V9(1EA5
M4&II<G-643AO4'%(8VHW<TM&;D4O>D@X4#99<3=I9C5J*T@Y359A)B-X03M6
M5%9V:5!8,CA"-UEQ,WA0.'@O1"MM2W5+;6XR:BM(.4U69'A0.'@O1"MM2W1-
M<'%V>$AR-V5".7-68C1N*UDO:"]41E=I<#5J-&HP)B-X03M0:#=E,DMT.%0O
M369W+W!I<4EH2'=D831%<&1R9FUB471$34$Q5SA&<CEA3$-$:W)(:U8T,2MY
M<F1/638T449T2VTO33-Y4VI&6DY2)B-X03MA2F=66&I,8C--6G%Z;$)S.%,W
M8VQ)2C=D.%!#55<Q82]M9C5)=4%Z2G%81E%Z2W)02$EV24E51$U+<%=N2U5$
M96YF<TUE17)A2C!R)B-X03MZ.352,6$K:'-.3S%)6$8S8T)M:6E73U560V]*
M1S-:04)25S=N,C8T1$5R8DEA2'AW2F11*T]+<U,Q4'E6<DXW<E0S,&9M4SAT
M<D]7)B-X03ME3U8W0TYP5E%2;VY!>$EY5%(X02LU2D$V-4LP57E45$Q.-TQ4
M<F$P:VYE-6MG:5-.-VE5<WIY36]!6C),1FUQ>#,V-49+2GA6-7(U)B-X03MJ
M,"]Z95!-3C%*0C5:,&Y5-T]E8T,R=7)I,6IE6F<P4V<X;E=3;T$T:T9P05!#
M=C)2:WA417%E;#9&-7-G:FMT-79+=6QM3F9R53!4)B-X03M34G!*5V533&U#
M1$ID5$U&961&5VYD979#;4I)5D4R;'HK871J0TQE=SAU86)A,F-:;#E/0T99
M;W=45C)1.$9U=W%C+V@U5355<51V)B-X03MJ<W4W379,8S-M0V93,&PQ*T-+
M,3%&:65D=D)U<4PP035C-652-S%R:U-Y0T$X,6573E0Q:V]B2%<W;E-/2S!K
M5T%V4FU6<6\S=U-2)B-X03M%541/1%$O1CA.9G-J149"0T)S9GDK9"M#95ED
M56PQ>4-'4&I"2$PV,%)35&Q*>6LU0UII>%I*=5!X5C)!,S)'2&E7:U)R;FQ(
M5TY2)B-X03LQ4F)U,3AW6$]N,GEH0CE5:#E4:CA*5W8R6E58.6XK5W14=5-V
M=S1!5G!:<&YK2DED5FLQ2%9D46XQ9#0S5CE.5V1P4CE706-/45 S)B-X03MJ
M0G%L13=$-T]',7!K96\R,'0S<#DQ87=Z=&)3>G=Y4E(S2U8U4G,V;%$V,$MM
M<6LQ1S1Y2U=,<C5*.'A,8S)K>F5A<GE63&1B8U-2)B-X03M/<D):5$%'1#AV
M5&MJ,FLU8CDY='DR4W1&37=Y2U5H=CE"=4QI.&QM6%=,*T%/86E'2F]1:3=D
M1D12369V3T<P24\T.'%88V]J03AW)B-X03MA;79#4DI$.&-.0T5935901TID
M:E-N.6-.;UI"9U,P=E9V;B]!04=+=#1Q-#E-5F1I<E1D5BMF.$1I<F5+=$@W
M62M2+VAI<F5+<3A8)B-X03LR34-59S@U438Q2F)X2%-T2W1.56Q#>6-K=3!2
M=T=(1C1W3V-K5D9:,$)*0D\T6&(Y<%-%1FAJ-F0U.31"13AK84E%:E9H1VYO
M,C=!)B-X03M!4T9L02\P:% U<3 X86XR>5<S96ID3F9,5VIE65 P>#97<2M6
M9$IT3DI:-3(Y5T=+,T1*5&@V6$956C8X*T%,5D9A*T9!34)+47I#)B-X03LQ
M.'9A0F%80UA.<G!L<&(S15EP2$Y&0D=J<4-V1V=:5D)(=VEN>7=7;6MW=TLW
M1E=+83$K675J85)09%)89'!E8V)79&)D<&M24%1D)B-X03LR4EI$-F).279,
M:4A7;S8K,4MN2D-+3%=72#5L84ID-GA"<$0R=#=:,VQW-E)X3&1):UE,4$8V
M=% W=W1S2T$W9%-",W@T5G1L,4)K)B-X03M5<U(Q,SAY+TPK:3-5,7)C4EA-
M,#EV23!C>5<V;S58:D=K;DEG>4M1<%=462MX>5%I:3!.3BMB9FQQ1WDP*SAK
M='(Q63E34G!B9&5%)B-X03M:64ES,V]K=4)+869&=CA!3#,R>#16=%)N+T]4
M>79#;&DW,C$W5%5)0F-19TI&54E:6&EO,5IF=&-O:6%#=3)00U5C5$EV2W9M
M>E1F)B-X03M-,7!C6%9J2$Y&2&)Z1T)X4'=$1F=O86]#4$IT4G4K*T%I:V=O
M*SDQ9E-,13!V8C9#,5!W-U13<$@Y=FQX*S!2.7)G,5!K9D1!;%%()B-X03MM
M8GEY44-.5W-Y1TA*4TQM3&-F1G50:2]Y1RLT-&%7,5<U,7923%=F-G9C-FAB
M450P1&5L3$UI4'A9,%4X5UE':$IO36%64F)Z4C59)B-X03M64WIA>%I"5E5-
M>$YZ1E%+44-#9FDV55E(-F-A2S)M86Q(54UR8VQ95E9G86=G.7AG5D-4-GAO
M.79C9E9R:2MT-&)M<6HP2DIK5C9Y)B-X03M6-$1I4T0X5D14>'A61UEQ:#56
M0FM06#=Z:%%P='=55EIQ0V]&4U-.>6%!9&9(1E<K23DO=D]+=$MO<3-8<C1N
M=T=+=#A2-R]!2&Y&)B-X03M81E)4=CDU>%8S164O=T(U>%9P;$96-CEF12M"
M>%9V:5!F-WII<E)58W@Q-DAU9F)&5RM).2]V3TMO:4555$%L2G9-,VTS5&9,
M=C%9)B-X03LS<TYX2TQN;'A.=6YQ0F5,26Q8,T9!5VQ51$-"84-73VXX-69,
M2T)7:W1,-59F:55C3$))<DLP:E)&9S!C>G%11VI.9"]L:#13:FED)B-X03M9
M+VY*-6%U,4QI,7956&TV>"]!<D5I37A+95A&>E$Q;39B-T0S07@T4VYI4G5G
M9FUJ-60Q>E9R8E,W3T,X4S5U;%HP33!A;V=#4DQ+)B-X03ME4C5K.4=P<T]V
M=%$T;4Y+0WI'9WE+6%5'2W5X5C)+=7A6:&UP84XK6E0V,V-V<'5S=U<K:GI4
M2DEI=49E6DDV24I&5EAT,U5D1S0O)B-X03M%9DAV:W)#3C%84DY.+TUE3%4W
M4V96=%5T<')%4$MB,C%J-$=Q1TE#3# R1G1#,C!V26UR9$MB;F9%,'4W3'-I
M;#)+<%1R=FQ4>2]R)B-X03LS1#E,5V$S2FI2;S!*6C!)5GER169!>3DP2#0K
M2G%185)31W-025AK*WAP.5@P=45H47=66G55-%AM4U=)17!C0FUR47-.>4YU
M9WAS)B-X03MR4TDQ2'EL;T=P5'1.95<W4TTU4FU55%1):&%/;D)V5%(Q5&M/
M24A+;&%B9$UB5%-N6F539DML;D<X8U=M475J<4595&<S2'=H46Y%)B-X03ME
M<UI+3%)2541R:EI24V1):4EI;VEH555!2V]&04%.9T%"9U-L5B\U5C!++S%+
M4%5R=3-A5SEH36)1>2MT379!>%9+1D96=W$P-4AO)B-X03M.*RM',7!.<T-P
M0F8K579,.3-E4S-.>&$X-7!4>60O56M&5%1W1$%:2S!)4UAY1#55;#1C<DDQ
M:F1*54EL;3):1T1$.78R>'1&36=W)B-X03M*85AQ,WHO9TU68GA6>#99<3=&
M5VTV<C@O=T-">%9V1E=J.7-F22]W>%9V1E9E3#='0DM595HW5'I48U%2:GDO
M95)78W=744\P=T)")B-X03M9<BLW3SA5,5%P-FEG.&$W8U=)<$)9>DIO,S5Z
M1W9(6&)"9&UP4D9'-65Q.6)6=6DW9C4Q=S)%8G!N-68P=CA!35,S,6MZ-GAQ
M;')C)B-X03LV63=41U,S:E@T-D=G9S1N,&\K4$5$96@K.&Y%,&YD;'524S=&
M6%EQ=U9035!N9&UT6DI.2W-)-#=I5# R5G T4U-F54MK4G5*>GEE)B-X03MM
M,TAJ,2]A-UI+9VA5,4AZ1C5X<SE5845A3EI003!K=W1)2F)Q0T-A-&I1<7-B
M27I34%)I5TAW*VXS,TLY,F=Q<DPU;3AY4C-Z=TAY)B-X03LO8G0V86]Z,GDS
M<T)N05IP4&E#2T-Z9D%G25AH=G91;6U.2V@U=&4X+U)W>G4K9U=K0FLU1WA-
M,#A39T@P,5I9-4%:5DQS5TQB:FIS)B-X03MV5'9J459':E4O3TUL.2LT,&$S
M97<U43%B;D=*1E9K<DM$5U@W44I(5E)19GID,UI60S<Q9GHQ83-T>'DP87EL
M<VM%-U$Q;6IH9&Q4)B-X03MJ-DHU3DEW;WA.0U-Q*R](=3=+,6(K8TYB9&)D
M1&]-13 X:V%3=5E,-C-D941+:#E7:3AY27%L-DUD=F@V-VI';%)-*W5E6D)A
M>'E*)B-X03MO8V-D,F=A5S0P+S%9-357:5=.5R]D;%=J-G53;DI1.414-%18
M6G!6<F$O-6IK='AD,C)I47EX=W9C4EA&<D101F-/6&EB:$=V<4EW)B-X03M#
M1G4T-$U2,&)J,7AP5F%(5F9.-T]P;#AS;VM:5TYN074T0U%8<'I7=F-X-RMZ
M8F1-9&Q1-C9P-2]-:S-,>35B3$=Y2V):9G)%4DMU)B-X03LP65EI4G58>$)(
M<7 T<G8Q1T]Y<7-';V5D6# V8C$Y170T3E)&<TAT=TI&:VIE-$$K3E=5379"
M9C5F,V@K94]Y<C)U=D\P9&YB>4A3)B-X03MB4V4U.5=4-GI"1WEO4%)#1F]G
M<E!*4EA,559J.%$Y<5E.;&)45B]/-G-S2CAV4D5!>#AR:UAC86]687!K-'@P
M6F=6-E5R=C0T-TMS)B-X03M855!02WA%5&%"83-&=W=C:59,;%EK1D-/0W-R
M0U)V<VYC:'5O-T-H=S=+:#E3,4@X=T)Q9'-U;6%&87DV5S5J3GA*339,2V])
M2'%!)B-X03M!>7!U<')1.&9O>#)6=38Q4#AW2712=45G.'57,7I927A.=DU,
M:4M.,U9A:T%H;4Y#=V]T97@S<#)X,E9Q2%50>D)A5TU0;T9Q<UEN)B-X03M:
M6E-:23$U43!*5FQ+>7EC9#9#=$0T.%(P>#)64VHQ2#AY>&933$PU97-M<VMM
M65)U<W%+-W<X,$-N95)U2C1C:E=M+V=/-W-U-TLY)B-X03M/33%X67=Z6&QK
M3$LV9%%:<E5S:W9P=#-8;6YW=#AX9U-I4%)H+VM8-VAG5C-O=R]Y3#EW>%8S
M;W<O>4PY=WA6,V]W+WE,.7=X5C-O)B-X03MW+WE,.7=X5F-Q<6]O;T%(9TU6
M84U56DY39TI0<TU69#956#AI+V--5F0V55@X:2]C359D-E58.&DO8TU69#95
M6#AI+V--5F0V55@X)B-X03MI+V--5EE42G!'=5,V2'!Y+V]/2#8U8C-%,&I7
M>GI.1TEG,TQI.%)J=4I+8W$W<GIP,4<Q8VQA16YB>3%Q3G1(14E02D%U66]M
M-5(R)B-X03LX=7!P>5AK:V5W66M+0D=914<O26YR6')5,S5O875F2S1G=6]R
M84QY0W,P9'A&2$<Y>75P<T%V<&]'-$\S,G9H27!Y4#)Q1#59,S5R)B-X03M3
M=$0U8W5P8E0P6#AI2D%!>D]K56UQ0C!$3$5K0SAU2D]Z4FMR>#9F1#<T,S5Q
M='902FUP4WI7>'1F3#AD<D)!,WAW1S4Y55-2.#)T)B-X03MY:VI'6D=P-D1T
M24%/;&%%:S%'3G!P>F58<FMX>5A.:C5*075:2&QU;UI,:E5'3DQL:55$4$4W
M23-X2S-+;%)4,DY-8C@P5718>7!Q)B-X03M.<%IH8E!Y9D-,:3)996U296YH
M2T](1&%->FIJ>5-2:UIM8SE+.%<R1TXK83 S9BM58GDK;%)*+TIT=3%L>&A0
M1C<U:DUP;&MA8358)B-X03LQ1FM8-TQU44%.=3EA9D-'+TYA8E1Y;G$Q;$I&
M9C94-5II=$HT;%=A2WIE.$5Q<$Y'<VAJ52]%9S0K<$U344<X3GA4:5<P,'EI
M-#%8)B-X03MZ>5DQ.41226QK66)L<FE/44M22E%G<GEJ<GEJ*TQ:=F@O>7-J
M459$4F$U*UES<65M,VQU2S-K-&\S,6QR<4M62W-W-4HV4W5R9D-P)B-X03M)
M-6,K;W%",G<P1C-:3G P.3-C5TU-,35A;7EU;E5'83%,<DPV8F0Q-7 X3&9-
M6D9+27A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W8O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M
M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X
M;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^
M>&UP+FEI9#HQ0D%$13$T1$1#,#%%0S$Q041$-C@P,T5&1D(U,3(P.3PO>&UP
M34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP
M+F1I9#HQ0D%$13$T1$1#,#%%0S$Q041$-C@P,T5&1D(U,3(P.3PO>&UP34TZ
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I
M;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @
M(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HQ04%$
M13$T1$1#,#%%0S$Q041$-C@P,T5&1D(U,3(P.3PO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HQ04%$
M13$T1$1#,#%%0S$Q041$-C@P,T5&1D(U,3(P.3PO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#
M;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-#0C(T,#=!,C5$
M-D5",3$X-#0Q.3,V0T)#,CDP.3E!/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 V+3(V5# Y.C(W.C4W
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HQ0D%$13$T1$1#,#%%0S$Q041$-C@P,T5&
M1D(U,3(P.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,2TP."TR,%0Q,#HU,3HQ-RTP-SHP,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @
M(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T
M<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6
M:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y
M/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @
M(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @
M/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM.G<^"B @
M(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^"B @(" @
M(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @
M(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N
M=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&
M;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO
M;B W+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86PN='1F
M/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI
M8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.D5X=&5N<VES1F]N=%-E;G-E/2)H='1P.B\O=W=W
M+F5X=&5N<VES+F-O;2]M971A+T9O;G1396YS92\B/@H@(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z<VQU9SX*(" @(" @(" @(" @/')D9CI"86<^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI
M;F0^3W!E;E1Y<&4@+2!45#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^
M"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&86UI;'D^
M07)I86P\+T5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3X*(" @(" @(" @(" @
M(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93XP/"]%
M>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^"B @(" @(" @(" @
M(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/DUO;F]T>7!E(%1Y
M<&]G<F%P:'D\+T5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^"B @(" @(" @
M(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I697)S:6]N/C<N,# \+T5X
M=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&
M;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3XS,#(W
M,C8Q,3@R/"]%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K
M<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z0VAE
M8VMS=6T^,S R-S(V,3$X,CPO17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^
M"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R
M:7!T3F%M93Y!<FEA;$U4/"]%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T
M3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D)A9SX*(" @(" @(" @/"]%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W
M(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_\  $0@ \0)8 P$1  (1 0,1 ?_$ !X  0 !!0$! 0$
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MQ[R<NU'L8[6&YVS$D<>+A./3CR/PCZWNG3>GA^H1MAC1B$0I/LYI@R3F0:P
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M$Q)QV3"N3GI;VM22S^X.?)W1Y:+;.K^P#-Y,&(-2N$^\U8,1!5F2> %"(\G
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ME?5.5'4C/=MM(U;3382*]>)#P>?KFLXG3&U208EI'#;V2-PBLP5)JHRN,D[
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M;V_11-< LBI,L=;8)]Z*:*"QXZ3&C!CXWL/QK%KG;-3-=W)*QI&!5IH)L?\
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M80$/08=KIZ1IZU$:1>RNR2%/OXTS" *AR9U>KM=&.VRMG$K$P;,&)5P_X^$
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M@4T'E3K.RTNMQG2PN Z521)08DC/93\RBB2R0 5"U>%1J/O-/%#E>TCQ3=M
M"K0+170(KUR<VF;!J]D'VT+&.C$R6XDE\C%RU+0VA]F4))3!!!A66'I$5]+)
M"!*::F094L?.:0B8.F2X+\>2[",6GX/'Q!/CT]/)T\Y0B6?$_1I_J9?^9FXX
MQF*F?9F/T*/WE\ZPZ?G_ (,Y3[/E_ERT\O(QQC,(V/LJAZBIIK86R[4(IE,K
MS+3Y>P&Y'AX43$A]J+%93A*7'Y,N9+?9B08,1E^;-EO-1HD=Y]U#:JC"4Y$8
M192>@[__ !YOEDRE& RDD0[7+5J7<FL-[4V+L#45T#7NH3)4F V8#./=A@A"
M[O,L=/ARV8I$61CH>8>=@$HD28F/(C2<L]Q)8<<V>G/3EMG%C+NGT?,>D^)\
M3RQ&<9FZ$B1ZG]GT?@YLSD96.,9%D?=H/_E+_@IG&8]Q^?\ AR5QFXXQCC&.
M,8XQE&?NB?S'/WF^,97QC'&,<8R)-]C_ -O$_BV.,F?NOY?W,E\96.,8XQCC
M&187L5G\W/[RN,9*XQCC&.,9E@?V$G](Y_GCG&?O/Y?V,ZPZ?G_@RZ<G+QQC
M/S=Z4@C=PRY=(786LX=^L0V)T5ZA3)-# H+OQ[7YR3>D4P4.4"*QC#,G:FN"
M+M)L/APZW#).HSB=?3"E&3=.<B>O0=--*$]I>M*1-KPH:7$G\$S<<\$@; E?
MFU29+4E$DAHQ&(7NMU18_P#*/A>.6/%+MJ3:-G])6 ]8(=5:N#EF8)W<,[49
M&I94ZI4ZDB(32=<[# VQ0!A5QL5HD8"K+@5VHVP]FQV*#$! I- -/M(PT6MS
M';X7=O!E)?'!C?AC'FG:=#N21AGJ%^]?B*V- !M1KQ,GRW-V@#%J01-])(>9
M&BB9"XWL#)V03"+23UR'AYB :5TE=#BZQ:7YU4K /MSS.O['?R9&?U1ZV0$U
MY@V("#$ #LXG@:*+X8NR^)O<M+49%27W9$0.Q:5L#9.H46R-R>Z<;=2&UX#E
MBJ^2%@4W:W-F])P+7 3AR1?YTR]5'6)N82A:P@P/YM[$9+WMNS@\R1VN;D^%
M%X%@ZQ%GR#NO]GG1ILLSEH3 &V**_6]V:*M$?"R WKO C3S.-\LNI0*\UCXL
MWZH1O=XHBNVMJWQ9&5'7+&2/P>-=C]G]*UG ^P3?YQAY"YA],HN6"=+L$ -1
M!D2H[@;L1:L1F]#W]X0;.WVO4Z#:V9^OC2X35E1XBO52"3 %Z];#0ZN"1=3;
M4A9.[3JZU(V$9*>,]WWI(C!/6X:D,B&ZQJ)MGR>"2+(!*:NZ+$WUMRS]()C4
M^A+W7*Q)*;;B5JPG[0'"@K?Y#CV.7H^UY=>(5MX,FR-Q8M@DMRA=6+@_+KYE
MJ!76QCQUUF(YR@:7M-2#*M-D K&V)J%<W3QW(:JY=9TFZFS3D%S!4"57[.5\
M5??0EW12\9IVT[QZ5(BG+?#PK:9+C?YQ#57("]=VDFW>85<A4%X"!LLE_HWA
M)I$K*-$[I!9$U[6NHA]@K0Y@M!V? >!E9I#I'2T67+$':2&<3:R9\G^\@41Y
M9ZB+3!LJ):FJ#5J;DJ*[@VT+[,OED41A87NXYWGJPYLVR](J!.N,N^)9%4?I
M)"#59GT$C7*!3I#>YM30=;QP=KS7QP^X3+'0@CYR+-DGK/,D-^63(I8(06R$
MC<ID#2=NRV6BB2&<CV>HS6.Y8U)!X :&TMZ19.J;MW$=03;43QP(@^:Q%+6^
M4H:.WN>?.^.,8XQCC&.,9KV\75VKE=< (,1F67V->V:G!S)6XF)!ACJU9;U9
M",GN?]]VFZO3C,,7V<*;589P5J7V8;DA:;C'<36ZA'=QYK(B'ZR%^ USDRE3
M$\Y2KY4,E_2*?-,Y-K_3<$V=K;3 $=5#9JMW6BUO60X;<8TABSB-E[C7T?:@
M<MLJ%'(R*VVK8D)ZPF68P\A+':ZL5.)HA2"Q7P*^S_#U[-5"49,UB^%AI^U2
M/6[P-'/ODC@SB:][Z!242 /"3G[.+)+V^+E_XHUSFR;'NR_ZI,T(-M:MB2T:
MY7^?5F#VJ*[L*Y3I8AK6-ON[4YC75>#VRWP"$(Y5\@YR$K.#'A#R;!XX?E4D
M:-DTXS).G)-L1K481!WQC6]8Q2F_Y6^*?.G4E!B3!)2H8$I*;67NQ%.2O,KG
MCRGZDZ03VR"M<8E@5B!=VF=(2'67I8\\#+L/Z'W42ULN&? V6"-,BR=FK;@J
MQ(&3AP^<%G";- (L)5F TWFII$!IMB:3+I/]S3)V2BHA*RRQ&*/>;#5WI90N
MH#R/^W/;2((IS3SPWY9TYSCG7'&,<8S4>X-8O[9&5.MO6*?7ZV-O=?N-I0'<
M>B&C3%/\6?JPT65:<3D.[!V%"IUHD3<M2LOQ*Z^)PPCRGF7%Z:<_9LI4*Q8E
M\ANXDIYC!E&O5ORIB<=Y$M D2:[=MH#Y5(BW\*\\Y^J'13L-$.1\";54+35(
MSH8()B;'I[UM-U"D5O:A;;06'6Y;Y1J#YPQB5D)UZ.3D16FA\2LZRL#+4@A2
MU#RW5UXR.8RC+E=D]I*3IFF[N.DB-'+NF74K.9HL7B46/ $X[ML2;,V\]BI;
MZ1>S+17^AR1I7\U)&KFZ.^0U9KK1-0;"&*B^BJVHSJ>E;]I!LZ6CCYZ'XCYV
M-N])@7*2T0F#B%92Q+S.:)YD0=?X@EO)$@G/5E9+Q1-26E(!3D/9TG%CQ54Y
M'1V[$8^"&G$$X6$=2*M=63X>:I[O+9'Z"45NA2:2N[Q&ITPG%6Y<1U71!.0@
MK711(=&U8P+C)-]T;&@32Q&TU\?@B_#$C'DU_MR'.^)O/]2[MS&RO=7A?;FM
M;QS=$5JU\7PS/]/X=NXN^PJCV3INWEKM0].,OD;H@3S=AM=DN9BAC)5I'W:&
MU%UW37PK-9FVC4^OM5P+%7WB9*<Y'L >)29!.'.2VP[$9)Q S#BVQ2B!#/;T
M1 F[6+XY7>V<YHT'"R^-HOGQIHK)9,>2148U5PC$2UY-J_"Z\N<9*=&'9D:]
M4FT#XFG2$O+*Z^8'HHTF+K2OA .I[50A1U5:=L>"DJQV!=F<A3,07'66*N-"
M4=U[,&$NT*HUH;)1?:'F.[QJZD9L=P4!7U+(Y\.8Z4]T9>#I/=N)44&KNVWX
M!QSWEI.]!2UO@)%3#[0&/!W@+H-J>= $$V-EUBL:M Q"\XV#+C3!U<U>M6I)
M*ORRT6KY(S(1R<*/R!#0^0/XD);F'-W1+P\RFI2(5OX:W4((*X?X=IB3XJK3
MQ>[ Y1+O;R=<W3F6*Z'ELQ:+(9'W^L@AQ&TG+,*&M5.=:(S)(U-V.3P3?C7,
MX;?@LQIE_=?GT@<5S0#)%!@NR"!),($CY=>+$&"H1+W$>#99X0&]G$JW!1;5
MYIHHOB*5:IEVR;\2U[W,1VO8'6;@Z.FBCNF7;Q+.V 6:?N2:4K$44T82P,=J
M5=S7'>RZ5(2&,LSF6(DB)!#"ZZ'"Q4M!H(C+4%,^;&KJFIM"*;=W+7.YLZ/+
MKE5[OFB]/38,E1W;>K\BOESW0 =5YO3?..=<Y^VCJBUV*U-W>AV$.*+3J(3U
MM:!5@\ZX<4O7)I1DT,GA;-1['6K54;" (9(J9GBY3WE*&5?C+R/F1!I6'UA.
M)';(4W$Q"*B"(DA)13R>D'GD><H++=%!8[)#?,;LIBB)S\[\J,U:KHS;&ECM
M5 3.VXAE.M9H\\.V+)"V%_:X,XEXSFT1*O8SUQLCSH"XC",*LRV[A,LQ,;6(
M9 ?)FV"85A$J_?MH#----]C"P@QXJXQC'F*+X=HJ(%4Q[*=0&9X*25.X>;I5
MXD--VA?+?&+:]Z(EOU>^!L-,LFNPMAJCE::&@857LK=$-NA]>7+7IZYGXKUI
MDFT7>Y,64 5,RHL]]O,>@@@3\LA(($K/BIZY.R1)C*[61N!E&9$XK;%) /XU
M\@S(Z+&F+$D5P#M4C*+)+NVQ>:\(<]Y]KW06 U48R\+L,8A<*Q<M*66BG#PV
M9."^2].ZAT[JML!<:BHHH ;\NHUH7-Q2[4-HK4C1T*?KTED[4ADQ27\2R7BH
MRCJ$@0;U-34G<95N*WA74@1*DX- #L4EIL5. A"$*D73>U;\E$YB.=]\\N>C
M'&,<8QQC'&,PS8U7G7?7M[I8PVY6B5OIMHJX^QLQ4S7@$T^$G"HAMJ&IZ.F6
MX*?EMSD1E2&,/J8PUEYK"^VFH)&<9)9&45/4$4_/K)F,HRB-,HR!]%$'\N\Y
MTUKT>[AKD):I%8L0VCEY9DC9*GKVKE#!75<<PG7U4IPMJY3;"-5<K$,D$ZE'
M.3V!+]<7 C$9 R)F;+8=-$>L]6,V.X9 $93D!.MTI.T';%"5%[N2WC@YQTY1
M)4D6[C&*[2HD3=9:-6]=US0YAKVAM^R*.FI2S6N)[MOM! _O0G)LER8,[D8?
M!#!+(LJ?@U6,]6P4Q$-(DG7*L+$0X]/$!:D#F# SI:)+KVND2W!,VQK3*C6G
MRMANY1;&3+E5%#,]G.JN+N5U%7=/BJ4"CRH"@ HO,AK_ $59%8V+8MKABPJ'
M:+O<R;5Y$8?/.UD_INQUBK B= 8B*DI0")5LO746NGF0D."EJ:HD,FM(C6HW
M+;QUB4"".V,3:T;HZD622L[$=LAOR3W3--)),Q!E+Q%M,&(,:\D2XU\?Q.=<
M@@8VM!QX$,R[&%"HR(<",],FSUQXK><]U'Q*(R)<Q;3"<X:80[(6EAA#<=G"
M&&FVT<%9*O:V\!S\BC.H  <!UEVYF;CC&<(=(CH%]&3I$[#5L3:U,/G+8X$&
M!5SQ^QMB5R-D>,5)\$TD57K0,%-*;P^YVW68;;CZE=X^IQS*EY]FA_$:NE!C
M"01W+3&+RA?*+_7/+K:&GJ3W2&Z"R4CJ_(:_IFBO]DMT&O\ II;/\8]O_;?G
M;_6:_P"*/_KA]N<?]+H^DOKE^^/]DMT&O^FEL_QCV_\ ;?C_ %FO^*/_ *X?
M;C_2Z/I+ZY?OFNMK_P C5T1[M1#==HD&W:RMLQMA8.Z>>U\O3(>7'D-/=J95
M;5;WA1>'):0Y%DQ\NP):6WLNPR,-]"'.5#^.UHR&6V8=QVQC?RD1L?U^(Y,_
MX32E%#=%\G<RK\EI_I\\Z6Z"O0U!]"34)'6HVY3[\5L5KFW*RV66+0!BR"<H
M:+#LQ1()LB6P-@1!XB(G_?DY\N7+7*DNR&V5QH4/E_$:[_$3WL2(&V)=\"MK
M1:WZ<=?%Z:&B:,6.YDK:U7-!P>G'FN=I\X9VQQC(LC[M!_\ *7_!3.,Q[C\_
M\.2N,W'&,<8QQC'&,HS]T3^8Y^\WQC*^,8XQCC&1)OL?^WB?Q;'&3/W7\O[F
M2^,K'&,<8QQC(L+V*S^;G]Y7&,E<8QQC'&,RP/["3^D<_P \<XS]Y_+^QG6'
M3\_\&73DY>.,9J,[N(*$N,^G-5F\6!T$.$D;8<K %HT'J*+ R9? QS##!!-B
MER2;8.8O*:X .LAV7ATNQ/!H1*%)>Z1TUB2W1+4B2:955UQ7%G:+S5TY#J!)
MC4F@9(6%W5\WY>0T<M&::'=-36AF#-=!5B]V L/GFH4VN5U6O+ 0C,5^H0;T
M4(O%@VPYU.;CQJY-R^N"JT8.MD8L@"\':.KA#9=_Z>9W*,1JF6\+DL0IAN[.
M]M5R-<Y!K1; DI?!M7@W/)).O);\JNL@V_I@A8+PZ74:V9*4R2W>$O;&)#D(
MJLJ=3*8NT3AH2-'+-V*7-A2E-#""28</"??CEF \\B^((IC;'0>24@D;?"/B
MIEMMLJGLI?*PLS):W%Q+*EXGJXET WQT\!Z+EV(=+,)#LRT(IEJS06J;?K%&
MN,INOCX]HF4S9NO]8X767R-FACH5=P7MQ!XL>O4FG01XR# L:WTU>>V8<PT%
MC[T=^Z$=O*A.$Y\T*M1*(DK6O>XS?;%^Z[=LI;N.=LHQXYX%D\R8@%]<YC4?
MIU:V<>($9 (Q%IJ:]2Y0*ROV#7D=H[<[3L7;>N)U(;E2[I%J\58@EJ"RSF[:
M[:5TDF-'%I[-A:@-UZ79J?X:919NN5E2XC&&G/=[NYLU(FW;N%.%W$</XB*O
M"1H16/*RG%CW13!Y94_*EZIUW?ZWM*E@;[492IE?L,9Y^$ZON<NMNPYDD:1A
MO*BORH;CX\G#F0'WH,N:/>>C+=@39D-;$IWA.+"3&12=_P!QYIY*>0?AG6,B
M<21T_P"&O[YFO)RL<8QQC'&,<8QQC'&,U[?]?QKTNG2E$9 DC2K:BSBYL;O^
MWEN;7K#2K(/RN),'RV%EJ9;[(.@$(LUI\(9D"[ TW+=$-PI%1DQW%62C2?))
M#YG$HBB<EG%WDRB2V\TQ;'YC%].XJ#Y-/-5F,D^CSITL(K &73(S8JFTB5KF
MM1QY(T(<$T^4NIR$C(TP22A3DOCY]%IY8(7S)R: &ZZ+-A2$ K&3,Y1JZ@KN
M;E+>V#<O%SR5R3D)TBB)F.G! VT!M*LXXXLIX8Q1[$$<]:YH76U9-#[-%'G2
MEI&GUV9FTVBXVZV6-XKFIF:.QB88L1LE,EC(%8L!H<,!ON+"#72<XI"'L%YD
MF>\=6:,>"*;:C&,2MQ+H#E05[>EK!IQ&^65W;)DO#'E5X!:.O/N\DA-/URO7
M,7:16518(*)M!X2"QXJ0AJS;HOS>Q-DV660GSICK[Y0W&9P&@QF(,8!&GV")
M'5(@$H$(/CJ+%B]NRW_CIQV0C0'1V\W0O):(!*S@\37/O3ENE*U\WHZ.:^&V
MN1EXXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQF*F?9F/T*/WE\ZPZ?G_@SE/L^7^7+3R\C'&,<8QQC'
M&,<8R+(^[0?_ "E_P4SC,>X_/_#DKC-QQC'&,<8QQC*,_=$_F.?O-\8ROC&.
M,8XQD2;['_MXG\6QQDS]U_+^YDOC*QQC'&,<8R+"]BL_FY_>5QC)7&,<8QQC
M,L#^PD_I'/\ /'.,_>?R_L9UAT_/_!ETY.7CC&:<O&A-8;&*E2UM#$YZ[ $C
M5ZRC8MKM@8!:!<!HPR+;LE?"FAX8U(%(/E<C9T^$]-BN/QG4/Y=%!UC^D=6<
M"HH4J-"QNKI12Z+.OU;B6G&3:/)26@U86':7W\O0RV NC=J8!,EDHP@]/*3X
M4P?-)'KO=+!-D1)]78IDAG+QD_-[EO-9BQ13+<9+#<5N.V_&0S+[3ZM=::!8
M B!&)R.[R+>5>;_3,-. WRO5LI/E7F^G''S[YRUN=%/2+JE(76S7D_P)*"T"
M3>KTW6XN#5>C58W-AUUNQI#1"ID+#CL$BK$)$^3+\46S(27)EITY[;4_$7QS
MMA;3N+=MH/1^70!GL8<\--\;FN0BT7Q8'Y\^;B?T5M,$9SQ&0&LB9/BY4\4E
MC8-]CPZM+FWL%LZ2]3AK5D2.JO>WNMB+ IL'$A,]N-@7W?D//DS#V^I57&N+
M\$+:BP\3MN7A4;N^^^<.C!;1]3Q2H\1/@NCQ \===<95'Z*^F87=+@![1 F,
M86XP6B[&V&DVT05?+=LILY@TY9W"CM@8MU_O,M!R1*>).#+A9*W)DR*V7F"7
M7MM1[1^#&-5MC"JJJ8PB)ZQ'LO'L8'0E=)*5CNE*[N[N4O/I1X:S=M<KPVJ
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M8?\ I.,8\.C\-_XP_P#2<8QX='X;_P 8?^DXQCPZ/PW_ (P_])QC'AT?AO\
MQA_Z3C&/#H_#?^,/_2<8QX='X;_QA_Z3C&/#H_#?^,/_ $G&,>'1^&_\8?\
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MAZ0I#,6&S'C-MI3GNLO*==<\\I,VVKH."N HSO&)$HOM>?5;S+N3E9B&PAY
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M ./]<C0_'>%9ZL1.KLY]?+W7_P 6?^W'RQX_^/\ 7)/J[[T3^][_ $XQX_\
MC_7'J[[T3^][_3C'C_X_UQZN^]$_O>_TXQX_^/\ 7,T!][X!/>]WV^]<^Y]K
ML]77CJ_XNK/7]_G&?O/Y?VSMIWMYJ[>NO++OR<Z9YJ[[KSV.Z[/]7:[77ZWI
MZ^KT>OU__'&,I]4?D?V^,8]4?D?V^,8]4?D?V^,8]4?D?V^,8]4?D?V^,8]4
M?D?V^,8]4?D?V^,8]4?D?V^,8]4?D?V^,8]4?D?V^,8]4?D?V^,8]4?D?V^,
M9]QW_7CK[GJZ_3U=OKZOZ^K_ +\8S3>Z]SP-,P:+(E@W#LJ_WG-#$,9L-8JL
M&*011[O?79I0Y;B@@/#AX%40G%9PJ5F1))RQ\5AE>7E*1TT]-U&5-;8[GB2U
MNC'@B*MR/+JW(G,AMLO?+:<@7ME+E4 J+^=9B;W2%)/JFL5G4EMNDRM5<!:K
MPQ6;%0I;(-JS1)10-7@1"19HT"[6R<#C-GHXX'(\E+&$@RLG42RT*([7LCC=
MJ1@2DQCN)%IPJ5<8CPJ7WQPU/M'DC!D@,J8\#:!SXI(6!QR<\Y99O2J%1[9L
M^NQJ7.EP]4>6?.(BNX40>7DI":V%;,ENBJ00/Q[E*8R+,PQZ7U"&FT3TRU.Y
M;BQ'GTC1=L),@WU7ADG,F!<B.WLOOK#J@S*]R[YB+42345OI],]:9TL*?8G3
M+)X),J^0^OH6RLR(EBJ%ZBR04\BR(B#,IHYLV1A6R<3E1((2M3AL>=9Y<A4.
ML9,3H).+"2T)%4DKGLZE'FKOQ1!C5JBD0N5"6-6+=E!'==QD5Z>%:?0>_*Z:
MWEK.]0MGZ[HVQQHXB''WNI@+="$F,1,%AD6P"XQ1B 3Q DS8.)\1N4EB7B',
ME1</H<[B2\UV7%<YQV2E%18R8J=.U2R^:X\\N,MT8RI-T25/99=/Q//,XY.5
MCC&81<KR/I<NCQ)\.9+7>[O!HPY43N.S#(3PIXVW,F]\ZWGP:(X"2TON,.O]
M\\QV6LH[Q:*C%ENJO#%DWZ"'Z\Y+(BQO^:6T^=+_ (RSS=P4,.>M]?L%@% I
M=-#%+(460(Q4I17  *OV"R&GD-K6N#$ P+,(=G8FX9?S'E(FL-.Q.T\G33DD
M4%W(%#VJ!\;1JO/CO#.(HH4*WZ *_E?/PYRT$.D-I<5FP8([ #0L5AS+!9<A
ML@VUB0U9A5*F11KN87='98JYG U1.1 2R4D#:"H^OFFH!:6S#7II:C507=R=
M=,60I=EQ&1=6"EADNKIE^,XX?GN(T>OB2+5TH>>7RS;?UQ34@%V>T1@^++"2
M4%^*A%,J0)R^-BK,ET,P75UT)'EF14.:9L*18N#,(1(DR6Q(>0UG(Z<Y7MC>
MWAI.^6CGEH4"UKC*9Q*MK=UWUZO'!R<M M984](?2RG+ RC8 A;M9D/PR;3;
M));CTZ+:VZ'*'!$(@J59R<6\/QJ;*&UK!>='M4V!7GHZ"T^'$?WV6IQX7GKK
M\.^WGPFT97*O"+T9GM=/GQ'''YWMH]7=X:+YX[Q7=]:^/:[8V>X0D#*O.M]M
MI@A;T*9/)&R=5O=DH:<!@P>.0+DW#<RM3"HL?"@O$\"G,/S(<94:8B.=*9/9
M5R(QD\T!*!/E:"B0*M7P+Q8U(L=UT,I1/.V,F/%7W2GPRWV/I*:> "RA!FX#
M3LF#3IMSACP[BI'EF)'I4S8<$0/++0V"38S5-A.V417Y1..8F5__ /KS<+(=
M*YJ1I:BGA0W;5?+Q;53NB7"U5\7?&8ZL 7<-"@/?#*AZM"PNZYZRRGNE+K&M
M@6BQ.:M1&4>4"B5P>XP4**7B]0]?)FD'H"GQP*([8)K<)E9V8.\210Z$B9D&
MD9@<HT)R:.JMEY>[OHNE0.:NCEHYS'5B1OXI7GQ+;\:YZNK>"\Z2YQSKCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9BIGV9C]"C]Y?.L.GY_
MX,Y3[/E_ERT\O(QQC'&,<8QQC'&,BR/NT'_RE_P4SC,>X_/_  Y*XS<<8QQC
M'&,<8RC/W1/YCG[S?&,KXQCC&.,9$F^Q_P"WB?Q;'&3/W7\O[F2^,K'&,<8Q
MQC(L+V*S^;G]Y7&,E<8QQC'&,RP/["3^D<_SQSC/WG\O[&=8=/S_ ,&73DY>
M.,9S=L#I.T?6]]NVO+ ,/I,5#23^[HLQIB(D/:!T-.P)$ZG!"#TMM";LP,UV
M9.,")R8N"(1N<2'O2(P ^L=UAHRG&,Q*EJ>S2^8KMJ2?A68673P]E\I:L8R8
M(V:?M+KA/%X;\I5%::LM+IK+9O2"TV+D&(AB_ A$BO#Y1$YDB\]&A#VQT8=,
M,1<EEL8$2R8&*7&2#XJ!.E$@D:=%DE(D1A]MQ6>RU&JBMM'QNZ:[!II0'RRO
M:0+N04*WZ%+\&KY"Z\\M,?I*Z>*.)B5^WP#!7RD.&N"%IE@YK+\F]UC7A2.\
MFP11B&RM;L%OK[!VOK4D\/69!LR!S3I\-B;OL=0[C12WP_R2F>ZOO$6GIIYX
M:SVL.A%].OYB+W73(OTLOLN;"Z1VDR<.?.&7\829@9"8RT.A&9T\EFQR2<()
MYNBXHUTE:<$)P4W 9S6HA;&)X,W!=RW+$$F8V>RU./ \WW0&T%M6HT(\UV>I
MCVNGS4AJNK>[J@.>1.+Y$RTP^E#IB<1+P8]F?=9&0*//B%(X8O/@6;^<$2<.
M@8-10-AS"-D*-!:\5*%APT>]*%084Z3+;0T*,*'ZZ.H IVR$4&.U!971$5 5
MY>NRQJZ:H2ZKR>=PI7FM"H'%/HUE=FW10ZM%H1F>9@.U*_L&"(VZ,$1ZJO#
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M0E,O"D.L.QWHT9;-FLQXC$#8Q"UJY;B5W[T7F+Y?+C(=(E2R;W$K*+HIB_\
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MR2:T[1A$S(Z?XV6Z.$>8H]Z!'C2"I-V5WTH1U(UU*,R4WG_H]37R-B'E;O\
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MG\6QQDS]U_+^YDOC*QQC'&,<8R+"]BL_FY_>5QC)7&,<8QQC,L#^PD_I'/\
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MNT1H,O T1>M/OE:^LG;M8W&C1[8W$*2)T9=KF;%DCQY>:3ES3=C$TV/<XD.
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MJN.'UK@42B#K!KA^H:<KQ8#<[ 6:N5B!-6O6SF45%@%FWV)<@58"PP=2G^=
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MJTI(R%1&'A^)I]J,PTD_P_% B2W5OL2/AVM1.9!_+1?-'. U^54K;M+A7O\
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9.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g189651g34k57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g34k57.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "( [P,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H P/'+%/A]XD920PTRY(([?NFH ;X$8M\/_#K
M,22=/@)).2?D% #?'NO_ /",^!]6U16Q-'"5A_ZZ-\J_J10!P'P=^W^&->U7
MP;J\SO.T$.HP%R3]Y ) ,^A('X&@"]\8?!NDS>&M9\4-]I75((%V,L[*HP0!
M\H..AH W?AYX*T?P_I=GJUB+C[7>V47G&6=G!R QP"<#F@#E/ OC#0]!\0^-
MH-:UFWM)'UF4QI/)@E<D<>U %_P;K-GK?QH\4W>FWR7=DUC;['C?<F0 #C\:
M +GQ=GN;^PT?PC83&*\UV\6,LIY2)/F=OP^7]: +/P?UB?4/ T=A>L?M^D3/
M8SACR"A^7]"!^% '%_'6ZU)M?T6/2Y62;3+674F"DCA67G\-IH U_BCK\NO^
M!-"T_1I"MQXB*RKM/(B5/,;IZ';^M '4?"G4?M_PMT*YDDR4MS&[,>FQBO)_
M"@!WA7QRGB&[F1Q:I"0#$T4I)4EF"QOD ;R%W#'4'TP2 8=S(^A?M VA,C"U
MU[36CVD\>;'S_)1^= ''Z%KU[_PN\>())G.E:O?7.E1#=\O[M4"G\2!^M ':
M^#G?6?BMXSU@NQM[,QZ= ,\ J,O^H'YT <C\6[G5=:\5W*Z-.Z)X3LEOI=A.
M#*SJ<''H@S^!H ]5,&F>/_!5O]H#FQU&&.8B*0HPZ-C(Y&",4 >3^'OAQH&H
M_$SQ7H=P+PV.G) ;=1=N"N]<MDYYYH ZOXS2K8>'/#S"8PQ1:Q;AF+8 4!LY
M/I@4 1:!'<?$KQ@/%-UYB>&=+D:/2X"2!<R _-,P[C(X^@]#D M_%&1TU[P&
M$=E#:U&#@XR.* &?'-))? $4,4IB:6_@CW@XQDD4 <[H_B>\N_A%XL\-ZL[)
MKN@VDUO+D_,Z!2%;/?IC/L#WH ZZWNM4M?@3;76D[WU)-&C:(J-S;O+'(]2.
M30!S'PJT;P)JT>F:S:WLMSXI@0271GNG\[S",-E">5R3@X].: /5QJ:_\) =
M)\H[A;"X\S/&-VW&/PH RY?%6WPU%J\5F&:6Y%LL4DVP9,WE9+8.!GGI0!IZ
M)JJZSI,=\L7E;G=&3>' 9'*'##@C*G![C% %#QRI;X?>)%4$L=,N0 ._[IJ
M.&\%_%7PW:>'-!T65;\7D=O!;,/LC;0X4+U],]Z )OBI#J'B7Q!X;\(:7(L,
MDLK7\TLD>]$6,'9N'<$YX^E &%XAT[Q7X2\:^&_&&N:K!J<:3BQF:VM?**1/
MG.['4#)/UH [SXLHTGPMU]44LQ@& HR3\ZT ;WA<%?"6C @@BRAR#V^04 >>
M_#K0=-U'7O'$FIZ3:W+#690C7%NKD#)Z%ATH L^%=.M]-^-WBN&SLX[6U%C;
M[4BC")G S@ 8H S+^R\1>+OB[J-]H.H0Z>GA^!;2.:XM_-5G<$OM![]03[4
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70 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g189651g41x73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g41x73.jpg
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M:6ZA$B2'UM:^2\$;,VR]VF8H3$K,E81,2$J#8G"2"0QRJ!EN8W+M&-4L&6I
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M08K7+SV(J>5_A[>?Z^=:H H@G3[,:4?/CR+Q@.2 0&<[9A_:E,F HT=OWO\
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M)5F589%H"E6^];-89D\S9B@L*1+M84F6V$JE!S]:F^K_ *8V'LE?-X3;CO\
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M4W?/-M#0<=>,= "22::!BSMOKRR]8_DK'*R8%0'8=1JU6JC9)F\HOT\/X_\
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M!7>5UAL;RS/_ +6KZ/ <KVZQ"1$Q<-9+KPY/0,QH^09(1MW*%DM[!K&-BA6
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M'E>-:_[0NR0%;RM (9GN>_-]O\;MKL !E'!7^G_]5W)'9V[V+./^L.Q+'_\
MR/\ +N7$=>SK5Z;848;B[B2QM[4Y<3 MRF,Y^GSDPY&*G*K[+_UT/ZA]DCE>
M5H<__!K[ID !_P!V\V;@\/\ Z/\ ^JYH.SEWTT_ZP[%$ZUIVC%: ;;,(Z8O6
MITV3;0(W[BEX&SU4$F$;BN*JJO:URA;B3B]J)W<.1BM55\+RBIJ']0NR7_O&
MT!__ (-?8_\ ]=&A_I__ %7"7'9V[\V+]L.Q)\O_ %B%"P=XS:-UD].'IIZ>
M=6CDX3E6;;[IO3V^]N$JGT_Z?T:O_:%V3.5XVCBUS7Y[_P"-<@\?*@@/]/\
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MYT&VCUR^_6>Y@1F0X-=SZ5X9#0-&B[JZZENGK;K?2KVGW:9DM='EXZ*_EY-
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M3;;44:%'I9>9T<3&[N]DS@"DS?\ X#76EM$@BGR_2A!8Z6Z0ZN@.ERA1$LV
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M&)__  J"\]'PMKGPK#A8AP[%(KEB^D^0)-=H\174[C%U4=2&Y6/94$HK>+U
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M'+K?K^H#)C7W&M6)KQIPC;]9=;F+6<%D>HMDLY1P>H*-7(Z2<K%:CD>C1=_
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M<K<Z\W"Q.7D"6$))6-8UBYCVK8(1^A902@IEE@4R)TU:E)"L*UR\2'!22<"
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M8=31X_CF.P+7(<AN[*2]!PJFDK)]@=&E(R.H@F(/"$*F'"D.6)-0  *DDD@
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M_P#/!DI\;LS,_%V9OJ?#6(8KNL?9ZMQ;&)^8Y62=?6NV-)NS;IMUMOO#EM)
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MDWVGX&,[W8;.;=EBX_3 )QW&DG*X[>Y>5D2"/2*AU9X<T04CQ@N_Y0&(KNY
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M2&(.-!"\?*!^(41'D?SWC"U$9VN(U[+#KCUG%^=L>AW#(M#%^'HH944+.\R
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M6;<"VWW7@97(VQQUV[6Y<B9B6<;N_:ER"LD6V>P)./9EEN.[;JY]%C63Y_\
M:EC#M3-LK&GK'Y)9FQVGJ"NBOBZQ&@!H&T#T;V(IZF J3H3JY&P:H9ZMDU&
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M>GT\2-5V3CINECU)-R2[HVL6,BDB5E#6V5K+N6=U4.' F$26OH/1,JDS$L2
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M+P(P@L#BQ8B^N()8#)LR]./L]T@S-LMU<*W"GYC%NJ[']JH4&]H@UYX_V[U
M2Q2:C+MY6F(5[0NOL7L;:D;7O0D@3+$[R27IPW29: N6I 203,+%\I((*99#
MYA0!)X""))2M*RIV0 0V<TN%3.#@D <36,]W/V<W+L<]S'.]J<DPJKE[G;34
M^T>9Q<YJKFQ%4QL7L\XLL6R_&TIY8/C9\!=QLHC6F-6*P8%PU*>0RYK7P90K
M',N:@(2B8%G!,,Q!00')"0I)<9?0""*BM(TN6HJ4I!2,: A6($LV(I4&(_\
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M%/83K>2HG2Y\Z5-D&._*[0%%\*J3DS*D$X4I2D EA5D[ 1I,D@$.ES*,LL&
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M/WPF@$%F$KNR#Q8D^0BY&O&CR(:0C]-:JJGC[E^OGS]-(1'.Z0G/B8YPB_\
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MY1XQO:0,9$1K7(QYE[N\2LL6+/\ 2+MW>6EON1MZ"PIX\G ST5A1RKZ/-L9
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M[&O=7MD\-1&*IW=B<-5-3;^O3[&-&H(WC<)17$.TKHT@1A+R$?<G>WQPQO\
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M;.@+96<MHSSI\U5DRY9W-9R21)+W/(_PG"*O"-1&-1K41$!SEZ]<ZZ9U$0D
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M1K[I_P"7_MI"/YZ OY.D(>@+^3I"'H"_DZ0AZ OY.D(>@+^3I"'H"_DZ0AZ
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M/N<B%?M3[[9;G.-EN$];.*3:2.8-_$>-0M5'-D,=X5$Y\H]43Z+PJI]WW:5
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MB6UZ6ZU6^M8(:P(-%>U\V4>5V<(OEJ&>Y&JG\$14U6?_ )"NC'__ )/+6(_
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MU?34-?$KH8T5KDX%%@B%'",:*CB/[$:QO+WN1$YU:;N3M1AQ=LZC;.(7)K0
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MCD^2T.,4KQ<Q^6A1'M7A/",Y7RO'"IYX7PG*<<>_%<"IX "NN3\/4FIWC#.
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$:0C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g189651g43p71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g43p71.jpg
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M 0$! 0$! 0$! 0$! ?_  !$( /4"7@,!$0 "$0$#$0'_Q  >   !! (# 0
M            !08'" 0) 0(#"O_$ %L0  $$ 0(# @<)#00) @,'!0$" P0%
M!@<1 !(A$S$(%!47(D%1%E)A<8&1DM'5"2,R4U165Y67H=+4\$*3EK$D,S=V
MH[7!T^%#8B4T@B<U8V5SQ/%&9W5WM/_$ !L! 0$!  ,! 0             !
M @,$!0<&_\0 0A$  0($ P8$!0,#! $# P4  0(1  ,A,01!404287&1\!.!
MH=$&(E*QP9+A\10R0@<C8M(5%C-R)"6"-$-38Z+_V@ , P$  A$#$0 _ /OX
M[N_A",=<EM'3?F^$;;?/OMPA'AY08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1P
MA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1P
MA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1P
MA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1P
MA!Y08]\C^]1PA!Y08]\C^]1PA!Y08]\C^]1PA'=,UI?=L>O7E4E6WS'A"/4R
M6@-PKF]H'>/CW[N$(\#/9!()2"/47$ _*-^G"$<>4&/?(_O4<(1V\>;]@^FG
MA"#QUOV#Z:>$(/'6_8/IIX0@\=;]@^FGA"#QUOV#Z:>$(/'6_8/IIX0@\=;]
M@^FGA"#QUOV#Z:>$(/'6_8/IIX0@\=;]@^FGA"#QUOV#Z:>$(/'6_8/IIX0@
M\=;]@^FGA"#QUOV#Z:>$(/'6_8/IIX0@\=;]@^FGA"#QUOV#Z:>$(/'6_8/I
MIX0@\=;]@^FGA"!,YI1V!!/L2M*C\V_"$>WC#6V_-U][MZ7?MW?UTX0CQ5.:
M2=B0#[%+2D_O/"$=?*#'OD?WJ.$(["<T1N.4CVA:2.$(/'6_8/IIX0@\=;]@
M^FGA".#/9'0E(/L+B1PA''E!CWR/[U'"$'E!CWR/[U'"$'E!CWR/[U'"$'E!
MCWR/[U'"$'E!CWR/[U'"$'E!CWR/[U'"$'E!CWR/[U'"$'E!CWR/[U'"$'E!
MCWR/[U'"$'E!CWR/[U'"$'E!CWR/[U'"$'E!CWR/[U'"$'E!CWR/[U'"$'E!
MCWR/[U'"$'E!CWR/[U'"$<BP8)VYD?(X@GYM^$(R$/MKZ;\IZ;!6PWW]A[C_
M %MOPA'MPA!PA!_7]?UZN)5[TJ[^3-3MX#CW_,'%A!PA"=/E!AM1W/H@\P[N
M8D;A._Q=3_\ QPA$.Y+F[-;S)<<W4DG9(4$I!&_<.@.V^Q5O[?;U1*D\,@W[
MN_D+YQ%4K5QE"U!+J!U/>4'Y.F_R>O;U>OA% /-^S;/7K&#YXD?CF_I(_AX1
MK<5IZCW@\\2/QS?TD?P\(;BM/4>\'GB1^.;^DC^'A#<5IZCW@\\2/QS?TD?P
M\(;BM/4>\'GB1^.;^DC^'A#<5IZCW@\\2/QS?TD?P\(;BM/4>\'GB1^.;^DC
M^'A#<5IZCW@\\2/QS?TD?P\(;BM/4>\'GB1^.;^DC^'A#<5IZCW@\\2/QS?T
MD?P\(;BM/4>\'GB1^.;^DC^'A#<5IZCW@\\2/QS?TD?P\(;BM/4>\'GB1^.;
M^DC^'A#<5IZCW@\\2/QS?TD?P\(;BM/4>\'GB1^.;^DC^'A#<5IZCW@\\2/Q
MS?TD?P\(;BM/4>\'GB1^.;^DC^'A#<5IZCW@\\2/QS?TD?P\(;BM/4>\'GB1
M^.;^DC^'A#<5IZCWCNC6%LJ +S?TDGKZNY/"!2K0^3&'#6ZL1GE#F>2#OU/.
M =@!OML H]X WWW))'MX1ECGH.'GP=[ALH<;NID9#&Y>Z$'9/:'T=DG\)6WI
M GH02=N_UC=$8Z_SQ8"F=QI:&A.U:8;60AY ZGKS [;>T@ G;X3U&W<>$4 \
MR?;*$@ZQI!(\9;_?_">$-PZ*/FJ,I.L+&PWDM]P_M#V?_I\(SN_\E=8Y\\+'
MY0W](?\ ;X0W?^2NL'GA8_*&_I#_ +?"&[_R5U@\\+'Y0W](?]OA#=_Y*ZP>
M>%C\H;^D/^WPAN_\E=8//"Q^4-_2'_;X0W?^2NL'GA8_*&_I#_M\(;O_ "5U
M@\\+'Y0W](?]OA#=_P"2NL'GA8_*&_I#_M\(;O\ R5U@\\+'Y0W](?\ ;X0W
M?^2NL'GA8_*&_I#_ +?"&[_R5U@\\+'Y0W](?]OA#=_Y*ZP>>%C\H;^D/^WP
MAN_\E=8//"Q^4-_2'_;X0W?^2NL'GA8_*&_I#_M\(;O_ "5U@\\+'Y0W](?]
MOA#=_P"2NL'GA8_*&_I#_M\(;O\ R5U@\\+'Y0W](?\ ;X0W?^2NL<C6!C<?
MZ0V>O=S#_MC_ #'QCA%":W4>#QFP-6X[JPE3R#U !Y@-]S[>7NV[^I&VWR(K
M:<NO"'>C4N.6@L/DI]G:'=6Y'IA6WH@=X!VZ;;<(GG^._OQAJV&K$=D^BZD'
MN_#![R=C^"2.X]-QL=^$5CUMRKZO]K0A+UB2D["2WM\OU'_/A#=)JRO+>_$>
M[>L+)0"J0WOUW](>T_\ X9X1DIXJ'!_>._GA8_*&_I#_ +?"&[_R5U@\\+'Y
M0W](?]OA#=_Y*ZQC.:QH"R$R6]NGKW]7P('"*$G_ )'BY_$=//(G\I;_ '_P
M\(NX=%=5>\'GD3^4M_O_ (>$-PZ*ZJ]X//(G\I;_ '_P\(;AT5U5[P>>1/Y2
MW^_^'A#<.BNJO>#SR)_*6_W_ ,/"&X=%=5>\'GD3^4M_O_AX0W#HKJKW@\\B
M?REO]_\ #PAN'1757O!YY$_E+?[_ .'A#<.BNJO>#SR)_*6_W_P\(;AT5U5[
MP>>1/Y2W^_\ AX0W#HKJKW@\\B?REO\ ?_#PAN'1757O!YY$_E+?[_X>$-PZ
M*ZJ]X//(G\I;_?\ P\(;AT5U5[P>>1/Y2W^_^'A#<.BNJO>#SR)_*6_W_P /
M"&X=%=5>\*$75YE:TA3Z#N1_:V&_RI.WRD>KA!FH7IU[^\2QB.:HN'>1+@(]
M'9/-N#OU/?ZSOT(&V_7?H>$.^^?YB8XKP<2.O>.F_J/3=/7V>KX.'G]O:$9?
M"$<==_ZZ?T=OBZ^KN0CG]W %X0<(0R\G?4U'>4.](<()/K"2!OM[-A[.$#3N
M_*-8'A9Y?:5>ENJ$ZLLIU;8Q<,R=^#/@2Y$*="E-54M;$F',C+:D1I+#J4NL
MOL.H=:<2'&U)4D'BBXYC[Q2/D4=!QM44\_MDU?G,D:W:OK4>TU<U14=]SOJ'
MF)]G_P"=?%UZ$^OCFW1H.@C@"EY$YYGS^T8WGJU:_2UJ?^T+,/MKANC0=!%\
M1?U&#SU:M?I:U/\ VA9A]M<&&@Z"'B+^HP>>K5K]+6I_[0LP^VN##0=!#Q%_
M48//5JU^EK4_]H68?;7!AH.@AXB_J,'GJU:_2UJ?^T+,/MK@PT'00\1?U&#S
MU:M?I:U/_:%F'VUP8:#H(>(OZC!YZM6OTM:G_M"S#[:X,-!T$/$7]1@\]6K7
MZ6M3_P!H68?;7!AH.@AXB_J,'GJU:_2UJ?\ M"S#[:X,-!T$/$7]1@\]6K7Z
M6M3_ -H68?;7!AH.@AXB_J,'GJU:_2UJ?^T+,/MK@PT'00\1?U&#SU:M?I:U
M/_:%F'VUP8:#H(>(OZC!YZM6OTM:G_M"S#[:X,-!T$/$7]1@\]6K7Z6M3_VA
M9A]M<&&@Z"'B+^HP>>K5K]+6I_[0LP^VN##0=!#Q%_48//5JU^EK4_\ :%F'
MVUP8:#H(>(OZC!YZM6OTM:G_ +0LP^VN##0=!#Q%_48//5JU^EK4_P#:%F'V
MUP8:#H(>(OZC'4:VZL$[#5S4TGV#4/+R?F\M[\&3H.@AOS/J5'<:UZM@]-6M
M3]__ /868?;7!AH.@AOK/^2O+]H?FGGA):I8GFF*Y!:ZEZ@7%)57M;(O*JWS
M3);6NFT8DH;N&)%?/LY$60KR:Y)7&#C"^RDH8>0 XVDB%(8L [489]T@%JW@
M2HFUR?<=?.-\#N?.N5WC#<CF062M*D.%2%)*=TJ21S<R>4@IV/7U=.IX?SS[
M$=EM006KH*N+= +T:EXT 9#K?J\;NY:&K.J"&D6MBAMI&H.7H:;;1+>2AM#:
M;@(0VA.R$H2E*0E(2D #;CGW4Z#I^T=7>54;RB*YFOKG"#YZM6OTM:G_ +0L
MP^VN&Z-!T$7?F"ZB([^>[5W]+FJ'[0LP^VN##0=!$WU_4K]1]X//=J[^ES5#
M]H68?;7!AH.@AOK^I7ZC[P>>[5W]+FJ'[0LP^VN##0=!#?7]2OU'W@\]VKOZ
M7-4/VA9A]M<&&@Z"&^OZE?J/O!Y[M7?TN:H?M"S#[:X,-!T$-]?U*_4?>#SW
M:N_I<U0_:%F'VUP8:#H(;Z_J5^H^\'GNU=_2YJA^T+,/MK@PT'00WU_4K]1]
MX//=J[^ES5#]H68?;7!AH.@AOK^I7ZC[P>>[5W]+FJ'[0LP^VN##0=!#?7]2
MOU'W@\]VKOZ7-4/VA9A]M<&&@Z"&^OZE?J/O!Y[M7?TN:H?M"S#[:X,-!T$-
M]?U*_4?>#SW:N_I<U0_:%F'VUP8:#H(;Z_J5^H^\'GNU=_2YJA^T+,/MK@PT
M'00WU_4K]1]X//=J[^ES5#]H68?;7!AH.@AOK^I7ZC[P>>[5W]+FJ'[0LP^V
MN##0=!#?7]2OU'W@\]VKOZ7-4/VA9A]M<&&@Z"&^OZE?J/O!Y[M7?TN:H?M"
MS#[:X,-!T$-]?U*_4?>.IUQU;!V.KVIP/L.HF7@_-Y;WX,-!T$-]?U*_4?>.
MWGNU=_2YJA^T+,/MKANC0=!#?7]2OU'WC-AZ[:S17&WHVKNIH=96AUH/9]EC
M[!<00IOM8SUPME]KF2.T9=0MMU',A:5(406ZG05T%1Z=(;Z_J534G*-]6 :O
MC-<'QK*HCG(B^I*VT5';<7M&>EQFWI,-1))#D227HKH(44N,K23N">."T=D"
M@(!+U#6U:MO,%VIPT]>$;K3J?$UHU A5&I>H535,6T=,.KJ<VR>MK8C2JN L
MMQ(,*S8B1VU.*6XI++*$J<<6L@K6HGF2 4AP.;<3G?O@(X%J4%J8D5(H3W?U
MK$%'6K5O<[ZM:G[^O_[0LP^VN+NC0=!$WY@;YE<'[K'8:VZN@;#5S5  ?_W"
MS#[:X,-!T$3?7]2NICGSW:N_I<U0_:%F'VUP8:#H(;Z_J5^H^\'GNU=_2YJA
M^T+,/MK@PT'00WU_4K]1]XZG6O5LG<ZMZGD_#J%F'VUP8:#H(OB+^H]8X\]6
MK7Z6M3_VA9A]M<&&@Z"'B+^HP>>K5K]+6I_[0LP^VN##0=!#Q%_48//5JU^E
MK4_]H68?;7!AH.@AXB_J,'GJU:_2UJ?^T+,/MK@PT'00\1?U&#SU:M?I:U/_
M &A9A]M<&&@Z"'B+^HP>>K5K]+6I_P"T+,/MK@PT'00\1?U&#SU:M?I:U/\
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M,.PY-M51[-J"]90FWP(/9;R-CY08]D9Q*6G_ (&F>RM5--,5U)BU\;%;W5S
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M#=O]HB[M/@_?_P".$(.T^#]__CA"#M/@_?\ ^.$(.T^#]_\ XX0@[3X/W_\
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M8^"IYH:-:ZUP2E9</!XP_39,>1&+I5'KDY/2S6Q-*BV(:6I@1RN!(-3S?_\
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M'1(]):@/8E.ZB-^_H-MQW<(=\M?.T82Y\1XE*N= /3F6VH)WW]HW '=U.PV
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M17R8LP()+2VW67.527$E!0I)!W"D+22-B-BDE)'?Q"4@$9YZ @FHTH^O.\4
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M-%:7$::[VKK<9':)2IH\BE=#UYD[*2E/7U[^O<#8<8()KD3=J&N79:.06 S
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M59&:67.7QBOE.OPGTI 4DD28T:5%<7UYHZTO)3MZ#[H.XI42SU'K76G"I)>
M %HZ.8->5%B]E,:*[/I+!Q4V;%AH6X[52UGF??4PVDN.PWU;OEU )CN+=[1"
M6>10$, 6>[-?3O72 ()(TCOE6J6.X)BEQEMY9MP:&KA%^8M1+BY*G%(CQH4-
M@;KF3["4XS!@0V$J?ERWV8S*5..)!W+0N8M*)8)6L@) N2;>_".'$XB1A)$W
M$XE:)4B0A4R9,60 E*0Y-;DV %26 !)$:H]!K3PD=.[+*;_0C$(=CB&272GY
MU/=5\&VBUEE7S+%<6!"EG+<4=E3*RGFUU'>2Z]F9 5858@,/>,5[Z1[F,1A'
MDR\5/4G$29*4K5+3OI< $!5"01]+&YCY?\/8C;\N5M'%[$V5+G[)Q^T<1B,*
MC%SA)FA!.Z52P5('AJ9@IR'#!V)B:\ZUVULU<R[!]&M;(5-I@BQM:Z7%9KZB
MPKJ^;)D)M%5EW;(L+Z]9M1!>I9D3&ZQJ2JN7E,F!-LPHPX 1B1+PV%E3L9)6
M<2J6 E#IW1*4K_)0.@M;, N\<VTL5MO;N-V?\/;3PZ=B2<8J9-Q&Y.\5>,DR
M!O&5+4AT@*(+I*F)8FB65<.%=8734%7IQB<BLA1JN-V#%6J<TJ>ZIU:W)5A,
M+SOC,V982G'9DR<]SNSI;SKZUK*RH>),F+FJ4M94I:BY4:&M;Y:,U+4#1])P
MN%D8/#RL-AI:94B2A,N6A(8)2FW,FI)-5*)47))+-S*(I.*VM46PE2&7"@J.
MQ4E04$J;[CS@]Q"@01OOW<8S#OJVE&8G2E+!P;TCL=]]UBQ.&/-V..50KYA\
ME/5<)<)"2%)1%,9OQ9*3OS>@UR)V5U!'>"!QH6^[6<=F#"[5UA"O[!^*\F'+
ME%2>?_1UCHHJ!)2D@%1)!&_0@*]G?Q#WWH,X0OKU!K8T+'JR_?%6Q)M&XXE3
M28\!Y],9YR.PN6X$QVB\4*4TEYQ!6XV$H!60.- NSBC\'(^^MZ](RS$D4<>N
MO8B0K6RB]LA':MIC0VFWW5@CE4HIYT)3L2#N"-NI!"@!UZ<51?D,OXI_)JS1
ME(+$W)L?N7O_ !QB",KK;"Q0O4!E"D5,2T8H@0DI#Z)!=6N8'%$!4>+,;C0&
MR.8*DS'D I4VL'-^[]]TC8#,!HW$M;^(F? ;,/1F05;E(3N-P.A2E)._7XC\
M1VWWX0<OP[XY:MF!$Y1%A3>WLZCXE;GX^AW[_BX18RN$(;^29318G6OVE[8Q
MX,=EM:T(<<0),I:02F/"C<W:RI#AV0VTRE2BH@GE2"H(1K[O,CR/4[-5T%=(
M7 M[R Y;75L/OSV+XJIY3%9352=^1JPE[D=JGE+96[. 6X\I:)?*QI8VSX9\
M818W%]%*2BQF/5PHC;4:,V$MH*2L[J)6XXZXK=3KKKBE.NNDE3CBE*423QK=
M!SJ:V-"U.HLU8QO9M\NK^5HCROBOZ9YG%9BJ**6YDF/)B _>(TI25+1(:;/H
M,I?Y%(>2@)2IU3;NP6IQ2I8L7H[Z7J''3EK%HI-,]=?Y[:+'2)X9YG4$*:>C
MH5N@C8;GIN!WD=YVW[N[C9(%A6M=V[G0Y7&=/,#B -A=[9T!SR][VCVF+KY%
M265AM7.T0=^4[\R/GZ;]=^X^P\:-7+AB" XJX_AQ7RBBA&H4.ECG7VB(D:C)
MQ=)J9!YG4*[.(0K8OIW(0$C8\RAT"D@DCO[CQQ;S!F=N <#.MAG=LVRCD*7+
MN0]"!G&+87EW/9;L/&U5[ZRHQ.SAIE%1V[BVJ2RXZWW<Q3V:COT*3LHB2:G2
MP',\/L#%  ##^8K_ )[AN':F2"-7]$M(-3'4(1&C9!D6!X[D-@F/NI*6WH^3
MTME-KT-A1*3#MIC04M1!:(!,"B*AP;>XIRY.U8,/S4D_?LQJ1\-[[CW766.6
M6O?@88<,=S:D2JTRS0^A?DKH<YKV$\[\O!:N8\XU097#9])F@JUQZ6Z993$A
M0(ED4.2NS*G+00HDJ2"'JYY\6?-^$<<Q"5 I;YB"W=APY5.NE'%M=%01)HK=
MF956]3)>JK>JLXSU=:U-G#<,>;76E=-;9F0+"(\A3$J'+:;D,/(4TZVE:2./
M9EST+ )4*A_L],KCMR?)FX904626!HUZCCR_:,VVU/A,<U@Q("UO$= O<DD@
M-A(3N5JYB$I2 5*40E()V!LR<E(=QS-CPKJ_2SDTS+D*<."'I;*Y-JUURID(
MM36^#'K[:8]C66ZF,SM&<6RZ.J1C\K)*&=(LY44AA7C<ZM5(KU4\=,60FQ>:
MFO>5&ZU"Y::MTH+9XI2OZ@+4B8'0A4PRPDJF$#@=U(=FH3E3*/*VMM56R)V%
MDJP$U:,5B96%3BYDY$G")F36:J?%G*W Y(,I"3NJ"5QO*\&OP0?!Q\$F8]:5
M=LG.M9+2([6O:C9I+K6[)N,^VEN="P>I04P,9KIW,L2W89FW<B*[XA9W<R+R
ML#Q9LU<PNIS=@+"G?$Y1^O0@(  %A4YD\]- >&D6QFQ51(4Z.M"")S#KR%E8
M[,J4DK6-]CS CJDCH=^AVZ\<0H?)F#D-D7:XM7GSW#ST4=2,*JX,"64-QW+"
M)-9!"N2<F?(7,WWYB.V><,A WV#3S92 GE'&H0Z<DD2*M*FGY95#7L"=P"V%
M=V_<.7O]6Z>@&X[H?/R[]N<(XC9[%HL7FMVJY$6NYHC3UF6W2PQ%>F1V77I#
MB$*++2&UGMWG.5EM',M:TCF/%2:'/0VTJV3BAU%;&(0Y!T]?X-8DURUKY-97
M-UTF)(B36!(;D1G6GHRHJ0 5H?:4MMU*]B$J0HC\+8].-$T R(&?-Z:O]N,8
M2*J)%03WE[%Q9HB3,*R9F*;694(4J'A<)5Q(?0DE#CC*5)5!1R@<SZZ]R;**
M$DJ0EEOF #K?-F-@->M7N>FK?S#BTUM0MEI'-ONE)2>G7KW;DGJ/8 !MPBF^
MHK_-_<UYQ9:N>YVT_P#O0%>SJ -_4-_9W#N)X0A3X0C%FSH5;&<F6$R-!B,C
MF=DS'VHS#8]JW7E(0GX-U#<]!UX0BAFKFJDC)LBA0\=2F>9EF<>PF+(YO$GI
M24!=ME$EDC=QB,T2I@K22(R(^R$^,/A<S\N\^>7G"))TVT/@T\.;+F+=L[:V
M<\<N+64@&5835(Y2XH*)#4=H?>XL9![-AH%"0"I95H -\QH3YMV1?*M<\E56
M2'/H._O#8RS&'< N6<FI^:.MAQ'E!EH<C<N*%@.%U (0IYA&ZV7#NM.Q;WY'
M%),4"G[BM*VOD31N+C6*"%#T(^XBP\2V1,KZZQ8Y%!YM)6E*AT*D GXQU]8]
MFPZ#CD"F -"YK1CG=BW*SCTX2&)!.5*7A2@RX3T1XNJ1S+4X5 D="=]P02#T
M  [NAV'7KP!)8DAAP<C(&KUS<\ZB@I#.""^1MSU\ZGRB)Y>7,85-EH6I*8,A
MU3S2^8!+;B^JFR1MRA2OP?:H\HV.V^'8D"KOQ%#ZG2FL<A&\ 7(+7M3U^]'C
M$D9999%'7*"S"A@!3;_8AQ8(.[13VCK0*U'\%*0HG??<[;<"2> <TRSXZ]+4
M@$@6B&<]KHN<QTTNI.G&GFJ^.,=HN+'S#$ZNVE05+W(4BJR*#=ULA2P!VCL>
M5!< ZB.ON$WBU'R_9B 2V5/L7B[HT]NELA&NGPGON1VC/A%8A891H1A^-Z':
MV4T!Z7C<G%(PH,*RAYI"GDXWE6+5R6J**Q9.!++5_5UT>UKWRT\\Y.AMNP7>
M1$U:2X)(#T+MZ\?(VSC*DI(9KTIKRTN3:VL?.][KLZT.RR[TFU<Q:[P+4#$I
M1@7N,9#%<@V$9:%+;:EQ@ZD-6-3-#9?K+> X_6V4529,*2\PI*^/8D8A"P'+
M4:IJ_$/Q//(U$>7/PRGHY%^@/6F75H4[34^#,!L$OH4MM.^Q6.[8%?3<[#V=
M#L0!W;\=@S4@.[U9_)W>OK6.NF0N@W;OD<S09\ZO7.+G^"KX'GA#^%Y7C)JF
M37:6Z4(>+2-0\UBSRF\"00M6&X^PAB7DC;*@E#L]4JLI0YSLMVSLIEZ.CSYN
M,"20BIL[TH;O6M,M:.([TO". 5OJWXJ>ZU>-JNBGW.GP<O!UR^#G^HN;NZTY
MS2/,2L;GY;%KJ+"J*V;)+5E7XHF98M2KB,_NY7/7=M:)AO(8F0(D>>PU*:Z,
MV>N8=TDMP! / DD\;TKR$=R7*0BH%<R2Y!_%^\[_ "EAQ]5T@M/LV (#S+C;
MK92KHVKM$*4A0))YMB0"=MSL..L=.)(?,EW%+4+AXY8[Z-.-Q+#,(L60&)ZK
MYN7)0A0(7$?ALM0UA*NG)VD>8 4@#GYR1N=SL:U!;D>ZPB8K]<RM:6^B45-.
M)YGT$#U[A2DG?U;=VQW^$[GA"$G&,R\BL3I"6Y,J*J.^\AR.RX^M"PTM>P0V
ME2W!S?@A"5$'<;;< ;C5W=Z,W'S&39:PA\V(S](?>.Y-266*1;*DL8=DU.*6
MT2(S[;^[ZTA3H?*5%3;R.;G=:<"'4$[+2#TXT[)XU'-VOY4H,KC/#.O@&]&M
MZ^L-?(*YW-'XN%52P7Y"5N3):4E:(#+/WUR6]ML$A#B4-,<RAS276FP?2)XS
MWWWK&VO8N7'DW.O?).TJM'VNUK904S)C.*9?97^&T^RI33S*P3OSMN(4V0.X
MI(X13P+T'VM_#TBT$)X+:0=R"4C;Y!U^7;O[]_;PB#NWX[>,OH>FV^V^_P !
M&WU\(L(>0?ZESXW/\APA%5I7^T3$/][J'_FT3A"+K<(0<(0<(0<(1#VHV6V3
M,UC$,>>5&L9D=,BSL63]_@0GEJ;:8BD;EJ9*Y%J[;;GCLA+C6SKK;C;AF;4)
M[_,(B^ST^KJJJG75FI(1&C.S9DN22X\I+22XMUQYTE;KJ]CL5J4M:B$[DD#B
M[I <\[^3'CP_,9"@2P[O[0R?!LI;")C\^[#"@B\R>\MB%;DK$B0E*SS=-PAU
MI;7LY6P!W <5()/#/@"^IK3O*(MF;/+RBU-MD2&*]2%M*YDH Y>0@D@$!/M)
MVZ;CO(]O%;=(-[MY4K[>L9!*OEMF==7%J$_>E+4PR>^D^[F#(C,/),=IYQS9
M!WY7%-I(V[SW%6P'>-COW<<;LY/??K2.2S=]^?W:)49RA$BN47'BXXM*5(!4
M0HN;@=W>D#IOW;;==MCL!![TO%8:</+2.D^?/F)9KJ\J>FR4@K<!/9QFCT]$
M '=1Z!)V^$]VW Z5L>[B$-5O!KFJL7;HL+EOQE%QQ!YE//-!/,6D*6>3KMZ"
M24(Y_6D$D&L&=J]*OU].D1QJ*VJ/2)JT^BU64U,.YCOMSVK)L2?&0=PM:^G9
M*"ANV8Z@6E,J"5M+2IM:0I! V &)(=F [$942[#WXT'OZ"I]LNQB+!D1Y$=I
M )<:0M*0/2V<3L0 -@H$@CY0.A/$(!8@9V-6.56T\X))L= 02UCW_%(DW'NP
M9CH2A0;]#JA6R>X#;V=>[N!W ]9 XIL&L!7@3KH^61RB)H2]W/+.O*[G+D3&
MD7[H*Y<VWA3:8:6JD.T6"9-"QNR@(JNQ8:=R6[EY?66.2%U]UM@9(VY35V+4
M39:,6JDY,B]^_P!C+2TCV,"$R<%BL9+&]B92@@ VEH6 TP4<ER7X)O4Q\Y^*
MILW:/Q-L'X:Q4SP-CX^7,Q:URRK?QF)PYF$X1:G 2G<2@I8DO,)8D):RV"7<
M3&J*%1.4R\2JZF&W JH#\-Z"CQ:,@(0(RWTH3(!2DN.NA;SKKBENOK4XXM2O
M%4I2R5%1*E%R35R<W:I)XFAM:/HTJ5+D2Y<F4A,N5*0F7+EH 2E"$@!*0!0
M 48"*1>&58P9\S3K)L>R7FSBHL[&;!KF7D^,)J*A</(8]J\4\W80J[(*BLKP
MMPH#CUZMAGM'EEOCU-EA2_ZJ0?\ VIDA16HN4H4/[22;9MD:TI'X;XXF2\+_
M .#V@A:?ZW";4EG#R0YF3Y4P-/EH2D;RA1#Y5W7=0!VY8ABF%Y)C]9)NL>8:
M5-KXLOL;B&A4J&N7':>5&<4ZCM&I#!66GDA:2EQ"@=^7CS  [$YL[AN)?[-Y
M1^Y=1"5 $. 2"/F#U8C46.8+Q&6IN UL&.Y$I'9#;)'(PRB2_(;2E?0H:0^X
MZ&D#?<-MA"!L.4;;#B%@;TLYIKWZTC8<@$BNG?V/[QX:.,7U.P<,G/()JV>W
MJWW$J0XY6//K"6G-EI278;JT-<P2D*:<9!!6E2E(L3E98>SV*Y$EU#C_ "E0
M4H[J2I/4<NY)V2=N_P"$]1U%*2&)'*S^\9"@2P>&!GF,+RG"I%?&:0]9'LYE
M/%W"?&)D)86 \X00PQ);[6(72#MV_-W@[2-1"N@EL]*U&E:=YQ.EMX[(:0[7
MUK[S\-^!>$(;8HI+SBT26H,HQYB$1T+;6+!$>,ULF6M/"$;%,KQF-<8;;XU#
MCLQVW:M;-;'8;0TS'E1 F16AMM("$-M2V(YY0 .4$=-^$(K1II<$]F@J(*DI
MW2>A!]$>D" =QZP>H/3V\('M]/Y:+653X<;0=]RI.Q[^\;D?/L?9PA"!GV6J
MQ.H;<AMMR+FSD"!41W05-%\I+CTI]*2E2H\-D*=6E)':.%ECF27@H(1";>G;
MEHTJXN'EV%A)079$R:I3SZE.>FH<SA);;!Z(9;Y6FD@(;0A"0$T))#VUKID^
M5Z6);2,E0!;^.]8AW1VE<G:D:E9'5@.5_C='51'AN6GFZIB;%4&5@%/(I+;<
MD;;#LWVUG?FW$ TRMWKZF*2 *YY:^7O%T5WHAP"AYE2"E !/*>_XQT.Y'JWZ
M>LCOV0/[B<ZII<DT_F[99<8)/RCK6E.HX<[6:G^K%X[*LZWQ5AT.FQ:=2>57
M3L MT@G8=#R;;]XWXXR=XFAI8V\@0QM2GG'( P %6[/O#UHLK2]"(ENN ]D&
MU-.$A22$[A/*3OT(!'38]X]6X$&QT[IKZ9V(BQ[.W$A,%L,A;TN2>SBQTJ(2
MC<?ZQU6^^R$C<[^O<)'M$VXV^]>G\0AJ3-/[N7.:L)/WZ0@)>:+I60A6^ZNS
MVW#8('*=D[E)](G?A\V;!Q2_E<5Y^D2]C8Y-T/;Q*& &#DJK K4E<RLGO4T^
M&HI[6L>@E 5$<0"0DNA:9*%IW0^RZEUM2DK&VDARY!8/;3G1G;\1%%F;.@]*
M\>O6'GE^)0F827VFFFW&@3S!( 4DI.Z5CV'?8@]_3N.QXK @D!FO5[]^YL\#
M@@$N[^19Z9$=C.%_#6V(\.,$_>E!"-TJ Z@I!(!'J&_0_"-^@X5W>&=,WRZ>
M3WK$)^8V?*M.1#FH+4%:.*T.EO[L#H]I.JVT@U1DZ1:<R,D?N,@]T6H+N+5I
MR2WETL"K70TF16K*8S]I21:R1D5^N-8+FNR3C3%<RN)#=D.<>ILF5+F3)ZU
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MIJ]C#;E'_P 0+AF=W0__ !)B:3U&R%)WVW'" SX=:N7Y7Y6X"?:2>7$(1[4
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MI:M$$"@+N'/&H;U:CO6,D@ERU*#/.IMHYKPH8?MMXFXURMI2M2_[*!S$G;H
MD;@G<]WJ.VQX@!H"S/8ENF?"Q#W%(*;)WK7F]SRJ*EQ?6*TZB8Z^A]BV<CEM
MF+(YTH(',4J!0XM20"4[(62E/?L#W;<84"= #YYO0@CAY5TC:2XNY #Q"N:9
M,BBR#3]EA+1CWUTY435D$J DP7$1%H(V2"F:M@E1W'8AT '?<&&0 H]OO;3T
MC43[C->ANZ@1W!SI9961W;$D@E1W/?ZB1U(&W&DBH%^=>OY]-(BBP,)/A5^$
M=A_@X8)"M);4:XSW(6;"/@F(&0&#:/0FF56%U<2!NJJQ''Q(BOW]NM)Y.WB5
ML)+]I8P8[O<P6%G8N<9<M@ "J9,5:6@.ZE/Z"Y(R )'YWXC^(,#\.;/.-Q9W
MYBSX>$PB*SL9B#_9*E)!J'(WU@,A))ONH.I;']$/";RS(ZK4W(-5LJTSR[6:
M;,LFI+>1ZBXD_(,6)(F5HMJ+&LAKZG&8<F(QRXUC#M+82X=&VQ(M9!M7+"&S
MZ,W%[,D*\!&"1B9<L;IGE>ZI:Z[R@0"X>Q<?\6 $?B\#\/\ QSM24=KXKXHQ
M.Q,9C5&=+V3+PXGX7!R"D>#*4A<Q(1-2D?.D)4?K)F%<+.>:N^%IX).9Z7OZ
MLZQ/ZC:3Y%D2H&2,R9\'*&TTK$JM9NP_:7&!T.55EI75%A(R.L+&06#$E%'.
MC/\ WGG[7(E[/QLK$?TN'FX>?*E^( J85I4$D$@!R^8+L;$"E>1>-^+_ (8Q
M^R3M_:V"VKLG'8T8*9.DX-.'G2%S4*$I<U6XD)&]4$*4"$J"F#1O?J)%>:]I
M6Z%MKCH4PXCTD+0I.Z7$+3NE;:T\JTJ&Z5)(4#L=^/&+_* <FH>A\PT?3@4U
M)J7X9L[5>C%M'>-8_P!TDE8[=:1Q<>L9#9NI674C^'PGRCGFSXBGF\D4A3SC
M;<:NAX5,R-VWLWUHAU\-?.ZM3SL1E_T]D>*=H2C*25@!8F-0"64E*E$B@']K
M:D 6H/PW^HW]'_Z3QXQDU,F8I<E6!+;TQ>-1-3,DHEI_N*B$J"B/[)94HT!>
MF^F'ARZP:0:88OAV6>#A<W=738W5T$?.)-]EE"SE-57P&(=;=O1LBTI16*>M
MH#<:;(0QD$^*ZZ^5M3'6UI6>69LN4N9-,G'X/=*UE*%3$I(&\2$Z.+. !0Y7
M\[!?'.T,/@L&C:/PG\1^++PN'$W$2L(N9+FK3*2%34ADJ"5L5 *+@'YFAPZ2
M:(Y)X=&<RM5+:@&"X#CB'V(%5'4[Y+E.(=65X7'F,-PHMO:9(\TU8ZD97 CM
MLUE$NEPBG4XYY3E-ZFF3LO"B3*6B;C9Z?]V=+(*92,DH4*.6!&8<J+?+'#@)
M>T/CC;0VGM##8C _#.RY@1@=G8N49,['XL %4_$(+'=EDLH J11,E.\3.5&T
M/&;F=40UTTJH$"57)\0=@(0VRF'V" VW'3'V1V32&TH2TA"0T6>S+)4V4J/@
MO4W/&E>=K\*<;M]4 # ,P#,-&L*::6\H8MW:64BU;8[1MB(IU*E1W7-PH\RE
M;;=.7J!ND$@]_=WPL07RYZ>?.G1XL.XPTO9!@S;RD-M>5X+:E-J!(4\AUM*?
M62%N.ALD'HE9VZ [Z&0M]AYQ#8\H=^1S)&,RNQ0\J1'=)0TTI94I+B@0E"".
M\*]0.^W=OMT!5"W$5YUKIIS@"X!UC+P^-*L+,)EE*6F$=LI(!4$R9*BMU)/3
M8AL-).^QV![MR> #GCH'OI]JTHYI8Q18'W;LZ7KE';7[2UO*\+,^G:;:RO'6
MG+/&[%MM)DM2FD*,B"KF!3(B6L4OP)$1X+8=3(YBCM&T+32Q!I;+)C1NIY7H
M(@^4BI.]KKW0Z&^4(/@FZBOY/CUCC$U:R[0(COPFEJ6KQ*.\M;,NM:4YNX8<
M5]+$N EQ2ELP[-F+T1&2!(W&9J]6FDS^!=M-\D?(Z]I3K@_MV526X;^^P.W^
M@+JTIY@"HI64E020A#RX]]YQ*^&V ?BL$D?@)&^_7\!/M(._P[=3MPB/5N>6
MG\CUY1%OA!:JXU0U=33!R7<V3.1UYLZZG:3(,)*6)@938R7'&HD59?+)##CQ
MD@E"RR-TJ(UBQ&M;KWD-W'7CV$8G)-BI CI?"A8R&%*2!SJ99:3$BJ2#N7Y<
ME;+>X4I!'=02S#*K\J^E3^T8*:DO>[OZ,0^0 _:)ATHT[E8D)]YD1\<RB_6A
MVRDA:GD1FN8OB$VZL%3JRZXMV7(V ??Y G[VRT3L"]02107IQJU20:T:^<9)
M=K[HS9GZ</S$\3%03&)3RE6VP .Y]7>!T]@[AW^SB)W@<PYJ]CYZZ0)21Y Y
M<0PJ2-2,AQ,0+J'C4BT@OJ;C%MA"2OG6CE*RD\R-DD%1&X22H@#I\9&5!W*>
MHL^;/<<Z D<(TDT )J7;EV#%;=0;\8W@TN[BMH7,KG:Y79+[BGRE#8DLJ ((
MYV7'6CL?1)W'<#Q@-2S_ ):O&VO!ZQN)7I&FI4>GEH/.Q9N19B=B-^S=;2XV
M!W] "">GKW[CQ?SY^^G*$6IKJYAZK2V&TA20GDZ#;< 'NZ^OO[_@XY"=TALL
MM'+L_)LS]Q'$$A0)S>_WI05RY\(K#KBR]B%_AVI,-M33N.6#5;=K;!].CL)"
M&G"^-MC':+LAM:CT;,Q$@CE8YDE&H4/+R/YSYWTJ1123[W]FB8IN;L2(@BM*
M#CSR0EM*>J?2'X7H[@IV)._J]?3IQ'%P"YN]16[9OSXQ0DO4T#6N6L.'V\W,
M./&DQH\-MM\;C;F4HI.Q4L\Q(W&W>H]W3;V<6K!N%KU=WL<@-*7C)(WB_;>[
M?R'=F9[-?<2(%8ETNOE0(0%%"$>TD@CH-^@W._J.^W$58!R2Q-];:'^;QI(J
M3E8%F]!Y=O#"Q6E?H8=C8..*\;2MQ:EN=>=2RK<]=NX#E2!W  >K;C(<5MRX
M]\'J8T6-"+_AOVC!H]+<9SH3K2TIV&+*:I2H]G7H1#F1E$J4TZE324MO*23V
MBDR$.H<4HAP*Z$5(<%\AESIW_(BB0S-Q?1NO0>Q3:HWN$6DK'KJ(E3\4D1I2
M0$-V$/?D9FL)<("D.@;J"5+[)T+97LM!3QD4IY]27R;\QJ&UF%U9N/I$<IB-
MO;APN+ "QT.X2"0">[FW[N#W!X7XDCU[X#WP[\^4=+=DNXBL++75*EK+:AOL
MD)',DGUA() .WJ'KX@L+_>F7HUK&ISA$PY/S8^E$Z))6J*XA#JVUK/(4K2DA
MP==P=CN?:/AZ\;(9LW -.G#NE8RDN'XM"!2.3;>SB=J AF4OMU) )(98V2QS
M@@;!2EK<&_K2#MN.(*D7#_Q^7R-*V:*: GSB4L\TVH\UP>?26$=#J7FBN/(2
M F1!F->E%GQ'TCM&)45X(=:<;4D@CD/,A2DJUJ+,'M5P'S+L?:@C -'=R[&K
M7LPH*?\ ;G%9O!;S:\ILOM=,,D=*IG:SV7V4CE8\L5Z'WA91FP A@64.#.3/
M;:"6ER(\*2E"/&%)XS')$^ZYU?9C%<H:1Z5?8KJ)JT]"(EBCMH[CA[NS8DQ5
M-)]?/.V[E$I0%^=,_P 7H_M"OC$T.-QW 004(.W?WC<[^H$@[ '?KW<(A_+?
MFC^O(YQ*3*AR GIOOZR=^OQ=X_=OM\/"+"3D'^I<^-S_ "'"$56E?[1,0_WN
MH?\ FT3A"+K<(0<(0<(15O4N;)S//VL1"U^1,83#>E1M]FIEW,93*2\\.G:(
MA0I#"(Z22$//2%[<P21#IYTO?\]O5H2S\ \1EJSI<F!*Q_,JIMN0]4SJ8VU4
MEL.*GU\*>U)[6.R 0_+C(+H#!V7):*6D[N-MMKT4[NGEPIIE:(%.]#WW^\68
MPS):2=7,R(DN-(0$E*N18*D+2!S-NMGE6TX@]'&G4H<;5Z*TI((%%4LX<'.F
MN=7X:.>$9+I46!8YC4E]"!I#U1;UY/.5M*ZDJV4D]-MNG4]WLZ=?7W\1KU%
M_7OD,R($@-0ALB_D]:5%+T>EH56)#4Q*C'V2-B.TY4[GO!">_?U[D@COV]O
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M*RN7&BR9+#WLSUF;LG#&6K=ERIIE3D)8!2A5"U4=R&+U!)<I>/F>R\-*P/\
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MC7S2O [H)U3I!'MIS2V1EEW;7]:TXE2%^1'G_%ZM]25=R9K+"IS"AT<C2F'
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M&?0?4MMQ(WWY@M/,A84VM:3X2P7 %F?1QIP=RQ-0T?3DDL7=WK^T:T_#TO\
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MQY#[ZO6T1E D  @BI/?'CYD&&,[>S[.RD65;6)E*:YHT23.*Q$C<RN5^0EA
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M>;.*)_<\<=L-+-"I.4M-OVMOJ;9MW#$=4QB.3B]%&73XX^Z_/F1F/&K@BSR
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M.](I^U"(.11FUKKI#:U!+"9:D;BOEJ!2E<>1RI4X3XNX^G97 %K>[T(J_/G
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MV>3%EQV_>0FBQ9F>MR4\YZ^'P4J1*.+VB"):D_[&'<)7/40?F(%4H (:EV<
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M7#P5\.L/%E_5Z*]HAC4S(<OS67'J8R"UBT5A$EYL2FFS:6BEJ*$RFBZEQ46
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M"*F+D=NUCR)$]Z3+?E<F/IJTM.OR7I!8#8?67@OCAF$%9*68LS!A8/3*L<B
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MA]!S^'A#?'UGT_[0>8=/Y$/H.?P\(;X^L^G_ &@\PZ?R(?0<_AX0WQ]9]/\
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2#8=PZ#A"#A"#A"#A"#A"/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g189651g46h40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g46h40.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M.1<EXXXXXXYSR^UU^;[;QX-CI[VUS>WL=D'(88'FH,2ID -K<9C%YH:K4S3
M:>EJJ4V>QM;V<>HO1P+E[9Y[4BNJ*?( 1H7(50R!#V+%];56=B=*49F  797
M8^ +-C[=94!9BKEQLA0F^Y5% VP=0IV6T&][U.E7H;F/S(XXXXXXYSUXANV1
MNN\Q+3@:G/Y39:6DTI5#:Z"PK AZL.@KD)L;06*TG@@M+A9R:^IS]/&A,QEU
M:"%2A$U-=;K#DUH3*_449T1D#*H8D]1T >GN%[%F;L H(V&*[Q[$OEKH,J.P
M;I+$  *.Y[D;/<!1ZDD=B >6YA[L?28W+7HMF)<Q6E#5EK: DCEBFSR!P_%3
M1D".>/(OQ*3-D]IWI9*U[/)JM5J0NI5V4@J0Q&B""._;L>X[<F0]2*P(.U!V
M#L'M\QR4\LY=QQQSXD>D<;Y%151C'/5$5J*J-:KE1%>YC$5?+R17N:U/NN<U
M/-4<<YIZ:O=S!=U-%VD1M8-?I\,5K!:ZVL\%:Y14JSZ ;30U#\C6#G %49VD
MIA1H;&RLX#:JPC)A+F*B+8+E3+&59H@A1).@LHD5^X8H6#L00P5CV"Z8:UK6
M\:%GVJREP[1EP&,97L5Z@.@ @J6 T21TD'9.]=,\Q>9/''''''.6^W]GLQ]K
M;9O.R;,*NRO5\>^,,Q;,:I+2;"XT%>AM@S8.2.W91CYI\X.7!<,R^?9%LL3(
M4$!7F7"D?EAG\LEY3&!)YFM!5/8IV7J+:+'NNAH:)YBS.X<JO6 D76>CH]26
M&SU^O2%V%'8[[GL.=*5)T%I55EF,0PL>QKPCARXX7CL*@+&C(B(9!(Y\D#)H
MY&R-AD>Y\2.1CG.<U57%(T2/31(U\M']7_D.9(.P#O8(!W\]CUYL.4Y7CCCF
M!:!2V-<8#!9'U$I4#X8[.K4-+$%ST\D(#6P#L DGC^ZQ20B8?/\ CPO3ZN5!
MT02 VCO1WH_<=$'7Z".4(V"-E=_$:V/T;!']8/*>Z1716=?I-39[+1ZC-WMW
M./A(-&S/J4/FZ&<NK2^4BBHJ)DRZ\Z,JX$CEA>P>@^0L:V,QU@^:>?I!5 BH
MZKN3IZM=; 'ITS-]0:4Z/=NKX:U#!U$,Q=G5F(CZ@NPJDCJVH&^L[(_Y>GL#
MOEX<Q^3\<<<<<<Y'["WNWK.Q[MU38Z%F6R-]U-5V-C7PYYV&S<.AM0R-D#O!
MCQUUUG9V&:MJV>K)RD=B!2,LJ,RR)ST3;8Z?,CC0Q+U!>MUF*@]7F/T@B,QD
M>X '4A@^B=, &V ,21W$AZ2W2C1 D=/EKU';B0:+DE2-%00O4I)4 GG7',/F
M7QQQQQQR!]GFZFNP.G-Q<14ND'KT?7_ !16=E"Q2(&6!E563QS0V=L#6.,,J
MJV6 B,^Q@&$<,2DRP221!3(H?723WV=#T.@2"- G0)V-#9WR.4L(W*;Z@.VA
MMOOZ1\6UO0UW.N03J#7&W5_V!G%L=7=T>;^B1U#<;:C(H-#-#HJT]3PIQ#*3
M.GRBB'U,LXA%C4#&/:?(QDA%:RNF=),@58VTBLW6&6-NI1TD:.PS@$AM$!B.
MWH#OED+]1D7;LJ])5G4JQ# [&B%/8J>Y4'O\1H\]^8_)^<H;R;LC6^(@7K7,
M]P;#J[-A=*INI8L?GNK;<BTT$NYGH&OL2.P^OMO.T*(!C&H+52U:ND19'2^I
M5=R=.A8B[1JY\SI]YG&AT[_D,OQ^>^0MUM+TB1D 0-[H0[)8COUJW;M\-?']
M7,I7?'<.BTG56--V_:%+..'XM\[N+7P_=98+6W.TTOA_[JZVZNSVJ?2[K$]B
MCYV@LJJZO+"\#J81X@=/9P53391!!6.R/)B"R-TH>\!42NZA5EB9RNU9=D$#
M1/J!Z#?(#)(61>MAVF#&)%8L8Y%0'3*VAHG8'H?B>6SNM%W+7U75C*O5^(R?
M%RYK766ZUF2ZXZ6LO$'#HGWU:F.;L.MKCK]]4+CHJIVC$D7KSK O0%F5U''8
M.A9,:7:1JL6WVL/5U*$5GE\K73[W2X;ZV^G^,;0V==P )&,FDTTO3TDLRI'Y
MO5L=/4A7076_JH2=#?;9,,O/%#NLQFZG2U>MSW8P\7A@["V#36Y8O*4EYV70
M=K83K>GO-)36 HNLRJ495W8C[W*+-6+4G07P<@ )=>*@5P@1B059/SZ+HMLA
M#&[L ?1BP4%&UW&B.QY:9F !#!OS+-OIZ07#JH)!T5Z=GJ7MKN#W U9[M1J>
MK>S\AB]-XAMON+C75N@!.S^XZ8$J<F??PXK1:^KDZRW^"ZKSN6J;8*/*VQ1>
M/VFYUY4^7&->LZ70+"K2SI62-F6%5"Z(9)"6"]84]:/(6([Z#*J]R/AR_J*.
M%:5F+ ]F30)T2.AE0 $:.PS-V!^.R:@Z;\3?:]YC_#5E>Q[<$;MO5Z;J6UU%
MF'450E?VEU#V?UIK];3ZRFKU"^%JYX+FMBRVS@HX@I*;5YTB45H&?TM'"9))
M!&&F9!N-4E"@L24DC8*0>^SV]Y=[VI[]QRR.5RL0<^^6CV= !T=20P^ []FU
MK1'8 $<Z:W5UNMEW@%TSE]Y<=74E/U:SLS1:;+5./M-A>EW&J,R]#0T\F]S6
MQS5945B4MO8Z0AV9L+0N4_/# FU$33''0($6(RLH<F3RU5BP4:4,6(4J23L!
M?> '<]SKDK%FD$:L4 3K)4*6)+: !8,H T2WNDGMW'?D&W6_[@Z'S68[*UFH
M@[CQN4L=)B.U:C(YZ@!O[""WT*@=9[RM$%C$]K<5A[Z''=AYH0\7*E)HK+44
M]31,H65\]ZI%,S(JF)F"LA9B5&A[Z$_9/=D;1;L%.][Y1FDC4,Q$@4E7"@ D
M$^XP_P";>E8;"^]U  #7/$.R[[O=GU_TWJ>RI\)I[[KW;]T]AZ+$46'L+.G3
MZ7YZDSG4> GU65O\])G\E'HIQ+_8WV;OM)?)5U94$U0^^D4 1"JO*J=:B18D
M#EM'W"2[@$';:V%! 7>N^M\IN4LL9?I)5I'*A21[P"HG4I&EWHL5+'0(UOM)
MZ+3]HYGM[I[K#4=AU>Y#MZ'Q"%WML%1T5;97<6-M>JGX1^HAK 8 ZO64]1KK
M :^CS ]#16Y!++%M&%"\,$*TJC1RR!"A!AT"3H=8?KZ=GNI*@CJV1Z;Y<I=7
M1&</M9=G0!/24Z>K7\H!CO6@3WT.P%8=F]A]BR^(;L+#5^]\0V>RV6Z_ZINJ
MBKZ+ZJZMW<+;/6G=C17A6FL-MU;O+,64B/-U+:D:$T,560V#VP/?ZG-O1(_)
M1BL19FD!,LDB;"]&@H5@.VSOMON.1R,_FLH>50$0@1QH_=B^R2R,1Z#7?Y\[
MMI&SLI:AA)EE8DLJP&D6%R,$%<'3M$B24RU#K0JVN$LB9$=,<,!7 !0%/EB%
M"%@9'!'BGU.@ -G0!V!W] 222!\"2=_/F2/0;V3H;)[$_I [ _HY=6?^\X/]
M"3]?+RG*\W/''.2O%%X>L'XCC.I*#M+<+4]=8#:D=BZ'KT>T+SA?8-P'0VE-
MC'RZRGTF?T&="REM9%WS75/O369\ D:$@/#;.N1!*\0D,:;9UZ ^NH("06]T
M@@EAH=_0? [Y!-&DG0KOI5;J*]726[$+W!! !V>WJ?B-<YB-\ W4]7E^Y>ON
MNNXLMG^KNU]]@^S(.LNP<Y0=X96EU>:I9*77OLR.R-78ZF]"[%]NIM;0ZLTF
M4VM#;TH4F?V@E<\FMFF%F4F-GC8O&K)UH3&Q5B"N@BA04[ZV&5@?>4GOR+R(
MP)%610CLK]+:D 8#1V68L0W8GN&!'9@.W*%[=\%43^O_  O>&K&:.\UU=GNU
M]A?]B=V,U^,S.,Q/1O8S;L+M[I^FSMON[K:"TFFH3:BCQV3K(-*.*M>/86FI
MAD&G5\D<YZII64*3&H2/H=F:5-&.0L%"[4[+,=;] O?D;Q#IBB5M@.2S]2JJ
MQOL.@!8G1!]U1O6AL]M\Z_[0\)G7?8Z^*5L?<=+G!O$Q6>'NKD$# HR(,*-T
M 8A5>ROC31!LMXK]B) Z%S*IE.QK?9^-1/3R!)I$\G\TQ\KS>YZO>\T:.^QU
MK]>_NY,\4;>;^<4>:(AZ@](C.QKOWW_X<VN4\/A&#[5UVFQ?BH7.]1;KN#1]
MZ:GJ$2DQLMA;[K6TK:_15Q'8Y-M*>F"M+6.#0$9B/.QGL,A9 /HX(//SHTA9
M%#0$R)&L:R'KT%4[!Z  .H#MO>M?R>5"*K,5F 1G9V0=.RS#1][?U?CTZWO^
M5KMRM:_P.=>U_6_5O7;>^JZ2+K+PN]\^&>&U6KI&27 ?>0%0"5KY1$U+FA$Y
MQ*I)8*9A!,5FL[FR607H1S[S8<N[^2WOS13:[]O+W[N^GOO?K\/D>6^2G2B^
M:/=ADBWV[B0 =7UOAKT^/SY,==X7Q)2>K-+U/XEJOJOL#K[P^IX9[G339C*;
M>KUW6:MHB%].:M-'6LS^C!NJ..YIK<6U.@#D(E"L*ZX"3VG6K*??#P%U:7S@
M-LI5^_Q .UT=$$#Y@CES1J2C),J,L?ED^ZP9#KX%AH[&P>X^8/(B_P "73X&
M+[%P.8[F@IL[N?"5B_"B$AJ4=Q8TE9CS]78_3@DMMY6Q7%O<$ZLB8ZJC$J 8
MIX%<+/%#,P<>[VF7J1FB)*SM.?4 E@HZ1V.@ .Q[_H^=GD1]+*)0 T*P^JDC
MI)/5ZC9.^XT.?6I\%&3T-QN*83Q(PT_2/;VTZS[$[BZFCI,D:=K-9UI!D(X'
MY_L&:[CM<?1ZF?!Y@K2U;*F[,?(&3%36]..;+$TL[J%)A+21JZ1N2VE5^KU3
M6F*];=)V/AO>N5:%&+#S@(W97=/=/4R]/HV]@'I&P0?N(YEQ>#RIA[.&U<7B
M9KDZ^K?%K9>,&JZX=F,LXP?L'04UO4Z"K,VWTF:6;2O^='3T,<=(&ZI:43#8
MLT#U#G!IYS=!7R#U& 0%P6UT @@]/21OL-]]'X:X\I>K?G#I$QF"^[V9@=@M
MON-DD=NVR#OMK(\.O@XQ/0?=]SW2SO#)6Q=GG]-0$TN0QF.ZF&UCM'?!73=!
MVB%C- W%:_34S0_@ZFQS>#Z_%8I19Q=<69-[C4L[RQB/RF&BI!8N_3T@CI0L
M"RJ=[(9W^0.ARL421R%_-0[!&E"IU;.]OTGI8CX:50-GL2=\_H3]+LI^4^>_
MMJM_U/,7H?[+?A/[.9'6GVE_$/V\^)-5D)HY(I=)FY8I6.CECDN*Q\<D;VJU
M['L<0K7,>U5:YKD5'-545%1>.A_LM^$_LXZT/\I?Q#]O*VHL5T1FGU3Z>+(C
MK2Y _!5R3Z)+!L>2M+!+6QIR&6-J6P]AAZ/GG+/:4>[WRXOBDA,+CFE:2PV^
MHN>IQ(?=U[X&@PT!K0[:&AV';L-1*D"ZUT#I0QCWM^X3LKW)WL_$[/KW[GF*
M-@NCQZ\^L=9!FC'AU%>U]KV/>VYU6!0'LM:(3.VEGIBK+,Q4UI'#8UBY\NMD
M$.&$*AD;,&*^&IEG)!T0023TQJH8L"&+ * W4"0>H$$$C6B>!'  1O8.A[TK
M,0%.U"DL2O2>XZ2"#W'-@'E.EQ&HCC:.RD=+?3E%7NR*T!EG-IJD6BNWW)=U
M=GSW*&TH0=2V.TD+B#KA1P@8Q1H8XVVEYC\&'U=!4"@=)+*%"J NF)/;6R=G
M9Y4)"/BIWU$EGZBW4.D]1));8 &CL   >@YB#8CI00VM-@M1?.KESI4(4W9%
MZ54E6&1%!#S5O<5!6FGK+VZIAJNK8'<70I]EZZNKGF)E(K*^4:IDG((T?>ZM
MD1*" Y)=58*"JMU':J0.Y&M$[H(X 001V*G7F,02H 5F!8AF70TQ!/8$DZ&I
M[>6?7^DJ+&AO+K,V-1;"3 V 4UV"UA T[%9(SW(C(YH9$\T?%/!)$0/*UDT$
ML<T;'MC42*P958,I!!"GL1^K_P#T?CR1C&P*LRD$:(+#N/Z^1K#G]:9JKG?6
M7]4&5=EI:7,UYN)=%>FV#1AZZ.2TNM%:FVYCQ@ 0PAHR9_;$$&A&'BBB8C>7
MR"1FT02%&EZ4"J!LGLJ *-DDG0[DDGED9C5=@@%CMNIRS$Z [LY+'0  V>P
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M]D937 @!LL+!C":JR@'DDE!);%71T#HZ)(!UV)&B0#Z; (V/AL?,<IL;UL;
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M)B$"$A0ET:.FGE<UB+)*^.&&-%62>>2."%CY9&,=55+$*H))[ #U/*$@ DD
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M:^P_NAO<1/NL^(^SB7[/J3ZO<^&G]'W?:?Y>E6XOLR?B7]SC4OVH_P +?O\
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MA1)O,KV"(*]9H/SG5Y<!&Z+U+(+,8[Y?9OC"L1XS7WP-=+HIS-Q1:J,PE:S
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MNO5[+2*:#:E5.TG)ZPZT;EKZ4>E*'/'MF^U>L$:LO<L05WL,48/$S?&,*NB
M5]]^H=QHCE#,[ ^@!ZNG1 9>B0+WT[,=C?5M4Z2-$;/)KI^Y-[5>%7L24>'L
M :Y"L.Y[(3NNQN (<=G$I/$-N:BLJ;?0+KQML&RKIJP.N2,"C?7A42B!06$
M\3XQK5C0SK]36D_-Z/4=PJ=@=/2=D[[G9.^W+B[")OK;V_ODCI&I&UL]0;0
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MN61A"K$@L6UO18$ER!H C8/H-L!Z;;7*B#\;G:JTN<O;07KH*HJ-!V16=EV
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MTA_TIM=776<4MC$4-7=<7NDB!=95!CO*,&0"=[I0 ;EQ,\8Q@8Q+!?A#N_\
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M=C)*F8,60\17:MWP=)F9/$RP6_$N K9^3/2UI)Z5*KF(;<-*IF+5B:]F*-S
MU,[.>$\'#XDRJ-)/]'&7/W%GH!ZN*K35\\N/3#F6##Y27%IC4E6.Q8GH2026
M)J$$4=>A9@R<\W[=T4>N\/>4U\4@TY%CLO#S?"RA#FB036;^YNN)/APH+)D=
MB+!8$OEK6Q$(A*B%R#R/E21SI/>_"F77/X'"YI7AD&4Q4%QWKQ68(&DGJ]4I
MAAN*MJ*(2E_+2=3(J@!F<CK;S+.4#C,GD,>5=32O20*LKPR2!8Y]1B22N6A=
MRG3U-$>AB3TA0=";<W','CCCCCCCCCEJ9O[RA?\ V?\ BY^..;SCCCCCCCCD
M7UOWLC_KD7ZJ?CCE;\<<<<<<<<\YF-DBE8Y[XVOC>QTD<BQ21M<U45[)6JCH
MWM15<V1JHK%1'(J*GGRH]1\>_IZ[_5\>.61@B&%X;&%1'D6D9.5SQ$=F7$\<
MNQ9-4B2,/*@D<^2$@MKD(FB>][XY)',<YSFJJW2#3N" "'8$ [ T3V!^('H#
M\>6IHHI!)!5=$C1(T.Y'P)^7*[Y9R[CCCCCCCCCCCCCCCCCCCCCF*=*3 &7.
M&)\<7"/-*,%[[!E,GCC<^(9")4=% Z=Z)$V61/;8YR.>J,153'M23PUK$M:O
M[78B@ED@J^:D'M,R(S1P":0&.(S.!&)''0A8,^E!(E@2.2:))I?(B>1$DGZ&
MD\E&8!I3&I#.(P2Q5?>8 A03H<H<GNNJL;'JB>NLJW.5NFNKENEJ-Q9U..U0
MP0E5=5(H@]!?FB'V4GTN^$A?+2L/'E6OE04J>.1JR>13_E3Q]V[^3N6C=HX2
MCGLKE%SF-\5W\;X9\00U:V/RF-KUH,/F+=>W>?\ A)[-&\F*2Y#(:4@@L2HX
M\SNX_!=NO7\5QV*UG(V<92IG&V\)6MYC%232VJ=N662_0@E@K+]$><ZK=:!T
M]H4RQ(RGIM#&[*#;06Y]?4W%?4UUP=1B&78,U43;E5,\@EJ4)5ELC/'KACXY
M*^&:PB%*)+%.1088(()R^^\,>)X?%,62N4\=DZ6.HY.WB:UG*U)<=/DK&.E>
MMD+%?'V42W#2@MH]..6Y'7L3V:]L&I%#%#-9Y?,8>3"O4KV+=.Q;L4X+LL-*
M=+4=2*W&LU6*6U$S026)(&6=T@:6*.*6 B=W=TBF7.GYI^...6OG_O.#_0D_
M7R\<<W/''''''''''''''''''''-#/E<P3?":HG.4)&G &>&#HYZ>OEO@A)$
MD2042XD'=8#C/265'P0D,B<DDB.:J/=YUZFUT]1Z3ZKLZ_J].4T-[T-_/0W_
M %^O/B/(Y.$ZWLXLQGHK+0**Z^L(Z6M8==N"<UP3K<MHR3V2B.:UPJFR3*.Y
MK5B]"HGDZFT!U'0]!LZ'Z!\/U<:'?L._KV'?]/SYL75-4X&6L=65[JV9\TDU
M>X,9099""7F$/E$6/V)'SER2%3.=&KI27OG>KI7.<K9WO9W\]]_E_P"7&AK6
MAKY?#FC3!85M=4U#<7DTJ:"P2VHJQ,Y3I74MHDLLZ652$@?PU;8)-/-,A@<4
M)"2S2R))ZY'JM>IMD]3;(T3L[(^1.^X_3QTKZ=(T.X&AV/SYE"X_) V@EV%E
M\Z'<U]5%1 6XM)6#V@5' U&P4PA\0K"QJJ%K6MBKH96"1M:B,A1$1.4+,006
M)!.R"3HGYD?/[_7C0!V -ZUO0WKY?HYB,P.$BIK+.18K)1YZX+>?;T+,Y3LI
MK4Z66*>4VRJVAH"<7)-!!,\DF"69\L,4CGJ^-BI7J;8/4VP- [.P/D#O8'<_
MU\=*^G2-'N1H=S\^;(O-9P^EGS9V?I#<Z3&Z(B@+J@":4B)T_P 2Z.>JF@>#
M+&XG_:',D@<U9_X5463[;E 2#L$@_,$[_K]>" 1H@$?(@:_J].8,F&Q,JU#I
M<?EI79\WYE0K)GZEZTEBC(8T/J%<(JUIOMCCQ_%!^S/Z((6>YZ8F(VO4W?WF
M[C1[GN/D?F/T\=*_9']0Y^287$3+H5EQN5E77(QNK63/5#UT[8_-(TT*N#7Y
MTD:.<C$LOB4;YKZ?+S7CJ;M[S>[]7N>WZ/E^KCI7OV'?U[#O^GY\C]AU/CK#
M08:]4.4&#KRQ/O,[FJGX2LROTB+H)\L)HK&G#$B0^UH\\;95=$LT_P %7Q6#
MR4"E/!IRZVHD8!AO?6-%CLMK?40"3V!/<Z[GTWHD&THI*G[))"C07>M;(UW(
M'I\!ZZWH\EX.:SE9:VE[6T%)7W=Y[*W=P#5 B6MPHZ*T=;2P'@C+L/8:JMA^
M+FF]I%5&>E.6DD@ DD#T!)T/T#X<N  )( !/J0!L_I/QYN^4Y7G&'7<S,KI-
MWU"?Y#DYK1Z'3XUK_)C+CK;7:&PN:MU:S_NU@Q-O86/7Y843Y2:\.DSMG8,&
MAU%0I,D@Z@LGJ& 5OC[Z@ @_]8:;OZ[('H>1H>DLGH5)9?O0G8U_U2>G[M#T
MV.6.#G<_61305M%3U\))<1Y$(-8$)$0</,PB V:.""-DI<)$4<\1,B.FCFC9
M*Q[7L:Y-15PN&HQRQ4L3C*<4]B*Y-%5H5:\<UN&5)H;4J0Q(LEB*:..6*=P9
M8Y4216#JI&PFR%^RR/8O7+#QQ/!&\UF:5HX)$:.2%&=V*Q/&S(\:D(R,RLI4
MD'Z,H:*Q:QEA2U)[(S4LHV&5P938[%$1$/8V>%Z,-1$1$*:B3HB(GN?5RZUA
M\1=55NXO'6U2U[<BVJ-:PJ70 !<42Q.%M  #V@ 2Z '7VY2&_>KEFKW;<!:'
MV9C#8FB+5_\ @,4=28?_ -H[3_EYF("$DC94#%25I,AC94'B21I<L#A92FO1
MGJ0F09[AY)T7W7P.="YRQN5JY(J50XD%:N)%G>RL@AC#BS)":\E@-T]0G>!F
M@>4'S&A8QLQ0E>0F:8J5,TI4QK"5,CE3$KB58B-Z,:R 2*FND. X 8 \W6;R
MV8L7S5]AG*$X",<66,$RHKRA(Y /8&!D8-..^%CPAVM@$>UB.'A:D4*L8B-Y
MA3X/"6JZU+.'Q5BHK5V6K/CZDM=6J1""JRPR0M&&K0JL-<A088@(XRJ #F1'
MDLC#*9X;]V*=A*K31VIXY66=S).ID60.1-(2\H)U(Y+/MCOEGLIZB,Y]G'55
MK+*7V/<L& BM.D^%@G%&]9;8D(?\.*42-!ZI%]J B>&/TQRR-=DKCZ"VFNK1
MIK<?R^NVM:$6F\F*6"'JL!!*WE0S30Q[<^7%++&NDD<&$VK30BN;,YKKU],!
MFD,(\QTDDU$6Z!UR1QR/I?>=$9MLJD:O+9:OR81@@4YQQ%G:G7=M:VDL,]G;
M6I[F),8=*..(.KXQH10!HX!H(!J\(,6*)L<#>86$P=3 UK$%:6S9ENWK.2OW
MKLD<MV]>M%1)8LR1101%DAC@JPI%#%'#5K5X(T"1#F1D<C/DIHI)4AA2O6AJ
M5JU=62O6K0@],4*N\C@-(\DTC/([R32RR,Q+GF2S,9N*6RFCSU''-<H4EO*R
MI 9+:H<D2&I92-'1QR%I! A2%+*A"0Q)+ZTC9Z9EPN&1[DB8G&))D1.,A(M"
MJKWA9""R+CB(-9%@11"<3%Q*(T$G5T+J,Y"^RP*UVVRU?+]E4V9BM;R2QB\@
M%]0^47<Q^6%Z"S=.NH[\5Q^242K 7+YU0:.?XJE"6DK%$IR4>LB$58RB^S7S
MH]5?[HC(9/6JN]7FOGR,^'\"8*54X3$&MC9?.QU<XVF8*$W5U^;2A\GRZLO5
M[WF0+&W5[V]]^7_2>2\VQ-](WO.N)Y=N7VNQYMJ/6NBQ)YG5.FNW3*677;6N
M<X:OK7/;!T+;.2PA!2(T<ZI!D#CK+4>QF?-8L*@(!*D#GL%F(B/LZ2:IMSAB
M9Q2["8=S8V:/Q%X%POB8QK?>Y%4\NU#;QU5ZR4,A#>E:6ZD\,]6P]:6X9)DN
M7L5+CLE;@GE@LW)82J+L<5XDR&'#FJM=Y^N&2"W,LS6:LE=%2NT3QSQ+-'!T
M1M!6NI;J0R1I+%720%C-V@A,=&]@8K7Q$3E1/:/$UT9122H43&Y&(K""4FF2
M>9JI),DLJ2.<DCO/JUJU59&6M75HYIK$;+#&&2Q8#B>="%VLTXEE$TH(>02.
M'9NMMZ4S3$,#+*0T:1,#(Q#11=)CC8$Z,<91"B':IT+T@=(U@F45:61/8-&'
M$NY:^>LAT(H8'SP(:=KT1!#R127-2&1_OQ0S,G$]YK72CRM]3'8MG$T;,TUQ
M:\-;*R4IJ,>9KUJGTM5@E5@!6N3UYV7RG;S8XI%EK^: 9(9%ZE,T-ZS%&E<R
MR34EL1V7Q\LT_L,TB$'<L$<L8/6HZ&=&27H)"2(=$8 .-S86?K,R^J#L:BJ2
M)XT%N/!:*\N)[YG61"EQ2-FLYRI9S"#58DTA<\T_J1\CN8=3PQ@ZN&H8%\?6
MO8W'B-H(<G##?+V(V>0WIC9C=9+TL\DMF:UTB1[$TLH(+GF1/F,C-?LY-;4U
M:W:ZUD>G(]4+"RJ@K1B%E*5DB1(8X 2BQ1HFB%'+(SF<SUK$9':45-91P'B6
M<+#ZL$QD-DULR-L(FD02-C-:C6HTMB).B(B)(GDG,VUA\1=5%NXO'6UCM"ZB
MVJ-:PJ7  !;02Q.%M   6 !*  .O0YCPW[U<LU>Y;@9H378PV)HBU<[W Q1U
M)A.SN([0[/N]^6&;75]B@Z6  1Z"$L,$0T6 I!2XV21QE#I/&](28XY96,GC
M],K62R-:Y&O<BY-BG4MB$6ZM>T*\RV(!8@BF$-A%=$GA\Q6\N9$D=5E3I=5=
MU# ,088IYX.OR)I8?-C,4GE2/'YD3%6,;]!'7&656*-M254D; YKJ[+YFH;$
MRISM%5M@>R2%M=45X389(U,6.2)HP\21O8MC8*QS$1S5.,5JI\5/Z\2IA,-C
MU1:&(QE)8V5XUJ4*M98W0V"C((8D",AMVRK* 5-JP01YTG5//D<A:+&S>N6"
MX96,]F:4LK>5U!C([;#>1!U [!\F+?\ %IKZ3,YQ# +%,_2)854<T56<E4 A
ME;$2^20B, E!_?#CG?+*^9@[XVROED<]'*]RK48;$"Q5MC%8T6Z*21TK0HU1
M8II,SM*E681>9725I':1860.SN6!+$FGM][RIH/;;?D665K$/M,WE3L@4(TT
M?7T2L@50I<,5"J!H <\?D=)3 WLE13U=5)9QF&64E;7B OL"W02^HHUXL,3B
MR7>IWG/.LDJ^IWF[ZUY)3QF-QS67Q^/HT7NS&Q<>G4KUFMV#O<]EH(T,\QZC
MN64NYV?>[GED]RW:$*VK5BRM>,10+//+,((AK4<(D9A'&-#2)TJ-#MVY2S,W
MG8X;,>.@I607;W2W,+*L%L-O(_U>N2SC; C#WO\ 4[U/+;*YWJ=YJOFOG"N#
MPB1WX4P^+2+*N9,I$N/J+'DG;?4]]!"%N.W4VVL"0GJ.SW/)3DLBSU9&OW3)
M24+3<VIR]11K2U6,G574:&A$4 T-#MS,@K*T6$$<6O!&@K$5*V& 0>&&O189
M!U0&..-K!$4>66!4@;&BPR21?Q'N:N3%0HUXZD,%*I#%0V*,45:&..D#$\!%
M1$15K;ADDA/DA-Q2/']1F!ADLV97GDEL3R26>]EY)9'>P>M9-SLS$R_G%5_S
MA;WU5OK $8[*&BC).-CI:F,RT6%UF6RN#:38N'<U\"G3MA24M8'-:Z%2'R+&
MYK59Z51%Y"N'Q*3V[*8O')9OF-KUA:599[K0L'A:W*(A)9,3*K1F9G*, 5T0
M#R1K]YHX(6NVVAJAQ6B:S,8ZXD!#B!"_3"'!(<1A>H$@[!X?044A\MK)25$E
MG.R*.>R?6AN/FC@3TP,E,="I$C(6_:Q-?(YL:?4Q$3E&PV(>Y)D7Q6-?(3+&
MDMYJ-5KDJ1+TQ))9,1G=8U]V-6<A%[* .%OWEKI56[;6K&79*RV9A71I#MV2
M$/Y:ESW<A06/<[/+3R@(4M,@TH8L@PMC#*,/(/"^ >4%H<P4L$3F+'%('-#%
M**^-K7#RQ1R0JQS&JF6U6J\44#5H&@@:!X(6AC,4+U722J\494I&U:2.-X&0
M PO&C1E652(!-,KO()9!)()%DD$C!Y%F5EF5V!ZG$JLRR!B0ZLP;8)!W)N;S
MMD"ZKL:&EL*QQDE@ZN-JP2@7'S$RF3'.$G@D'4R4N><J0E8UF>3-+.YZRR/<
M[%LX?$W*II7,7CK=,V'MFI9I5IZIM2326)+)KRQ/$;#V)99WFZ/,::225F+N
MS&>&_>KS"Q!<MP6!$L GAL31S"%(UB6$2HZN(EB1(UCZN@1HJ !5 'I)0T<U
MD)<RTM3+;UX[Q +62N#?9!"O1S7C"'.A4H8=Z/>CX8961N1SD5JHY?.]\7C)
M+E?(R8ZB^0J1-!5OO4KM<K0,&#0U[31F>&)@[AHXW5"&8$'J.[5N6U@EJK:L
MK5G<2S5EGE$$TBZ(DEA#>7(X(!#NI8:&CVYX%Y?,V B@'YVB-!4,.O4(NHKR
M1% KWND !4:8=\/P8,CWR!C>CV1GO<Z%C'.55AL83"VX#5M8C%V:QKUZAK6*
M%2: U:C,]6L89(FC->L[,]>'I\N%F9HU4DDWQ9'(0R^=#>N0S>;+/YL5F>.7
MSIP%FF\Q'#^;,H"RR;ZY  ') Y1?;<L6KTF,ZFIF1*!G#\[VGV$P9C6#4V=R
M5K\7UM2N6%/(*ST?8U54W%./[:0DY[K[81/6!WP23[:"..O"%CC2*-(Q!!'&
MJHB*%"=,:* JQQQ>X%4 +U(%  T,&1FEDVS,[,YEE=B69CLMMF))+._O$G9;
M3;[G?)#RWEW'''''''''+4S?WE"_^S_Q<_''-YQQQQQQQQR+ZW[V1_UR+]5/
MQQRM^........1_0F2L%2IKK(2NO[R,P.CD)C4CVR(A9)R#D%2*=LS*T9CR?
M22QH4I*"A$31N-B1]Z ;ZF!**06UV[;[#>QHD]NQWK9'H>6L>W2" S;"[[_#
MN==]Z'?OVWH'UYT!4-:RJK6,:UC&@"-:UJ(UK6M@8C6M:GDB-1$1$1$1$1/)
M/JY9R[E/\<<<<<<<<<<<Y_U?? \>B.P7565L>W-_6O;%= TI@U9D<?*Y?)&[
M7<&-EJJ<I$;*Y*4&*VOWK!)$M7$Y6.7-BIDH)K,BUH&[J7!:677_  HA[S?]
M9NE/CU'G,W?$:BU)C<-3ES>2B/38CKNL-&BQ]!?R,@:&!_4^1&)K)T1Y(.N:
MN/&>)G3(A6C[DR/7#9/_ .P]98 30O@C7[C9=3V%,>I,Z(OIDE'RX$:O3UQ-
M8WR;R[S<?'VCJRV-;]^>8Q[^\1P@ #X@%R?GL]Q"*'BVY[]K/4<4#_\ EL1C
M4M%1\C<R;2%V^!*TX@3W  [<]4Z4[-7ZW>)_MA7*JJJMH.K6-\U7S^IOT&7T
MI_,B+Y)]Q/)/JY3VJO\ T?7_ +2?_P#R\N^@,O\ _P!7YK^[8?\ T[M^CX<A
M6S\./;FB=E_EWBG[-#=2Z<6Z*)*J\F/-&)!768LL8#<S2YV0DHEQD8KQ[<LN
MD4.8J0NK/EC&AY-#>K1^9O'P'KC* !I""2RD=7F,X &M[4!M@:9>YYK[_A7-
MVC3\KQCED->XEAW>&DK*BQ3(1$*E>J7=C($*SR/7Z&<O#(P0<Z+T6<T!V6AJ
MJSL6^S=H&$R,C7,K,B:>:Z$=(YS;,,VA^3QOF5KB9EJ0Z:**1SU'0>)K(V<5
MXIQF3R^-GAQ'B>]X/L@2.,ECZ>'O"-.DEEEAS=*]'Y2+MNN*2M,O=O/&@1Z9
M@;57'6(#D,5#XC15CC:"[/;K23.NAY@;%34U\V0_67R7A).EA [<_D=W/TSV
M5V]V2[?8%LN_RN]D$'S>DF*$IEE=2AC4AL$X5T2 0,,.17S%"E#PRUQE?- 6
M(1+)+-%'^:OY4/R8>.?RD^.6\8>#Q)XQ\/\ C"2O#@\Y+8JXLR-BZT&+MPRU
M,I/3EKP034Y9Z]B"*2C:I20V:TTCR21I]>>#O&/ASPEX<&!SI3 93 K+)D<:
MD4USH%R:6["\<]..=)9)(YTCEBD=;,-A)(I8U54=_P"E'2@UE85-:?#VO<Z:
MNS5;68:YS:TU4(&-J\?4A45^067;4WTN]RR.%?<PLF+KUF&/%+6.2,A'2?<W
MY+(+UW'4+L7Y0\GG:.#H4/">3P9Q="M5B\1>&<=5Q&8GL6<EC/X1E[UN!\G&
MLEBF98+=>P4=)>J3YQ\:25Z]JS7?PI3QEG)6;6<IY'VRU+-)BLO;GO4(XH:E
MSZ)Z:\$HINR16 DD$L096CTG07/9>>?\<<<M?/\ WG!_H2?KY>..;GCCCCCC
MCCCCCCCCCCCCCCCCCCCCG-G?7?:=*W&,6<)IU#]&.X>SNP810)K/1?8YZDPZ
MF'18\-EG6#R:>QWFIZYI@&'N)$,ALRJIL,!UD%95\T47F!N^CU1HG?0ZW;U8
MZ)Z0BN3K1&M[T"#%))T%?EIV;YE47T4=MDL5 _J^.Q*LSW77Z.J[7L)\1NL]
M8=/FS Z7-W,&6(O3I4PU'V&$VE^C^KO:>8BRSNBJG#U]E;U=F*80R"U#KXI(
M")K3&04'4I\P;4CJT/>*=]J#V(/< CMV)Y42 A^S I]8'IW]4-VTQ'<$>I!^
M>N5'M_&)@Z&"*PI(--;U-35MUNDL:K*UU^+-0 ]+;#O6\SE?)+N<S*#JZ[#T
M68-+*4:[K@C.Q,'6(&>Z^LC<S>L#'U*@DZ +$=_,6('ZK J7+#6P?<8]@!U6
M-.H[CJ( V2 &&@AD(^L""%T?TLH[[[32Y\369%UEWA\IBNP.R=)1R7_OBXP?
M'L",%R%9FK#9GU]QK-EEJD@7*E[/*9NQ]9D,Y6LN9*"GALR<[L79N@A;I#,R
M(#KZW5OWBP4$*K'9Z6/IV V=;7=QE79"JS$;^KTZ]T L=LRC0) ]>Y.AO3:R
M=7XD,Q19OJW2YS([KLB'N+.F:O$5^-%RXIQ5 #CX]U/86,FXU>-KJQCLY(A$
M,))_Q$I?IKVP_&3012T6%F+@LB>60K%BVMEBH Z58GN->FOCZ;/*M( %(5GZ
MQM0O3LC75OWF4#M]_(72>,7):#Y2%7=;=J+IM:/UQ9]>8\D7 CWG8&>[4SG9
M&OR6DIYW]@+04=;)F>H>Q[JV$V]WE;ZH%S,PY=,VSL*FO/N,##>W3I4L'8=6
MD*%%8'W0209$ Z0P.^QT"1:)P=>Z^VZ>A3T@L'#,K#WM*-(Y(8A@%.QO0,5V
M_C.&3'7MGU?UYL[_ $.:'I7[1+>MS;*?JX\[MK1]1V-%NH&;NMLK&WK=/@][
M6FQ]?+L JU**.[,.^06%4;97)7VP#NJAM].BVW C60%?<( *NI'7T[V1Z@CE
M&F]TE%8D:ZNRZ0]90AO>!)#*P/3U :V>Q&]1JO'QUU-!MJ7KU8#-;1+JQ\T5
M<VF,M*;1'8/7@9760R9S,;TKL.ACA?-8%TI&QS62%O@:^:RJ2#0W"?'56J^U
M+]E/23H," R%U[E>@[[ ]+,03W'KJAL+W"^HWHG1!Z6"MV#=0]>Q8#>MCMK=
M^=6^(W'=M[G=83.5%X)88&QT55<%V5AAY4:;F=')F3H#L]2;&YVV3F-*8VSH
M(-YELI/H,_-%<U,10R3)#$\3(BN2"&UH -_*&QHE0K:'8]+-H]CKMN1)5=F4
M [4D'97X'1V 2P/Q 8#8((]>= \BY)SF'LO!A;0IA,5B?F]3G+:P/R>PIOAT
MN,^:0YT)<:1E13A6M+:P-8+?9ZT')JK<9D+Y88[ &LL +T<KOL"K#3*?0C_S
M!![AAW!^XD&UE#:[Z8=U8>H^?Z0?0@]C^D B#1;KL3+)\)O^N;*\B@^U=M>J
MF17]&9"W[1I9N(/LHNP*,\ER+*M'2 =@A QJUCM6;)]?+BB-W1PO_+)V(_0W
MU6'WDJ?NY:&=>SJ3_P R=P?OZ=]0/W ,/O\ 7GM]G+%_RT?<*+_*G_5Z[]=Y
M+_*GJ9UHYCO)?J\VN<U?NM<J>2\IY3?./^VB_?Y7S%^3_P!G)^[Q]G+%?B3N
M'_#QW_\ NSX\IOG'_;1?O\>8OR?^SD_=Y*<GWOB(C27.H^Y51151/;\.?B$F
M7S]Z)?K;#U@]R)]7W51$\_)//S5$X\IOG'_;1?O\>8OR?^SD_=Y/?L_87\0]
MU_X:_$9^ZOCRF^<?]M%^_P >8OR?^SD_=X^S]A?Q#W7_ (:_$9^ZOCRF^<?]
MM%^_QYB_)_[.3]WC[/V%_$/=?^&OQ&?NKX\IOG'_ &T7[_'F+\G_ +.3]WC[
M/V%_$/=?^&OQ&?NKX\IOG'_;1?O\>8OR?^SD_=Y3/V<L5^).X?\ #QW_ /NS
MX\IOG'_;1?O\>8OR?^SD_=X^SEBOQ)W#_AX[_P#W9\>4WSC_ +:+]_CS%^3_
M -G)^[Q]G+%?B3N'_#QW_P#NSX\IOG'_ &T7[_'F+\G_ +.3]WC[.6*_$G</
M^'CO_P#=GQY3?./^VB_?X\Q?D_\ 9R?N\FN1[XQ$33_51]S+ZG#>7M>''Q#3
M?<2?[OL]7R>G[OU>KR\_K\O/R7CRF^<?]M%^_P >8OR?^SD_<Y,?L_87\0]U
M_P"&OQ&?NKX\IOG'_;1?O\>8OR?^SD_=X^S]A?Q#W7_AK\1G[J^/*;YQ_P!M
M%^_QYB_)_P"SD_=X^S]A?Q#W7_AK\1G[J^/*;YQ_VT7[_'F+\G_LY/W>8=CW
M[AG5YS4HNZO-P9*)ZO#9XBFM\UA>B>;G=6(UJ?SN<J-1/K543Z^/*;YQ_P!M
M%^_QYB_)_P"SD_=Y4OV<L5^).X?\/'?_ .[/CRF^<?\ ;1?O\>8OR?\ LY/W
M>/LY8K\2=P_X>.__ -V?'E-\X_[:+]_CS%^3_P!G)^[Q]G+%?B3N'_#QW_\
MNSX\IOG'_;1?O\>8OR?^SD_=X^SEBOQ)W#_AX[__ '9\>4WSC_MHOW^/,7Y/
M_9R?N\L'*]]8>*NE:ZB[G55,D7SC\.'B'F;Y+".GUNBZN>U%^KZVJOJ1/)53
MR5/-Y3?./^VB_?X\Q?D_]G)^[R2_9^POXA[K_P -?B,_=7QY3?./^VB_?X\Q
M?D_]G)^[Q]GW$+]4>?[KD>OU-9_U;O$-%ZW+]2-]TCK"&"/S7_SS31QM^Z][
M6HJH\IOG'_:Q?_1^/,7Y/_9R?N\QI]GVQM&J!@NOBL"'.BM?O^VDKHV"C/\
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M+Y56?B\+\UA_R<<<?*JS\7A?FL/^3CCCY56?B\+\UA_R<<<?*JS\7A?FL/\
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M/]!X^G_8'X9COT7N_P!M>/I+)?;H_P!TL?Y_C^#_ (<_X&;_ ,6H?Z#Q]/\
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ME?7-U>GCA5ZF6%K;$E&3M"IZJGH:H;W6C5=#3552%#"&#!$VYG+ZWKW1T@
M  $G0  '<DDGU)))[GEJJ%WK?<[))))/8;)/?T  ^0  [#DSY;R[G% T27O8
M>\U9")+#57MOBLQY_;1C@UIC'ZDR%%3SB+L]1%/4G^E59*+E*A6HQZ3([@E
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M>J^!*0\5K3PMB0QS>'[\%V"X1U&IX:RMH4,Y&Q.R\5')7<=DZ=<%8XFMYN8
MO:<\A^6H&9JC#J_?4PMJ2EVUF]B,FM[LZ5Y=Q;D-;]JV:QL)B"EB9Y0C,D8*
M.R(:"&)F#3K"K7CAZO,D +S3$ -/8D)>>=@/1I9"SZ'900B@*J@;;,9)LKD)
M[GEB" E8:516+1T<?7004:49/=DJU4BA#MMY65II6>61W:0\RN:SCCCD>U-
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M)L'7?K/5+(5Z5UH[!4COW!_KC^AT_<,7QU3F6>).WZJL^P0H<[JM'2]L9S9
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M4LUY86H1>Z1YD-=88H[*(RI9ZK1'2MEAR3Q)XAIT+6*CJQO=\/8U)L)-"?\
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M*<%497K[8:^RMAIR)X[7=ZO3Z8:()UY./!.UG;,57IV00-@Z)E$KDG7<LP4
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M$9C\2B1+ON% [<RO;/!;^\_A_P 21L>[)7\5XX0=1]5B6?PA/-%&#]42SVI
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;1\Z^O_N\'_8Q?^A>>47_ /?KO_>[/_O/S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g189651g55q10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g55q10.jpg
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M]9S]*ZYX+Z1KO#_4<6BZ-AZIF\6]!_4/H^8=2TG6^JC"^IPX^K')@3J.KR=
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ML:<?MY"UN\I]]&L!8[C3JN_]H:N2*KDJ387B5\TWM\Q-MC^+0VBU+;?W;0>
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M"0*&]BJ[B&H'@"'S.0[(25.3'B4J%-7R[C=0)L[ &.T%>1WE=MG:_$W0>?\
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M9C]%HOJ?K?I-+]9MV_5_3XOJ=M;=OG[/-V[>*WU7%5.O_6NL'IO^C'JW4_\
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M&FW<!\:MKKGC*17[+W?Q'5J+F^0][%68NNECQX3/TKX/5$R6FQ*NS7Y%6M1
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M&+I:+%,7 \2N2 ([\-'/SJX\#7GLCBH'++:?DY\I96W45#!:50!N!#4H4+;
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MCB!RTV5]^8./3:)QE 4[O+ ):R@-L1?-4)%#)_"M<:;<3*3N];UY9+"M_ 4
M.00 010.RFJO53.W3[<19..7>]]IZSWKG$Z=%\T+A_$5Q:*50[Q%-69NV2UB
M7/-PM.CX&#K#BGZK7JO88NV0,G6)TEB9B7[53<PQ@D9%7%CPN+<'%D(93MH"
M@6))!#$@J0P[U>@<AY1FR/E0TA&3&-K -9/90 O8*0RD'D7T4?X9+9/6)VRG
MVFIP" H98<%3ZO4XL:HN2(,E29&/8L[0T5#2%FHTMJF!@R],F'Y V*C61!8:
MVK=906SB-0JC:%8@D6S,=P%,"5Y(#>HD,*!-DKS-CB8FRRB@:4*-O\M7P"0=
MO(-UV!G:"?>VE.UZ3I?NZ][25;4G2O9_VTE6TIVI.M^W6E;2G>]?OVG6_P!V
MN6;S]Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B<R^(_@<CW.1\
M/9L?8PJ^GBGB(H';3VS 7S=SP%,9F&GX$13#[&@S#MR:-M&O:>99TTK2V5^]
MKV;X<HQ#,""?-PMC%5P6KD_;B8YL1R'$00/+RKD-\V%]A^?F8OB-\/<GW&T>
M'"P1]E!K[7#.YUKKD@,8 0:Y8 H%I]MR%#<8(92$41MW6T%OI>:;UK?O-*]N
M,.88ES J3YN)L8HU1/N?M&7$<C8B"!Y>0.>+NO8?'YGO\6?AFK_BEY412#9-
MVJW&#D@[;S#H8#;FYB@WN'7YT1. N#O#%;&<5K8<H*P2PX^&[MX9T>3$CC1&
MGSG!DW5N5@5R(>SH>X_/N#_;L2"SX1F3:258'<C#NK#L?Q\CC[$&B-R\UCKW
M$4.JQ/39Z'M-\C(@8"S6:!CWXF,L,B)K;&YIJ+?<=5'OR3+;19XC2]BLGNDI
M"2V)IAI&>0H78XP50DE5-6H/-<>P[#[5?,T0,%4.06  )' )'O7M?<_>7C*2
MT8B<RM>'A3<^W-[L8BMHO7:;IMGX)O2U;ZW7W8%H/;WQ#?\ ZP;3FMNE[1OX
MBRC0Z60T^Q6M_.&W;1_9B6[_ /XV)O\ O?'Q,O+-W8_<[#C^L5_Q_P#F:EJO
M@M*K<K%(>OWQ6N#%5B?.&)7T-LK5EKG)(7EVGHR"'Z6SSIIE]V""GF)23I4G
M.A@K*JVRBAEA2L?J=4"#Z*;U <)^ULA?EBA?W((#!2?50Y$HN"B/5QZ21ZNX
M0)V#A/8&RI/M\$>L'PB]!4_1T3O68L^.ILGQJ2;!"A;K'1C@_*(BM0CT0W4V
MNC?0@_=@^C[T]])+97+38HTN5>@6"7(./B- #J,8#;<9LC(/44)_B$M>\('%
M75*5!%GN3<# UBW!HH16ZJ10M;=VTW1-L";-755(U3PGWFKM0&Q.HQ0^JM::
M7,U^$:@;;,5B&$KU,Z=0Y]R  NG0;4?6UST1TK1<14HZ37SZH%5.(%C*X0/*
M3KAD-J%-C82"K FU5CN;&XW%$4&CCY:M[;C9! H,# #UC@J0*8J*5U.T,S$
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M=4\1$-'=%@9A1UA\6M:C(.+(G6NK\M8IW&>@="@+JU9&K>^J,@XB6KL/ QP
MM5B6(MVWU4N/L+1^FHZ2[TQ(QPDH5I<#%B!Y>3=E1"I&WEB&)LMR%:Q7(Y'R
M,HR@,#9R@ 7O2L;,&N^ "*["MRT;X-INOC*O55M]D!APZE9( +?;8:*%=B68
M\L&8X_6YF0,D),Y/43;I)@1DM7I!NUK?Y%5H5Z->015[1)-"AR-D@:9"MG<I
M_AF[-$9&% #9L%@C;60FZW <@#G<$UM(IP+ %% ;).\N:(.X[ *[$\7D0'=+
M]']#OU==[+R&0"D^D>B1U&5C9A[ED"+7>#T2V:I\-7=]34/!SM@,/DI@K3-\
M)%4#!VF83&JD2MM1PXD.-#Y60$(?X8(#F\K+N+;+*KVY4<D"Z',C(P9@<B'U
M_O(.T 8U;:!OX)))_=V!-$FY4.*^*?K3D1QRL% Q4T(+3/#;79B1M,K77+5>
MB.@\/HMUG>ALSU@Z]$7>1?&DK!*ZT(!R2VMV!^EVUMZU-2A)VZG;)I\?\1@2
M/7F(VAJ4)E90E#&4 H V<BD;AZ2*NF/.]8UX("8A;5;EL:L7LY Q[GLC65:V
ML^GI8+K_ $V.\,5$ZW9Y#GN[AT!''3%R0M:G(BA4&+Z[.TJ*?/G #;M(RDT!
M11;.8>;([L=9'FT@L>J36!%E&CX>7C.=\:A]J#)Q8+N<88\': "U=J-#M9FP
MR.,*9&V[G\OD A5&1E%D;K(0-9-BZYVCD:8OWB[N=.(8#B+3RJ]+K?P!^UR%
M<KBPX:<#G^O6GG@^@3;1V"O/Q9*1*K)QBV:.#V@@>X1\F_("Q\(S'"3&BZ96
M%E<B;KVAFL@C&KFPN-KY8'UG%Z"/YN11L[ @!D:JW$#@VY0<EQ1X((7>=PN@
M*!E#_$WV&##%F9;_ (R=BK@QUM$$INL62.'YXUSGQ'\VXDW;+I)D7LMNSUN/
MK70#+_<6@QJ7L >KDBC2;(I+LB*&#&Q*@."GEW1!+[\+Y-J@KZ6)0(IMKNZ]
MH.7(M$E"&WT:(V;,JIN8WZA3%F_;55=<B*OOBRZA494V"@#.5W_=8K$Y92;7
M$,0E=J]]/C[69!:ID81>>WU7Z/2<$V*'$VV6J3W9-@V"R0;J:^*XGZ,24II\
M;"R,B60NTV62UO<0F)B0;M0XQ>D&SR&D-F<&E*/0)L4 U-6T;L@HBJ)7?R10
M_EG0,!U+I+O)^[]5F4U62339GQ! \^JL!7I>/.:$XI>.E4X!NR2QEIF6[%)V
M7Z&QI;FXJ(K8X#KY3#3):7VE"8'&GF8L8L;O*+L6%?Q%1C0VC:%W'N2?GM-5
M=RF1R =IRA5 -_PV=:)LV3M]@!\7.7Y#H]^X]UQV0'N%FOD"=PKD_-X:!FIR
M3DX6;[??X[HE@YY;G!5O/1\89>;/4#*=+2(3 ^CC+?6!-J2)& #M=.Q,F.BJ
MH1E=R0M,,:,JNG:SM5@P!Y]!]R9B6;&]AF8'&B $\'(P9E8^PW,"I/;U#XFG
MW[?TB!YD9 R/5;K.$PC'(*\=8K)U:X4AR70K]HU/\VG)&>OL(25.5!NP4D--
M9L5IAV"9&+JNUC#L%!@C@;N50Y 0B*"68 8U8"]&CBD- TWJ"D@%O>^9F68(
M078UM!)=@2/JRAMA9%KZ21V7CMQ-D4Z^GDS/T$N/138?DJ^_N1-BL=4\0%VZ
M'6(L"1X8%.4WG(_B2G2*[T'8\]>@3YVP"'$5PF.GI.O<] *+@; (+.490!O7
M&#D\JU#8E1B1D(?)Y(#)PM!2-U@%B+!K16-[6:L9R42N1F"@XQM3S>&]3 D@
MU1(4$KWZ.@K+ 0Q_)'.7]%N'0*N3WNX\K+=L%BEK8"9#2O/;39Y>!@+/+><3
M<X^CV>IQA@%J.E+3)PK43<J<S84C-R$>%@0S#)O14;RER< *;#@!F4<*65B"
MH"W:M7SH" 4V,S#S63DD\;"2 3^X*RW=DBF6^#.S,YIT1B)(Q'UI'_Q;'^1.
M(DI:_K7^69_NYB)6L1.>[SVGE,-<9&K3]7N=MLE""A[%(NUGC=YZ,W51YYHT
MF*,U(UBK3J S"F8DQ]MD)S9^TB;]C.U:0G>R8\A4,&55>P-V14W;31X9A=<3
M)LB!B"K,5 )K&ST#='A3]^W,BY'O7AV8-AIM1(DRU,05*O'TVA.?V"Q0,'7K
MX[[E%LUKN457#8NJ!SJV-O@%S\C'N"!,*EC] Q3*CD2,6>BO(HLNPN%)*_O"
MJ2"U>X -G@6>(.7%P;NPK;E4L &/I+, 0M^Q)'%DT!<V7*]3YG#]"<YS+6"*
M%O2>:SW3CXY]I?F <WK4S$PTK.2TCY.PX^.;E)\9L8<TIITS2)(D5AUF/.=9
MH$R%-X!V>8$!^78$@ >YI>2.W'S+%T#;21NV%R"/Y 0"2>U6>WY^)0('O_!G
MJ99Y 4IZLU6I0==G)>'GN>VNH/.UKH11X5.E(:HS%;C96Q1]\DQ)&)K;4%$R
M)%@GF2H$45Z;2X!ESBS;EOU,Q(#!PWJ3]P+!B 4%$V10Y[<RHRXJ:O2% )!4
MKPW"D*0"0QX% DGCOQ)6DW/D_2G'J)&UV8KDC2WJW=$T*VT:R<WD@QVYAX^L
M6J-@)J,A$R<0B?B'G&S8]!H84V!L640+)M)'U#KEQ^LL&#!DWJZY >*9=P)H
MT?>C7;B%;&_I (*D-M*E".;#40+%C_(YF]\QFL8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1(WX+#[(**W$QFRCAG C2?0"^H,#=<6ZZ(4
M]Y7F$#.NN...,.J6TMQQ:U(VI:M[G<U 6:!L"S0/R/@_>10YX'/?CO\ F$0T
M0T8_(-14:V>2XV\2<@$5!A#S(SH;+KY*6M/.N-!OOB-K<6I2!GG6$[TTXM&V
MYJK<:'86:'-]OSS^8H<FA9[FN_MS_;B>A%<KS06HUN"AFXY+S)*0$18* DD#
MN)>'?T*EC3&GF'4(=9=TW[[3B$K0I*DZWJ=S7>YKHB[-T>X_!]XVKVH5\4/;
MM_B>_4-$))$,3%1J2P!%  E:!%T2$ I.DJ"$?TUYHPBDZTE0S*D,[3K6MHWK
M6LC<W/)Y-GD\GY/R?O%#O0L< UV'Q,I08BQ% +%'4"H?8B@E,-*$4)MOR=BJ
M&VG;.Q]L_P#EMG:/+VW_ --I]W]V1)D?NO0&_1:W!P^]1HC@$=K<8%OT +R$
MMNAA?^'_ /%$=;0A#@['ELK0E*5(VE.M:G<W/J/)L\GD_)^3]Y&U?@<<#@<#
MXF;N/ VGW-@A[3Y1;/N[&9VGR3W$NG->SW/9Y1KJ$.%M^SW2'$I6]I:DZWI9
M^3_GX[?XBA\"8FH""2S&CIA(C0\*ZA^'8U&AZ9B7F];TV]&M:9]P%U&E;TAP
M5+2TZWO6MZ]N\;FY.XVW!-GD?!^?[Q0XX'';@<?CXF?H89++@Z1V-,/*(4\Q
MIIO3+JBW''BE.-:3[BU$NO.ND;4G>WG'7%N>\I:M[BS\_P#P=O\ $F0%:J$!
M5(&&K40"A,5  1D5$ME[T8^)&PB?+@P_5D:62^W##Z;&CG2''B6FVD+6^X1M
MQYRS,S,6)Y8DFN!9[\?<\GVN5"A0 !P*KW[=N>_ X$E'H:')9>'(BHU]@A/N
M/L/ BNLOHT4L[2'FUM*0XG1JUF>ZM*M>J6LCV>:K:]QN;Y/SW/>JO_''XDT/
M@?XCX+#_  U<-\)C/A#K:V7(KT OPUQIQ6U.-+!\KTJVW%;VI:%-;2M6][5K
M>][WC<UWN-_-F_\ />*%50KXKC_$BGZ=7R):K3"P&T/4MF5;K0;/L8BXIZ7"
M9C"#AHYI*!6Y >)29$ %H;2Z%%S$T$QM+$H4E<[FIA9]5;B>2:-\GO5\GY(!
M]A(VBP:_;=? O@\=KKC\$_,L^5EHQ$D8CZTC_P"+8_R)Q$E+7]:_RS/]W,1*
MUB)PQT7PXW_H'1_$'9H2\7GF9%II7,8SG<Y6;Q(PD!-S=;CK9\4$ML-6I06=
M=B$%'1T9(DM.PDWJ*DSG:M+AR+;9XG6F9$3"I1'VLY<,I)4,114GBZL@>H6!
MN!'!YWQ,SY6#,NY4"D,0"0&O< 0:YH\@T>#[BK2<3UJ:!Y?R^0\+-[J_#*W1
M^=[LU.YQ;>"':FK#7],)'YK*RUD[-69$?E5(^%QRR=1,?(R_16EMQAKT-!B3
M$-;9W8P7<9U;*SOM=QE&U3?K 7&1YCWW) 2C0)(*U(<[$.%EQA4L(V+DC^0V
MX.Q*'8$MVX (;"D/#CXD8OK,M<(JZ<LMCMDX[XK(LVV2G,CHPC5QZ:?QK?-Z
MQ9&)3K%I8E8V.'HD+'QAH5.<KD32>>S$!.P1TY=HV;"D9L!QA2KKMR8#M#WZ
M4&3>P(1:)W$GU!B[ @@*1(\K,,A8,C6F8;BA M]FQ2"YO]HYV[0JD$$L"*G
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M0+(CS)T(>@5>&LS<S'@MRB)J6B (X"7CR9@QJO2<"BF)=4&(Y6#*/, W^6H
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M@S;(T7)5BR3$/ZF<A7'3XYZ0#CRY<!+_ ,.=5??G \W<U.P&ZQ9=10/R& )
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MH,.+/DU.+%HF+DZ7'BU.;-J,>/ <:IGRY,J@9'9CCE5VOG0GT:-@H8RN>D8
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M96Z< 8L9FL6F*L!0>F 5Q9"M28\<Y'J4DQ"&]$;6XV\VE32^C!J6Q9 [%L@
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MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(GQ.Y=?^R^(
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MNCE"D2#;X[S:M;2XTZVAQ"M;TI.MZ]F7&-R+".0>00IHCY[2NY1W9?\ (_\
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M-@.3.=0N1#A9ER;RX!4"O3M_=N %*H!)X'>P,\68)A&!L;C*JLGE[33'D7N
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MC_7ZMBQMN*A5*8$W@U7KQ(RY0#V]1(8CL=IXW3-<CJ &)._*VPV;XRD-C/\
MZ1:_(W#^6;' \4?5)".H20M\EEI;K-=XW;((B( LA47S8/J?0(&F$0-T81;7
M"K7(1XT\^; 2X1-#193ZK9@'H&#0-ZEBGT^,%[\Q1C.0$';N?RTW6IV@*"0
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MS9S9HX[L4^SMEQEX>40&^T4A0;C:2O\ QRI5@2*Y'>B#_BB;'/<6*Y[20RD
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M%L$*U8(Y,<\^X.A,G!R>G6TI6KS(.;CYMIKV*]FO<?=CT,.*_P#R2VXM2?\
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MF"B.IDD0+&SFI8"8:&6I#D*W$N^N<D;'4DDG: 3O['@;]WR"?3NX(()YW6*
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g189651g56o91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g56o91.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1864&AO=&]S:&]P(#,N,  X0DE-! 0
M    %?J^5B8X0DE-! 0      #L< 5H  QLE1QP"   "9BT< E  "')R,C8W
M.#DT' (% !I-:6-R;W-O9G0@5V]R9" M(%1Y<F$N9&]C>  X0DE-!"4
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (  @.__C4
M @ ".$))300F       .             #^    X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@              R    H\          0
M               !              */    R                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    R     !29VAT;&]N9P   H\
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    ".$))300,      N?
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P#H^J]8ZI7U/)JKR7LKK?M8QH;   _DJI^V^L?]R[/^C_Y!
M;F?]5;,K-NR6908VYV[:6208 ^D'M5'.^J]N'@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" !  -(# 1$  A$! Q$!_\0 '@   @(#  ,!
M"0H " $#!P($!@7_Q !'$  !! $# @,#" 4* PD    " 0,$!08 !Q$($@D3
M(105,1DB.$%7=[354725EK86%R4U-U1A<932,C/P)D)B=7:!D;*U_\0 '0$
M @,  P$!            !P@ !@D! @4#!/_$ %01  (" 0,#  4!$0D/! ,
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M+K[[[I"#3++($XXZX9*@@VV D9D2H@BBJJ\)KJS*BL[$*JJ68D@ *HY))/@
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M<)>UGW#D;K=5.<D*JHBM0E?:L4Y^:+D,"5%X]+9LC+G"[GQ5LOV0O92I:)/
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MS,3P  3\-7&ZV>FZ-TY9UA]53B\=!DN"4$UN2X2N"YD=3"9J<J$3)$)"D63
M7"M_\+06P-AP " 7C?VU4VMD:4, 8UK>/K2*Y/(-J%!!= )'([IE$Y7W*)U
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MT:;1ZTBVI\=34TMAXDVP,?:7>8<SQRO<BX=NBS)O41MKM@UV6-2"'(:Y@A!
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8_CS^'65YXY/;R1R>"?!(Y\<CY>/?K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g189651g56t68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g56t68.jpg
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M4@DR46$8(R0E-51TLS,V<I&A)T)Q@;3_Q  < 0$  P$! 0$!
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MT$PZ!9BIY16VC&=S8 4$G'YB!DG^]:T]1'4SO.-7YNJ M&^ZG=;VQ.E\;-F
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M!FK%Z4^J:MYUQLL)O7J+U/;[!H6[CZS;MW9N% "TBV@[^.A6S7I]1D3*&TZ
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MSQ49 ]=1*8 $6^RZ-,U2L6;7^\+/5Y#UZ ES$VT=/@Z?+OM6*"1X[,<2)G2
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M-*G'"5]K4$X<,#TQT*B3[!W<!-FR8#3$M,92PD"JKR([[0<J(U9 J#.  C$
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M,RHC**_L"NP0]QJCE9ND=,TXF!88DQR5,D;FZRH8QQM*9Y)3N5MJEDB"E0'
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M9FVS.OZ.,,A=>:@/'JY]W%*#F6\1<"6(P*I [3<!@(9Y0>J0-F6J\1*P-4A
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M]UL::W?Q8JJWA+Q4P1;(P<EG8;*2Y#._\M'0N&42*PVD(J9 1UP&"KE"67@
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MDLW&,PW9$1^#3IGR#A<K$\(X/Y7#@D\_FZYP>!P.#SF_0I@C+<RI*>1^9"A
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MYQ4AD@W N&& $C"!73HNOL(<@L22YDR2%.=^1M4#@8JW0 @DNY<LK=)U-P*
MA<#9L  )&-ASDDY)S6=UUTIT;7-G!7.-:]AVBT!;-M6XO&+:7 S'SEBW)"JD
M.Z3RS(FL!8J&W%U ?+$#PS @:'=E38D.&D4D<.'0\[NK*51598UPH(VK&6*
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M9$*)F?,CQ)+T2#AU#&9LEIE;C$3#[F,H9S(=2AG#J\90WE?EJQG&,\D8R,G
MSR>W [\4/8<<GW#LS7R^U/OSJ<V4_1 4LY7 LNY6/7L:VEAU*FEB&M"!O7.Z
M[;>:5+'S XH$%DB"M%J0F"!LY0Q?J7+(._;C!2/8ZUAWMDA@3><$A5<J"X ?
M#Q*C#DL00S'<H"/CJD8-<223-M!8#<4R0G*$K(S+R !C:O!RR\[NT9BB^H+:
M[!^);RMX)QCI?6]>$7&MPZ-!' =$7@_M&%'L%-/F;06&5 ._7!<98=-NNJ+
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M8([$=508YYP3N((DO+QGK N1C;C'1W4<:G(/:R,S'L&1D *"##8/5?MK$=N
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MKU9[MLN24?&H'ER\FAR 0V;"M1260?NR1R/G 8E]NP.J (9IE9QC'Y55 ,Y
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MLYR%+*^%8AMI#*I!VD'&"I!(K+H%55$81&0AE(0 %@I3+*N,@JS \@\\&JZ
M]#U8E'QY[:<G7VQ(B-@'+^3H*M5H;UBN83U^NBPV0M5N=QV$\*FQG7';(3+S
M"IA14N\]F' !LJ0ENYN3@B,,AV! V_K\/O)+*J9S^4# P.TFJBW&07V.-Q8I
MLZF2NWA69\=^23D]@%9N\]$FLK@;N]OC#Z>"O<R3K4EJ&WQ]<@)9/3)'5 0:
M.JL,3Y;["C-.5-%LNEZ2T]7PQ$+)F@O^H4\T4CU2Y=0JY8IUQ(F]@) Y.[/<
MV#PW)!P?A4O;HQ9L*&.PHVP$QE  ,'()''*@@$$BI_K;3VRZOM:Z;+OFRJ/L
M)=IP3@#,,ZLL=;M-1JBB34RO4>OV"5N*TUP?6!3;+;IQD90QA.ZG&X]@L!-V
M7#A-1ZO(C1JBHZ;<$_S RLV,%BO1JQ8^[+D*,@#!-72-U=G9U?=D#J%65<Y"
MAC(PVCW@*"QY)K9/F-:TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE5'9
M=>DS>Y]4[*CS8#0F@U#;%=)0'LR/$9DJ_P C7+PQ^#A#"XV8\---GXG9D2&7
M,9E1.[MO8R]EK17 BD3!R[1D'W )OSG^^X8_UK,H3(CY&%612/>=Y0@C^VPY
M_O6J6[^EK96Y;*[;2D#4$FSG=94VFAK65+6A\]TQ76NVBR6$IM'0+OV0DK,6
M NZ8KTSR94S69%PKKZM)-'C0/+085O%.D8V@R!0[,5&T"9655V2]88 P?&,.
MV IY.$D#R$L1'N**H8ELPL"3OBZIR3D$C*<J,DCL^A/.2NNG%*<4IQ2G%*<4
MIQ2G%*HL'K^YU*Z[SNP1ZL$9.S[9KLP"'E)A6$Q!&5RF5&FV%):1$%S'$3U1
MPY:>&:AM2H\AY0YB<_";>DN1M2ZLL:G< BN"1@DEF9AC)'&2 <_'%9!&5I&&
MTEV0@'/ 554YP.W@XQ\,U4U&Z?+^ O-"BF2-.<U?J#:^\MP48@-(&G[Q8#.Y
M5[):AUVR 9(&&# C*.+V_=!J2X^T6*5:\P:[->%UYU!!M[1YD*/@-TDB11N"
M!M CV=96W$L7,:G!5=N3R>*HL3*R@E=D;R2*1G<3)OZK#& %Z0\@G=@<+S6Y
MO.:NBG%*<4IQ2G%*<4K7GJ#T,]O$4%1"V1=]?&*FQ;I->75D466(FFK-5YU6
M;F6,=>J#?8SOAPTD4A0)XB*-,#8IPSF%-2_):6SM#+T1.45PVW.[<" K!N"C
MIVD D'() R.*REBZ0##LA4-@KM[6&.=R/[L@$ $9.#FL56]>[KHNF*EK.O6"
MD6<O2M>ZV!M';YYYQJX%0,_$>^54[%KE1%#@M5,5")&KM6M8\,5-BY$UPJ;J
MIQT4ID_)>)I&<JRAG<X3_*".JPW,26#<LI(![ 1GB LBHJ*RL55!E_\ ,0>L
M#M4 *5X# $@G)!QSF.F_4I;3M/LH,E&J@"-8=@6.Y@]=T!Z;(U]JP.<9%M(I
M%*D3Q-=>D",D8!&V3G6JS6H*K):CN!H$:/Q&9Y6:02,"-Q(0*7?\\A&>NV">
M<$*.LQVJ,DG-3%'T:D84;F+!%_(F<=5<@<9&[\HY)P *V#YE6M.*4XI3BE.*
M4XI6LW4!J>Q[$GUTB!U_H/8S<"J[!J,P5NX3*\Z)3>45I*3=:LL"JW*8U!;0
M <BVJDI$BV;K'>$K5;J^Y7VDD-XI%0$%Y4)9&!C/;MSPPW+SSE6R=O/5.>,9
M49R"%B<;64B0=F['64A6[N5P-W'6&.:ZN'3?>3.J-,ZKF?8#:M;T?,UEYRM[
M2)&V@6_!M,U:7I!!G;'FZQ;HXN7&N)$5LL#_ -R7X9(L-5$.%1B):F" RRS*
M))).O&TH?K(!F(LX8&/E<C:"AY0X8X..#5HG*1H=KB,IU7)(E"H5(D)5N0Q#
M@X;K*"1GLOCI]UL6U'J6M4 U.'2Y8:7:I4>$$7.<KM5#'[@?LE>U]572:&B#
MU1UL +C:!5'ID>$^[7:V,<4.&85@?%RE<22%P#R%Y.-S$*%9VQQN=@7;MY8\
MGM.D2%$"D@D%CQG !8L%7/.U 0JYQP!P.RKFYG6E.*4XI3BE.*55>W@-VL=9
MCC*:*UU:6)!%R-=*'M)$MJH7^DD Q<65J\PO" VUT$ZN9.&%TS7J?:H4^.)D
MUZ:(3'-+)CM(RJMEBZX'5>/&Y&!!# $KGL(QN4C.0>,&D@8KA0C<]97SM92"
M"I(#8[0<[6!Q@CG(T<D] EP?H5.@0-]7&JW #8-8.8!UUB@$-:4^C4?J:A[Y
MATK7B;UJJY7,9&H0=$2KT?/C X/97=?ZU:O@&36PV0,;I_%+N;,2LI#\MO#L
M[0&+<^R1%.XY9N"5WOM.XYKE_"MM7$K!E*<#;L55F$NU=R,PVC"KS@E4W+@8
MK8G>.I]C;+<KI$>"UZ0)TVRV;%=?>VAN+5-B16#U<@P$34[#U5$8/#9#Y5F2
MW;=?^%%JO;Q+(=S)X(5%Q)#&,4B(&!+@,J[NI'(-P8DC8YQV8VOD,ISP036T
MB.^T@*2I.,NZ'! _S(,]HZRX*L,<@XQ;FD=91-+Z?UGJ>%,028U[2:[5,DFH
MB1[1*0'&QXDPBR/0Z^@>Q/F(?ELCT/OH@M/(BH>=2UA:J2OTDCR8QO8MCMP"
M>!GWX'&??VUI$G1QI&#G8H7/9G Y./=D^[W=E6ES.KTXI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE>-V,^XXI:",ME.>SL:;;@*0CLQC'8G+T)US/;G';
MGRG%9[<Y[,XQV8Q.?@/KZU4@D_F8? ;<?52?K77W.3Z6G?RAGR_C([A]?6F#
MXV^2?;3N<G/\"T[^4,^7\9'</KZTVGQM\D^VG<Y/I:=_*&?+^,CN'U]:;3XV
M^2?;3N<GTM._E#/E_&1W#Z^M-I\;?)/MIW.3Z6G?RAGR_C([A]?6FT^-ODGV
MT[G)]+3OY0SY?QD=P^OK3:?&WR3[:=SD^EIW\H9\OXR.X?7UIM/C;Y)]M.YR
M?2T[^4,^7\9'</KZTVGQM\D^VG<Y/I:=_*&?+^,CN'U]:;3XV^2?;3N<GTM.
M_E#/E_&1W#Z^M-I\;?)/MIW.3Z6G?RAGR_C([A]?6FT^-ODGVT[G)]+3OY0S
MY?QD=P^OK3:?&WR3[:=SD^EIW\H9\OXR.X?7UIM/C;Y)]M.YR?2T[^4,^7\9
M'</KZTVGQM\D^VG<Y/I:=_*&?+^,CN'U]:;3XV^2?;3N<GTM._E#/E_&1W#Z
M^M-I\;?)/MIW.3Z6G?RAGR_C([A]?6FT^-ODGVT[G)]+3OY0SY?QD=P^OK3:
M?&WR3[:=SD^EIW\H9\OXR.X?7UIM/C;Y)]M<<QG\*2C)B9A:\*RA.6Q>%*PG
ML\K*4Y']JL)[<>5V8SV=N.WL[<<9'</KZTVGQM\D^VOQ4=Y"VVU&9:5NY5AI
M"D"L+<RA.5JPVG,#&5Y2G&5*PG&?)3C*L]F,=O&?^B/_ (O6F#XV_P#@^VN?
M<Y/I:=_*&?+^,CN'U]:;3XV^2?;3N<GTM._E#/E_&1W#Z^M-I\;?)/MIW.3Z
M6G?RAGR_C([A]?6FT^-ODGVT[G)]+3OY0SY?QD=P^OK3:?&WR3[:=SD^EIW\
MH9\OXR.X?7UIM/C;Y)]M.YR?2T[^4,^7\9'</KZTVGQM\D^VG<Y/I:=_*&?+
M^,CN'U]:;3XV^2?;3N<GTM._E#/E_&1W#Z^M-I\;?)/MK@B.\YY>&S,M>6UY
M;<PA I7D.8QC.6U^3 SY*\84G.4J[%8PK&<X[,XXS_T1]?6F#XV_^#[:8CNJ
M<6TDS+4ZVE"G&\(%9<0ESRO-J6C$#RDI7Y"_(RK&,*\E7D]ODY[&?^B/KZTP
M?&WR3[:Y]SD^EIW\H9\OXR.X?7UIM/C;Y)]M.YR?2T[^4,^7\9'</KZTVGQM
M\D^VG<Y/I:=_*&?+^,CN'U]:;3XV^2?;3N<GTM._E#/E_&1W#Z^M-I\;?)/M
MIW.3Z6G?RAGR_C([A]?6FT^-ODGVT[G)]+3OY0SY?QD=P^OK3:?&WR3[:_,Q
M)"<=JB\W&/\ CEH7C'_WR/XR.X?7UIM/C;Y)]M,Q9&$Y5DO-PG&,JRK+8OR<
M)QCMSG.?#^S&,8_'.>WLQCC([A]?6F#XV^2?;7XB,\ZA#C1F8XVXG"T.(0+6
MA:%8[4J0I(_*5)5C.,X5C.<9QGMQGLXS_P!$?7UI@^-ODGVUR[G)]+3OY0SY
M?QD=P^OK3:?&WR3[:=SD^EIW\H9\OXR.X?7UIM/C;Y)]M.YR?2T[^4,^7\9'
M</KZTVGQM\D^VG<Y/I:=_*&?+^,CN'U]:;3XV^2?;3N<GTM._E#/E_&1W#Z^
MM-I\;?)/MIW.3Z6G?RAGR_C([A]?6FT^-ODGVUP<CO-)\ITS+;3E2$84X@4A
M.5N*PAM/:J!C'E+6I*$)[>U2E83C&<YQCC/_ $1]?6F".UV'D^VCD=YI"G'3
M,MMM"<J6XX@4A"$X_'*E+4/PE*<8_CG.<8Q_GQG_ *(^OK3!\;?_  ?;7/N<
MGTM._E#/E_&1W#Z^M-I\;?)/MIW.3Z6G?RAGR_C([A]?6FT^-ODGVT[G)]+3
MOY0SY?QD=P^OK3:?&WR3[:=SD^EIW\H9\OXR.X?7UIM/C;Y)]M.YR?2T[^4,
M^7\9'</KZTVGQM\D^VG<Y/I:=_*&?+^,CN'U]:;3XV^2?;3N<GTM._E#/E_&
M1W#Z^M-I\;?)/MKBJ*^C&,K,3$8RI",94V+3C*W%I0A.,Y'XQY2UJ2A"?XJ6
MI*<8SG.,<9_Z(^OK3!\;?)/MK\<CNM)\MTS+:1VI3Y;B!2$^4M6$(3Y2H&,=
MJUJ2A..WM4I6$X[<YQCC/_1'U]:8/C;Y)]M=S<60A:5*)3'4ISC.6UM#\(7C
M'\4JRW!;<QC/^>4+2K_AG'&1W#Z^M #XF/P(7_[*#]:]O(JU.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI5;[DA3R6H=JCA429/*3];WF$-@CV'I4^;/E
M5@HQ#B08T9"Y$B9)D.-LQF&$+>>>6AMI"EJ3C-XR!(A)P ZDD]@&1R:I("8W
M &248 #M)P>*T+C=/<W7&J=5+/ZXUD7I<N[:\*]0%/T1TY$J%8K3K@5K2^0X
M(G8%-%V[8-CV]BO;;.4.S6$%$'MR)@8796EU4NU*FC)'5TH>23#N&VN(FEF#
MA7+J<JY""/,8=0Q/!(ZP[:YNAVHF40J64RK%$49D"-PRAG:3$A0D8Y ;@U7$
M'45AVA8:=7*[I?7%6U@.W==SP?%\Z;MF$M.O#I6D40GRB]$7^PZ[E4IO-A99
M&0",)58K!RX**V@2.+DC<^;-N9 @8M(Y<Q*IV3(),]+G'2H'#'&20=S!<*2,
M 501ERH6-%3I&(WPN8\&/MZ)BA7GC/ )R0#G)[-N]-5U68W<7 :VUB]7:Z-T
MN$:?JO3S/8VL/JPBCAXMWLG2+9(]T5&IMDIN<3C%)I(T';Y+=F'MC(YF6:=B
MQY$13+_+!=PQ,AZTPZ,L6)5;A=O65N [%EZISC%)(6S(0D> (QD0G>%"@,8"
M&ZI7M50&Y&,YK9/7H:.WU8/6>F4*XUP,0J.YQ>QWK#KNXU63+LD[8-++@+?8
M-E6"83";8A'XXR:C4E<#S6Y.K*01+!DCP4=<VK@<G/\ ("LZL0T93#JV%V,"
MH0 &,C/\PG_>, <GACL@'3[E5AE9 ^Y6!R74JQ<Y#@X/1J#U%)  &0-[.<M=
M-.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6H-NJ#</K2TA=$D;//D&-2
M;Z%.PIIHC)JX*(-EZ45%8" $K0%%S"<EZ;-)E,QG#9=S#4:21=&BQ<&!TJV;
M:5<* )(CP &8GI.T]IP. ,X'.!DDG!EQ<1MD\QRCDG:,&+  [ 3R3CDXYR ,
M:Z=7U@TU:5!+I4YU4+;?R)TK=->J)AS).Y[5I(W8\RQB:=TL66070,JFQ#96
M-*CVL]4JO92;(@G5\7P=&"N5<\%UMQ(N5;<(\RJ^" L;%-I:X7&60#E0S 9#
M;"3N4XW!C;# C?B-DR"6<*^[$!)&UR>&*@G!7=@;2/J3SAKMIQ2G%*<4IQ2G
M%*<4K 6S!M56LJ:UG";&JOF< %*RWA.#>1TG K*LN_\ 58QB=YC.<N?]7C'^
M_P#X>WDKC<N[\N1G^V>?I4-G:V.W!Q_?''UKYI])IK5M6L=1-T60%KU7@]+.
MM0O4#-C-)@K:WR3MH876ANSW$MHD+W5F?/O\6WM6/"KPW**P56?*<3A:G.VX
M$C!@V6;IW,623_*"DDH.SHL!-I7"X!QV'') 8U8%2 !"HE_[7< -Y_J9WA@>
MMR,]HJ&:)CH8ZN1IQJ54I-H.[?ZNX-PI 8(Y"WS0JY..&R%;LV_+FJ8^]<-4
MD?LD#'ZH RJQ4H%?AW35L2MV78 NM>+2+2Y-N1A@JQV^UB?Y3G #+$O8L@+$
MR$,V2KDJA;%5BQTX/5+%YP5 _FH,D@RMGK(0H" JN R %L$U]?N>?7=3BE.*
M4XI3BE.*5I)UM5BA6X'IT7L^\TBAT>#M.6=)3]HZY%[!UB7(1=8[#$A@MT^T
MY0920+&)ASQX!,M_>Q\ZT@@HV!'4:D#L9Z;9G4R%%9V,> $8JX!="2NT%CP,
M';R%))XS7/<*K",.RJN_)WJ&0X1\!MQ"CDY&[@L !R15?.;7TP.Z,J^K?%3K
M0$*&JM .D=.T@+]@P)\.[L:0'U8V.HQ">,'5W7^T"U5BSG:G<2C52&UF85%7
M^=FL03TQ5]DAN#T3,26<"1CO*D)F3+@$EXPWYE&XM@H-Q JA>-;<=* H"KF-
M1L!&["#;G"HY&=K':%R&. U73T:0JNQJHR2J=BUR5'6?8ELM3];U"6A&=9ZQ
MFG,#9*M<5&6/:BPW&0T7NA,[+CCA$<S:S9^PQ0PF(88@,9W)8R ,'!"*NZ3(
M=\9&]L]YR ,G"A1DD9K2WQL)4H0SLV(SE$SCJJ>.SM)P,L2<#-;9\YZWIQ2G
M%*<4IQ2G%*^:W7"/CDME:FCWP_JRKZB1JK?#KIG==(>O^NG-H9EZN9JP1P$J
MQU<<U=C-5=NS%2FK(/6!P&W?0U/AY.&&YX[MMCB.38)&DZ2+B)MC]&!(6.<-
MU0VTMQ@':S' P>.Y&73<4$?1R\R+N7?E,#&5 <C.TYR1O"X)S7#;5BK]GT1T
MT$;G#U]7GJ(>T_8MJ:3WA8[+%UY$GV71UK\,H&W;W/K5]57E58R;'6BO6/9
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M05$6Y8B$T<'G3C$K+'>I\N>'$$)$AY;L\2,EK>@L83X$TN"I'2/@J,+RQ/5
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MG?'_ $7/_6.^8<8'>/KZ4R>X_3UIWQ_T7/\ UCOF'&!WCZ^E,GN/T]:=\?\
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M]%S_ -8[YAQ@=X^OI3)[C]/6G?'_ $7/_6.^8<8'>/KZ4R>X_3UIWQ_T7/\
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MY4ZCQ9M5FR!LD"%M!VO%IQ98.SQ1QB(LS-NZ02!"OYTQA$.#CDA6;#8.2JL
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M92I9NP'(XT.,BR+*A%&@01\^ R-BQ!Y:PQNX.>))7'DR':Z@* [*Q '9MW8
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MT=5:]KRKN6DS-=K8A1TRZY$;EQ/,1H8Q*Y"WE.9QG"%8QCMQS2.)I Q#(H0
ML78*.3@<GXUF\@C*@AF+DA0HR>!D^\>ZHZ4ZG:>"K59,G*5MH39;N?)UND:J
ME4 @YM6V$ T+Q,I)%5*&_*RR#'#<+GDK*6GC*\*C)0HH3A+DPT2+"!BS -&0
MH!9PXZ-03@9;O)X &23V U4S* "5D!8D*FPEVQR2%&> .220!W]E8.9UA:P%
MT>\V\T"V4$+:WLVO*A<-:%J3+B[-''-KV8)4M=M1*]WI<(X/MI@_"8#' )@F
M#F*8*1VB*IP<G#BR+=RRJ"A#J[*X8;"(U+/D^XJ 200"...10SH%9B'!0H&0
MKUP78*G&>0Q. 02#@\Y!KD2ZLZR!J\ZU6;5.^JM&8M-"I0D58=;.#CMKLVQS
MJJW6Q=5'J++P5?R6S&CD,Y?CHA8GP5K4I+_^$(&+!5>)NJ[$JX(54&YBQ'9Q
MR._!H9P 2R2+RJ@%,%BQP O///\ XUZ(?5UJQI5UC7,9L75A:AT.5L\N"V/0
M3@0N1HD&<@3-/U=B T78M6(AA^"'D"@,F<=;*%0T-0OSI<;B2_#R':5*.'?8
M"C@@,1D!LXV\ G)P, G/!H)TZP8.A5-Y#(02N<94#.[GC YR1QR*LC6&YJOM
M23:10L9;:Q:*4^';M-.O=;FU>SAX]C@N$JZ2=@R<NQY0H[#8EJ'D!\R7'[U
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M9:PZ\I*<J2TWEYQEG#CF<80C+KS36%9QEQQ".U6,JTJ*T.[U_9%/ 7BK2'I
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MHV61/:N69ZQEZVEW62^AUXQ1W8-MH;8D%/7*#KB65EEP;YLJ02[!N"#)ME(
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MLB2QDI$SO&ZG!6,E%=2AP#MR'W GC<#DC.1#*R212 /(JI)&W(9QO9&#\D9
M*8('.#P#C%:R7*C=2.Y*1N01+?ZC#FM#^PNBI[7+FV:]J'7^W8)"J=40BU[I
MLM9@ZLJ5-L 6I5>AQJL1!3K] 198Q !82$!IV-A$B7NK01M&0(E<)<[^C:1X
MR&MRL2DR,P+,Y8$*=O(!/N&++,ZR#^:4+6^S>$5P5F#2%0BJ0JK@C< <@X&,
M5L-O[IN//:KI]&I]PW==7Y_4MT[VDP>.7\C9KC4*W7=G5J;8S]<-E$+<!LU\
M1%DFENLM/8COQ\R\,NK3Y&<8IATC,RQH!#,H"J%5F:-@H(';N.!6TL1**JM(
MV9HF)+990'!)!QQ@<]E1ZMZWVGT\;KVS:H=2V/U12#VI<$-0WVY7YUZU!8P(
MS!EW3IWGDR.?LD Q8):H%XH-A9K8)%MF1)57NQUU^M S/+,\<L<:[D@"OB1%
M4[6)!"S ?F.T95EW':.L@ZQ%55'BDD;:\V4S&S-U@ <M$23M&>&4@#<00QZH
M-3[IBK)^'N/J$O(VM;/K^KMAPM9$AS^[VY_WBD]F"V[C#NZ!&;'*FW:%K,/7
M7:&.K@2PR$!!I]-I71(44%+?=F4G8&.)2R%TW@]%C8$)4KG&%+D[B2.2-NXD
MBK0AA)*P#A&V8Z3.XN-P;&<L$QM !X!W;1@UKX<UC:=ATR]:YB-6E-K!_P"T
MP'6Z\$JF0=$6@%1B][!;"K=N@EF5)E06 NI+!3T1"L?+F8B!:HS/:[ =89V$
MBHR.=NTV150PRI8(492.\R*W![<_$5D49E90#N%X&<J>0I8,&'=B-EYYQCX5
M<V[=&R*^!TU#EPMJ=1.I:UO"1=]RTBX&9.V+(;KDG6-NK=9<^SYE:7;K5J7L
M213[?(HC#!%W,QAVRP!),@(:B+SBEW-)@QPR-%LC91T:@](K-UA^5F0,NXD#
M'5) -:2QD"/AY4$FZ16.\LI0J.J>&57VMM ]VX D'.I1CIZWJ5%'4:RU[9J%
M6C%'ZZ8VH:6Y*B5290:?L@ATS.5#7[.(T],76LO94NG;/,U$*W)'II$0^Q&F
MMUV0*?@C]Q+$"N]U=@]KTC\L'9!.&?D N$#1ACSNQG+9S6!BD*L$5E!6YZ-<
M@%5<PD)P2$+%7*C/5S[L5M5TPT&N!.HO;=VUQT]V'0FL3NC=(5>%#+T8?KF"
M;N57MVXI=B3 J<!SLBR XD]6AQ BY%C(,NM(G05DAJH9@CA.[&&-7E65Q+*Q
M(8N0K+%MRQYY(8X]W8<'(&\**LLC)$8D,<:@%0@+*TF<*.X%1DXS[LCDX !;
M=D:J.=7U6@].FX]@6#9>\;7;M<R X %'U]9(!_4^LJL)<+W2PV(0(#"?'*\2
M8-R9:7%PQ[#KS$6<^IF([)5)!;L9HT5(@KY)+J1+(QPB@L3AACC!/O';4 NA
MG7HI&+R,R8 VL#&BC+%@ ,@YSV >^J!C=%]E&PZ+KNZZV&;2$T"?_LX*N\:,
M5T98@)87J,:=K>W28]DY&>SX%#&O>8,LNQT9>"SFX<IJ0VMUK.QN5.YU?HRX
MO& 4D$&0AHP<>_.2.X\\5B+=AM1D#A#:C)4$$(I5R <\#L([NWBHY)Z5;'40
M^L?_ -'(0S5PS<'742NE)!:%JVV(V3%TW^5?Z?+N;U"F0.;LPB-IV"4K%0.L
M0C4FBA#X2%&'0 LYV8&DW 9I,2$N8[4(YE:/ 6%>F02<[29.67C>P/)(P70L
MH3^6 F^XW*(U?EI28F*<9 C!53R5# 8 )(GE*Z3MADXYR>2II-K8]=Z&!U.T
M#==E1@$@OK#;LR_=1A2H1QTL<0/C*Q;-=@K/01\<@')SI]:!+0*CG9*'R2I5
M6GC&!N!0W1:54SAX]L(8D$ LKE7.",%N2.RK+"YR2IWBVVQLX4E'+RE<=H5E
M5E QDJ.,]N:H%]--[GZ]O0>J:PO];:GZ6H-)N%68U#6M*P;#;X^XM8&\H(/
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MYFH!N^4!;E9[56R#%S?T,<-08VJVMC"8YR+5V!,!;&OHK)&.99I2KZ79Y99
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M99TST]HS,"2&Z..=78L0"Q!90S8PQ.[G.:R,4FWA&P8;I5!"C!=T*+M!(4$
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M&<-Y4GMS\][3Q7(_ADUMJ>HV)FU72]/ECM)HDC>"[NQ',Q62"4]*4<JKAAM
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M+6RS8>'5G#=DM$2#1\L3X]IH<$"7D 4U+9#<][*F=CCY8Z6_:X$2$.@!9DQ
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MHR_.%#RYN'"9,3N:1.C=DR3L.TDC'6'#8!YQNR%)P2,$@$X'3&Q=%?  8;E
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M:*/Y7.E);7-?RRD6^YAM4Q_S>$YDN>7VRCV?FN[&^G_@\M]*%73+N7\$]U*
M6V"QG?,K@&5]HMV.#*^W_>-GS(&]L;73]6TJV/M+;Z5;,SZYIT'\4BL+=F""
M1M5M(]MO$66"/>;N-=P@CW9Z)-L?,2-%549?9I&-KB%#>8[WL:/''U]^00:?
M(O1DJM(Z(PY)(=X+SI+*<$V'?.$9DG&?^T/OY5QW+^REA!JTLZ:)%$R])K2+
M#9LTRO,Z?\OAC1GFWW,LB 3HVZ>23/7=\^E91_X@ZO=^SL%K+[43SQR=#[,2
M27.I1QVSQVT<I&D7,TB16W165O%(3:2)LM8(C_NHXP)3(C4,4&BTYT+7HU-G
M@C,G(WP\,S3F@<+NCQ),R&YYL:F#)P4Q)7_V5R(\G,EZ2M';A3O>Z:3!;1Z:
MUM9)ILUI<R=!T-LNFBUC,;3B2([81$_XC>?Y9C8;V<C(W>1'+[0WE]-K:7^I
MS:Y;ZA8Q"Z%S?/K;ZA/TT=JT$Z[KHW$1M.B7^:DR$1)$K8(3'Q(>GQP0:B#&
MUM"KIV*2KHC$9JL,!C4(_(PZ8!C\MI3")1C<MG#I,;'R^V2DM87+9?=1VXQC
MB]G(+6 11Z+%97:3V=L$6Q2VN8[Q]US:P[0(ITNI%W3PIN$\B[I%=AFNF:?V
MVNK^Z:XF]J;C4]/FM=3O3*^K27UC/IT16RU"ZW$SVLMA#(5M+J7HVM8G*PO&
MC8,>!V;34FTW&PPX%/#FZV<8I1F\S8]6%/$C3L&/A\'%-YDI+278K,:(/DM3
M$1D/KBM1869K4%7=^.UO?9J34-2O(X=-MKNQNETNYU66.PMWFN6B0/:QW1<7
M#M&L<<+K($#F-4BZ58CL]/4-*]N(=(T339[C6[VPU33Y->L?9^"75[N.UL%N
M)3'?S6 B-E$DTDLUS$\#2M&LSS3] ]P.DD4J#I\2U.!38>MAC+%:CU\D'E1Z
MO";9I\'#LR($G#W4-);K</!-Z5'&OLI%Q\$'7VF4=[6ISLDB]G+=9;26/1(%
M2Q2SGMI$L8@FFQ!I([66%@H6RB$[2) ZB!.F9U4=(2?,AN/;6]:WU""?VINW
MDU634K2^AEU:=GUNXV0S7]O<HSEM5G-I'%)=1N;N7\,D;2-T*A<Y4UT6)$4"
MHSE4CP1S;,U8>JN"&XT)LSA1"/,<@"58;CI+8=7.:D+:1B?AQ<E"W?+RO/7I
MYTJ.,VFE'3TBA"RFVT\VZQQ+=9F24PV^%07&XRJY4=-N,@+9)KS]97VAFG&H
M^T"ZQ+<73/ +[6%O6FN'L<6TD"W%Z"\IL]BV[Q!V-MM6$JFT*);ST*\:G%*\
M3LYAI:VEMS%9Q^"O-C2#[><9QC/9AQF*XTO'9GLSY*U8QGM3G\<9QB<?V^8]
M:J6 X(/^BL1\P"*ZLD8BDY0IF=E&4Y3E&0Y3*<ISCLRG*<PNS*<X_#.,X[,X
M_#L[.,'X?,>M-P[F\C_;7!J8/8;::8B2V6F4^2RTT%)-MM)[.SR6D(@X2VGL
M_#L1C&.S\.SLXP?AYAZTW#N;R/\ ;7/)")GRNUB=GR\=B^T.4_Q8[.SL5_V+
M_%CL_#\>W\/P_AQ@_#YCUIN'<WD?[:_<$8F,]N&9^,]F$]N!!3&?)3V^2G\(
M7\,=N>S'\,=N>S^/&#\/F/6FX=S>1_MK]\3C?ED/9)7X+C!^'S'K3<.YO(_V
MT\3C?ED/9)7X+C!^'S'K3<.YO(_VT\3C?ED/9)7X+C!^'S'K3<.YO(_VT\3C
M?ED/9)7X+C!^'S'K3<.YO(_VT\3C?ED/9)7X+C!^'S'K3<.YO(_VT\3C?ED/
M9)7X+C!^'S'K3<.YO(_VT\3C?ED/9)7X+C!^'S'K3<.YO(_VT\3C?ED/9)7X
M/C!^'S'K3<.YO*WI3Q.-^60]DE?@N,'X?,>M-P[F\C_;3Q.-^60]DE?@N,'X
M?,>M-P[F\C_;3Q.-^60]DE?@N,'X?,>M-P[F\C_;3Q.-^60]DE?@N,'X?,>M
M-P[F\C_;3Q.-^60]DE?@N,'X?,>M-P[F\C_;3Q.-^60]DE?@N,'X?,>M-P[F
M\C_;7@*H!'A9(&<$9,A3,"8*,!RM=FD19461CN0R TD/F#GHDZ!.B//19D.4
MR['E1W7&'VUM+4G,C(((.""""& ((Y!!!R"#V&H+*0002""""C$$'@@@K@@C
MM%0FVZRTY?F9D>]ZJI5UCD)(B9/8MNLQ]C9G3*_%(P0,J8T8K\Q$F2$A%RT,
M0^\E;HV*4(QX:V6ILE#ME>1,;)&3&0-LFW .,@888S@9[\#/956$;_FC#9()
MW1$\@$ \J>0"0.X$]]= ?5&DZ\&F5P!J&A@Z\1!S:P0 A]6BQ@:=6B4V81(U
MZ8+A5UB#*!SR!"?/FB7V%P)4V=,E/QW'Y+SBQDE8@M(Q((8$R$D,!@$$MG(
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MEK(=.S63IDMX^7-5_,JONY#%BIW_ +Z)$1W=IDXOV$I3SLW&'N6#R#=B1AN
M5L28W*!@!NMR . #P!P.*J1$<9C!VDE<Q$X).21U>"3R2.<\]M9]NMT-F3&F
M,TP.U+AV0A<HDINE8;DQ;>7@S!A6U1GTA\.L60F-(D!Y XTI).;!GS(DF4ZQ
M*?;7&7[-QP5"D;_\H.0O;^4$ @=@(J>IP=IR"6!Z-N&.06'5X)!()[3DU)_$
MXWY9#V25^#Y7!^'S'K5MP[F\K>E/$XWY9#V25^"XP?A\QZTW#N;R/]M/$XWY
M9#V25^"XP?A\QZTW#N;R/]M/$XWY9#V25^"XP?A\QZTW#N;R/]M/$XWY9#V2
M5^"XP?A\QZTW#N;R/]M8TRS7[$()@+ &2=!&Q\P29"&:W+)B"XLA'<B3QI,;
M-&OPYX^=%==C3(<MEV-)CN.,O-K;6I.9&X$$'!!!!# $$<@@@Y!!Y!'94%E(
M(()!!!!1B"#P005P01VBJYJNE]!T7$C%(TGK>G8ED09B7BJZC"5[$DM69$B7
M6RDC BM0\/$:_+ERY0.:YY4D3(E2'X#L=UYQ2KM),_YY7; (&Z0M@-PPY8\$
M<$>_WU55B7\L87D'JQ$<CL/"#D>[N]U30N HY]Z3).U 6;D38HJ%,?+TS))Z
M7"!%\GP<22[,$/+?BACN<FA4=U2VAQ?.241#,S.7N5!<<!B "2 ' Y(P3P>T
MC@]XX[*L2A[5)SC.8V/8<CM7W'D=QYK(#X]=$2"\L4#;&2K 2P9/21]9E0I!
MLOB!!%X*EWHPUIPD2P,&#1V)TQ3TKN ^##\[W>(PVW!W'&3G P,L#@9)P.>!
MDDX'O)/OH"HS@$9.3A&&3@#)ZO)P ,GW #W5E/$XWY9#V25^#Y&#\/F/6IW#
MN;RMZ4\3C?ED/9)7X+C!^'S'K3<.YO(_VT\3C?ED/9)7X+C!^'S'K3<.YO(_
MVT\3C?ED/9)7X+C!^'S'K3<.YO(_VT\3C?ED/9)7X+C!^'S'K3<.YO(_VU$+
M[5:1L^HFZ'? $FQ5&QL,Q3822/L,>.0CQY<><TR\] ;B2TMXE16'5):D-X<P
MWYMSRVEK0JR%T8.A 93D'*\'_7(JK;'4JRL5/:-C\\Y]PJ$"=(:<""%@H%5-
M^%+G%2*HTXKL<LKO9JJEZ23<Q)*E)LI+<JL'BPW,=+^(S69>9S#31%F/+9N9
M96.XL,X XV#L8,.  .& /9\.SBJA8QP%;WGD2'M!4]H/N)'U[:PU7Z;NG^FP
MH8NOZ_F1A Z;52$ +,F;",A(4NC$(Y:GKBA39(B+816RD."1$,-1$QX<T>.E
M--8>'PUL2TTS')<9.X9&P'KC#<@ ]8$@\\Y/?4".)< (V!@@%9"!M.5X((X(
M!''NJW*J#J5(%N ZF$>!!W"QPW@9!$F40625D,33YM^)&7&6U":GF2,\BY$A
MI8AM2);ZF([25Y3S)BS'+$$X R2N<* ![^<  =_%:*54852!DG 1P,DDGW8&
M223[LFJU-S&E%R6<(E=F9LC..V#-3G_XBOXI5'PK&?\ EG&,\^8ND)N9CE/]
MXW;(@]_<6S7Z%ITJBQM 1)Q!'V0S$?E'80A!_P!#6+[VU_HD_P!%,_L<Y^C;
MO3]2/[J[.F3NE_0G_;IWMK_1)_HIG]CCHV[T_4C^ZG3)W2_H3_MT[VU_HD_T
M4S^QQT;=Z?J1_=3ID[I?T)_VZ=[:_P!$G^BF?V..C;O3]2/[J=,G=+^A/^W3
MO;7^B3_13/[''1MWI^I']U.F3NE_0G_;J$?8&@9FE9ZZO'?>-QR\0DU)@$94
M!YBPJPY84M"Y*71D-5@<2ETZ["B1W3+N,.DERG/\7/*_@&EF6XE-E:NUTES'
M.KNLD++>$&\"V[R-!&;Q@&NVCC1KENM,78DU[_\ M=KO06=NNIW\:6$ME-:O
M%#)#<QR:8"NFE[N*!+N8::I*:<D\TB6*=2U6)>*_1U$HPM4=R+7U+>BD\&6Y
M,YLT4EK*(&/AF)LF837,E3'H8J2^/@9F//I'Q'5LP4QT9[.3#H.FP%#':PEH
MYQ<J\LYGD,X@:U25Y)YI'D:*W=H8>D9A#&Q6((*BZ]K=;NQ*LU_<A)K4V+10
M6@M(5M&NX[Z2"*"UMH88$GO(H[FYZ!(S<S('N#(W-3:HB0(_(&MP1:&@<1<2
M!$%.P)3L!B&TM.&(B6Y;3C:(D=.$ML,*SAB.RAMII+;32$)]/3[&WMA:VD44
M*VL/1Q1P;D>-(D/4C5&9NH@ 5$ VHH55 50!X6L:O>7AU#4IKFZ;4;@33RWG
M1S0SR3R*>DG>5(X_YLA):64D/([,\C,[LQV0QC&,8QC&,8QC&,8QCLQC&/PQ
MC&,?AC&,?AC&/X<^N[.ROS,DDDDY)Y)/:3WFHS<LX37".<_PQF%G/_\ &"$3
M.><E_P 6LI[C'_\ 52O5T3G5+8=XG_\ ]::JHVWJ^RW4^",UEX# E0A_AD@H
M3G34NQ&,&QQ?&)=;E [-5[J,\N%AY <E#KI*'.9;DC;7"5(7F-\Y[0Z%>ZG>
M6ES8M:1210] ]Q/++NC3\5#<?S+&2UOK#5(,Q!A;3Q64\<JAX-0B+G9]C[&>
MUNE:%IVHV.K1ZA<PSW(NXK2U@@*32_@+JR_DZK#?Z5JV@W>VX,;7UK-JEK/;
MR-%=:-<")1+1%OUI;0! ]78-?9MLG8,X<\T0<KMB(#P#*]^[!V(SD<<A!YH<
M?+A"[A'D&D6@C4HHV; C%04ZV.K=%0_E-1T34+2:[LX;-=1DUB6!A,UG>S0V
M:GVNUC65,-U%;2VT,D5OJ2/<B^GTZ."6)+FUEU%BUM'^A:+[5:-J5MI^IW&I
M2:-%[-6UU&ULNIZ9;7.HR+_AO[->S$@N;">^M[ZYAN+S1)(K!M)M=9ENH+B6
MSU&VT:,+>3V24Z?2DJ#$:@S*Y$G(-;B)3YB69+3DUG8^W!6PQC;KS4+SS[D(
M:,:AD,/9RC$]J-B,I^.TEY'MS^R$\D4:Q264<HNO:2>60*ZM(NM>T5OK,(9E
MBW.8X(%BF#<=,L>PLBAA\O:?XD6D4\[7$&J36[6'L/:6\!DB=()/9;V+O/9F
MZ=$>?8BSW5V\]ML ;\/)+THCE<QMPEZ!/]K4B'-K+KD"Q6^RL"Y>)K(LN\7Z
MAHNY1 DLMD<^IB(H/#9"39J(D]0TJF/,CCRT.'B/(B7V2N^J\4MBQBOM2OU@
MDZ58+EKGVQC]I;>VN"L+E8S;1K:RRB.8PW 25(;B.,(\P?XC:< T4\&JJMQI
M>B:3)=P] ]W9)9?X9R^PU[>V:O<QB287T\E_;P--;"ZLS)!+<V4TYDBQMHT?
ML:RRGGD8UN!BDFPLIX?6U2PL842%['/7J0F9(CTYPS>>_MDXN,3I9BI#XEC4
M:LF*K(=,2(F<+_V6UJ]=F'\%M$G%M(\-B9+6.WF@UJ[U5Q*Z::UUJIE6>,"6
M6YT^&.]-S>C3W:X>,]>D^W_LQI4*(W^U&HRVKW\4=SJHAOY;RUO/9;3?9Z,P
MQ2ZVMC[/BW:TFS;P66LW,^E"PTLZQ$EC'-60.=/16<#D0Q[]69*/9WR^\^\S
M)8;(2-H[*AWNOM3I+(YZ1EF&R/B0S+RF9*X\EIEZ"Q/1':[=KKV/N);9TA:P
M6X8^UKEV5U69]>UN/5K-99%A9]L2PQQW+[79'16B28(M<UA_B59P7\<UU'J[
MVB?_ *=QI&CQ2-:Q>R/LM/[/:E);Q274<0DG>YFGL8Q)$LL3NEQ+;-*YJP=H
M:S+7_(60V@"G(^H6L-+$SB!V-$=(GIU*(140RX1J"4A,Q'*Q)0P88:;E09#D
M @D1/0R^-<]?7=#N-7_#.!:#H=.U"UDMY9KI(VFNYM+FC$=S:K#/$L;6#A+E
M%62)VAF%O*%: _->R7M59^S?XZ-FU$BYUK1[Z&\M[73Y9DM=.M]>MIFGL;][
MBTG>9=6B:2QD=X;B);FV-[;L\=TM88T7?\"I[4IZB'IM@J^P*;+BV)YU]FL#
MKJ4BD$&8A8521&;H60IEQ9_!$!5)UE4T)3,L#4@8Z0(>$/935^@F$CZ5=R7E
MAJ^FR1WK%UL8-3GCF%S'<0:7;G4[@;3^+$]I82WVVWZ6\5X&EF^M_P#U!]F_
MQEL\,?M#IT&FZM[-ZY#-IB+')JUSH-I+;-8SV=YK]Z-"LF#J---KJ6L0:2'O
M3!IKQ7:6UKG&])60&22:%(IULD)?V/#6)N+Y"(.F0+]$H["3DZ5%!FEOGAWV
M.D1)4+(_S),;9"\9)B!E:\O]2^R]]:3BYMQIFH,'UJ,V^IM-'#+#J\>E*+J5
MX[6Y+W<!TUXY(NAVSP7MS&+F'<V_SW]O=+U"U-C>'7-&C,?LO,M[H:6TUS!<
M^SDWM!(=/MX9K^P6/3KK^.1313BYZ2TNM*LI38W.U1%^UKIY6"CP8\Z8%/O0
M;]K*R.&2,)2RI0+KW4=)H*62"W6)"O$)%@J\JPQH^9,B&QWQM_,G$W+N,39>
MQQM$B266UNWBU?0[UKF:(FXN+;1_9W2](VS%D<],]Y827B)O>).D#[Q*6PU7
M_$M=1EN);>"_TY+CV<]J]+6QM9U6SM+_ -I?;37_ &C9[94DC'X:/3-7ATV6
M411SR= T8B, 0F6:VU$]0BM>G(R#:8%U.X@)K0J.N,J5*L-ZBVJ ^E.(K"'&
M(<5$IAW+N4N(E2%^90IMQQSGHZ)[/-I,]G(/PBK!I^HVDJVZ%"\EYJJ7\3C^
M6@*H@=6W8(D<[05):O&]J?;2/VBM-3@8:@\EYK.AZC;O>2K*(8=,]GY='N(R
M3-(5DFE:&1-@*M#$O2,&1%J]N?55^>TXI47N]F12Z7;[BY#40;J=7/V9R A[
M$9<Y (3+**AHD*:>2PJ2F+EE+V67<-97A>6G,)\G-E&YE7.-S 9[<9.,U5CM
M5FQG:I..S.!G%:D4KJ]F76L@"8(+I6YV2^V>LTG7M:U1U$-;%87:CE1ME_*P
M=EG$:P -ZZBUJD4NP6*<Y%'W(I.9$DH0P-)(MCXI/=K?:Q#&50JEG:2'9U0R
MH"@,A+[F90/RXR"3C.,%N"P!"QL68*@CF#Y8JS]<[!L 523PQX.!7GN'6).I
M$*MQ[+7]*5LZ;V$?H4@O:>I,2$U$QD)2475!2#LI&O2)1UR>VIVNM@K%0*H9
M;L0XHTF,^):'%RLK;AR=IE8! X"PDR'+;<;-X''YLJ[#:1[\@&N"H&5C!+%3
MNF 087=D/L/]L,JG(/&,$X&V]<OV/+V(5.!:6(2JG7*/890 1U%-RK[L%NYU
MN)9F(VAJ<]JR*O;*I$66W!JZ_%JJY;2BF8<6/ 5(:5F5MMP!!E 9F7<8>HA4
MX_FMTG4[VX;:.34-<[201'D*IVB;K-N&0(EV?S.T '*Y/ '?L:%V_89.W6-8
M6/7Z*XP<#["/U,DW;8AL_*!Z[LX"KR#MLJT,0U&J82WO6"*4HTR/9K$^1'8\
MQ8(=8.Y6%9Q,:B/>K[B"@8;2 "ZEL*Q.6*XPW54 _E+#FM1(Q?84QD.5.[)(
M1@N64#"ALY7K$X[0#Q5\<RK6G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*H
MOJ(W4]H76Y*^QJ'9-A2(3C:," *HT&)"C_[\LS9#\_/<@((='2MUY_#4\G.D
M9CC0HDF1E,QLZ11]*X3<$S[SD_V  Y)/^@':2!S6<LG1(6VE\>X8'^I)[ !S
M[R>P D@&P[]> NN:F6MY[$MZ&-1&9C#AK&)9D\9)S(XNOUD!!RXUDC8;*;FC
MP0$<EQM4XL0B1L.-X=RM-44NP48Y[2>  .2S'W*H!)/N JS,$4LW8,?W))P
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M7(Q.,UN+7TDZ=%U<P4% (U?M5J3'(MSW*M-J6_XK+2,8P>E.)!D+F/'*#:H
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MN^@:J157'#IV5=JN7E1XYUVB0U(R-5I')'&P;HR2K*Z$2;2&4<AB$.4+=;:
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MK(W8ZE3_ &8$'Z&J=H&FMBUBS&+]:-J +;?CH?5M&(F(FM9-=#KUKK(E;2^
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M_'K#&P,0NC:3V$LO1NK*1<6-S/97<1!BO+20V]U'-"%09(!70M6&H$@![(V
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MU]/.,1^)_P!-?W*9?PKYC]E.^W_U9I_OR:^GG&(_$_Z:_N4R_A7S'[*=]O\
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M?B?]-?W*9?PKYC]E.^W_ -6:?[\FOIYQB/Q/^FO[E,OX5\Q^RG?;_P"K-/\
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J@*JQPP)%!#%&BK'%##''%%&JQQHJ*JC-<Z:X*<4IQ2G%*<4IQ2G%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g189651g57k04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g57k04.jpg
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M%I4RAO!!)B\3$$PR9'@TT-&D<<C;0QWH\>[G\T3Y+%]G!(8'ZHHZE79W060
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M@0*L=N_)-UQP;XH.P]L'D%%7XKA%3:,S57,7EG?CU!&\<C6!.7Q1?U5)EBY
M)P&6/@=YJ?)*W(3KAMZ%8<KZL1!:Y#_=8-5QT9BNY@5V;C0HAU+>3GX4*L^8
M6WEJCF9F !VKYM^T;C8V,%\QKX_&A:FASR1AV_M:<Q\<J.0G-JJ7&30:BL.=
MZ?%A&PLX&[BU<2\#V'GQ2]F]RP3$HKCA2DVJ3-+F9DQ#8?\ U ,]E$G]E%+!
M&Q0*S@MX3<A>%DD$9''<B]P/;X5\=0TSJ&)53M,B\$\F.,R79[ U7V=[^&M[
MQVAN5I.1H.#M%7%V.0CF8I UVB-L9?&T"$OCTV^^U>AQ*,Y9W6'(.X42Z)L
M.;59HN0_"%%C:I9KX4>SQ+?:!RM+OO>%N^0%HW9'TO)S]+5_$?=LI-U_2L[:
M*EJ]=W'K5>;_ $=8?'_;"/O-;56#>JI4\K?DKL^405=EY,=B:#F2NU1RU8K3
MO3A9;CK9'+F2N'0A"PNTZN%G,*+XR88#P;219-)*Q-56QF !'-'A=PLT37VD
MLQ8 T =T:U=_3"DT?CW.TT+ LCOK4ZGVN>67*/C#=Q4..@'O.E"X%O%!($8V
M26OU"+F9F8OG"O&Q.D)3:92,.&2IU3SIM7K]J)3LR@_R-G,EH$!>F>HVE5K
MMO# (VUVLV#=T!NY^B*K,Y5"54&18V7EJ&\\[N/@*KD;B:X[F"H?:CY71:)
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MOD7R_1\H\O\ L\<?JULR*MUVK"$ 5E EK@);)DY*"1*@5 A+=P7*P;M2!E\
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ME692W<AB"?CS1YYYYU!52 "JD#D @$ CL18XK[-8V_%?&$CFPV.3CBA[V&W
M[K+6]WJ%>V<V=;)@;61=86FR[)SH&34(/7<1E.2/M@0;&T><01>!O>@N]MJF
MU&XT#Z@70/VC38ED[5MN"=HLCT)JSV'?6/=^*Z/?JS;:NZ1+X8+D)8H6C5<N
M5P/8&5GI)W'+.RKV,X!61[1\$L2JU [EB(*U2;^T2YF59W"WE792""?+5 DU
M08. 1?T=PW5VOGOSHR*P(('-\@"[*E20:[[21?IQVU@"<'<-"5"2@:<4\<24
MLDZ!L?5YJ-5I*^S=#Q00QO&:7VG54:ZSH-!XF<X>Q><Q1YQ+C&FF-7BR;M_B
M/NJ@VYMP'H#=@?9=:CPT"[=B[3R1M%$^I%43]NI0KBCBTYO7[ =QK0#']3"5
MK:J[*IM=(;UI<C+T8)0*^RF7;FI@DY\<9JL5=,- O+CT)$CAFUUWQ&]P" [
M,22-QHDBB2+Y)'!ON.^I*(2"54D4 2HL <@ U8H]JUFE\=<?'JO8CJ)334?L
M&U4]F+K"0E5\+[3#D;5OVZ8'</V#8@06?9/Y/MV9AAY<C>.&/;4'<&PS WNL
M,0=WK=W?)Y[\Z;5JMJU550JO2O3[.VH37A3AK2&M#Z<2<9:CTPN8^GP:T*JZ
MPU,\DL=@0;6HL*L:(BYSQ!39B5>HLTI8PY.^^TT,>^L^))SYW\W#>9O,*JCS
MSQQS\--B<>1>.1Y1P;NQQQSSQ\=1'(:SL^O7BP3E=?PVXLHP,PB87D,2DL'D
M"UWOZ<@99#9(YCX@6\D'DS0BZZCG[P^7OK+M'X<2OB@$IX@'Q*[@./4CCC[>
MVH81DTX0FJ&[:31[CGX']^IQUOQ @&ADL6W&R43<IBQ'D=;5A:-L9>(W&6QT
M.QV88MBK?%J_RQ)TSF6P1ZN,D[EZX-Z@>(?H[R:KC<>%JAQ\%-?HX^S4G8.^
MT=SS0^E=G]?-GX\ZS*94N,*.%HAX\K-#J"YW!*\C2TQ+7J^$W%TC"%F<:+D8
MPD!\&D12X>5AK#+'K&2%#M-C6:#7:&9V-N68C@EB2039JS==CQ]AT4(O"A0"
M+I0!8]:'P[<ZQ%O#G$299&E3\5\<*4\-C77&)2MH]8!616Y/)#,IM48 JN(7
M2QJY1QY5SS6+#,&2"'<8J+:+3.LF20FR[DT5LLU[3W6[['XCL=-B 4$6K#5M
M%;@;!JNX/(/<'4B=QGQPS3YKK+C^D,*_LA4U79$=5$):?:L(9_5(JYE80!(%
ME"E)Q@A2GS![>NG_ )4,>&3^-U =P;#,#9:PQO<>[7=V?B>YT*J1152* H@$
M4.PJJH? =AK#VCXIXJ%7;;:<>\;A86!UE3MMK6Z>+A.HE--7U]=G.%T.%BN9
MDP+#5#?W*%*P-GA'BV*GWDGSR$_3<WN/=C9X)/?D\"]/(E?17BAV' [ =N!Z
M?#5=7CBOLYW6L79HV3\9*M.34%QKCSD],%25ME)C?U"PU.R,@;S(#/)N[$JQ
M=A$D/GG,V% C8PF12 1FP;65YE90"YV%2$)8CA@P!6^VZC7'-?'562-@UA1O
M!!8;038*GS>H%C[!>L G@WLSW)%0X@ZMQ<70ZW>3[2IKZ)/1)N/[5<6M2?T2
M;9ZH@5DI+ PR ](FAQ'K&RPY7*R,S[Z@Y&DGQ)E+67#LH!8E@X 8,*-@@6/T
M43J/#B8+00J&)H!=K,05.X51/)^V]7650Z.<J:HC:95#$CU>"H=IRJZH(5.%
M2L?4-8L:KY@]Q&"]<)KJ*"$7#,,(/KK /%'%C&O6>Y@00S @D@V;!/)(-V"3
MR3K3:I!! ((HBA1':B.U5\-%M#HZ4&M+$]-JBE;2R2#:<O6UU0 #4S"PF2TH
MNM""AQ#HB25SEN 1.KC%EF":LA9-]H#BHY19B6)9B6^D222U$$;N>>0#S?(!
M^&@510"@!?HT -O!''IP2./@3K6F/'W"];BNME;4CB]##<A9A>1G[&M517%:
MPF,^8R![JU)"@T>"G$E9CFB>SE0E3D9UWUWDF[MI#2': SG;]  L=M?5%\?J
MU4J@W$J@W?2) %_[1^/Z]?E.%X5 JC--Q^-Q<'1]HY=W"JG0U,>J9B91;JYM
MV8*3711F,^$#==+L5%X2H@MP]\R:#YCT-XFX%]^[X%MV[CG@GG@F_P!=Z+L
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MI*^E;%BTYLS8S11';OLTR)(OL G>2#ER.<8*81'/IMUC(RL2RJ02=QL_$CS
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MK+Q^MA^_5!%=E@G!K#*5]I7!M^9U-NKS%<5">XJ/%ZRI.<PT>MBV6M6! O'
MY&N%Y=IZ_*L-0K4UAV$")%B"5*E>HGX%BZC*D$4&<L+9B&!/D51=@DJ+'))I
MX1YYJW!!!Y5 /HBP0/,6-<BC^@#4Z_V7^5T[/CRPZW2H"N>(&./A&(<=B8)9
M=;1=[8RYEM[R8E4/\*/^6*K:,;F51$ ZK%9LRM;$F-RD "T'L9D(8;6/B#S7
M7!50(U%&V"$?2)#$$WR3JHB<;3N%H>*!YMB7/H"X-$ $ @5P-=Q(PV@"H,-T
MXR_:0Z2:EM\KQE>3=]II-]-_0![;##>7%M'#X8MLXW\OS,_QM]L=<QHDD"AZ
M7=?KUN+  )L^M5?ZM2W4:G3IIITTTZ::=--.FFG333IIITTTZ::=--.FFG33
M3IIK6G5-J5C,!86"LHG9RR=:2M,:J@CR0"4[I=9%1 <Q,,D@TZVP*%;H&6';
M3<9FO#-AVT('BWUD,RV 2 ;! )%V"IO]()'Z"1JI5202 2*J_L-CY$ _I UJ
M.O!W#FDTA.G%]%C(D4+T&T\=94QRX3*1J^&L7QR:"Z[0C@"5*IC"XBSIM#!5
MZW%IMC1$JP);Q)/KMW)^D:LW9K_YF^\WJ;CPT^HMU5T+H "OD /U#T%?(_!G
M#8D>L0O%]%'CTE'FTTBK*K373<-8X2A:ZXU&QC6()-8'2<*#'= &I8DK1HX@
MM\08>))]=OO'U!_Q /Z1??G3PT^HORKU'^!(_0:[:SA^'^*A-&L8O'5+@C>0
MLQF^D5<5:ZL1'(A@#4(K&!NZ4$X)BQ%(!V_N3>%@?IY.-3"<2O$?CSMQ5<GB
MC8/Z00#?V:;$Y\J\W\/6P?U&SQVU8_5-7TZ::=--.FFM'+XRX[/L4UN-I%6+
MM$\RTF9^0D7S-9"TY20U69N;O!M-DT$JM5R4<SQ>JT^'D>F)?+4+]![!W VA
MFV\\6:Y!!%>A#-Q]I]3JI12=Q47QS7/!!'RH?(>FH W@KAAE.V*/XLH1A#X[
MW)U,35U$LC0W.+)C>8[;<7.2<3XN5P]5%+XH2_BRS^ICER_;>KD22  !V  H
M>8\#CMZ?16O3:*[#4&.,V2BDDV37<\_Q-\SZZSS>'>*6(L@1W'-,+%ESG,D$
M]=5R1R>*-Q#)X\;#9\6)8+"_@FQG.<3#NVT$N-X6)>DP2.#8=K_2?L_ ?(>@
MT\-/JC_\O\3^HD?$ZRF7%?&CF(N!M0:@SA81OH3H3Z\K+B,AM.MKTLD14<XV
M^A$3[2]W75O'+KMHPUM=AU*Q+AL=B8'<=F85543QMV[?EM6O]D>@U)13W4&[
M^'KNOY[FOULZV2O5Q!4U4*.LIUR)0/*61$O5BQ""ZDL"YSSRMHH==<2%'GDD
MFFDR>*<LPB<DB22>63?:I)8V22?4\G@4/D.!Z#C4@ "@ !]G[S^D_$ZFNHU.
MM";\6<;/W E@=T2IMG@#F*Q!MF")<4P'>P9K6T#;0J8?:;U\,E+I\T).=\R1
M$56NDZ;:SI5T@U@[@$!B 1M(!X(\W!^SS-\SZZJ40FRH)O=R/CQS^GRK\AJ+
M@X2X?&F3D#\94>&:O';LD<D=:5:;*39,5G&TX&<#8]-G'P53<QZ1^&.+:I5C
M>+33= JV$GQ)""-[411Y/(\W!^\WWCZG38@H[1QR..W;M]U?T;178:^ .#>&
MU6H>JWB^B@ZKRAC L"UI5!Z4D$#=4#)#F,;7.F 56^%@,>,^4&NA%!&TB%#$
MBA&20W;N;N[8_$V?C\3R?7F^^H$:"J1>*K@<4*'R''Z*'P&LXWB#BMB,.&?Q
MW32Q1%"9 )!/7EDD8J2NDKS4"L;&1O[G!2&*EA:H>'.D:\E>%.+B*4:'?0)'
M!L.P-ENY[MP3^DV;_2="B&K4<  ?H'8?J^&MT3IU-?5@)$2T%.G5BQ!+5:T6
M$( $2#7&D(PHH^D<,$,>N.[72/377'VY[N_.<]5))))-D\DG5@   !0'  U7
M$/!O%>AUO:&4M$W97EM*XL1[A:">:23(6C81QPE2#8G&A%85JO,1/*DQ/ >B
M2F:SY(4+)!+>(_E&X@**%&N.1^O@D'["1V)U4(HLT"6))OGDD']7(!_2!Z#4
MZ+Q;QL$%LM#H51$7;AS+M@1J^K@$V (3HJ].'D>(;6'TTR*L5U/+#X/+W7(U
M0>VN8 1](Q=SR6:[N[-W9/\ BS']).IV)5;17_\ 8#_  ?H&J[*[,G$!]US=
M&%97F[Z X$$KLR:LZ5\ C4-<!HS%V&0P6#)D JL/T<!+\E2O,CT;+U@K>$8^
M"WC2;=H8][)LV>2>;-=SR0+/8FK!J8D)LB^* XH=N>UWP.Y(XNKUN@W#'$@>
MXFXG&U)&V UAU"S!6U46!<#,;"W'\C70;76+,#2VVAA#MIC&T9=A<SZ9Q(Q*
MVEJ9)#W=N;OS'XA0?F%4'U  U.Q/JKQVX]"3_BS']9U],.&N)FQ>#F?&])/,
MP<>R]276U4\^QS5F:Y:$[R2"[;22,VK-B>R\S.VIY)YLA>LV2I_,"1QV=AP!
MPQ'   ^/P  'Z!J=B$V5![GM\222?UDF_P!)^&MM9UBN.F"MJW1JF;-)YGLY
MYP Q1BOSCU#67T!$T>\HOF,D"0_?R=M/$8H7$9[Y0X-M*AB 0"0#W -7P1S^
MHD?H)U) )!(!(['TY!_Q ^6J[LO!'&5BKLM<AK":N0[1JX1CT-=JN2P($^:3
MH$.,*]0O$D@V@?'%&7>F.4&#Z!56OZ01PS)54P=UE<&]Q/?N3\=W/!!OSL;!
M'TCZG53&I%57PL <5M]01_97N#V'H->8'9\X9"IB.@S\=55O6D"I>G%#=I%K
M+)(BZI**+ILRVG%\+"4FJ($R0_,\>T9@"P ::+:$,:.)XTFXMO8,238)'=BW
M'Z&8D>EGUU BC"A=HV@51'V!?\ !^@#6R;<3\8[R-I=Z!4=Y'VKG1UON@6[[
M--+%+9B'VAV=A\^IT<SW2WSL])?%J;-9WTI&))&QVT\;WX\S<57)XK;7RVK7
M^R/35MB<^4<W?'>]UW^G<U_I.O8'B_CA99?C%?1JJ%:\3L2OB$5&OA;^K;$N
M"V1GKHX-9\F&$6&PR3EYW]1ME^\U\W&CACJ3!=R-I9BO'%FN  !7H !Q]@]-
M B@[@HOGFN>;L_IY//VG6]]5U;5.<[#OR^/#1JQ1VW(3F9HET$K:RPCUP;;O
M819E:/YR++5,MJZFCQLS95B!Q!+9_30H]MQASISP[QT&\S!11YHD_H%!J)[
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MA&9GK](T>0D*QL5]8V6(4< $]R+)X'Z:!H[)&+*WW/ '902>Y [ T.YU(O\
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M;=RJK?72\Y"LM=3%;112S(CQD!B>02.3\"1\0+%C@BU/P)T1D<$J!P:-@?$
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M&T3!HRL2&U5TQ"4#[]&V7FK#!O/@F@8^!AW##[A:BQ[2Q%BA(06(*VQ4@@$
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M@ !30%#MV'Z]9_K<?*F_3Y_6ZBAZC]_X:FSZ']WXZ>MQ\J;]/G];I0]1^_\
M#2SZ']WXZK2^\>K[^VI;DUQ=$I%%:%.E(R31'(M*9DQC0Q'LUEA1/PISUD$)
M$*9D/"(R4Z-&N03(9#-M];JVT,/(=PHV&NO0$41?Q]:&JLNZB=PKD45[^I!)
M%CX'X6:UJ8_ M%'0V"M8WNLB:Q(PJ@0)N;!K@&B)0;0)5Z*MDA AE@KE2GM[
MEFBVFW)=ZG["Z,W+)<)"!K;Q&L-:6"6[-],E2SG_ $FV@'X5V /.J[!1%-1
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M P#VSUW%-KJ]8%8,V5?##;0I+<420RD7Q;->T\'A2E@$N2=MU9C(R[BP /<
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MSF1#J,,2<9GC*Z>$B:.2$[&1)-=2,9CZ 6:"L2>0!W(J[K;?;G]'.A- DLH
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M$##?3P%#+M23(BI"@RQY1HIH-],>?A^T&!E8*9\Y/3(GQ\/,\/J,^%',F)U
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M,$_.C@*38<V4HX'07.FDNV\D^QRMH%Y<6LFV#%;(7.,3KS(X;_E_HA$S#JN
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MDJ^3<6&Q"!0L$B3>H(# [?B>021]N[6#1GS[54[FLV>0"A#$6#;?V1? !OL
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MT&0()LU,F&/!&3DPRR1]-AAQ81"R2R3>,G#VFIHIJ^ZV9=LFM=DN59'B&K9
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M7VY]DH\6#!RL49;8\CSOF-[.]-AQLOJT_1LG '6FP()T$+8C#%P]B_G9A_\
MQ\1CJL9QWD].'N6]$GBBN[+2TYGF$T-*Y M14,5<EX9.K6BG8F $&+8S'(VR
MUI)8(D<3G,8<5ES+,Y'U%EW'LU[1#%)7JLXSR[Q^+)UCJ#JN"WLQ+@C',B0Q
M*9!UHP9!S%Q!DU$F>2V4@C;E;VV]C6ZA3] Q6Z0(XYC!#[-]'A=^J)[<P=5;
M,$4F1D.(#[,#*PUZ9)U!\'=._2@B8,C3)L:"LW8/D6N Z^])JIA:=9;,IWL=
MMLJH&5,R=BTY*#97$,0I1ECGM)CNQIEY<L*8.@UQ7,/LI8@S&]N)@]5CZUA1
M7E8O3_ ESL[']^ZCFP1-BSY4?3<6+.R42.23-;/DRLW%BD9<:/I&% R'&FA:
M7R^H]5Z#/[,=3R#[AG=8]ZQ^E=*S1TOHO2LO(3-Q,";K>?D=+PG>:*#I<?2(
M,#I>=D0H^=/[1]4RTD7-Q<A((QKQ'?HK#9V5>98A'L=C=NELFEVLZG6L-F1%
M4D&M,ZL6*<*P;0B*68^:^5G0'73RE6F/:[$[E!PR/9SJZYN=/AS[$S<W+RH6
M7JF?CC!R9Y,!DZ@V/&K19A2/'GC]SD(B K' ]WS<IHNO#]M/9U^F=*Q>I8GB
M2],Z7T_ RE?H/2<P]6P\6+K"R])3+F=)^FAYLS$E'4H0V06WYC'WOI> F1=_
M'-:/JE04*6YI3%WK!J0\.+<-'FQ3:;73U<L)K>:4G47.VFNHXT>HXT$>N-8!
MHL9SC/U71,&;IW3<;&R99)\H*'RYI,G(RS)D,!XC++DLSB.P B*$C0"D1>=?
M ^T_5,?K'6LS,PH(<7 ,ABZ?CPX.'T\0X:$^"DD&$B1&:F)EE8R2R,29)7-$
M;QUZNO TZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333I
MIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIIT
MTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ
M::=--.FFG333IIITTTZ::=--4C9B+6)PW5B*2).?98I>'M@ (2RU\9T&;?3-
M6@;!@"(>0 D*4Y.@?FZ@F1"))&!!(TXT<L6WS/5'ZA'[/8C]*C:;.6;V>,,*
MRR0K*OY4Z:)XIIHHYGAQ9,<RIF2B*58\5IG>-T#*?ONE1='F]N>KQ=>FCQNE
M.GMN,C)D@AR6QY/R+UTXD^-C9$V-%D9\.:,>3IT!R('FSUQHXIHY61Q6PO)'
M.K1R*M6UP$7<E%KZ:.Q5&UJO6-<T$YT2<5,-$R2HQP>0(-*A*"=9]](UXDTD
M1S,I]764_@1];]K,C*3'@PH8R^(-@S>G=0Q_$R/R1+DO+(Z+/BXJQ=93\FM#
M+G%1#$Q66>3,P9I/IYO9C^CW$P9<O*ZID3+%U$B5NF=:Z-F>#A_](L?!A@A2
M5\7.ZA)D>S4C=:3)Q^D@MDS(KX^)%T[JF+%8"VZ7JX4JCV6O01IOX0;5)(%*
M;7BV4R+CPX!^?7VS$#!XODLF2X!*=+*;+"( 8ZT73#3YAUUG]F'JG5>I=+Z5
MG82#&_+'4"8FFPI)VQ.C2PYDN'D3PB:/;-/%#BRLTKK'%)E"%D?: _SF5T+V
M?Z)U[K_2NI2/G?\ 1OI"K.D'4H<5.H>TN/D=.Q^HX>-D''F\3%Q<K)SL=$@1
MYLF# ;)CEC#DQUAKR?SJ.F%(9H\1'E4K6UC[A\:6LS0BX%5.JME?&&ZT9F44
M#H8Z8V0(AV61%,'A/$L*E%8R8GF\ ==]K$Q8GGQ0LTG2_P H(T70^H2*_4GZ
M=T[)Q^A&!)Y)(EERI\Z)\J1U>(8JP.T<S;V^L/LG_1[+GS18O4"V-#UX]'D6
M?VJZ/"T?1(NL]8P\SVL7*EQ(8<AH,#%Z7/'@0Q.DYS7RX4EQD,<>/IR)SRE9
M'K5]1E;Q#FWDQ2 ]5VV<VR8WN')DP0T-A%6$JE@JY>KJX::,\P ;5<0+KOON
M-8:].'1>M>UV+--!%TTY*I-U:7&BR\?J+2YH/4NNM%&N9' ^/!'##!T^/%66
M2%! T8)*9N$\6K>S/]'>=B8^7D]:7">2#V?@S,CI^7T:.#I97HGLHD\K],ER
MXLS+FRLG+ZO/G-C09,IRHYBJK+TSJ<<VW1\H7T0T<'45K8QF;2D J'&.)KM7
MM)\L+E5UUVU,'(W,U!'1UUPR-@8LO:1A\A3Z2X82(VA17I)U[JT<J1".?.2?
M(Z7%CY(]GNJ80?QNI]/@ZF)$=I1$F)A94\JSS>[H@B<,)CB9$C^*_LE[.S02
MY!FQ.ERXN)U_(S<(^V70.IF,8W0^K9/03!)&L)R).H=3PL6"3%Q??)9!D1LA
MQEZAAQ15XFY.YU"655,*A<%EQ4FJKF)-FHEJ).@L$G&U;>$NSSXR<ZN<[V$A
MJM8S&L49,Q\1:>-3DY0:Z*\7%Z][618_3\:/#R995Z7T^"9\[I'4'E7,;H>#
MER9<LJR5E7FMDP3&2;$D:828PQ_%QI<J7Z7.]E/Z/\C+ZOG2]1P88'Z]UC)Q
MHNE>T71X<>3IR>U/5.GQ8&-CM%NP0O3(\+*QDQ\;J$4>,\.<V8,?-@P(;<O+
MSD*N7>L1IRF36.6L*1"P8:@]9)+*[EMR<%CC<Q:1LIJ!64I#-A@QA++@$:+4
MV6292I9#E_1]5R^LX75<%<9Y\D-T_&CDB7IN7-BYV6W4L:&>Y8'./TV0XKSS
M>+,S"%%$S%\?&G27XSV?Z?[-=3Z#U9LZ'%Q'3JV9-#D/UKI^+G]+Z>G1<[(Q
MBL&5&,SK4/O\>)C&'&5#D2N<=$3,S,62"N6?)'.$*^H#2*326-BI]2<6 <#C
MVR+L*BKKJV'9+P&8IK>6%K3-HP,F:,=$65<V82#IF,CH-8M\2?K?M4L'3D;'
MEDFS.F=.RLQ(>C9T @DZH,B.>&'(27)9<CIA$)E$ZXG@/M:1ICE1P8_TV+[+
M^P+Y/6I$S8(L;IG7.M8/39,CVEZ5DG,AZ$<.7$R<C%F@PD?$ZX&RA V*W4/>
MT$D>/'C+@3Y>5]K.3.>((:8N-JD89^TV@CZ-E7;BRA((U:5P4)6.^6+&.)\%
M51CO82[&; NC]X,-T*'7Q4NTIM;0==]K47ID,O3A',6$>6L^#U.9&D$^#''
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MG-O5A6GB@-\+Q/;UE*P0J(?B:[<MU+D ZB;UY<5<[ .);5[H6OA1[B"E4SA
M'W>(@4U(074M1H_FV7=N.U?*0;>))MX>R55G)4*(V)Y2PC!>+'G5BI'F-'70
MI?+=^*[./%%VV;V:I3V:U5U!R/R*SJE<DL--IV7+=6TY!C3P+W5)](WG6*8@
M;;*A(IPZ"SPWXBO+TD.RX++8HF=:5@JEE3<0&- A;L-8!-J#NL;0Q/.M"[>$
MC65M@':A:BR"U45[US1 !W$4"-:!P>/;^1^T%5.1KTT>V02H<8<MJ./WK>H5
ME4O>)]>:&U30\@"Z;5$1@BL%ZH 2@M@?6#T"FT+8X6RE.%5',*GJ\I5(F10%
M+2(64,20?##%?I'<JL2!N!*G@DL"=5CMI [$M2,%)4"QO(##R@@LH%T0#W H
M@:I(+C.S+K<!R4RIU%15J?MS<@3V'EFN4%MMV@D*D'M#6*6JC-K-HT!P5Q3>
M# UO'5M99&:!I..+/KM*CG3>OLM;T++14,Q/NRTA8>$285W$#GSKRX[6Z][X
M;,*0VXJH!R&MU4^(*D-!FOZ#4$)H@*>0!YA(5OM!]J%K5+0R<V^L5U[BIU]Q
M;E!H32<GA>X%<L4U(SI<YRWLY,$_'(F:@SNBN5IRE)S%,F*2)^1)<L>/8+$V
MTAHH0PI25M@IL 2+X;$-1EM_,%(">'=E>&VC4B24@V0#M!;N2C;U!%B.E%$B
MWWU0:BMZR\<W<QF*CK:$[GJ99%,X@6,;U;J_5JX>Y $YA[5R%E+%R0MXSY$X
MY6+FRRJU)I5+L_HL''CY>^#8A)^/"^3ELRAX4?:@?-)2AB1_5PL/*71S19@R
MAMZD'Z>RB\1Z)O;Y4!8@ FGE'#;77S  @E=INZ7=Q@Q\V<F+FC&SL+YRE6VG
M)-'[,\0H]EK?'E85UH8A1ROM:K5.>_K5GJG'JUP[K0@Y]D)77Y=*YMZE"OJL
M95CJ<E:>&G;;&P1I>59V+&TVK0*EB+[>3A2Q8@'<\1K)W.I98^"% '#6;(('
M8"_-98"N16RT[F;M-6>M36TVT/54]!HO##8FN#\?HMA.0GS_ +3'.G&%TBLL
MSJB*+$/B7CSCVL'E"55?Q\:L9LXWV%J,(CV*6K1PJVV@=S2<[CY%$,;KMIB/
MI.0"Q8$"N>^I5Y2"22-J1GZ(\S&21&!M1_95>%"D$W0!K60\YZYM%JQC%3?F
MI%Y-L& >4:6PH*E6C[.*;^%@"N;L1KG!0;!(D\JKD3#CE\CH.4 WJ[,W+H,:
M^C5MH$S".,D H H%HP8DS'PRU%2ZWYJ^@4(L(;8@@9'VDACNNF4J (Z>B0VT
MUQ]8.#]+A0=;K>=[KS-V'K,LOAN; RM5O65/9Y3\.1C+!2/X>$J %V.7\%T#
M))Q%1TQ,99JU4U%3?9BEM=4@BK3,#2.HVID*4&T!=VUJ.UO#)(^DW ;X,Q8=
MFY!U+;GQV#&R3ML6-R[P+[+\/B  >XX.N?7=QYY*M*KEN8"W0W;AC@SFSA_3
M3-=9'A..1^-4]-9<E\C)D>XA(SI5>K#**!6==A#Y6,%(DV4;%:&[9GU"Q &,
M$;9)(W)L A'8A$)L456R?0M\.=4)D+!Z.Y$D3L>64#<P'Q#'Z)YL#COS97('
M.MN;7QAR/7KG=Y>../.3.6U=!AIE+%>J+V&)V-J!>4JZ!26L7D\@S$\E$WT*
MJ:!69)AZTG-KZ^PP["KB5E%B4*%*IO>-"Q9B"G_M#H38/E\@4MP:%$CDW9I#
MN+ACM5G";5O=^91@*(MO/NJB+/%ZTD#E;F"W6:E:6#D>T'5*K<Z520.QJ]*6
M[6V91>NS?SZ-'6;(]K7$=/IE@KQ?)2FN5*.!*L8P*W]FW3[W(ZX+D)]:L4C5
M6I%W&(\'<""LT7F ,C,K;"6Y/(%[0I(-=[L5MFH2#D;:(:&2@2$4$;P!P#1/
MTBP!7<Z'S3S..MHX67;%7;1L\05U5P4-QZF$1MN+6W!M-L-KY3]7K6<6$+>M
MV=E:=HF*RQ+J(H*JHG&1M8ELI&Q!<-'';< K^<;Q-YL.)&54JZ-@+P1N.XN&
MJAJXD?R^:CY (]HK:44L]U?!)YO:-NTC=KR+Y;[2->J279URB5B:Q<9]F;DA
MQ9;-6*G1M*^YY)7\U_PBTM%;!.'[K2J4N&/I%*D3%\JT^Q8#)/)J36X@-;I6
M&Z8(XBQI!P\R!0S-N">%L8KXBLWTFOPV7X$*0K P7E %O])8F+%0H!;?N4'8
MRJ/*M;PQ[B[9:NSD6Q.[OV<N!;9<5]PWIKFQ\7N.T"N)KA*FPFT A0?AO+9*
MK6)F<T%:GNLE3:7Q2MD+4;4/%@C:1;U?9I!UFBA9954KN <1&[&ZQ6UFKS!=
MVPGG=5&Z.M&),<98-19/$&VB5-CD*30W;2W)&V[XO6A:WCCZIEB*^"G5BX-X
M#?7=_P#%G+%8J:63C<>SK* H*2H>)%]K16:DUZLV0W$VED>KZ7!6W-W2L*]7
MS9+K86)FMMKMS*%ED"BD9R'VEJ)<J0Q(O@%MP4VPVJ!JA95XC)CC)-N%&T-M
M! 0," #S9"T3P/,;U%5;D7M3WC-29NKA9N.YFMNX*IKNL*^,ZI#$&OY!X:"L
M][LFT5PJSYZH=K;+/J0C#8GSK:>SV+26U5:8HM5HHI"NX!0U+*P8NW)1R%'E
M8 V.]#S"BI6[T#2M1W%>8U("KV9 6/F!(()XOA>0P;X:\D[0W-D]A'0L>16F
M;TBK?"FU=XSUX]KD.W+K.P\[<L<>7AA8)]:M(S!]31:0J?D[T]C4E=*WV/N3
M >6IZ2+([F*.KV *S2 OO/YL")'6N:/F8CS;BU!1YN3597)(+'< E+M'G)D=
M6NA?*K?%!?I'CC40-VB^T-8K48GK%L?Q 6W1=I%,SIM0+<\7LYNU3P5QB0L(
MJJZAZ"U)@/QOR/;3CJG>N0.4;1$.F"LS'>J01=S=X406V46MW3'SCP)7O=NY
M\Z"BJ(.2OF^#Q923M8D$=RJVA\6-:H+QY&8D,7/ /E^,^XYN[5E<NG(J%,>%
M;[#3HN7E%?XX=J\%6&TI:-Q!8G7&_(&*[3.&E$@[7D.[JJN<98I^4%O&+3XF
M:<>UJM);EHH7AP(X2$)&U6\,EPU!2T@#I;2'A5+ #87%!V9ELF3)*&8 [BH<
M;2.3M0E6 5!RS!227"&RH -#5W]G8PRRW/M'F+.5[5R6O9).+1$')!E=0(C]
M3LU*R:GQ*(5M21T\\Q S([MLPUF31:;C2O62!@X4--I\Y:"P@HJ47M 2P^DO
M>V9N1]O/<4"-:1\F6G+FEIB #>T\"@!QZUQV-D'7.W"/,?+H=%X45;\AVUA9
M0$793K=;XZ=TY.P*Y;06H:G*^=+/97DE2AL^K;C LV_I#BT[I!K1I.-@W7)0
MUDF?3R-=9(TW2G8H4M,2X8CPR"QB4"ZIQL(!!W;J0K7&4;N%C&YB0(@$*BV!
MVB0D[01L\PNQMVV]WKJB[\@U_B'M'VNV<A'GHJG;.S_1$U58Y6.3USJU4N]\
MK,K#7%F5H9D4UKD6W.L3+44>/>'L,TF%0IN%Q>!\%4O$JJ 6$K%N185D0 GT
M4%6L]A\:O6S,$E)8T#&H!YHE68D#[:84.Y_5KG[AMKVB*-1N)4S1[95 O&"K
ML,\6-N-RJA7R1&<=]JG'53Y8(L;PU"7;I&%6.;G,@RDU@40)F2HS5_JX7S9#
M#U<1,SD $O[RX<,?[+.4H A:-<V#8/%5SDAD58P2?*,="M WN"A[)!/'?@BO
MB:UCUKD7M29JM8N#7DNU,2IN&.S1RVTK<O&=!$"+L_)'(9M<O=$EV$I<#<6N
MA5<2,HH,<V&X+7<^6^EE!3>"O]2R0[F4(M>)*@(=K"HEJWTB"2Q[D;2!5$\Z
M!Y=H8L;V1.5*KW9MK#Z(-5S5[@?[5<:A>3.<N4+G38J?#<+97G%?JG+SKF Z
MKU0<!S5&U![4W ]?J,1IAU68 K\_P6-.0&12N$>31Y5MOB-@,8JD!-F)&BMN
MVJ06C"!F)!#PR,W9@3Y@OQX/'!XU#N[ (&((5RY4405FC"]Q0M"UBN1SVK6K
M<Q<X\VVJ#G*K5:YWG9"=QYVKDL0*Y)5PK15F'&JEM-0SU"A!QXP?5F:Y!(C-
MD#:S\CMFO)*!K-<:/2J9KNOTKMXXXU,;,JWN@/))5MY 8$EZ;:2+"H A&UF/
M]JKR2,) &:BLP' !&RZH!+!8 D6Y+#E5'(&\/.T%VFA+??HJ.Q57&=*-R1I1
M..V $C)I=JC7^$'-KXWY"$2U+AT S8V]W0.NF26N;E)7QDQP\.XU45Q/=]U<
M(V8BAI-P*WLWN" %8RA74EG(\JD\!"P(W$E0=7,LNY]O.W< I[L!&65@ @Y9
M@.2P0WM #5J^.SBY/97?M%OE'(3WF@/91Q5M7;:^0JJ[JW8BU2QRF)1L5ZNU
M2NE>A:28#,E6)QB%4\F4#R2=\G8D24F%+$"@CHO:@DUYASR6(L?:0>XX(&M(
MSS(0Q?A:)%? \4  1^@?8;()US?1.(C^7[-PTVFK7$EX .['W$=SL+;FSC5A
M?PF5TOMPNEKO#A)K&Y2BI;58'35@VL/F8)V\9@D6P<$$&D>=6<1K(+=:GD4!
M&"D*JJ%!M38   X'Z=9*F\QV$8>"K$NI:V9B6(Y%$DFQ\^VO?M!<F<L'T;GN
MFKWCPMT>@[6U#<<'K:4# '0N(JQPGRT3Q3RDF=+Z_%;MC[DV1<;:A,S;.SK#
M@SD<NKU]"(X19G71$B!HFH5<#"0MRTC2H'0@FJ4%^-H/DW$T>4KOMD4$V1,O
MAA1Y4$;E'! W6Q"5YB#N( XXM1-;[G;.TQQG!9[D^]WK_,?:(5,.(M:H"$CI
M5&1UJ^H>+;CL^%0CNIM>0JE$BM>A%CLCA6\8V4@:JBJ\51H)I0JHB8JHHI$1
M)N)+,2I=:)KRM:\ $ <D[AJX9FD6R;$D@V4*"@.$:P+\P /)YO@<$ZJ+E==0
MYK7VWM0J_M/VK#>3T&W9L<)ZVWEY$&??_#!V>1^/#$5E5+]C0*"!R9 XEM>\
M[*&HCKX;CFRZ^W;N-9-(RVW&Y_,A&\8$C:1X\VZU)HOLK;QNLKMYK5'"[LBA
M^>WKX1 .Z_"BVD$#Z(>]WP[WWUI',?']NY(<<A,SR;2LU0(NTNHKJY'2:-NO
MBC;]JD.ILBP?>Z ].C:W?CXR8*QLP3H3;*@U(P1+*O9/-6=HF5-GT>3$6)9K
MXA+ &F I7%J"/*W;D"JNA9F)L4)  %6K,H!(M6(+*>:/([\$WO!'-/:4JT?+
M:"M,$"DB@5CM%)ZQQQI6X3C*4@XNB;J^"[8MIE;X81BJHK.N55-KX;'R2RIE
MU"LQ<?'Z1+E>/7UU1'$Q0L&(<PDONK<TE&123(22"6 I0P(!8F[-C)*HD H%
M1(%4"]H4D1D*$'<!;MB&OR@=M60RY/[1M3YWGXYFN\3=6@N5#KJ *U+5@[OE
M2@/*2F?73D7->H_!L\A)Z"PM+8A"?(;Q2:'7B*( %=D>GNDS9O4)"T8?81:L
M6()(1PU*EM(*#*%)!5F.X[3P +%Y5<J6L J%L %UV@LU!#=$D6"JC;R #>H9
M'RUVAE-<HV;KR+8M%5\XR[+]_P"0.1RN/:6"5PU-R3OR-'R5JA"%IVJ$9**P
MKM+3:;7Y1;R:-'86%AL# U;%'&"*1$MM0 H\RJF]COV;-FXEKW$%SY=@;: !
M=Z@/* NYC3)$S-M4%-V[?0JJ% >8,5LD\#7Q%SOS[+R;5$BJZ#,:OLWXJ7U&
M>U5 RGG<X52PW@Y/>+CFGJ^(;:\9E!UV*7(3FFV_C:K5G8!?R7<*^#Q_8Q0(
M!CC"$E?-4A;:P81LJ@JNXN .>X8.QO8IW#3Q)-X4'BTHL-N]68AFH(3P.Q4J
MH^DP"GBY.7;!R<+S_FM4=B95 ;*I[-B!C<E%/0N7 BE]:^TYM:XQ63](X6[3
M+Q45>E78;",UM>-9>OD5SQ.2Q6-$5/"W,-Q!F(4L0#2P[; (/<FZHGM? K1R
MPDI> 1$-P )Y:2Q9!'87S==ZHF\6VN+_ &OLI03V65JWN2[G.H5<MC&HT5M7
M:J@]L1)40[$8K3AA!CS.JG71GS?=6O!3;Z%F%@AAJ=XH(@"B8A12F-F NP"T
M!8@$DDTQH6;[?'4$LT()LGQ%%UR0LX%D  <J+- #]6M"XXCXE%LRS^$6KV9I
MVN=>?[7A@Q2)W$?)^B@GDVP:(&^]DDR!C7LX!<6$*"I0LM]J+M3(=40RL^^Y
MA23V?>00C*(!$" 2-EA!8V\_GB]\UNW<V$YU5=E@LK&;Q"#0\];S1)O^J"T>
M^VN "QH]HG73B?D5&75)[4C:*;O5VL>XVC#TN6=;8KVL)98I&V8=M("ER]X6
MO,BDUV*$3.&2[>8=,P(%YPKH0VT@J0;JZ(([_H- CU(![C6Y9&&VP0P^8(/_
M * G]6L3L\6*QV_@+A&UW"2::UV7B7CM]9""8?3$%.VU14'LS"!<ZZ9$G+,G
MF)F$VUUV%DEV'VQC://4R@+)(J_1#L!\: )H7\:[7\>^D1+1QEOI%%)_20+/
MV7WKX=M7%UGJ^G333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIJM8
M;+!4N-*LXF"*8[;K:$E" #V'CG,:V<M%64P^)2YAQH(I6K</0DF:7708;,L^
M=9,QXCW\=\Y.G=(Q,EXY)B4Z7BQ11% \N1GS8N!BIND9$16R<F)7D=@(T+/3
M;=I^IDZ5)UGVJZOA1SPXP&7[19\^1.)6CAP^DP]1ZKG2[(8Y99'3#PIVBB1"
MTLH2.UW;EJBQ]H:O2+35)M$:,MCQ;:D9I64M;8@Q-%)=Y02HK$,&T9Q1JVQ]
M+8 [&&1ZKS!F@'H_<=?=8UOS6;[989@EQI>DSS&:/J.+/BSM@SQ+D8\G5L-L
M3-CBGG"X^3-TN:(R2J(98YXO#\8>\"#[#I?]&O4ERH,R#VAQ,48TW1>H8N?B
MIU7%G?$S(/9_J2=0Z9+/B8KOEX6-U[&R!! QR<>7$R/']U/N;96&1VE5X*F/
M4:G/PLK9:F"<9$@.95\>4AM3 K*I6Q(\SFD$KE]D,'01C02Y8M4Q(L(DL>RO
M1SE)[<0PXPV=,RXCCOT^&:08DL^&C-D],BSL>!<4M*[PPYTJ88C5O&R,9T6-
ME..,G>+^BS)R<US)UOIL_O2=9R,>%^HX^+U*5(\/KL_2LW+?J C@CBR<GI<$
MG4FED08N)G12O,C#+.#.%]IFI@12FD5JX2J0ZW'9&;5:O#<!KHB*47R (%*4
MK.* GFFKL F-B13IE^K-PJ$A+('W.. [)/;GIT2M*^%U)L:+!&=/DP0QY,4*
MOTN3K$4;28\LD3L^$D=R1RO")\G'C61T,LL/GP?T5=8R76"+JO1$S)^JMTO$
MQ,O)FP9LIX^O0^S<\Z19>/#DQ1Q]3EF(BFQX\DXF#F3/#%*L&/D9P_:!7S;[
MZ2T>XAX78)FL,I@ZX&-.O&,K(N[&"-@<&8Z'VTM:\O7"L.??:,)R+C&6@0Z\
M[5/;"%B0W2NIQ>"'?,:5((EQH8Y<&,S*)IHY<I"O4(9![O&Y*Q9,?]?$D,O/
M)_1QDHJLG7^ASG),4?34@ERLALW)FAZK*N+(V-CS08,N[H^3"?>YHU#Y&#,2
M,2>7)QU:[0BJVDUX9)2KG)\4M$(Z0HT,)8"2E?H[=9!W^Q; T:+:$5/3&91J
MX3)C"+8Y'%I%)LPD])&#[98_47PTQ>E]3;\H3XB8KS118\4F-F8O4<U,OQ)I
M$4K'C=+R'E@C\693+B@*3,?#GJO]&V9T:+J<N?UWH2_DC$ZC+GPP9$^7D19W
M3L_HO3)>G"#&@E8/-F]=Q(H,J;P,9QC]0=G48R^-EVSG42J-[6NDI5G9B5##
MCW)N$36XQ)<UZCUWD-SZ4<UV,PWP/6[&/@?;<6/!;8>8'&(H-M#LZ=1]K(^G
MY/4(#TO/R(^F^\^/D1282QM[ETK"ZUE>&DN5'*VS!S4"%HU$F0C0^52)=8]&
M_H^FZQA='REZ]TG$FZV<+W7"GBZHTR?E+K_4_9G!\:2# EQE,O5.ERF4+,_@
MX<J9!WR!L<?CGG$04NO JD1A4S>SFIC9#B0 QUZU+>F5%=,<R;FZXVWU-5S%
MA1[9UUW$DCD(S%+I)!K.3[51QR8<6/B2NV1GRXLK3/#$D,&+U>;I&5.6,H!(
ME@:2)20#$P9RK!DTP?8&:6#J>1F]0AA3"Z3CYT"8\63/+DY6?[/8WM!@8H58
M"0#!E)#.P!(G5EC#HRRG3M^TO&?)#JIJK$(>,=N4T-9>W'ZBB#U]4^3F+HE[
MH<-Y PPRW"GE7MLAQ$AS["'FA[0&2^9_TX$[*,; FB14R),B68PS".-</&R\
M66$0Y219:3>\&)VAR#&KQN8Y98BLC>XO]%;8RN<SK&+/*\F%#AX^+[UC--/+
MU+,Z=FP939.!+/T^3&.*LZ)DX8G:*>,38\$XD@3;(^>PRID B^DV<TVX1A'T
M\?!5;'U=HSTMQ?#N)9YW>D:G3V^E'SR@L?*/TU9*8]1Y"MV8JOT1[71N^''#
MTK/EEZD(I>FIXF"@RL6;%ZGF)DLSY0&,/!Z7*S13A91X^,H5I#/'C^,W]'4\
M,?49\GKW2<>#HC3X_6Y##U20X&?C9W0^GRX*)%@,V:WO/7L>-,C%WXS'%S6,
MJPKB39<_1^9$M[L&$2],[6:D5H.TJCG>@ &KA86#73\S+ ]S=C6(\&ME#%(/
M5Q,%X+ 0\!J2N*RKB:=?2O:7%ZOF>ZPXV5 'P8L_'ERA##[SCR0X4V^&(RF6
M9%&?%&\L"S0Q31S0Y$D$AQUR/.Z_[$9_L]TW\H9.=T_*,75)^D9F/@-D9)PL
MN'(ZGC;,J=8!!C22-TJ>6+'RWQLG(QIL?)PX<J$9;XD70N:Q;B370-D#B'5V
M,F&TL.\2H-64_9<8USE/<.%3&^;M@8,5^P:X\<\AD,# 0@#!QFF(#R>?I'M1
M'U.3#A.'DH,I,6-<QEQXH),R?H6%U\Q)CC+R<B)!AY@Y9I52:-X1+* LS]?M
M%[!S=#BZED#J."[8,N=*W35?,GRX>G8OM7U/V16=\QNG86'D2'J733Y46!Y,
M::/)./ 3)CQ6:67<M"9M $-8)#UWS@><NVM0B98_YMYA(:4PB@WS]O?'H:3K
MC^:7/?\ 9]> E<LX/Q 0$?/Q!?R&OSVV^ 7[Q_A.L;UM]^[50_&[G]WW2H_K
M/^S7^9I;_57[Q_@T];??NU4/QNY_=]TJ/ZS_ +-?YFEO]5?O'^#3UM]^[50_
M&[G]WW2H_K/^S7^9I;_57[Q_@T];??NU4/QNY_=]TJ/ZS_LU_F:6_P!5?O'^
M#3UM]^[50_&[G]WW2H_K/^S7^9I;_57[Q_@T];??NU4/QNY_=]TJ/ZS_ +-?
MYFEO]5?O'^#6?,_T#VU@-&WT+UBAV(T%DP0/'-)%I))'#/+H)+/'IOMG327<
M4?:37&-]H8L[9TU!">017PO@_+G_ !.N>3*2)BC*Q( )JJY%\$D$_(:\?BD+
M^H*_U8OS>FP^H_?^&J>_1_4?_=_'3XI"_J"O]6+\WIL/J/W_ (:>_1_4?_=_
M'3XI"_J"O]6+\WIL/J/W_AI[]']1_P#=_'3XI"_J"O\ 5B_-Z;#ZC]_X:>_1
M_4?_ '?QT^*0OZ@K_5B_-Z;#ZC]_X:>_1_4?_=_'44ZM+H3 ,J5&K9#EPRR2
M;-+ 6FFADBGWA\&D0E=>Z3:;8TSMYFT\.V,Y\/EY_P"EU*H#89B"*[*&'/VE
ME_PU+Y@5481DAPQY;:1M8K\ WIZZ@_C:Y_=&L?CAK_8#JWAI]=ON#^9K/W__
M %7^_P#\FGQM<_NC6/QPU_L!T\-/KM]P?S-/?_\ 5?[_ /R:?&US^Z-8_'#7
M^P'3PT^NWW!_,T]__P!5_O\ _)I\;7/[HUC\<-?[ =/#3Z[?<'\S3W__ %7^
M_P#\FOW6ZW/;;77%1K'?MG&/_P"N&O\ /GN^X'3PT^NWW!_,T&=9 \+O_K/^
M37J1<+H//-!M4JOMM#)O'MMK>&W=G.FV=<YQWT#O[LYQ]G?]O01H0#O;G_0'
M\S5GS"CLABLJ2+#]Z_\ DUX_&US^Z-8_'#7^P'3PT^NWW!_,U7W_ /U7^_\
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MR%692);4D?03X&O^\T3I63(B.'@ =%< M)8# $ _FN_.O/XVN?W1K'XX:_V
MZCWV#TE^XG\S5OR/D_7@^])_*T^-KG]T:Q^.&O\ 8#I[[!Z2_<3^9I^1\GZ\
M'WI/Y6GQM<_NC6/QPU_L!T]]@])?N)_,T_(^3]>#[TG\K3XVN?W1K'XX:_V
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MIIKOXL:ZZZXQC'U"\JI\W*CZ0 ;M_:   ;U   /8#7Y=( )' " !V $99HP
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M5(8^K>% <F+&$\<:_DY-RG&D'B3-E-U"-IIL:'#E>Q>O3U\SJ19?WP7_ /7
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MGJU,%;0S 02Y?V!DW<K5"=*C&,.;M2HUZV DO?6+;78]+6SS"P+2ZHFR#R
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M9T>6:Y52'3/S#AM) H@EB[D6HSGGR$:B#98SQ;R^:K:Z!0$<J7I=H /9>Q+
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MK'I+MK SGESK%+O-%')MB,G;.(Y)!R(]-\]VN^\$VFN<[1;XUZUF5B0K1L0
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M"< G@4+-?$57I:D  6AYPS&J)IBW-#D\USJQ[ >)[J1_+Z?]&#^;;'_]F/\
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M.D4L<H*DQR)( 2:)1@P!^PU6JQ;T<L]%7*T+;8ATB&%2.0M-0['BOAE"V(*
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ME,2=<PA,^-%%+/(F?!A3JD:[4EED,9D>S8\,I8#JKRKMD@$D1$@CO_B-XLG
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M!$U&72-0CC -%<35XID !\4LFH0)8;I_(I71N9DNWNK4G-%D>1K!VA4VD[2
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M+BX^5(P(\()DQ1R1%-Q$I\3?( K1I(@B+3+&)<<S6GUCKU-;"U_PZ3_NA/\
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ML),!7S[(U60BJ9!]U*S;5G;[(Q-G6 AD-3FQ!364V?6'>*"U@*6) )(\H[D
M'F[[*!SV XU(%$D 60 ?,?@21Q5#EB30Y)YO1I7F3$R0OQ P^9K'CR_4$2=W
M@CUT[_%Z/3O[_#W_ /1QW=_=]OZ>M4E"+MHGDF^!W^>N&?"::5I/$"W0K:6[
M #O8]/34?\(,OZ\'_:D?\MU;QQ]4_,:R_)I_[X?</\6O$BCE%::Q%85DQ:S#
M$ZQD8DFTU(#(B,#(UTD$VUQ,*7! 4-+C&)("(8IXMM)8]-L2,@#L&'!'!K@B
MB/T$$@^H-:JW2PPII$8!E8!H[ 9&#HU%B-R.JLI[JP#"B =8!G&0K'>61@LK
M9V\\<D,^Y@<96\T4H9*Z6*7:<#?,D<J\PP&33?.VNX91(VV,P3RZ;2,HBJ+B
MN13$4;#6*/'(!_2 >X&LWZ+#(29!!(6!#%\=&+ HT9!+$D@QNZ$'@HS*?*Q!
ME<5!EC'=B8'&,?9C&))^[&/\G^#=5\<?5/S&MOR:?^]'W#_%I\(,OZ\'_:D?
M\MT\<?5/S&GY-/\ WP^X?XM9<]:93#!#^8#KZ2.;3Q^>1GS/-GWG[_#Z3'A\
M/C\/=W[=_=W]^._NQ F +&CYB#\.* '_ *:NV 66-?% V!A>P\[F+=MW%77Q
M]=8GP@R_KP?]J1_RW4^./JGYC5/R:?\ OA]P_P 6O&>CE%::QE85DQZ3#DZ:
M3XDFTT($GC*$(UUD$VUUF&)AB('EQC$D,\4<T>VLFFNV)&0!V##@C@UP11'Z
M""0?4&M5;I8< /(C ,K -'N 9&#HP!8TRL RGNK $$$ ZCR>,A3=YY#%E;+W
M*S/L3N2%'/N1L2(*O)S/M*!OF;)  004^9,[9E$$%&D\4(\6FDC)(JMXJJIJ
MJB2*]*))'H23W.J-T:%RQ<0N7W;BT"L6W(L;;K)O<B(C7=HBJ;"@"6^$&7]>
M#_M2/^6ZKXX^J?F-:_DT_P#?#[A_BU]:5)EIOKMYP.?#MKMW>:1CO\.<9[N_
MTN>[O[O\G0S@@C:>17PT'3F!!\4<<_0/\6O<RL,BBB"?,!C\^:27P><1MX?'
MMG;P^+TFOB[N_N[_  X[_P#)CJ%F"J%HFA5\:O)@-)([^*!O9FK:35FZO<+^
M0U@$T@HP><0OVLH0J&48D8GS)QR1Y]-HIH)X91-HYH9H]MHY8I-=M)--MM-]
M<ZYSC-AD $$!@0;!!H@CL0?@1K)NEAU9'D1T92K*T>Y65A3*REB"I!(((((-
M'C6O?P-5[RPX?ABE>2N@.&7Q>R@^6",T\[#,</3VOPBP,<$D8.B@QI&7Y\WJ
M-9/-W\5O?'Y\TG)!/G/)6MI//)6A5]J%=M<__1_#I!X.)40D6,>Z15&LM^*J
M"J02;F\0+0?<=UV=3PM#F"UEU#C4":SS;DS:BZ;CZS$28UUDGEQ$'IB2;?73
M37>7?&=]L::XVVSC7'=4Y /<,?AR;X]-;ITI8P1&\:!F+$)$%!8U;$!A;&A9
M/)H:R?A!E_7@_P"U(_Y;J/''U3\QJ_Y-/_?#[A_BUEG5ID87.5Y@,?G;XV\'
MGD;^'^+C7N\7I->_]'?W^''_ ..H68*H6B:%7QJ\N 9'9_% W$&MI-4 .^X>
MGIJ.)HY1HQ 9F%18A<$HQ0I.))QB1IX]HIQR()1-XIH)HM]HY8I-=HY(]MM-
M]<ZYSC-AD $$!@0;!!H@CL0?@1K)NEAU9'D1T=2KHT>Y65@0RLI8AE8$@@@@
M@D$5KE'M(+>;E%IX?2\;<?T*[H.0+9'6^0-[) $7G(*G7>Q+0B-6,X.8EX:D
M:XOHC(QFVX1B[^YQHRB8A6W=AR8S)D--++$T,>^+82.6\A(V@\EC$E>6PU$U
M97Y+VFQNM09?1H.EX.#GX_4,L8W4#E)$:2$>\Q(1)(OYM(4S<@.%E*/%Y5#L
MJR]0"<:#KYM" %U="GCCEACG$$T&FCBGB7P3Q:20@:;ZQS0J%4,NFNV-9(EB
M^/?&V@0V(N(Y)(H[R.#1:Q8W$'GT+-7^TWJ=?5)T:&-@T8AC8 @,D"JP#"-6
M *D$!EBB!'8B*,'A%J4^$&7]>#_M2/\ ENJ^./JGYC6OY-/_ 'P^X?XM2)=?
M9%3[3>('3Q:1:^'U!&W=Y4,<7?W^CU_Z7@\7=W?9W]W?GN[\^7-B>+*\GB;=
MQ!K9=4 .^X>GIKZC$ZE[KC18_@[_  U(W^+MW6S->WPVKO7<ZQ-ZJPDTVCDV
M7[Z;Z[:;Z;RS[:;Z;8SKMKMKL)G&VNV,YQMKG&<9QG.,X[L]8G !!!E!!%$&
M.P0>X(W\@ZZAULJ0RXY5E(*L)R""#8((BL$'D$<@ZA@.,ERL?4-8CJRX308L
M/04 " 0?0,^;!!PNL ZV.+48R?76<N#&N(B)L8DFTWWQC;K&/HV+$H2*.")
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MF49'49YA(6GDRB9!(&#WDRRY!W7<\DDQ_..S&9^%V7]8#_MB/^4ZW]P_UO\
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M%W)+: P10DBAG2."(\Z):T4C'@R,2,_D-W*KB[9L!"TAW/&JR24-I8"-9GB
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ML.=,-Y92W@X>0D[$*5(W11EYQX1^V_--<!+KP*Y:V=F/;/-7=8AH-!_0: 7
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M1Y,8:HU?S!&[P&6QY $0XRW;:KB8Q3VS&2+U.]GRYF)(*HM * D9*@*BTK;
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BW9&3*D4 6%?#BBEF>*/<,>'>Z(KR% TC,Q8FP.L=>CK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g189651g57n46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g57n46.jpg
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M1*.7]I3KE:E@KU>393D:IW52YF=9.JJNU3EC.F+]%L6VF<*RH2&QI)*@-DD
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MT\*O9;"G&M'0UZ'L,+"2].0L1FQ(V*553:R3N/:O$U#\T ,D$\2'^J[1L%R
MTBJ6U*,D9*DAB,Y/<#BNB8A)H)7_ ,I5D4MC(1FTZ6;D" 1JX#OQFL4P%(I/
M&QO;C+L=)1<.N'7:W#)0M#O]BI1#UE7-C[9C92Z2:=VJ*[UNS+:C:SAI: BT
M;&W(JR2D6K5K'O'+=/IA<NUM%;JVZ9)FET;M21D*-+;SC603C<<<150JSR7!
M7/5/$D9;> SC4=2GOT@J,C.\8[JM?A8L.V=W2.Q=^;5UM*V"W\)7#Q+<+L#0
M9=LHJ&P]]1D:M,;_ )6-2=MU ,I<W$!K^G,W:39PFZ9OY-J!5""J1:9PD82-
M' 6>43EQCLQDXB!(QO7+L1D8W?Q6$O)JD923#$80I&-4@&92.)PV$ X]_?6E
MVRMO.MA<)VMVC?B"C)MY'VG0<U8.$[1/#Y"4ZB\/[6'V339"7@]ARCJ)LEVJ
M$1KM9,\"Q?/;)40GK&6-ZI"2B'CANITI'HG<]40-,H$\LI9Y<HP!0 JK%_S$
M!6P.1&_!WU0(!*#@Q%H(XPJQX=20^064)@C>5R<=VX^O?#6V<)<9/FC:ZK=9
M)!U?.&TS591)0B3DJ7#G4TE3(*&*!%BIJE,FH*8F B@"0P@8!#.";_L]I_IF
M_P#6:NV+_/N_]<7_ **5OQG+733%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I6K7'$BLXX,^*U!NDHNNMP[[B2111(955552@SQ2)I)D QU%#F$"D(4
MHF,80  $1Y9O;?\ :(/_ !4_XA6%S_V>?_PG_P"$UH]N[5]WH&D=*\8^D8-U
M*;!U_P -U5HN\-?L"'27W!H22H\<,TR,V*016NFL'BAKC47 E(Y.@UE8E87Z
M1V46ITQNKRRV\A 1YF>-S_W<H8X/^EQV6[N!W<:PE1EC2>,$LL061!Q>,KOW
M>\F=2]_$=];<>9VH+M>!WA>;N456[A'4%635073.BLD<K8W2(HDH4IR'#URF
M* AZX9SW?_:9O_$;[UM:?]FA_P##7[5N=G/713%*8I3%*\]?-"FKETQX, ;-
MUW M_-"N%5TN""*BW4MD;%-"LX5ZLINK02 0%58_133 0$Q@ <Z[3C<?_P!2
M?["N2[!(M\ G%W 3CN&3O^51^/W9;_7"W#DL4E!I$)+;6DTICB3V/KPVR(3A
MU694V85B9^.BQ<Q[6'L5T<JJU&+LLK(MX:)1=/ADB*)+%5;+5 _7?F8B/="K
MZ#-DC()XD+N8J!D[@/C-R^CJ3V%!DWRNFL1=DD,-X +?EU$X&<UY[&GWMRVK
MQTS2.U[COUE,^9?["CH3:<QKF$H->MR\1)78SUAK1K5ZQ7HNSU.$4GV+).>3
M4LCQS/.9ECW0O6C1BV:=> J6H,:Q$7J$H'+%00N]RS$JS:2<=D8 [(WUS9+/
M<G6TH-HV'*A0<%\A<* 0-0W[\DG?W#:'8==6J/#-YFAL0:I*RVJ- SFB;SM6
MMUVO/YUY 5\=+2-=C]@J5B):.Y640U[:9UC/RQ8]@^E6B:KF:(V5,Q<JI\Z-
MJFNUR!),)50D@ L9 Q3)( U@$#) [L[ZU<%8;1M),<1C9U )('5E0VD#)T$@
MGO''&XUC>]7^L<4?&+L]OPY=L']@GO,Q.(>AUS8YH":JL99+?,7FGM*RT@I:
MP1T.M,-JK+2R!7$VT*M%,9&57CTWHO(^00;:*K06Z==N O(F*9#$*%);(!."
MP&X'!(&>\55V$TYZG>3:3 /@J"2RA<$XSI)XC@3QR#C7F!D("]\/^B^'%_Q0
M;KG;PR?Z8K \(U,X=M2P>U]77.B3E>=+KR3Y[3JU.5&#U[+0KF4E=B3%DC4)
MF$9NW*\O)#-.4G.I!66640QA2)#U[3.8W5@1N&HABP. F#AMV!BL5.J*.+KG
M+ QCJ%A0.C*RG>2H("$9+$C('$DUZ5Z0ML!6?-#.-^A3[U2)M>RVG#O<J#%/
M6,@CW6UFI:<1@K++PKTS3M<\;0DNF>/?@1WUB3HIDN@8R:@$Y)%+6ELX&5CZ
MU'(([+-*64$9R,@Y'IBNR-@MU<*3AGZID!SV@L>"1W8!!!^->CN<==5,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE83U3I*(U3;=X6V-FI&5<[QV4GLN7:/D6R2$(_3J-
M;J(1L:=  479BVK:#L570BMU[E4G/JRDS1Y"ZQ*0!U2% 1W@L6R?'%9I&$:5
M@2>M<.0>XA0N!X9I9])1-GWMJK>[B:D6LQJFG[)I\;!(H-C1DJUV4>K'?O'R
MYP%TDO&]RS<&9$!!-3LI;KN?03PLA6)XL#$C(Q/>-&K 'SU;Z-&&E27)S&KJ
M!W'7IR3\M.ZLV9G6E,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE8:W?J1YM^L0T7#;'N^I[15+
M;#WBI7:B.V97T?/PJ+YL@VFX65;/8*WU:0:23UI.52?9.8N41424.5%VU:.4
M-(Y.K))175E*LK9X'!W$$%6&!A@<CY$UG(G6  ,R,K!E9<9!&>(((93G>IW&
ML?Z@X;9&C;,L&[MF[9LV[-OSE+9ZV9V:8@*Q38*JZ_:3(V-6MU>HU)BV9-.V
M\^",M.RDD\EI*0<,8Y)-=HU: @I>28,@C2-8XPVLJ"S%GQIU,S'?@;@  !D\
MZJD15S([M(Y72"0JA5SG"A0.)WDDDG X8K:7,*VIBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4K&]L?S+VUU:F1$PZKZ<K%V2P2TM'-XU>3*R@
ME(5DV8,1EV,G'HB\>SJ:KE=1@NJ5!D*2(I&7%4FB@!6<C5@JH!SC)R23@@[@
M-V\#)[^%9L265 2N0S$C&<#& "<@;SOW5-U[-R<Q#/T9E<KR5K]DL58>2!$$
MFH28PDFNU:R)FR %0;KO&/8JSI% I$".S+@@FFCU:9$BA2,# 958#.<:AG&3
MQP<X^%2A)!SQ#,N>>#N.[X<?C5]YG5Z8I3%*8I3%*8I3%*M&U,I]Z,>6-LA*
MM"M^SG=CE&Z; \P#=!L LT(]28CI.(:-A5%5>3>.VQEDD&Z:;7HBLJLE=2HS
ME=3;@HWXSWYP03W8 XY.?C5@3C#:1O+'=G'PR" ..3Q'=6)8.U6ZR!4:Z6P/
M6B%@D[X\:W-M&Q*$U.4VIKL6\2_;LWL:YAFKB;6F61S/20Y47,<U%XQ:->ST
MSHZ,JKJ;2#I"=C)(5VSD$@Y.-)W9XG&_%9!F;2NH]HN=8 !*K@ @$8!.1O Q
M@9'&LEZ^F925C9EG,N0?R59M$W6%Y/J$6II1*.6358OUFS8B;9!TM'NV@/"-
MDTFPNR+G;HH(G(BGG(H!4@8#*K <L[B,Y)QD'&=^./.M$)((.\JQ7/#..!QP
M&XCAN[QC.*OW*5>F*4Q2F*4Q2F*4Q2L*IW><E]EUEE%JIHT5V2W1Q5>I3.K9
M)6!:MCO)!NN<ACIP\8[4&.8JMCI]L'B,FL<561&"BNW5A8V)_.-!Q[H;. ?B
M1O(/ 8[\UEK8R*!N0ZAW=HJ#D_('=\2,UTT7:K6>,I^P'$^X7C;;=&<$O4C,
M(DD2P@Y^;=0,(HQ=),"3?;9DH:.>/7+J4<MG9COD09()]C WDJN7CTC*H6#Y
M.20H8YWZ<$9  &[GQ-0&;"OJW,^"N!C!)48[\@X)W[SD<@-@\PK:F*4Q2F*4
MQ2F*4Q2L4;.MKN!7J,&Q>R$:O:99ZW6?0T22;FR,8N-6?+-8.-5:/VZDF_<B
MS:E<NV;EI'LCO7ZZ8$;=:GK&@;42 =(&XG2N2<98Y!P!DX!!)P!6<C%=*C(U
M$[P,M@#.%'#)W#?P&3W5:<?:YZ63K5786V0,\F[A8HM].NX%A&6Z#AZ]"'F5
MXB3BGL8$.E93+J,VO; L-V"K$N4Y!NS4653<#<HJZF*C"HI"AB58L<!@<YTX
MR=).<C!QPJ@8G2H8Y+,"2 & 49P1C&HY&_&,'([LY#H4O*/.ZN#F7QI5]4+2
MO!%EE4&K9S)L%HF(G8YR]18HMF17J;69(R=&:-6J"RC07!6Z/7"0,G &D@8#
M*&QO(!R00"=^-V=Y)&>)K1"3J!.2K:<[@2, @X  '''\5D#*5>F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2K)M%:D9&3@K) R;*+GJ\E+-$C
MR<>M)QCZ*FB,QD6+ULU?QCHH@XC8YZU<H/"BBLT$AT54G"A0NK !E8$JV#N.
M""N<$$@CO((([\]U4922K*0"N1O&00V,\".0P:AU L'5X@S!6P-I-^\DI6:E
MY(4@: _EYI^XDG[A)H4ZQ6C8%G H,VH++"W:(H(G66.0RQSDL<Z2  % WG
MP!G&_P")YU"%5&-63DDG!WD\3W_?A5T=T4'X3:_#'R97!Y'P-6UKS\CZ4[HH
M/PFU^&/DQ@\CX&FM>?D?2G=%!^$VOPQ\F,'D? TUKS\CZ546?AC%.8LBV$J9
M0.H(''D0HG*F CWN\ G.4H?YF#&#R/A34O/A\#Z53W10?A-K\,?)C!Y'P--:
M\_(^E.Z*#\)M?ACY,8/(^!IK7GY'TIW10?A-K\,?)C!Y'P--:\_(^E8UV+'#
M="0K6/N,#'1+!VJ]EX68AGDU&V)0A4NUR$DDRG8%55@Q6!5TI'J++,W[CL87
MB*J38$5-(R$U$HQ)& 1N*\R#@X)W#(W@9QQK.3M8 90.\,I(/+/#('([CWU\
M=Q\FZ3KDXK<JJ2U5MY+HQ[YO6W[:O.XB39M&\A#.X@UC<O2& 46#M-XVF$^J
M7;-0[%.CUJ:C*Y8!'TL!D$Y8,"2&!T_,8(/$[^3?A3K74I."%(4@\01G/#@?
M*KAJ!86L1CALXL+23DY.6DYZ9D2HBS2>2LLY,Y<F;,^M<]B,T"=2S9-S.'"B
M;1LB59PNMUBIZN2Q!"D  *!O. !WG R>\G%60JH.6R22Q.",D\AOP.[B:NKN
MB@_";7X8^3*X/(^!JVM>?D?2G=%!^$VOPQ\F,'D? TUKS\CZ4[HH/PFU^&/D
MQ@\CX&FM>?D?2JSS\,F(%/(MBF$B9P 3CS$BI"J)F]+TCIG*8/Q@8!Q@\CX&
MFI>?D>_^*H[HH/PFU^&/DQ@\CX&FM>?D?2G=%!^$VOPQ\F,'D? TUKS\CZ52
M>P0*A#IGDFHD.4Q#!UA@YE, E,',  0Y@(AS 0$/6$!QAAW'P--2GO\ (^E8
ME;ZUUJULU0F(-9O')UI1Z*,8F^F%R.G#DC0D;U)EI04VA&"[?K.QRH*(.RJ
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MSVB7N.VM6LJU6U7,]+6]5!ULB+K-W<$/,4ZI;*?INWMJ@D6DJ[14FIU.MS,
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M(T7L Z?UN2OK*"Z*#=5D:8(W(JHITFXE(J50>B4X!TRZ<VVK\O4QAL<<:WU
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M$]U?I'I3SMZ![0J?\EH7[#CK)/U'^IO6FA/=7Z1Z5-4UMK_M<U'N!IW2%Z_
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M]*>BRT/[<7'R9M/\FQ[+/^G_ .9/^:G6Q^]Y-Z4]%EH?VXN/DS:?Y-CV6?\
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MEBO]1U*ET1%+@#!=FPSK\0.SJ''>P._- #E%.0K,[:"3D*%W*>_&26T]VY>
MQ68-0&4:%V-6DUG"T13]DRD%72N7"[L[.'<5^L6(D8FX<J*KG;1C^>?LF::B
MIP:LTF[),2I-B$)E-OZML8+QJS?$ZF7.[O(4$_'/?5XMW6+W+(0N23@%5;&3
MG@6..0P*S#F-:U<-4_""._/7^:KY5_RG^/N*E>(^8^]9OS&MZPY=?5U3]6;_
M ,)LV3\H_G[FL7_,?X^PK$&P;M'ZYITY=)2*LLXTA$&ZG:6G0$A:;3+NGKUM
M&Q\9!P$6FJ\D9!_(/&K5%,H)H)"J+AXX:LD7#E+15+L%! )[V(51@9)).X
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MMG#^$8WXVU^LQ@\CX&F1S'B*=LX?PC&_&VOUF,'D? TR.8\150R44!0.+^/
MAC&*4PNFW1$Q0*)R@/6<A,4#D$P /, ,41Y 8.;!Y'P-,CF/$53VSA_",;\;
M:_68P>1\#3(YCQ%.V</X1C?C;7ZS&#R/@:9',>(IVSA_",;\;:_68P>1\#3(
MYCQ%.V</X1C?C;7ZS&#R/@:9',>(JHTE%%$ ._CRB)2& #.FP")#E*<A@ 5
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M!VU6,L";A(QXTM@'2<$X!P<$\@>!.X[ARJ.K?2'T/H8Z5;2=);>,!L8)R",
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M9%6&<J1@E3D$88<0<]X[QQ%=NJ\:(+(-EG3=%PZZSL9!5=)-9SU70ZWJ$CF
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M[WDWI3T4FA_;\A^P+5_(L>S3_IGQ7UIUL?O>3>E/12:']OR'[ M7\BQ[-/\
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M4CG34+]Z=,YB& 2F$!TV?_VR#_4W_ U>[L3_ /VMG_K?_P!*2M;N&ZA>9\\
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MXA+!Q8-=T4IM-W9]'79*A:JJD]4VLFY?VAV^1) 3$@]=MCQ+MAUZBINR172
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M/WKAP>#=3&W%L6_H@YTX&=S:@">)&K?OY#E0[1NFLQ8F0>S@[ETJ&QKZS3K
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M";:W3J8P9I(NKPPFDZN6=;9?T3H;L>7HSLR+8A/MDT<KW-]<HQ2WCFN0K=7
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ML3PW-O+&[1WD\MQ%.ZM/#(P,<JA5 L88B=17M:^LU!F5M>D)G4I!WJ I&=)
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M=V=F)8DCOP<LQ8L2"-T<^7K:H<BT;/X]^Q>(D<-'K-TT=(*<Q(NV<H'171.
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MAN@7F2,Z'2-T>96O0Z?(G3Z/>Y=+D"?2Y=_ET.?>Z..U^[S_ /G.G9_;Y?\
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MI=9?1?X??"79BR/M*(VD_6;/6*40RM?)U>JT6.9EAD:<1A)6$;$,0*YATAV
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M]E;5"1LVCJG?8&SZREY-LZ7CI^T5V<G;FTD]?$<-.P9>PI2$.I7BN$Y&2!5
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MG9>DY1:JM](Y#'JPJMJ&DZM60.\#2RXSW_#=P)SG)&)-.69=)R-.G>>XD,K
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M8SV2=2LI)9BQ#8# L26.0HWDY&-Q&^HZZ3(.H#2RNH55559"Q4A54*,%F.X
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M<AX"G:Z']@QOQ9K]#&3S/B:8'(> IVNA_8,;\6:_0QD\SXFF!R'@*J,PBC"
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MFOT,9/,^)IA>0\!3M=#^P8WXLU^AC)YGQ-,#D/ 4[70_L&-^+-?H8R>9\33
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M<X].B.'TCV)82/XY1J5G)GCYJ==/IV$2?,D%F2LPFN]2;/;@ 2W!PH"E]+,
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M'7"4W5"F 8-IU'3J"]VK&K^<8'&NA=6!JQJ[].<9^&=_C5V96IKL(GU5C/\
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MJL6B:FY>+E2S1VZ[5=I/*,9"-(XZI5%T4R:,-%&8TEC+A3*(F5\%@Q&K*LH
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M$.$T+A3\-S9;\IXG&_.*R+P+FZ=:V 8"E(!K!%FZ)0Y%+S8+CT2@(B(%+SY
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M8QAY>D'/D    &0+N?WAQ/\ :O<3\*DPQC^WN'>W> >=0_0GZ&]I2ORGMO\
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M;<IBF*("4Q3 F @8H@ @(#S 0YAC)YGQ-,#D/ 53VEA_!4=\2;_5XR>9\33
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M(8Y"G4$G0*)R@(@)@YP4=1EE8#F5('B14AE/!@?D0?M5Y"(]K"]\?[^IZ_\
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M9)Y6)>21W)8]VT=I[1VM<O>;3O;F_NI"2TUU,\S[_P"U2Y(1!P5$"HH "J
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M)QJ!(TK@9WU?G$-LKBNT]$[&V:SD>%>+TY3FBTNR<W0FVUKFI'$3;HM6#MM
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M97Z"=+MC-MB/:>T-AI!)'M2SN0XN;3:,UO<J\=Q$Y)>WN'NK24J_],)&N0&
MJJ9LVR>'#7/FFO#W98BU:29[(X((/?FC-3U[B4FN)NM4LM*G#TC9%K+M"7FS
MVNG6>V2TM!ND(,T6S8/63)7E)&4BXU!>(X;3:MUT1VG"\&T&M.D4FS=I7LFR
M(]CS7!N(Q<6D)LXX^HGB@CCD4R:RRLP[ #N1:XFO=CVG379<T=SLP7/1<;4V
M591[:FVU%;>R-);7UPM[,XN;:>>6:W*Q!%C98V(<LF*Y-(25VK3'CXK-*KVX
M^&&GTWS)FT6V^:4W#O:P;,L>R]JV^JR<O5.(?5*#^Q69O#UIM MW47*S-9L0
MIP\I)Q\ ^8,9)91!G&T$MYFZ,S7$MAMB>XZ:PPVVT+#9L5I%:64$\<<^R[TK
M%"7F:5EDCCFAR\:-*CLF]IV?)=0_]+(;>WVEL."UZ"W$]QLW:.UIK^>ZO[B&
M62VVO8%KBZ6.&.*.6&62"XPLLD<<D<<JX%U:QK>T>&GS,_<_%]K?6*^M.(,_
M"UIY*D[1@^+?8W$)/6>G[0EZ0.XMJR.H+ Z+!:ML=5K78]U9IL&4DI67+E\D
MW>-6,*Y(^RO);/:W2ZPV'=W:WFRQMF_-Q9R;#M-E1PSV<=P+"R2_A'6WL4TN
M;=B[()E"DJS2 KO;1W^QNAFT=O6EB]CM;_!-GB"\3;]_MN2:WO'MCM"_:PN,
M0V4MO%B[4(DO5L&566-&#^E>J^"WS/37<WP]7/7_ !;;(877?+*3J[N5)Q3V
M"QN^-%G<=>3B4[#VZ(GIZ;9O%GB;@]@:R=+8U:5@)UM'M(B0C9U:&,C\E>[?
MZ3W4>U+>ZV+:-!LUDE"?X/%$-@-!=1&-X)(HHV4 KU12X:9)8V9I$= ^?L+'
MH_T8LY=E75IMJ]6?:2R1"1MNW$W_ $B6>TE,J3Q3SS)(Q4FY5[18)89$7JY$
M[(K5+4G#%PH:%XZ_-%[1>G.U6FHN :F\*F]=;LWV^-S2257?.]<V+95M5=HR
M%\4[M1FIVN1XM8"U*3$>Y5$D.W: U>*-E/;OMK[:VET<Z*PVRV37W26?;.SK
MMDV9L]#,JW<5I %*6P]GZN.5M4L C8#,C-E=5>#L_9&Q=F=)>EL]R]\MAT9M
MMA[1M!+M;:DB6Y>SN;NY9EDO"+GK'A0B*XZU"0(U4!BIZWS(?CB;[GW1OS2?
M$/L_7.SV'&13I_C"AJRC/1T]":K>RDE,UO8?#U:.RW2I6#^O:N@J)94X-=%J
MWB8B+G5E0!T1VLIS?B/T/LY=AVZILF0V6S__ /&-H17=MF/:ML\2/%?B-DTS
M17%U+=0,_:+N\07LZ .O\+NG>TK3I&]S#MY8MJWC)TPV/=;.O0MUL*\BFTML
MY9HI#);W%E;PV5PBY30%G)!82$^[W#5PV<.VEJ>E!Z5%O8Z:TN$M>JJ20M"&
MPF-'L%D9I-I]6@2CI1^O5&4]T%WTG'0[U!F\D9*9D#(]DS4JH[_);2Q?96S-
MF[%)NWM]E6R6=H;]Y)KOV:"25K6*>>8=;.+*.4VMFTNI[>SCAM4;JH8U7]HV
M_MR;I5T@VSTIO(MG1[1V]?/M+: V5:6]A8-M">&**\NH+*U"VUK-M&2(WNT.
MH6-;O:%Q=WLJFXNIG?:_-:\NF*59^P_P O/_  ?9O^BO<O'_ )D?^M?^(5#<
M#\C]J_,/GTM>13%*8I3%*D)?V+K]&G_ST\J?S+_O?:E1\M2F*4Q2F*5S&_NZ
M7Z9?^!OD=Y^0^[4KAR:4Q2F*4Q2N9?[\OZ%O\W2Q2N'%*8I3%*Y4/[=']*G_
M !ER&X'Y'[4J@_WYOSC?O')J%X#Y#[53BIIBE,4KF1]);]";^,F*5PXI6S&E
M['1&-</'6/<.RM6RT;>(JTHMX5.5F:5.QC-NBFLF2"@P0=L[B55#HI33]PK&
MF8E:M3-P,0ZI.:99"X*PQR@HRY;"NI/[CG*_  'COK6,KC#.ZD,#@9*D?(?W
M#F=W 8[ZV)C^)'6MAE;U(,[A8M&R,ONB-V":>AZZ\EG=UID9#,XE.JRXP2W9
M+5PZ<M',RY8O3N8 [N37*X!X95PJ'.;:10@*"<"$II9\*CELZEU<=V!D -@"
MM.M5BQU&,F0-D#)90 -)(^6<'(R>^K6T)9*_<.*J^VBJQ(0==G(ZU2$1&=2B
MV,W9KR40)#J-6YC-VJKHP&>+-4#G1;JKG12.<A"G&TZLEK&KG4RE03DG?AN\
M[SCAGOQ41D-*[ :002!RWC_\UZ7CZEE_7U/FZ>>=714#%*8I6-=C:Y#89*^F
MI9YJO)UZ6":21BVE?D&<A((D K!:4C['#34>]+%G%1RP26:F21>G3>@0735F
MLAI')U>KLAM0QDE@0._!4@C/?OX;N!-9R1Z]/:9=)SN"D$]V0P(.#O'([^(!
M$9UK>1D(^*[9[ LTC9Z].KSM=N*L=46DI%"YC#Q+J*-'Q=<CX-_$/&:[TCM!
M[&*N53.^L*\35:,#M9$@!.(U"LNEDRY!P<@Y+%@0<<#C=PWFG5D@9=BRMJ5B
M%!&[!&% 4@C/$'C\!5NRVC&<G%1,>2ZVAFZ96M]>):3!K5I!2SVI[U8)2<Y%
MRU>?P2R<4"29(5@C%I,HXK=BHDB+F/9N$K"<@DZ%(*A%&6&E!W*0P;?WG.3D
MY.\U5HL@#6P(8N3A3J;N+ J0<;M(Q@8'> 1<3K6\C(1\5VSV!9I&SUZ=7G:[
M<58ZHM)2*%S&'B744:/BZY'P;^(>,UWI':#V,5<JF=]85XFJT8':U$@!.(U"
MLNEDRY!P<@Y+%@0<<#C=PWFK=62!EV+*VI6(4$;L$84!2",\0>/P%713ZDTI
M\:Z9HO7TJ]E)5_/3DS)BV[/F)J3.0SIZX(R;M&2!2I)-V;1JS:H-FC%HU;))
M\DNF:KN7()   "JHSA5' #))YDDDDDDGC5E72,9)))))QDD]YP /@!C< !W5
M=>4JU7#5/P@COSU_FJ^5?\I_C[BI7B/F/O6;\QK>L.77U=4_5F_\)LV3\H_G
M[FL7_,?X^PJTLM5:Z&U1\=+5BQQ<Q#K6&(DH&8CY2 ;D347G(YY'N&[Z'0(J
MX:)'6DVRBK),BCMLF8ZY0.X1*(J%D$@@@X(((/(YX_Q4$ @@C((((YC'#^:\
M$;E%5+:/#W1- ZLXJ;WL]K<[-0:GJOA=F8FC1^S=8MX>WQ*\LQWJ]KR#NZ)5
M[2U<CIIT*,V:'A6LG"00FD)E@SB@'TE+)*TKPJFE79YP6T.2IP8M6%U2$@;L
MD@G<,FO/8*T2Q+,[:F4)"=(= &!(EQEL1C.<[A@'M#%>C_$<B&T>)?A4T$Z_
MK%38O[?Q&[#C1#^BE&NJ$XN,US&O"#TDWD6O?K*VDY%BY*=LN,(T*HFH<4S)
M<L/8AGE_NPL2'D7R7(Y'2,9&_><$5TR]N6&/^W+2L.8CP%'U,#_%;VYS5T4Q
M2NPB?56,_P!09?.4LAN!^1^U2O$?,?>H)_OS?G&_>.3453BE>+%_B9!C=>.+
M<]>:+.[3PU<3NCMZ1R#4O)R_KM5TU4V>RX3K2B"@-9?64M;45T2CT5UDFO2Z
M)DTU4O00]FWC)PLT,D9^!:1]!_A]/\9KA(PUPXXQ31R#=G(6-0X_E"P^>*YT
MDE;78^%+B!D$EBR/$AQT.]B1 NTE$GC75\9JF^4W3L<<BA2&314H%>BK*"/0
M+T'UGD5#!TU3Y![(FB'"&V"'' N9$:0_42/DHIQ,,GZMP7&?<ZMUCW=V4 ..
M9-8XUSZ"_P \KB[]$/N9_KV[^C!W1VOA&N]=C:S3<5GIU_L&3& J5IA(QR=>
M2[<-AEE6AWK@&96BK@Z+%NFE=_:-$'51AEZB/),:/VNUD98$\,;N&_/?6:^S
MZY^MD*MU\F )'7L[L'"L!QSOQG=7K-PU3.CI/6Y6'#_?"[#HU=G).*5F37B>
MV&[;3CGL>=?1SZRV62EYA==)&8:.$FSE\J1HS=-DFY4T 33+Q3"4/F5=+$ X
MTA1C@,  #N\:[83&4Q$VI02,ZBV_B0223W\^^L'^9^?]WF\O_B[XDO\ Z]<9
MI=?GC_\  B_X:I;?D?\ \:;_ -0UOCG-713%*8I3%*8I3%*8I6R&<]=%:XO>
M$/AFDDEF\CI:C/VKG>;OB8=,GL6+I@\WV_ H.]IO6"ZQV;RUJ@0O]==(*ID'
MF9-$@F,(^HNV]K*05O[A6&SEV0K*^EEV:O"R5@ RP#/Y01GO)KS&V+LEP5?9
M]HRG:)VL5:%64[3)R;XJ00;G._K""V=XWBHE^X,^%;9\E.R][T/KF?D;11$]
M8V1RK HLAGJ E9F5S1JDNG&&9(R$0C:HYA/(H.DU3(R+1!=,Y13* 7MMO;9L
MTBCMMI7<20W)O(0)2W571A:W,\9?45D,#-$64C*,1WU2YV%L:\>9[G9EG,\]
MK[%.SP)F6TZY;@6\F -<0F590C9 <!N-6E2?,]^"77%3V#1Z+PQZCK%8VM!]
MS&QHZ*J[9%2X5OKDW P$S)&,>5<0HN4DG(QA7Q&0N4TW HBL0IPVN.D_2"[F
MM;BYVO?3364G76KO.QZB7!'6QK^028)&O3JP2,XW5A;]&.CMI!=VUKL79T$-
M]&8;R..UB47,)XQ3$+J>/._JR=.=^,[ZR/=>%?AWV(]@I*ZZBIU@D:UKBRZ@
MA7[M@=-ZTU;;X8T!9* HZ:K-UWM4E8DZC5:%?J.620J*.6Z2+M0ZYN2WVQM.
MU61+>]GB26ZAOI%5^R;RWDZV&Y ((6>-^T)%PW<25W5V7&R-F73I)<6-M,\=
MI/8H[Q@L+*Y3JY[75Q,$J=EXF)0\<9WUCC4'F?/!3H*T/+IISAJU;0+1(5Z6
MJ;^7@X+HKOJU/%0)-0;Q-TNY;N8R3(V0(]:K(G2<)I@FH42"8H]=]TFZ0;2A
M6WO]K7MU"LJ3+'+*2%FCSU<BX (="258'()R*X[#HQT>V7,UQL[8VS[.=XG@
M>6"VC1VAD*F2)B!O1RJZE.XX&:EZCX!N##0VPWNV-.\-.I=>[%>@]*6UUVJL
MVTC%DDBJ$D$ZV53KFM42?(K+-G2-9;Q*2[151FH0S4YDAK?=)=O[2M5LK_:U
M]=6JZ3U,T[,CE/RF7@9BI *F4N0P##?OJ;'HST?V9=-?;/V/L^SNV##KX+:-
M)$#YUB(A<0JX)#"((&!P01NJ][KPH\.>Q5MNKW?4-0LBV_&5'C=S*2+-<QMC
MQ^M>AW",K1U3E()!K603($:@8"IE*4"JE5+S#,+?;6U;46(M[Z>(;-:X>P"L
M/^J-=Y]I:'(.AILG61O/=BNF?8VRKHWQN+"VF_Q-+>/:&N,'VQ+7_LZ7'ZBP
MC<BMD $C&#7<2O#=H29LE N#[45"&T:L<2KG7LZSKK",DJFI.1 P$P6*<1B3
M,Z;>3A3#&/6BG6M7#,>I41,4 S)-J[2CAN8%OKGJ;P(MU&TKNDXC?K(]8<MD
MI)VU.XAMX-:/LO9TDUM<M96QGLC(UI,(462W,L9BDZIE *AXR48 X925(Q5^
M4[7U&UZVDV=%J5?J+6:E'$Y+H5^+:1:4I,NP*#J5?E:)) [D7($("[Q?IN%2
MD(4ZA@(4 YY[FXN2K7$TLS(@C0RNSE$7\J*6)PH[E&X=PKKCBBA#"*-(PS%V
M"*%#.W%C@#+' R3OW5>&85I3%*Z^78-I6)E(MZ0RC.2CGK!VF4YDS';/&RK=
M<A5""!R&,DH<H'((&*(](H@( .2"5((X@@CY@Y%#O!'.O.?T(NC?:Y)?*.<^
MVYZ'M<_O#Z5]*X^JC]WS;UIZ$71OM<DOE'.?;<>US^\/I7TIU4?N^;>M/0BZ
M-]KDE\HYS[;CVN?WA]*^E.JC]WS;UIZ$71OM<DOE'.?;<>US^\/I7TIU4?N^
M;>M3&W"'HPS>0$:W)<R-TC%_VDG/3%XV)S'^N]_[DQ@_^?/U@R#=SY7M#B?[
M5Y'X?"G4Q[^SP',\P.=0_0BZ-]KDE\HYS[;D^US^\/I7TIU4?N^;>M/0BZ-]
MKDE\HYS[;CVN?WA]*^E.JC]WS;UIZ$71OM<DOE'.?;<>US^\/I7TIU4?N^;>
MM/0BZ-]KDE\HYS[;CVN?WA]*^E.JC]WS;UJ8?A"T6#!LIW-R72,\?$$>Z2<Y
M=$B,>8O>[-]85#<Q]?F'XLCVN?)[0X#^U>9^%.JC]WS;UJ'Z$71OM<DOE'.?
M;<GVN?WA]*^E.JC]WS;UIZ$71OM<DOE'.?;<>US^\/I7TIU4?N^;>M/0BZ-]
MKDE\HYS[;CVN?WA]*^E.JC]WS;UIZ$71OM<DOE'.?;<>US^\/I7TIU4?N^;>
MM3'W"%HLBQ"EK<D "SCS_A).#]THP;*&'OO?7,81Y>D'/D'>R!=S^\.)_M7N
M)^%288Q_;W#O;O /.H?H1=&^UR2^4<Y]MR?:Y_>'TKZ5'51^[YMZT]"+HWVN
M27RCG/MN/:Y_>'TKZ4ZJ/W?-O6GH1=&^UR2^4<Y]MQ[7/[P^E?2G51^[YMZU
M+8<(6BU'S),U;DA*=VV(8.Z2<#F4RQ"B','O,.8#Z8=_(:[GP>T.!_M7E\JD
M0QD@:>)'>WK44W"+HWI&_P!G)+TQ_P#,<Y^/]=R?:Y_>'TKZ5'4QC^WS;UKY
MZ$71OM<DOE'.?;<>US^\/I7TIU4?N^;>M/0BZ-]KDE\HYS[;CVN?WA]*^E.J
MC]WS;UIZ$71OM<DOE'.?;<>US^\/I7TIU4?N^;>M3&O"%HLQ'HFK<D(ILQ.7
M_:2<#D;LAN3G_?>_]R<W>'O>OZV/:Y_>'TKZ4ZJ/W?-O6H?H1=&^UR2^4<Y]
MMQ[7/[P^E?2G51^[YMZT]"+HWVN27RCG/MN/:Y_>'TKZ4ZJ/W?-O6GH1=&^U
MR2^4<Y]MQ[7/[P^E?2G51^[YMZU>E#T+K36TX:Q5*(>,94[%Q'&67EY)\06C
ME1!18G4NW*J0&,=ND(' O3+T1 ! ##SI)/+(NER",YX ;Q\A4JBJ<J,'&.).
M[^36<Q]2R_KZGS=/,:O4#%*8I3%*8I3%*8I3%*8I5PU3\(([\]?YJOE7_*?X
M^XJ5XCYC[UF_,:WK#EU]75/U9O\ PFS9/RC^?N:Q?\Q_C["K2RU5IBE=8WA8
M9I(/)=I$QC65D"D(_DV[!JC(/B)\N@1X]32*Y<E)T2] JRIP+T0Y '(,G)(
M)) X#.X?(5& -X R>)QQJ<+= 5RNA01%R5(R!7 ID%<J!SE4,B5;H]8"1CD*
M<R8&Z!CE*80$0 0BIKEQ2F*5V$3ZJQG^H,OG*60W _(_:I7B/F/O4$_WYOSC
M?O')J*IQ2H_8C0.R1!JW 7O]\_H4_P"M_P!&"/\ 6?N?Z?\ H@!+^EZ?]& $
M^][V,GGPX?"F!RX\?C7SL-IT6Q.Q6W09"069.H2Z+04TQ23%L7H\D!(D(ID%
M(""5,1(7D41#&3SX\:5!5K\"X5477A(A994YE%5E8UDHJJH<1$QU%#HF.<YA
M$1,8PB81$1$1')R>9\348'(>%36C%C'IF18,VK)(YQ4,DT;HMDS*"4I14,1$
MA"F.)2$*)Q 3"4I0$>10 (R3Q.:G ' 8KD1;MVQ3E;H(H%45464*BD1(IUE3
M=)58X$*4#*J&^Z44, G.;OF$1[^*5S8I3%*8I3%*8I3%*8I6R&<]=%,4IBE,
M4IBE,4IBE,4IBE,4IBE,4KX( (" AS 0$!#\8#WA#%*Z?N>A/!C3Q8>7+:VY
M^0]*KH7EYGUIW/0G@QIXL/+C6W/R'I30O+S/K3N>A/!C3Q8>7&MN?D/2FA>7
MF?6G<]">#&GBP\N-;<_(>E-"\O,^M5%@88I3E+'-0*H4"* "8<CE Y5  >_W
MP Y"F#_,H8U-NW\/E32N_=Q^=4]ST)X,:>+#RXUMS\AZ4T+R\SZT[GH3P8T\
M6'EQK;GY#TIH7EYGUIW/0G@QIXL/+C6W/R'I30O+S/K3N>A/!C3Q8>7&MN?D
M/2FA>7F?6JA@882%3&.:B0ACG*3JPZ)3J 0IS '/TS FF CZX$+^+&IN?D/3
MXTTKR^]4]ST)X,:>+#RXUMS\AZ4T+R\SZT[GH3P8T\6'EQK;GY#TIH7EYGUI
MW/0G@QIXL/+C6W/R'I30O+S/K3N>A/!C3Q8>7&MN?D/2FA>7F?6JCP,,H(&/
M'-3"!2$ 13 1 B9"IIE]/TB$(4A0]8I0#&IN?D._^*:5Y>9[OYJGN>A/!C3Q
M8>7&MN?D/2FA>7F?6G<]">#&GBP\N-;<_(>E-"\O,^M.YZ$\&-/%AY<:VY^0
M]*:%Y>9]:J) PR9R*$C6I3IF*<A@3 !*<H@8I@'GWA 0 0_S#&ICW^0]*:5'
M=YGUJGN>A/!C3Q8>7&IN?VII7E]Z=ST)X,:>+#RXUMS\AZ4T+R\SZT[GH3P8
MT\6'EQK;GY#TIH7EYGUIW/0G@QIXL/+C6W/R'I30O+S/K518&&(!P+'-2@H7
MH' $P#I$Z13=$>_WPZ12CR_& 8U-S^U-*\OO5/<]">#&GBP\N-;<_(>E-"\O
M,^M.YZ$\&-/%AY<:VY^0]*:%Y>9]:=ST)X,:>+#RXUMS\AZ4T+R\SZT[GH3P
M8T\6'EQK;GY#TIH7EYGUJOM##=#J^US7JP.)^AU?W/3$ *)N7/TQ* !S_$&-
M3<_M32O+[U1W/0G@QIXL/+C6W/R'I30O+S/K3N>A/!C3Q8>7&MN?D/2FA>7F
M?6G<]">#&GBP\N-;<_(>E-"\O,^M.YZ$\&-/%AY<:VY^0]*:%Y>9]:=ST)X,
M:>+#RXUMS\AZ4T+R\SZT[GH3P8T\6'EQK;GY#TIH7EYGUIW/0G@QIXL/+C6W
M/R'I30O+S/K3N>A/!C3Q8>7&MN?D/2FA>7F?6N9"%BFJQ%V[!LBLF(B10B8
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M(>__ +\J_P"4_P ?<5*\1\Q6:\QK>L/W-50DXH!%#E#L9N/(IS%#GT1[_(!
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M6KQ+J^H,KCK.\2D]#6+:C*.L#AI/,4%'\4D%+&6;,!D6A';Q]$%0.S.M=[&
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M_L .&]I9DE9I=:32<KO4+&K7$6#1V\(=5STMR%'6.%0LB(&  *"1FPQ"XTG
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MG^/N*E>(^8^]9OS&MZPY=?5U3]6;_P )LV3\H_G[FL7_ #'^/L*M++56O@B
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M8 .:KF-6C-M,69G4&(.9%*9[65))32N2&R, <.6Z7'G_ -V.J?\ XI^&?_\
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MQ2F*4Q2F*4Q2KAJGX01WYZ_S5?*O^4_Q]Q4KQ'S'WK-^8UO6'+KZNJ?JS?\
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'+R\SZU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g189651g69w77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g69w77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5A[:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/G)I9&5R,3$W/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @
M(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*
M(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I
M;&4@3F%M93H@(" @(" @(" @(" @("!R:61E<C$Q-RYA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!R<C$Q-C Q-"8C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,3DM075G+3(P,C$@,3DZ,C@Z-#8F(WA!.T535"!4:6UE.B @
M(" @(" @(" @(" @,3DM075G+3(P,C$@,C(Z,C@Z-#8F(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF
M(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@
M4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R
M('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L
M350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($--64LF(WA!.R @(" @
M(" @("!";&%C:R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @
M(" @(" @("!R:61E<C$Q-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C$Q-C Q-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3DM075G
M+3(P,C$@,3DZ,S,Z-3$F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,3DM
M075G+3(P,C$@,C(Z,S,Z-3$F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE
M('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M
M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L350F(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[(" @(" @(" @($--64LF(WA!.R @(" @(" @("!";&%C:R8C>$$[
M)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D
M871A1&%T93XR,#(Q+3 X+3$Y5#$Y.C,T+3 W.C P/"]X;7 Z365T861A=&%$
M871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP."TQ.50Q.3HS
M-"TP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E
M1&%T93XR,#(Q+3 X+3$Y5#$Y.C,S.C4Y+3 W.C P/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O
M<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX
M;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED
M=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ,C0\+WAM
M<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M
M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S
M54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F
M(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"
M9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$
M07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW
M14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9B\X04%%46=!9D%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%
M0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!
M04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$
M0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F
M(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:
M2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:
M6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%
M:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M
M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%
M4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D12
M1&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S
M.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM
M9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F
M(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!
M07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867$W1EA9<3<F(WA!.T9867$W
M1EA9<39U2W)426]X5F(V>2M/2W1I5E0S>%9C1T)X5G9&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$F(WA!.S=&5G).43!!<3-H+UA)
M:W!!831Y2'$Y4%I12V9J6$)2-S R1G!T>%=O9#$K5$4O<G)G3TQZ4'I4>"LU
M,T9L-G-A9GIG:S K65!,0E(F(WA!.T,S82]G>#933B]W=CE-;G=N=CA!=5DS
M-4YC1R\S-#,O04%V.4U(0V4X+UHK<$XK5&9"=C4R+S18*VU(:%!E:2]*,T)V
M-3(O-%@K;5 F(WA!.T-E.6(X;75$9C<X8B]H9C993T4Y-2MZ.5-B.&UM<6\O
M=D<O-%@K;4AH4&8Y>4PX:TLX,&I.=VI,33-T5"MM4D\S52]9:V4U<U=.=RLF
M(WA!.SAK>%@O2E=H+T=M1&AK971*<V1Y-&%B1EAE4U$O36HK07=I0B]N2#=0
M,4DT:#-F930V94(Y:5)H.#DO-EI+:C,O:C=%5T9.:&118G,F(WA!.T]A1'%Y
M-R]H:GA6>E=U-451,TMU0E1*259W831Q-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$P-V-62C9N;T(W;EDF(WA!.UE*1V=K0DM.5#%I.# K
M-$5C96Y3,V-01D=E-&I*<GIC<T])54MX2F]N-&=B5GEI95%W3E9F;35M1%12
M>5)S>D54,V9,.68S<49N-6PF(WA!.S%'5SEH=')J4TI91$M24BM824%&0S%D
M,5%B8D$W-4=';VM44FE7>DIO<V-9;5%Y03$K=C-P6F4K8DI9=%5L:DUP:F%*
M,U)9;31H1'<F(WA!.TI(13<Y5%0K;554,4I%:3573',X2$=$5C)'6EIS6%-,
M0CA,.&8R5S-8-3EX:T)S85IC=W9Y8D8R2W5X5G!M;TU646)&-VE49VAO;RLF
M(WA!.S(R4DHV0DE#3&II4TYE2T-G+UAH07!35C)&1'-69&ER<U91;'IA;%0V
M,$]X1S=O3VA(:5!F23AV8VYM=G1P=S8Y8VMH15EQ-T9867$F(WA!.S=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1E9J+V)J2'54*T)Y17596D1K54YC=5=6
M:DA)1U)765-306IL0W=554E!1S1"*S!$,E F(WA!.VAT;&I"<#5"4&).1DEW
M.65);S S;S%C<5(X87-O*S%V5&)9+U1I<D1.9G1,2V573%5!:6DV*TIR:&]'
M22M-55E%96]",5)G=TY.-EHF(WA!.V=A;D)(:4(W,V-A1%9Z-$1%;7=/:DLO
M3&QZ3$IP.4II84I+,%5"8G%Y<4LO5%1C9E)L*VY*360S0S%K44HW9%5Y;#)#
M;G5'1E!P3E F(WA!.S0U6E!P-S-(:79Y8D8R2W5X5D188W9&5%1R,G=%,$Q5
M0E9T-&93:4,O=$AD:C=N0D5*2T=F5G)D2FMI2T]'9#)J571X5&1:16I*060F
M(WA!.VQ,0W-G,U5(-S9!>$]56%1C3E!):2],,SE#96YU-G%-*W8R:TMS>GA4
M04E11%=0:#%P<T]:5W)F1G-V,FHR0GE*>F=D0WIJ<$I3-44F(WA!.V90.$%6
M.2],=DLW5W1287IT07E-16%1.%)+96EG:G%+9W)7=$M!-&-S*T5),#)(:FQV
M,%,W4SEB;6MU5E9P9EAI:V(P>E-J8U=*+WDF(WA!.U(T:U9R,$=6=WEM,TIZ
M-EE#3F=55U)::W5T9&EQ06Q8-G9D5D=Y4V)J-3DX:DA9,&LY-DY1,4=3475X
M5C)+=7A6,DMU>%8R2W%%,2\F(WA!.UE1>G!B>EA-56,X;%!4:&0Q5C)R54-I
M:S%05$97;TY3,#8T<#E8=6]:=51C5CE/4E=Q,4,Q0E%N9FE#8U9C,F]70VMH
M<FU)1F%H9U@F(WA!.UAA:D)$6&9S-4,O4&)&55)I<4,Q>6$Y9S!454IR2&HY
M96ET<&YT95A%3#9Q>&MP6&M1=$]63W!P:$-L:$9Z9"]M>$1Q8T9I>E=I45,F
M(WA!.TUI3G%*.4E217-!9FA$56-S5S5,5&@T8F1Y9&MB;WIY:G%F-6A4-FQ"
M0G)C550R-FE4-C=,1C981D=-56)):$M0>35Q-5I72$0V5S8F(WA!.S1K0E)B
M3EI2.6MN;T<S*VM%9GAY<5A1<W=H-5DW;$%/2CE22V=F-5-R<TMB.'59,BM+
M=2]7;EE:67=1<#E'3D9N9U%084=V<GAG37<F(WA!.TED*TQ"54)P6&QV5&I5
M54EP5G-6875R4T543&-235IO4WEZ4&%Q95E#,%I794]08T=O97!#:F9Q2VY9
M=E!9<$)O,D9.-5I93DYE,G,F(WA!.S1Z138Q1G1)0TA%<'$P:F-30CEQ4TUC
M=6Q+;DE40C1D;65+565)8UA*6#!I5R]B5#!/;V]9<%%Z1F<U0DE23G=34C1(
M8B]/=54T>DDF(WA!.V=#6$\R+U5I06UE1&Q33G9,9U<Y<DQ.4W!24U98>&)O
M;S-P,4\R6D%C5F1"1WEQ5V1U8VHW;'%5,C=+4%E9<7%(<&EQ1&8T-WE.5# F
M(WA!.T(U9F1V:UID0C5P0TME4E5&5%AX,D)**S1B-4I#9SEX26IE<4]-;'%A
M07-R9D=$6&EE24%O,B]A=&9#=7=W;U)%:3AK6F$X86=J:TLF(WA!.V)E*SE2
M9U-K97-7375T85-9;VEO=4QE56Q15S)*0TUQ:U!4<55K1&1062LQ3V]X1U5A
M1&PV2%5$1D]Z>4\S-E=)-E)&<4=K83!6;E8F(WA!.R]75FMC9W5#1FE&95A)
M:C%&3WI%52]J,'=C8TI1:S=V55I96G-D06EQ-W5V,E!1-T<K=#<R,U=E03%5
M-TUP<'E6=79&<58S,R]I3G,F(WA!.S)56D%J6C4S2FI-1%)21U-A,$IQ4R\V
M3T@W;W=0,$4P>4UU:%-&5S)A<40U6DI#=&ER<U9D:7%H9#-S1G!(-FLW0DEU
M:&M::U)15#(F(WA!.W$W3&EQ2&)83D]1;%AM:E9G5U5G>7=G9V]+<U!T+W-J
M<FAP5F%'+VEN<5E"-G1!0V5$>'1S=W%P,F9U3VU"56\X=RM69$XQ-E%36'0F
M(WA!.W9)2D9T<&)66%51.&=*6&IK1&=K:SAK84@T9FUF2$-$4TM33T@X<3E%
M9S%!6'1V2F97.&=K37%I1U-+36@R8W-31U=J1#1'2T%$;T,F(WA!.U-.>EA$
M>$Q31'9F>7 X='909'I81C-D;S U<DYY93%(15-/46Y58E9Q>6IX3R]5665*
M1E!24%=K+W=".% Y-F8X,5I":W<S>DPK6$8F(WA!.VAR*V\S1CEC,TXO06)L
M63%E1T-32E5P2$<X9E$Q-F@X:TI59VA,-79Y:C!5>'=I-79T4F%+1U)75G!*
M64]69E9:=T))9FE7<E!463DF(WA!.V9C-&5*1DDO>3$U1'-T23%P8C)Z=3=I
M94="-6UM:&0T,DIU6E9#.'!#:D-P5D=B<4LO1EA!4VM";35!24E/-$]X>4I&
M<%%5:V,X8FPF(WA!.T5-:D=12&I,>4)+;F,W2S4T*S%+6D5'=&EK:G51,7IA
M6'-L,T1D,F\T=G=B-#)"46HT4E):5C5F2'E+,$Y&,B](2G-5370V3$]73EHF
M(WA!.S1Z8E1-63%66F9I1$9L1'9#:DM0:DLQ8U(P,C5F1%)F9W%55W9A0S-K
M=EAT2D(V<V)"<G$Q8FLU-&]Y;W%O<CEQ=4=)0VY9061T<T(F(WA!.VQ14T)A
M3W9*0DA',$DT<$I,1WEX13!#<5-Y>'AR5#-A45I'239L2E!25'5B-7IC4F]V
M2TE):GE3:'=Q9T=V1D-X8C1E231U+W=T6#0F(WA!.V4K4W!#-U1R=3=U5T5H
M5"]!155G,&M/>%DW9$9)0D%R<TMI=3(K*TI52F<S5$%L0DPO=F5N>5 V<VI,
M;5!F.$%O2U(Q4E5X65)K<6XF(WA!.W%.+TI50V]*,S8U2D-#945K5G-W<U5Y
M:%1,6G5!<4UR0VA$.%%D>49O1S,K>E%B8V=3:#%R2D-J:3)24V)36F8Y2$I)
M9$%E3E=I-C$F(WA!.S9B9V)I;F5L045Q9VUU-V$Q=DEW:W-*84UC6F=V1TMS
M6$YV55IH>% Y,SEV6FA8-&TW655*4&9A3F-V9C-0,5=*:VIA5C1P6$Q)45<F
M(WA!.VU5>4Q5,4)!1%,W1#-!>D9L:4E/>G1-97!I66EZ4D<S>50S46QK=$Y+
M4U=D+U8K=%-Q-#0P*T%3;%524U(Q<'18,SES<WA124<W:6$F(WA!.VY)2E,R
M-4)/37-A14YQ4"LX8VXK>"\T:TUJ4&PX=G941G4P*W=0;&MK26I&6%EQ-T95
M<CAW-D19-C-A4E=D.&IY5SAC>51S:4U&-4<F(WA!.T]T1DIQ1%$Q-UE15EES
M=C52*UAF5VYL;&4W;4UQ=6M985)+4G$O1W9(:E1F:7!&5#%R6#=7*TAI4E-C
M*U9V2G1J-6-N=7!,3G U0F0F(WA!.TI&2#9C;G!!2VM03&@Y:TM74'AM<DY5
M;D%486=-:#E2=CDY="]W04PO6$%L,W%.+W9T=BM&+W)I<D=D9CAJ869R370T
M.'-L>$(Y94XF(WA!.W4Q=TE414MV83%#34-15%AI,4UK0VEM5&,R+S,R,R]#
M+W="8VEL,W%.+W9T=BM&+W)I<4(Q;E,W9E9R25=L>D<T45-X5$MY.$]184<F
M(WA!.U):1G!5;BM7;45+:S)I*U)R6%,Y6F)65G5B;6$T:VMM;&M75#!1:E!C
M-WE-46=89FQU<$A116IP:$I25$MS:6QP=490:7!X3D)V,#,F(WA!.T\R06DQ
M=&%5640T1U!S1#A1+TAF.&-J=VYO5U9O3G)X84%8:V]T4T=*2'A"45%P;TMU
M1UE#<% R5#-R,7<X374Y1FA#5&%5.7%H=4PF(WA!.V4R:64T:DM33DQ!;VEL
M;4LP-4DT2$5C4U)8-U(O=T)5-4E!35,S8S-D=F,S;'9,1$Q'.$U38W!73S9C
M2'$T9FM.:'=A04YV+T%"1U,F(WA!.U9:1D)&9$Q%='HO8S-"4FE$*SEE9&Q#
M;G9Y06E5279*9T)Z3RMW<'E52FA/-U)G5VQO=DIL5W)Q1V]Y4G153%%K-U99
M8F9)*T9-0U8F(WA!.S Q,3E71455:$1Z5$AI<D5H1DQ$9G539FPQ3TMO3F(U
M2'9G5E5Q<69A3"]#9#EV<T@T=6TO=T(S,%%M2T8Y>DM*-DIL4$-*04-+0U(F
M(WA!.U-#:FM%,&]A.6EP,RME4U%G-VAM:&QJ85EM<3%28G!19&QB:5 S9T%#
M8G112'(T,$%R46]76$YM2GI/635$1F1+05=!0VUH1$)O,F\F(WA!.U9)6E%Y
M:V=L4V$Q;U)V:F%O;&91=G)9<31"6D=+=%9D,&Q1+V%!871#1#A3;C5(1E5'
M8DE*2$IP8G-&:&YI071*:E5S2E9R='8S:E8F(WA!.U5+8CAI1DHW130R<6UB
M;#5B0C1P1CE+6FYH6G5*<5DS=4QG9TQT*S%(=%=N9D-Q6"M7,C%586TO<E=5
M:TU42U9L;&1Y95150D0Q4#DF(WA!.S4P-#$Y.6HQ>D-X0U%N5F9J.4QT9%1,
M2$Q%0TIB.4)8,F589C-F66XR<'173DEU-W-$.4%Z2E!-0C%G-4LY=71%2'EY
M4T981EA9<3<F(WA!.T95;C@P-D5U=#)%9&DY>$QB4FE:2EI8:$(U<VE6<6=)
M<4)8,W)H0E5S65!K1%984S%:=%IA1S9T5FEI.65+1U5M4T]'55-$;GIC+T4F
M(WA!.U%!1%-N:#!R:'1&33@Y5F9"=CA!9U<O<&M5=3E69D)V*T)B*VU+=3E6
M9D)V*T)B*VU+<U=V+TQ';S-7;V%R375O1T,S,4@V=G=21G4F(WA!.V5A1S-)
M3F8W=TPX4C).0E%J=#1Y=$1+9E98=V(O9U<O<&M5=3E69D)V*T)B*VU+;T18
M3$4V;%EI,FIN:W1N13!-;VQ14T$O=7!68V<F(WA!.VAE3E%W5VQ-259*=$8X
M=6$S6C8Y3G%.>G%Z5%<Y>$Q*3$I92DA-:UA+4D9516,U2'!W2SE/;2]A9W=K
M;UI8:U5O4RMM:E)"-C1!6&LF(WA!.T],1FIX<61L-3!O9#9N<U%+5C=946A8
M9W59<&<S02]%:&\V2'%P.$1G4S(T;$)5>#AE24I,;U)U469!,3)0,&8Q>%9"
M>E!"=VAA1FHF(WA!.T-866Q8:G%%-78R66=&2W5Z8D9L4'1V:%%K8UIL17-T
M<SA56#%U1E)$8W=P.$U$<7A:-'1V:68P;&I.5W)19D1W1F$P>51&14QQ264F
M(WA!.TEI>45K<4MH<$A%2%HR8F-G5%-,>4U:4'A-17%$+TUY,7!G<$YU='(S
M54I:3'-10U,S;S5A<E)-=TQ61F%C67EQ2')59D=4.#A64FLF(WA!.T-A6F-5
M1GEQ1V-$,4A6<$A::7=*4%)W<D5,6&)B-&$P1TM58DQA;W-80DLP+W=!;VQJ
M.3=%;DEP6%=S>E!&>$Y05E199SDO035'3S(F(WA!.WE4,W%A5#-S:B]&8G V
M2$%L;#4Q9&E2<T%R2W9Y4$MM5%EO3%5"2&%'0U=.,G1H2%$P84UU:V%5;U5"
M56A2>F)G<%1L5&%O04DU65$F(WA!.W!83&-).'-Z46QG46=856]566PT;4LX
M;&1",4Q#<$=Y-V=B8F]&>%96:C14<DQ9=$Y744M*65IG5C4O87%S9TA%0G%(
M:7A.3TI9:V0F(WA!.W%91E%+<F143$5K0TY(3D1D>7!C;TXQ5C59>DLP=$=P
M>4-34T%P5VQ2.#A+131S:E-Y:61G15AG1T-#9U9&<%5+2V9Y:F)):W-G;'(F
M(WA!.UAY5%A:67-O5V]324U10V$Q<#DY1&U.-'!U,GIH5$%82E5!14%%-T0Y
M95!J1F5"<$PY6#)2:UDP1&9#83=(;V1J,W<K364U94%+:3,F(WA!.T1&9TM$
M8S!X:FU*2VU#=FU1,7!0-7 P2F1B<TDW1C=I5S)J17E3>79#1'I:17)605)5
M0W9V6$-#<%EH+WEQ*RMK=4QI5S0Q-C5C3THF(WA!.U)!<7AU=$1,>%5U.5-E
M5$91,65M.4\S=S5,:5)39F554$Q.-6]6>&1T8UAZ,VM5<V--54Y24'EP0T=(
M2G<W3W9)9VHW24%W13)O6DXF(WA!.S9Q*T1F.$,S.4UI;#-Q<C1.+W=,9C!X
M5FAE<RM3=%=V-W96<%ED6FMH:#%+4S-L:FI-56IE:6)C56]+36])4%=L4$-U
M4T)25$Y05E@F(WA!.W=B+V=7+W!K574Y5F9"=BM"8BMM2W!6-6PP>38Q87=I
M=')3*VPP.3!U25HS;%-.;4Q,13-,,'HY;EEK1'8R.$U)455R,$AY>G)D:'(F
M(WA!.U5T+V,V=3EX8GIZ5'IY,F%X>DQ'5VXS6#=4=%0P=G-Q3VY(,T=%;%=7
M6D9+2'5P-TY92FA/5F5.4E-:1%%I:$9A341T=5!(0W%5,G,F(WA!.W-1=4IB
M:7<Q1T=E4C9H-V%:=4A).&=A<W=Q=TMR54$X1'0W05E72TMU.59G24LX2FHV
M5$XV.&-C5%1$-$LO0U-I4TIV<V%C;$E(:&<F(WA!.W!.<V5/=DE*:GAI835D
M45EZ13!B<3%X1E%Q<4]*1DQ%,'%4.4@R=#93<&IA1G1T4SAX6&UP6$17<SAT
M<F%),65%:TU5.7=':6I33FTF(WA!.TU:0TYZ6611=G941%%26EI43&-8>7E-
M9E-G,4)91%%E:65%.&-H5VAQ<$QC9&ED=V$W.4UG>EA2='!Y96TV>7E+.'9X
M0FML;&QJ3$4F(WA!.U5P>5!+36YU0C%/2V\K0U)307%Q,4]03&UY.$MK:S%Q
M2TQV,T\R0DMQ4E59<6<U;VY2>$Q(<W<O2$%286=R655T6FDV=5A6-4-3,%@F
M(WA!.TYL6&5L84)30G8Q>$5U:%13,D11=$]J4VI1>'5W3E5K16%)>6IT>%I!
M<E9(:E=U4W1J5%9X;VM$<7!T<%I,5U=-56ED1'I!,C9&6#4F(WA!.T1J5VI-
M0E1K44LQ>'1A46]'<5=D=W%L67)L46%W>'A-23571&8S<7%K=7=4.6]$,4-A
M:G)X3D9+1B\Q*V%(53!K=4Q35S)T-VA3<6PF(WA!.W933DI65FU9=5DS97!:
M23!68T))05-/835M6C=:8F5-1F)E2D%P2C=H4E1V,GEU5S1.<WAS;&PQ;U9P
M8UA8,7A:=49W<4EI<65$4FLF(WA!.TE86596;&)Q6#9J9G=Z2$5I3FU:0VDK
M:C-U<%<V1%8W=%5L5#%%2#%9.%%6:T-%3G8P6EA48D1X5GE#2W9M=3!8>7A9
M851D0V5#-FLF(WA!.VLO9&U-<DEY;BM7;E%$64)E;4UP;5$U2D5112]J:VI-
M:6=-2S%(8V5/4FE.=VLX:V1M63!P4#5P,$ID8G-)-T8W:5<R:D5Y4WEV0T0F
M(WA!.WI:17)605)50W9V6$-#<%EH+WEQ*RMK=4QI5S0Q-C5C3TI207%X=71$
M3'A5=3E3951&43%E;3E/,W<U3&E25$E02TAL<3DP1C=R-GHF(WA!.W%C,F]X
M5$I$2$%K:5 K-U=$;4)1<U<K,$="24<Q83 R<&=*=%%Y5#%6.$<O-$9V-EI&
M3&I):$)"1%5/,GES4#%$1E=$5"M1=%5B5&(F(WA!.VEX:#%U9&9R06=(<DUS
M-T]H9UIZ5E0V;FA)1"]!2W=">59O<&Y0<7(T3B]W3&8P>4M897%V9S,O04%,
M9C!X5DHO3D]K6$]S-F9$8E<F(WA!.W0W3%E34EA%535L4DA02EEZ57%A8V9N
M.'=-25%L,FAE5V1A<TYC;3%#-#%D-VDR=4IP<#5,15)Y<DAY;55!535/,4%H
M2'=G,3)0<TTF(WA!.TI+<V]N;3E*83!Q5'-U-$$U16=!95 S1$EP4S9B-C!J
M;55X=S(Q;W!$6$UH3$=5;G%3<DQX,C-P52]Q=V]5.4]%5C=,23=3,T4P8V(F
M(WA!.T]H5V1W1F1Q04U05&HT;WE+1W!V6&-M=31W;%%J8GA)9E131TU&6%AI
M:4I#>DEY27@T.'%)1#A)<#-&34%604\K<&5J3$I#+V]O2#0F(WA!.W1W:E8U
M6%E,4FUB,'A,=TI99GE..'-+14Y:86E,0SAV66)M3U=E9#-7-%)H>$IR26Y(
M:#A40VI"67DK+T@T82]#<3=9,'1P-4Y*1UDF(WA!.RM5.$UI9T-Q;%9,<T-1
M4650<&-M0F]E;W=-;&Y+,&M#:T]&95@T5U-18U1*54%%4$=W56LP<#(O1&)&
M0TQ!049"*T\O-CA#6%EQ,%$F(WA!.T1I<4AM=$9F-2M/2D-Q248W1G-J.&PX
M1S,O='E01#-&3G)5;G9K9'EA4'E/>6YO=GEP:E5U.&9,.7$W3$I28WHQ-4EI
M,3)99T=R0V@F(WA!.T9'<6%-3BMH1DUA4&5U>2M/>61I1$LW3U(O36$O<G=I
M24,R:2]25EDR<#1(.5=#9DEQ3V)%3EA:-4PK5EI254E115$W9T-G3S-Z-C4F
M(WA!.W%-;35D-7!G0D%5;5!L*U-5=WEO86U*0T%N9T-A,4$O1$Q-2C)C6%=!
M5T0Q4C$X,39T<$LQ:6MC;#)&+V-P2WA60V9C9T4U9D=R,V,F(WA!.TUO3%-*
M=DU$-GIC<&9W<6QG231'=&Y8:5 S:%5E<75Z3U0X9&5V4VYF3%%)-U9Z=&AV
M=7E036QR4W9Z2TY89E-:;V1)94]/+VQO:V,F(WA!.VMS;G X07AO6$)#=E5R
M-%E1<D-M,%@X,$9H:T5M<WA816YP0DEJ1$])5#9R4T8O5E!+3C9H1E!$:C-(
M9DIB23-E:7AY;TDQ1'EQ6$$F(WA!.TA),4<U-RM'45,S-C!0.$%V>&9V1TMQ
M9#%*>71P;&=L5EHR4FA%>%E#:FMF0V$P96TO.$%K;C59<3@O9S!F.$%-.6)'
M-VEK,6%"<FDF(WA!.V(V<6)E5#$R*T0P:%-25#A!,F(Y=6TU<#$S>65Y3C-O
M;G)1+WIR.31Y0UAE=$0O=GAF=D=+;TQ7>F-Y-E)D>&%F2T9V6&E:8F1H27,F
M(WA!.UI$:V)F1U9K-"]0:FA#<V4X<C)V;F4S=C!'<EAS8S%I4WAL5G!5;&Q:
M:D5I;U8T>%(P6&UR17(W:G(X5E-A44=7>G9+:U)-4VAN-V,F(WA!.VIX56)D
M5U!H.'-I;$)R8B]!1G=.25-Y4FQY04=R>BM(:W9*47AB,'I5-U5!4#152T5C
M:V-C86A9,4-+04%&555!049",#ES0U5,<48F(WA!.S5:>$)B968T;FUO<V-9
M04I*2BM(-UAW9%(K,6A!455$3DI0335.<7-R=7$W*V]X061W;DE+.$DT0F8R
M9G1.2%@S2%5Q<W5B4T\R=30F(WA!.U)-=SE">5EH1E5J:6MR>')'23!864=+
M54I2=T8T9SDR*TQ&0TI3-S%'2T0Q0V]U;%=4,&Y3;D=11G!#06512'!T>$1+
M2&]!0E)T>E,F(WA!.VU"3%5M<E%Y4F@P=DE)4T=Q.&)X<WA64E94-FEL;S)7
M:DMF:4E&36%7,3A7<FED66YT=45Y<V5-;$-Z1E-P26)A2EI14'!B1VQT1THF
M(WA!.V-X1V-W1G=*9'EQ16=-45!"4V57,VI406Q7>%8R2W1&4FER6'!R:7)9
M4F-68F]-5E=Y9C-B9DDO<7E-=5)33V)'=&%L=%5L4DI)5% F(WA!.TQX-58U
M96Y24U149%%39'=C,6U7479K-U!3=VM14T11*V%.,#$T<&).1VA":E%60FI&
M3FE$=C(K;DQ)145B3U!N:5),8S)O6'5U-EHF(WA!.UDV:&(R1C%C*VQ08W%Z
M>&-Q0F%,-'-24W W1$Q206M703!M44)7-DHU:S!V5G)T;TQ/5U)P25%R=4A1
M;TM.43 S03-!658K950X37@F(WA!.TET:GA!<VIZ2F$P<S$K4%=(=&]',')I
M6C0W:4XU66UK.4E34D-V3D]F1C96<C1947%395<Y13@T,D=S1U15.5%.-W!P
M5U96:F%6;5HF(WA!.U=,,6IC,5%C=F=(1VQ25')V:$I#1UA:1DQS5E5,-4QQ
M4WAU23=345)88GA/='9+=W%&:TMK27A'*W=B1E=&851O;C5L>%=T-49F86HF
M(WA!.T<X<S8R,S%E6EI35$59<65O2T=-:CDT3FTW,3-R:W)#3C)E6D9,<U91
M5W1W-G!.<$XS1G!5<5%A:DI'5G1P<$%3<4]D=5<Q96YB,W<F(WA!.VA5:S!4
M5"]/.71Q=V)58C9/-3!X9T=K5W%L=R\Q94YA3"LW6#1"37-N-U945E0O3E9.
M25I29U,W1E9/84]6-DMR.$4S-6MF84\Q0E$F(WA!.SEV;FEQ;$A94E)Z*W%U
M,4)153)9+W=#=3E3>CEE:$Y0<'<R:6Q,-C%A,G)M0E5K-4$P:5)2.$Q.>'%%
M:D$K1558='0T*TIX5D(S1FTF(WA!.VMZ96MW5T9(1'9,8F=C5E)#:'%4=TY'
M;$QL3U(S;W4S8VQI<79B<D9D,B]*;S$U:#-T<BM0:7=75&1L8U4K2W%L;35,
M6'-E,51G5D0F(WA!.S)U;C-I>DY(3D\T:U-V,64U65)%<WA13%8Q02M);%8R
M8C=605)59%=.;W!E;'1D,FMJ.%1*37162&]033AZ4$A53%943'-V:7<S+S$F
M(WA!.V=-57!J879(3$=V1THT0D=+3$5W-$5#;$(X24Y+94="2W9G5C)+=7A6
M,DMU>%8R2W):4#=T<65"+U9K6F-I:V,P:C%+,'1*94UL>30F(WA!.V=)*T53
M8W=T93E0:4)'82MC66YM-3)$2DUB4D9O;3%H5T="23114%1!<7 U5G)88VYP
M,W)K;V=!8DY5-4=2<S@Q<S%J8E18159Z3F(F(WA!.U)36$5!26AL64%S;DQR
M>$I',E1"-DYD3E=/;5=.<F-M83)T25E*6F5+>5-29TMZ0E1T56=:25-*23-1
M46Y'6F)5:R]M;5!8,W-),3 F(WA!.TE20RME6D9A4UE+55-),35S86<O9T1H
M0VQI2'$O;3-,8UA!5WIT;TEO>$M53$Q%96)N:7%+;$]8=W%72D)B<4%A-R]$
M:W1K8G-K.'$F(WA!.V8T;FM%=SAW,CA-6E=/15)'3D97<V=-:7I6;WHQ*WEP
M0C(R4%%:17%'465J1"]V=&9U1T),=E)H+W=".7(Y=WA69T]R,U U;U)8=#8F
M(WA!.VUN,D9V3F)R6#9M+W!X04U0<D%!<GEK<B]D52\T63=B6DU5:F1N,V]W
M+WE,.7=Y0UAE:D0O=G1F=4=+<&8U9UA5271&=DI.26=J;#$F(WA!.TI9:6)6
M1T,P3"]4458X2S11<DAV2VPW-2ML=GA&<BML=W=7<E!)5&-)239O06EM3E)X
M8S$U1W17;V0Y=31O5%-!>E1)<&1I<G-6534F(WA!.VY:63)+-T9A16MQ5S(X
M04)3<%!B1E5*0D)*0F%X=#9:3C W8VY:,DUR2S=+4E9J,W P,F]0:TU+1D\T
M=%96<$I6*T\T:6AC0D51:FLF(WA!.S Y2VMN9717:C9$<&EQ,F1:8E8T<CAQ
M-U-0>5-D9311;'!%5BM*9&5-6$EI;U5N=TY+,59256-Q6&=5+T-584PT=TYW
M>7DO>70X3$$F(WA!.V9$,30W-'%V=$5L:4Q1>4U8<'9%>$I.5D%!4#)I5W%'
M.%-F;C)#<7,V0G=+,4)"0D)(6%DQ=TI867$W1EA9<3=&6%EQ-T96<VXY,C,F
M(WA!.WE0-G-J3&M5:FUK3W$R3#-N<$Y',T9O*U%O=V%H1%4W9T@K6$YF:WAM
M5&XV9D])6&961E=K4S(Y=$A$5FTT0VAA:#8Y9G5Y55DP2V$F(WA!.V-K*TM2
M2U186&PR-FPQ1V$X:#%+93-%<G-W44(R0V@T:VI)05EL9C)01&%U,EAI93%5
M,&U/-C-Y:C5:=F1'=7!(=4Y293A75E5267DF(WA!.W)Q1C1N+TM:=&@R-S=M
M=5-L:T5I3G5Q0D=M635E=U-F>E1(<C<R16$V14EH9E!-:71*349+2D5A.#).
M469W0G=H4W@V0U@X=TIL9VTF(WA!.RMR3$-5:FA7-71P65EF:6Q%-G!-55I:
M2SA415-W3TA:1$YV4F@O,S)V,T1)<&0V35 K*S$K-%EQ-S!99CDY<CEW>%9G
M0S-F-6UV<4XF(WA!.S)Q5T51<VQ:=G%Z>5%X27A!;$9D:$TS-T@R4%DW-VI*
M-TDS6B]W0VI$+TEV,T1)2F0V35 K*S$K-%EQ:VYM;S8Y0F)W4V%*06MR8W F
M(WA!.U)C;TEK:VLT+U8U1$=5-79'=CA!96A".5!H5W!#0VQ0;$\Y."]3,WEX
M82]P:TU6<7I/5&-O<4M605)41T%O8VXT:E=P,V]D=31O5%,F(WA!.VAM;5)3
M-T9867$P5E9Q8V=$43%&9D59<3-I<59I07),9GDS3EHT,FIJ4U%*.6]L4S=&
M94EB6F5%:3=6.%0S=V]26#%C>E=34C%A32\F(WA!.T%Y;'0R2$)G>3%Q5'9T
M,R]!3$U686ET4D90=S0O=5-!,&)G,%I85W164#=256<Q1F$Y*S%-5E)24E-W
M66=C;'%!931R,2]69U,S:7(F(WA!.W-69&ER<U9D:7)S5F1I<E5N.3(S>4]2
M;GE+4GI36%9%=C-I45=H24YF:D-K0FE/,C5Z6#5!96IM-$1!2#%,9%1G,4]B
M4G!O8E=54F$F(WA!.V<X6$9*465)1# S24Y'<#=B6EIJ3D57,'HV,&MK;6UE
M9'A:*VUL.4<P-6UH8U-"<491<U59:T93:D)K.5)8;W9'<#)*8G%$9'A1=FLF
M(WA!.S%62D4K571/.#)7;#-+,G0S:3--3$)206=B;58K3%E(-$4S039N=CE'
M1U5O:VIH0V=(93)8-65W4W9Z3'%B85IP33$U2&%T95A#,%<F(WA!.T-"23-K
M3%--84M$=T1%0W9F0T995690+T%*<$5-:G8U665'4T],;4DS:6U9=DLP:#1X
M1&=J54II;SEE9S-'4W!&=E)5:FA:43-P058F(WA!.T%.0V]"1F9(24IB.4=(
M+V9A+V--5F0V35 K*S$K-%EQ.#=U9E S;5=/-G99-&9,;G)W,GI&67!9-#=G
M*V]"3W-:;T=J5&164# Q0D<F(WA!.S(R5'!&=E)04F@O:U@W:&M%=3E'2"]F
M82]C35935'I6<6PW<$YV0DY:5T-84WE.2W-Z1EI'.5!H8GE3;V5%4T]X1%!'
M1BMK1'9514DF(WA!.TM695903BMR87!F<F%A:&],,E!*;DLS25=4,&Q#>'$V
M:7)2<CA41FI4<#!0:'531D):;FM5=7A6,DMU>%8R2V]A,&AJ.4M5;$ME=$DF
M(WA!.S=/1W%A-SA184AX5E%C2T549U-P6$U*;&IO<#1Y2V558B]Y<U X-F9,
M1E981EA9<3=&6%EQ-T9867$W1EA9<31G145(;V1J:7%L.5<F(WA!.V@X1"]!
M344S.6-J=T1U5%ID.5=H.$0O=U1F,7@T0C-,6F0Y5V@X1"]!344S.6-E061Y
M,E=X8GA!9V=';S-'-2]R:G=J=5=Y<5I*0S$F(WA!.S1L8S%*668V<DUV-FE-
M5E<O5C0O1B\X06M9+SEC5F0Y6&HX6"]W0U)J+S%X5C,Q95!X9B]!2D=0+UA&
M6&96-"]&+SA!:UDO.6-69#DF(WA!.UAJ.%@O=T-2:B\Q>%8S,650>&8O04I'
M4"]81EAF5C0O1B\X06M9+SEC5F0Y6&HX6"]W0U)J+S%X5C,Q95!X9B]!2D=0
M+UA&5E1&6%DF(WA!.W$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$F
M(WA!.R]W1"\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#HR03$U-S(R1C5",#%%0S$Q0D0P,$8Y,30V,C9%0S1&.#PO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HR
M03$U-S(R1C5",#%%0S$Q0D0P,$8Y,30V,C9%0S1&.#PO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S
M<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM
M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HR.3$U-S(R1C5"
M,#%%0S$Q0D0P,$8Y,30V,C9%0S1&.#PO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HR.3$U-S(R1C5"
M,#%%0S$Q0D0P,$8Y,30V,C9%0S1&.#PO<W12968Z9&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X
M.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD
M969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D%%-C$Q,#)&031%,D5!,3$X
M-S$S1#(P.#$X1$4S0C(X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 X+3$Y5#(S.C4V.C$Q+3 W.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HR03$U-S(R1C5",#%%0S$Q0D0P,$8Y,30V,C9%0S1&
M.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,2TP."TQ.50Q.3HS-"TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL
M=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N
M<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU
M<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A
M<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z
M<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @
M(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/E1R=64\+WAM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G
M.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA
M>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @
M/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @
M(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M
M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA
M<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T
M1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC
M;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @
M(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'
M<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP
M,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z17AT96YS:7-&;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS:7,N
M8V]M+VUE=&$O1F]N=%-E;G-E+R(^"B @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93IS;'5G/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP
M92 M(%14/"]%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y!<FEA;#PO17AT
M96YS:7-&;VYT4V5N<V4Z1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/C \+T5X=&5N<VES1F]N
M=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93X*(" @(" @(" @(" @(" @(" @/$5X
M=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^36]N;W1Y<&4@5'EP;V=R87!H>3PO
M17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3X*(" @(" @(" @(" @(" @(" @
M/$5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^-RXP,#PO17AT96YS:7-&;VYT
M4V5N<V4Z5F5R<VEO;CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N
M=%-E;G-E.DME<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G1396YS93I+
M97)N:6YG0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O
M;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/C,P,C<R-C$Q.#(\+T5X
M=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B @(" @
M(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XS,#(W
M,C8Q,3@R/"]%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3X*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/D%R
M:6%L350\+T5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@
M(" @(" @(" \+T5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" $9 E # 1$  A$! Q$!_\0 '@ !  (" P$! 0            8'!0@! P0"
M"0K_Q !4$  !!0 " 0(# @<+!PL# 0D$ 0(#!08 !Q$2$Q05(0@Q%B)!4565
MU2-A<8&1E):AU-;P)#)35%:3L1<E,S5RL\'1T^'Q0E)BTC1#-F-DDI>RPO_$
M !T! 0 " P$! 0$            " P$$!08'" G_Q !9$0 " 0,# 04$!@4)
M! @# PT! @, !!$%$B$Q$R)!46$&,G&1%$)2@='2%2-BDJ$',U-RHK'!T_ 6
M)%2"-#63LK/4X?%#8Y0E1&1T"!<V<W5V@Y6CMM66_]H # ,!  (1 Q$ /P#^
M_CBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*5PKFI^5/\ C_PXI7SZV_OK_C]_QQ2GK3\R_P!7_GQ2
MGK3\R_U?^?%*Y];?S_U+Q2N?*+]RHO\ 'Q2N>*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7RKD3\O\2<4KJ=+X_*B?UK_ !_D_P"'
M%*\[R&M^]?Y5\_3_ .?WUXI7F><QOGRY$_Q_+_(OT_/Q4=P^/PYKS.M(D\^9
M$3Q^957_ ,^*;CX*?OXKI6UA_(]/X_S_ ,2?=Q3+?9_B*^VVL/\ I$\_F\^$
M7^3BF3]DX]""?E7>RQC=_P#6G\OW_P J_3Z_O<4W>A&?3TSX?Z\Z]3"V.\?5
M/K_C_P!ONXK((/0UZ6S(OW+_ .*>/^/]2?\ #BLUW)(B_?\ RI]4_P ?R\4K
ML1?/U3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M1HO9Y &=XI>HS\!<:^'AOMP/C$7SX\?").I*N\HJ>E(E7RGW<\]<^UOLM9S/
M;77M'H<-TG#6CZI9?2P?+Z*)C<$^@C)]*Z46C:O.@EATR_DB;I,MI/V)\?YT
MQB,#U+8KQNW^18BN?<,:Q&JY9'"6"1>E$555)5$]M4\(OCPY?/W)Y543FNWM
MK[,("SZJBH 6WM;7HCP!DD2&VV'CD88Y\,U:-"U9C@6C$DXVB6 MD\8V]KN'
M7RX\:\@_:'7I9$P@NNI22QX(B9Q!RTG+BAFD9%&]XT2.G:JR2,8YBQ^MCE5)
M&M]+O&I!_*+[#7,\MK;>U&D7%U!#'<36L%RLMS%#+(D2.\$8:529)%0J4WHQ
M(=5VMBZ3V9]H(HTEETF]CBD=HXY9(BD3NBLS!96(0X520=V&&"I.1G.IJ*!9
MO8^90^\IS*WT*R=%^-D5R1C^5B1/6Y6N1%\^A51?QN=K_:+1>U[#Z?%VOTQ-
M/V%)0?IDA8)!S'C<Q4@'.WCWNE:)TR_";_HS[.P:YW90CL%QNDX;H,CCKZ5U
MQZ_-2LC>RX$<V6(N:-?,B>N(")\QDB>6(OI'BCD?(OCZ-8OCSXY6GM1[/R*C
M)JEL5DCNID.7&Z*RC>:Z<90';!%&[N?LJ2,U)M)U)2P-I+E&B1N%.'G94A4X
M8\R,RJH\211VOS#&/D?=@-9$-"7(YTR-:P8B2.*"9RJB>&2R31,:OY72-3Q]
M>8;VI]G521VUBR5(K>&ZD9I0 EO</'%#,V0,)))+&BGQ9U'C0:3J3,JK93EG
MD>%0$R6EC5GD08^LBHS,/ *379^%6<658/G5=[R&Q5RQJ3&C_CIO5[0GA5_Z
M>3T/]$?^<Y6JB(J\M'M'H)E[']+V':B[CL>S-S&'^F3;NRMMI(/;2;6"1^\Q
M4@#BH?HS4=F_Z%<;#"UQN[)MO8)C?+G&-B[AN;H,\UULV&5>V-S-#3JV6,R6
M-?CQT22*OB?.=(WS(GJ8'#&^4ER?2&-KGO5K45>5I[4^S;K&R:[I3++'=2QD
M7L&'CL8WFO)%[_*6L2/).PXB1&9R ":FVD:HI8-I]X"C0HP^CR=U[APD"GN\
M&5V5(P>78@+DUP[8Y-K))':6C9'$-"9(]]H&UD8A$L<$!+W.F1&P3330Q1RJ
MJ,?)+&QJJY[44?:GV:".[:_HZI';Q7<CMJ-HJI:S21PPW#EI0%AEEFBBCD.$
M:21$!+, 7Z(U4E5&FWQ9Y'A55M9F9I8U=WC4!"2Z(CNR@9"HS$84D=OX5Y?W
M%A_"*C29#(:]8EM04D0\A'K $K%G]2%SHQZQ#*GO2(QWH8OI7Q8/:3V=,AA&
MO:/VJW45B8OTG9=H+V?<8+0IVVX7,P1^R@QVLFQMJG:<1_16I[0_Z.OMAA>X
M#_19]I@CV]I,&V8,2;EWR9V+N&2,BNMFQR4B,='J,\])6&2QJVYKE22.NA<1
M82,5"?QV P,?,8YOEHT3'23*QC5<E:^U7LPX1D]H]"82I=R1E=6L")([")I[
MZ1"+C#)90H\UVXRMO$C23%%4D9;2-54L&TS4%*-"K V=P"K7+B.W5OU?#3NR
MI"#S*Y"H&8@5PNQR#8WRNU6<;%&+$=)(Z\K&LC"GFB'A+>]2D:P68B>&"(AR
MI%)--%$QZOD8U<'VK]EPCR'VDT$1QV\=W(YUC3PB6DTL<$-T[&X"K;2SS0PQ
MSDB*266.-'+NH.1H^KEE4:7J)9I7@518W)9ID1Y'A4"+)E2-'=XQWU1'8@*I
M([?PLRWN.A_"7/\ O-+@KW1?.:[W&GE(]1@G,^)]2%DI'(L RHDTR,>L;'>E
MWBS_ &F]F^T,7^T&B=JMU#8M'^E;#M%O;@.;>S*?2-PNIPCF&W([64(^Q&VG
M$?T5JFT/^C;_ &&&2X#?0[C:8(MHEG#=G@PQEE$D@.Q-R[F&176W89)Z1N9J
M<X]LK3'Q.;=UCDD971*18.C5"E1[08&NF,<WR@L2+).K&(KN07VI]F'"%/:/
M07$BW;1E=7T]@ZV$1FOF0BX(9;*%6ENRN1;Q R3%$!-2.D:LI8-I>H@H80X-
ME<@J;AQ';A@8NZ9Y"$A!P97(5-S<5PNRR",?*NJS:11BQG/D6\K$8P*:>(6(
MQ[U*]+192IX!HR%5(7SS10M>LDC&K@^U?LN$>0^TF@"-+9+UW.L:<$2SEFBM
MHKMV^D[5MI+B:&!)R1$\TL42N7D52_0^KE@HTO42S2M %^@W.XSI&TKP@=ED
MRI$CR-&!O6-&<@*I([/PMROK=%^$V?\ <86. ^/YS7>MIQ;9'"!.9\3ZFEE-
MBE<..J)-,V.18V.1CO$_]IO9O>T7^T&A]HES!9/'^EK#>MY=!VMK1D^D;EN;
MA8Y&@@($LPC<QHP5L8_1.J;0_P"C=0VF*2<-]#N=I@B*B68'L\&*(LHDD!V(
M64,1D5\MU^3>C%9J,Z])4,6)6W=:Y)$KXO?/5G@E?6@,'[L9Z?/PT7[I-Z&?
M7D5]J?9APA3VCT%A)]*[,KJ^GL'^@Q=M>["+@[OH</ZZZVY^CQ?K)MB<T.D:
MJN[=IFH+M['=FRN1M^D/V=ONS%QV[]R'/\Z_=3<>*?A?DD8Z1=1G?;8+&<^3
MYW6>A@4I$8D1CG_$^EHLA4T0T9"JD3R)8X6O61[6J_VI]F-C2?[1Z#V:VR7C
M/^E]/V+:23QVL=TS?2-HMI+F6*W2<D1-/+'"K&1U4OT1JNX+^C-0W&5H OT*
MYW&98VE:$#LLF58D>1HP-XC5G("J2.S\*LQZW1_A'0^MA(X;V?-Z]7L+,;(\
M05S?B/4TDID4KQX%1)9FQR.C:Y&.5+?]H_9[<R?I[1MZ7$%HR?I2QW+=72NU
MM;,O;Y%Q<K%(T$) DF6-S&K!&(C^B]3P&_1U]M:.28-]$N,&&(J)90>SP8XB
MZB20=U"RAB"PSTKK,RY&JW143FR*4UGIMZ]WK4*-LQJ-5"%1RB1.;*4B+_D\
M;D?+Z6JB\POM'[/.%*:]HK!S<A"NJ6+!S91B6\"XG.XVD1$MR!GL(R'EV*0:
M'3-2&<Z=?#:(BV;2X&T3MLA)S'P)G!6+/\XPVID\5XY-?FD8LB:&D6-H[2U>
MEJ"K$%?,T=A*N2?P@[R'L';,JI&LSV1(Y7N1JY'M%[/E#(-=T8H(%NBXU.R*
M"U>9;=+DMV^! UPZ0+,3V;3.L08NP4X.FZD&"G3K[<9#"%^B7&XRJAE:(#L\
M]HL2M(4]X1J7(V@FL03M*)CG-;<U;G,EA@<B6 B*V<AKWCPJGNJJ2SLC>^&-
M?#I6QO<Q'(U52S].Z)EE_3&E;EF@MV'Z0M,K/<J[VT##MLB:X2.1H(SAY5C=
MHU8(Q$/T?J) /T*[4,DDBGZ-.28XBJRR [ -D;,JR,.$+*&()&8\1MZE?\RW
MK5173,;Z3AE]3AVI).U/$JJKH&N:Z5/OB8J.D1J*B\RNMZ*V"NL:6VYIU7;J
M%H=S6J+)<JN)N6MXV5YP,F)&#2!5.:PVGWJYW6-YP(V.;:;@2DK$3E  )2"L
M?VV&%R1@8*?;U7A7); *WVO>\H:.J>RKTC27RDB_N2R.2-'_ $:LGAOJ]2HG
M)#6=&*[QJ^F;!"+@M]/M-HMS,(!/GML=B9B(1+[AE(C!WD X-E?AMOT&[#&0
MQ ?1ILF0*TACQL'ZP(-Y7.X)EB, FL9+MJUJN_YQ#\M?'&[R5#Y:^5'+$Q?$
MB>'R(USHVJGJ<UKE1%1JKRS]*:4,@ZIIRE)(HGS?6W=EG5W@C([3NR3)&[Q(
M3ND5&9 0K8A]$O>#]$NL,C.N+:7E4*AV&4.41F4.PX4L <9&?&[<U35\+9A)
M]?'U+A^]/R?],GU_>^_D#K.C#KK&E#G;SJ%J.]]GF7KZ=:S]#O\ C_<KSD9'
M^[R\@]"/U72O8/KA9OK"5#*GT\^W*UZ>/S_BO5$_+X\KS<@N+:Y!-M<V]P!X
MP31S#QZF-F ^_CUJF2.:(XEBEB...T0IY>#(IQSX9-96'2-7Q^Z?F_+^_P#1
M/N_+^5//Y/O_ "<O*GR/_OTYXYSP?+UJ 8^8^7/J>&/0>(Z^%9P70^?'B3S_
M !K]?KX_/^7Z_P O\',8/QZ?Q&?]?=T/%-RGJ/'Y8QG/0_'@]#X5(Q;UKO'E
MR*B^$3^3^3_WYBLX\FQ@\@\^/KR/\>OJ9&-8LD1/#D\K^_\ X\_55_/^]XXI
MG'48]>H^_P O#J/QK*1SH[[E\?\ #^-/_G[_ *^.*E7J:]%_>7^I>*5]\4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2NN::(>*6>>6."""-\LTTSVQ
M10Q1M5\DLLCU:R..-B*Y[WN1K6HKG*B(J\KEEB@BDGGDCAAAC>6::5UCBBBC
M4O)))(Y")&B@L[L0JJ"6( )J2(\CK'&K.[LJ(B*6=W8A5554$LS$@*H!))
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M[W_2<EW;K(5RI>WMK?()  !Q4I#ZNZX!7UP8;+.F56JI15( >:]6(K6+(<=
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ME^_[N=DUH@AO'!'3'GYCSXZ@\CH:GHAC9&HJ+Y1?'E//U3^'_'_NK()Z'K_
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M="'H-KM9[9HF@!O4IJ%=I05<<@66W.<D6K4OL*].H9;&391&G0TY8=0X>B!
M^4O(F,M9]<Z#-<74=S?W[3;+F.X["V^GVT*M'9ZC:GL=^IW$EN93?B21872
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MJJPFRJ)'5R-^=5<L5Q1/>Y(T2WKO5*,/)+]\0UE&LU38.;X<ZML#(D5$D7G
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M$R5M&UK6-:QC6L8UJ-:UJ(UK6M3PUK6IX1&HB(B(B(B(GA/ISU:JJ*J(H55
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M&[#9VL5(5L G@X\0"1TW 97(J,5'VN^N+G!0=G09;MT7"V-#D-%0:*RZPT8
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M:CVIA'NR6WL]?D>':SP:A8NWQ,6F0*3UPJCH!CK77>TG27/5)=2MQ_422VG
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M]?0H<9Z$C@BJS-'8-T%?= 41%#V70/)=?X>>">O'[$S\OLKHB<*49[(%X=[
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MTF<:!W"E@H.>3CP4G')49.-HRRC)&2!DU"1BB%@I8C' SGD@> )P,Y. 3@'
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MC*1P5P5//-17JH_\#KV?KB9]O-G;J.PTO7UM;6(UW%*0I<\VPR8NB&DD2U0
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M.#@@\JP.58>!!'\1U!R" 015BL&''!!PRGJI\B/X@]",$9!%2'D:E7D/ !M
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ME[>/TUX!NRO;^*[&KKK1RSWUQ7;Z;2 VEP039'#SEDSS26=I,"3O7)Q]:/C
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MD5Z[&8F  R8(>4LN,>5PPT+1W2RSHQ?;:QA9E>,]?7X7T3'",>B*U2(O/K3
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MMM2,KHI<W6T@1T2Q45LZ\/I(H!)CI=DN"QD 3<55MK99@ 6PN,@+N&XDCJ,
MYXCVI)"B,EMNY@&7"@DA<MG!+8. /(YQ6!+^TU>$ZRNQF:Z6U)5_-UED.R[J
MIV6HQW7=MFX-CH=KF0\X>#>V4S3;L"QPEPA\E02?4OAE!*KK$\,P<F3/8C:6
M,BXWL@*AG!*A3D$#H0PQD ]<BAE.0!&<E Y#,JD9+#!R>2"IZ$CRK'VWVLW4
M9FH-L>K;Q,-C^UJWJ*[U8NMQDEA'H;.^SN9B,"QY5F%=6E=#;Z:O;)!6N*N2
MA6$R5539%-A!GR(,X D&YD+@%6Q@!FY;! R%/7@>) R:P9L9RAPKA"0RYR2!
MD+P2 6'3D^ -69E^\([[M8GJJSPNGRUE-2[729T^W*H)G7%!@]51Y"SM[&DK
M;4R\RP-^=H:ZSPTUX% S49]"SO-<:*^L6#1X3>&4C*@@9X+ L "1AB "'P>Z
M2!SU$Q)E]A4@D,03CD*0I) .5SD%<^\/(C%7MRJK*<4IQ2G%*<4IQ2JBZW[B
MH^SM+V=G*:CU-4[K#05>=..T]&;GFWT]E416S;*BKK6,:VEHT21PP=J8"(/<
MI$ZSIOCJ,FNM#K'C*!"2IW@G .<8.,$CC/F/#H<$$"M) Y< ,-A RPQG(SD
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M\8]X$$J<=67C(_JC(\B.:I%;L##:C)]E4T4(^+[)&BU8[ W1( !8VX(,O95
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M!YCD'=8\CG<H@&$@V/@28./ ./$@>(\'0Y(]1ACD^E=;8P$W/4>N:2+K,/!
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MSXGDQ5=B]0RA+",YC=<XA<?7AD!921R4;*M@^#J,JPZ9 )!&*N!,J'ZLT?#
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MH1YUS:<4K%VU+57HR!VX Y\#9&S1).SS(.0SZQE"3M5LX9<*_C0%BRPDPO\
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M'%R[7(R>EJ(R*6CU!!=A7B-\-\CY6_S'GPJ^XBR2*^7:[OYQ%?\ : "/]S(
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M6J-KZR_;))'IJ^\'<L"W1SE<AE$BD ,#P64>!.#GT+ E?JD&JGA#<J2C#E2
M#M/F >GJ 0".&!%1.]OWC4C\#]H<88,(_P"%@J^UZ*(BNR)]G!-%+56<Q:R$
MS]:; $^,<VO=9%+4.L8H9J6\FF=\M'FJY;M+<Y(R3"V"X'B ..U0C(.!G'#+
MXF#-W>SN!@' $JY"$]5.<YC<'!&3C(!5N<":]?;&WBLG]=;LAA.M!"?89_3P
MPQ0U7964A=%'%I*Y1O\ (H+P-)QQ]91P*SX(V2*T A2DM %CKD08[2,80G#K
MXQ/SE#X[3@[&/4<$[@:G&[9,;\L!E7XQ*G #C'&[GO@< D$<,*B_='7,>I".
M,6NDK#!I0KJBW&6).9H,OJ*-(R*#07.=@9\/J:^K-C7WW1J7905<A (U<^ H
MLB.<$NP@9!!!5HW VNC9W*K=4+#X MR3TJ,T>X$XP1@JZDY5A[K,OU@#@^)Q
MD=#4DZT[37>]>?A$H7HU--)-0["DJ8VW/R;3@>B$^048<N*>VI9FR17U.X&=
MY5QGBPIZ])IR8V+"6+LY-N>X>\C-W=R'ISC ;ZK9P%<$'&#4DEWQ[L=Y<JZC
MG:PZ^()7HP(Y*D$5BU[<L"G' 553%9WU"/%8V]-7M*ELBJUI3&_'@4YD85P@
M1T'O!31_"S7.<O5!B-JK*I+AL9I=B!@L2%;@,<;0<'@L,C(X/4!ER001BL=J
M2< 9*C) !R1Y@8S@].,E3UXYJT8GYKL7(^9(!KO+ZNHDA)",A]410!T+H2P3
MA9$1\!$7JE%,%E1A 94<L$K8IX7(VKOQ/U*NAX(."".A!_B".".>E6]V1.@9
M6!!!'4=""/X'R-4;UK(13&ZO[-F\)*MHZ^A+*P5S9R>^1L>J+1'U3@BR9O<0
MN]QDQ'X.7/N(LI($E+:21*TZ14OEPP2ZCPN6 D4<;)AWL@#HK@;E\CN'A5$?
M=+6SDMA249N=\1XP<]63W6Y)(VD]:AW0>8O;;[.5S3E6$<NS;=Z*L^*<Y'.&
MU'65@-C\_,6K9'>F?W\)36!*M<UWJF=(Q[E5L[[+AE%TK8[FU#C]B4;V&?A(
MP!]/NJ$ +6Y!)+@LN?'=&=JY'_(N><GKGG->2AW%>=K^P]=&US*GK;J>^UX\
M;EC22!W<<-+M)PI7(KI&6,%GB[<)XZ1/<R9ZQKXE5(E-&P2->-TLRI\3!E ?
M@1(IS]] X+N_A'$S=#TEPW!R><QGPXZ>9JX.BZT?)X+.XN^(%?M)*P,S4@^A
MSFI;&U 9DU5&LB.0F'/TKZFH55<](@8*Q)U:XN!LE%S^M=W"YB.57(R"F2N2
M#GASN.#U);C JZW)B5!DK*N')4D%7X;NL,$%. #P0 O.:NP,$*O@:* &*",Q
M7.:.&/$- USU\N<V*%C(T5R_5RHU%5?JOE>:L<<<2A(D2-!DA(U5%!)R2%4
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MW=]WW'HNVXR\W!G<OE;O*-Z^DF4MF@T&/TV3"OJ[3:((E6MJ9KY9GVU13I!
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MUH_SV2.\KHL* AWRJ99Y#E(CDD$\[Y .>]GNK[QZ]WNFLLW:#9"PB@C!#RC
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MEI\>=_KI?\YF_P#U\?3[[_C;O_ZF;\]/H]O_ $$/_9)^6GQYW^NE_P YF_\
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M1&8=X@;@XR=^W)P_ /:A=Q;(!D7]9QM8MA7*.JL-H+;=A([F[&"ISCLV.T*
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M]!.QHX"C9:X*(9",I\>AFNC#+9PS6\9W@22DDD,3&O..&.3(Q8$YRZCD^[@
M'/8W,@";HH54 %0LC<9.5&!&H4X  4D@#(;))J0']$]Y6X==3[NSH]IELX6+
M+F\K@.PS>DLZ-" UL54R6CH.JK*Z8ZI8QLH;U[')8+.V*4,6&:%LO(BX@4EH
MPT;L#O>2,3L<]>\TH7O>/ZL>(R<U(V]P0%D*R(I&U(I#;J,>[W5B+#;X?KC@
MX(' QEJ*$/$DE!W/V8L)BU=.J3::^O+S9)<L:C&I8V6XJ>IM>J^XC&KZ]?>U
MQZJSU20M7PJQ;+@;;J208]P*J;>O C,R@ ?L*1SQ4E CR&M8X^?>9B^[  R7
M$+GH/KD'BOFRUN"M+5P4Y?V;8X8W0SMJ*&WQNC>@[6M<Z.^,U5!G*U[YIF*L
M(89])8PPR/1D9BQJ5"5)%&<7/EDAUY] C,?'K@@^8Z4+QL<$VW@<*4?C'UBZ
MJ,Y' R#CP/6IO6]?=>WLBP9JYZ,AFG\*X;#YLJG(<YZ._&7\#^U*][YU17(I
M#6^X_P!+51WB-GI@9)5P76?CQD8,../KQ'@>705,1Q-[K09/78I4G]R4<_"O
MN+HP++E#$ YV"YBFF3XZRJ=1J@;(9$5'1JZEUI^ZBM(%5%;)+\\'GCE0?R*\
M59IPG;EARQ!&, HA'[R=G@_%3GGG(&<]@%.0N0>I5W!_=<R9ZG/.<XXZD6:O
M6A:/ADK]_N*81((XDJ!ERL8P\7E9'P13B9V*QA]4CE65([26)'IZH/0JJ]U7
M:CG,:-ZG?G/GRV#]ZU9V1XQ(ZC'3NX^'"@_=G%2+.Y!]$:183W]S:$D1(.]A
MA]@4(Z&-&^R]T5J=;31$M7UND4 H$"1TBO2NCD]3W19]P "J .>  <_$ 9'@
M,@D>=35-IR68GIR3C'WDG/B<$#/A4PD;Y3S_ !+_ ."_X_>Y"IU@SQ4E8Y/'
M_P _D_E_-Y_BXJ)&#N'@.?4=?G567M5ZD>BL_/X3Q_CROT^GY%3\OW<RIP<_
MZ/X5%AGD=#X^77GX<\^77SK!8C5+B#_D%Q+Z,K9%N6M,D7PS.V9<JND&(<JH
MC**S)D66*9?"55C-(V5RUQK757C&S[(WKNQQ[*:I<M*S=$]F=5NY2TK/C(30
M-5N9#(TC$#1]4F<R,=-OP=([ZG]-0*HYUBTB" ?6U6TA3"*OBVI6<2! HYOK
M6,!!]*M\7L_["=.TJI5,H-JV,C(E""),T3X%/BDBD12*@*AL<RY\/H'D!M-+
M95K!)G3(,0*U)YG^WC .>^4YY("YP?)BP?GG*J#D=<^'GY.H.T-P>"6QZY 4
MKY8+$?P%0EW;6@&C'<>;T^).3)+'!71[>ZL2O,;7R)!)-4Y@Z!#(X8WR%CBH
M9&-[<JL()AB69UG8J<X$Q Y+=FH&..<,P.,G@G&>. :AVK>)B&> -[$Y\.BD
M=,DXSCSP":^']\,K(WSW%5DSD:K_ -RQ785?<6#D1%5J*'K*?!)[CO">J%A4
MKT]36Q>\_P M0+?/NLX]7B*C/Q1I./7'W4[; RRJ?ZC@G/0XWJG/7C/I7@/W
M^9[0J&17?V>^S]-5>ZY1?GN+RGMQSL5BH763V>JADA<UWI>/: 21HCF)) 4C
MF(J9$;1'NW,*,1SM=^A'1L)CT(/GR*P9%E'-O*P'0LB>'BI+Y^!'XU3=[UWL
MJLN>UZZS>DR%6^5B7</=^[I!,R\/U#L>D&NR.LONU!_3#)+#!!879]-"L+86
MU:QO3U7+(C#;*ZNWU>PC8OZ91T6''7) 5\'KX52T;@_JE9!XB9U"]1DAD9I<
M@=,DKQ@K4"LFY*\'^%MKK4=43Y\N(NLW-%!!OND +]Z/:'?T/8>:KL]845O
M_P!;C+*^+HI)A9'5NBDN:V60.6T;U.0$FW#!C;]7<%?%6B8LK \8"AN1E0IY
MJ)*-P2T17D.HWQ!CD!UE0 @^9;;UPVY36R&0[DOJL&OR/;[<J?=7H[QL5V-2
M&Q?\D_:[7M\0 LN$A*&S6H,B]<9%%8P? GS-DEHYS!W*+!JO"I)>'>%4]^)A
M^NA\SM."Z _6!R.C8/-7I*P 2;86;A) 1V4WH#R%<\C:>"?=ST$=S&M Z UT
M.*M5LJ?I[5G^<NF@%/@DZGU%E(DDF2*LG0$4QF%NC)99*"W NC0L]:2K2%S,
M!) GBDR&X0N,-.@[^W![91]<#.X2*,;E*@L.\!D-6%<0.$/$+G"YSF)S]0DC
M'9MR5.>#QT*U-MCF3>NM/BMS36L#,'7;1L%WG2QY'R4 _8:RYT\G/6C"&M$S
M\^ELZ*\M*(P4@8.4)Y=496B,D DA&PD22-E)D9,JP/O&/O@,"#EM@9001G(!
M!.#4W4HR2*>X&PRXS@2=WND?5W,K$'(&,C R*V6YJUL5J3TQ25/4'<_;W4H@
MD0%7NBH>[<3Z',;%*):,&S^OI88D<U(_D5U7C$"#0QN]JKLX5>Y&1LYN3L9H
M(9B26C'82?$99&)_:4X)/5@:U(56&::(# <]NGKNPK@?U6 /P85,?LYQU\N'
MU>F&BB4O5=K]Q7%F>V*..:Q<)V1IZ:MFG>QC7/0>EJJX2%'JOMQ0HB>/*^87
M60Z*2<)#" "?=S$I('_,234[?&QV R6EF)..6Q(P&?/   SX5[OLU$3F],XH
M^>>>=2ZD-L2S2.>R(>M"%IH81VJOIB@8RM158Q$1\SIIG^J661SL76!/(  ,
M,>GF26/@,^]\N/"LV_\ ,H3XJ/D  /EBK$VVR$Q]:V7VT.N3UD'HZ=LGMRV!
M;6M5\DKT:]1JT)'LFLCG,<T>%611,G.)"$)\WK>L'34@MK. 7^M:DTD.D::'
M,8N)4"F:ZNY560VFE6"NDVI7QC<0QM'!!'<ZA=6-E==:QLA<F26>0V]A:A7O
M+O;N[)6SLBB0E1-=W!5DM;<,O:,&DD:*VAN)X=001["VL3+>X(4ZVM"7%V!:
ML6-LDSFLC9'#$KG^P*-#'$*$-ZW_  XL$,/N2.8Z1_SVQLWM%GDN;@WNHWUP
MUYJE^R=FUY>R(D;.L>YS!;01116EC:]I(+2RM[>W$DG9F5_17-PL[1K%'V%K
M;QB"TMPVX00*68*7P.TED=GFN)=J]M<222;5#!%ZINQ!J:XL,V+0FVVABOL]
MF:.M@*%&;>6][GK+4KZBB%;%6U]314]M9VI<J$2-$KR/@Q3"WCAS]46I>-9&
MD5(NSDEE<@GLTCE6(< 99GD=$0 CEAN*KEAI]J%8J%+.&5$48[[,C/U)[H55
M+,3T X!R ;AR%M<6XY\=]F2LQ:5AZ@3#R%PV=8>Q1!C(K*CMX8AOF-;(PGX9
M[R :XP<\8T8@&-(HI9]26.-&#12B9'4,K;2CKRP*2(2=K C/#.I!4ANH&Q&S
M,#O0QLIP1D,#P"&5@!D<XZ @@@CBI38'AU->;9V!$8E?6!DGG%3+XB&##A>0
M41*J(JI'##&^5ZHBJC6JOA>056=E102S,%4#J68X 'J2<5(D*"Q.  22>@ &
M23\!5? ]LX^22BK[BQAH-#>"YXE,\9[\QE8_6O2/-A7!0XS@*XVV(<E<'&23
M'"9;MEK*Z<Z=C5DV6M)L2,BF2.,RCM%P%<0\RL@)#,J#O,0,JA#,%!XJ$Z=T
M,=CL$.TYRI?W QQ@%B=H!/+95<D57C/M(T+NMB]^[.VK2A-HN)=EOB15LI#O
M?B-:7&3X0=1%QTR;5ZJU)&54<T'I<1']=DZ9)]*6W[5-K0=N)<':%P1@CKN[
M<&#KC?@]*J%VAA,NUN).SV<9SD'.>F-A[3^KQUJ[:'1P79FEK?8>)8Y:\=36
M(SY&RHYLX -S5'P2(UGN#V--: $KX9X&-4VM<^64"61VA)&4$39RLL>]3C'1
MF1U(R<%71AUY7:^ & K85PQ<="C;6'Q 92/0JP/H<CP-2/E=3IQ2K&S_ /U4
M/_VI_P#OY.?0="_ZKMOC-_X\M><U#_I<GP3_ +BUFN=>M*G%*X<UKFJUR(YK
MD5KFN1%:YJIX5%1?HJ*GT5%^BI]%XI53=B;?JCJH:A)V\8M<FHN9,_GA:S&7
M6IM+BXAJ+2_F!!I\I0W=M.^"EI;6S(D:%[$ 8!$TTK&L^MB+(^=ISM&22P4
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M)H8CI7L>1*(2L3'L@D<V&'VA^]M+%0V3@L!D@>H!&?C4\IN*]W< &(P,@$D
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M9!@ZZ -L#YB8Y)" TKA*TSEAW@"WBWUCCS/4GS)SG \<DE0*3M)"_9^J/@/
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M2K%Y%ED(5\L%1PR,&[H:0R%<)E%.3NQ@"OL9"" " L;1Q@LF$+.A5E*X)"!
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MCA;!6@<D$")O LJR(2/#*]D%!\#AO5L58RSH 03*,\A6:-\>>&[7=C.2 5/
MP#TK*XG>=HZ %M;6YK.U\5?[T,LHU^W47+TCG5"XYOF%-UI5@6@CYFQ3.8%>
MPPEIZ+".<A9T7#I$IR68YYP5V#&..C2D@\^*^AQBLQO,PQM08)'#;SP?'*Q
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MCRGYU_A\<Z%:_3H,MCY?@/(<=*K^ HN/\5,[<*C57PJ39_POU7Z_6\3[_O\
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MZF+_ &[QQY'YC\*<^8^1_&NR**V21BSG5TD2+^Z,BJR89'-_*C)7W$[6+_\
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M)>,FF6X(/*R6]E+<74JD]&CU&R;&-R\D5(H<S.>9%8W)1UW91HJ1V%P3(=/
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M07&TJ=K*Y@DD",#QM8@^E0AGCN%WQB4+A2#)#+#N##(*]JB;@1SE<@9&>M;
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MQ0!PR%H*YMDT66MA+*'Q'"'Y9@!C.<]!XDDC QTZ]>[UK,LVS 526)VC(\?
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MOI;/TMEB@L[0&XZ[S]8^,?USF-/&JQX!T><\J(."5_,JD)&2),<$L66-0/'
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M4FM/#L1T>L2S@E0%PI(UK7.C64=\C$>UKV.5BN]2->U53PY%401U!'Q&/[Z
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M:RHKJ@DZ*,*PLQ::8 "*,. !SAZW(2U@438(JLVP41L99$IRQ,I:0%F)" !
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M:8C$=R\1*F#*P&1G;P6.<= K$^H)V@^8YJ@RLQQ&I8@^\,A1\2RJ,>8&YAX
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M]%'_ .\J_P!I<Z.Q?Z:/Y2_Y5>8W'[#?-/S4^,(_11_^\J_VEQL7^FC^4O\
ME4W'[#?-/S4^,(_11_\ O*O]I<;%_IH_E+_E4W'[#?-/S4^,(_11_P#O*O\
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M8NY.^^N=9IMU3W6@*IB;&P7KH.!T6"L+*G<^F,.KJZM%L@0>39$122(E)E8
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MY7FFAV=-M= 9-H8VPBX#"18F*AB59HSM#9)#Y=&)9.@#>!456DKKEF)(,;2
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M  )))/ 'J3@ D19BH&%+$D  8\?$D\  #DGX#)(!UU&^V1D#0TLPL)NYZJA
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MC&XVLXVOM8 $A@RLK*I!%;'9_P#ZJ'_[4_\ W\G/;:%_U7;?&;_QY:X>H?\
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M[)_;2V9@>S51A53/3J68G<?$[EVGGGP).*J@4CM&/+,_)_JJ!@>BMN'&!Y
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M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*JIU7>^I?%"<J>5\*A=)X7Z_?\
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..Q2G%*<4IQ2G%*<4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g189651g88d38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g88d38.jpg
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M=%J%.8?R,&V%BI5&I*U'F#:"772P,ULNVIRO.(\_RRS\NWDR>7YNTB.ZW$@
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M;]\D*E T:1CL0 ]YAIMEN^DFAWT;XQM@3:/?$^V,1_1MG;Z<ZP())HT;E68
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M>-4\1]+B\/P=!CU0$&DF&D;J,,4'3!'">D*59?HDC J4<+EDGJ'8[(_U0_\
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M2F6&0+)&9M)J8-0JNH;RY4) O)7>2:U:;SW\^*I\5%AK$H-:NUL[BP.L3V7
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MV]J3/F5AB@7#VDAK"L6P!6;4MN)54529"5"T&\P;26HW>WCTD!>=M6;@0+M
M8LQ 0 EKV["&&VQV#"^02: 8D 5)=/5#F6^T\C$^Z/)V=FN=GLD[NQ:L-[7)
MT6D)J%>TC[3<#2#>N65*A7R$*5L*V-45'F*NR)E6D"R&OU#^P44JJM"MNQBZ
M%>>ZDGDW?=K-G)\A/?<;+%K-[MZA6#<53 "P*KVH<9]Z>K-"E'GW;V/HMCL$
M(E0 K-S>VK!5LHP-"<[6"I#5-A N%$'V7.-\ELCFP#AG;M,:@W<VRKM- ]7U
M#^RQ@6Y90OI<N*;=9)/':B IY6CSCR5]RY-* Q;U*$.Y:->QY-@ENS6.,^Y_
M5^GR9V,%NO5E5A9*W".XV]5=I [1?4CUP6].661AJOWA"B&9,&&]?+IXE59T
M\8\T"GG(02)!LOJ&[;8R 0RJ4]*$"K4 CN*O=N#$ FSCR%[[G#$$,P8AF!.Z
MF/Y'[=M%02%(&=QQZO<G?2VK=J"[*AN2WHRAX+EX9'',#U*L4.I6J,>>+Z#Q
MIME'.*WA:7&9@P S0PR.?>8G&T0:B0;:(].PC@'_ );.RW['EVOCD5@P1G=P
M?4'!Y]I H:OCA%H]P1>8W7U3YR46:RL[B^W=NU9A-73>TV?$YS:=?SZ_<O%A
MG_B0% @(FE.Z/80=ATHJO7<S ;?;.6FIA9KZAP %"* " %6JMT?Y)O<@-F_<
M=JIY"&RQ9B2#9//"LGL!_2Y'Z\]^<X5?J;SL'==,P?\ 0+(0H7<S2K)GM@!S
M& CY!T6N=0H*@1>H2J%, ZFSUD'\HJ)?JU=@3F#O&+&;(I(DG4R&Z"+9<FE-
MDR(8W)))[JW;L"!0'-A GN6-!!R1V1PZB@ /N'/N1W]JV?\ .?-L>,8\8QXQ
MCQC'C&/&,AW0J*BZ;2+1S^SZE[UZWIC$3C4 G\0S(!T>8I\#$_1)]B;Z<_\
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M\6>*NGZ[5]4T'B;Q!H>IZ]0FNZCH^L]1TVNUB* %35ZN'4IJ-0H  "S2.
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MH1A).K NX&YF4DGO7!-  <<  <#VSLAFT[J8X&4A%O:JLH [7R!_[^YS2?\
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M7NN_UN/B>G/DUK8TX3G%C?H*>_P,*WK%A".RO5H;-87G1+:!SIV/;5L*Z>L
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M[0=96)?'EJ!EO*QE7,EKK&(% SH7=N?'DQ$;:VU'I7,FXW_.\H/8)VA1O)'
M((Y)'&6\V4 L#N]>H14VBOY0E*41ZB24 /-$'M?.8XSO/38STE3HW<ZYU >W
MZ>NYAO25M8IIT=#/ZKU4&F.T@H=?BA1R!OJV2<ZHRVQQGV-)*C,F=MK((7#J
M.\J.BSPM'L\X;-S@OL3<#;6;#<,5I38I00;J97M5657W^5Z@%]&]]I  XHCE
M0UD$&R0<Y).Z]>YZ'FU7'J&M@KRZ\^U7.F$!/.$1'XZ;AM-ZC<:Y>BEU7_@6
MSRX?//HQGRE.TKU:>KR]A5:.O,=,-9)\F-_2L>TE-.X]9Y,K(K("U@+Z^"0S
M @63VP99$&YGL!YT/H' C21PU+1+>@7152/8'G+2]6NRW2_=&ZO1K19I[2OJ
ME%X]<51C4GDQE@ 9WP_J 3]4:3Q<YG3(5T8].K[-.ID9.'ZP9MONT>M8#UTL
M>>HB1(XW5=I9Y$('F $($((\P!K]1LT%)[ 5FD$C,[JS;@$1N=FX%R]C^7Z:
MH"AR1[DV,W?\Y,Z<>,8\8QXQCQC'C&/&,>,8\8QXQCQC'C&/&,>,8\8QXQCQ
MC'C&/&,>,8\8QXQCQC'C&/&,>,8\8QXQCQC/)SUUGZV?2>$=5@"[FA#7IB+I
MV?IG9O836U\JOE+AH]GE/T3T8SJW2V2&5C89$+4%E_Q_0R*TO7E%3;;1125U
MEZ$WE!I8SY3$D+&D<.V1&W*!;A$!H V-S[B:[FQP0^85BD_FCC=(\DNY&7:U
M@(7<BSM-[%H ]NQS3_V@[?8U1E?5F5FMNBM_6BY([5'S3I-4$PBZ+[ U3GEA
MKNB2_N5%BLZ4@=E#I!=XP*=J^32N@A:ZD83",UT"")2&IF \Y"I=&]21,X;<
MJE5/'V^LJ:)8C@RTTI! VJ;A8-L=2%>4(RTY!8?ZO38)% \Y(B/:7HJID_I]
M+JF6KA*[]BK0T-:I^B=$&/747NEPH:2O!;K7/YE0#:92E3FOC3&%<H 6Z=6F
MJ#!;+ (NCR(R%=FH,L*@ HAMHPQ).VF//  #.026NR;F9P2J@$@RL20[6%D*
M@"CZ0:/).U> %([3Q;[*=4=.CG@];I"GGJWL_&./$(V>CLR^[D]DYIR"WZ.-
MVP+:.MBYI[OK(0)2Z-:PTL0"\W\=BCG@'(8T:"-119RYBDDL4%J-W6J(OU!"
M>_!(X.2)G))VJ%$B1T;+6Z(UV#0VE^11! X-]ZLK'LSVZH<^HKFXD5-TF_A[
M%;+UT4NG71RM""CZ99T6%UIAH[JP/^5(UZ)(<>+TMO3[33)(QY5I02>&N-F4
MMS!$SN%W V%5 R@D[ ?3N"AR21Z P:_<EE&5$TBHA8J119GVL0/413;69D
MY8J5'(H5FX75[UT91?.7\[YQ%2QV/05W0F!CZZA/&H*2*DAUPP?,"9&V1$--
MV4SG($T.[=?@7671EI.1^#LL8\\:(4D>3>0FR@A )WDCNP:JJ^W/;WL;NSAD
M5-MONLL"0 H!X (N[KN/GVHZK'>ZEUGJM'O25%59%Y5+X7:;U5!*UT6SE+2^
MM&+(VBPWI D**A<^W6!-1C*L*XUM[ZT12CS&(Z^,8!,7T?2IN9"S7NE",2@!
M""P=G+O?(8C8JT>31S#ZAZ1@J\K$76G:C(0"-X 12+L7N+? L9G(_8ASR3_:
M&MGU;V:I:6;N'.4<S1P2R>G]'Y&# QY[50/KCA%RPZH@5W3[_P!$6FV]H3+(
M!-,QM,Q#P85DVA:5]L4A   V2FG/S49*U_I)]QS(F*%MULH:1%Y)8N@!5>>+
M=0WQ;#X/&34>SW5Y^AZUP^A 3IJ]U*D<6N>%58MWVM[)8%%2_P!BN"OH!;+%
M33J$5@M>FRZD,ES1X\JP.C6&QP-&H"3:I@CV$AS9C:1+(^T%MJE0-Q)"\MP
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M)VNPV69?/Q.>]))".$B7@GCLN9ZFB"RV+&2CZ=5WG<2L?FJ_:PZ$",=N-^]
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MUTX25*/,1R:BR[BL6;2+&U?!^UDMTUU>M=9H,18A)".=Z:MYUA,<JW9GC\[
MF"LYES83S#_\QNP'>^ *%7V-<6.?SROE1?V+WOL.Y-G]03S1XOFLM$I$F-;J
M7Q:P(ETB@9C)FDP\<ARP=SJ)HVA"(VUS(/&QT!#U+UCVUQ/@6#&^,_;U^,PQ
M (!(#58]C7:_T]LN0"02.1='XOO_ )RKB?73A)FX&Y7):'/_ !:A*B CDKJ_
M: 976]=M*X-H-]G\?;:O1[;1HB=XMBT\6^\:Z<;3?;7.GGS41YC<DD\\V>_/
M?GW^?>\H88CW130 [>PY7_T^WQ[5DR+YO0#QM SJ;6S!([F-T6,<I0&1#'?
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MS\B,)YI=_+*JRT@W<NZ$$%@."AH@FP>P-C-/-<MY81=X9E-L0O"*X((4DV'
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M((YQ9M=I<24\Q_[CV=?V<DN/_,2;]^<MY:?VCNA_=*V?^G:*';C(PZ];N,6
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M$VWACSK/GR^GU5M-J%55 )!%[54 FB19!/YY40Q@$;;W"B69F:KNMS$L!?-
M@7[99#-/3KUNMV.T6V#>DVX9P#^.?F;*&XHX)HX-Y\ DZ_:9+X&<N) #<;8T
MU*UVG&S]46V* NEU:[UHV/N1OU'8UW'QP<N0K5=':UCGLP_3W%]LY0:55UEM
M?WI>HA"M=I5HTUC;#2E1;.@*WNQW188AZ3X7DEK-6QXXK.03++4*;4#8O8(<
M8>$78J$)]*DD"AP35\U=&NUU?-63@*H8L!3, ";/(%U8NK%]ZNN+K,?'S6CP
MT!ARZ.OC:4%HD>UP^N8(.R*2ELNA\;P#<C)63]8V&C,[662,O2:/\C;[$L6=
M8\Z3O<N)+]8(8&AW6J-57%#VQM7:4KTD$$<]C=CYYLYA9>)<KF:OGF]+5_R]
MG<<RL%@8:;G1$MG/&SP&?,CS)(R],R2U$U6OF7Z_&(IL"QPGQEP?5'M/FR4%
MW&@'4#B@) 0X[?U F_UXK*^5'9.T62A)]R8Z*$GWVT*_WR,#>L7#!B'L^M$A
MGUL2"\51@">^M+-0-5^E2Z$7RN(4;%X4GJR*TDQZ%-5%8!4 3%Z_E:CZ$9S)
MFQGE->OL584%!W)]A) !8K[%B2,CR8^?3W#*068BG^\ $TH;N0 +//?/H;UG
MXN*S ;:59G.6L?5:V"1GWGH#-=K;Z7"G%KUSG3LK24H,N@XB!4$?;S 9[(\!
M'E">M&0IIT)(SRD$%AR"I]" [6NUL+87U$A0=H/( (%!#&#8!X*MR[D;EH!B
M"Q!:@ 6(+$"B3G8B];^*P@.5FE'@V!>0D0&03.K(3@6*>V?[W'JBW(<RRUC*
MZYXULZ+>M[J=Z\ZCA/1;+IX8M](\^6P=_(-@TO\ ;LYX]0*DJ0UA@:-Y/E1T
M1MX/YMQZMW'/IIO4-M;3R*.2"K<9YK3#%C*OUS,+=479&,#UBYL#^P&,K<.G
M#L;1Y8'[5HYLC5H%7T8$S.PG-#X@%*\$8B$46&'6&ED8$%N"%% *HI22H 4
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MFAUYFTKB%R9G2%,QNYU=4Q:SJKJ]!*7E;OLJPE)5-J[1L6.1PL((:B-AW[F
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M  T/3O0&MDLQ[BPF8$4J#:05&WA2"2"+-]R2025/%@@"J^2I!MGMK#'=RP(
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I1^]Y4+ZF;W(51^06S_DEC?Y ?&3CRF6QXQCQC'C&/&,>,8\8QXQG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g189651g89h11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189651g89h11.jpg
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M,;4C07'PL24R4V&A_\0 ' $!  ,! 0$! 0            $" P0%!@<(_\0
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M:5?Q/\$]=U75NJ]9Z;EUNJZ,>E>(-)U[J6#&V71X/%!Z9U37:;%J3TK39_\
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M0_&<E+(DH\9LC*9E284-R6M]Y:)3\*(N1MQR*QMN"SE0I9BH^D$D@'L*';Y
M^.0)8*@8D!0Q[D 6>W?W^/WXDI?GQ&&5O*>TYI#,I_349*Y<EY$/2MR4Q8D5
M+LF6\UM.T;8C-.O*=VEI+:G%)1NM&ZKX'QW[7?;^9-C_ .?^._\ B>,$E$(Q
MH,IA3S>B$)DA'C3HLD:13&?:9>3ZT+(,QB,%]I,AI,J)-BL2H;R_02F67]*;
MT(([CWK[?P1P?X@$'L?:_O\ R#R/YGOW*C:;<>W(8TTRIU#KNWF]-M+9\[TR
M7%^=YJ%->:KTJ5;UMOS5>=K7DWY(H_'?M)G[N3'2EY2GV=)C:\LA6W4:3'UZ
M/3OE>WM7D:UZ)27/*YM/_IJTO_\ ;O6\FC\'_'QWD6/D33V.S!:I7R=H.34Q
M0HF$N?*E-M/2W%LZTG3+4*+$;?E$)LUU;44= @LR)I&:_'AP6'Y4AEI<JI9@
MH%DF@/\ ]_ 'N3V')@D %B> +_\ \^;]OF5X6[QS41IQI10P4)IMARCLUVN5
M&V6:SSK+6HC$ZPQ!U= A2!>=""1)49\H=C1' $%$F/ZR4;5(82Y<87/]H&T-
MN+*J[22%.XD#FN!W/Q*G(H^2;*T 2Q(JZ !-"^3V'SVFO=\17*_9M>(CB5DL
M;MG9L$@8!JG/[]:+>RQ4BOL&V.&Z:"K4ZTUG=8/>6OG6K&)%/C[#K5?>:T;6
MW 6&#); A5V[;+.@7UBUIBVUMPY%$V.>TCS4H$$M>Z@JLQ])IK4"UVG@[@*/
M'<@2;T[I5)O_ )-U$[',H<KM<MK#C+,II$FMVSVF@"7C[DL,[7'ER0AJ ZWO
M294$B*GP"$>+*8VUNK8W3ZE(Y*\^S+5@_>B#]P018EE=6^D@\!OW5KH_M8(^
MQ!!DZRDM+!I_\G+^\Z_*1B)%3W]7G?W4_EHQ$U&(G(I?PM6!?1NH7^C^(_K_
M "YOKQH&>N%;IX?D$V LB"IP"CL2!12Z<SMAX6\Z&KT+:EQB6DM2U.R&6T*\
MW2>@:@;,:/AQY/*!"ECD!HL6-A753R?<3 X3N=ERY$\P@L%"$6 %X+(2.![&
M2FM>%WG=.UQ!%<E6**WPZW7B]#7IQ)!<I=+7T6HW.JVT]>S!".\0,EC#EY,V
M"7.9>A.+,:CH1IL8RD?JK9W;S=U?U51#0H*J,K*J < #:!7/%^YN6&%%\NK'
MEEF%FRS.I5BQ/))W$D_/VXGN*^&FF&:EX@:?.+6#<+Q"W&7>SLYEZ T1JEE7
M4*/5!)&I/)@[;C2*Z_S\!9@SI)HBMD^TMY[;\3345N1G8-A8!?Z*[ .:926)
M#<_JW$&JX^_,'"I&4$G^J=Q(H%2%4 KQP1M!!-\\S5S?"S56*)Q>J4JU6N@6
M'@$=MGF_00OL0C86%2 +M>LJ;)!/B"@&S1+O#??E6R+.&(7.*J:+0Y(\C&CR
M6WGL7RLZJZYC;H; X-KM((92I^D@]N""+$CR0%QJK,IQ5L843VH[@000P[@C
MOR*,]\#PU0E-4N5:^F=%O5FJ7:V>[2++9)XE3A:T1Z<>H\8#&"0!4,!5Z5!"
MG5I@U^KCA>FY4-N=)ES"$PI+G#G/J"HBJ<1Q!1?"E@Q8DFV8D<D_X  $#"/2
M6=F9<GF;C7)"E0*  50&X"@<\\F[L[L',!'9><V3FIZ>2%B;,V-;ESQ&XJ2,
M?0PR.-,[C;F1Y4;6W) UIISTL=S7H7'/-TE?FK3GC<XW5P 2MT#VY!'/^9=T
M#J5)(!KD=^"#_P!IK2''01#I-QZ:Z3+(+W3D83CI" VJ'[-B@@1Z[6",3AZ5
M%5*T6>E7DBR^I^0]#VQ$A:;BH<T^MZPRD8UQT*7*<H/-V552#[52CVOO(.,%
MV>S;8QC(]J!8@_OZC_Q*7B^$*'7]<X7S_L'2^>S:/PRE>'4T2!,4B=-NW-:$
MA_=>U/78*H7: VF%)GF9,:RUMD<_&4:GI:C:\V$J)I^9O?OQHX;*V8 EP%=N
M]4PM: %-?8<][IY &W:[KMQKB)&T[D7M=J0"+/( [G[5C#_!72A ?E@ 1>+P
M.#\YXK<O#X4AM;KCV[]RN\($+*ACTJ4"?F"2+$\$+(0#M5D!"3#K#C#CKT9]
MQK).J8ER40E\B91=^ATX!%$6"."&L'[2!IU 0!F 3&V(]O4C42#8L&P""M&9
ME,\)6ZW8>'6 YVGH]R3X=_:,+F8$@,Y^#KT0&2H1GG3\(Y!JU0#/G"FP!5G2
M3DF8V['D#&%#XD%$\V@G#Z@,,@&)%\VMYMV8L&#@J68[18^GD$$W?%2N"CC)
MR.WE?0*0  J4YI19H]_:N*LWXTOP:4RKPJ0$,7&W7BL<[B=FK]6KUC8K+$1B
MC=J'"1IVEDI($$(FEAXIL?,<&$Y;^S;FS$QF?/E1HX]F(;4LQ8A51G.)F8$D
M[\1)#BR0";Y%5P"!WLN!5"@LS*HR* U?3DJU- 6!7!//)L]JVM(\*\:LFN:2
MK-UGHW2JSQ';SG'J;;45!D;4YBJ_-J0\L8)U^LAS=V-UZJDB "NDK)/DJ@Q)
MTN=)9GG7=%T0VHL/MQIC;+QD9=WJ%[B "2$!(!8#OV%#B2N$ IN=G&/_ &U;
M;Z31 )( +$*:%GMR03S-R!\,-/K_ #SP[<XC'K(^)\-]FK]HJDU]P9[0.3*[
M5+948L>PJ:'MQU1GX-NG29'LQ@>]N7&B[:=;:T\T[#9V9\V0JMYE*L!="RI)
M'-_I]R>\#"H3$EFL3!E/%F@RT>/ACVKG_$T-;\*C8NU\X-6CL/2NC5WCAXQ9
M>6U:Y)J4R4 +E@QJO-.F[U&K<:^7!D*%L)."):.'W%NZ5#E6!X_-'Q)+4MJ+
M5PN-$.0!<C*6I@I!X0DJI) Y XYJKD+AID)=V&,DH&V\$@CEJW-0) L\]VL@
M3K/.>;QB(Q$8B,1/E-3^<=QE\UB6:R?XV:Z34N:>#==48DVV_17&K9 :"?XO
MJE@&C+(P^5DH1*A7Y)^ 4<?B:EQB"=(E3?3^@SXO, !Q["VHW':IXYV<U8';
M91'/;M.)$R;+89-X7!7J8>H$;[ /)_NN['\WF6:I7<W2;^#FU'OISM!!_IR+
MM/>E71WEY(.[TV-.I&@L<R^[1+#$<K3(3W$&\Y:6;J(E@LQ:&@\ATU$G0K(&
M4AL(QTFP>G>#Y9#77J4V3O.3AC6V^*EE9E8%<IR>O=RVP@N"M7Z#Q6W;Z@ 0
MU<B;VRR_$1*A(H-'%]6B=("=>\9IQBT%1UACT1 2X5?Q(%?#QI^X$_-K-@KZ
M)]HYHP(%Q)A.!4" : )+Q@4R"&C2(7R0-['&4./3 J"N^U;$,PVCU T'LT"P
M)/-F#YO*J'WA]00Q!VTRY#B]1X(LIQR%( -$"5J;I5Z<+74YQJN=]K%5(4_P
MPA;W/Z$'[*;M9&!7KYUPCTT6 &$;97.EV)R T<K,R\0^?6> BSP)A^34WSLH
MQ*]LZ!TVJN1L+,'S,FPXP!:)L).QD!X8+O4E36X"A52K L<:Y54KB#;@Y/#.
M6"@LKGNI8*1N!-79GLM%7[.S1*](;)]N/QH1#L[U- N<S[T!&D(<YZF;J ?T
M50[18NX<W/,D8-C?Y7>.N(, :R *&A9NNUEEFM^M0&Q;C_M@UCW-OQ$V VXV
M<8QY%JMZH 6(!!:Z KDVCG(1>2ALR@$&MHXR'(A[[7>PMFP.)W3V<%9R_.:3
MT 372#G2>1GJKU0;68#S1DW*6/@O"ND4D=(BH:08+6/G9Z[U,9N.EMB><GC)
M:&5Z;;:WRXRHR.A8>7D#(6[ <VC_ &"L%/V%_>=.0,45@+?&5<#N30IU'W92
MRC[D&<]2N;+&5;DMPZ8%[M!M-BL74.JW<CQ9)<@:I_0NG"F%#:[8A5.$&;S+
MCU>K/-<S &J^AH2-C5>/$MKKPDPIS>N\%LBH<6U1CQJ,@%,B'E@6(7DC>0>3
MN](! $RVTJ,XR6Q=VV62K..%(4%CM7T C@ >HT94+-,\1L)PP<NR>I$.M7VA
M\!<IT$-5@YSGYFT5M4L;9Z]W&4* DZH(;&H6DQ:F3A$'4H^K">)<Q?D6;6]0
MM=^$T%.,8T?+N)8AU#<AL0O<2>R[02:4/0Y- ,HLL'+LN/;PI4D7N7(0"HKN
MUT/4=EFY;HWGYB;T:53  [OHT1>>F]ZWX@@UY5+7RR7R^\"NA/0#%(LL8/ J
MBRQ6U$:))HR*<2EWL'7)!01T'_,(?VSD7 3<3A;;CQ>25K?O4I89;+4 '#[@
M%)&Y._-PIW;5&0!GR>:&'IV,'-JU;;W%=NTE@.'NIT([X8Z;./[MQJR7(Y<F
M-%'PUJEJIT I6S1.14Y6K, C@*<'#0K#%>J$-"IK@J0R9'DSH*SQ3M>(^R6,
MO/<#: H7BU&XA@ PHVQ)%-7?B@00>3IY*D[B6+"R&.VP37(I0 ?3\<@D&Q*X
M\6,2Z&#-# @@=TDA)5;Z$^^<KL/K%A$-6U+E1C5<(2K'(;-1B+9PE'?-R:W<
MKI=J[1*IN&5<G..$IX^8+OIR@#,2H8,M G&IVTUG=E#B@=H*JK.U_ ,KFW$J
M &HJ_J <C=Q0VXROJ:S3,P5:/N92%3HO;RU.BWRT?XT:Z<$7X)7PC$JRWF V
MR]H=R)CO"WZDR4C@B2I:'KG#Z(DJ)G(4VR4U+2TZT\[FA?&&**<>P_FKX4\?
MU/*IB+'-;*(/:9A<FW<V_>/R_NW<;/,]-T?U;K'S<D?)*C:_\:N.F+/6^QN]
M!KJ>\-]FM-GU>9/.EE3LAE%8D5F<<D.TB0,*0V=IIZ>?IW&"UIM@#8&Q9!B&
M,;967RL@5L6PC%Y2J4W@"MP( #V#]6_DGD6+,L@/F(2K[E\P.QW;+)XHD[3=
M6"O8<&C0F5TGD?1(_1O$;V_GE9(2+X)EUZ(%$^CW#8[/S"=Q^IB+S0(LIS26
M)9"*6&I,TJ8O:D#;]7XHQU^*).V),B,>1-F'$Y&PW9[G$XR$J_V!!IOE"2+(
M$,C;\N10=PVT.WF+L 9>>_RI]F%6 6D+KU,OM1@T153">(*M=LD4SPHA(3:8
MLJ5QDD!JH&KB[T.MZH@7==KT*NC7[Q$LH7H!9FWH(*]I\U1[2*16-V9D8ON.
M%L6[4,;H9 69BA6SN):E(*BJX?L)4*RA*&49-N$"OHI0 P;C: !NL,=U\IR1
M-=:N:=(+UCH7-^2B.[QG+56?%!OK%0ZLI6J"2*76;:K%7(]*LD@2*I4XK=[R
M<4X.G<_F2H>J<;-[Z0ILTQ$\V5?&"KY&Q&C@&-D^H!0%8NMEJ5  0]<@;)#(
MY5D09.1FWKD^DEK9=IK:2SGC;[$[^9?4/F$#Q!=/Z'?RHGI=!IVZ[Q =3WR(
M4CSJV*Z'SR/WMPO9HH6TA]%&&Z_$[#7(8HLX,0/)6"HMN0Y!H .TF?B<APXT
M0%'8-E+40Z[&\JE)4\V4)J[ ;L&[:A?,R,Y#HH7&%L%6+KYMFB+](< 'L2.Y
M %VG4O"YSFDWF-? ,@S'GPK&>LT,>J)34Q(LNP0CXZ2-CEHU1CW!FNQ8MBF)
MA5UNSI#I=CPI,N'+DM.O/YMG=UVFN5"D^JR 0;(W;;X'.V_BI<845@PO@D@<
M5S?O6ZN3QNKY!G2&8S6,1&(C$1B(Q$8B,1.7_&=P>5XEO#/U7CHM^-%L%E"Q
M)M6DS%[:BHM%:+C[, 8E2-:5N+#(D1# N=*TAS<:%.DO::=\ST:M]-E&'/CR
M'Z5--[G:P*FON ;'[3'/C\W$Z#N1:\UZ@;%_:Q1G"?1_$3XBNW^'<IX9A/A0
M[]7O$7T2GHY1>[#;:;L-Q:MM&(2*_>KJGI^YCP@D#GB'"DD,B AYYUZ9IIA<
MY<1G1+K3#AQ9AG.?"<*-YB!6O(:-HNS@@@@7^WWXYWRY<F(X1ARC*Z[&++6,
M6*=M]T5(NJ[W7/OVO/(G/"7QSP]\VH')[IVJ,*E<[XT053F'TR:X%B =CR'2
M; TP.*^B#QY S4DGY_JS29!)&MS&OW:5R@#49,SOD7$3NR#=^HDV$'(YYX_;
MM-[.#'B14;)6U#M[@ 46/!XXY_>4/XF*'TOD_BLYAXUN:\XL/7@(WFY7C':*
M!1X[,[H+=3DEI1X);Z:$>=9W8Y\ G+TR2%1743'8H^#&:2B-,G$Q6N!TR8'T
MSN,9+C)C=OHL"BK'VL#@UW)^P.>973,FH1#D&PX\B+RU7891[\\$?85W)$/]
M+T+QJ>*CP\= B<:ZGR#A?AEEVN[3;'V6J.T*TWZ^6 =#'!@58K$V1()*#AWA
M\:=.,.)3#D(23AO>KR$"O7;4FFP9D.1,F7.%4+C;<JJ#9+,!5_;]OO5;;49L
M;!'3%A)8EQM+N0  %/-#O?;N" :N=^$/G-WJGB\_:&W"STRP *]?+SR651K&
M8"S( RUCQHB\MEGZX2DL-L%8L)^4/3-7!==:9=?BZ>WI2V_+34.K8-(JL"41
MPR@@E22M;@#P2/G[_$O@1ESZIBI 9L>TD4& #71]_:Z^TKGI?+NG^$+Q:0?$
M;P&A6R_\5\0!-D)XE>3T(+./% 5D\Y^3&ZO7Z^+9?D..;V[-)3]M1E)V1<.#
MGI#2K@.6,T1TU&G.'*ZIDPB\.1R%!';82:^P'VH^QNCH^#.,N)2V/(:RHHL@
M]]X _P GCO8_4*^LK:TNMH<3I>DN(2M.G&W&7-)6G2M:6TZE#K2]:W_F;<0A
MQ"O*E:4JUO6O/G;//$1B)\^KSX8[9:W.A"':+S K(MMYLMDD]9,%YZ;D=IUD
MM(4Q$Y_-@Q :)"(P -!8JWH2I@N ]@U.N.C8+92?YU9[$SHNP[\@"JJ^6 -H
M9007!O\ 426L -N)OCOS-B8EAL0[BQWD^HAB"%(KL!QR2*45SV\C_A<-0;5:
M)H7F_*KISF:8Z?JI\F.3&Z]5*XOH5$X:+A7*$-:JA@.,(#;-0NB,E&APW19@
M7?2)@%-7.(FA)(N=2%!?(C@8]V0#<S>6^0[?J!((9""31*@,*HR#A.YB%1EM
M]J$T!O7&-U40""K7Q8W$CDD&M+?X/NT%*9+ICTNEW-V6&Z'!3:C<D$LT]9K)
M0^5U8;92SMWYWT5J"-)R:=8)U@=JT&!>X\UT-H59V(LLHY'NNHQ!MWJ7E"%
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M@822(D+#T^B0QNB8_9J6$J:2=@F)E#@HB'+:@;7"Y'9V#[7(*E0V3$VP'<2
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MC;E'W7NG"^P/PRTPM*H3!V.0KA;C5CA$!.@"VS Z0,)#B$>1*EBQ=5P8V0Y
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M"9D]B2J S$')CSG6&FG]ONW.]M@(8\!4%&R+( 7CGDD"KYXE1M7<00!9+F^
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M %L1'O&"^S7/PD/];$1[Q@OLUS\)#_6Q$>\8+[-<_"0_UL1'O&"^S7/PD/\
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MY4PIC\]G;2Y,+'+BR8]3CRMAR8<J.'7U*OHZ/\+FU/B/-TA_%'1QT=?".O\
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MSGR#,"<_IMQQR"RVIK:]<V!\!17JW0/0NULD4; Y%<U<RQ9DS!BETK%+-42
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M9IPIT,[8YA8J%-&] ZV7ACY$/RL3AG7LQIC\PH&(QXSM);:6=\@+M1#$ (
M"!9!/WYRSL^S<5!=_4 -P"HA"K8(LEB22":! ^1N1QF_6;H@;BS/?)SD<%5.
MAV4ST.F@>=,76SDP'0(%5@U H@K6[13().@0",=OH;H.HA7BQ\E7GHX^K#ES
M@I."$5#E\D>ID 1RY50R%MPHJQ#D'8"QH ]^" W,PQ^::"L690H=B&  -AAZ
M0?40!9([=ITKSB=)(4H$_-N@;HDYEJ6.G70!"ACAI^<((2Q4R7J"/FSQ\6<W
M)A.Q2[,!]$)!>/.U$ACH_HQ\7#(*=@%*#@A3R18![GFN;%^U<F;*;4>H-[%@
M*!(-$T"1W'-<7VDWRDM&(C$1B(Q$8B,1&(C$1B(Q$8B,1+!I_P#)R_O.ORD8
MB14]_5YW]U/Y:,1-1B)P/;N<%E^(-CAL(_N+Q/MXJU>(2\U;SI7M!)/F=BH(
M.[TH)-2YI,"F]>L/1*)9+<.3OS5:!=#'-HVWT:0Z,[%R5A\ZKRXBN%6XJG5R
MKGCEL81@I^ZG]//,RDY?*O\ IY <K#F[1E#*#?TN64L.W#"O6:C<J%S5WQ(<
M\54)==L@CH]N[[S?J46,6,O]5+61-=NLX^%Z0**MM.N<6I>JQ[O5V XS'8KQ
M,ESQRL/>[IC2RTVWDON!5D7$^.P/+"VH!QD7_4;=;<DL ^[E:$>GS4*T0[9$
M?D^820Q.X'D8UVT/BU(X,@$7E-"G\AOE_!D:3R !V[ME J]<6>&V"91HG*^<
M=>ACZP(+# I81MUSLD^ODBIF9-L%=04&WH/3IE@'-C!:F[G(XR(A#9#BQLS4
M5WG(^,EBM@C^F& 4!6^DM1N4V*<;,",8R9%"W>W8F2E!H_\ F$$DV+#!;X G
MC59U*-6#E7/>H#.:#N A;=XC*=(?K[4D+PKK77*Q+YH]09,P/8SM@@.PI%?)
M]@8;J!RRVH2YT"E%E1Y9":%$*9,&"Y'0N<Q7"P!ILN-&W[QZ57D$);!0=K#@
M68&TE$<)Y0;*I(L8W<!-M@EO;?Z2S#<I]U!G;'"2W%QP<Q6^26-MZJ:Z%:P]
M:&N%=/5SVL,'C25I <DW(7IHC2Z[+>G)<AUQ<X* -,V45"5$BBE0H7+E&4D-
MD7U;%+&N:)(4Y*[,P Y/)&TGDSHQ''17&?2&8 7Q8HD)_P!*W5#@&P.!.A<Q
MFL8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$\V_XC?\ K3_RUB)D3_YZ;][D_G+Q$Q,1&(GSO\0]
M)N9OQ[> &XAJC9R]1IL7Q()N%I& "L^N511WF[$$(FR'(D1T8"V8G:W#%:*2
MHNR$K6X\3TSVMHSMPN@T>J4LH9CCVJ6 9J87M!-FO>AQ.3,K'4Z9@K%5\S<P
M!(6UXL]A?M?>=0]OZZ?Y%"H<L#R/H/7'+ET(%2"$7GPF85?IPTPU-<D7:QIA
MP)^X=9#JBMMD9KZ8\=E<IC2Y+>U:TKGQ8ADWWD3'M4L-Y W$?I%D63-\F0IM
MK&S[F"G:"=H/ZC0/ ]^TN_,II/G?^SSI-SI4+Q>HN51L]259O&UV^UUQ-F %
M0*K!5BS56T*LH316)$V5 $]QY&AYF!J0.F[8>U&DN>B7YO;K71S@VLK;=/C4
M[6#4P)L&B:(]P>9R:567S]RLMYW(W BP:HB^X/R.)I/!_P ^N-:\8?[1*W66
MD64 $N=YY*]2+.=K104*M8V$(O"2[M5-$(3$0["B2'AVB2Q$F4Q'>=A:D[0M
M;'E:AU;3Z15=251]RA@2IM:W &P:NK OFO>,"L,^J8J0&;'M)! 8 ->TD4:X
MNOM*ZZ)SGI7@P\6<7Q <+Y_=.@\"\1)9D1XBN6<XK)JV%JA<%+?DL=6!5FO0
MI\_<=S;TTF04Q#<8W+<L I]Z.[9:[H=='34Z<XLKJN7"+PY'8*&6OH+']@.>
M:VD=C*.KX,XRXU9L64UE1%+%6'ZP!S\GMWL=R*^MK:TNMH<3I>DN(2M.G&W&
M7-)6G2M:6TZE#K2]:W_F;<0AQ"O*E:4JUO6O/G=//$3.F?P!OW%7_D)^(E7'
M^3<UM$$@./TFO%(I2R)N4S4B UJ1NVI&L!TV:/-:]',A'DB8S(O1:%(CSM#]
M*A:?]7==;7=<N12"K$$+L'_IN]M=B+YH^\J41N"H/.[_ -U5?[UQ?>:PCPWC
MY2NU^IS.<U-5>J:YCE9&QQ,>"@ X3VXHLX)?@IC2X"S2GGEG%QWVU&EOOK*[
MF*>=VN1ER!BP=MS?42;NNU@V#7MQQ[5(.-" -BTM[:%5?>JY%^]=_>6(&#"*
MZ)&@*^+'A 8:#&&" XF'''"Q8Z$RB/#@#X$1MJ+#AQ6&T,QXT=IMEEI"4-H2
MG6M90DL222239)Y))[DF6      '  % #X ':;+(DQB(Q$8B,1&(C$1B(Q$8
MB,1&(C$2P:?_ "<O[SK\I&(D5/?U>=_=3^6C$348B<_W+Q#\AI5B.1CCIZ2_
M1&40KQ;0?/[?9:SS>.7BC33D6YW4& (!:RTH=L.>.Q91)'L0,H78K*T,#N0B
M*MEPY'45M]?*(756<BQ:J2"3=@<<FPMGB9-EQJ6N[6@S!6(2Z/J8 @<43SP*
M)H49F0^L\73U"36X/HT7DJ6:I4JU1:.<0%*6:-6]6]BD/=,:!:K,ZP,5AO1=
MD NQ.R&V6MQ6VM3VE0T0<>799O:!NV[A84MMW;+W!=WO7O?8W)#IOH?43MW;
M318#=MWU1.WFK]J[@B1^!XB_#X>JYWR$E)J VK1K'J,7Y];( :VTHH50 '%Z
M,.(UEEKH@0R;DPQ M-.BG=EII8$U!CR46,"LG8X<P9>+8L5]+J2K ;B&(/H(
M%D[B* )/8U49<1!Y](%\J0&4F@5%>H$T!MNR17<2>TFR<SZA7#->"A$*#UB>
MQ5[%1+51R-7D ):!PTW &$Z5:@PQ^+%?$DA944[[-4-F0I4>2/?>1K>T489,
M;!BW+ D.K;@PL@D,I-\@@\W\RZE'! '"FBK+1!J^5(%<$$<40;$FJZE6U2*S
M)T&A,N4U<IRKMQF]Q(H-R:,DA9"H$*,IJ&UM0F9+'M^5A6F(TF0VQZ+3SGG5
MW-ZA9]=;KY)H@\D\]P#WYKF6VCC@>FZ^UBNW[&2+*R8Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M)YM_Q&_]:?\ EK$3(G_STW[W)_.7B)B8B,1&(C$1B(Q$8B,1&(C$3.F?P!OW
M%7_D)^(F#B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1+!I_\G+^\Z_*1B)%3
MW]7G?W4_EHQ$U&(G&$*-V7D<GM55J/&9O2G>A]#MG0.?7+5CHP^BLR+Y#@/2
M1G5F#=K#W0;$JIQ$V/*55JS;5EJ;'%-B-J-*?#P^G^ED\IFRC'L14==K%_03
M1QTI4EA7U,M-=\<G#^HGF 8R^YF92"H7U </9!%'O0:UJK/$]/1:OU^[=0YO
M)A\_*!C?,^B1"XCHNKF)(\5GT:14R \_/(\[F67VZGH$E)LO60JVJ,Z7KRUL
MS!W0$@))-F7*-C7&]N"KH04*L,N[<" ' V[. 3;T;-INJ0XR,Z>D@HUA@P./
M:5()*DWNY(!"6+X:B0:-Y;S'N'&A:;-3>'W&P6^L< 313E4O71N>EPURZQJY
MU&:"E<;5+OFP_.>4UU"K]93-6@[Y2!)"-T02"IT*Q _0"=<CXLA"ME15;+O#
M(C@JFUP?-I+?(?0H;UL#N+&CSFB9$%C$Q9<6TJSJ0S[E(\NW(5!ZB1Z!6T!;
M6AU]X<P9X4 M)*Y4WHE=OUJLNK#>+!TE_E^R=T.+#C!;4X&-Y5T?I0.NU$$)
M&#JU6ZY(+L31HX8TJ6HR2DDK"6Y\[ E0K(45=J+C\RE%D\G(B%F)))8"B?CM
M-\0(#%E<,S6Q?9;&JX".X"@ *!=T.;/)Z)S":QB(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)YM
M_P 1O_6G_EK$3(G_ ,]-^]R?SEXB8F(C$2EK9X@.7TSK_,>$&#WG=/ZTU8I=
M5K<%GUR0R-K(0D>GECNVW->QALF,)GQA4B4G7M2?%DQX2'=0YKD;5<.1L;Y0
MOHQUN8\"R0 !\GD77;WF;945TQD^M[VJ.> +)/P/B^_M+IS*:1B)1?+_ !'<
MG[)?^P<WYX?=/V#AI4$$O[[$-U :*6/Z.(9@#"BM^A*O0)=<,CBNXVO1PI\)
MR/Y[G[E[VR8,F),;N-HR@E03S0KDCVL$$?8S-,J.[HIML9 ;CBS?8]C1!!^#
M,SG7?.>=1Z'V+F%3E%'K7PLM70M_9FBWH4*-.M$8M+%)&37%J03;6R%G;?<:
M2C3*DMI5Y?2:\E7Q/C3&[5MR@E*-F@0#8]N\+D5WR(I.[&0&XJMUU1]^QD=Z
MKXI.3\CZ#0.3&YARP]2Z9(VW5>?T@)(LUG=AI4M*C16'%6VR" I4U(WLN8DP
MH7H81*7Z3U(24DP[)@R9$?(*5$[LYVC]A?<_8<DT!S(?-C1UQDDN_P!*J"Q_
M<UV'W-#@GL#717_^?_?_ .LQFL8B9TS^ -^XJ_\ (3\1,'$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B6#3_ .3E_>=?E(Q$BI[^KSO[J?RT8B:C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$3S;_ (C?^M/_ "UB)D3_ .>F_>Y/YR\1,3$3
M46"$3) 38X*7V ,SQ!*$)/)ALD5!"<J&\Q +Z'R%(CS]C93C4S4-]:&96V?0
M.J2A:MZE2 P)%@$$CY /(_D<2""00#1((![T?FN.W[SXDR_#-7O#Q^T*\!4U
M-PNO3>C])>\29GIO4+^7>)6&WE!/)-QA:$Q=+]0"A@[,Z;'"B82%JA0Y&HS\
MZ:EB.IKU!F.;1ZKTJB)Y01$%!07!//<D]R3W/L)YYQ#%J=-ZF=F.0N[&RQ"\
M?8 70 GW-SRIZ,XH\6_7[C#>J/AJX;-2SX@>[HF0QAEO2GFN2<UBJ]!=>Q&D
MLJ2N,@+$4\/J3;KD=9:TNM-P%2Y UV"_U:?&IW9LO^SBHD?_ ''/TXQ^_P"K
MX'?O.?/D8%<6/_=R=C5A$_5D/["]ORWS53EG]G=RVK<4\5O[0/E=+9DM5NE:
M\*XB N:^J3/G._X>7.62+$I*M:].4-%),TN3>0AMMR?-D+::9:VAI&^LR-ET
M^ER-6YCF)KL/6  /L!0'V$PTJ#'GU*+V48@/D^DV3]R;)^YG*\?Q7SO#1XI?
MVDXVAT<WTWM_1KUSY/+:,'#DRK#J:A4+X2M5K/Z&-J?T J,&?"G38$9QLB6<
M?CPXRXD79 L+W_+^?AT19@F)48.Q(!]3+2B_=JKGMWY[3+SCAS:L(I?([)L4
M D>E6+,:]E!!KN?L+([S_9M\XYP:YHWXK%75SL_=>YL+G]-ZB<9:08 $VUM(
M(\O##/.6FJA:I)88'.#XFF&RS<(=/82BO-UH>-Y-;D</Y&WR\6+A$'8CV<G]
M1/<'V[=[G1I$0IY^[?DR"W<]P?=!\ $5Q5T/8 #Z99Q3LC$3.F?P!OW%7_D)
M^(G'9OL]S'\_[58V-BM%*'W<5SL!I<!2F?=^=9N;"E)F,^L:W)GKB6LEZ.3I
M3>O2+BKTUO3?D7T#&IR8EYI\0=N??:Q)^P%#_',P.1MN0BK7($''L2@_D^HR
MOX_C9: C'T7BD.^\D(QV*<1%5TL-VMJB\ZZ]<.;!W@\6?+5*LER+IJI!MBO0
M-LM%)H(M*1+$Z) !4V_Y6SZ7H5C'(/UOC5R"1P%&X6;-6.#1,J,_'J7F\A(!
M'TKD9!7NS$ T.+KFK DEL'BT0':+6=^C6B-3JZ5[>)BK9=K,V;?Y'%)%F%61
M8EEPQ&D &$%*VM E9?4=PH[+]%):@18RICL#3W2[EW$8B;W )YM%;-431]7L
M!VL]K'-5MM;:IR#C:2QQV#7/'(XLB[F58/%^+JQ&55#]")BN@PK+8 <JKSK3
M5HX_U&N4WGMYF&(UI7,]F2/6!74J8*A#MM-27+)/EQ)"HP,?(L>H&F+#<KJ4
M*@AJ:R2SI6VKX*,2?[18LG;!S@$J5(8$@BQ5!5:[NN0Z@#Y/-#F0CHGB/NY0
MOS^3S64:"TNZ6RC55QR/S&9=;_&GF^!=([N68334RFI>GD!G>2L2FE-J<#;5
M:=/^D4WYT:Z84 ?>%9E5C_N;%XRIB%MVJQD(^?3*OE8L@2PK,!>VVYQ/D/'S
M6R_CF3LEXC"W.*TVY8JO=[[)!\VMW8+J>FU\/S$B&H52/28)AUZEFB+9!1V)
M!1N8*$,H0@W B.2E$(3TF&S*IY*N>&5 77&J@G("[ $>H<5S1-\'M<L<I0'<
M&:E;(Q("D*I(/I/OQ8'N/<3667Q6SPUE#EDT@RWRQ:>U06R[;P*8:NA_F%B&
M4F(-"C5E8JP2S=O7/AU]TP^W$*#U,D"TFNH3II=ETX*L-X\P>62*8! XW&S1
M#4IYKD$4+D-F(((4[/Z@OBV*';0Y]-MVON.37:;H]XJI5>(F*K+Y)97[Y6H=
ML+6*N1+'5EP(0*IU.M79XU$L+\V/'(1"@6RM0!C&H4>?[RP90R?$A"]M'UU&
MG! 895V-05MK66+%=NWN""+))K;R+/$DYB"5\MMPLD6M4%#7=UR#7[\?>:LE
MXRP0C<0:6HA@):#4T(NO!3=BK,*%+K5AI\RZC["6/QYDZ"(<;'P'A,\.RV5F
M,V)^!%BN31+\@Y#D:4GD."H!W$*U@AMA ! )Y[$UP.:- QY]4"A!)% LO8KN
MLGL./87S]N9@ _%N>/6+U03RHN7%VHSS2O\ .!WM(.!L;I.Z<FN'4S2;@DL2
M4.&-@(=.*09"X+DE.UL:5 ]KI>9<<EM.%6SD *C(SFB12NJ#;0!-[@>:[\D5
M S$GZ#3% HL VR,QW<\51'\=IEPO%^"'HYM#+#%DWKK(H4*3,]NU 6?9>Z1T
M1_G0&9%H4<T1.R!@PQJ,_82;Z1HYD<]Z0')L!..0%0ATQ.\J:"AB!3$'8@<@
MO04$CL.?O0HEYX&T$625!-J#ZWV [;N@:)/'':R#70/$;>7O_):#<S^XNS-C
MKL0F1W"8W&B[E/[7I?H&-K=VTW_EUY$;<7Y/IWF&50N1E'8'C_ FN-BR*Q[D
M G^9:>9R\8B,1&(E@T_^3E_>=?E(Q$BI[^KSO[J?RT8B:C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$3S;_B-_P"M/_+6(F1/_GIOWN3^<O$3$Q$8B?-?Q)BB
M<K]H9^SJ)11T^2.&1/$[HD08AR'H0_<OF$=J+J=*;;4Q$W)=UMJ/ZPXWZ9S7
MF-^<K]V=V @:/5@D DXJ%BS3"Z'<U./,#^:TIHT/,L^PM>+_ 'G7/;^\UG@T
M*ASK-7+Q8V^@]!!<X%MT<%&.O#"Q]J:]%*GD22@S4"O1DP7$SB+2I;S"W&=)
MAN^?O:>;%B;*6"LB[5+'>VVP/8<&S]IT9,HQ[;5FW,%&T T3[FR*'R>?VG-/
M3? 1J^]UO/?JWXEN_<FMM]%5P$2B<Z.!!D&&#K8<6,BAX#\D1*(M"Y,L:H[*
M@[E[C.&ILN9Z+2U(\W9-65Q)B.'"ZH21O5B222233 7S5UVF3Z;=D;(,N5&8
M '8P   H <77O5]R3.1?!UX:;U7?'-XM)9+NW>YL'F-BX9+E$S9-I+'>&R])
MLSWJ_1):AK3%CC5+:-#Q>AJV/46I*VG][6M.=&HS(VETX&+$"XR#:!_M4PY0
M7Z=W<W=S#!B8:G->3*0AQ\D_[EJ>'->JO:JKWN7?X,:GN-XXOVD5J)UM4>8[
M=.40*[8IXA34AT3/%W&0:AA2LB.E;@^9+&!7B;$%_<=]^ ,7*2IR-%VC+4O_
M /3:- W&QRR@^X*U8^0":OY-=YI@7_ZG5,1S>,*2/8AKH_>A=?:5_8A)_P#9
MU^*O5[J00P2\'7BCL26>AUP ,FDHW%NKOI4M-M'"Q[+ZX5?*-I>FRFH;26MB
M$%QR8NU5BI1'] 5UFGVLP&HP#T%C7F8_[22:)_YNC[F5(.ES;E!.#,?6!9&/
M(?U >P/^*L>RB?8UMQMYM#K2T.M.H2XVXVI*VW&UITI"T+3O:5H6G>E)4G>T
MJ3O6];WK>>;.Z>>(F=,_@#?N*O\ R$_$2CRG ^6F;>_=R 0LLO,/@K83'1[I
M>(---6JLH%HKUG/\\@V.-03]A#Z! EP3)FM3B++X,)(]8W(##'8N@S9 NT$4
M 5!VH6"M=@.5W@&S8# <GYF9Q(6W$&[#5N;:6%4Q0':2*%$@G@<\353/#5QV
M<Y-<=KQMCVD1MY$HV/Z!T47'*(OIY=HMX,G&&VN)'(4\W8GI9F11YC3U.9GD
MS+T0''V;+ZFR,^05R#04"T0UL&U6%J:8"AO'JH"R:$'$A]B++$TS"]QM@:;E
M2;)4^GDT!9F\*\*Y4;$J!DZFW)%+G]%)JB>US[*=SNLDBI?H+^G8Y5I_7O"0
M-$Y"V].Z:&[E;:#MCV6F&VH&;(#8;FD'9>V, )[>P _?WN2<:$45XMCW/=R2
MWO[D_P >U3\L?"^9VDF2.$@Q:(>+&'CL^P5NY7:GGW9\JJ@*5-0T<J5B"%8@
MTA6:M7!Q()$EL!B#@4<2FP'RL5J<DN5U  (( H*RJRU98<,""0S$@D6+-<<2
M#B1B2002;)5F4G@+W4@T0 ".QJZOF8)#P]<I(@P5>V%-B8%8M$FY5Y^IWJ^4
M<T&/RJ^2J2Y,"QTJRU^P,QFZH6FUE@9HGL:R"4R-1$U&BQD-3YV2RU@EE"MN
M56! (;E64CZANNKOF#B1@ 0?2Q8%692"05X*LI^DD5=5Q,K_  (YFX&- B(R
MPV"%8Z18^<&W[;T'H=Q,D:3;'77CP&18[3:C%AW'EK><TQ(041.&M;TP+E0V
M4(;3'FO8(*C:X<;410&7L:50/;M5'W!CRTHJ02"I0[F=B5:[!+,3[_-CL.)K
M9OANXT1)F"I"IRISAQBY,2QTNV7.17(NNAR43[P\#JCMA56:U-M!-"3)@A71
M N?*.:V;5)T64J9NPSY0  P%;>0J;CM%*&;;N8*. &)%<=H\G'9.WO?!9MHW
M?40M[03W) '//>; ;P/E8S<UUNOD)\XG$LT$J9/VZYV6PEHMP# JZ?;+6*PV
M$F<)[D@JR!$0W)Q"0X'@#(T8,L>WI:5U.7(:Y JB %50-I+"E"@#U,2: NS=
MR1C0>QLV"2S$G< #9))/  %G@"A4_2O!.6F'8\MX"2'DH20"(!NO7"ZU:PC4
M5D$4K(AL98JU81)L:VV ,DQ4UN%/808B2UMF$S]H:4V&;(/<$'=8958'<0QL
M$$'U $<<$<5!QH?8CMR&8$;10H@@CC@T>1WGF)X/RH&? 68567H1:KHKZ0:F
M[%:5#X3M7J=FHH2<H(X;6%EE8M2N-B"/%YP^24(19S2B,N6^/&/0QRY"I4M8
M;=?I6Z9E8BZL LH- T*XJS QH""!RM5R:&T,H-75TQ%U9XLFA6BUX8^*HD07
MV:L3BMP)-0FMCH-XO\$)+(4$_JT4PD7 0[0P%.DZX=2U/&D34"?-:5&AL*?7
M&@PF8]O/R\^H<AA>U+ 8;6 .VP"." 0._N3(\G&?TGNIK<U6IW*2-U$@\V1_
MP);M8K(.F5\35JU!T, @X;< 5 3(E2M1(C7E]&SJ1.?DRWM)\[?^>1(=<WY?
MWKW^[,F8L2S&R>YX'_QQ+@!0% H 4!]OYF^R),8B,1&(E@T_^3E_>=?E(Q$B
MI[^KSO[J?RT8B:C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$3S;_B-_ZT_P#+
M6(F1/_GIOWN3^<O$3$Q$8B,1&(C$1B(Q$8B,1&(F=,_@#?N*O_(3\1,'$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B6#3_Y.7]YU^4C$2*GOZO._NI_+1B)J
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1/-O^(W_ *T_\M8B9$_^>F_>Y/YR
M\1,3$1B(Q$8B,1&(C$1B(Q$8B9TS^ -^XJ_\A/Q$^<%\J CG'4/%!?Z77'56
M+G7AGYMU&DLNR;$6'1;\2L'BF<L!6.%V2<C39A6-6:VR1AM,*V_'&CVFVD;2
MUY>Q'+I@1R-KYG1N%6T PT+ !%;C7/O.5QL?,R@VF%'7DD!BV:S5UR%%_8"9
M1_Q"7R[W*ZB.17RK*IHB=>' =Q" A]RA$X=1XCS>]1XPHKJ:L(3;?NMD+C24
M]C<U'J3$\+%5#+PTSH)<**J'(C!R$M22IM\KIR*OZ & X-\GCB#E9F?8PV@M
M3 !@0N-6X-T?42">1[=YKV>[]6@%:]7[UT6L4RNVF!SFU'.L3JJ*#"Z(F\\Z
MNME]RHZC9"178$:79ZK$@ 3=N=(R]0I,NO2I!&Q$P9%@<6,ABN-F*EE&/<26
MVNJ[N!N) ;D* +YH $&?,<$!G55(4ERH !96.WD[0+'!/_ILD@RT_#GU#J?2
MIUDLG0B@L#6ZU5::K5>C59P&T1GV"K#[#.N<DB8FRBHT7)CH]I"*^YYKHJ&8
M>CEYY%^)&<8IFQXT"J@)9F;G== -06@*)NP6XLKP!S+8W=BQ8@*H7@+5VH):
MR2?N .UT;XKG )UWLU)DW'L;U,N6H7B'I%WLW/X]F?B'0$&T5*";MO&( >F
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M?KSS;4E[VBIAM]Z-/D/M9B!Z2. 5-C;D9C8) *C&;!Y^TCSDW*.?4#1H@=T
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MSMZ$4@)5EV8K7_M6B6]NP]Z/-NS>?JDPK;.5M^P0*K?_ ,FNE_DUQ8^A/[+
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M<3IX^+8!!B'#J4<2.CQVY8J&0;L-3DLGCF[JUNP >592+(W$@@EB23S(\A*
MYXJKINQ:OJ!!H,5%@TM =A-#8O"'PT_2W8\XZ7C4UVNSE3YZ)U)E 9 *?1*M
M4YQQ"C55*  LKW>J, C N->CAC5>7-.NULT&$F9T%R1J<H;L-VX<4VX,&) X
M()Y-%38-"P2+D'!C*]S5=[6J*A2>5('"@@BB.=I%S:"Z+X>NA1!#M0ZH-/O#
M['=&Z\;J%^IYN3#NUXZ+6?$)+5!5#8)#99X58N:CK"'#2X<V(JM#BS!D09$.
M35)%\Z$AD*VJ[@R,+14;%S=$ KD()!!LBB#4!,3T5<-3-15E-,S+DXKBP4!
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M2[XL&!\.+(,KYF4Y'"E554)(4$\L2??M1,A5R9<R9<B>6F(,$4D%F9Q18T:
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M!U:GAH,KH18^FLCYEXZ(9/3)D-YJ!7WW@]<+4<>^0<B3"ST.NM!H]A..0(Y
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MG;(^UVQP]I#S)"0Q)9EM1+?EWKN+XXI[KUV:VV**$55DG@?,?F$^#[^Z]P5
M'#59# W= =SWJ;5?IE=MIEP&,;(,S$!8AYOV@W#B;DP)<43)]+&AJG**.LQ]
MF8D5^?J!H4J>W-@QB$B3!E-M4?$R+N-5N*\6>06'/%"]I(!.ZJ) !$NN17;:
M+O:&YH6#7879JP":J[%V)86932,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$3")3%#X,J:B%-).1F5N-CQS;3LZ8YK]R(T5$A^-'],\O
M>D)7)DQHS?E])(D,,I6ZB0+(%@7[FZ'W- G_  "?M()H$T37L.Y_:Z'_ #*]
MA3:*_1#=ED!$C*O&K1FOGQ\V+'?TS6:-(L0N<*<B#)1*!+'1-).)B:'/RF9L
M.3I3#CS;K2=:5D\Q5#6Y964@GEGVL#9 ())%W1!E 4.,L5I K*P-<*FY2."0
M1P:K@B:8U<*%,E,HZ+6YE=)AVXDT;$LL& 3EO0BC)0HIR'NK$+$S(B--TPB0
M.0'GO,@)K[14E&3#C#IZ[*F0#^DX8-8)4E18*CG>%KEP%/ONH&[$J70G^HNT
MBBH8 FCN-C;N[;"6'L%L\49J$#N$!Q.@4N.*GQ1BO9SK\P=.)2"*X$ I#(:3
M,C05(,18$2$<]XD#O3B1"V"[A=J"MN7M,WJ"VX$@GG@@ 65*\$^DFUVWZC:T
M3Q*U@ VD T:Y!-D @\@40 #NKTCG=4V$I?#79DYIV$"ES'G"2'&(@<A.44DR
MT2P)ET0Q!AO(.3U-R)H@M*"(FS&6XLF%.=;2)<;B0//XHM5+1L< 4RV2?2.
MP#4/<=^9_H>KZ3W!X)LGTFA1W'NIJSQ1[<>#A/AR)"Y+;%:D+1J.XY+1'9:'
M;9)2AL5\J@C-W&#S'(B+0.43G1)4DG$&'(K*_P#IRL6/*FM1S9<?8DDV Q"T
M+(O8:! !*_(X7@_Z?;["B0+LT#6X619 ;X/.?/,\S,/UJM.@MEX]@,FWH[.Q
M*HL<:5G^O$2:SL,DL<1AZLJ9I9_;+L%]DY&<G+?9>A/><[4+E7<^ZBJK^J[
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M>3-GC2+!Z.5A/OL>A5ZJ6U8R#Y",UIMAV:T+GMMM31 Q^+89\@V@$ *00 .
M05(-&^VT5]B0;#$&#A0WN!)(())YHA@1_P"[<;^X4]U%0:S\ZJM<(\\$P8.W
M$6:_ HQ.4\O33_F5>!>[=#]5CCT01D5$Y^:1"EXK0_4&?7"4X6J*WMU$AO1,
MCLN5B?IQM0YKUE$/<D\4&4W88 W[3-\:J<2@<-D%_/I#L*J@+LJ>.5-?>6V:
MH0(\0D3YBR;224>#$.CH9!Z,+L408\\]!CFHB/+I]II3[S,CU=<59. O0HNL
M@*0W"1BN1E  K@DJ2+92P )4^W85WH^H4W,V;&K$DWR & -!@#8L>_Q]QP;'
M$UCG+*OM^-+BN&1DV(-BAF)XLO*A3D"HSM@<7!1*;WZ5I$KWF*:>D,*:FM+]
M2EPI42</A2F9\Y^0=I!))!4$60HNC\;%KV[@V"1(\M>""P( 4$&C0W<6/G<?
M^"*(N<_=^JPJDU<:L'N>V_8I"J J2\2G>L"*=( 6O20 9<9^-IF%%]IS_5=3
M4SW4;>8VXX[L:)W Z-.Q=CNKTUD[#E]Z6QN^30NJ[?=KY\ZA H6_63C/)L(5
M?A:JJLU=^UW0E^C>24H27DFH,%YF7(+$#.M(>0VTS,+1K)'([3IEIIU]N3NV
M&G?^M=ENL*>C1XKK$$?!B1^<YG90I(H*%^] H1W^-BCBO>[))FXQ("2 022>
M_N0P/[_43S=?L*F37N8UNK3(DL$X9@:C,MLO1&BTG4,DF,Z8>A>TVO+YTI,%
MT\5<9:](B.\N0RN:S+6.&*A0V5G!#!39N]HL<*#7Q84??XJS<KC538+#L*LT
M:NK'O6X_YYNA5AYG-(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
4B(Q$8B,1&(C$1B(Q$8B,1&(G_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
